<SEC-DOCUMENT>0000899923-22-000033.txt : 20220225
<SEC-HEADER>0000899923-22-000033.hdr.sgml : 20220225
<ACCEPTANCE-DATETIME>20220225165734
ACCESSION NUMBER:		0000899923-22-000033
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220225
DATE AS OF CHANGE:		20220225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		22681453

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mygn-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4990a358-c12e-4899-92d4-a6c626b561e2,g:4a66b582-ad59-47ea-a8a2-59085acc693c,d:fead9d28cda549c1af769d1d50d95807--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:mygn="http://www.myriad.com/20211231" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mygn-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF80LTEtMS0xLTM2MzU5_6008d18f-b9e7-4886-8cb5-3cdf28497d70">false</ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF81LTEtMS0xLTM2MzU5_95168b37-3031-45fa-a20c-d7367fda0c78">2021</ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF82LTEtMS0xLTM2MzU5_05c72a36-c4c1-42ce-8ced-eea36558439e">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF83LTEtMS0xLTM2MzU5_38310361-d0d6-4b9d-a165-3e1c2a79b19b">0000899923</ix:nonNumeric><ix:nonNumeric contextRef="i55202b0f51cd439d9b1c5849f46eaeca_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i63f8cb8dfa0542e0b8ad06c716ac9a06_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i60c092841990477a992d7f353b1ed612_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4MA_466cec83-963f-4b74-b010-f7a16d9ef195">P1Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTcwL2ZyYWc6N2YwM2EzMDVhMWNlNGQ2YThlNDI0ZGQ4MTY0YmRlNzMvdGV4dHJlZ2lvbjo3ZjAzYTMwNWExY2U0ZDZhOGU0MjRkZDgxNjRiZGU3M18xNjQ5MjY3NDQxNjcwNg_1fce3220-dff5-4c7f-b770-945e4708f9df">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mygn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011796a61d54499b94960d86773ccedd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id7e46e716764498e9302a87cd85a5607_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iaceaf21b23b24746aa59d14b069c4f07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb206a81fa074a46aa6939c9e5bcf636_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3490fe6c43d44fcb68f2c3625bd038a_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ca914745a941f2966e50ba77e955a7_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e7b1ebad7642a0add5c645bc552fee_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18300b74b3df4d46b493a707d825fa4a_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia567c09cf0824dc693153bb83c1fd300_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b54a1e9583a4c6e990c5bbb9c0a73f8_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1599623c9f04291a999dead8f1a5395_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59def4575be14308a65eb8292ac6d700_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d812645f92f414592b573945dc3f6b1_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186bb32cbaf64bd6b7957d74964ad3b8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f04a427cbe430a863042cf46917020_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83e7c3186b049569961b26ad3e07b35_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d0772a72c84c40ad62e094c4956f82_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c1ff8d939f49a5bc5fda3040bcf994_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727bfef5fdaf4a68b74905d96ed0bd75_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0952f21f7474270a815f3514f44ab52_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c18b43bb290475583b6c04c962cc4f5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67c1f04497634a03acfacae132470000_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3255cc95fb79446f82e34f0ba20d9dcb_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c16edcf998c4da5b8b0515c6fd6a34e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9a7dea4d3a492eab5b13130045cf86_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f010022d8844beba34499bcd02fcfa_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f56df5636b24717996902df4b351edb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b042f9bbfff4fd7b823711711b5022a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8e819d3e2be4e7589e9091e181dd161_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ecb918ca8845c18dd2d6175330f6df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81acdb427fb040d1b79807f720522dcf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406964000440469a8b2a3301d473abfa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4402fe2fdb042e993c87738c61d4381_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide1a7957d8ba47e8b3c57b590a8f1c6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5861584aeaf34ebd8b71efbbb80709c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5633da0a55ce4fbfbc6f2f94c0888afd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7070eac7a949dcbb79b9e02a3aacf2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0e54e9b3ce4a3a9110635bf28d65bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iad15d513ac03478199e9e31a63c2e46d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i701057b14190407c804d2064afc26532_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa5bdf689894b6ab2ba9eb4389ee963_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55202b0f51cd439d9b1c5849f46eaeca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25baf947458498cbc5ec1d41a505594_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f8cb8dfa0542e0b8ad06c716ac9a06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0b6b5784d44e638df0d82d2332ca5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i804cc2b055a3466fbb3e15bd020c759d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fd5561929d497eaf7992c43061cee2_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484dc209f37b4adf909bfa0878315aac_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd1e4144cb64cc2be192b5f21702ee2_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23674b92559340f5b730b6afcc5f3e1f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44258853a0d44e2b9701f666527520b1_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14004bb5c3043ef94f2f37784092276_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868860485c4b4abeb0e46251d83d47df_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c94826adb64c97800cb3e9f2f19447_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56d8f8d202742b8adbccfc987f7d6aa_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15aec7363f947d18a16d8514fa80f9a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab9b81676e64707a024e71a8dadfab0_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f918798d8d4876955bdfe1781192bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0720541a493427c9ac9e47764246d06_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2d8ee96d1842a89bf2eb52509f39c8_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090f85aa323b4d5aa89a4ef95bbff252_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f3a2eee80d4e39b6b467a461ee1164_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79122a39eed648d294ae1358b2622bf2_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8608277b4c9f4d1d8452c383fd7509c3_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150c0623a2d04f00b701fe362396760e_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i288dd68612f8451489b037c3444d9bf4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2397e1764fa64b159eaa4444a72537d4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dddabbe8f644f90b6c63a2383f8793c_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129a1c23ee0f4732a50e53e3e8927e0f_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0298c605b2cc48e9a78c5e3cd557802a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cca08c16e854e23a8787d0bc760adbc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3970c7875cbc464db2a7a85cb7ba05be_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9608c73ed34af285fe6c4c9fb6f968_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ef79d3516c4f77b9ffd69e6257d787_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c78ab7c6f04b4cb49ccbc3b2572957_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac2a8aac44f4c039ce9c9739247a018_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74f7d15a9df4096b33799ed18b6d983_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04f84748937427db317a660c8aa5694_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8de44f5f1c410599b481b8c80dbffb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445a32ad37ae4a4cbcbea691e2e68241_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d75f83f7f84447a1524a301b921946_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdaec0b909474eda8eee58534fbd0e9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04da1cbfee0c46dcbaec497c3feb4cb6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf55993a60224a2990dd01e9cff341d4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706f35d8790f490f917a84f064c29039_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6b105e8804486dad3802a06c5f3c30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e31518757a047b4b8acd5c9c6584b2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a6d32ed385415289c8a82922c2e387_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1202a0ed3b3942fc98fdc69ccb249509_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5801c36efd234e02b91dbea98f7d3e00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ef34040e2948f2abbaab8f194748d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d2040b564247bfb340b997780ebec6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60635ff66fa64b69966774de4439af5e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33fb7f026e344cc98c08acf5ec62babe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a23258ea8e458393c125d83313b4a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1fa64c828d4462a20186e9d1460d97_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba16b7c64ec499aa4e9285f47ed97e8_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f89783405a449ba8e650af0370be7b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903acccd51c14e7db28f40da3937c802_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6524bb7e0441428b64b01d2565544d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d422ad60e04435ba4213ff4258db4ea_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf717ff001aa48f3898b6bad81b7074e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b308819639648ebb0241dce3fee0e0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4ddb7736b546099130bd23f3e3bf81_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6371c107dc4037900af9562f284dd2_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a25d7789ed04de38b87467b38c075c0_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0371d7615c143a1a2f93c9c51117fd2_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc48edd4cd4e4d54b269125a5eddbe4d_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b993db4c69b427d8483546c0c8b8414_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d121e6f796d42b5862758d3e57021f4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b0e5857240418899f53180ceb70c6d_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2729ff5f4d4076a392c72d3aff48fc_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40ae86ad5c541fcaf7e88efb9f20b4e_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702d3c75cf5c4f2fb78e549b2d2e07b0_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e9d08b5b5b4218a39576afaba6ff6d_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie936759bad6c4f768bfdcaad6c185260_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86ab20ba60c457c91783c694e76c402_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7934e0625841d3a44b1f9aecb81682_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0036422f15ae438fb80d6285f3b97550_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2b20aa35ae4a3ea1712a93847ca7b2_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb8491e37cb24bc3b4dc9fb8f3c5e60f_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d596e3878504d22b86d326e8ca08613_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97117ebb3cae4051af1ac90be6bb19c0_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102893003cb44b69875935664fcd4cfe_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4ca98d253f439984d89ffe162f4048_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib644def5081d44de96b13a4ec090e55d_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa7d7f8f59743e19ec25ad143e2a6f4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5819703f324d41349027f3813ef7b49b_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc1fef06d7444e6bd2ce7b0f247ad53_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204cd1955cec41cf9852a26d4402e885_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e5e361d21d4734af2a1a30525f5d04_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58b31ce77e7445aae0d209f9e0fbc19_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e64446e4bae4f2ebd45cae070670f11_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6faa7a7476b140628d02a78558ca348b_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b4f16f2653401187ed5044b51e074f_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c85822b51b4d35985a06435eee8bfa_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0903d5f700b14c0f82cced2c6973459a_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3faafc5dbad46dba5234c91f2b7c8d2_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea93dfc8c9b4d418d726e1503143b00_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433ffee4dc83441d8a68d42763e78e7d_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia021741aa8d343d79f2d259b408c46a0_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief14d1a627f44e8aa55a13b03bf21cfd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2684048ee70b4d07beca518b514fbc45_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e458e0265a748528393f9775e33c560_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ba6d883e7547e7af3798c78f6badf4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15cb1bb25065402192f586c58c6ea68d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1095829af9974d7ab288fb2d7ac09c8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a3b6101149c43809996e3a4fa47cce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1643807ee3c4be2affc28b493b9971d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40284936a2134287b22a5d55f29d89c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb01a0871980449b8e481ac37f3f1f9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3445c0b98e214b96840337b96fa87ab1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74dc0fe0c62e4eea8fd54a19e76b42e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50744aeaad04d8e898fb75a7a4cd403_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377b3cbb17e643b7a874393768f6b99a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>mygn:security</xbrli:measure></xbrli:unit><xbrli:context id="i247f388a3aa24cea9da562bc5232fa78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c7a2cd0dae41d7a18fabc16b2d6351_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifacab91f64734e07850b1d1ccdcef519_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d33dac4dba4cc4a2b1b2e4b46390a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieea675210e024b6c916b2862b628898c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ea39f951fe43d7bd7edbf117b03d28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649ff7da9f344b3594372e0db1334cf1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9950e80ecb934b8aad3038826649ece1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6caf215e4694c5297b327ebab5489f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d609efbd994ab6a4717ae77454f9c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ea51262455422b9b58287df633fdba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfc35c6df6dd437cba1f343922b27753_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1173e0a575429c87230088f831bd1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d46cebc1ad34bfd93e108133ea4a5a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c2ac1ffa79241d7ae0a435a564bec54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6aef68764004a7ab2c3d1cafa4e6070_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22dbec5ca02d419cb74d488ed87eaf6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ca8c5b9c4f42a7b049cd5568304428_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48a6e30e15d44c27a12c044d297fe0ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1bafe663bf4dd2af911643d8115191_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i330057192ddd491eb64b21392abce0f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i155d082ec2ff4209a45f170e667ea25c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a3f606f6ce45719deb8e96cd7ddf12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34fd0ce23d9465eafda8ac8e370a4d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f303592870940ab8b8f59b374e18736_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d9ee368f974e858e239cc4f7cc09d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1e01d25b7bf4a20a4ae7b3bc411229b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068bcc7826fd40a29f15703667578d91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295380b6567e4eb1b4eeb49fa5fe93d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43572fc1976464398da328af82d7f20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5a59ec1d4d4de1ba8ba076c80e3226_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3c7d94999a4ee5a93ec6842932756b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95aadf27c0ee42a2b79894a26f7a6303_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4a40cfd6c04ce599bbc8e4a83deadc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4f8a6107a54f86952fd151b5a13c08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id43790812a0c4238a84dddd512d335ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3fc1feaa3146ef881ca19357b23ae2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6b9a6da1e624a6299e316b70d8feaac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d3ae940d944d56b1fa894aaf7ce150_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4b8c164b3e1486ebec72f7e98f21e80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e83b77ce534f3b9bd0073625848436_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f0556ba0524239b520e549288db90f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c0e0850ab04139a8cc19022cb08ee3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae2473b59214583a165b28061b320ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c0dba4e084466d8bddadc615f6025a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b398db0d1554733a657d72060893c6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d6ed83b23f459e9db3a9380f2701a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c5626096e543389cd9c3f775245cfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803545905c564efc93735544226e6480_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ab8cfb4e2c4f0d807f2b535c421e2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12da925d57d847f29779b2a54f0c1d8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76caa3c0609e438280d6a0504611599f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ec5554c31b4ce8828d34f1b36e247a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:MyriadAutoimmuneReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c34d03cc5d4ce3adff6edc114a7d3d_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:ClinicReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2300757198c24415b7c3c129a5f3fabf_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba866a3cd6cf4800bbcea6f210f6455a_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3b8d69d56b45199b92513424091532_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i275498a5a52849dea83b241134bb7e51_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1425b0bad34a70afc41eb45c93a582_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic75f471c9cdf49ab96d540192ad0b502_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9f2d157d1e4cadaae10cf7ad53658e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d57af1e55643e69c2cef6564b8c029_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c3ca18e45c49898939a280f53e8a87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib683c703779c41d19954bb1ac378479f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a4983803bd4497b2c5b4c486bbbbe6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefacdace64394337b4ef1aba897012f9_D20180731-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-31</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica35c1f0cab448d081723c1fef35a424_I20161223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168fbf7f34f14b48b159064776b4fdfc_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54fc9148f3ce4861a7ad8db525b9a0a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id223da0fe55a40c58f22c4b23b424f4d_I20210221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961cf7e1f4884ffdace1af14ca9070a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82d39802808f4ef89f2381762fc4eb35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a989512a05b4160b8ec803a03de9836_D20200401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333e25208a214f52b7d6bdff1719f67a_D20200401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5178ceac7d4f5fbc4391a28c678d89_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3265f06cbffc47d085ee813629587542_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f99bcdbffc6436f919414c49880ae46_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc6b324d8d7d49119edb7e86615e72bb_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915c2ce66e394e6ebfd548241511f5c7_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id54bd12e649d48069a7463458d653da6_I20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5017805749294720bfc1102605257804_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3842c62c98f4eff8442478a102c1f76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id019278a4e69463fa389582d302cd096_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67b2cb2c62d457c8bfa89045a0ac26f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0941bbd4ec3549fe8c0210b756b9c68d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:ExecutiveOfficersAndSeniorPositionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0493562cfc8d469d90ebecc52d7cf045_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:ExecutiveOfficersAndSeniorPositionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0aea44508ff4dfbb5ee1282d27b02b2_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee48b219c6314207b2b8c51e655bad7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic585d4b282fa403da809d437637d7786_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aaf305cdc4c4b3783ad7772ad83b376_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b47a20179364be1a601e6386dcdc7c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edc8741087a458da983569f09876507_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i561d9e41bc564e37b2cdadb9540775cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3c3decbc9b4749a615c444461f2714_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14d08a6c91d4a4d9a5f3397abc5c101_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17009626ef9e40fea086f24d4e4d938e_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c1d65d2fea4fb897497c39c3c543bb_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55a0576781b4fe09cd0002c1cf57591_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d4e8c980d4d749c48652760c59dcb_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3271f5fd8d4f9cae87d273d0119cf6_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d82b14159db4173bec06da40fa3fba0_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e5585fea71439f950bf077fd864a6b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a7c61994bb46c687fdf99107cfd671_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c6f499764943a9b6668276c03a7dca_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd00bad76d24a0ba7fbe37165e9ea1e_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932fedfaff694d47a9c810a8ed5c652a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36668e3bf1614b139d53bd0dd4a1737f_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220876603bc44dc4b5d5cba857b18a98_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0fbec0d2524cbfb381bcf39f515a31_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14606df79fcb41208a7deba7ab883c8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id273969844de4a42b563bdd13fe471ee_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b5430845bd4bf0bdf1c90acbf50400_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df27cee9a9e44d4b90685ca4d691bfe_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8feb4bec474149ac84ceec0cbaaa45af_I20121205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57656916c4ad4a29bc0dda34d93091b5_D20210923-20210923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-23</xbrli:startDate><xbrli:endDate>2021-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2deacdf28047ffa7f76605879c01a3_D20211205-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="divestiture"><xbrli:measure>mygn:divestiture</xbrli:measure></xbrli:unit><xbrli:context id="i83383bd4b0654a95842e069decbe0d94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d865748020e4effaae21a66a663077b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfa542a04ef4e41ac83b425d14fdea0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ceba9140e2414aa168f8323513eb92_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb7a3dbd0394b3a98b2fa3967024ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9589f80194a941a98f9394776dc93210_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e65e9f289e470e8192dacb960d4a43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5670d0442144a9827fb94b02527d5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief421c0a8d774da3a0d3e029188f8bb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia343da359530413f9f43cba7387074bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3acf17d910cc465bb94c96ceb1075337_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78965414e66747c19486ba7a6e74f9c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfce3d729fbe4d2982bbceb25a61b887_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203e33449c4d47478858a4e96feba476_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b129110cdcf40da82c792a626cb5140_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc7f4bae0a24544870e68c5081d1eae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice0285b61cc74e72912725920fceec85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de9b7a4b6ea43ce99df84afe005c51f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1dd974f0a354b7e918ff359564e3487_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60e9618d910a43b3b0cf3e5ca1018738_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ff73e805544f00a995a79e7beabfd7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39aada1c97204d7ba76be4c96523dd65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9d97eb20794fe5ad342b5b3244164a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a2fec96267b42df8bdcd32ac76c5bfc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f5587e0ffc403b998eeeaf70866baa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7bfc4c89d34726b342ff9738bb6c21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e54383ae03647b4bdc0042c788b7d92_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d1f694a2b246dd97539cfbc90fdaa5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c32f4affc04ac8ad57b0fb12effb75_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e766bbdac2412db386420a0fd67410_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ac628246aa47a9856eff8943bb53da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ab306877b54340b9ceca58fc63cf74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40459a0ffb804202863c2399057f5faa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed6f2b7a99e46259c13006a1c7fb525_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3720a9cb33664b36ac16fd27520f3445_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65ea439046741879c10f71b82d8c8af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb51262d87a469e9b16924d435ec74e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a7872b3c3e43d1a1a6e18f0a9a61eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:CrescendoBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b60c3a470b443f8bbf026504b9c59d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:AbelliAndPricoloMatterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971ef08a521a4060839a354e9f1482db_D20220124-20220124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:AbelliAndPricoloMatterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-24</xbrli:startDate><xbrli:endDate>2022-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c092841990477a992d7f353b1ed612_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403644c63d2f42ce9be417d4645c4d3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1bf33b7a68483c99cef4bfc39ec4d0_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:OperatingLeaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i50f6939f15de4b44bc5d205c498f9bb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i730cf00f21e24233aa2438bc079c00fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1693400cad7b453cbf24b4b49eaaf843_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035d000528f94d29bec8473ab8e23f80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ae176a47c5401292f15f20d1f2b493_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a3f1dfa4a24709971fbcfbce8f1bdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mygn:segment</xbrli:measure></xbrli:unit><xbrli:context id="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-13</xbrli:startDate><xbrli:endDate>2021-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860c89a3309f4862aa45108d2d164008_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4881a7b97e68483588b542d1107dfc7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93081e2cf534cd9ae7518a1f0407820_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd8184e7f9d64fdfa830a7580e392ea8_D20180731-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:CounsylIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-31</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6757f736730d439fb934901528230b15_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:CounsylIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff236b6484f74a869a405f4676bd6810_D20180701-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:CounsylIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83408ec29ac462bb67762046411429e_D20220101-20220224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:SaltLakeCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27de6b0d5d5e480a85e618df1ee1b0e1_I20220224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:SaltLakeCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaeba814f5004cb58a2f97d102345f21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9293cf2bcc0f4d2a920e6ccd2d4f11d1_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5947d8d1f246f8b9440687d0122811_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123f7f47f2d641448a50320ff8fc12b3_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifead9d28cda549c1af769d1d50d95807_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ5_5b9db3f8-284e-481c-8bdd-213d43cf7c12">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6NTNlNDI5NGRhMTM5NDAzNDg3M2QyOTkyYTcwNzE1ZDgvdGFibGVyYW5nZTo1M2U0Mjk0ZGExMzk0MDM0ODczZDI5OTJhNzA3MTVkOF8wLTAtMS0xLTM2MzU5_2e7ef74c-c0b8-4d08-befd-e016cfb001a0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18xNjQ5MjY3NDQ1NjAw_04ec8150-f409-4c73-a5a0-ae7019a0b7d7"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18xNjQ5MjY3NDQ1NjAw_75899769-2424-4e1d-b26e-519059d77f05">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6NTk5ODdkZWRkNDUwNGE4NTljNDQ1MDliYmI0NzA1ZTEvdGFibGVyYW5nZTo1OTk4N2RlZGQ0NTA0YTg1OWM0NDUwOWJiYjQ3MDVlMV8wLTAtMS0xLTM2MzU5_07b75915-9f4d-4bc8-9e7b-a96cc36818f1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODUx_741fc5f4-f7ed-4855-bf4c-ab18102415df">0-26642</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODMx_453bb259-2012-4d5a-9526-a5983b3f2cc3">MYRIAD GENETICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ2_f6d75739-53e4-4168-8a8a-a7c230396c89">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of incorporation or organization)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQz_0047b0fb-d522-46e7-9427-66cc956d106c">320 Wakara Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODM3_5ac20428-7e11-456b-bdd3-1a41f1592a63">Salt Lake City</ix:nonNumeric>, <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODMy_839e0f8b-c79b-490c-bf64-7ad2bcecc886">UT</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODMz_09e992ce-5275-448c-ac75-021b7078e174">87-0494517</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODYw_f4704bfb-9b05-4434-b7c2-28ec6372c3dd">84108</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code: (<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODU0_dcaf83d3-b58b-4b92-81ca-ec3fbbee3bd5">801</ix:nonNumeric>) <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODM0_ea5db6aa-0dc6-4d20-98ad-496f26af696b">584-3600</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZDJlY2Q5NzIxMjA1NDIxOTlkNzkxNjgxMWFhNjJmYmIvdGFibGVyYW5nZTpkMmVjZDk3MjEyMDU0MjE5OWQ3OTE2ODExYWE2MmZiYl8xLTAtMS0xLTM2MzU5_96878073-8645-41a6-8d5c-b72b1c37f257">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZDJlY2Q5NzIxMjA1NDIxOTlkNzkxNjgxMWFhNjJmYmIvdGFibGVyYW5nZTpkMmVjZDk3MjEyMDU0MjE5OWQ3OTE2ODExYWE2MmZiYl8xLTItMS0xLTM2MzU5_099b39db-0f44-4496-b97e-5625c61081a4">MYGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZDJlY2Q5NzIxMjA1NDIxOTlkNzkxNjgxMWFhNjJmYmIvdGFibGVyYW5nZTpkMmVjZDk3MjEyMDU0MjE5OWQ3OTE2ODExYWE2MmZiYl8xLTQtMS0xLTM2MzU5_f7830835-c9ab-4655-844a-da6d053d6607">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODYx_e3e2e5c2-f25f-4832-90f4-46a77cb7d34c">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODYy_9ef408de-90aa-4695-b0aa-43827c5d936c">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ0_166c9694-8655-4479-971c-1222fb174569">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODU2_8e5433bb-ecc6-4eab-aefb-15bf03551591">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.731%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZWFlYzljNWNjZjdhNDZhMTg0NTRkMzNkYjZmNjI5NDQvdGFibGVyYW5nZTplYWVjOWM1Y2NmN2E0NmExODQ1NGQzM2RiNmY2Mjk0NF8wLTAtMS0xLTM2MzU5_1999bb30-58ea-4980-a930-42d05f1f251a">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZWFlYzljNWNjZjdhNDZhMTg0NTRkMzNkYjZmNjI5NDQvdGFibGVyYW5nZTplYWVjOWM1Y2NmN2E0NmExODQ1NGQzM2RiNmY2Mjk0NF8xLTQtMS0xLTM2MzU5_afde5b04-1153-4532-ba7a-d338d67375a7">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZWFlYzljNWNjZjdhNDZhMTg0NTRkMzNkYjZmNjI5NDQvdGFibGVyYW5nZTplYWVjOWM1Y2NmN2E0NmExODQ1NGQzM2RiNmY2Mjk0NF8yLTEtMS0xLTM2MzU5_fcff0440-cecc-40b8-ab17-d13a4ebf9f25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQw_bae9d7c8-bfb7-4496-9f42-48c63ae3280c">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ1_a274be14-3788-49e2-8c2c-4dbf05e075af">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate), computed by reference to the price at which the common stock was last sold on June 30</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="i011796a61d54499b94960d86773ccedd_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM180OTQ3ODAyMzI5MTkw_a6429c6e-a0bf-4136-83d9-dd0f01d7a1ef">2,376,886,737</ix:nonFraction>.&#160;&#160;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;18, 2022 the registrant had <ix:nonFraction unitRef="shares" contextRef="id7e46e716764498e9302a87cd85a5607_I20220218" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zMzg2_90b317bb-c150-4f62-914c-f4d9a506ee53">80,022,885</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODU3_6ed0da46-a9d2-4332-9418-0c39df84fd83" escape="true">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:&#160;&#160;Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December&#160;31, 2021, for the Annual Meeting of Stockholders to be held on June 2, 2022.</ix:nonNumeric></span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_13">PART I</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_19">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_22">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_25">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_28">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_31">51</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_34">PART II</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_37">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Reserved]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_40">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_43">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_64">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_64">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_67">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_67">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_154">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_154">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_154">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_157">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_157">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_157">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_160">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_160">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_160">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_1559">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_1559">104</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_163">PART III</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_166">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_166">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_166">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_169">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_169">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_169">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_172">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_172">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_172">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_175">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_175">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_175">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_178">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_178">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_178">105</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_181">PART IV</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_184">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_184">Exhibits</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_184"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_184"> Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_184">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_187">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_187">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_187">109</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_190">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifead9d28cda549c1af769d1d50d95807_190">110</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company&#8217;s future prospects and make informed investment decisions. This Annual Report on Form 10&#8209;K contains such &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Words such as &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seek,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;strategy&#8221; and &#8220;goal&#8221; and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management&#8217;s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to efficiently and flexibly manage our business amid uncertainties associated with COVID-19; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that sales and profit margins of our existing molecular diagnostic tests may decline or that we may not be able to operate our business on a profitable basis; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to changes in governmental or private insurers&#8217; coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to increased competition and the development of new competing tests and services; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may not successfully develop new markets for our molecular diagnostic tests, including our ability to successfully generate revenue outside the United States; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that licenses to the technology underlying our molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to delays or other problems with operating and constructing our laboratory testing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to public concern over genetic testing in general or our tests in particular;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license, acquire or develop; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our projections about the potential market opportunity for our current and future products; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of patent-infringement claims or challenges to the validity of our patents; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to changes in intellectual property laws covering our molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to security breaches, loss of data and other disruptions, including from cyberattacks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks of new, changing and competitive technologies and regulations in the United States and internationally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the material weaknesses related to our quarterly income tax provision process and general information technology controls, including the impact thereof and our remediation plan, and our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to current and future lawsuits, including product or professional liability claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other factors discussed under the heading &#8220;Risk Factors&#8221; contained in Item 1A of this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Annual Report or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements in this Annual Report attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Myriad&#8221; and the &#8220;Company&#8221; as used in this Annual Report on Form 10&#8209;K refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, ColarisAP, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, myChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are registered trademarks or trademarks of Myriad. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report on Form 10-K may appear without the &#174;, &#8482; or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_1583"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Market, Industry and Other Data</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K may contain estimates, projections and other information concerning our industry, our business and relevant molecular diagnostics markets, including data regarding the estimated size of relevant molecular diagnostic markets, patient populations, and the perceptions and preferences of patients and physicians regarding certain therapies, as well as data regarding market research and estimates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources that we believe to be reliable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ifead9d28cda549c1af769d1d50d95807_16"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Mission</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. We provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. We discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower health care costs. </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fiscal Year</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, we changed our fiscal year end from the last day of June to a calendar fiscal year. Our calendar fiscal year commenced on January 1, 2021 and ended on December 31, 2021. The six month period that commenced on July 1, 2020 and ended on December 31, 2020 was a transition period (the "transition period").  In this Annual Report, references to &#8220;fiscal year&#8221; refer to years ended June 30th or December 31st, as applicable. References in this report to the &#8220;transition period" refer to the six-month period ended December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the year ended December 31, 2021, we took meaningful steps to fulfill our mission and execute our strategic transformation and growth plan. Our announcements in 2021 included the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launched a new version of the MyRisk Hereditary Cancer Test with RiskScore, which allows, for the first time, women of all ancestries to receive a personalized polygenic breast cancer risk assessment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Entered into a collaboration with Illumina, Inc. ("Illumina") and Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services. The strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to improve precision oncology care.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed the sales of Myriad RBM, Inc., select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit, and the Myriad myPath, LLC laboratory.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced the hiring of several new Company leaders, including a new Chief Growth Officer, Diversity, Equity and Inclusion Leader, Chief Medical Officer, and Chief Legal Officer, as well as the new appointment of our Chief Marketing Officer, Chief Technology Officer, President of Myriad Oncology, President of Myriad Women's Health and Chief Operating Officer. In January 2022, we also announced the retirement of our Chief Scientific Officer.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Peer-reviewed journal Psychiatry Research published a new analysis showing that the combinatorial approach available in the GeneSight&#174; Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented new data at the American Society of Clinical Oncology Genitourinary Conference demonstrating that the Prolaris test can accurately predict which patients will benefit from multi-modality therapy. Using the newly established threshold, an estimated 27% of men with newly diagnosed high-risk disease and 73% with unfavorable intermediate-risk disease could avoid multi-modality therapy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Received the first reimbursement decision for MyChoice&#174; Diagnostic System in Japan, enabling women with ovarian cancer to benefit from treatment with the PARP inhibitor Zejula&#174; (niraparib). MyChoice is the only companion diagnostic test of its kind to be approved for reimbursement in Japan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Strategy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personalized genetic data, digital, and virtual consumer trends are converging to change traditional models of care. Significant growth opportunities exist to help patient populations with pressing health care needs through innovative solutions and services. We are currently executing a strategic transformation and growth plan that aims to capitalize on those trends by focusing on the following strategic priorities: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Innovation that improves clinical outcomes, ease of use, and access;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Enterprise capabilities to accelerate growth and scale to market opportunity; and  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Focus on execution and delivery of consistent results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with these strategic priorities, we are focusing our efforts in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In each of these areas, we intend to develop and enhance best-in-class products to support growth, improve patient and provider experience, and reach more patients of all backgrounds. By investing in tech-enabled commercial tools, we believe we will be able to drive increased engagement, improve revenue cycle management, and reduce complexity and cost. We are committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability. With a foundation of financial, commercial, operational and technological strength, we expect to accelerate growth as we launch a new enterprise commercial model, launch a unified ordering portal, invest in new sequencing technologies, further develop direct-to-consumer channels, and build commercial capabilities to support new products and offerings.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Molecular Diagnostic Testing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our molecular diagnostic tests are designed to analyze genes and their expression levels to assess an individual&#8217;s risk for developing disease, determine a patient&#8217;s likelihood of responding to a particular drug, or assess a patient&#8217;s risk of disease progression.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs and treatments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Women's Health:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Serves women of all ancestries, assesses risk of cancer, and offers prenatal testing solutions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mental Health:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Genetic testing to help physicians understand how genetic alterations impact patient response to anti-depressants and other drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tests are included in the respective key areas outlined above:</span></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Oncology </span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Women's Health </span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Mental Health </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyRisk</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyRisk</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GeneSight</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precise Tumor</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prequel</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyChoice CDx</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foresight</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRACAnalysis CDx</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EndoPredict</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolaris</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descriptions of our tests are as follows: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MyRisk&#8482; Hereditary Cancer Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA sequencing test for assessing the risks for hereditary cancers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MyRisk test is designed to determine a patient&#8217;s hereditary cancer risk for breast, ovarian, colorectal, endometrial, melanoma, pancreatic, prostate, and gastric cancers. The test analyzes 35 separate genes to look for deleterious mutations that put a patient at a substantially higher risk than the general population for developing one or more of these cancers. All 35 genes in the panel are well documented in clinical literature for the role they play in hereditary cancer and have been shown to have actionable clinical interventions for the patient to facilitate earlier cancer detection, lower disease risk or reduce risk of cancer recurrence. The MyRisk Genetic Test Result and MyRisk Management Tool</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> summarize medical society guidelines for managing a patient with a genetic mutation in view of their personal and family history of cancer. MyRisk also includes RiskScore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for all ancestries. RiskScore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> incorporates the patient&#8217;s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers and provides a personalized five-year and lifetime risk of developing breast cancer&#8212;regardless of ancestry.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRACAnalysis CDx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Germline Companion Diagnostic Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA sequencing test to help determine the most beneficial therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of the test are used as an aid to identify patents who are eligible for treatment with U.S. Food and Drug Administration (FDA) approved poly-ADP ribose polymerase (PARP) inhibitors. This is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genes using genomic DNA obtained from whole blood specimens collected in ethylenediaminetetraacetic acid (EDTA).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CDx Companion Diagnostic Test: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the most comprehensive tumor test that determines homologous recombination deficiency (HRD) status in patients with ovarian cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This FDA-approved test helps provide information on the magnitude of benefit for PARP inhibitor therapy. HRD status is determined using two independent methods: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> status that encompasses sequence variants and large rearrangements, and Genomic Instability Status (GIS) encompassing loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions across the entire genome. The combination of these methods is a more comprehensive way to measure HRD status, versus either one alone.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prolaris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Prostate Cancer Prognostic Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RNA expression tumor analysis for assessing the aggressiveness of prostate cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Prolaris test is a gene expression assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that may warrant aggressive intervention such as a radical prostatectomy or radiation therapy. The Prolaris test was developed to improve physicians&#8217; ability to predict disease outcome and thereby to optimize patient treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EndoPredict</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Breast Cancer Prognostic Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RNA expression test for assessing the aggressiveness of breast cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The EndoPredict test is a next-generation RNA expression test used to determine which women with breast cancer may benefit from chemotherapy. EndoPredict predicts the likelihood of metastases to help guide treatment decisions for chemotherapy and extended endocrine therapy. EndoPredict has been shown to accurately predict risk of distant recurrence in Her 2-, ER+, node negative and node positive breast cancer patients with no confusing intermediate results in 13 published clinical studies with more than 2,200 patients and is Conformit&#232; Europ&#235;enne ("CE") marked, which signifies European certification for clinical use.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precise&#8482; Tumor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a comprehensive solution for advanced precision oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Precise&#8482; Oncology Solutions, which we expect to launch in the first quarter of 2022, combines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our leading germline hereditary cancer test (MyRisk/BRACAnalysis CDx), our HRD companion diagnostic test (MyChoice CDx), and a comprehensive genetic tumor panel powered by Intermountain Precision Genomics, a service of Intermountain Healthcare. Precise Oncology Solutions will help providers determine a clear, integrated and personalized treatment plan for patients with cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prequel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Prenatal Screen:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a non-invasive prenatal screening (NIPS) test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The screening test uses whole genome sequencing to assess for trisomies and monosomies in all 23 chromosomal pairs including the sex chromosomes, along with microdeletions associated with common genetic diseases. Prequel has a low test failure rate at less than 1 in 1,000 patients and has been validated in multiple clinical studies to be highly accurate. Prequel uses AMPLIFY&#8482; technology that raises NIPS test performance most significantly for the types of patients who have traditionally had test failures on standard NIPS tests due to certain clinical factors.  AMPLIFY is the only NIPS technology that substantially reduces low fetal fraction test failures in order to allow for equity in care across all patients, regardless of body mass index (BMI), race, or ethnicity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foresight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrier Screen:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The test screens for carrier status of up to 175 serious and clinically actionable conditions in parents. The test has been shown to have a detection rate of 99% across all ethnicities. Studies have shown that with prior knowledge of recessive genetic conditions, 76% of patients took preventive actions such as in-vitro fertilization with pre-implantation genetic testing to reduce the risk of having an affected offspring.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GeneSight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Psychotropic Mental Health Medication Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD and other mental health conditions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneSight&#174; test provides  healthcare professionals with information about which medications may require dose adjustments, may be less likely to work for a patient, or may have an increased risk of side effects based on a patient's genetic makeup. Genesight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> covers 61 medications commonly prescribed for depression, anxiety, ADHD, and psychiatric conditions. Because genes influence the way a person&#8217;s body responds to specific medications, the medications may work differently for each person. Using DNA gathered with a simple cheek swab, the GeneSight test analyzes a patient&#8217;s genes and provides individualized information to help healthcare providers select medications that better match the patient&#8217;s genetic variations. Multiple clinical studies have shown that when clinicians used the GeneSight test to help guide treatment decisions, patients were more likely to respond to treatment compared to standard of care.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sales and Marketing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our tests through our own direct sales force and marketing efforts in the United States, France, Germany and Japan, and service additional global accounts through indirect sales channels. Our United States sales force is comprised of approximately 500 individuals across our dedicated sales channels. Our inside sales team focuses on a broader base of leads, freeing up the field sales team to target high potential, high revenue clinical leads. We continue to optimize our sales and marketing channels through increased digital marketing, direct to patient marketing, enhanced virtual sales tools, and inside sales teams to drive efficiency in our sales model. As we elevate our existing products to their full potential and further differentiate our products, we intend to increase awareness and access while we reinforce clinical utility data, and maximize cross-selling and synergies across the enterprise. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our molecular diagnostic products stem from expert and innovative investigation into the biological underpinnings of serious human disease. We plan to continue to use our proprietary DNA sequencing and RNA expression technologies, including our supporting bioinformatics and robotic technologies, in an effort to efficiently discover and validate important biomarkers. We embed these biomarkers along with relevant clinical information in complex, proprietary tests that are highly accurate and informative and intended to help physicians better manage their patients&#8217; health care. We believe that our technologies provide us with a significant competitive advantage and the potential for numerous product opportunities. For the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019, we incurred research and development expense of $81.9 million, $35.8 million, $77.2 million and $85.9 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry and Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients, healthcare providers, payors and health systems are looking to apply the power of genetic insights, molecular diagnostics and precision medicine to achieve improved clinical outcomes and lower cost. Key industry trends include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerating shifts in consumer engagement, early detection, home-based care models, the rise of low-cost sequencing, telemedicine and virtual care; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in the way outpatient care is delivered in the midst of the COVID-19 pandemic, coupled with broadened awareness of the vital role of diagnostic testing; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding access to genetic insights, particularly among underserved populations with increased focus on health equity, reducing disparities in health care outcomes and ensuring increased access for challenged communities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader, more innovative use of large data sets and analytics; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">growth in personalized medicine </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the interest in new partnership models to advance companion diagnostics and serve patients with specific treatments based on their own genetic makeup and biology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These market trends create new opportunities to position Myriad for growth and commercial success through enhanced customer service levels and a stronger alignment of our value proposition with physicians and payors. Our focus is on innovative science that improves health outcomes, access for all, and ease of experience in the genetic testing process. We expect to use our ability to innovate not only in research, development and technology, but also in go-to-market approaches, commercial capabilities, and tech-enabled applications so that we can adapt quickly to customer preferences and market dynamics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In oncology, we offer genetic testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. Our competitors in the oncology market include Invitae Corporation, Ambry Genetics Corporation, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Exact Sciences Corporation, Foundation Medicine, Inc. and other commercial and academic laboratories.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the key opportunities to grow our business are our expansion of companion diagnostics, market expansion through new clinical guidelines, and providing new offerings. In the first quarter of 2022, we plan to launch Precise Tumor, part of a differentiated, comprehensive solution for advanced precision oncology, in partnership with Intermountain Precision Genomics and Illumina. In mid-2021, we launched our MyRisk Hereditary Cancer Test enhanced with RiskScore for all ancestries, creating the first and only hereditary cancer test that incorporates genetic markers for patients without a high-risk gene mutation. In early 2021, we partnered with Illumina to offer a MyChoice CDx kit as part of their Trusight oncology offering. This kit will be marketed to international markets and we expect it will increase global access to our MyChoice CDx solution. This partnership combines Illumina's expertise in next-generation sequencing with Myriad's proprietary MyChoice CDx assay technology to advance comprehensive genetic profiling of tumor samples and drive improved outcomes in oncology. These collaborations reflect our focus on partnering with high-caliber health care leaders to bring innovative solutions to the oncology market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently offer our FDA-approved BRACAnalysis CDx test as a companion diagnostic for the prediction of response to PARP inhibitors. Currently, we are the only laboratory with an FDA-approved germline test for this indication and have received approvals from the FDA in ovarian cancer, metastatic breast cancer, pancreatic cancer, and advanced prostate cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we received FDA approval for the MyChoice CDx&#174; test for use as a companion diagnostic by healthcare professionals to identify advanced ovarian cancer patients with positive homologous recombination deficiency status, who are eligible or may become eligible, for treatment with Lynparza (olaparib) in combination with bevacizumab. We recently received additional approvals from U.S., European, and Japanese regulatory agencies for the use of MyChoice CDx&#174; in predicting response to PARP-inhibitors in ovarian cancer. In addition, we plan to further expand MyChoice CDx&#174; for use as a companion diagnostic indicator for additional cancer types, including pancreatic, prostate, and breast cancer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Women&#8217;s Health </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the women&#8217;s health market, we serve women assessing their genetic predisposition to cancer, offer prenatal tests for the assessment of fetal chromosomal disorders, and screen prospective parents for recessive genetic conditions that can be passed on to their offspring. We compete with multiple companies including large national reference laboratories, specialty laboratories, academic/university laboratories, and kit-based products with our MyRisk, RiskScore, Foresight, and Prequel tests. Our competitors include Invitae Corporation, Natera, Inc., Ambry Genetics Corporation, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and Sema4 Holdings Corp. We compete mainly based on our test breadth and accuracy, commercial scale in the prenatal market, and the quality of our customer service and informatics tools.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We see opportunities to improve both our economics and the customer experience on these products. We remain focused on the reimbursement for carrier screening and finding streamlined patient payment models. As mentioned above, we recently launched our MyRisk Hereditary Cancer Test enhanced with RiskScore for all ancestries. This test provides a genetically informed breast cancer risk assessment as part of a comprehensive panel, with equity in care for all patients and expanded access to genetic insights for more ethnic groups. We are expanding new channels to interact with patients and for customers to have greater access to our products. We also plan to improve customer experience with a new online MyRisk portal to engage with patients and physicians, patient cost estimators across our product lines, and AI-based tools for interacting with patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The launch of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMPLIFY&#8482; technology in 2020 further increased the accuracy of the Prequel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test, enabling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more women to receive highly accurate test results </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of BMI, race, or ethnicity, permitting them to make more informed choices about whether to pursue diagnostic testing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moving forward we expect to further simplify and advance prenatal care with the launch of FirstGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482; for comprehensive prenatal screening.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FirstGene combines the power of our Prequel NIPS with our Foresight Carrier Screen and provides insight into fetal recessive status. This new test, which is expected to launch in 2023, is designed to streamline the testing process and simplify workflow with a single maternal blood draw while providing early insight on the fetus with improved sensitivity for all pregnancies, helping to reduce unnecessary amniocentesis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Mental Health </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In mental health, we help physicians understand how genetic alterations impact patient response to antidepressants and other drugs. Our GeneSight Mental Health Medication Test meets a significant unmet clinical need and is a leading product to help physicians anticipate patient response to psychotropic drugs, the selection of which has historically been done through trial and error based approaches. The test is clinically proven to improve response rates in patients. Our competitors in this market include Genomind, AltheaDx, Inc., and numerous other commercial and academic laboratories. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key opportunities to grow our business in this market include primary care expansion, commercial payor reimbursement, and telehealth partnerships. We are broadening access to GeneSight among front-line providers of mental health treatment, including primary care physicians and nurse practitioners who treat the majority of depression and anxiety patients, and through the expansion of sales and digital marketing capabilities. Moving forward we are exploring the extension of GeneSight in other potential areas including postpartum depression through our Women's Health channel. Separately, based on the market need, we are exploring new partnerships to develop tests for early detection and treatment of degenerative neurological conditions such as Alzheimer's disease and dementia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across the core specialties of our business &#8211; Women&#8217;s Health, Oncology, and Mental Health &#8211; we have numerous opportunities to elevate our products. We have a respected portfolio and internationally recognized scientific know-how. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced seasonality in our testing business. The quarter ended December 31st is generally strong as we typically experience an increase in volumes from patients who have met their annual insurance deductible. Conversely, in the quarter ended March 31st we typically experience a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. These seasonality patterns have generally continued during the COVID-19 pandemic, but due to the continued uncertainty surrounding the COVID-19 pandemic, we cannot predict if seasonality will follow the same pattern as in prior years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad's mission is to advance health and well-being for all, empower individuals with vital genetic insights and enable healthcare providers to better detect, treat and prevent disease. We believe the success of our mission depends, in part, on our ability to attract and retain qualified personnel. Our key human capital management objectives are to recruit, retain and motivate the exceptional people needed to carry out our mission. To support these objectives and help our employees balance their work and personal lives, we maintain a flexible work environment, competitive compensation and benefits programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we have approximately 2,400 full-time equivalent employees. Most of our employees are engaged directly in customer experience, research, technology, development, production, sales and marketing activities.&#160;Our employees are not covered by a collective bargaining agreement, and we consider our relations with our employees to be good.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity and Inclusion (DE&amp;I)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DE&amp;I objective is to make Myriad a place where all employees have a sense of belonging. To achieve this objective, we have adopted diversity, equity and inclusion goals into our human capital management strategy. Myriad has three employee-led resource groups (ERGs) that represent and support three diverse communities in our workforce: the Pride Alliance Group, the Black Employees at Myriad Group and the Women's Leadership Group. We plan to add more ERGs that serve other interest and cultural groups. These ERGs mentor, foster, encourage and inspire employees in all stages of their careers by providing access to senior leadership, peer groups, mentoring and other valuable resources to help them pursue their career ambitions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 61% of our employees are women and women hold 42% of leadership roles (vice president and above).  One third of the members of our Board of Directors are women, including the chairperson.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation, health, wellness, family resources, and other benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation program is designed to attract and reward talented individuals who possess the skills necessary to support our business objectives, assist in the achievement of our strategic goals and create long-term value for our stockholders. We provide competitive salaries, stock ownership opportunities, and enhanced incentive and bonus programs. We also provide an expansive benefit offering including medical, dental and vision health care coverage, insurance and disability coverage, 401(k) investment plans with Company matching, tax advantaged savings accounts, paid time off and leaves of absence, employee assistance programs, community outreach programs, training and development opportunities and wellness programs. We provide added work life balance to our employees through hybrid work arrangements. We also provide free mental health resources for employees and their dependents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Career Development and Training</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer several career development and training opportunities to our employees, including a curriculum of Company-sponsored technical, business and leadership courses, on-the-job training and a support network to all new employees, and tuition reimbursement for approved external training and educational pursuits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oversight and Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly conduct surveys to seek feedback from our employees on a variety of topics, including but not limited to, employee engagement, Company strengths and focus areas, and culture drivers. The results are reviewed by the Board of Directors, the Compensation and Human Capital Committee and senior leadership, who analyze areas of progress or deterioration and prioritize actions and activities in response to this feedback to drive meaningful improvements in employee engagement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Social Responsibility and Community</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Myriad, corporate responsibility plays an important role in our approach to discovering and delivering valuable and transformative diagnostic tests across major diseases to improve patients' lives. We believe that our corporate social responsibility programs build greater value for our patients, healthcare professionals and stockholders, support and improve the communities where we live and work, and empower our employees to become more engaged in the well-being of their own communities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporate social responsibility programs at Myriad align with a clearly defined set of strategic priorities including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Philanthropy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Myriad provides financial support to nonprofit organizations and shares the expertise of Myriad employees in the communities where we operate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Advocacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Myriad collaborates with and supports key patient advocacy and support organizations where we can make a positive difference in addressing complex health challenges, providing and improving the quality of life for patients.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Scholarship</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Myriad provides financial support for academic scholarship and education at both the undergraduate and post-graduate levels and contributes to advancing education and training for women and minorities in medicine and science.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Patient Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Myriad is working to improve overall health care quality and increase access to diagnostic testing for uninsured and underinsured populations by offering robust financial assistance and free testing to those in need.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Environmental</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: As described further below, Myriad has created a Green Team to foster environmental and sustainability stewardship. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental and Sustainability</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to do business in ways that protect both the health and safety of our employees and the world in which we operate by establishing, promoting, maintaining and improving a culture of sustainability and environmental responsibility. In order to achieve our objectives, we have increased our focus on environmental and sustainability efforts by adopting a Sustainability Strategy and Vision Statement that we are working towards fully implementing. The Nominating, Environmental, Social and Governance Committee of our Board of Directors is responsible for reviewing and evaluating our environmental, climate, safety, social and other corporate responsibility strategies, practices, and initiatives. We have also formed an internal Environmental, Social, and Governance (ESG) Committee, led by our President and Chief Executive Officer, and created a Green Team in an effort to reduce material waste, optimize energy and emissions usage, reduce water use, air pollution, and hazardous material use, perform community outreach, promote employee health and safety and manage other environmental projects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health and safety of our employees and have formed a health and safety committee. During the COVID-19 pandemic, we have aligned with CDC guidelines to help protect our employees. In addition to requiring all employees to wear masks and adhere to social distancing guidelines, we have also made an effort to track and mitigate internal exposure to COVID-19 when we learn of employee exposure or infection. Additionally, we offer COVID-19 test kits to employees who may have come in contact with someone exposed to COVID-19 as an additional benefit to our employees and to limit disruption to our business operations. We have also postponed all non-essential and international business travel and encouraged all employees to get vaccinated against COVID-19, maintaining a voluntary count of employees that have been vaccinated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have license rights to various issued patents and patent applications in the United States and foreign countries. These patents and patent applications relate to a variety of subject matter, including diagnostic biomarkers, gene expression signatures, assays, assay reagents, informatics and data analytics, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for determining disease treatment, and general molecular diagnostic techniques. For some of the patent assets, we hold rights through exclusive or non-exclusive license agreements. Material patent assets relating to our tests that generate material revenue are described in the table below. These issued patents are expected to begin expiring on the respective dates noted below and any related applications, if issued as patents and depending on term adjustments or terminal disclaimers, if applicable, are expected to have similar expiration timeframes. These patents and applications contain multiple claims including but not limited to those claims described below.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Test</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Patent Assets</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Expiration</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Claims</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Prolaris Prostate Cancer Prognostic Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to Prolaris&#174; testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These issued U.S. patents have terms expected to begin expiring in 2030.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for detecting, diagnosing, prognosing and selecting therapy for prostate cancer.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">EndoPredict Breast Cancer Prognostic Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S., Europe and other jurisdictions relating to EndoPredict&#174; testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2031.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for prognosing and selecting therapy for breast cancer.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">MyChoice CDx Companion Diagnostic Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to MyChoice&#174; CDx testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These issued patents have terms expected to expire in 2031.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for detecting homologous recombination deficiency and selecting therapy based on such detection.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">GeneSight Mental Health Medication Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to GeneSight&#174; testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2024.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for detecting single nucleotide polymorphisms and selecting and/or optimizing therapy based on such detection.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Foresight Carrier Screen</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions that relate to laboratory and informatic methods used to enhance Foresight&#174; testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2032.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Claims relating to systems and methods for detecting genetic sequences.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Prequel Prenatal Screen</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own or hold a license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions that relate to laboratory and informatic methods used to enhance Prequel&#8482; testing.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2032.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Claims relating to systems and methods for detecting genetic sequences.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek patent protection in the United States and major foreign jurisdictions for these and other inventions which we believe are patentable and where we believe our interests would be best served by seeking patent protection. However, any patents issued to us or our licensors may not afford meaningful protection for our products or technology or may be subsequently circumvented, invalidated or narrowed or found unenforceable. Any patent applications which we have filed, or will file, or to which we have licensed or will license rights may not issue, and patents that do issue may not contain commercially valuable claims. In addition, others may obtain patents having claims which cover aspects of our tests or processes which are necessary for or useful to the development, use or performance of our diagnostic products. Should any other group obtain patent protection with respect to our discoveries, our commercialization of our molecular diagnostic tests could be limited or prohibited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may offer clinical diagnostic genomic laboratory testing services which may infringe patents we control. We may seek to negotiate a license to use our patent rights or decide to seek enforcement of our patent rights through litigation. Patent litigation is expensive, the outcome is often uncertain and we may not be able to enforce our patent rights against others.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tests and processes may also conflict with patents which have been or may be granted to competitors, academic institutions or others. In addition, third parties could bring legal actions against us seeking to invalidate our owned or licensed patents, claiming damages, or seeking to enjoin clinical testing, development and marketing of our tests or processes. If any of these actions are successful, in addition to any potential liability for damages, we could lose patent coverage for our tests, be required to cease the infringing activity or obtain a license in order to continue to develop or market the relevant test or process. We may not prevail in any such action, and any license required under any such patent may not be made available on acceptable terms, if at all. Our failure to maintain patent protection for our tests and processes or to obtain a license to any technology that we may require to commercialize our tests and technologies could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technology, and in the future may determine in some cases that our interests would be better served by protecting certain technologies as trade secrets or through confidentiality agreements rather than patents or licenses. These include some of our genomic, proteomic, RNA expression, mutation analysis, robotic and bioinformatic technologies which may be used in discovering and characterizing new biomarkers and ultimately used in the development or analysis of molecular diagnostic tests. We also maintain a database of gene mutations and their status as either harmful or benign for some of our tests. To further protect our trade secrets and other proprietary information, we require that our employees and consultants enter into confidentiality and invention assignment agreements. However, those confidentiality and invention assignment agreements may not provide us with adequate protection. We may not be able to protect our rights to such unpatented proprietary technology and others may independently develop substantially equivalent technologies. If we are unable to obtain strong proprietary rights to our processes or tests, competitors may be able to market competing processes and tests.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements which give us the rights to use certain technologies in the research, development, testing processes, and commercialization of our molecular diagnostic tests.  These licenses generally end on the expiration of the last to expire patent rights covered by the applicable license agreement. We may not be able to continue to license these technologies on commercially reasonable terms, if at all.  In addition, each license may be terminated by the licensor in the event of an uncured breach by us of any material term of the applicable license agreement. Patents underlying our license agreements may not afford meaningful protection for our technology or tests or may be subsequently circumvented, invalidated or narrowed, or found unenforceable. Our failure to maintain rights to this technology could have a material adverse effect on our business. We have licenses with the following entities:</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Entity</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Subject</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Royalties</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exclusive world-wide license to certain rights of Mayo in intellectual property relating to our GeneSight testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We pay Mayo a royalty based on net sales of our GeneSight test.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2024.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">University of Texas M.D. Anderson Cancer Center (&#8220;UTMDACC&#8221;)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exclusive world-wide right to certain rights of UTMDACC in intellectual property relating to our MyChoice&#174; HRD testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We will pay UTMDACC a royalty based on net sales of our MyChoice&#174; HRD test.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2032.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Children&#8217;s Medical Center in Boston (&#8220;CMCC&#8221;)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exclusive world-wide right to certain rights of CMCC in intellectual property relating to our MyChoice&#174; HRD testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We expect to pay CMCC a royalty based on net sales of our MyChoice&#174; HRD test.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2032.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Institut Curie and INSERM (&#8220;INSERM&#8221;)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exclusive world-wide right to certain rights of INSERM in intellectual property relating to our MyChoice&#174; HRD testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We expect to pay INSERM a royalty based on net sales of our MyChoice&#174; HRD test.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2032.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Illumina, Inc.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-exclusive license to certain rights held by or licensed to Illumina to intellectual property relating to non-invasive prenatal screening and the Prequel test.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We pay Illumina a royalty based on the volume of Prequel testing administered by us.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">License runs for the term of the Illumina agreement and, in any event, expires upon expiration of the last to expire patent right covered by the Illumina agreement.</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are regulated by federal, state and foreign governmental authorities.  Failure to comply with the applicable laws and regulations can subject us to repayment of amounts previously paid to us, significant civil and criminal penalties, loss of licensure, certification, or accreditation, or exclusion from state and federal health care programs. The significant areas of regulation are summarized below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Laboratory Improvement Amendments of 1988 and State Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our clinical laboratories must hold certain federal, state and local licenses, certifications, and permits to conduct our business.  Laboratories in the United States that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention, or treatment of disease are subject to the Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;).  CLIA requires such laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely.  CLIA certification also is a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payors, for laboratory testing services. Our laboratories in Salt Lake City, Utah, Mason, Ohio, and South San Francisco, California are CLIA certified to perform high complexity tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, CLIA requires each of our certified laboratories to enroll in an approved proficiency testing program if performing testing in any category for which proficiency testing is required.  Each of our laboratories periodically tests specimens received from an outside proficiency testing organization and then submits the results back to that organization for evaluation.  If one of our laboratories fails to achieve a passing score on a proficiency test, then it may lose its right to perform testing.  Further, failure to comply with other proficiency testing regulations, such as the prohibition on referral of a proficiency testing specimen to another laboratory for analysis, can result in revocation of the laboratory&#8217;s CLIA certification.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections.  The biennial survey is conducted by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), a CMS agent (typically a state agency), or a CMS-approved accreditation organization.  Because our laboratories are accredited by the College of American Pathologists (&#8220;CAP&#8221;), which is a CMS-approved accreditation organization, they are typically subject to CAP inspections.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratories are licensed by the appropriate state agencies in the states in which they operate, if such licensure is required.  In addition, our laboratories hold state licenses or permits, as applicable, from various states, including, but not limited to, California, New York, Pennsylvania, Rhode Island and Maryland, to the extent that they accept specimens from one or more of these states, each of which requires out-of-state laboratories to obtain licensure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a laboratory is out of compliance with state laws or regulations governing licensed laboratories or with CLIA, penalties may include suspension, limitation or revocation of the license or CLIA certificate, assessment of financial penalties or fines, or imprisonment.  Loss of a laboratory&#8217;s CLIA certificate or state license may also result in the inability to receive payments from state and federal health care programs as well as private third party payors.  We believe that we are in material compliance with CLIA and all applicable licensing laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Food and Drug Administration</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, in vitro diagnostic (&#8220;IVD&#8221;) products are subject to regulation by the FDA as medical devices to the extent that they are intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease. They are subject to premarket review and post-market controls that will differ depending on how the FDA classifies a specific IVD, which is further defined in FDA&#8217;s implementing regulations as a device intended for use in the collection, preparation, and examination of specimens taken from the human body. For certain types of tests known as laboratory developed tests (&#8220;LDTs&#8221;)&#8212;which are in vitro diagnostic tests that are designed, manufactured and used within a single laboratory&#8212;FDA regulation is less clear than for IVDs. Historically FDA has exercised enforcement discretion for LDTs, which means that FDA generally has not enforced premarket review and other applicable FDA requirements. However, as LDTs have increased in complexity, the FDA has taken a risk-based approach to their regulation. Congress has also signaled interest in clarifying the regulatory landscape for LDTs. In 2020, the Verifying Accurate, Leading-edge IVCT Development (&#8220;VALID&#8221;) Act was introduced in both chambers of Congress, and it was reintroduced in revised form for the 117th Congress in July 2021. If enacted, clinical laboratories that develop and offer LDTs and traditional IVD medical device manufacturers would be subjected to the same regulatory oversight. The VALID Act defines both LDTs and IVDs as in vitro clinical tests (&#8220;IVCT&#8221;) and would establish a new regulatory framework separate and apart from the medical device framework under the Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) for the review and oversight of IVCTs. The proposed regulatory framework adopts various concepts from the FDCA, utilizing a risk-based approach that aims to ensure that all marketed IVCTs have a reasonable assurance of both analytical and clinical validity. The VALID Act would also create a new system for clinical laboratories and hospitals to submit their clinical tests electronically to the FDA for approval. This system is aimed at reducing the amount of time that it takes for the agency to approve such tests, and it establishes a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by the President.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro Diagnostics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information that must be submitted to the FDA in order to obtain clearance or approval to market a new IVD varies depending on how the device is classified by the FDA. Medical devices are classified into one of three classes on the basis of the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices are subject to general controls, including labeling, and adherence to the FDA&#8217;s quality system regulations, which are device-specific good manufacturing practices. Class II devices are subject to premarket notification, general controls and sometimes special controls, such as performance standards and post-market surveillance. Class III devices are subject to most of the previously identified requirements as well as to premarket approval. All Class I devices are exempt from premarket review, most Class II devices require 510(k) clearance, and all Class III devices must receive premarket approval before they can be sold in the United States. If a previously unclassified new medical device does not qualify for the 510(k) pathway because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. However, if such a device would be considered low or moderate risk, it may be eligible for the De Novo classification process. The De Novo classification process allows a device developer to request that the novel medical device be reclassified as either a Class I or Class II device, rather than having it regulated as a high-risk Class III device subject to the premarket approval requirements. The payment of a fee, typically adjusted annually, to the FDA is usually required when a 510(k) notification, premarket approval application, or De Novo classification request is submitted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">510(k) Premarket Notification and De Novo Classification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 510(k) notification requires the sponsor to demonstrate that an IVD is substantially equivalent to another marketed device, termed a &#8220;predicate device,&#8221; that is legally marketed in the United States and for which a premarket approval application (&#8220;PMA&#8221;) was not required. A device is substantially equivalent to a predicate device if it has the same intended use and technological characteristics as the predicate; or has the same intended use but different technological characteristics, where the information submitted to the FDA does not raise new questions of safety and effectiveness and demonstrates that the device is at least as safe and effective as the legally marketed device. Clinical trials are almost always required to support a PMA application and are sometimes required for a De Novo classification request or a 510(k) premarket notification.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that the applicant&#8217;s device is substantially equivalent to the identified predicate device(s), the agency will issue a 510(k) clearance letter that authorizes commercial marketing of the device for one or more specific indications for use. Requests for additional data, including clinical data, will increase the time necessary to review the notice. If the FDA believes that the IVD is not substantially equivalent to a predicate device, it will issue a &#8220;Not Substantially Equivalent&#8221; letter, stating that the new device may not be commercially distributed and designating the device as a Class III device, which will require the submission and approval of a PMA before the new device may be marketed. Alternatively, the applicant may be able to submit a De Novo classification request to have it regulated as a Class I or Class II device. In October 2021, the FDA issued a final rule to formally codify requirements for the procedures and criteria for product developers to follow when preparing a De Novo classification request; the new Do Novo regulations became effective on January 3, 2022. Among other things, if the manufacturer seeks reclassification into Class II, the classification request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the device. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative to the De Novo classification process, the manufacturer could also file a reclassification petition seeking to change the automatic Class III designation of a novel post-amendment device under Section 513(f)(3) of the FDCA. The FDA can also initiate reclassification of an existing device type on its own initiative. The FDA issued a final rule in December 2018 to clarify the administrative process through which the agency reclassifies a medical device. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a new medical device receives 510(k) clearance from the FDA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require the submission of a PMA. The FDA continues to reevaluate the 510(k) pathway and other medical device programs and has taken what it describes as a risk-based approach to develop innovative regulatory policy to propose a more &#8220;contemporary&#8221; approach to the life cycle oversight of medical devices and IVDs. We cannot predict what if any additional changes will occur or how they will affect our current or future products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premarket Approval</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PMA process is more complex, costly and time consuming than the 510(k) process. As with a De Novo classification request, a PMA application must be supported by more detailed and comprehensive scientific evidence, including clinical data, to demonstrate the safety and efficacy of the IVD for its intended purpose. If the device is determined to present a &#8220;significant risk,&#8221; the sponsor may not begin a clinical trial until it submits an investigational device exemption (&#8220;IDE&#8221;) to the FDA and obtains approval to begin the trial. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the PMA is submitted, the FDA has 45 days to make a threshold determination that the PMA is sufficiently complete to permit a substantive review. If the PMA is complete, the FDA will file the PMA. The FDA is subject to a performance goal review time for a PMA that is 180 days from the date of filing, although in practice this review time is longer. Questions from the FDA, requests for additional data including additional clinical data and referrals to advisory committees may delay the process considerably. The total process may take several years and there is no guarantee that the PMA will ever be approved. Even if approved, the FDA may limit the indications for which the device may be marketed. New PMA applications or PMA supplements may be required for modifications to the manufacturing process, labeling, device specifications, materials or design of a device that is approved through the PMA process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Companion Diagnostic Devices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a sponsor or the FDA believes that a diagnostic test is essential for the safe and effective use of a corresponding therapeutic product, the sponsor of the therapeutic product will typically work with a collaborator to develop an IVD companion diagnostic device. The FDA issued a final guidance document in 2014 entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Companion Diagnostic Devices&#8221; that is intended to assist companies developing in vitro companion diagnostic devices and companies developing therapeutic products that depend on the use of a specific in vitro companion diagnostic for the safe and effective use of the product. In the guidance, the FDA defined an IVD companion diagnostic device as a device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. The FDA also noted that in some cases, if evidence is sufficient to conclude that the IVD companion diagnostic device is appropriate for use with a class of therapeutic products, the intended use/indications for use should name the therapeutic class, rather than each specific product within the class. In April 2020, FDA published a final guidance entitled &#8220;Developing and Labeling In Vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeutic Products&#8221; that expands on the idea of a class of therapeutic products introduced in the 2014 guidance.  The more recent guidance describes considerations for the development and labeling of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products, when appropriate.  The FDA expects that the therapeutic sponsor will address the need for an approved or cleared IVD companion diagnostic device in its therapeutic product development plan and that, in most cases, the therapeutic product and its corresponding IVD companion diagnostic will be developed contemporaneously. To that end, the FDA issued draft guidance in July 2016 entitled &#8220;Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product&#8221; to serve as a practical guide to assist therapeutic product sponsors and IVD sponsors in developing a therapeutic product and an accompanying IVD companion diagnostic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has indicated that it will apply a risk-based approach to determine the regulatory pathway for IVD companion diagnostic devices, as it does with all medical devices. This means that the regulatory pathway will depend on the level of risk to patients, based on the intended use of the IVD companion diagnostic device and the controls necessary to provide a reasonable assurance of safety and effectiveness.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the companion diagnostic test will be used to make critical treatment decisions such as patient selection, treatment assignment, or treatment arm, it will likely be considered a significant risk device for which a clinical trial will be required. The sponsor of the IVD companion diagnostic device will be required to comply with the FDA&#8217;s IDE requirements that apply to clinical trials of significant risk devices. If the diagnostic test and the therapeutic drug are studied together to support their respective approvals, the clinical trial must meet both the IDE and investigational new drug application (IND) requirements. We expect that any IVD companion diagnostic device developed for use with drug products will utilize the PMA pathway and that a clinical trial performed under an IDE will have to be completed before the PMA may be submitted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing companion diagnostic tests for use with drug products in development by pharmaceutical companies, such as our collaborations with pharmaceutical companies on PARP inhibitors for the treatment of ovarian, breast and other cancers.  The FDA has also introduced the concept of a complementary diagnostic that it defines as a test that is not required but which provides significant information about the use of a drug.  A complementary test can help guide treatment strategy and identify which patients are likely to derive the greatest benefit from therapy, and if approved by the FDA information regarding the IVD will be included in the therapeutic product labeling. Although the FDA has not yet issued any written guidance regarding complementary diagnostics, it has already approved some complementary diagnostics, including a supplementary premarket approval for BRACAnalysis CDx and MyChoice CDx as complementary diagnostic tests in ovarian cancer patients associated with enhanced progression-free survival (PFS) when used with the PARP inhibitor Zejula&#8482; (niraparib).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we first obtained premarket approval for BRAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CDx, which is used as a companion diagnostic test to identify ovarian cancer patients who may benefit from AstraZeneca&#8217;s PARP inhibitor Lynparza&#8482; (olaparib). Since then, other indications for BRAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CDx in ovarian, breast, prostate and pancreatic cancer have received supplemental PMA approval as a companion diagnostic for Lynparza. The MyChoice CDx test has also received approvals as a companion diagnostic test. The premarket approval process is a complex, costly and time consuming procedure.  Approvals must be supported by valid scientific evidence, submitted as part of a PMA, which typically requires extensive data, including quality technical, preclinical, clinical and manufacturing data to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the companion diagnostic. We are currently collaborating with several bio-pharmaceutical companies for additional indications and geographical commercialization opportunities for BRACAnalysis CDx and MyChoice CDx as companion diagnostics with other drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ongoing Post-Market Regulatory Requirements in the United States</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products sold by us pursuant to FDA clearances or approvals will be subject to pervasive and continuing regulation by the FDA. In particular, after a medical device is placed on the market, applicable regulatory requirements include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FDA&#8217;s Quality System Regulation (QSR), which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling and advertising regulations, which prohibit the promotion of products for uncleared, or unapproved uses, or &#8220;off-label&#8221; uses, and impose other restrictions on labeling; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting obligations, which require that manufacturers investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, device manufacturers are required to register their establishments and list their devices with the FDA and are subject to periodic inspections by the FDA and certain state agencies. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA and other enforcement agencies, which may include sanctions, including but not limited to, warning letters; fines, injunctions and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or approval of PMAs of new devices; withdrawal of clearance or approval; and civil or criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rest of World Regulation of In Vitro Diagnostics and Companion Diagnostic Devices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products intended for use in in vitro diagnostic applications require regulatory approvals in many other countries and geographic areas, some of which also provide for approval of companion diagnostics. For example: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">European Union</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the European Union (&#8220;EU&#8221;), in vitro diagnostic medical devices have been regulated under the European Union Directive 98/79/EC (the &#8220;Directive&#8221;), since 2003, and all products and kits used for in vitro diagnostic applications must be compliant with the Directive.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IVDs have not been subject to pre-market authorization under the Directive, but instead they had to comply with essential requirements based on conformity with harmonized standards. The majority of IVDs have been self-certified by manufacturers which can place a CE mark on most products to show that they meet the conformity assessment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EU Member States must ensure that IVDs are only placed on the market if they conform to the requirements, and must ensure the free movement of such devices in the internal market. Member States will designate independent organizations, or Notified Bodies, that ensure that a conformity assessment is carried out for devices. These Notified Bodies may carry out inspections of certain manufacturers, and manufacturers must report any incident causing death to, or damaging the health of, a patient to the competent authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Directive will be replaced by the In Vitro Diagnostic Device Regulation (IVDR) European Union (EU) 2017/746 that was published in May 2017, and given a 5-year transition period until its implementation on May 27, 2022. Unlike the Directive that specifies certain results that must be achieved by each Member State and permits each Member State to decide how to transpose the Directive into national law, the IVDR has binding legal force throughout every Member State and it will become effective on a set date in all the Member States. The major goals of the IVDR are to standardize diagnostic procedures within the EU, increase reliability of diagnostic analysis and enhance patient safety. Under the IVDR, as enacted by the European Commission (EC), in vitro diagnostics will be subject to additional legal regulatory requirements after it comes into full effect.  Among other things, the IVDR introduces a new risk classification system and requirements for conformity assessments. Products already certified by a Notified Body may remain on the market until May 25, 2024 under some conditions including fulfillment of specific requirements in the IVDR, but ultimately most products will have to be approved.  Compliance with the IVDR may be expensive and time-consuming.  Manufacturers will need to provide more data to demonstrate that a device performs safely and effectively.  As noted above, the vast majority of IVDs under the Directive are self-certified, so many device manufacturers have not previously been subject to the Notified Body audits that will occur under the IVDR and will have to revise their Quality Management System (QMS) and Technical Documentation which will be reviewed.  There will also be a greater emphasis on post-market surveillance and submission of post-market performance follow-up reports.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The withdrawal of the United Kingdom (&#8220;UK&#8221;) from the EU has had significant ramifications for IVD manufacturers. Among other things, IVD manufacturers have to follow new procedures in the UK including appointment of UK Responsible Persons rather than relying on European Authorized Representatives to manage their compliance efforts in the UK.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK Medicine and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) issued guidance on regulation of IVDs in the UK following January 1, 2021. After a transition period, IVDs will require certification in Great Britain, which is defined as England, Scotland and Wales, while companies will still be able to sell tests in Northern Ireland under existing EU IVD regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in the guidance, MHRA will continue to recognize CE marks until June 30, 2023.  Companies wishing to place IVDs on the UK market have been required to register with MHRA since January 1, 2021, but will still be able to sell CE-IVD marked products until June 30, 2023. Starting July 1, 2023, companies selling in the UK will have to obtain a new marking called a UK Conformity Assessed mark (&#8220;UKCA&#8221;) in order to place a diagnostic device into commerce in Great Britain. This mark will not be automatically recognized in EU countries, meaning that companies that wish to sell in the UK and the EU will have to seek both a UKCA and CE-IVD mark in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IVDs are regulated in Japan by the Pharmaceutical and Medical Devices Agency (PMDA) and are assigned to one of three classes depending on the perceived level of risk. Those in the least risky class may be registered and marketed after filing a pre-market submission, while those in the middle class are subject to pre-market certification by a registered certification body.  The riskiest IVDs must be approved. Submissions may be made only by marketing authorization holders, which must satisfy specific requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant revisions to Japanese regulations of medical devices, IVDs and other health care products are ongoing, with phased implementations of new and updated requirements planned through 2022. The first round of changes to Japan&#8217;s Pharmaceuticals and Medical Devices Act took effect September 1, 2020 and August 2021, with additional revisions coming into force in December 2022. Some of those changes will affect IVDs, including the ability to qualify for fast track designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Additional International Regulation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market, directly or through distributors, some of our tests outside of the United States and are subject to foreign regulatory requirements governing laboratory licensure, human clinical testing, use of tissue, privacy and data security, and marketing approval for our tests. These requirements vary by jurisdiction, differ from those in the United States and may require us to implement additional compliance measures or perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required. We are also required to maintain accurate information on and control over sales and distributors&#8217; activities that may fall within the purview of the Foreign Corrupt Practices Act, its books and records provisions and its anti-bribery provisions, as well the UK Bribery Act and other anti-corruption laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HIPAA and Other Privacy Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which applies to health plans, healthcare clearing houses, and healthcare providers that conduct certain health care transactions electronically (&#8220;Covered Entities&#8221;) contains provisions that address the privacy and security of individually identifiable health information (called &#8220;protected health information&#8221; under HIPAA), the standardization of identifying numbers used in the healthcare system and the standardization of certain health care transactions. HIPAA's privacy regulations protect health information by limiting its use and disclosure to certain purposes, such as treatment or payment, without patient authorization. HIPAA also gives patients certain rights including the right to access their medical records and the right to an accounting of certain disclosures of protected health information. HIPAA's privacy rule also limits many disclosures of protected health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2009, Congress enacted the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), which expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements for Covered Entities. Under HITECH&#8217;s breach notification requirements, Covered Entities must report breaches of protected health information that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of the U.S. Department of Health and Human Services (the &#8220;Secretary&#8221;). Required breach notices must be made as soon as is reasonably practicable, but no later than 60 days following discovery of the breach. Reports must be made to affected individuals and to the Secretary and, in some cases depending on the size of the breach, they must be reported through local and national media. Breach reports can lead to investigation, enforcement, civil monetary penalties and civil litigation, including class action lawsuits and enforcement by state.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently subject to the HIPAA regulations and maintain an active compliance program that is designed to meet requirements of the privacy and security rules and to identify security incidents and other issues in a timely fashion so that we may remediate, mitigate harm and report if required by law. However, even if we take steps to comply with HIPAA, we may be subject to complaints and investigation at the federal and/or state level. In the event of a breach, even if we mitigate harm and make required reports on a timely basis, we may still be subject to penalties for the underlying breach.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the federal privacy and security regulations, there are a number of state laws regarding the privacy and security of health information and personal data that are applicable to our clinical laboratories.  Many states have also implemented genetic testing and privacy laws imposing specific patient consent requirements and protecting test results by strictly limiting the disclosure of those results. State requirements are particularly stringent regarding predictive genetic tests, due to the risk of genetic discrimination against healthy patients identified through testing as being at risk for disease. We believe that we have taken the steps required of us to comply with health information privacy and security statutes and regulations, including genetic testing and genetic information privacy laws in all jurisdictions, both state and federal. However, these laws often change, and we may not be able to maintain compliance in all jurisdictions where we do business. Failure to maintain compliance with state or federal laws regarding privacy or security could result in civil and/or criminal penalties and significant reputational damage and could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The General Data Protection Regulation (&#8220;GDPR&#8221;), which imposes requirements regarding the handling of personal data about EU residents, also applies to some of our operations. The GDPR is discussed in more detail under the heading &#8220;Risk Factors&#8221; contained in Item 1A of this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Transparency Laws and Regulations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A federal law known as the Physician Payments Sunshine Act requires medical device manufacturers to track and report to CMS certain payments and other transfers of value made to covered recipients, which include physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives who are not bona fide employees of the manufacturer, as well as teaching hospitals, and ownership or investment interests held by physicians and their immediate family members. Manufacturers must report data for the previous calendar year by the 90th day of the then-current calendar year. CMS then publishes the data on a publicly available website no later than June 30th. There are also state &#8220;sunshine&#8221; laws that require manufacturers to provide reports to state governments on pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our sales, marketing, and other activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or to otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement and Billing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement and billing for diagnostic services is highly complex. Laboratories must bill various payors, such as private third-party payors, including managed care organizations (&#8220;MCO&#8221;), and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements. Additionally, the audit requirements imposed by these payors, as well as our internal compliance policies and procedures, add further complexity to the billing process. Other factors that complicate billing include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">variability in coverage and information requirements among various payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">patient financial assistance programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">missing, incomplete or inaccurate billing information provided by ordering physicians;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">billings to payors with whom we do not have contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes with payors as to which party is responsible for payment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes with payors as to the appropriate level of reimbursement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our services may be:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a third party who provides coverage to the patient, such as an MCO;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a state or federal health care program; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the patient.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently, approximately 65% of our revenue comes from private third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), which included substantial changes to the way in which CMS pays for clinical laboratory services under Medicare&#8217;s Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;). PAMA took effect on January 1, 2018 and requires applicable laboratories to report to CMS private insurer payment rates and volumes for their tests. CMS uses the data reported and the HCPCS code associated with the test to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for tests that are considered to be clinical diagnostic laboratory tests (&#8220;CDLTs&#8221;), subject to certain phase-in limits. For tests furnished on or after January 1, 2019, Medicare payments for CDLTs are based on reported private payor rates. For a CDLT that is assigned a new or substantially revised current procedural terminology ("CPT") code, the initial payment rate is assigned using the gap-fill methodology, as under prior law. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the test falls into the category of new advanced diagnostic laboratory test (&#8220;ADLT&#8221;) instead of a CDLT, the test will be paid based on an actual list charge for an initial period of three quarters before being shifted to the weighted median private payor rate reported by the laboratory performing the ADLT. Laboratories offering ADLTs are subject to recoupment if the actual list charge exceeds the weighted median private payor rate by a certain amount. Accordingly, if newly developed tests receive Medicare coverage in the future, the reimbursement rate we receive for such tests may be affected by payment rates made by private payors for such tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2019, the President signed the Further Consolidated Appropriations Act, which included the Laboratory Access for Beneficiaries Act (&#8220;LAB Act&#8221;). The LAB Act delayed until the first quarter of 2021 reporting of payment data under PAMA for CDLTs that are not ADLTs. The Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), which Congress passed in March 2020, again delayed the reporting by an additional year, this time until the first quarter of 2022. Then, on December 10, 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which included a provision that further delayed the next PAMA reporting period for CDLTs that are not ADLTs to January 1, 2023 through March 31, 2023. New CLFS rates for CDLTs will be established based on that data beginning in 2024, subject to phase-in limits. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS&#8217;s methodology under PAMA (as well as the willingness of commercial insurers to recognize the value of diagnostic testing and pay for that testing accordingly) renders commercial insurer payment levels even more significant. This calculation methodology has resulted in significant reductions in reimbursement, even though CMS imposed caps on those reductions. For example, PAMA (as amended) includes provisions that limit the amount by which payment for testing may be reduced. For example, for 2018 through 2020, a test price could not be reduced by more than 10% per year. Reductions for 2023 through 2025 are limited to 15%. (The CARES Act delayed for one year the 15% cut that was scheduled to take effect on January 1, 2021, and the Protecting Medicare and American Farmers from Sequester Cuts Act further delayed those cuts until 2023.)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The subsequent data reporting period for CDLTs that are not ADLTs will occur in three-year cycles, with the next cycle beginning in 2026. Given the many uncertainties built into PAMA&#8217;s price-setting process, we cannot predict how payments we receive under the CLFS, and thus our revenue, may change from year to year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The No Surprises Act was signed into law on December 27, 2020, as part of the Consolidated Appropriations Act, 2021.  The Department of Health and Human Services, the Department of Treasury, and the Department of Labor have since released &#8220;Tri-Agency&#8221; regulations to implement the No Surprises Act, which became effective on January 1, 2022.  The law and regulations generally apply to group health plans and health insurance issuers offering group or individual health insurance coverage for plan years starting January 1, 2022, and to certain health care providers and facilities.  For non-emergency services provided by an out-of-network provider (such as a laboratory) during a visit at an in-network facility (which includes a hospital but not a physician office), the No Surprises Act requires the non-emergency services provider to hold a patient harmless for amounts beyond the in-network cost-sharing requirement.  In other words, balance billing generally is prohibited.  Because these billing requirements do not apply to patient specimens collected in a physician office, Myriad is impacted primarily when a patient&#8217;s specimen is collected at an in-network hospital, and Myriad is out-of-network with the patient&#8217;s insurance plan.  Out-of-network rates for covered services are determined by a state All-Payer Model Agreement, a specified state law, an agreed-upon amount, or, if none apply, an amount determined by an independent dispute resolution entity.  The cost-sharing amount is limited to an amount determined by an All-Payor Model Agreement, a specified state law, or, if neither applies, the lesser of the billed charge or the &#8220;qualifying payment amount,&#8221; which is generally the plan or issuer&#8217;s median contracted rate for the same or similar service in the specific geographic area.  Non-covered services are not impacted by these rules.  In addition, providers, including Myriad, must post consumer notices on their website about the applicability of the law. Providers, including physician offices, must provide a good faith estimate of the service when requested by a patient who is uninsured or seeking to forgo insurance and pay cash instead.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Federal and State Fraud and Abuse Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of state and federal laws prohibit fraud and abuse involving state and federal health care programs, such as Medicare and Medicaid.  These laws are interpreted broadly and enforced aggressively by various state and federal agencies, including CMS, the Department of Justice, the Office of Inspector General for the Department of Health and Human Services (&#8220;OIG&#8221;), and various state agencies.  In addition, the Medicare and Medicaid programs increasingly use a variety of contractors to review claims data and to identify improper payments as well as fraud and abuse.  Any overpayments must be repaid within 60 days of identification unless a favorable decision is obtained on appeal.  In some cases, these overpayments can be used as the basis for an extrapolation by which the error rate is applied to a larger set of claims, which can result in even higher repayments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anti-Kickback Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program. &#8220;Remuneration&#8221; is broadly interpreted to include anything of monetary value, such as, for example, cash payments, gifts or gift certificates, discounts, or the furnishing of services, supplies or equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognizing the potential breadth of interpretation of the Anti-Kickback Statute and the fact that it may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the OIG has promulgated safe harbors intended to protect such arrangements. Compliance with all requirements of a safe harbor immunizes the parties to the business arrangement from prosecution under the Anti-Kickback Statute. The failure of a business arrangement to fit within a safe harbor does not necessarily mean that the arrangement is illegal or that enforcement agencies will pursue prosecution. Still, in the absence of an applicable safe harbor, a violation of the Anti-Kickback Statute may occur even if only one purpose of an arrangement is to induce referrals. The penalties for violating the Anti-Kickback Statute can be severe. These sanctions include criminal and civil penalties, imprisonment and possible exclusion from federal health care programs. Many states have adopted laws similar to the Anti-Kickback Statute, and some apply to items and services reimbursable by any payor, including private third-party payors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the &#8220;SUPPORT Act&#8221;). EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA&#8217;s exceptions are inconsistent with the Anti-Kickback Statute regulations. Significantly, EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA&#8217;s exceptions or adding additional exceptions, but such regulations have not yet been issued. Further, there is no agency guidance and little court precedent to indicate how and to what extent EKRA will be applied and enforced.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Physician Self-Referral Bans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal ban on physician self-referrals, commonly known as the Stark Law, prohibits, subject to certain exceptions, physician referrals of Medicare patients to an entity providing certain designated health services, which include laboratory services, if the physician or an immediate family member of the physician has any financial relationship with the entity. Several Stark Law exceptions are relevant to arrangements involving clinical laboratories, including but not limited to: (1) fair market value compensation for the provision of items or services; (2) payments by physicians to a laboratory for clinical laboratory services; (3) space and equipment rental arrangements that satisfy certain requirements; and (4) personal services arrangements. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">State and Federal Prohibitions on False Claims</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government. Under the False Claims Act, a person acts knowingly if he or she has actual knowledge of the information or acts in deliberate ignorance or in reckless disregard of the truth or falsity of the information. Specific intent to defraud is not required. The qui tam provisions of the False Claims Act allow a private individual to bring an action on behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action.  Penalties include payment of up to three times the actual damages sustained by the government, plus civil penalties of between $5,500 and $11,000 for each false claim, as well as possible exclusion from federal health care programs. However, the civil penalty amounts are adjusted annually for inflation. For civil penalties assessed after December 13, 2021, whose associated violations occurred after November 2, 2015, the civil penalty amount ranges between $11,803 and $23,607 per claim. In addition, various states have enacted similar laws modeled after the False Claims Act that apply to items and services reimbursed under Medicaid and other state health care programs, and, in several states, such laws apply to claims submitted to any payor. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Civil Monetary Penalties Law</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Civil Monetary Penalties Law (the &#8220;CMP Law&#8221;), prohibits, among other things, (1) the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal health care program; (3) billing for services requested by an unlicensed physician or an excluded provider; and (4) billing for medically unnecessary services. The penalties for violating the CMP Law include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other U.S. Regulatory Requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. For example, the U.S. Occupational Safety and Health Administration (OSHA) has established extensive requirements relating specifically to workplace safety for healthcare employers in the United States. This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries. For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the United States Postal Service, the Office of Foreign Assets Control, and the International Air Transport Association. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratories are subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, radioactive materials, hazardous waste and biohazardous waste, including chemical and biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a Delaware corporation with our principal executive offices located at 320 Wakara Way, Salt Lake City, Utah 84108. Our telephone number is (801) 584-3600 and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.myriad.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available free of charge through the Investor Information section of our website our Code of Conduct, our Audit and Finance Committee and other committee charters and our other corporate governance policies, as well as our Annual and Transition Reports on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission. The Securities and Exchange Commission maintains an internet site (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Securities and Exchange Commission. We include our website address in this Annual Report on Form 10-K only as an inactive textual reference and do not intend it to be an active link to our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Our Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our financial condition and results of operations could be further adversely affected by the ongoing coronavirus pandemic.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to generate sufficient revenue from our existing tests or develop new tests to be profitable.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to maintain revenue growth or operate our business on a profitable basis, and our transformation plan may not achieve the anticipated results.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not continue to generate sufficient revenue from sales of our molecular diagnostic tests and are unable to secure additional funding, we may have to reduce our operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An inability to attract and retain experienced and qualified personnel, including key management personnel, could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to debt covenants that impose operating and financial restrictions on us and if we are not able to comply with them, it could have a material adverse impact on our operations and liquidity.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our current operating plan changes and we find that our existing capital resources will not meet our needs, we may find it necessary to raise additional funding, which may not be available.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may acquire technologies, assets or other businesses that could cause us to incur significant expense and expose us to a number of unanticipated operational and financial risks, which could adversely affect our financial condition, results of operations and business prospects. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to, and in the future may be subject to, securities class action lawsuits and stockholder derivative actions, as well as product or professional liability claims. These, and potential similar or related litigation, could result in substantial damages and may divert management&#8217;s time and attention from our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Security breaches, loss of data and other disruptions, including from cyberattacks, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience a significant disruption in our information technology systems, including security breaches, or if we fail to implement new systems and software successfully, our business operations and financial condition could be adversely affected. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business involves environmental risks that may result in liability for us.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in health care policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our tests.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on commercial courier delivery services to transport biological materials to our facilities in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Tests, Our Services and Test Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our molecular diagnostic and companion diagnostic tests in development may never achieve significant commercial market acceptance.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our tests, increase our revenue or achieve and sustain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign governments may impose reimbursement standards, which may adversely affect our future profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and international data protection laws and regulations may restrict our activities and increase our costs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each of our molecular diagnostic tests is processed in a single one of our laboratory facilities, and any loss or prolonged interruption of our ability to use these laboratories or failure to maintain their operation in compliance with applicable regulations would seriously harm our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on a limited number of third parties for some of our supplies of equipment and reagents. If these supplies become unavailable or are disrupted, including as a result of COVID-19 and responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to discover genes, proteins, and biomarkers, and to validate and commercialize molecular diagnostic and companion diagnostic tests could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to protect our proprietary technology, others could compete against us more directly, which would harm our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we were sued for patent infringement by third parties, we might incur significant costs and delays in test introduction.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to adequately prevent disclosure of trade secrets, proprietary databases, and other proprietary information.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our obligations under license or technology agreements with third parties, we could lose license rights that are critical to our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the government and third-party payors fail to provide coverage and adequate payment for our existing and future tests, if any, our revenue and prospects for profitability will be harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA regulation of our industry generally or our tests specifically could be disruptive to our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to comply with laws and regulations related to submission of claims for our services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs and corresponding foreign reimbursement programs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may from time to time be subject to government investigation(s), the unfavorable outcome of which may have a material adverse effect on our financial condition, results of operations and cash flows. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be harmed by the loss, suspension, or other restriction on a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companion and complementary diagnostic tests require FDA approval and we may not be able to secure such approval in a timely manner or at all. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is highly volatile, and our stock may lose all or a significant part of its value.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have identified two material weaknesses in our internal control over financial reporting related to our income tax provision process and our general information technology controls and such weaknesses led to a conclusion that our internal control over financial reporting and disclosure controls and procedures were not effective as of December 31, 2021. Our inability to remediate these material weaknesses, our discovery of any additional weaknesses, or our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence in us.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-takeover provisions of Delaware law, provisions in our charter and bylaws and re-adoption of our stockholders&#8217; rights plan, or poison pill, could make a third-party acquisition of us difficult.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not intend to pay dividends on our common stock so any returns will be limited to changes in the value of our common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our restated bylaws provide that a state court located within the State of Delaware is the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial condition and results of operations could be further adversely affected by the ongoing coronavirus pandemic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any outbreaks of COVID-19 (including its variant strains, such as the highly transmissible Omicron and Delta variants) or any other outbreak of contagious disease or adverse public health development, could have a further material and adverse effect on our business operations, financial condition, or results of operations. For example, government public health officials have implemented, and may continue to implement restrictions to curb the spread of COVID-19, which has limited, and may continue to limit,  patients&#8217; access to our services, and has caused, and may continue to cause, patients to elect to defer certain testing, each of which has impeded, and may continue to impede, our progress in returning to profitability and recovering from the earlier effects of the COVID-19 pandemic. Such adverse effects have included, and may continue to include, diversion or prioritization of health care resources away from the conduct of genetic testing, disruptions, or restrictions affecting the ability of laboratories to process our tests, and delays or difficulties in patients accessing our tests. Future surges in COVID-19 cases and related employee absences may strain our workforce and impact our ability to process tests in a timely way due to reduced staff availability. In addition, failure to comply with potential federal or state regulations requiring us to mandate COVID-19 vaccination for our employees could result in our losing access to government funding or facing monetary penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As COVID-19 continues to affect individuals and businesses around the globe, we will likely experience further disruptions from time to time that could severely impact our business, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased volume of testing as a result of disruptions to health care providers and limitations on the ability of providers to administer tests, including the suspension of non-emergency appointments and services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions or restrictions on the ability of our customers, our collaborators&#8217;, or our suppliers&#8217; personnel to travel, including as a result of shelter-in-place or stay-at-home orders from state and local governments, and temporary closures of our facilities or the facilities of our collaborators or suppliers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the development of our products, processing our diagnostic tests, and the conduct of our clinical trials, including because of sickness of employees or their families or requirements imposed on employees to avoid contact with large groups of people; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or access.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the continued spread of COVID-19 globally could continue to adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and both international and domestic components have been, and may continue to be, subject to disruption as a result of COVID-19 and ongoing responses to it. If the supplies and components necessary to manufacture our products become unavailable or are disrupted as a result of COVID-19 and ongoing responses to it, then we may not be able to successfully perform our research, sell our diagnostic tests, or operate our business on a timely basis or at all. Additionally, our results of operations could be adversely affected to the extent that the continued spread of COVID-19 or any other public health emergency harms our business or the economy in general either domestically or in any other region in which we do business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The extent to which COVID-19 continues to affect our business, results of operations, financial condition and impede our recovery from the earlier effects of the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration, spread and severity of COVID-19 outbreaks, the rate of vaccination and efficacy of approved vaccines against COVID-19 and its variant strains, actions taken to contain COVID-19 or treat its impact, new information that may emerge concerning the health effects of COVID-19, and how quickly and to what extent normal economic and operating conditions would resume if the pandemic subsided, any of which could have a further adverse effect on our business and financial condition. Even after the COVID-19 pandemic subsides, we may continue to experience an adverse impact to our business as a result of its global economic impact, including from increased inflation and the prospect that policy responses to inflation could delay economic recovery or lead to another recession. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to generate sufficient revenue from our existing tests or develop new tests to be profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our future success is dependent upon our ability to successfully market our existing molecular diagnostic tests to additional patients within the United States, to expand into new markets within and outside the United States, and to develop and commercialize new molecular diagnostic and companion diagnostic tests. However, we may not be able to generate sufficient revenue from our existing tests and launching and commercializing our new tests to be profitable. The demand for our existing molecular diagnostic tests may decrease or may not continue to increase at historical rates due to sales of new tests that may replace or cannibalize our existing product portfolio, or for other reasons such as the introduction of competing molecular diagnostic testing products by competitors. For example, because most of our molecular diagnostic tests are only utilized once per patient, we will need to sell our services through physicians to new patients or develop new molecular diagnostic tests in order to continue to generate revenue. Our average reimbursement rate per test may also decline, which may cause our revenues to decrease. Our pipeline of new molecular diagnostic and companion diagnostic test candidates is in various stages of development, some of which may take many more years to develop, and must undergo extensive clinical validation. We may be unable to discover or develop any additional molecular diagnostic or companion diagnostic tests through the utilization of our technologies or technologies we license or acquire from others. Even if we develop tests or services for commercial use, we may not be able to develop tests or services that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">meet applicable regulatory standards, in a timely manner or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully compete with other technologies and tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avoid infringing the proprietary rights of others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">are adequately reimbursed by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">can be performed at commercial levels or at reasonable cost; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">can be successfully marketed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must generate significant revenue to achieve profitability. Even if we succeed in marketing our existing molecular diagnostic tests to physicians for use in new patients and in developing and commercializing any additional molecular diagnostic tests and companion diagnostic tests, we may not be able to generate sufficient revenue and we may not be profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to maintain revenue growth or operate our business on a profitable basis, and our transformation plan may not achieve the anticipated results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to generate revenue growth or maintain existing revenue levels. Historically, our molecular diagnostic business has operated profitably providing a cash contribution to our funding and operational needs. We may not, however, be able to operate our molecular diagnostic business on a profitable basis in the future. Potential events or factors that may have a significant impact on our ability to sustain revenue growth and achieve or maintain profitability for our molecular diagnostic business include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts of third-party payors to limit or decrease the amounts that they are willing to pay for our tests, recoup amounts already paid, or institute burdensome administrative requirements for reimbursement, such as prior authorization requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs of reagents and other consumables required for molecular diagnostic testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased personnel and facility costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to hire competent, trained staff, including laboratory directors required to review and approve all reports we issue in our molecular diagnostic business, and sales personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain necessary equipment or reagents to perform molecular diagnostic testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to increase production capacity as demand increases;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to expand into new markets within or outside the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased licensing or royalty costs, and our ability to maintain and enforce the intellectual property rights underlying our tests and services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in intellectual propriety law applicable to our patents or enforcement in the United States and foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential obsolescence of our tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to increase commercial acceptance of our molecular diagnostic tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition and loss of market share;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material litigation costs and judgments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently executing upon a strategic transformation plan, which, among other things, is focused on developing and enhancing best-in-class products to support growth, improving the patient and provider experience, and reaching more patients of all backgrounds. In addition, as part of that transformation plan, we intend to accelerate growth through the launch of a new enterprise commercial model, the launch of a unified ordering portal, investment in new sequencing technologies, the development of direct-to-consumer channels, and building commercial capabilities to support new products and offerings. Our future performance and growth depends on the success of our transformation plan, including management's ability to execute upon that plan and the ability of our employees to respond quickly and effectively to transformational projects and rapid changes in our operations and business practices. The implementation of our transformation plan has resulted and is expected to continue to result in changes to business priorities and operations, capital allocation priorities, operational and organizational structures, and increased demands on management. The execution of our transformation plan may take longer than anticipated, and once implemented, we may not realize, in full or part, the anticipated benefits, including growth in our testing volumes and revenue, or such benefits may be realized more slowly than anticipated. The failure to realize benefits, which may be due to our inability to execute plans, delays in the implementation of the transformation plan, global or local economic conditions, competition, changes in the molecular diagnostics industry, the ongoing COVID-19 pandemic, and the other risk factors described herein, could have a material adverse effect on our business, prospects, financial condition, results of operations, cash flows, as well as the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not continue to generate sufficient revenue from sales of our molecular diagnostic tests and are unable to secure additional funding, we may have to reduce our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we anticipate that our existing cash, cash equivalents and marketable securities, cash flow from operations, and in certain circumstances, amounts available for borrowing under our Amended Facility (as defined below) will be sufficient to fund our current operations for the foreseeable future, changes could occur that would consume available capital resources more quickly than we currently expect and we may need or want to raise additional financing. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, we entered into a senior secured revolving credit facility as borrower, with the lenders from time to time party thereto, which was amended on July 31, 2018, May 1, 2020 and February 22, 2021 (the "Amended Facility"). On July 30, 2021, using cash generated from our recent divestitures, we repaid all outstanding borrowings under our Amended Facility. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0 million, unless such borrowings are used in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents and marketable securities totaled $398.8 million as of December 31, 2021. Our revolving commitment amount is $250.0 million as of December 31, 2021. As our total unrestricted cash, cash equivalents, and marketable securities exceeded $150.0 million as of December 31, 2021, we will be unable to make future borrowings unless related to a permitted acquisition. In addition, following the expiration of the waiver of the leverage ratio and interest coverage ratio covenants, which waiver is effective until March 31, 2022, our ability to borrow under the Amended Facility will be limited if we are unable to comply with those financial covenants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to secure additional financing in a timely manner or on favorable terms, if at all. In addition, we are subject to financial covenants as part of our Amended Facility that could limit our ability to incur additional indebtedness. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing activities, research and development activities, or other operations, and potentially delay development of our diagnostic tests in an effort to provide sufficient funds to continue our operations. If any of these events occur, our ability to achieve our development and commercialization goals could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors that are currently unknown to us, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and cost of development, clinical testing and pre-market studies of any new molecular diagnostic tests that we may discover or acquire;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, results, and costs to develop additional molecular diagnostic tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business on a profitable basis;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our current issued patents, and defending intellectual property-related claims;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into collaborations, licensing or other arrangements favorable to us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring technologies or businesses, and our ability to successfully integrate and achieve the expected benefits of our business development activities and acquisitions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, cost and results of our international efforts;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of expanding our sales and marketing functions and commercial operation facilities in the United States and in new markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of any litigation against us; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to satisfy our current and future obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An inability to attract and retain experienced and qualified personnel, including key management personnel, could adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain highly qualified and experienced personnel, including key management personnel. Competition for these personnel is intense, especially for management, sales, scientific, medical, information technology, research and development and other technical personnel. We may not be able to attract or retain qualified personnel in the future due to the competition for qualified personnel among life science and technology businesses as well as universities and public and private research institutions, particularly in the San Francisco Bay Area, where we have office and laboratory facilities. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Our compensation arrangements, such as our equity award programs, may not be successful in attracting new employees and retaining and motivating our existing employees. Our agreements with our employees generally provide for employment that can be terminated by either party without cause at any time, subject to specified notice requirements. Further, the non-competition provision that certain key employees are subject to may not be enforceable under certain state, particularly California, or federal laws or such provisions may be prohibitively expensive to enforce. Competition and compensation for highly qualified and experienced personnel increased as employment vacancies surged over the past year, which has increased the difficulty and cost of hiring and retaining qualified personnel. Our transformation and commercial activities have placed a greater workload and strain on our existing employees, increasing the risk that our employees experience fatigue or burnout or terminate their employment with us. Potential federal or state regulations may require us to mandate COVID-19 vaccinations for our employees, or any future decision on our part to voluntarily require our employees to receive a COVID-19 vaccine, could also impact our ability to hire and retain employees. In addition, inflation has had, and we expect that it will continue to have, an impact on the costs that we incur to attract and retain qualified personnel, and may make it more difficult for us to attract and retain such personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on the skills, experience and performance of key members of our senior management team, who are critical to directing and managing our growth and development in the future. The loss of any member of our senior management team may cause us to experience difficulties in competing effectively, developing our technologies, and implementing our business strategies. Furthermore, the loss of the services of or failure to recruit key scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our molecular diagnostic business and it may have a material adverse effect on our business as a whole. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to debt covenants that impose operating and financial restrictions on us and if we are not able to comply with them, it could have a material adverse impact on our operations and liquidity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on us. These restrictions may prohibit or place limitations on, among other things, our ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. Under the Amended Facility, a change in control of the Company, which means that a stockholder or a group of stockholders is or becomes the beneficial owner, directly or indirectly, of more than 35% of the total voting power of the voting stock of the Company, would require mandatory prepayment of any outstanding debt. The Amended Facility may also prohibit or place limitations on our ability to sell assets, pay dividends or provide other distributions to stockholders. These restrictions could also limit our ability to take advantage of business opportunities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must maintain specified leverage and interest ratios measured as of the end of each applicable quarter as financial covenants in the Amended Facility. The Amended Facility, through Amendment No. 2 entered into on May 1, 2020 and Amendment No. 3 entered into on February 22, 2021, modified compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2022, and added a minimum liquidity covenant. If we are unable to improve our results of operations, it is possible that we could be in violation of certain financial covenants contained in the Amended Facility in the future. If we are unable to comply with the covenants and ratio in the Amended Facility, we may be in default under the agreement. A default would result in an increase in the rate of interest and limits on our ability to incur certain additional indebtedness and it could potentially cause any loan repayment to be accelerated, any of which could have a material adverse impact on our operations and liquidity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our current operating plan changes and we find that our existing capital resources will not meet our needs, we may find it necessary to raise additional funding, which may not be available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our existing capital resources and expected net cash to be generated from sales of our molecular diagnostic tests will enable us to maintain our currently planned operations for the foreseeable future. However, we base this expectation on our current operating plan, which may change. We have incurred, and will continue to incur, significant costs in the discovery, development and marketing of current and prospective molecular diagnostic and companion diagnostic tests. Our ongoing efforts to develop tests and expand our business, which may be through internally developed products, partnerships, in-licensing and mergers and acquisitions, will require substantial cash resources. If, due to changes in our current operating plan, adequate funds are not available, we may be required to raise additional funds. Sources of potential additional capital resources may include, but are not limited to, public or private equity financings, expanding or supplementing our Amended Facility, or selling convertible or non-convertible debt securities. This additional funding, if necessary, may not be available to us on reasonable terms, or at all.  If we issue shares of stock or other securities to acquire new companies or technologies, the ownership interests of our existing stockholders may be significantly diluted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of our potential long-term capital requirements, we may access the public or private equity or debt markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. Under Securities and Exchange Commission rules, we currently qualify as a well-known seasoned issuer, or WKSI, and can at any time file a registration statement registering securities to be sold to the public which would become effective upon filing.  If additional funds are raised by issuing equity securities, existing stockholders may suffer significant dilution. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances, partnerships and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or tests or grant licenses on terms that are not favorable to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire technologies, assets or other businesses that could cause us to incur significant expense and expose us to a number of unanticipated operational and financial risks, which could adversely affect our financial condition, results of operations and business prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to organic growth, we intend to continue to pursue growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities, expand our geographic market and sales channels, add experienced management personnel and increase our test offerings. However, these acquisitions may not achieve profitability or generate a positive return on our investment. Additionally, we may be unable to implement our growth strategy if we cannot identify suitable acquisition candidates, reach agreement on potential acquisitions on acceptable terms, successfully integrate personnel or assets that we acquire or for other reasons. We may also experience increased expenses, distraction of our management, and personnel and customer uncertainty. Our acquisition efforts may involve certain risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have difficulty integrating operations and systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">key personnel and customers of the acquired company may terminate their relationships with the acquired company as a result of the acquisition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in launching new molecular diagnostic tests or companion diagnostic tests, or if those tests are launched, they may not prove successful in the marketplace;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience additional financial and accounting challenges and complexities in areas such as tax planning and financial reporting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may assume or be held liable for risks and liabilities as a result of our acquisitions, including for legal, compliance, recoupment, and environmental-related costs and liabilities, some of which we may not discover during our due diligence;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may incur significant additional operating expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience inconsistencies in standards, controls, procedures, policies and compensation structures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter risks and limitations on our ability to consolidate our corporate and administrative infrastructures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ongoing business may be disrupted or receive insufficient management attention; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to realize synergies, the cost savings or other financial and operational benefits we anticipated, or such synergies, savings or benefits may take longer than we expected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of negotiating acquisitions and integrating acquired tests, services, technologies, personnel or businesses might result in operating difficulties and expenditures and might require significant management attention that would otherwise be available for ongoing development of our business, whether or not any such transaction is ever consummated. Moreover, we might never realize the anticipated benefits of any acquisition such as increase in our scale, diversification, cash flows and operational efficiency and meaningful accretion to our diluted earnings per share. Future acquisitions could result in the use of our available cash and marketable securities, potentially dilutive issuances of equity securities, the need to incur additional debt, contingent liabilities, or impairment expenses related to goodwill, and impairment or amortization expenses related to other intangible assets, which could harm our financial condition. In addition, if we are unable to integrate any acquired businesses, tests or technologies effectively, our business, financial condition and results of operations may be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to divest assets from time to time, including but not limited to, large capital equipment, diagnostic tests, intellectual property, business units, or corporate affiliates. The prices that we receive we are able to command for such assets may not be high and, in some cases, may be lower than the amount we invested in or paid for such assets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to, and in the future may be subject to, securities class action lawsuits and stockholder derivative actions, as well as product or professional liability claims. These, and potential similar or related litigation, could result in substantial damages and may divert management&#8217;s time and attention from our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently subject to a variety of litigation, including a securities class action lawsuit filed in the United States District Court for the District of Utah, and stockholder derivative actions filed in the Delaware Court of Chancery and the United States District Court for the District of Delaware, each of which could result in substantial damages and may divert management&#8217;s time and attention from our business.  We also may be subject to future securities class action and stockholder derivative claims, which may adversely impact our business, results of operations, financial condition or cash flows and divert management&#8217;s time and attention from our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the marketing, sale and use of our genetic tests could subject us to liability for errors in, misunderstandings of, or inappropriate reliance on, information we provide to clinicians, geneticists or patients, and lead to claims against us if someone were to allege that a test failed to perform as it was designed or marketed, if we failed to provide a correct test result to a patient, if we failed to correctly interpret the test results, if we failed to update the test results due to a reclassification of the variants according to new published guidelines, or if the ordering physician or patient were to misinterpret test results or improperly rely on them when making a clinical decision. We could also be subject to claims, lawsuits or liability if the biological materials we receive for analysis were not properly attributed to the correct patient or if we failed to maintain custody of or properly track the biological materials. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Although we maintain liability insurance for certain claims, including for errors and omissions, we cannot assure you that such insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any liability claim, including an errors and omissions liability claim, brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. If we were successfully sued for product or professional liability claims, we could face substantial liabilities that exceed our insurance coverage and our other resources. Additionally, any liability lawsuit could cause injury to our reputation or cause us to suspend sales of our tests. The occurrence of any of these events could have an adverse effect on our reputation and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Security breaches, loss of data and other disruptions, including from cyberattacks, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, credit card information, personally identifiable information about our employees, intellectual property, and proprietary business information, including that of our customers, payors and collaboration partners. We manage and maintain our applications and data utilizing on-site, remote, or cloud-based systems. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, malware, including ransomware, breaches or interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any such malicious cyberattack, virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, held for ransom, lost or stolen. We have measures in place that are designed to prevent, and if necessary, to detect and respond to such cybersecurity incidents and breaches of privacy and security mandates. While we have experienced unauthorized accesses to our information technology systems and infrastructure in the past, which may occur again in the future, our security measures have been able to detect, respond to and prevent any material adverse effect to our information systems and business operations from such breaches. However, in the future, any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA, government enforcement actions and civil or even criminal penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, bill payors or patients, provide customer support services, conduct research and development activities, process and prepare company financial information, and manage various general and administrative aspects of our business, and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we face increased cybersecurity risks and potential disruption to our technology infrastructure due to the number of employees that are working remotely as a result of remote work policies and other hybrid work arrangements. Increased levels of remote access create additional opportunities for cybercriminals to exploit vulnerabilities, and employees may be more susceptible to phishing and social engineering attempts. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience a significant disruption in our information technology systems, including security breaches, or if we fail to implement new systems and software successfully, our business operations and financial condition could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information technology and communication systems are an important part of our business operations. These IT and communications systems support a variety of functions, including sample processing, tracking, quality control, customer service and support, billing, research and development activities, and various general and administrative activities. The availability of our products and services and fulfillment of our customer contracts depends on the continuing operation of our information technology and communication systems. Our information technology and communication systems may be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, computer viruses, attacks by computer hackers, telecommunication failures, user errors, catastrophes or other unforeseen events. Our information technology and communication systems also may experience interruptions, delays or cessations of service or produce errors in connection with system integration, upgrades or system migration work that takes place from time to time. If we were to experience a prolonged system disruption in the information technology and communication systems that involve our interactions with customers, providers or suppliers, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business. In addition, security breaches of our information technology systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to our employees, partners, customers or suppliers, which could result in our suffering significant financial or reputational damage</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks that may result in liability for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our research and development activities, we are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, including hazardous materials, biological specimens, chemicals and waste. The cost of compliance with these laws and regulations may become significant and could negatively affect our operating results. Although we believe that we have complied with the applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources or any applicable insurance coverage we may have. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in health care policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our tests. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively called the ACA, became law.  This law substantially changed the way health care is financed by both government and private third-party payors and continues to significantly impact our business and operations in ways we cannot currently predict. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and as a result, certain sections of the ACA have not been fully implemented or were effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the ACA&#8217;s constitutionality. Further legislative and regulatory changes under the ACA remain possible, although the federal administration under President Biden has signaled that it plans to build on the ACA and expand the number of people who are eligible for health insurance subsidies under it. Future changes or additions to the ACA or the Medicare and Medicaid programs, such as changes allowing the federal government to directly negotiate drug prices, or changes stemming from other health care reform measures, especially with regard to health care access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels and the number of insured individuals, may lead to delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. Further, if reimbursement levels are inadequate, our business and results of operations could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and private third-party payors to reduce costs while expanding individual health care benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our tests or the amounts of reimbursement available for our tests from governmental agencies or private third-party payors.  Any future changes to legal or regulatory requirements or new cost containment initiatives could have a materially adverse effect on our business, financial condition, results of operation, and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic testing has raised ethical, legal and social issues regarding privacy rights and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, genomic tests even if permissible; they may also refuse genetic testing due to concerns regarding eligibility for life or other insurance. Ethical and social concerns may also influence U.S. and foreign patent offices and courts with regard to patent protection for technology relevant to our business. Although the Genetic Information Non-discrimination Act has criminalized the disallowance of health insurance on the basis of genetic information, modification or retraction of this federal law could dramatically reduce public demand for genetic testing. These and other ethical, legal and social concerns may limit market acceptance of our tests or reduce the potential markets for our tests, either of which could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on commercial courier delivery services to transport biological materials to our facilities in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business depends on our ability to quickly and reliably deliver test results to our customers. We typically receive biological material for analysis at our laboratory facilities within days of collection from the patient. Disruptions in delivery service, whether due to errors by the courier service, labor disruptions, bad weather, natural disasters, terrorist acts or threats or other reasons, some of which we have experienced in the past, could adversely affect specimen integrity, our ability to process or store samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a portion of our revenues and pay a portion of our expenses in currencies other than the United States dollar, such as the Euro, the Swiss franc, the Japanese yen, and the British pound. As a result, we are at risk for exchange rate fluctuations between such foreign currencies and the United States dollar, which could affect the results of our operations. If the U.S. dollar strengthens against foreign currencies, the translation of these foreign currency denominated transactions will result in decreased revenues and operating expenses. We may not be able to offset adverse foreign currency impact with increased revenues. We do not currently utilize hedging strategies to mitigate foreign currency risk and even if we were to implement hedging strategies to mitigate foreign currency risk, these strategies might not eliminate our exposure to foreign exchange rate fluctuations and would involve costs and risks of their own, such as ongoing management time and expertise, external costs to implement the strategies and potential accounting implications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Tests, Our Services and Test Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our molecular diagnostic and companion diagnostic tests in development may never achieve significant commercial market acceptance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not succeed in achieving significant commercial market acceptance of our diagnostic test offerings that we have launched in recent years or are currently developing. Our ability to successfully develop and commercialize our current molecular diagnostic and companion diagnostic tests, as well as any future molecular diagnostic and companion diagnostic tests that we may develop, will depend on several factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to convince the medical community of the clinical utility of our tests and their potential advantages over existing tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to collaborate with biotechnology and pharmaceutical companies to develop and commercialize companion diagnostic tests for their therapeutic drugs and drug candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the agreement by third-party payors to reimburse our tests, the scope and extent of which will affect patients&#8217; willingness or ability to pay for our tests and will likely heavily influence physicians&#8217; decisions to recommend our tests; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to utilize our tests, which can be difficult to interpret. This difficulty is caused by the ability of our tests to predict only as to a probability, not certainty, that a tested individual will develop the disease, will benefit from a particular therapy or has an aggressive form of the disease that the test is intended to predict.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors present obstacles to commercial acceptance of our tests, which we would have to spend substantial time and money to overcome, if we can do so at all. Our inability to successfully do so would harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our tests, increase our revenue or achieve and sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical laboratory and genetics testing fields are intense, highly competitive and characterized by rapid technological change, frequent new product introductions, reimbursement challenges, emerging competition, intellectual property disputes and litigation, price competition, aggressive marketing practices, evolving industry standards, and changing customer preferences. Our competitors in the United States and abroad are numerous and include, among others, major diagnostic companies, reference laboratories, molecular diagnostic firms, direct-to-consumer genetic companies, low-priced competitors, clinical laboratories, universities and other research institutions. Some of our competitors and potential competitors have larger customer bases, greater brand recognition and market penetration, better selling and marketing capabilities, more experience with third-party payors and considerably greater financial, technical, marketing and other resources than we do, which may allow these competitors to discover important genes and determine their function before we do, respond more quickly to changes in customer preferences, devote greater resources to the development, promotion and sale of their tests than we do, sell their tests at prices designed to win significant levels of market share, or obtain reimbursement from more third-party payors and at higher prices than we do. We could be adversely affected if we do not discover genes, proteins or biomarkers and characterize their function, develop molecular diagnostic tests based on these discoveries, obtain required regulatory and other approvals and launch these tests and their related services before our competitors. We may also not be able to keep pace with the rapid technological changes in our industry, or properly leverage new technologies to achieve or sustain competitive advantages in our tests, systems and processes. We also expect to encounter significant competition with respect to any molecular diagnostic and companion diagnostic tests that we may develop or commercialize. Those companies that bring to market new molecular diagnostic and companion tests before we do may achieve a significant competitive advantage in marketing and commercializing their tests. We may not be able to develop additional molecular diagnostic tests successfully and we or our licensors may not obtain or enforce patents covering these tests that provide protection against our competitors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our competitors may succeed in developing molecular diagnostic and companion diagnostic tests that circumvent our technologies or tests. Furthermore, our competitors may succeed in developing technologies or tests that are more effective or less costly than those developed by us or that would render our technologies or tests less competitive or obsolete. Increased competition and cost-saving initiatives on the part of governmental entities and third-party payors are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known and changes in intellectual property laws generate challenges to our intellectual property position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we operate in international markets. Although we recently narrowed our international operations, we have active sales operations in Germany, France, and Japan and production operations in Germany. We may establish additional operations or acquire additional properties outside the United States in order to advance our international sales. Doing business internationally involves a number of risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, data and privacy laws such as the EU GDPR, regulatory requirements and other governmental approvals, permits and licenses; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us to obtain regulatory approvals or adequate reimbursement for the use of our tests in various countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective marketing campaigns leading to failure in establishing a viable, profitable, and sustainable presence in our international markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in staffing and managing foreign operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing multiple payor reimbursement regimes, government payors and self-pay systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics and regulations associated with shipping patient samples, including infrastructure conditions, customs and transportation delays, including compliance with the Office of Foreign Assets Control and other international trade sanctions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits in our ability to penetrate international markets if we are not able to process tests locally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practice Act, UK Bribery Act, anti-boycott laws and other anti-corruption laws; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the disruptions caused by COVID-19 and ongoing responses to it.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our international operations and, consequently, our revenues and results of operations. In addition, any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, and restrictions on certain business activities. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our distribution and sales activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations could be affected by changes in laws, trade regulations, labor and employment regulations, and procedures and actions affecting approval, production, pricing, reimbursement and marketing of tests, as well as by inter-governmental disputes. Any of these changes could adversely affect our business. Our success internationally will depend, in part, on our ability to develop and implement policies and strategies that are effective in anticipating and managing these and other risks in the countries in which we do business. Failure to manage these and other risks may have a material adverse effect on our operations in any particular country and on our business as a whole.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign governments may impose reimbursement standards, which may adversely affect our future profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our tests in foreign jurisdictions and as such may be subject to rules and regulations in those jurisdictions relating to our testing. In some foreign countries, the reimbursement of diagnostic tests is subject to governmental control. In these countries, reimbursement negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a test candidate. If reimbursement of our future tests is unavailable or limited in scope or amount, or if reimbursement rates are set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Domestic and international data protection laws and regulations may restrict our activities and increase our costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and international data protection laws and regulations may affect our collection, use, storage, and transfer of information obtained within and outside of the United States. State privacy and data security laws in the United States are becoming more stringent.  For example, California adopted the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), which was effective in January 2020.  The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches.  In addition to the CCPA, other states are introducing similar legislation which will impact compliance obligations and increase complexity and cost of compliance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union ("EU") has adopted the GDPR, which applies to all EU member states. The GDPR requires us to meet new and more stringent requirements regarding the handling of personal data about European Union residents. Failure to meet GDPR requirements could result in penalties of up to $20 million Euros or 4% of our worldwide revenue, whichever is higher.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional procedures to ensure compliance with the new EU data protection rules. The GDPR is a complex law with still evolving regulatory guidance, including with respect to how the GDPR should be applied in the context of clinical studies or other transactions from which we may gain access to personal data. Furthermore, many of the countries within the European Union are still in the process of drafting supplementary data protection legislation in key fields where the GDPR allows for national variation, including the fields of clinical study and other health-related information. These variations in European data protection laws may raise our costs of compliance and result in greater legal risks. Failure to comply with data protection laws and regulations could result in government enforcement actions, which may involve civil and criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Each of our molecular diagnostic tests is processed in a single one of our laboratory facilities, and any loss or prolonged interruption of our ability to use these laboratories or failure to maintain their operation in compliance with applicable regulations would seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a CLIA-certified facility in Salt Lake City, Utah to perform most of our molecular diagnostic tests; a CLIA-certified laboratory in South San Francisco, California to perform our Foresight and Prequel tests; a single laboratory facility in Cologne, Germany to perform and produce our EndoPredict test kits; and a CLIA-certified laboratory in Mason, Ohio to perform our GeneSight test. Our laboratory in South San Francisco is near major earthquake faults known for seismic activity and in a region affected by wildfires. These facilities and certain pieces of laboratory equipment would be difficult to replace and may require significant lead time to replace and qualify for use if they became inoperable. We currently have no backup or redundant facility to perform each of our molecular diagnostic tests. In the event any of our clinical testing facilities were to lose its CLIA certification or other required certifications or licenses or were affected by a pandemic or man-made or natural disaster, such as an earthquake, severe weather, flooding, rising sea levels, other physical effects of climate change, power outages or contamination, we would be unable to continue our molecular diagnostic business at current levels to meet customer demands for a significant period of time. Although we maintain insurance on these facilities, including business interruption insurance, it may not be adequate to protect us from all potential losses if these facilities were damaged or destroyed. In addition, any interruption in our molecular diagnostic business would result in a loss of goodwill, including damage to our reputation. If our molecular diagnostic business were interrupted, it would seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a limited number of third parties for some of our supplies of equipment and reagents. If these supplies become unavailable or are disrupted, including as a result of COVID-19 and responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a small number of suppliers to provide our gene sequencing equipment, content enrichment equipment, multiplex protein analysis equipment, robots, and specialty reagents and laboratory supplies required in connection with our testing and research. We believe that currently there are limited alternative suppliers of the equipment, robots, and reagents. The equipment, robots, or reagents may not remain available in commercial quantities at acceptable costs. If we are unable to obtain when needed additional or alternative equipment or robots, or an adequate supply of reagents or other ingredients at commercially reasonable rates, our ability to continue to identify genes and perform molecular diagnostic testing would be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the continued spread of COVID-19 globally could further adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and both international and domestic components may continue to be subject to disruption as a result of COVID-19 and ongoing responses to it. We have experienced and may continue to experience a shortage of certain laboratory supplies and equipment, and we may experience a suspension of services from other laboratories or third parties as a result of COVID&#8209;19 and ongoing responses to it. Political, administrative, legislative, legal or regulatory actions in response to COVID&#8209;19, including the possible use of the Defense Production Act in the United States to compel manufacturers to prioritize other products or customers over us, could create additional supply shortages, disruptions or other uncertainties affecting our research and business. If the supplies and components necessary to manufacture our products become unavailable or are disrupted as a result of COVID-19 and ongoing responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to discover genes, proteins, and biomarkers, and to validate and commercialize molecular diagnostic and companion diagnostic tests could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with research collaborators at academic and other institutions who conduct research at our request. These research collaborators are not our employees. As a result, we have limited control over their activities and, except as otherwise required by our collaboration agreements, can expect only limited amounts of their time to be dedicated to our activities. Our ability to discover genes, proteins, and biomarkers involved in human disease and validate and commercialize molecular diagnostic and companion diagnostic tests will depend in part on the continuation of these collaborations. If any of these collaborations are terminated, we may not be able to enter into other acceptable collaborations. In addition, our existing collaborations may not be successful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborators and scientific advisors may have relationships with other commercial entities, some of which could compete with us. Our research collaborators and scientific advisors sign agreements which provide for the confidentiality of our proprietary information. We may not, however, be able to maintain the confidentiality of our technology and other confidential information related to all collaborations. The dissemination of our confidential information to third parties could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to protect our proprietary technology, others could compete against us more directly, which would harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, our patent portfolio included issued patents owned or licensed by us and numerous patent applications in the United States and other countries with claims protecting our intellectual property rights. Our commercial success will depend, in part, on our ability to obtain additional patents and licenses and protect our existing patent position, both in the United States and in other countries, for compositions, processes, methods and other inventions that we believe are patentable. Our ability to preserve our trade secrets, proprietary data bases and other intellectual property is also important to our long-term success. If our intellectual property is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. Patents may also issue to third parties which could interfere with our ability to bring our molecular diagnostic tests to market. The laws of some foreign countries do not protect our proprietary rights to the same extent as U.S. laws, and we may encounter significant problems in protecting our proprietary rights in these countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of diagnostic companies, including our patent position, are generally highly uncertain and involve complex legal and factual questions, and, therefore, any patents issued to us may be challenged, deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and any future tests are covered by valid and enforceable patents or are effectively maintained as trade secrets. Our patent applications may never issue as patents, and the claims of any issued patents may not afford meaningful protection for our technology or tests. In addition, any patents issued to us or our licensors may be challenged, and subsequently narrowed, invalidated or circumvented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where necessary, we may initiate litigation to enforce our patent or other intellectual property rights. Any such litigation may require us to spend a substantial amount of time and money and could distract management from our day-to-day operations. Moreover, there is no assurance that we will be successful in any such litigation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors were the first to make the inventions covered by each of our patent applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our or our licensors&#8217; patent applications will result in issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our or our licensors&#8217; patents will be valid or enforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us or our licensors and collaborators will provide a basis for commercially viable tests, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional proprietary technologies or tests that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have an adverse effect on our business; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our patents or patents that we license from others will survive legal challenges and remain valid and enforceable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party files a patent application with claims to subject matter we have invented, the United States Patent and Trademark Office (&#8220;USPTO&#8221;) may declare interference between competing patent applications. If an interference is declared, we may not prevail in the interference. If the other party prevails in the interference, we may be precluded from commercializing services or tests based on the invention or may be required to seek a license. A license may not be available to us on commercially acceptable terms, if at all. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technologies and databases. Although we require employees, consultants and collaborators to sign confidentiality agreements, we may not be able to adequately protect our rights in such unpatented proprietary technologies and databases, which could have a material adverse effect on our business. For example, others may independently develop substantially equivalent proprietary information or techniques or otherwise gain access to our proprietary technologies or disclose our technologies to our competitors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were sued for patent infringement by third parties, we might incur significant costs and delays in test introduction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tests may also conflict with patents that have been or may be granted to others. Our industry includes many organizations that have or are seeking to discern biomarkers and develop genomic, proteomic and other technologies. To the extent any patents are issued or have been issued to those organizations, the risk increases that the sale of our molecular diagnostic and companion diagnostic tests currently being marketed or under development may give rise to claims of patent infringement. Others may have filed and in the future are likely to file patent applications covering biomarkers that are similar or identical to our tests. Any of these patent applications may have priority over our patent applications and these entities or persons could bring legal proceedings against us seeking damages or seeking to enjoin us from testing or marketing our tests. Patent litigation is costly, and even if we prevail, the cost of such litigation could have a material adverse effect on us. If the other parties in any such actions are successful, in addition to any liability for damages, we could be required to cease the infringing activity or obtain a license. Any license required may not be available to us on commercially acceptable terms, if at all. Our failure to obtain a license to any technology that we may require to commercialize our tests could have a material adverse effect on our business. In addition, we could experience delays in product introductions or sales growth while we attempt to develop non-infringing alternatives. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there may be significant litigation in the industry regarding patent and other intellectual property rights. If we become involved in this litigation, it could consume a substantial portion of our managerial and financial resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately prevent disclosure of trade secrets, proprietary databases, and other proprietary information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect our proprietary technologies and databases, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and others to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy if unauthorized disclosure of confidential information occurs. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive position.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under license or technology agreements with third parties, we could lose license rights that are critical to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license intellectual property that is important to our business, including licenses underlying the technology in our molecular diagnostic tests, and in the future, we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. These licenses impose various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from distributing our current tests, or inhibit our ability to commercialize future test candidates. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in our industry, we employ individuals who were previously employed at universities or genetic testing, diagnostic, biotechnology or other health care companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of a former employer or other third parties. Litigation may be necessary to defend against these claims, and if we are unsuccessful, we could be required to pay substantial damages and could lose rights to important intellectual property. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to extensive federal, state, local and foreign laws and regulations, all of which are subject to change.  These laws and regulations currently include, among other things:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLIA, which requires that laboratories obtain certification from the federal government, and state licensure laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA laws and regulations that apply to medical devices such as our in vitro diagnostics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions; amendments to HIPAA under HITECH, which strengthened and expanded HIPAA privacy and security compliance requirements, increased penalties for violators, extended enforcement authority to state attorneys general and imposed requirements for breach notification;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws regulating genetic testing and protecting the privacy of genetic test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018 (EKRA), which is an all-payor anti-kickback prohibition on, among other things, knowingly and willfully paying or offering any remuneration directly or indirectly to induce a referral of an individual to a clinical laboratory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician self-referral prohibition (Stark Law), which, absent an exception, prohibits a physician from making a referral for certain designated health services, including clinical laboratory services, if the physician or an immediate family member of the physician has an applicable financial relationship with the entity providing the designated health services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires medical device manufactures to track and report to the federal government certain payments and other transfers of value made to physicians and teaching hospitals and ownership or investment interests held by physicians and their immediate family members;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Section 216 of the federal Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), which requires the Centers for Medicare &amp; Medicaid Services to set Medicare rates for clinical laboratory testing based on private payor data reported by applicable laboratories;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that impose reporting and other compliance-related requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">similar foreign laws and regulations that apply to us in the countries in which we operate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical laboratory, our business practices may face heightened scrutiny from government enforcement agencies such as the Department of Justice, the OIG, and CMS. The OIG has issued fraud alerts in recent years, including a fraud alert relating to speaker programs in November 2020, that identify certain arrangements between clinical laboratories and referring physicians as implicating the Anti-Kickback Statute. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from the patient. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the federal self-referral prohibition, commonly known as the Stark Law or the Physician Self-Referral Law, unless the arrangement meets all criteria of an applicable exception. The government has actively enforced these laws against clinical laboratories in recent years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. Our failure to comply could lead to civil or criminal penalties, exclusion from participation in state and federal health care programs, or prohibitions or restrictions on our laboratories&#8217; ability to provide or receive payment for our services. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our business and our expansion outside of the United States may increase the potential of violating similar foreign laws or our internal policies and procedures. The risk of us being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the government and third-party payors fail to provide coverage and adequate payment for our existing and future tests, if any, our revenue and prospects for profitability will be harmed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our molecular diagnostic tests or any future diagnostic tests will depend in large part, upon the availability of reimbursement from third-party payors. Such third-party payors include state and federal health care programs such as Medicare, managed care organizations, private health insurers and other organizations. These third-party payors are increasingly attempting to contain health care costs by demanding price discounts and limiting both coverage regarding which diagnostic tests they will pay for and the amounts that they will pay for existing and new molecular diagnostic tests. We have experienced price reductions from CMS for some of our products, including for our GeneSight&#174; psychotropic test subsequent to the July 2020 release of the final pharmacogenomics LCD, and we may experience future price reductions from CMS, managed care organizations, and other third-party payors. The fact that a diagnostic test has been approved for reimbursement in the past, for any particular indication or in any particular jurisdiction, does not guarantee that such a diagnostic test will remain approved for reimbursement, that the reimbursement amount approved for such test will not be reduced in the future, or that similar or additional diagnostic tests will be approved in the future. Moreover, there can be no assurance that any new tests we have launched or may launch will be reimbursed at rates that are comparable to the rates that we historically obtained for our existing product portfolio. As a result, third-party payors may not cover or provide adequate payment for our current or future molecular diagnostic tests to enable us to maintain past levels of revenue or profitability with respect to such tests. Further, third-party reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development. In addition, under PAMA, Medicare reimbursement for any given diagnostic test is based on the weighted-median of the payments made by private payors for such test, rendering private payor payment levels even more significant. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of diagnostic tests generally and any given test individually. On December 10, 2021, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which included a provision that delays the next PAMA reporting period for clinical laboratory tests that are not advanced diagnostic tests to January 1, 2023 through March 31, 2023. In addition, the next round of rate cuts will not be implemented until 2023, with tests receiving cuts of up to 15 percent a year from 2023 through 2025. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any declines in average selling prices of our products due to pricing pressures may have an adverse impact on our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign governments continue to propose and pass legislation designed to reduce the cost of health care.  For example, in some foreign markets, the government controls the pricing of many health care products. We expect that there will continue to be federal and state proposals to implement governmental controls or impose health care requirements. In addition, the Medicare program and increasing emphasis on managed care in the United States will continue to put pressure on product pricing. Cost control initiatives could decrease the price that we would receive for any tests in the future, which would limit our revenue and profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA regulation of our industry generally or our tests specifically could be disruptive to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described further below, the FDA has long claimed authority to regulate laboratory-developed tests but has exercised its &#8220;enforcement discretion&#8221; to limit enforcement of in vitro diagnostic regulatory requirements on this category of products. The FDA has from time to time appeared to increase its attention to the marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding &#8220;genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications.&#8221; This safety communication explained that the FDA had reached out to several firms marketing such pharmacogenetic tests where the FDA believed the relationship between genetic variations and a medication&#8217;s effects had not been established, including a warning letter to Inova Genomics Laboratory.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, we provided the FDA with clinical evidence and other information to support our GeneSight Psychotropic test. Later that year, the FDA requested changes to the GeneSight test offering. Although we disagreed that changes to the test were required, we submitted a proposal regarding the reporting of GeneSight test results to healthcare providers that we believed addressed the FDA&#8217;s principal concerns and would not affect the benefits that we believe are provided by the GeneSight test.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since submitting our proposal to the FDA, we engaged with our trade association in their efforts to defend the offering of pharmacogenomic tests as LDTs and to monitor broader developments across the stakeholder community. In response to public letters from the national laboratory trade association and patient groups, on February 20, 2020, the FDA announced a new &#8220;collaboration between FDA&#8217;s Center for Devices and Radiological Health and Center for Drug Evaluation and Research intended to provide the agency&#8217;s view of the state of the current science in pharmacogenetics.&#8221; Although the announcement again asserted that some of these test offerings may be potentially dangerous, the agency also acknowledged that pharmacogenetic testing &#8220;offers promise for informing the selection or dosing of some medications for certain individuals.&#8221; In conjunction with the announcement, the FDA also released an updated &#8220;Table of Pharmacogenetic Associations,&#8221; which lists gene-drug interactions that the agency believes are supported by FDA-approved drug labeling and/or &#8220;sufficient scientific evidence based on published literature.&#8221; The Table has been updated periodically since that time. Based on our discussions with the agency and these recent developments, we have not implemented our earlier proposal. While we see these developments as signaling a positive shift in the FDA&#8217;s approach to regulating pharmacogenetic tests, we cannot predict with certainty the outcome of this matter or its timing, or whether the ultimate form of the GeneSight Psychotropic test offering will have an adverse effect on our revenues from the test.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with laws and regulations related to submission of claims for our services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs and corresponding foreign reimbursement programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other state, federal and foreign health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Our failure to comply with applicable laws and regulations could result in our inability to receive payment for our services or in attempts by state and federal health care programs, such as Medicare and Medicaid, to recover payments already made. Submission of claims in violation of these laws and regulations can result in recoupment of payments already received, substantial civil monetary penalties, and exclusion from state and federal health care programs, and can subject us to liability under the federal False Claims Act and similar laws. The failure to report and return an overpayment to the Medicare or Medicaid program within 60 days of identifying its existence can give rise to liability under the False Claims Act. Further, a government agency could attempt to hold us liable for causing the improper submission of claims by another entity for services that we performed if we were found to have knowingly participated in the arrangement at issue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may from time to time be subject to government investigation(s), the unfavorable outcome of which may have a material adverse effect on our financial condition, results of operations and cash flows.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time be subject to government investigations, which may divert management resources and attention, cause us to incur substantial costs, and/or result in negative publicity, and any unfavorable outcome arising from such investigation may have a material adverse effect on our financial condition, results of operations and cash flows. In June 2016, our wholly-owned subsidiary, Crescendo Bioscience, LLC (formerly known as Crescendo Bioscience, Inc.) (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act. On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On April 16, 2020, CBI filed a motion to dismiss the action with prejudice. On May 23, 2020, the court denied that motion. We have accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend against this action, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued. We may be subject to future claims or investigations under the Federal False Claims Act or a similar state law, and any unfavorable outcome arising from such claims or investigation could have a material adverse effect on our financial condition, results of operations and cash flows. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be harmed by the loss, suspension, or other restriction on a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payors, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant fines or criminal penalties. In addition, we are subject to regulation under state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. We are also subject to laws and regulations governing our reference laboratory in Germany. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the FDA has exercised enforcement discretion with respect to most LDTs and has generally not required laboratories that furnish LDTs to comply with the agency&#8217;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and issued two draft guidance documents that set forth a proposed phased-in risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. However, these guidance documents were not finalized, and the framework was abandoned and replaced by an informal discussion paper reflecting some of the feedback that FDA had received on LDT regulation. The FDA acknowledged that the January 2017 discussion paper does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of the feedback that it had received in the hope that it might advance public discussion on future LDT oversight. Notwithstanding the discussion paper, the FDA continues to exercise enforcement discretion and may attempt to regulate certain LDTs on a case-by-case basis at any time, which could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to potential enforcement priority changes from the FDA, in December 2018, bipartisan members of Congress released a discussion draft of a legislation to regulate in vitro clinical tests including LDTs under a shared FDA/CMS framework, and provided opportunities for stakeholders to comment on the proposed legislation. In 2020, the Verifying Accurate, Leading-edge IVCT Development (&#8220;VALID&#8221;) Act was formally introduced in both chambers of Congress, and it was reintroduced in revised form for the 117th Congress in July 2021.  If enacted, the VALID Act would codify into law the term &#8220;in vitro clinical test&#8221; (IVCT) to create a new medical product category separate from medical devices that includes products currently regulated as in vitro diagnostics (IVDs) as well as LDTs.  The framework would give the FDA the authority to ensure IVCTs are both analytically and clinically valid.  CMS would retain the authority to ensure the quality of operations within laboratories.  All LDTs on the market prior to enactment of the legislation would be grandfathered and not subject to the new regulation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is unclear whether the VALID Act will be passed by Congress in its current form or signed into law by the President. Until the FDA finalizes its regulatory position regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government&#8217;s regulation of LDTs, it is unknown how the FDA may attempt to regulate our tests in the future and what testing and data may be required to support any required clearance or approval of our tests by the agency. If the VALID Act is implemented as drafted it could have an adverse material impact on our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Companion and complementary diagnostic tests require FDA approval and we may not be able to secure such approval in a timely manner or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our companion and complementary diagnostic products, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA), by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, companion diagnostics must receive FDA clearance or approval before they can be commercially marketed in the U.S. The process of obtaining marketing approval or clearance from the FDA or by comparable agencies in foreign countries for new products could:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant period of time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous pre-clinical testing, as well as increased post-market surveillance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require changes to products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in limitations on the indicated uses of products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have successfully achieved FDA approval for some tests (e.g., our BRAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CDx and MyChoice CDx tests), we cannot predict whether or when we will be able to obtain FDA approval for other companion diagnostics that we are developing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is highly volatile, and our stock may lose all or a significant part of its value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of molecular diagnostic companies have been volatile. This volatility has significantly affected the market prices for these securities for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock. The market price for our common stock has fluctuated significantly since public trading commenced in October 1995, and it is likely that the market price will continue to fluctuate in the future. In the year ended December 31, 2021, our stock price has ranged from $19.92 per share to $36.66 per share.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general has experienced extreme price and volume fluctuations. Events or factors that may have a significant impact on our business and on the market price of our common stock include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">major market events, such as the market&#8217;s reaction to the COVID-19 pandemic generally and its specific impact on the Company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our recently launched tests and any new test candidates to achieve commercial success;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to sustain revenue growth or margins in our molecular diagnostic business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems and changes in governmental or private insurer reimbursement levels for our molecular diagnostic tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new commercial tests or technological innovations by competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of the licenses underlying our molecular diagnostic tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or other problems with operating our laboratory facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our research and development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in intellectual property laws or the enforcement or validity of our patents in the United States and foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights involving us directly or otherwise affecting the industry as a whole;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">missing or changing the financial guidance we provide;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts relating to our common stock or the securities of our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the government regulatory approval process for our existing and new tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet estimates or recommendations by securities analysts that cover our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our approved tests and any test candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and regulatory investigations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales or anticipated sales of our common stock by us or our stockholders;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of any repurchases of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seasonal slowness in sales, particularly in the quarters ending September 30th and March 31st, the effects of which may be difficult to understand during periods of growth;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general perception of the molecular diagnostic industry and our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, health care and diagnostic trends, disasters or crises and other external factors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other external factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, securities class action litigation such as the current stockholder suit pending against the Company discussed elsewhere in this section and certain related matters may affect the market price and demand for our common stock. If any of our other stockholders brought another lawsuit against us, we could incur substantial costs defending the lawsuit regardless of the outcome. Such a lawsuit could also divert the time and attention of our management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified two material weaknesses in our internal control over financial reporting related to our income tax provision process and our general information technology controls and such weaknesses led to a conclusion that our internal control over financial reporting and disclosure controls and procedures were not effective as of December 31, 2021. Our inability to remediate these material weaknesses, our discovery of any additional weaknesses, or our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence in us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404 of the Sarbanes-Oxley Act of 2002 requires that companies evaluate and report on the effectiveness of their internal control over financial reporting. In addition, we regularly engage our independent registered public accounting firm to report on its evaluation of those controls. As disclosed in more detail under Item 9A, &#8220;Controls and Procedures&#8221; below, during the preparation of our condensed consolidated quarterly financial statements as of September 30, 2021, management concluded that a material weakness in internal control over financial reporting existed related to our income tax provision process. Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the gain/loss calculation related to a divestiture within the interim consolidated income tax provision and related accrual. While we have taken steps to remediate the material weakness, including steps to design and implement enhanced controls over the review of information underlying discrete transactions in the income tax provision, and we plan to continue taking additional steps to remediate the material weakness, this material weakness has not been remediated as of December 31, 2021. Management also concluded that a material weakness in internal control over financial reporting exists related to general information technology controls for information systems that are relevant to the preparation of the financial statements. Specifically, the material weakness resulted from the aggregation of control deficiencies related to systems supporting our internal control processes. Due to the material weaknesses in our internal control over financial reporting, we have also concluded that our disclosure controls and procedures were not effective as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to have effective internal control over financial reporting and disclosure controls and procedures could impair our ability to produce accurate financial statements on a timely basis and could lead to a restatement of our financial statements. If, as a result of the ineffectiveness of our internal control over financial reporting and disclosure controls and procedures, we cannot provide reliable financial statements, our business decision processes may be adversely affected, our business and results of operations could be harmed, investors could lose confidence in our reported financial information, and our ability to obtain additional financing, or additional financing on favorable terms, could be adversely affected. In addition, failure to maintain effective internal control over financial reporting could result in investigations or sanctions by regulatory authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has taken steps to remediate the material weakness related to our income tax provision process and our management will take steps to remediate the material weaknesses, including continuing to take steps to design and implement enhanced controls over the review of information underlying discrete transactions in the income tax provision, implementing improved IT policies, procedures and control activities for key systems which impact our financial reporting, and increasing resources dedicated to monitoring general information technology controls related to financial reporting to ensure compliance with policies and procedures. We intend to remediate these material weaknesses as soon as possible, but we cannot be certain as to when remediation will be completed. Additional details regarding the remediation efforts are disclosed under Item 9A, &#8220;Controls and Procedures&#8221; below. In addition, we may in the future identify additional internal control deficiencies that could rise to the level of a material weakness or uncover other errors in financial reporting. During the course of our evaluation of these material weaknesses, we may identify areas requiring improvement and may be required to design additional enhanced processes and controls to address issues identified through this review. In addition, there can be no assurance that such remediation efforts will be successful, that our internal control over financial reporting will be effective as a result of these efforts or that any such future deficiencies identified may not be material weaknesses that would be required to be reported in future periods. In addition, we cannot assure you that our independent registered public accounting firm will be able to attest that such internal controls are effective when they are required to do so.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to remediate the material weaknesses and maintain effective disclosure controls and procedures or internal control over financial reporting, you may not be able to rely on the integrity of our financial results, which could result in inaccurate or late reporting of our financial results, as well as delays or the inability to meet our reporting obligations or to comply with SEC rules and regulations. Any of these could result in delisting actions by the Nasdaq Stock Market, investigation and sanctions by regulatory authorities, stockholder investigations and lawsuits, and could adversely affect our business and the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions of Delaware law, provisions in our charter and bylaws and re-adoption of our stockholders&#8217; rights plan, or poison pill, could make a third-party acquisition of us difficult.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are a Delaware corporation, the anti-takeover provisions of Delaware law could make it more difficult for a third party to acquire control of us, even if the change in control would be beneficial to stockholders. We are subject to the provisions of Section 203 of the General Corporation Law of Delaware, which prohibits us from engaging in certain business combinations, unless the business combination is approved in a prescribed manner. In addition, our restated certificate of incorporation and restated bylaws also contain certain provisions that may make a third-party acquisition of us difficult, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified board of directors, with three classes of directors each serving a staggered three-year term;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the board of directors to issue preferred stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a 70% super-majority stockholder vote to amend our bylaws and certain provisions of our certificate of incorporation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of our stockholders to call a special meeting or act by written consent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we implemented a stockholders&#8217; rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire the Company on a hostile basis. Although the plan expired in July 2011, our Board of Directors could adopt a new plan at any time. The provisions in a stockholders&#8217; rights plan, as well as Section 203, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over the then-current market price, and may limit the ability of our stockholders to approve transactions that they think may be in their best interests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to changes in the value of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of our Amended Facility restrict our ability to pay dividends. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our Board of Directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If few analysts commence coverage of us, the trading of our stock would likely decrease. Even if we do obtain sufficient analyst coverage, there can be no assurance that analysts will provide favorable coverage. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restated bylaws provide that a state court located within the State of Delaware is the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated bylaws provide that a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our restated bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the exclusive forum provision contained in our restated bylaws to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_22"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_25"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters and facilities are located in Salt Lake City, Utah. We currently lease a total of approximately 343,000 square feet of building space in Salt Lake City dedicated to research and development, administration and our laboratory that has received federal certification under CLIA. Activities related to our oncology, urology, and women&#8217;s health molecular diagnostic business are performed at this location.&#160;&#160;The leases on our existing Salt Lake City facilities have terms of five to fifteen years, expiring from 2025 through 2036, and provide for renewal options for up to ten additional years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease approximately 93,000 square feet in South San Francisco, California under two leases that expire in April 2025 and September 2025.&#160; This space is dedicated to administration, research and development and the CLIA-certified laboratory for our Women&#8217;s Health business.&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease a space in Mason, Ohio, with approximately 24,000 total square feet, which will expire in August 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in late 2021, we entered into a non-cancelable operating lease for approximately 63,000 square feet in South San Francisco, California, which will commence in 2023 and expire in 2033. In the first quarter of 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in Salt Lake City, Utah, which will commence in 2022 and expire in 2038.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease several small office locations, including our manufacturing facility located in Cologne, Germany. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities and equipment are well maintained and in good working condition. We believe our current facilities and those planned will provide adequate capacity for the foreseeable future. We continue to make investments in capital equipment as needed to meet the anticipated demand for our molecular diagnostic tests.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ifead9d28cda549c1af769d1d50d95807_28"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, our wholly-owned subsidiary, Crescendo Bioscience, LLC (formerly known as Crescendo Bioscience, Inc.) (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.&#160;&#160;On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. We have accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend against this case, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah, against the Company, our former President and Chief Executive Officer, Mark C. Capone, and our Chief Financial Officer, R. Bryan Riggsbee (&#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added our former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. We intend to vigorously defend against this action.&#160;Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against our former President and Chief Executive Officer, Mark C. Capone, our Chief Financial Officer, R. Bryan Riggsbee, our former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of our current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding our business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On January 18, 2022, a third stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock and Marcey stockholder derivative actions. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo (the "Abelli lawsuit"). The plaintiffs claimed negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004. The plaintiffs sought damages allegedly s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ustained by them by reason of the allegations set forth in their complaint, together with interest and costs. As of December 31, 2021, we accrued $14.0 million for a potential settlement of this lawsuit, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet as of December 31, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On January 24, 2022, the Company entered into an agreement with the plaintiffs to settle the lawsuit. Pursuant to the terms of the settlement agreement, the Company agreed to pay $14.0 million to the plaintiffs. The settlement agreement also provides for a full release by the plaintiffs of all claims against the Company and contains no admission of liability, wrongdoing or responsibility on the part of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other than as set forth above, we are not a party to any legal proceedings that we believe will have a material impact on our business, financial position or results of operations.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_31"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ifead9d28cda549c1af769d1d50d95807_37"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol "MYGN."&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 18, 2022, there were approximately 99 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ard of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock, of which $110.7 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is still available to repurchase as of December&#160;31, 2021. We are authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management&#8217;s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. The repurchase program may be suspended or discontinued at any time without prior notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock repurchases were made under our stock repurchase program during the year ended December&#160;31, 2021.</span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph set forth below compares the annual percentage change in our cumulative total stockholder return on our common stock during a period commencing on December 31, 2016 and ending on December&#160;31, 2021 (as measured by dividing (A) the difference between our share price at the end and the beginning of the measurement period by (B) our share price at the beginning of the measurement period) with the cumulative total return of The Nasdaq Composite Index (IXIC) and the Nasdaq Health Care Index (IXHC) during such period.&#160;&#160;We have not paid any cash dividends on our common stock, and we do not include cash dividends in the representation of our performance.&#160;&#160;The price of a share of common stock is based upon the closing price per share as quoted on The Nasdaq Global Select Market on the last trading day of the year shown.&#160;&#160;The graph lines merely connect year-end values and do not reflect fluctuations between those dates.&#160;&#160;The comparison assumes $100 was invested on December 31, 2016 in our common stock and in each of the foregoing indices.&#160;&#160;The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.</span></div><div style="margin-top:6pt;text-align:center"><img src="mygn-20211231_g1.gif" alt="mygn-20211231_g1.gif" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myriad Genetics, Inc.</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;206.06 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;174.39 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;163.35 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;118.60 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.81 </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Composite Index (IXIC)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;128.24 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;123.26 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;166.68 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;239.42 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.42</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Health Care Index (IXHC)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;121.30 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;116.25 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;146.27 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;190.21 </span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.47</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note:&#160;&#160;Information used on the graph was obtained from the CRSP Total Return Indexes, a source believed to be reliable, but we are not responsible for any errors or omission in such information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_40"></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div id="ifead9d28cda549c1af769d1d50d95807_43"></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included elsewhere in this Report. Unless otherwise noted, all of the financial information in this Report is consolidated financial information for the Company.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower health care costs. Our mission is to advance health and well-being for all, empower individuals with vital genetic insights and enable healthcare providers to better detect, treat and prevent disease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently executing upon a strategic transformation plan that is focused on the following strategic priorities: (1) innovation that improves clinical outcomes, ease of use, and access; (2) enterprise capabilities to accelerate growth and scale to market opportunity; and (3) focus on execution and delivery of consistent results. In connection with these strategic priorities, we are focusing our efforts on our Oncology, Women's Health, and Mental Health products. We intend to develop and enhance best-in-class products to support growth, improve patient and provider experience, and reach more patients of all backgrounds. By investing in tech-enabled commercial tools, we believe we will be able to drive increased engagement, improve revenue cycle management, and reduce complexity and cost. We are committed to disciplined management of our initiatives to fulfill our mission and drive long-term growth and profitability. With a foundation of financial, commercial, operational and technological strength, we expect to accelerate growth as we launch a new enterprise commercial model, launch a unified ordering portal, invest in new sequencing technologies, further develop direct-to-consumer channels, and build commercial capabilities to support new products and offerings.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated revenues consist primarily of sales of molecular diagnostic tests through our wholly-owned subsidiaries.&#160;&#160;During the year ended December&#160;31, 2021, we reported total revenues of $690.6 million, net loss attributable to Myriad Genetics, Inc. stockholders of $27.2 million and basic and diluted loss per share of $0.35.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry and Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients, healthcare providers, payors and health systems are looking to apply the power of genetic insights, molecular diagnostics and precision medicine to achieve improved clinical outcomes and lower cost. Key industry trends include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerating shifts in consumer engagement, early detection, home-based care models, the rise of low-cost sequencing, telemedicine and virtual care; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in the way outpatient care is delivered in the midst of the COVID-19 pandemic, coupled with broadened awareness of the vital role of diagnostic testing; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding access to genetic insights, particularly among underserved populations with increased focus on health equity, reducing disparities in health care outcomes and ensuring increased access for challenged communities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader, more innovative use of large data sets and analytics; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">growth in personalized medicine </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the interest in new partnership models to advance companion diagnostics and serve patients with specific treatments based on their own genetic makeup and biology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These market trends create new opportunities to position us, and our products, for growth and commercial success through enhanced customer service levels and a stronger alignment of our value proposition with physicians and payors. Our focus is on innovative science that improves health outcomes, access for all, and ease of experience in the genetic testing process. We expect to use our ability to innovate not only in research, development and technology, but also in go-to-market approaches, commercial capabilities, and tech-enabled applications so that we can adapt quickly to customer preferences and market dynamics.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced seasonality in our testing business. The quarter ended December 31st is generally strong as we typically experience an increase in volumes from patients who have met their annual insurance deductible. Conversely, in the quarter ended March 31st we typically experience a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. These seasonality patterns have generally continued during the COVID-19 pandemic, but due to the continued uncertainty surrounding the COVID-19 pandemic, we cannot predict if seasonality will follow the same pattern as in prior years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Consolidated Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Molecular Diagnostic Testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our molecular diagnostic tests are designed to analyze genes and their expression levels to assess an individual&#8217;s risk for developing disease later in life, determine a patient&#8217;s likelihood of responding to a particular drug, or assess a patient&#8217;s risk of disease progression. Provided with this valuable information, physicians may more effectively manage their patients&#8217; health care. Revenue is recognized when the communication of test results has occurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutical and Clinical Service</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On July 1, 2021, we divested Myriad RBM, Inc., which provided pharmaceutical and clinical services. As a result, we ceased providing pharmaceutical and clinical services as of that date. We also divested of other clinical operations in February 2020. Through Myriad RBM, Inc., we provided biomarker discovery, pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing our multiplexed immunoassay technology. Revenue for these services was recognized at the completion of the pharmaceutical and clinical services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs and Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related costs for each category of Costs and Expenses includes salaries, bonuses, employee benefit costs, employer payroll taxes, and stock-based compensation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Molecular Diagnostic Testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of molecular diagnostic testing consists primarily of costs related to lab supplies, personnel-related costs, and overhead costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Pharmaceutical and Clinical Service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of pharmaceutical and clinical service consists primarily of costs related to lab supplies and personnel-related costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consists primarily of personnel-related costs and lab supplies, which includes costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our current molecular diagnostic test offerings and costs incurred for the discovery, development and validation of our pipeline of molecular diagnostic and companion diagnostic candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative expenses include costs associated with managing and growing our businesses. Selling, general and administrative expenses consist primarily of salaries, commissions, related personnel costs, and third-party costs for sales, marketing, customer service, billing and collection, legal, finance and accounting, information technology, and human resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill and long-lived asset impairment charges includes the impairment loss recognized on the Company's goodwill or long-lived assets, including impairments recognized on intangible assets and right-of-use lease assets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) includes interest income earned on our cash and cash equivalents holdings in short-term interest-bearing accounts; interest expense associated with our debt and amortization of deferred financing costs and original issue discount costs; gains or losses on the sale of assets or businesses; and foreign currency gains and losses, realized gain or loss on marketable securities, and other nonrecurring income and expenses.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_49"></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section of Management&#8217;s Discussion and Analysis generally discusses year-to-year comparisons between the year ended December 31, 2021 and the comparative year ended December 31, 2020. Due to our change in fiscal year from June 30th to December 31st, effective January 1, 2021, the comparative year ended December 31, 2020 was unaudited. Discussions of comparisons between (1) the transition period for the six months ended December 31, 2020 and the comparative period of the six months ended December 31, 2019 and (2) the years ended June 30, 2020 and June 30, 2019 that are not included in this Annual Report on Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Item 7 of Part II of our Transition Report on Form 10-K for the transition period ended December 31, 2020, filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December 31, 2021 and 2020 </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.264%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical service revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues for the year ended December 31, 2021 increased $152.9 million compared to the same period in the prior year. Revenue for the year ended December 31, 2020 was negatively impacted by the pandemic as patients faced significant obstacles accessing healthcare professionals. Tumor Profiling revenues increased $62.5 million compared to the same period in the prior year due to a $31.9 million increase in revenue for Prolaris due to expanded coverage and the submission of claims for previously performed tests that were pending clarification of the coverage policy, as well as a $25.3 million increase in revenues from MyChoice CDx due to expansion in Japan and other areas. Revenue from Pharmacogenomics increased $35.0 million compared to the same period in the prior year due primarily to a 58% increase in volume. Prenatal revenues increased $32.3 million compared to the same period in the prior year due primarily to an increase of 19% in the average reimbursement per test and an increase of 12% in volume, as well as a change in estimate related to revenues from prior periods. Hereditary Cancer revenues increased $31.9 million compared to the same period in the prior year due primarily to a 13% increase in volume as well as a change in estimate related to revenues from prior periods. These increases were partially offset by a $7.5 million decrease in Autoimmune compared to the same period in the prior year due primarily to the completion of the sale of select operating assets and intellectual property, including the Vectra test, from the Myriad Autoimmune business unit, on September 13, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical service revenue for the year ended December 31, 2021 declined $19.4 million compared to the year ended December 31, 2020, primarily due to the sale of Myriad RBM, Inc. on July 1, 2021 and the inclusion of revenue from Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the "Clinic") for two months in the previous period prior to the sale of the Clinic in February 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of molecular diagnostic testing as a percentage of revenue decreased from 28.3% to 26.9% during the year ended December 31, 2021 compared to the year ended December 31, 2020.&#160;&#160;The decrease was primarily driven by the increase in revenue from higher test volumes during the current period, as higher revenues were generated to cover fixed costs of performing the tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of pharmaceutical and clinical services as a percentage of revenue decreased from 3.6% to 1.7% during the year ended December 31, 2021 compared to the year ended December 31, 2020 due to the sale of Myriad RBM, Inc. on July 1, 2021 and the inclusion of the costs related to the Clinic for two months in the previous period prior to the sale of the Clinic in February 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the year ended December 31, 2021 increased by $8.6 million compared to the prior year due primarily to costs incurred in the current year as part of the Company's strategic transformation initiatives, increases in lab expenses, and increases in compensation costs as a result of employee bonus reductions in the prior period stemming from the significant impact of COVID-19 on our financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:109%">Selling, General and Administrative Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Selling, general and administrative expense increased by $40.9 million for the year ended December 31, 2021 compared to the prior year due primarily to a $12.6 million increase in stock-based compensation due to lower stock-based compensation in the prior period as a result of adjustments to stock-based compensation related to the departure of our former Chief Executive Officer, and a $16.2 million increase in costs incurred in the current period as part of the Company's strategic transformation initiatives, as well as an $8.2 million increase in bonus expense as a result of employee bonus reductions in the prior year stemming from the significant impact of the COVID-19 pandemic on our financial results, a $6.3 million increase in legal expenses, a $5.0 million increase in consulting fees, and a $3.3 million increase in IT hardware costs. Increases were partially offset by a $10.5 million decrease in amortization expense and a decrease in sales and marketing expenses of $3.4 million due primarily to fewer in-person sales and marketing events and travel-related expenses.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legal Charges Pending Settlement</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Legal charges pending settlement increased for the year ended December 31, 2021 compared to the prior year due to $62.0 million of accruals related to potential legal settlements, including $48.0 million in connection with the qui tam lawsuit against Crescendo Bioscience, LLC and the Company and $14.0 million in connection with the Abelli lawsuit. There was no corresponding legal charges pending settlement in the prior year. The Abelli lawsuit was subsequently settled on January 24, 2022, pursuant to which the Company agreed to pay $14.0 million to the plaintiffs.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill and Long-lived Asset Impairment Charges</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill and long-lived asset impairment charges decreased for the year ended December 31, 2021 compared to the prior year  due primarily to the Company recognizing goodwill impairment charges in the prior year related to the Autoimmune reporting unit, as well as additional charges related to the abandonment of in-process research and development intangible assets. In the current year, we recognized a $1.8&#160;million impairment to right-of-use assets as a result of the voluntary early termination of certain lease agreements to consolidate space.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Other income (expense) increased for the year ended December 31, 2021 due primarily to the combined $152.2&#160;million net gain recognized on the sales of Myriad RBM, Inc. and the Myriad myPath, LLC laboratory in the current period, partially offset by expenses or losses in the current period, including the $0.6&#160;million net loss recognized on the sale of the Myriad Autoimmune business unit and losses of $5.2&#160;million and $6.5&#160;million for a non-cancelable purchase commitment and inventory, respectively, recognized in connection with the divestiture transactions. The increase in Other income (expenses) was partially offset by the receipt of $14.6&#160;million in stimulus funds from the CARES Act in the prior period. Interest expense decreased due primarily to the repayment of the Company's Amended Facility in full on July 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:109%">Income Tax Benefit </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax rate is the product of a U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit for the year ended December 31, 2021 was $(29.9) million, and our effective tax rate was 52.4%. The change in the effective tax rate for the year ended December 31, 2021 as compared to the prior year is due primarily to the tax benefit recorded in the prior year related to the CARES Act, tax expense recorded in the prior year related to asset impairments, tax benefit recorded in the current year related to the differences between the book and tax basis of assets divested, disallowed executive compensation expenses, the release of a valuation allowance, and stock compensation expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Our primary sources of liquidity are our cash, cash equivalents and marketable investment securities, our cash flows from operations, our cash flows from investing activities, and, in certain circumstances as discussed below, amounts available for borrowing under our Amended Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development, technology and acquisitions. We believe that investing organically through research and development or acquisitively to support business strategy provides the best return on invested capita</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:119%">l. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">During the year ended December 31, 2021, our liquidity increased by $379.1 million from the combined proceeds from the sales of Myriad RBM, Inc., the Myriad Autoimmune business, and the Myriad myPath, LLC laboratory. The cash generated from these divestitures provides us with additional liquidity as we seek out strategic opportunities for capital deployment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources will be sufficient to meet our projected operating requirements for the foreseeable future. In addition, our capital resources and cash on hand may be used for acquisitions or other strategic investments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining borrowings under our Amended Facility, which matures on July 31, 2023, were repaid on July 30, 2021 using cash generated from our recent divestitures. Our available capital resources, however, may be consumed more rapidly than currently expected, and we may need or want to raise additional financing. We may not be able to secure such financing in a timely manner or on favorable terms, if at all. In addition, we are subject to financial covenants as part of our outstanding Amended Facility that could limit our ability to incur additional indebtedness. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations, and potentially delay development of our diagnostic tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0&#160;million, unless such borrowings are in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents, and marketable securities totaled $398.8 million as of December 31, 2021. Our revolving commitment amount is $250.0&#160;million as of December 31, 2021. As the Company's total unrestricted cash, cash equivalents, and marketable securities exceeded $150.0&#160;million as of December 31, 2021, we will be unable to make future borrowings unless related to a permitted acquisition. In addition, following the expiration of the waiver of the leverage ratio and interest coverage ratio covenants, which waiver is effective until March 31, 2022, our ability to borrow under the Amended Facility will be limited if we are unable to comply with those financial covenants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into purchase commitments or other agreements that may materially impact our liquidity position in future periods.  In April 2021, a non-cancelable operating lease for our new corporate headquarters in Salt Lake City, Utah, commenced with a lease term of 15 years and total future lease payments of approximately $66.0&#160;million as of December 31, 2021. In addition, in late 2021, we entered into two non-cancelable operating leases, one for approximately 7,500 square feet in Durham, North Carolina, which expires in 2029, and one for approximately 63,000 square feet in South San Francisco, California, which expires in 2033. The total future lease payments of the new North Carolina and California leases are approximately $2.3&#160;million and $58.8&#160;million, respectively, as of December 31, 2021. As of December 31, 2021, the Company had approximately $4.0 million of non-cancelable contractual purchase obligations with varying terms over the next two years. In the first quarter of 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in Salt Lake City, Utah, which will commence in 2022, with a lease term of 15 years and total future lease payments of approximately $77.8 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the continually evolving global situation from the COVID-19 pandemic, including the emergence of the more highly transmissible Delta and Omicron coronavirus variants and their impact on the ongoing recovery from the earlier effects of the COVID-19 pandemic, it is not possible to predict whether ongoing consequences of the pandemic are reasonably likely to materially affect our liquidity and capital resources in the future. Because of the technical nature of our business and our focus on science, research and development, we are highly dependent upon our ability to attract and retain highly qualified and experienced management, scientific, and technical personnel. Competition and compensation for such personnel and other qualified personnel increased as employment vacancies surged during the year ended December 31, 2021, which has increased the difficulty and cost of hiring and retaining qualified personnel. In addition, potential federal or state regulations that require us to mandate COVID-19 vaccinations for our employees, or any future decision on our part to voluntarily require our employees to receive a COVID-19 vaccine, could impact our ability to hire and retain employees. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our molecular diagnostic business, and it may have a material adverse effect on our business as a whole. Additionally, disruptions to our supply chain as a result of the COVID-19 pandemic could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, inflation has had, and we expect it will continue to have, an impact on the costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the balances of cash, cash equivalents and marketable investment securities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable investment securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable investment securities</span></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash, cash equivalents, and marketable investments securities for the year ended December 31, 2021 was primarily driven by $379.1 million in total cash consideration from the sale of Myriad RBM, Inc., the Myriad Autoimmune business, and the Myriad myPath, LLC laboratory, the receipt of a U.S. federal tax refund of $89.6 million, and proceeds of $91.8 million from the exercise of stock options, partially offset by $226.4 million in repayments of our Amended Facility and $10.5 million in transaction expenses related to the foregoing divestitures, as well as by cash used in operating activities as part of our normal course of business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the transition period ended December 31, 2020, the decrease in cash, cash equivalents and marketable investment securities was primarily driven by the Company using $73.7 million in cash for operating activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the condensed cash flow statement:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents classified as held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at the beginning of the<br/>&#160;&#160;&#160;&#160;&#160;period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2021, the increase in cash flows was primarily due to the change in the balance of prepaid taxes due to the receipt of a $89.6 million U.S. federal tax refund, partially offset by a decrease in cash flows from operating activities primarily driven by a $37.7 million change in trade accounts receivable in the current period compared to the prior period due to the change in sales volumes and cash collections as a result of the significant impact of the COVID-19 pandemic on our financial results during the prior period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2021, the increase in cash flows from investing activities as compared to the same period in the prior year was primarily due to incremental cash proceeds of $357.8 million from divestitures in the current period as compared to the prior period. This increase is partially offset by an increase of $132.0 million of purchases of marketable investment securities in the current period as compared to the prior period, a decrease of $8.2 million in proceeds from marketable investment securities during the current period, and an increase of $4.8 million in capital expenditures in the current period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2021, the decrease in cash flows from financing activities as compared to the same period in the prior year was primarily due to the use of $226.4 million in cash for repayments of the Amended Facility during the current year. The decrease was partially offset by an increase of $80.2 million in proceeds from the exercise of stock options, net of shares exchanged for payroll withholding tax in the current year as compared to the prior year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented. However, inflation has had, and we expect that it will continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies. Inflationary costs may impact our profitability and could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock. We may repurchase our common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by our management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.  As of December&#160;31, 2021, we are authorized to repurchase up to $110.7 million under our current share repurchase authorization.  See &#8220;Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds &#8211; Issuer Purchases of Equity Securities&#8221; below.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those policies which are both important to the portrayal of a company&#8217;s financial condition and results and require management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">revenue recognition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">goodwill; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Revenue is recognized when, or as, performance obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to a customer. We exclude sales, use, value-added, and other taxes we collect on behalf of third parties from revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily by performing molecular diagnostic testing. We perform our obligation under a contract with a customer by processing those diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. Revenue from the sale of molecular diagnostic tests is recorded at the estimated transaction price. We have determined that the communication of test results indicates transfer of control for revenue recognition purposes. We have the right to bill our customers upon the completion of performance obligations and thus do not record contract assets.&#160;Occasionally customers make payments prior to our performance of our contractual obligations.&#160;When this occurs, we record a contract liability as deferred revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments are required in determining the transaction price and satisfying performance obligations under the revenue standard. In determining the transaction price, we estimate the expected amount of consideration as revenue. We apply this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled.&#160;&#160;An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. We consider all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. To determine our estimated transaction price, we apply the expected value method for sales where we have a large number of contracts with similar characteristics. We then consider the probability of the variable consideration for each possible scenario. We have significant experience with historical collection patterns and use this experience to estimate transaction prices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor mix and in payor behavior such as changes in payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss).</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill.&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test goodwill for impairment on an annual basis and in the interim by reporting unit if events and circumstances indicate that goodwill may be impaired.&#160;&#160;The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is evaluated on a qualitative basis before calculating the fair value of the reporting unit. If the qualitative assessment suggests that impairment is more likely than not, a quantitative impairment analysis is performed.&#160;&#160;The quantitative analysis involves comparison of the fair value of a reporting unit with its carrying amount.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of a reporting unit requires judgment in estimating future cash flows, discount rates, residual growth rates and other factors. In making these judgments, we evaluate the financial health of our business, including such factors as industry performance, market saturation and opportunity, changes in technology and operating cash flows.&#160;Changes in our forecasts or decreases in the value of our common stock could cause book value of reporting units to exceed their fair values.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we have recorded goodwill of $239.2 million on our Consolidated Balance Sheet. This goodwill is attributable to the Myriad Mental Health, Myriad International, and Myriad Women's Health reporting units. We qualitatively evaluated the Myriad Mental Health and Myriad International reporting units for impairment. The factors that are considered in the qualitative analysis include macroeconomic conditions, industry and market considerations, revenue growth rates, current and financial performance, other factors that would have a negative effect on earnings and cash flows, and other relevant entity-specific events and information. Significant judgment is required in assessing the weight of the qualitative factors. We noted no indicators of impairment during the year ended December 31, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our Myriad Women's Health reporting unit, we elected to perform a quantitative assessment of goodwill. We measured the fair value of the Myriad Women's Health reporting unit utilizing the market approach and the discounted cash flow method under the income approach. As a result of the assessment, no goodwill impairment charges were recorded as the estimated fair value of the reporting unit exceeded the carrying value of the goodwill as of December 31, 2021. We performed a sensitivity analysis of the discount rate and the revenue growth rate, which are significant assumptions in the calculation of fair value. We determined that a 1% increase in the discount rate or a 1% decline in forecasted revenue growth would not have changed our determination that the fair value of the reporting unit was in excess of its carrying value. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, and other financial assumptions, which are based upon our long-term plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While we use the best available information to prepare our cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology used has remained unchanged.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Our income tax provision is based on income before taxes and is computed using the liability method in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 740 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using tax rates projected to be in effect for the year in which the differences are expected to reverse.&#160;&#160;Significant estimates are required in determining our provision for income taxes.&#160;&#160;Some of these estimates are based on interpretations of existing tax laws or regulations, or the expected results from any future tax examinations.&#160;&#160;Various internal and external factors may have favorable or unfavorable effects on our future provision for income taxes.&#160;&#160;Those factors include, but are not limited to, changes in tax laws, regulations and/or rates, the results of any future tax examinations, changing interpretations of existing tax laws or regulations, changes in estimates of prior years&#8217; items, past levels of research and development spending, acquisitions, changes in our corporate structure, and changes in overall levels of income before taxes all of which may result in periodic revisions to our provision for income taxes.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our provision for income taxes, including our effective tax rate and analysis of potential uncertain tax positions, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowance we deem necessary to offset deferred tax assets.&#160;&#160;If we do not maintain taxable income from operations in future periods, we may increase the valuation allowance for our deferred tax assets and record material adjustments to our income tax expense.&#160;&#160;Our judgment and tax strategies are subject to audit by various taxing authorities.&#160;&#160;While we believe we have provided adequately for our uncertain income tax positions in our consolidated financial statements, an adverse determination by these taxing authorities could have a material adverse effect on our consolidated financial condition, results of operations or cash flows.&#160;Interest and penalties on income tax items are included as a component of overall income tax expense.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Note 1 to the Consolidated Financial Statements included in Item 8 of this Report for a description of recent accounting pronouncements.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_64"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates and foreign currency exchange risks. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an investment portfolio in accordance with our written investment policy. The primary objectives of our investment policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of debt securities of various types and maturities of five years or less, with an average maturity of two years. These securities are classified as available-for-sale. Available-for-sale securities are recorded on the balance sheet at fair market value with unrealized gains or losses reported as part of Accumulated other comprehensive income (loss). Realized gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. A decline in the market value of any available-for-sale security below cost that is deemed other-than-temporary results in a charge to earnings and establishes a new cost basis for the security.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our investment policy guidelines are intended to ensure the preservation of principal, market conditions can result in high levels of uncertainty.&#160;Our ability to trade or redeem the marketable investment securities in which we invest, including certain corporate bonds, may become difficult.&#160;Valuation and pricing of these securities can also become variable and subject to uncertainty. As of December&#160;31, 2021, we had $0.2&#160;million in unrealized losses in our investment portfolio. We do not utilize derivative financial instruments to manage our interest rate risks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be exposed to fluctuations in foreign currencies with regard to certain agreements with service providers. Depending on the strengthening or weakening of the United States dollar, realized and unrealized currency fluctuations could be significant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_67">Index to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_70">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN182Ny9mcmFnOjlkMTk5ZDI3NzAxMjRlZDg5M2RiNGJiYTViMGJhNjBlL3RhYmxlOjg0NDc0MDZjODY5YjQzNWM4MDE0Y2EwY2FlZWUwMjI5L3RhYmxlcmFuZ2U6ODQ0NzQwNmM4NjliNDM1YzgwMTRjYTBjYWVlZTAyMjlfMi0wLTEtMS02NDQyNC90ZXh0cmVnaW9uOmZlMjk5MzFkM2NhMDQyMjdiMTM5YWMyMTlhM2MzZmZkXzMyOTg1MzQ4ODM0MTY_0c522558-bfce-4031-84a5-3600e2fe5f60">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_70">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_73">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_73">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">Consolidated Statements of Operations for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76"> Year Ended D</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">ecember 31, 2021, the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">Transition Period </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">E</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">nded </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">December 31, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76"> and for the Years</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">Ended June 30, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_76">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">Consolidated Statements of Comprehensive Income (Loss) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">Year Ended D</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">ecember 31, 2021, the </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">Transition Period </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">E</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">nded December 31, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79"> and for the Years Ended June 30, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79"> 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_79">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">Consolidated Statements of Stockholders' Equity for </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">the Year Ended December 31, 2021, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">the Transition Period </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">December 31, 2020 and for</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82"> the Years Ended June 30, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_82">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">Year Ended December 31, 2021, the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">Transition Period </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">E</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">nded </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">December 31, 2020 and for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">s </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">Ended June 30, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88"> a</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">nd</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88"> 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_88">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_91">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_91">73</a></span></div></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Myriad Genetics, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Myriad Genetics, Inc. and subsidiaries (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for the year ended December 31, 2021, the six month period ended December&#160;31, 2020 and each of the two years in the period ended June 30, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the year ended December 31, 2021, the six month period ended December&#160;31, 2020 and each of the two years in the period ended June 30, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;25, 2022 expressed an adverse opinion thereon.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 84.25pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Measurement of molecular diagnostic testing revenue</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2021, the Company&#8217;s molecular diagnostic testing revenue was $666.4 million. As discussed in Note 1 of the consolidated financial statements, molecular diagnostic testing revenue is recognized when the performance obligation is complete. Auditing the measurement of the Company&#8217;s molecular diagnostic testing revenue was complex and judgmental due to the significant estimation required in estimating the amount that will be collected for each test. In particular, the estimate of revenue is affected by assumptions related to payors such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.572%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s revenue recognition process. As part of our testing, we considered controls over management&#8217;s review of the significant assumptions above and inputs used in calculating the estimated amount that would be collected for each test and tested management&#8217;s controls to compare actual payments received to previously forecasted activity. We also tested controls used by management to compare the current and historical data used in making the estimates for completeness and accuracy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit procedures over the Company&#8217;s molecular diagnostic testing revenue included, among others, assessing valuation methodologies and models and testing the significant assumptions above and the underlying data used by the Company in its analysis. We agreed transactions selected for testing back to the actual customer contract terms. We compared the significant assumptions above and inputs used by management to changes in the Company&#8217;s contracted rates, third-party payor collection trends, and other relevant factors. We assessed the historical accuracy of the cash collections used in the Company&#8217;s revenue models and assessed the completeness of adjustments to estimates of future cash collections as a result of significant contract amendments, changes in collection trends and changes in payor behavior.</span></div></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183MC9mcmFnOmRkMTJiMWM3YzdiZTQ5NDJhMjgwMzIwMTk1NDBkZjNkL3RleHRyZWdpb246ZGQxMmIxYzdjN2JlNDk0MmEyODAzMjAxOTU0MGRmM2RfMzI5ODUzNDg4Njk1MA_510381d2-ae61-43be-bc5a-ab7decca2b15">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2006.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183MC9mcmFnOmRkMTJiMWM3YzdiZTQ5NDJhMjgwMzIwMTk1NDBkZjNkL3RleHRyZWdpb246ZGQxMmIxYzdjN2JlNDk0MmEyODAzMjAxOTU0MGRmM2RfMzI5ODUzNDg4Njk1Mg_9829e32b-c947-46a8-966d-14ea0519fd09">Salt Lake City, UT</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:63.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNC0xLTEtMS0zNzM4OQ_d353ab4d-fc30-4659-ba30-6e53065a7f85">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNC0xLTEtMS0zNjM1OQ_6db8b4a1-6371-4e89-8f94-67c7d1107c92">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNS0xLTEtMS0zNzM4OQ_6097f452-335e-43be-942d-0f7d7049094d">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNS0xLTEtMS0zNjM1OQ_bc27b936-94fb-4c0e-a6ba-20990232bb33">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNi0xLTEtMS0zOTA1Ng_a8e4162a-6255-4cfe-a9a9-15a29f24a6d4">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNi0zLTEtMS0zOTA1Ng_0e55208c-6339-4a8d-8f1e-625d00e3e07e">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNy0xLTEtMS0zNzM4OQ_7a534a8d-1389-4ce6-8f64-dd4102b70b6f">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNy0xLTEtMS0zNjM1OQ_ba2eb238-d71c-409d-9980-ee895064b103">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfOS0xLTEtMS0zNzM4OQ_f166590e-1f3c-4413-8c8a-90e49a07cd82">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfOS0xLTEtMS0zNjM1OQ_c7843afa-3cab-4fd1-aef7-f6967857991a">108.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTAtMS0xLTEtMzczODk_46b919b3-8f02-456c-b8ec-90c8b74c3663">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTAtMS0xLTEtMzYzNTk_1421b5f4-6713-4119-8db3-f728f3000214">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTEtMS0xLTEtMzczODk_9cfb09f1-c354-4a15-9e2e-0ab0f63aa08a">484.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTEtMS0xLTEtMzYzNTk_8338031b-1f91-4f18-b610-d981e32c84ca">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMS0xLTEtMzczODk_a1f47c52-8d4d-48d4-b6a5-63e3ca7926ac">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMS0xLTEtMzYzNTk_ef23de6b-479e-49e4-b6a3-f875424aa9b8">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMS0xLTEtMzkwNzg_b14964bf-ef4c-45ae-9931-37dea8134a7c">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMy0xLTEtMzkwNzg_d280357a-ea08-40d1-a8a2-724fb41413da">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTQtMS0xLTEtMzczODk_80c7ad52-bacb-4ff0-8601-83638be3a77c">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTQtMS0xLTEtMzYzNTk_a20f919b-df4d-41ef-b387-f0a6a668c1d9">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTUtMS0xLTEtMzczODk_17e94b39-41c9-48ca-a68f-54ac494689de">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTUtMS0xLTEtMzYzNTk_44c73a4e-a94b-486f-a085-8de8b09aebbc">576.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTYtMS0xLTEtMzczODk_5fac40ba-5dbf-4a82-83fc-a96adacc5a41">239.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTYtMS0xLTEtMzYzNTk_69599445-e01a-4ac3-8186-a9b4ca458234">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTctMS0xLTEtMzczODk_05aa2732-8b58-4994-a1d0-d7409e0ce472">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTctMS0xLTEtMzYzNTk_501cc74d-70a8-4da1-a809-93a194fedb4b">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTgtMS0xLTEtMzczODk_d6e9a9bb-7967-40a9-8074-23200707fcd0">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTgtMS0xLTEtMzYzNTk_69fc245c-76d9-4e07-b22e-bb84e9023105">1,418.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjEtMS0xLTEtMzczOTU_e6418bad-2222-4ba7-b4f6-223673b21795">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjEtMS0xLTEtMzYzNTk_383f16fe-f2b2-400b-b7bb-a6e26e829501">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjItMS0xLTEtMzczOTU_8a63cab3-a62b-49a8-acf2-d8191596538d">156.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjItMS0xLTEtMzYzNTk_bb62e48e-d75c-49d2-bbf6-f5fc35c34248">79.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjMtMS0xLTEtMzczOTU_aa5f9b1b-df5a-41da-8396-5978ac590b8d">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjMtMS0xLTEtMzYzNTk_5e9609ce-e4aa-4989-a9b8-c329932a0e59">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjQtMS0xLTEtMzczOTU_658bf126-ba87-4bf2-b788-cdc3b8f53701">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjQtMS0xLTEtMzYzNTk_9cc23f7f-7a4c-4131-b41b-352105fcd793">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjUtMS0xLTEtMzczOTU_a45e821f-1281-432e-8404-71f44fcbe2f8">204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjUtMS0xLTEtMzYzNTk_582adb75-8a8a-482d-9004-44a6a91437d5">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:UnrecognizedTaxBenefitsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjYtMS0xLTEtMzczOTU_e710d7e3-bcf8-49c6-9668-b6558aec9a2b">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:UnrecognizedTaxBenefitsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjYtMS0xLTEtMzYzNTk_d4b61978-22db-423c-b41d-b1ecad8049de">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjctMS0xLTEtMzczOTU_8b5403b7-72b1-401b-a88c-184fe39c078a">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjctMS0xLTEtMzYzNTk_d868bb4c-f12f-40de-84be-9c8d38f3b209">71.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjgtMS0xLTEtMzczOTU_128eb676-c2fa-4f96-aa61-bbbfcea286a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjgtMS0xLTEtMzYzNTk_f653adcb-7949-42f6-9de5-a75f83ea85ec">224.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjktMS0xLTEtMzczOTU_62e675c5-1550-480d-823e-41ccaed4fac4">79.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjktMS0xLTEtMzYzNTk_0974a583-e433-4142-a4a7-362872f1c4b1">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzAtMS0xLTEtMzczOTU_4da3bb9e-fde8-44bf-8114-67fca6822259">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzAtMS0xLTEtMzYzNTk_a98023ed-ceb8-42f6-86ea-cc8bd6190693">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzEtMS0xLTEtMzczOTU_377919b7-7d2c-448b-a9a5-45f1a9a04023">352.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzEtMS0xLTEtMzYzNTk_52a31a00-5734-4546-9c33-dd842b5c8e9b">537.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzItMS0xLTEtMzczOTU_6fc19e49-85d0-4afa-a9ac-532e2f17419f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzItMS0xLTEtMzYzNTk_fe1532c1-9bfe-4270-a93b-ecc70c21e93b"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN18xNjQ5MjY3NDQxNjg0Nw_b221cda9-b1d8-4b33-84e1-b0c9f5cc1143"><ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN18xNjQ5MjY3NDQxNjg0Nw_d4ad09d5-7454-4d39-b7e1-01a4aa291e96">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN180OTQ3ODAyMzI1MTMy_477167f9-8080-47e1-9941-b74bd5c410b4">80.0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN18xOA_1a35b63c-9b25-4751-a5a6-d2fcf122cd0f">75.4</ix:nonFraction> shares outstanding at December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMS0xLTEtMzc0MTM_46d0a840-29d7-4c58-9826-ba61065bfb33">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMS0xLTEtMzYzNTk_9ac2da0c-9ca7-419d-b54b-857d5ec2aa91">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzUtMS0xLTEtMzc0MTM_a8b0f5e5-834f-46cd-a631-65b22e75fff6">1,226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzUtMS0xLTEtMzYzNTk_59444c3b-0e21-4b5b-95a4-2ec34501d10f">1,109.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzYtMS0xLTEtMzc0MTM_65513996-177b-42e2-b08a-c740d4254fad">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzYtMS0xLTEtMzYzNTk_475adef8-d869-442d-ad2d-fd8ba7c8169a">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzctMS0xLTEtMzc0MTM_4b8c0349-f86d-4da9-a8ab-e3b87346b35f">254.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzctMS0xLTEtMzYzNTk_bab9ea63-29ee-435e-8ecd-ef15983c204a">227.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Myriad Genetics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzgtMS0xLTEtMzc0MTM_c3944181-79a4-4ed8-b647-5cb4987cd0c3">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzgtMS0xLTEtMzYzNTk_805bd443-b88c-4894-9f05-55b00fd7c65e">881.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzktMS0xLTEtMzc0MTM_f5636b38-d855-4edc-b590-77c0f410cf11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzktMS0xLTEtMzYzNTk_e246d4c8-2139-455e-87d5-46ff66d9368c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDAtMS0xLTEtMzc0MTM_900298ba-9982-4bef-bad2-83d7d83e5867">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDAtMS0xLTEtMzYzNTk_e343b38a-b992-4ed0-985e-c80e0d9c88cd">881.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDAtMS0xLTEtNDM0OTA_4683d066-222d-4861-b9db-5da9807e07f9">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDEtMS0xLTEtMzYzNTk_555e1c3a-ee85-4459-a304-9d5e56e2b01c">1,418.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:11pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi0xLTEtMS0zNzUxNg_55694e24-04d0-4572-a79d-999dced95188">666.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi0xLTEtMS0zNjM1OQ_38cfb534-f50d-42f3-aa1b-27d7d58ff19b">279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi0zLTEtMS0zNjM1OQ_08d88c61-b58c-46ba-8b3d-69894eb7c5cf">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi01LTEtMS0zNjM1OQ_6315a314-69cb-4dcd-9be9-d596c0c75727">789.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy0xLTEtMS0zNzUxNg_e249b058-5ad0-4f92-96cb-b40752eb4422">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy0xLTEtMS0zNjM1OQ_a5d7eb97-8741-4636-ae21-f25e07ed7beb">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy0zLTEtMS0zNjM1OQ_bba63231-a553-4b14-907e-82a540d58681">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy01LTEtMS0zNjM1OQ_2c44318c-dc25-4066-b10f-44a08fcc0f49">61.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC0xLTEtMS0zNzUxNg_19bde853-a3c2-4705-9272-7ef58f3588ae">690.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC0xLTEtMS0zNjM1OQ_63658f0a-e792-4a58-84d5-5da21948e925">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC0zLTEtMS0zNjM1OQ_8c562015-1e8b-4682-b613-8f949e04e75d">638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC01LTEtMS0zNjM1OQ_f5591803-5bcc-4cfc-9620-8192910cf5b9">851.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi0xLTEtMS0zNzUxNg_453f62ed-51b0-4979-8d62-6287a5d3f5bb">185.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi0xLTEtMS0zNjM1OQ_e723d402-5a3e-47e0-be0d-fa2bd4b5f47d">82.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi0zLTEtMS0zNjM1OQ_76fa23c5-5863-43ea-996d-99f6abe6344f">157.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi01LTEtMS0zNjM1OQ_77237df2-091f-4fb8-a503-01899ae07776">168.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy0xLTEtMS0zNzUxNg_ada9bf8b-da09-49d9-9beb-3b21cbf5b3a0">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy0xLTEtMS0zNjM1OQ_45595ef0-5e5d-4c20-b7fa-502d2d96328f">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy0zLTEtMS0zNjM1OQ_2c0f5bf2-f27d-4ea1-94eb-dd7be54824e3">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy01LTEtMS0zNjM1OQ_dc646224-f4ee-473e-bc44-6a6d3edb1b31">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC0xLTEtMS0zNzUxNg_853c1e8a-de04-4f7c-a15a-a4597fa4364f">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC0xLTEtMS0zNjM1OQ_41d0d173-4d0f-458f-870a-945319f9067a">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC0zLTEtMS0zNjM1OQ_73f29c43-72a8-432c-94b2-b84bdd905aaa">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC01LTEtMS0zNjM1OQ_49cd036d-37f8-4bc5-b730-34fc233e0997">85.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS0xLTEtMS0zOTE4OA_2669481c-0359-4383-a9b2-74a2aacc582e">537.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS0zLTEtMS0zOTE4OA_88d5b5f4-2545-4a98-8648-5c128d38124a">260.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS01LTEtMS0zOTE4OA_0a4bacde-4c6c-4f5a-971e-ae813c79a7bb">507.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS03LTEtMS0zOTE4OA_6a0b79f7-b9da-41b3-95da-e8181b46b5b6">556.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtMS0xLTEtNDk5MTg_1d114045-575c-402c-9ebc-be30821c4679">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtMy0xLTEtNDk5Mjg_8b6da10c-1a29-4e7e-bd07-0cb740bda697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtNS0xLTEtNDk5Mjg_13bcc9c9-28ec-420b-bc15-d2683fa40c24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtNy0xLTEtNDk5Mjg_8cbc587c-bbe3-4392-8aeb-cb39bdfd85c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtMS0xLTEtMzc1MTY_d526b778-238f-4e1a-a019-d3e9b2db8a21">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtMS0xLTEtMzYzNTk_859ba6a7-6b22-4e12-adeb-953c4888821e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtMy0xLTEtMzYzNTk_28a17364-3806-45bd-bcbb-9fc25375869b">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtNS0xLTEtMzYzNTk_9e45c501-b487-4ed6-aa8f-32d0660c4a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItMS0xLTEtMzc1MTY_3cfb9b68-3e86-4311-96f4-7d21e2acc0c1">881.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItMS0xLTEtMzYzNTk_815c953a-3f68-4f08-a1ec-cb6829d09f6b">387.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItMy0xLTEtMzYzNTk_bb200a81-5694-46fe-a1ce-28ee1d5234f7">870.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItNS0xLTEtMzYzNTk_f1a66ed6-74f3-4f4d-bed0-9bf1a00b766d">843.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtMS0xLTEtMzc1MTY_77dc282c-e475-43c0-b491-8990fc7cd5a1">190.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtMS0xLTEtMzYzNTk_af4faaec-fa42-4b0f-a7ff-467ec11e91b2">87.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtMy0xLTEtMzYzNTk_7ddf282b-5a7a-4faf-9b60-18f0d8c30ede">231.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtNS0xLTEtMzYzNTk_86525e84-ec3a-4e0f-8b7d-f277f5efac8a">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtMS0xLTEtMzc1MTY_e84433d2-972e-4a88-8317-2771c0394fff">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtMS0xLTEtMzYzNTk_ed345dc6-5577-4bf0-a560-aafefa1cbeb7">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtMy0xLTEtMzYzNTk_ca0f15c4-8624-4d11-9846-460f0c47e3e9">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtNS0xLTEtMzYzNTk_a5316298-c60d-42cf-938b-342ad929f57f">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtMS0xLTEtMzc1MTY_c04ac715-07f8-4b58-b27d-65725c9aeb45">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtMS0xLTEtMzYzNTk_50df3339-4daa-438e-afdd-2d581204382f">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtMy0xLTEtMzYzNTk_3f640d66-4f0e-44b7-b87c-ccdb4922f86f">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtNS0xLTEtMzYzNTk_f5b27b55-ff55-4ef5-9e5d-8bf84e42e5c6">12.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctMS0xLTEtMzc1MTY_3206da36-5aa7-4e7c-8c70-e4fcf9f0e508">139.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctMS0xLTEtMzYzNTk_f2047320-fdba-41f0-aea0-323f26146a76">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctMy0xLTEtMzYzNTk_ce3a8cf5-4420-4029-88ce-d12e1447e83e">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctNS0xLTEtMzYzNTk_e8b03820-e756-4a32-985a-8ddad844c31f">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtMS0xLTEtMzc1MTY_c1652076-dd51-470f-b3fb-8c8089c20b1f">133.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtMS0xLTEtMzYzNTk_a784ff6f-9009-4015-a966-afa24e651825">6.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtMy0xLTEtMzYzNTk_1c6d23cc-4d83-46df-b1c7-bed0856b2bdd">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtNS0xLTEtMzYzNTk_fbdb403d-6988-4366-91f7-68363cc3a829">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktMS0xLTEtMzc1MTY_ccfac10d-c0bc-40bf-8833-bfea5ea54f0f">57.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktMS0xLTEtMzYzNTk_c664550c-a590-49ae-97c0-51856ce79f89">94.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktMy0xLTEtMzYzNTk_af615a0b-f7e1-49f4-bab7-a5462c79ebcd">223.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktNS0xLTEtMzYzNTk_3a1a4440-2362-4cf1-8d52-ca849c6bb5b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtMS0xLTEtMzc1MTY_2a66141a-7fdf-4067-a171-a98d70b7443d">29.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtMS0xLTEtMzYzNTk_72ee5bf7-5bd4-4374-babd-2769878ac9c1">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtMy0xLTEtMzYzNTk_edab9c4c-25e8-4c21-93ed-1e1258f790f1">23.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtNS0xLTEtMzYzNTk_04714302-ff25-495e-a95e-d488cb4c1c8f">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtMS0xLTEtMzc1MTY_102d21cf-3a75-46b2-ab95-48e94e9f3543">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtMS0xLTEtMzYzNTk_0f780454-3a03-4a1f-8a83-01d790a0276d">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtMy0xLTEtMzYzNTk_e248eb77-0258-48e0-a6cc-dc081d6a505e">199.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtNS0xLTEtMzYzNTk_a9d29cb0-a12a-47cb-bde5-ec4f3fe538b5">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItMS0xLTEtMzc1MTY_a3d98b01-04ef-4de7-94a4-19f478e659ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItMS0xLTEtMzYzNTk_8830558a-8818-48dd-8d9b-02ac8f893b2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItMy0xLTEtMzYzNTk_d33d6230-7d9b-43b3-8f4a-420b176b7ec4">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItNS0xLTEtMzYzNTk_88ba0960-8758-4c28-be6c-5d42b4bfa568">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtMS0xLTEtMzc1MTY_4cb0230c-1e2c-4f1e-ba3b-3f51818118c9">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtMS0xLTEtMzYzNTk_255b4388-8fd0-4dc3-a901-3df315257f67">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtMy0xLTEtMzYzNTk_d5970281-4b8a-4863-96d9-874c0a248d24">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtNS0xLTEtMzYzNTk_01dd1d9f-931b-4db5-8198-bdb278c2ae1c">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtMS0xLTEtMzc1MjM_99f0e88f-742c-4a4e-bf51-13afd906b362">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtMS0xLTEtMzYzNTk_55103031-f704-4a26-8788-a8ef5a6bcec9">0.71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtMy0xLTEtMzYzNTk_cee6a0ad-c706-4029-aa80-1b864674fd31">2.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtNS0xLTEtMzYzNTk_73cc575d-14ef-4b18-be8c-925c1c654c3b">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtMS0xLTEtMzc1MjM_4ef3cd65-9572-4d2d-80bf-3b60664a53ac">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtMS0xLTEtMzYzNTk_10b5809c-f581-41c9-bee8-e85a6d50a8a3">0.71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtMy0xLTEtMzYzNTk_249e1ede-66ee-4c1b-9034-f1995ef66b82">2.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtNS0xLTEtMzYzNTk_5c11732d-ad67-40a9-80a1-7e8db35fa57d">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtMS0xLTEtMzc1MjM_2ba862d5-d9d5-4d85-b3fc-6fdf6cea2c63">78.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtMS0xLTEtMzYzNTk_a6e16e56-5e36-4277-80ae-273229ab7960">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtMy0xLTEtMzYzNTk_e3104486-3fc7-45a8-ad9d-7820ebd169f5">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtNS0xLTEtMzYzNTk_6c5e6ea8-4ed7-4a82-9b10-b39626ba0be3">73.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktMS0xLTEtMzc1MjM_bbeb6472-3483-43ba-81ae-a7fc08b42210">78.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktMS0xLTEtMzYzNTk_8dbb0b0c-8c42-4edd-990d-4b947499ae3e">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktMy0xLTEtMzYzNTk_462797e8-b180-446a-bf3c-a5e178bea6be">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktNS0xLTEtMzYzNTk_455381f3-4b3f-493a-9a89-3563793b6f99">76.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi0xLTEtMS0zNzU5OQ_23a11766-3487-4ea9-aaa0-0723513adb62">27.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi0xLTEtMS0zNjM1OQ_f660310a-4479-4489-b128-36f9e36f3b7a">53.1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi0zLTEtMS0zNjM1OQ_52757f64-f7d9-4203-9e7c-b612d85824c0">199.5</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi01LTEtMS0zNjM1OQ_78bb2bd4-eb52-4cd7-abb3-ce0eb1e0834f">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy0xLTEtMS0zNzU5OQ_bc9daa81-12fa-436d-bd2e-87c83804ea7c">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy0xLTEtMS0zNjM1OQ_78f72bb8-ce72-4e05-966a-4573533231fc">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy0zLTEtMS0zNjM1OQ_e60e007b-9d03-47d6-ab8a-9eb3a6ebea35">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy01LTEtMS0zNjM1OQ_94214cf5-83ce-4028-a541-a98cdcf67f2b">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in pension liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC0xLTEtMS0zNzU5OQ_5e7687ea-e1e4-4b56-94f2-d2ab3de5ce59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC0xLTEtMS0zNjM1OQ_cce4d034-d8a6-48c3-8f83-f19a8e30dff7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC0zLTEtMS0zNjM1OQ_1f7afdbf-dd80-4c08-bf97-8015e89a8d3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC01LTEtMS0zNjM1OQ_206ed6e2-4d12-4b82-ba41-a966aad0fba9">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation adjustment, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS0xLTEtMS0zNzU5OQ_11a6ee21-45be-456b-83a3-87609ff673c5">1.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS0xLTEtMS0zNjM1OQ_7f203565-ffa4-4761-a1af-030246222ff2">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS0zLTEtMS0zNjM1OQ_1905a6fe-9fa4-431b-a060-cbca0faa4caa">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS01LTEtMS0zNjM1OQ_183dcf99-b2a9-4545-9de2-b0e0d42c05ea">3.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi0xLTEtMS0zNzU5OQ_e54476b2-9c1a-4b2a-9304-7549d5706073">30.0</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi0xLTEtMS0zNjM1OQ_d6f45803-6ec5-4f7e-a7f1-bdd632c8aff4">50.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi0zLTEtMS0zNjM1OQ_0d57f8e8-a957-40b2-a54f-9426d9dbbfe4">199.4</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi01LTEtMS0zNjM1OQ_a6f28374-34f4-4aec-af2a-5b26fe8b2b52">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings<br/>(accumulated<br/>deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Myriad<br/>Genetics, Inc.<br/>Stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT JUNE 30, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3490fe6c43d44fcb68f2c3625bd038a_I20180630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi0xLTEtMS0zNjM1OQ_881c8aae-2f2d-4519-ab21-1dc55ae42019">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ca914745a941f2966e50ba77e955a7_I20180630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi0zLTEtMS0zNjM1OQ_978e1b70-56a2-4e6b-9526-ef436bb4d964">915.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16e7b1ebad7642a0add5c645bc552fee_I20180630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi01LTEtMS0zNjM1OQ_e731cad9-f366-4e22-a437-6dbcddd85ab7">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18300b74b3df4d46b493a707d825fa4a_I20180630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi03LTEtMS0zNjM1OQ_fc9b70f5-1e0b-4925-aa52-6530d6990d62">54.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi05LTEtMS0zNjM1OQ_15d2ce8d-c670-4256-b423-78ea760313c4">966.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNy0zLTEtMS0zNjM1OQ_079d375a-a9b0-4517-8316-38a5453bf0a5">136.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNy05LTEtMS0zNjM1OQ_917d77f2-978c-47eb-b584-88476d7857fb">136.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOC0zLTEtMS0zNjM1OQ_f0556e06-129d-46cc-858e-dca8f1abf97d">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOC05LTEtMS0zNjM1OQ_cc2da388-ebf2-4292-b292-b2b2961da871">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOS0zLTEtMS0zNjM1OQ_9805612c-bc7a-4f60-af46-8c67f5fd6e63">16.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b54a1e9583a4c6e990c5bbb9c0a73f8_D20180701-20190630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOS03LTEtMS0zNjM1OQ_c4250a01-6c73-456d-b0af-7472c6240032">33.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOS05LTEtMS0zNjM1OQ_f615f87f-a600-4b2f-8af3-0d9fedbd6c20">50.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b54a1e9583a4c6e990c5bbb9c0a73f8_D20180701-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTAtNy0xLTEtMzYzNTk_5aede6c6-97d2-4278-96d1-df3a690c9cba">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTAtOS0xLTEtMzYzNTk_556c578e-055c-459c-8138-cb7da83004b9">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1599623c9f04291a999dead8f1a5395_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTEtNS0xLTEtMzYzNTk_a81f5cdb-b120-4bd0-ad2a-2d279db65765">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTEtOS0xLTEtMzYzNTk_a1086e70-4c64-4455-897e-77c01e1bbf48">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT JUNE 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59def4575be14308a65eb8292ac6d700_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItMS0xLTEtMzYzNTk_8cf1346d-3aac-4866-8ece-b8259a8dc854">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d812645f92f414592b573945dc3f6b1_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItMy0xLTEtMzYzNTk_f228cf73-1459-4005-913e-05b081b700c5">1,068.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186bb32cbaf64bd6b7957d74964ad3b8_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItNS0xLTEtMzYzNTk_2ad3b8b6-fd69-479f-80e1-7a44e8e2a3fb">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f04a427cbe430a863042cf46917020_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItNy0xLTEtMzYzNTk_faef8a04-316f-4e66-b586-c2e94549f8fb">25.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItOS0xLTEtMzYzNTk_44081fa9-41dc-4559-8acb-b8e42ce7cb6a">1,088.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83e7c3186b049569961b26ad3e07b35_D20190701-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTMtMy0xLTEtMzYzNTk_246b6416-b529-4cbc-bf65-23ed9aa38706">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTMtOS0xLTEtMzYzNTk_15797ea2-f638-4292-847b-07491cdfb3c4">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83e7c3186b049569961b26ad3e07b35_D20190701-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTQtMy0xLTEtMzYzNTk_3613068e-a54b-47dd-9e5e-f8f3758fe5c7">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTQtOS0xLTEtMzYzNTk_051679ca-4b44-4e3f-bf8f-16c096a50ca9">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04d0772a72c84c40ad62e094c4956f82_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTUtNy0xLTEtMzYzNTk_65eb85ff-9ddb-4950-9dd7-05765f5185cf">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTUtOS0xLTEtMzYzNTk_55b7109d-274b-47b1-938e-255214431206">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c1ff8d939f49a5bc5fda3040bcf994_D20190701-20200630" decimals="-5" name="mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTYtNS0xLTEtMzYzNTk_4be5513a-9e64-434a-80be-c11412a862dc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTYtOS0xLTEtMzYzNTk_7d30dedb-c3ff-4247-b57b-4351fddcc303">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c1ff8d939f49a5bc5fda3040bcf994_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTctNS0xLTEtMzYzNTk_1a0302c9-5f1f-45ef-9704-b613ea2e50d7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTctOS0xLTEtMzYzNTk_5f412f6f-15f4-4fcf-86cf-aec50b6b6838">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT JUNE 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727bfef5fdaf4a68b74905d96ed0bd75_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtMS0xLTEtMzYzNTk_a549a134-1c73-42a0-a681-67af2aee9cf2">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0952f21f7474270a815f3514f44ab52_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtMy0xLTEtMzYzNTk_d1ce2a7e-2b3e-409b-9eef-4fa32d096564">1,096.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c18b43bb290475583b6c04c962cc4f5_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtNS0xLTEtMzYzNTk_ff5dbd2a-8286-4993-b381-423d93c847bd">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67c1f04497634a03acfacae132470000_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtNy0xLTEtMzYzNTk_627509f6-decc-4b3a-adcb-194b3d07e558">173.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtOS0xLTEtMzYzNTk_95f05caa-bb0a-4527-9983-58cc3e70686f">918.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3255cc95fb79446f82e34f0ba20d9dcb_D20200701-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktMS0xLTEtMzYzNTk_1fcae54c-a60e-4492-ac5b-0173d6a744a5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c16edcf998c4da5b8b0515c6fd6a34e_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktMy0xLTEtMzYzNTk_666387e3-64b3-47a0-a93c-591975d660e4">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktOS0xLTEtMzYzNTk_b93ec8d3-bc55-4403-8a67-cb8211792434">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c16edcf998c4da5b8b0515c6fd6a34e_D20200701-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtMy0xLTEtMzYzNTk_aa5dbdad-272a-4a9b-b7ac-d2efcd97bf35">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtOS0xLTEtMzYzNTk_ae8d4ea6-ea72-4154-90c3-321b28d8f2d1">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d9a7dea4d3a492eab5b13130045cf86_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtNy0xLTEtMzYzNTk_14de7b31-f8ce-4381-8605-ce086c6b74c0">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtOS0xLTEtMzYzNTk_63038e6b-5208-4eec-8c01-9e7f45e686b6">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f010022d8844beba34499bcd02fcfa_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItNS0xLTEtMzYzNTk_9eefe851-b939-4a6c-87e1-a022362e27e5">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItOS0xLTEtMzYzNTk_56c62480-f03d-43d7-a2b2-fc3ffc1c7461">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT DECEMBER 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f56df5636b24717996902df4b351edb_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMS0xLTEtMzYzNTk_c7f5cb7f-7499-4032-a0f9-6247f1d7848a">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b042f9bbfff4fd7b823711711b5022a_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMy0xLTEtMzYzNTk_3b281c90-1a7d-46e1-9af9-bc29f4b9d982">1,109.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8e819d3e2be4e7589e9091e181dd161_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNS0xLTEtMzYzNTk_6bfdb436-5e5a-48f0-b477-a2b7653b099a">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04ecb918ca8845c18dd2d6175330f6df_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNy0xLTEtMzYzNTk_1ab767d0-2373-4e18-bf32-eb4cee613b7f">227.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtOS0xLTEtMzYzNTk_ef25b678-35b2-49ad-9b6d-21cbde646882">881.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81acdb427fb040d1b79807f720522dcf_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktMy0xLTEtMzc4ODc_9f52e90d-f55a-4ab2-aeca-893b30eb3f3f">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktOS0xLTEtMzc4OTM_88fc66de-bd0d-4a95-82e1-c3874c8d4305">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81acdb427fb040d1b79807f720522dcf_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtMy0xLTEtMzc4ODc_3aff33f2-881a-40d7-958c-4294aa82af51">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtOS0xLTEtMzc4OTM_8b206af5-8d2d-438f-b246-263646dd1f0f">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406964000440469a8b2a3301d473abfa_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtNy0xLTEtMzc4OTM_96db4e17-e382-446f-83f2-8ac8ca95dd5d">27.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtOS0xLTEtMzc4OTM_3eaf5538-92f4-45c4-a6d6-1d1172bcc662">27.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4402fe2fdb042e993c87738c61d4381_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItNS0xLTEtMzc4OTM_44fe69b6-eb5f-42fc-b9c7-07368ac218da">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItOS0xLTEtMzc4OTM_4c8b5f54-2e78-4521-a520-7f7690b60056">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT DECEMBER 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1a7957d8ba47e8b3c57b590a8f1c6e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMS0xLTEtMzc4ODc_c6bd90af-b9d6-4bfe-a788-f53c41b2d4f7">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5861584aeaf34ebd8b71efbbb80709c9_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMy0xLTEtMzc4ODc_f7ee726a-b8de-4c5a-8515-ed3e667ae074">1,226.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5633da0a55ce4fbfbc6f2f94c0888afd_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNS0xLTEtMzc4OTM_7ae31273-3c5d-4cc3-9d68-2fb9399b32b5">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d7070eac7a949dcbb79b9e02a3aacf2_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNy0xLTEtMzc4OTM_cfda61eb-b258-4029-89b8-8ba28a2c37cb">254.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtOS0xLTEtMzc4OTM_bae6a0a2-6b79-47f4-abce-7f95f2a5608a">967.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy0xLTEtMS0zNzY5Ng_223cf017-9cb6-449a-b380-1831d13ce9ac">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy0xLTEtMS0zNjM1OQ_2c0aeb99-5f54-4b7f-8696-8defa7f761bf">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy0zLTEtMS0zNjM1OQ_3d8e67db-e57a-4e03-96c8-f82d166a250f">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy01LTEtMS0zNjM1OQ_49ed4d63-c3a8-4af8-9df9-aac89c6d34d2">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS0xLTEtMS0zNzY5Ng_33bd5291-3e50-4c5c-8e0c-7eb4dbe3ee07">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS0xLTEtMS0zNjM1OQ_168db79b-7430-483a-8f5a-5f4756dfb123">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS0zLTEtMS0zNjM1OQ_a869adee-3e4f-4ffb-ab50-bc19e654619b">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS01LTEtMS0zNjM1OQ_c9b27252-4196-46d2-8b09-7eb55e9dd178">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi0xLTEtMS0zNzY5Ng_6c188d29-abdc-4739-87d1-0b43ae1b66f4">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi0xLTEtMS0zNjM1OQ_340fd115-6322-449d-8801-f9b14e75dc9f">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi0zLTEtMS0zNjM1OQ_75969505-b23a-44bf-878a-2012a12d76b6">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi01LTEtMS0zNjM1OQ_793a0b0f-6481-463e-8a1e-a27356df8489">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy0xLTEtMS0zNzY5Ng_f367dd71-2a76-424c-9b70-cbb566f0d38b">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy0xLTEtMS0zNjM1OQ_12ca7baa-b9ba-4be9-8761-e8d2370c7e44">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy0zLTEtMS0zNjM1OQ_7d75babe-08b4-4a8d-a364-cae3be2e093a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy01LTEtMS0zNjM1OQ_64bbdbf3-a382-4b4a-97ae-00b486ed0113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC0xLTEtMS0zOTIxMw_054d7ebd-53ea-4b64-993b-5db7041aaf72">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC0zLTEtMS0zOTIxMw_26aa22f2-1fc2-4d78-870d-6655597fed2a">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC01LTEtMS0zOTIxMw_73687c95-9f9a-462d-b394-416f5d47f855">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC03LTEtMS0zOTIxMw_a1074479-21c0-4dbe-929c-a9f2bc46c554">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItMS0xLTEtMzc2OTY_1709a580-df66-428d-be5f-16a84555365c">32.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItMS0xLTEtMzYzNTk_5194c7ee-38fd-4c23-94d2-eff52734e318">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItMy0xLTEtMzYzNTk_2431e41a-3031-4eac-8ed6-ae54aa1e0f5b">55.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItNS0xLTEtMzYzNTk_e967bf79-3186-43e8-b1fb-794e62283ca6">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMS0xLTEtMzc2OTY_473c7772-f7c6-442c-acb5-0f7b962ea34c">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMS0xLTEtMzYzNTk_82034a27-80dd-4538-86b5-3f3cd7c81a5f">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMy0xLTEtMzYzNTk_1cc20358-2e3a-41cc-bf7e-1c7683689cd7">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtNS0xLTEtMzYzNTk_5da6b4db-745b-494d-b015-ae9eecdfc9dd">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash impact of foreign currency transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMS0xLTEtMzkyNzc_af63ad37-9897-4044-9f2a-e3405d756ca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMy0xLTEtMzkyNzc_3de724ac-0133-4c03-8807-335be88724a1">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtNS0xLTEtMzkyNzc_b4ac5708-b14d-4f31-8cd8-d6eac835d1b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtNy0xLTEtMzkyNzc_ec97ae7e-d855-49ad-aecd-dc43671a8e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMS0xLTEtNDM2MjA_2b003d96-3abc-48a2-a8c0-9908f8478d52">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMy0xLTEtNDM2Mjc_c2b81f73-212f-4a65-b971-e1789f3003fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtNS0xLTEtNDM2MzQ_55e37ae4-602f-41e6-ad72-c4d9acbe6e01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtNy0xLTEtNDM2MzQ_4e04c381-872e-42a2-b7e9-b88cdf4fe081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of goodwill and long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtMS0xLTEtMzc2OTY_44157838-e1dd-4036-80db-268bab651974">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtMS0xLTEtMzYzNTk_beb2c444-6719-41a2-99ce-e7794622dc4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtMy0xLTEtMzYzNTk_f763b495-fa1b-4d23-bbbb-75b35c8f15a9">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtNS0xLTEtMzYzNTk_8cf4239c-3d09-45b0-9625-b85831c3b9d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of businesses and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMS0xLTEtMzc2OTY_dcc2d345-2eaa-46ef-9879-f77da16434ec">162.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMS0xLTEtMzYzNTk_9f553bde-1562-4475-9387-3da9488b6508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMy0xLTEtMzYzNTk_b862252b-af92-4e00-ae3d-e49c943159df">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtNS0xLTEtMzYzNTk_61e3c13e-50a1-4437-9d44-cbc4ecd21885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtMS0xLTEtMzc2OTY_34220428-62a2-421c-8bd5-89d81671b35c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtMS0xLTEtMzYzNTk_ecaccc7d-477e-43bb-8211-6f9103076dcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtMy0xLTEtMzYzNTk_3224c62f-6ba6-4cfc-abaf-85a7ab6aac06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtNS0xLTEtMzYzNTk_e5e536de-63d4-4c7c-914c-a09326fce782">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtMS0xLTEtMzc3MDI_af615186-7ba7-4493-bd56-f63dce7d406e">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtMS0xLTEtMzYzNTk_7bd2efa0-bfbe-46e0-9594-2204e7a06af6">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtMy0xLTEtMzYzNTk_de7bb576-9ac6-4131-8be3-2221db7068f1">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtNS0xLTEtMzYzNTk_51576ca6-fa48-48a9-8868-a93ae5122363">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktMS0xLTEtMzc3MDI_b4ee6948-230a-4e1d-98bc-416fe62b6ef8">8.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktMS0xLTEtMzYzNTk_54b9361c-c31f-4919-8a80-6112e0761e51">21.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktMy0xLTEtMzYzNTk_c84e0aa1-6d13-4dfe-80b6-de8f25abc532">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktNS0xLTEtMzYzNTk_2ec185fa-3d69-4c8f-a3a7-2b47a63a40b1">18.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtMS0xLTEtMzc3MDI_79ec963a-2f0c-4b2c-9bdd-e25836764f8f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtMS0xLTEtMzYzNTk_db0a674b-ca4c-4528-bd2c-ff0036e63b16">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtMy0xLTEtMzYzNTk_4535ff4f-6332-4f69-9802-1c006fec770a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtNS0xLTEtMzYzNTk_d2733898-3c4f-4838-8b73-cb74fb27b85a">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItMS0xLTEtMzc3MDI_c346fc0b-4431-4098-81bf-9689d1f90956">89.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItMS0xLTEtMzYzNTk_186a6754-95f5-4a57-84f4-d3c937204d42">108.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItMy0xLTEtMzYzNTk_10fbf562-1923-4819-ab71-ebc530d97b45">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItNS0xLTEtMzYzNTk_5181f88d-9441-47f4-b87f-ecc24226684d">25.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtMS0xLTEtMzc3MDI_807b925c-30b8-42de-8f9a-e8a1352627a6">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtMS0xLTEtMzYzNTk_b57bad1b-e4bd-4ee6-bdd8-edfe93548ec0">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtMy0xLTEtMzYzNTk_1e44fc99-2381-4dea-aa53-0773661f9e25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtNS0xLTEtMzYzNTk_3808bce9-a1af-4f0a-8048-6f8ef401a95e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtMS0xLTEtMzc3MDI_b93f655b-e905-4f2a-9fd6-4ecd1c16e9f6">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtMS0xLTEtMzYzNTk_1947057b-8a09-40ee-aad5-be80e4ee3029">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtMy0xLTEtMzYzNTk_d26b895d-a759-41e1-afcd-6df53d3a0389">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtNS0xLTEtMzYzNTk_01d442d1-5fbe-446a-891c-9c768ef763f8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtMS0xLTEtMzc3MDI_88e8c9d6-d180-4565-8198-99de5b0f83b7">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtMS0xLTEtMzYzNTk_c0aabe08-80c1-4907-832e-dc2ac98244a6">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtMy0xLTEtMzYzNTk_ba7b2604-f59d-4497-937e-4bb7ff4cbfd7">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtNS0xLTEtMzYzNTk_6ca658ac-945e-479b-8887-0fee5f05ed27">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtMS0xLTEtMzc3MDI_d3eabea3-bbf9-423d-94d5-8561115653a2">26.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtMS0xLTEtMzYzNTk_903db587-321b-4713-ab40-16b2eac643c4">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtMy0xLTEtMzYzNTk_3c9ec302-d858-4387-a162-90a78b4554d8">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtNS0xLTEtMzYzNTk_bdd10d84-a1a7-4048-89e5-78f3efed2bb7">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctMS0xLTEtMzc3MDI_185792e8-127b-4d0e-a7eb-501d67e49c39">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctMS0xLTEtMzYzNTk_5b7fd162-d38c-49c5-aeff-1f6cf4eda5c6">73.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctMy0xLTEtMzYzNTk_1fd38e92-8523-4014-9379-4ab90aee59eb">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctNS0xLTEtMzYzNTk_88a038e8-e7d7-419f-a5bf-0c055f9d60e4">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktMS0xLTEtMzc3MDg_aa35696a-b69d-4e1e-a94d-ee8fcf505687">18.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktMS0xLTEtMzYzNTk_5ad96947-6006-4d4c-af74-2970c29f84ee">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktMy0xLTEtMzYzNTk_f29357e4-adfb-4e07-8f31-c5afd6c5bd86">10.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktNS0xLTEtMzYzNTk_555af17b-6c69-4086-bad0-133325b4fac0">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtMS0xLTEtMzc3MDg_78ec30e2-cee1-4792-a2f8-2db01ebb6d55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtMS0xLTEtMzYzNTk_ad6cd2ec-1fc8-42fc-a9e6-a46d85439f1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtMy0xLTEtMzYzNTk_8174625c-a61a-4a9f-aeff-40a96adcfe5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtNS0xLTEtMzYzNTk_f88c96be-5673-4a38-80d1-db69fe86b20c">278.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of business and assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtMS0xLTEtMzc3MDg_ee5ee437-1e04-470a-9927-f9062b1fc016">379.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtMS0xLTEtMzYzNTk_f12e6691-a61c-4a66-9bc4-9f048d7569b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtMy0xLTEtMzYzNTk_c99f7e64-4a5b-45e6-8661-6e41ff02d3b6">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtNS0xLTEtMzYzNTk_a7ed0dab-382a-49d8-b897-0900bbcf85ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItMS0xLTEtMzc3MDg_c0074a61-946a-4e3f-8405-02b8b78128be">147.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItMS0xLTEtMzYzNTk_773d9af7-ed66-4342-b4e5-3d3759021a64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItMy0xLTEtMzYzNTk_473e2119-1865-4807-a048-7d799c881d87">60.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItNS0xLTEtMzYzNTk_92e86e81-9298-45b3-9dde-e18fdc0b6ace">78.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtMS0xLTEtMzc3MDg_8913cc47-4c6e-49d9-ae50-55fd98c1770e">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtMS0xLTEtMzYzNTk_aef23412-1874-48e8-9614-80459f461e93">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtMy0xLTEtMzYzNTk_b5a069f4-94f0-495f-bcb7-704b43cd8d21">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtNS0xLTEtMzYzNTk_63640ff9-3eb6-4401-bba7-2ae90c4be66b">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtMS0xLTEtMzc3MDg_62aa5c51-2a60-494f-a756-057e8ac0e2bd">274.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtMS0xLTEtMzYzNTk_f5229314-ec18-43dc-aad5-90b2904b193f">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtMy0xLTEtMzYzNTk_b1175724-1847-4d6a-9549-23635de84645">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtNS0xLTEtMzYzNTk_79aef71c-818c-45ed-ad88-97a0c24d5e21">286.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtMS0xLTEtMzc3MTQ_5bfc3200-0bf3-49e7-896f-d437a809d4b4">91.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtMS0xLTEtMzYzNTk_1c65e264-5464-449a-a27a-ad762a087839">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtMy0xLTEtMzYzNTk_26caa3c7-cacb-4ce0-968e-afe62611a487">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtNS0xLTEtMzYzNTk_37b411b5-5338-4f0d-b6cb-1a4070a83440">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of tax withheld for common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctMS0xLTEtMzc3MTQ_dbeba20c-b2f7-49ca-bada-de175d4855ad">11.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctMS0xLTEtMzYzNTk_f0fad2d6-831a-4f62-8451-7f119b089781">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctMy0xLTEtMzYzNTk_def818e9-dfa2-4c16-8bae-19ad4e306eed">9.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctNS0xLTEtMzYzNTk_cb591a00-ff68-4444-a910-d7f6034b0630">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMS0xLTEtMzk0MTA_084afbc7-76c0-4560-a5e0-e9442b03245e">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMy0xLTEtMzk0MTA_cce87246-93b1-44ba-9fef-95ee00a48932">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtNS0xLTEtMzk0MTA_21c47071-e280-43e0-9e08-a7de7d700b1e">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtNy0xLTEtMzk0MTA_4c464892-5f85-47c9-872e-93d2371416ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMS0xLTEtMzc3MTQ_7c0f819d-4ce0-49a1-a1c3-ee8c268a694b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMS0xLTEtMzYzNTk_848e35f9-70b9-4037-a81d-b73dde5ad629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMy0xLTEtMzYzNTk_3849328b-01a6-4a61-9141-a13d9d3fd2b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtNS0xLTEtMzYzNTk_e1b7db23-4d28-4b57-a5ad-fbe6188b078f">340.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fees associated with refinancing of revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktMS0xLTEtMzc3MTQ_a1ec80d8-338c-4c3c-9a92-8e128a7214ff">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktMS0xLTEtMzYzNTk_ea23c613-2fcc-4b60-ba50-4200b0c383c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktMy0xLTEtMzYzNTk_7b02e7d5-05a9-4a76-80fb-f56069d5e663">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktNS0xLTEtMzYzNTk_b7f07c43-0c67-4ff2-8931-302b48fa59e5">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtMS0xLTEtMzc3MTQ_9d45ea0d-55d9-42ba-9060-25767cb03dff">226.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtMS0xLTEtMzYzNTk_278305c1-5ce4-4048-aa26-be668b438853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtMy0xLTEtMzYzNTk_ac471b81-a5cd-4a3f-aed3-ff12cf046606">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtNS0xLTEtMzYzNTk_8ba2a51b-ceaa-40f7-a4c2-2cb3207f4805">115.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItMS0xLTEtMzc3MTQ_7d905a04-5e3d-4da7-9a9f-457dba8e2979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItMS0xLTEtMzYzNTk_08641a12-8807-42d1-a37c-b182f8a1144a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItMy0xLTEtMzYzNTk_420dac49-eab2-41e7-87b9-3d97438cb090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItNS0xLTEtMzYzNTk_6a4c2ed6-0e41-48e1-bd32-095c18dc1b65">50.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtMS0xLTEtMzc3MTQ_de520992-7141-4eaa-bbc1-38ef0fe373ed">150.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtMS0xLTEtMzYzNTk_446c45e8-2c15-4e76-9be3-cd954d7e36a9">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtMy0xLTEtMzYzNTk_faabaa3d-0edd-4f64-9b97-ea1d222e7c7e">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtNS0xLTEtMzYzNTk_8fb08a20-3dca-455c-9527-43af1b4a4c3a">182.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtMS0xLTEtMzc3MTQ_9816f1e4-e3db-4178-a250-12837c67ee12">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtMS0xLTEtMzYzNTk_a5ec92b7-5250-4d30-9c86-f54bb4a18e4f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtMy0xLTEtMzYzNTk_a0df22b4-fa32-4f1f-8265-376bd2df760b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtNS0xLTEtMzYzNTk_94904673-e35e-4c44-be2f-90af6854b0fc">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtMS0xLTEtMzc3MTQ_ad95947d-f2fe-45be-8c73-83b74b66c6d5">141.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtMS0xLTEtMzYzNTk_fa50e68f-a23c-4e32-a575-c43f97fec550">46.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtMy0xLTEtMzYzNTk_c3a8e6e5-c5bc-4b7e-9afd-f16b46c006f2">70.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtNS0xLTEtMzYzNTk_4875e6e4-782e-4521-9c97-5ddeb9d25582">17.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctMS0xLTEtMzc3MTQ_c915b898-6d00-45b1-b55f-7820446d6560">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctMS0xLTEtMzYzNTk_9bfd1774-da1d-4f94-b8df-1785f6a3e6cb">163.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctMy0xLTEtMzYzNTk_b7f62452-5ffb-4769-a84e-fd68fab98273">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctNS0xLTEtMzYzNTk_20484388-580f-4d0d-bd46-46d092d9e3ed">110.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtMS0xLTEtMzc3MTQ_05afba1f-758c-41a9-9d85-0fd7e15799ed">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtMS0xLTEtMzYzNTk_db84693c-1c06-4ae1-9414-91f34c537800">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtMy0xLTEtMzYzNTk_af1d52b9-d0c4-4412-934c-4bbfeec501c3">163.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtNS0xLTEtMzYzNTk_df8317db-7226-4eb4-be97-ff0851523b4b">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div id="ifead9d28cda549c1af769d1d50d95807_91"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share data)</span></div><div id="ifead9d28cda549c1af769d1d50d95807_85"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODI_2c03e61c-db3f-4dbe-b69d-0766aa76db50" continuedAt="i330bef8b8cf74cdfbfede9ef9edb349b" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i330bef8b8cf74cdfbfede9ef9edb349b" continuedAt="i5342ee0c422a4fc48178ace3b492f7b6"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjM_8c257998-ad37-4be0-bf19-065020cd8d7f" continuedAt="i7b9508cebc6948b8b7a490c0d7f941dd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Financial Statement Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and subsidiaries (collectively, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties.&#160;The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.&#160;The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.  </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b9508cebc6948b8b7a490c0d7f941dd">The accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.</ix:continuation>&#160;&#160;</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Njg_d4714a50-320d-4049-9861-c4310fbcfa57" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of the COVID-19 outbreak continues to evolve and its future impacts remain uncertain and unpredictable. The Omicron variant, which has become the most common form of the virus circulating throughout the world and appears to be more transmissible than other variants to date, is causing significant uncertainty. The impact of the Omicron variant and other variants that may emerge cannot be predicted at this time and could depend on numerous factors, including, but not limited to, vaccination rates among the population, the effectiveness of COVID-19 vaccinations against emerging variants, and any new measures that may be introduced by governments or other parties in response to an increase in COVID-19 cases. Management is actively monitoring the impact of the global situation on the Company&#8217;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods. </span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODE_051e07d2-b17e-430e-b13e-faf66e2d7d26" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i5342ee0c422a4fc48178ace3b492f7b6" continuedAt="i6dc581bb27d144269e933223d6693ba8"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODA_a29de0e1-10b6-45fb-afe6-9ccd079ae14f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately <ix:nonFraction unitRef="number" contextRef="i8e0e54e9b3ce4a3a9110635bf28d65bf_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM3NA_d9bdadbd-6c9d-4dd4-8478-2bc921fc6f10">17</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="iad15d513ac03478199e9e31a63c2e46d_D20200701-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM2Mg_2a760be2-8fe8-4b2c-a40f-6917d8c6f5bc">16</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i701057b14190407c804d2064afc26532_D20190701-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM1OA_46426637-610b-42e9-9e1b-cc9f7e134e62">15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1aa5bdf689894b6ab2ba9eb4389ee963_D20180701-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM1NA_49b05797-ac72-48e2-8270-a43736e2941c">14</ix:nonFraction>% of total revenue for the year ended December 31, 2021, the six-month transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No customer accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2021 or December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMzI5ODUzNDk0NDY2Mw_ec6bcf03-4bed-4bd1-afaf-99da33266731" continuedAt="if848a0c3547a4d46aaae800141e88f66" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if848a0c3547a4d46aaae800141e88f66">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.</ix:continuation>  </span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Njk_820d9db9-64fd-4323-8045-6bb96759f09b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Investment Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#8217;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#8217;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were <ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_27c8b3d7-b619-4006-bee7-d2cd97cb0a32"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_5e361c5b-7edd-4692-b25c-6ab87f42bf1e"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_a1399c5b-9d1c-40a5-b1fb-b25ff2fcdedd"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_c31b76ab-80e9-4230-b3da-5c9c4f831fda">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December&#160;31, 2020 or during the years ended June 30, 2020 and 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODM_321bcf38-9c32-4ec8-8bb5-a95cc954ec77" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#8217;s assessment of current and expected orders from the Company&#8217;s customers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Njc_ebf6c44f-e551-4948-a9ee-7cbbbaeab093" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i6dc581bb27d144269e933223d6693ba8" continuedAt="i8844e3e164704aadb15ddc5711790e2d"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjI_1218d81a-b099-4511-86e5-fed17f21cce8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f">five</span> to <ix:nonNumeric contextRef="ic25baf947458498cbc5ec1d41a505594_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODQwMg_fd24e593-ee6f-48d6-9e16-a2bbc09999e4">seven years</ix:nonNumeric>. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b">one</span> to <ix:nonNumeric contextRef="i0f0b6b5784d44e638df0d82d2332ca5d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0Ng_75518da4-2d6f-4d87-82f0-8a98be9b051f">seven years</ix:nonNumeric>. Repairs and maintenance costs are charged to expense as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Nzg_56505bb8-472a-4c4a-b48b-e729e0fdebf6" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company&#8217;s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM4NDU0Mg_297b8e78-1eb2-4239-8101-602ff29d9827">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY4ODIxMQ_e829ac67-7050-4bda-bb84-805abc71a291">2.3</ix:nonFraction> million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM4NDU5Mw_2ad21699-5747-46fa-9140-638798267b43">0.2</ix:nonFraction> million. There was <ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODQ_378d248b-d7cb-4a6d-8410-b28789cdd3dd"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODQ_7a11d979-6684-4f71-9741-d33829b92f31"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODQ_a994876f-b2dc-41f6-996d-c97270ac0f89">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> capitalized software amortization expense for the remaining periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzE_9c8d5fb5-1510-478d-951d-7a7436d0a0a3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzY_a02df348-17be-4f2b-8b9b-6130bc632e73" continuedAt="iffeab4805e144a93885a32122003def3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i8844e3e164704aadb15ddc5711790e2d" continuedAt="i61456f9cc3184fe6be943fae6a4cfb60"><ix:continuation id="iffeab4805e144a93885a32122003def3" continuedAt="i6303b0f1ebee4deda2fce667aaec3bf1"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Nzk_17cbcd72-54cd-4303-b5ca-ff3bafb5359b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804cc2b055a3466fbb3e15bd020c759d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy0xLTEtMS0zNjM1OQ_5535ddb0-4a0f-4676-b0d2-9262d0ea0134">316.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fd5561929d497eaf7992c43061cee2_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy0zLTEtMS0zNjM1OQ_c1ca3f13-27b3-4eaf-ad63-de061514bc83">159.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i484dc209f37b4adf909bfa0878315aac_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy01LTEtMS0zNjM1OQ_2566b0d8-031a-4634-8bd0-2bed26b0d80c">347.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd1e4144cb64cc2be192b5f21702ee2_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy03LTEtMS0zNjM1OQ_d879c5f3-08f7-497d-ad1c-b0abe2afa345">479.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23674b92559340f5b730b6afcc5f3e1f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC0xLTEtMS0zNjM1OQ_f449f439-4019-466a-8dfe-e0c2914b0171">120.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44258853a0d44e2b9701f666527520b1_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC0zLTEtMS0zNjM1OQ_a5782b6b-6325-440c-9c2b-4666478108b9">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14004bb5c3043ef94f2f37784092276_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC01LTEtMS0zNjM1OQ_24ae0379-fdbe-4355-a440-7ba335ba8e41">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868860485c4b4abeb0e46251d83d47df_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC03LTEtMS0zNjM1OQ_88abe1f9-e83d-441f-8b19-53f53aaf59d7">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c94826adb64c97800cb3e9f2f19447_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS0xLTEtMS0zNjM1OQ_858361a3-240f-41ff-8c87-131c7f17ea4a">106.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56d8f8d202742b8adbccfc987f7d6aa_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS0zLTEtMS0zNjM1OQ_2ae14b1d-c274-4d3a-836b-38e3f17a636b">37.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15aec7363f947d18a16d8514fa80f9a_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS01LTEtMS0zNjM1OQ_69119936-00b6-4fde-8ffd-ba733cbc860b">76.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab9b81676e64707a024e71a8dadfab0_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS03LTEtMS0zNjM1OQ_6e5b3619-4b01-464e-a4ed-834b03b9b4b8">104.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f918798d8d4876955bdfe1781192bb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC0xLTEtMS0zNjM1OQ_2e37adf1-a03a-4bf5-b06e-15f797a6d417">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0720541a493427c9ac9e47764246d06_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC0zLTEtMS0zNjM1OQ_4d4885e7-7eb4-48f0-a9e3-faf09a6ca37a">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2d8ee96d1842a89bf2eb52509f39c8_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC01LTEtMS0zNjM1OQ_1c969869-271a-4b14-b1d2-cde5744fec26">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090f85aa323b4d5aa89a4ef95bbff252_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC03LTEtMS0zNjM1OQ_19e3245a-99fb-49b3-9ac5-f678d8bbcea3">112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f3a2eee80d4e39b6b467a461ee1164_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS0xLTEtMS0zNjM1OQ_a9a80ef1-bb27-4bb3-8dfe-10232a01210b">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79122a39eed648d294ae1358b2622bf2_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS0zLTEtMS0zNjM1OQ_1d82ff88-c1ec-48ea-9381-36289c5c5ded">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8608277b4c9f4d1d8452c383fd7509c3_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS01LTEtMS0zNjM1OQ_7de928fa-22ac-47b5-8fbe-2d8c37098282">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150c0623a2d04f00b701fe362396760e_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS03LTEtMS0zNjM1OQ_8a9e962a-2cff-450d-a00e-f09a2ed2d7c5">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288dd68612f8451489b037c3444d9bf4_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtMS0xLTEtMzYzNTk_ce157f6b-003f-42c8-8b44-043a418583cf">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2397e1764fa64b159eaa4444a72537d4_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtMy0xLTEtMzYzNTk_be7b3d60-9f7b-469d-8b2c-ee551f3a4092">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dddabbe8f644f90b6c63a2383f8793c_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtNS0xLTEtMzYzNTk_42fec872-7e6a-4067-b211-9daca0a43627">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129a1c23ee0f4732a50e53e3e8927e0f_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtNy0xLTEtMzYzNTk_776238a6-440b-4c36-8db2-097dae35fe28">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtMS0xLTEtMzYzNTk_fd105afe-9164-428f-9fa8-b729a49de6f8">666.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtMy0xLTEtMzYzNTk_c2610da8-b05b-4b4b-98d2-4cdb1db44f35">279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtNS0xLTEtMzYzNTk_7baba135-f64e-43a9-a888-0b6603b77867">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtNy0xLTEtMzYzNTk_bf6027e3-672b-403a-8d56-b6f27834f6c9">789.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItMS0xLTEtMzYzNTk_fd06370f-f0a2-48ff-a0cc-14fcc2604bff">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItMy0xLTEtMzYzNTk_6b7f9a4b-6718-4bc2-8642-8db0413138d1">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItNS0xLTEtMzYzNTk_92ff9d6c-024a-4268-b081-73dc4d127219">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItNy0xLTEtMzYzNTk_49dcc769-36c6-47ac-96e7-ef774abbb4ed">61.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtMS0xLTEtMzYzNTk_46f4d4d3-6b3b-4222-95c0-f8b244996498">690.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtMy0xLTEtMzYzNTk_0ac3a682-7410-4b35-a474-c4c5544c3411">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtNS0xLTEtMzYzNTk_c98eb615-623e-43db-9018-8b6ad1a83c3a">638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtNy0xLTEtMzYzNTk_7c5c3515-9bbb-4cad-9816-53f428b9743d">851.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTU5NDI5MTg2NjUyMzk_4bf099ee-34c9-4f9d-b2bd-e681c1ce5e50" continuedAt="i3957672075f84b2d8c1241916fea1e17" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0298c605b2cc48e9a78c5e3cd557802a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0xLTEtMS02MjYzNw_8343a211-9035-475c-8ee7-e13092ecb817">271.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6cca08c16e854e23a8787d0bc760adbc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0zLTEtMS02MjYzNw_c2d55748-8003-4eff-84dd-142ac67e76f9">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i804cc2b055a3466fbb3e15bd020c759d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC01LTEtMS02MjYzNw_4dcabe2d-82a9-46d1-8c0d-d3f3f17b4afe">316.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3970c7875cbc464db2a7a85cb7ba05be_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC04LTEtMS02MjYzNw_54871fef-104f-4e46-92a5-7401cbcd382a">140.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b9608c73ed34af285fe6c4c9fb6f968_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0xMC0xLTEtNjI2Mzc_08f6fb35-7399-49ed-9121-537f09ac495b">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i58fd5561929d497eaf7992c43061cee2_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0xMi0xLTEtNjI2Mzc_83d9c3ef-4046-4821-9ce1-5039a9d7b890">159.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id4ef79d3516c4f77b9ffd69e6257d787_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0xLTEtMS02MjYzNw_cac9b447-dbbe-4ab1-949e-d6590ea7e1a3">80.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c78ab7c6f04b4cb49ccbc3b2572957_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0zLTEtMS02MjYzNw_9d8de5d0-7e6f-4686-bb38-8f1dace1124d">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23674b92559340f5b730b6afcc5f3e1f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS01LTEtMS02MjYzNw_256952e4-c466-471f-93ae-638666776c4b">120.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2ac2a8aac44f4c039ce9c9739247a018_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS04LTEtMS02MjYzNw_07c460ea-10bd-43cb-9167-5dd5dcbee6d8">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74f7d15a9df4096b33799ed18b6d983_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0xMC0xLTEtNjI2Mzc_363f4f2f-ec0d-41df-ba90-50d0857cb5e1">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i44258853a0d44e2b9701f666527520b1_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0xMi0xLTEtNjI2Mzc_4f693552-56dc-4715-aafa-2b7208d097ea">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic04f84748937427db317a660c8aa5694_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0xLTEtMS02MjYzNw_b3ff95ee-2fe5-4852-9340-ef1fe579fc3a">106.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8de44f5f1c410599b481b8c80dbffb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0zLTEtMS02MjYzNw_59c0fc92-2342-4f5f-92a6-82ff2cb53c3c">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0c94826adb64c97800cb3e9f2f19447_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi01LTEtMS02MjYzNw_ef0459e3-e761-40c0-9e7a-032c0d6f6d32">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i445a32ad37ae4a4cbcbea691e2e68241_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi04LTEtMS02MjYzNw_f440cc90-f7a7-4bd5-ae4a-26131e9b3d1f">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d75f83f7f84447a1524a301b921946_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0xMC0xLTEtNjI2Mzc_58e1be6c-a32e-4237-9f9f-34b88ac551e9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib56d8f8d202742b8adbccfc987f7d6aa_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0xMi0xLTEtNjI2Mzc_a844139a-e4ee-4fee-94e6-bf69ee83c19b">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibdaec0b909474eda8eee58534fbd0e9b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0xLTEtMS02MjYzNw_f4ec0327-d3ad-466b-9f3c-4401b8211bc6">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04da1cbfee0c46dcbaec497c3feb4cb6_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0zLTEtMS02MjYzNw_ba0d2083-539e-45aa-8b4d-5ca5e4e3eabf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i31f918798d8d4876955bdfe1781192bb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy01LTEtMS02MjYzNw_0de0a11c-3c16-488b-9d97-280e60726988">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf55993a60224a2990dd01e9cff341d4_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy04LTEtMS02MjYzNw_e243ef18-6c04-4613-837b-c96815b68ac1">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706f35d8790f490f917a84f064c29039_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0xMC0xLTEtNjI2Mzc_9f80ff97-da7d-4121-8745-36684c31e98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0720541a493427c9ac9e47764246d06_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0xMi0xLTEtNjI2Mzc_72f3d645-6fcd-47f3-b4f4-54227eb7da8d">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c6b105e8804486dad3802a06c5f3c30_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0xLTEtMS02MjYzNw_cd6e82e4-5bc0-4d79-9771-17be2280d5dc">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e31518757a047b4b8acd5c9c6584b2e_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0zLTEtMS02MjYzNw_7ed7e58f-606c-4fba-9991-7cd5f4569d80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i83f3a2eee80d4e39b6b467a461ee1164_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC01LTEtMS02MjYzNw_f76537c1-d194-443d-97d5-ea75e90009e9">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96a6d32ed385415289c8a82922c2e387_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC04LTEtMS02MjYzNw_a5badb56-a2ea-49a7-8582-d73df0ef1ae5">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1202a0ed3b3942fc98fdc69ccb249509_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0xMC0xLTEtNjI2Mzc_92bb0bd4-142b-4ffa-814b-e67fd53ce8d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79122a39eed648d294ae1358b2622bf2_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0xMi0xLTEtNjI2Mzc_050278f0-1f34-4636-a95d-e4979bc4af39">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5801c36efd234e02b91dbea98f7d3e00_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0xLTEtMS02MjYzNw_72efec53-ea92-4fb9-ac4f-e5b9759d8c9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95ef34040e2948f2abbaab8f194748d9_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0zLTEtMS02MjYzNw_2d3a5241-1eb0-4ec0-827b-1d60a1b48591">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i288dd68612f8451489b037c3444d9bf4_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS01LTEtMS02MjYzNw_4e7f8da8-1c03-43dd-b294-8cdc0ba37d9f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i73d2040b564247bfb340b997780ebec6_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS04LTEtMS02MjYzNw_b974a7a0-4fe1-4bc4-ac5a-28dbd0058dc3">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i60635ff66fa64b69966774de4439af5e_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0xMC0xLTEtNjI2Mzc_cff4142a-4047-4eb0-95e2-68a4b4ae0834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2397e1764fa64b159eaa4444a72537d4_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0xMi0xLTEtNjI2Mzc_947e8d8e-18bb-429c-8122-e55cb4009e51">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i33fb7f026e344cc98c08acf5ec62babe_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMS0xLTEtNjI2Mzc_f9e558de-0bad-489a-a055-11651100198f">579.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i05a23258ea8e458393c125d83313b4a8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMy0xLTEtNjI2Mzc_8643843f-1a64-4a82-9530-962b62a9d419">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtNS0xLTEtNjI2Mzc_e21ba23b-a1e2-4bf1-9344-c36a3dd5819c">666.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e1fa64c828d4462a20186e9d1460d97_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtOC0xLTEtNjI2Mzc_7bc9a8f0-d796-4efd-850e-09492dd24199">255.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ba16b7c64ec499aa4e9285f47ed97e8_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMTAtMS0xLTYyNjM3_bf8dde31-548a-4c64-bbe7-2f9de79cb334">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMTItMS0xLTYyNjM3_c690c319-a312-4195-aa64-20eea21aec33">279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55f89783405a449ba8e650af0370be7b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMS0xLTEtNjI2Mzc_34296b9d-a5f3-4ec9-ae76-0cb55be72f7f">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i903acccd51c14e7db28f40da3937c802_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMy0xLTEtNjI2Mzc_f4c20c24-b671-4181-9ed2-eee6afd3ad68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtNS0xLTEtNjI2Mzc_047a9511-7e25-41e6-927e-afa6c3c1fd0c">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d6524bb7e0441428b64b01d2565544d_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtOC0xLTEtNjI2Mzc_983e3d47-78c7-476e-96ca-7686f3c6fc16">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3d422ad60e04435ba4213ff4258db4ea_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMTAtMS0xLTYyNjM3_db105192-6c69-487a-ac6d-068e64035163">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMTItMS0xLTYyNjM3_5231d768-6cb4-4840-82e5-99853095de33">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf717ff001aa48f3898b6bad81b7074e_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMS0xLTEtNjI2Mzc_bac8969f-1c16-4d4c-ac43-4655f2726a9a">603.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1b308819639648ebb0241dce3fee0e0f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMy0xLTEtNjI2Mzc_b1ce0ce4-4579-41ec-ae46-91f23dfb34ae">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItNS0xLTEtNjI2Mzc_d3d5952e-7e44-4a4c-8d9c-b6506f6bfbf5">690.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6f4ddb7736b546099130bd23f3e3bf81_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItOC0xLTEtNjI2Mzc_2a462c8b-b366-4efc-a0e1-3c1ab700a6ed">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd6371c107dc4037900af9562f284dd2_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMTAtMS0xLTYyNjM3_c980e5ef-c616-476a-bd94-d7a43bbc400f">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMTItMS0xLTYyNjM3_ffb61337-7711-426a-87f4-b93b695bd180">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:right"><span><br/></span></div><div style="margin-top:5pt;text-align:right"><span><br/></span></div><div style="margin-top:5pt;text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i61456f9cc3184fe6be943fae6a4cfb60" continuedAt="i374f66a5ccf748ca8bb306c0032a9d2e"><ix:continuation id="i6303b0f1ebee4deda2fce667aaec3bf1" continuedAt="i752d02fdf4654ed1bc541fd026b61404"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i3957672075f84b2d8c1241916fea1e17"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a25d7789ed04de38b87467b38c075c0_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMS0xLTEtNjI2NDU_99212a8c-89d6-4058-9cf2-434d36c823f1">329.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0371d7615c143a1a2f93c9c51117fd2_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMy0xLTEtNjI2NDU_a55a9c6c-8122-44d9-9624-c33d81bb50c5">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i484dc209f37b4adf909bfa0878315aac_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtNS0xLTEtNjI2NDU_4b87b9d2-9b07-4e3f-93e3-16fd5a45053c">347.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc48edd4cd4e4d54b269125a5eddbe4d_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtOC0xLTEtNjI2NDU_6ad6576a-621a-48c7-a23e-4e557a7e858d">466.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3b993db4c69b427d8483546c0c8b8414_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMTAtMS0xLTYyNjQ1_676ed0e7-44b9-41f2-933d-a7f60ce91f26">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idfd1e4144cb64cc2be192b5f21702ee2_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMTItMS0xLTYyNjQ1_e28ea755-2178-499a-b4cb-12505f4a8355">479.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d121e6f796d42b5862758d3e57021f4_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMS0xLTEtNjI2NDU_5fd9a1e1-3cc6-42fc-80b5-ff3adcb55cbe">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b0e5857240418899f53180ceb70c6d_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMy0xLTEtNjI2NDU_663d200e-9203-4e41-975b-f5103d5e6a88">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic14004bb5c3043ef94f2f37784092276_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktNS0xLTEtNjI2NDU_7080056c-3126-4746-90e5-b7bf1f25adb6">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba2729ff5f4d4076a392c72d3aff48fc_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktOC0xLTEtNjI2NDU_0821be39-4ecc-43de-b09b-6fcc29f77936">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40ae86ad5c541fcaf7e88efb9f20b4e_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMTAtMS0xLTYyNjQ1_9a151b31-f584-46f7-aee7-8b57f2f7ff6a">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i868860485c4b4abeb0e46251d83d47df_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMTItMS0xLTYyNjQ1_fead91e8-35c1-48c9-83a3-8738023bdfd3">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i702d3c75cf5c4f2fb78e549b2d2e07b0_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMS0xLTEtNjI2NDU_d5e9164a-46e3-4c86-a879-8a09f73462a5">76.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e9d08b5b5b4218a39576afaba6ff6d_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMy0xLTEtNjI2NDU_9b42f550-8f31-4def-96c5-9694ba7cca2d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if15aec7363f947d18a16d8514fa80f9a_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtNS0xLTEtNjI2NDU_3975b0af-aa35-4e20-9803-d25c1dbef8c7">76.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie936759bad6c4f768bfdcaad6c185260_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtOC0xLTEtNjI2NDU_25c33adb-0fa3-4e75-9bd5-37bd9f79bf46">104.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86ab20ba60c457c91783c694e76c402_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMTAtMS0xLTYyNjQ1_e5d6dd86-c546-4e7b-9fa0-13dd42e3f3d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ab9b81676e64707a024e71a8dadfab0_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMTItMS0xLTYyNjQ1_7eaec78a-af58-4923-bb79-7d5cd4d0e633">104.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab7934e0625841d3a44b1f9aecb81682_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMS0xLTEtNjI2NDU_52339543-4292-4d58-bb1a-3d97cc5239ec">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0036422f15ae438fb80d6285f3b97550_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMy0xLTEtNjI2NDU_827ea960-3d68-46d3-a93e-c0426acffb9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf2d8ee96d1842a89bf2eb52509f39c8_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtNS0xLTEtNjI2NDU_f81dfd8b-592f-4da7-88ec-67f4df47bcd2">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2b20aa35ae4a3ea1712a93847ca7b2_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtOC0xLTEtNjI2NDU_0c85b02b-082d-4003-8a82-6ebf59e13257">112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8491e37cb24bc3b4dc9fb8f3c5e60f_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMTAtMS0xLTYyNjQ1_6929083c-9c31-4f0c-9374-b93cb10e6a61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i090f85aa323b4d5aa89a4ef95bbff252_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMTItMS0xLTYyNjQ1_9d4e9301-88eb-4cb3-a459-96afd9519600">112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2d596e3878504d22b86d326e8ca08613_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMS0xLTEtNjI2NDU_250d6732-0293-4136-8d94-e13da48ee336">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97117ebb3cae4051af1ac90be6bb19c0_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMy0xLTEtNjI2NDU_1d0c6132-8baa-4a5e-b2e9-71721b0ed25b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8608277b4c9f4d1d8452c383fd7509c3_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItNS0xLTEtNjI2NDU_f0de1eca-37f9-4d26-9af6-3a233633409b">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i102893003cb44b69875935664fcd4cfe_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItOC0xLTEtNjI2NDU_846cdfa3-cd5e-433e-8a25-50b3adf0344f">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c4ca98d253f439984d89ffe162f4048_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMTAtMS0xLTYyNjQ1_5069dd74-981d-457a-aae1-fbb42aa5460d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i150c0623a2d04f00b701fe362396760e_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMTItMS0xLTYyNjQ1_462e0a00-04d0-4a4a-8560-5b9b79b74618">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib644def5081d44de96b13a4ec090e55d_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMS0xLTEtNjI2NDU_57a43d71-1003-4803-af84-71a96a6a4e27">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idaa7d7f8f59743e19ec25ad143e2a6f4_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMy0xLTEtNjI2NDU_d871245e-4083-4791-9c95-7944ca6bd645">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dddabbe8f644f90b6c63a2383f8793c_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtNS0xLTEtNjI2NDU_8d1e1d85-c825-45f7-a760-8c7bea484ab1">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5819703f324d41349027f3813ef7b49b_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtOC0xLTEtNjI2NDU_d60bf789-6fee-48bd-80ce-ade18710ebd7">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3bc1fef06d7444e6bd2ce7b0f247ad53_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMTAtMS0xLTYyNjQ1_b93427b1-0e35-4fd6-a472-69999aee9330">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i129a1c23ee0f4732a50e53e3e8927e0f_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMTItMS0xLTYyNjQ1_08527678-617f-483a-8297-da062dff9e6d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i204cd1955cec41cf9852a26d4402e885_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMS0xLTEtNjI2NDU_9ff3b8e5-9450-41b4-82c9-1e2f960b44fc">559.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i43e5e361d21d4734af2a1a30525f5d04_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMy0xLTEtNjI2NDU_4345a52c-fc1f-427b-9267-5ca46071e280">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtNS0xLTEtNjI2NDU_28b51b37-0789-4ceb-9ddf-7abc518a9c14">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib58b31ce77e7445aae0d209f9e0fbc19_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtOC0xLTEtNjI2NDU_0bc0dd23-3473-4086-89f0-4711c74a3466">767.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e64446e4bae4f2ebd45cae070670f11_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMTAtMS0xLTYyNjQ1_4e30df2b-37a6-4ee0-865a-3d5fb32fefc8">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMTItMS0xLTYyNjQ1_cc5b0e7e-f94a-409e-aace-1cd872aeaaaa">789.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6faa7a7476b140628d02a78558ca348b_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMS0xLTEtNjI2NDU_10957e8b-02a1-4b6e-b83f-8507e7f3d5e6">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i78b4f16f2653401187ed5044b51e074f_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMy0xLTEtNjI2NDU_70a1f1b4-c84c-4e62-8ae7-9ac521f4289a">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtNS0xLTEtNjI2NDU_4bfc6a55-8743-4766-9596-005c339b3edf">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i90c85822b51b4d35985a06435eee8bfa_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtOC0xLTEtNjI2NDU_a7747f02-398e-4d9a-a8a5-633c46ef3f2b">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0903d5f700b14c0f82cced2c6973459a_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMTAtMS0xLTYyNjQ1_69bb8ca9-259f-4cdd-9b9c-809f9e8c5209">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMTItMS0xLTYyNjQ1_f444d526-671c-430e-a4f6-e988fc0ad757">61.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic3faafc5dbad46dba5234c91f2b7c8d2_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMS0xLTEtNjI2NDU_586c8529-6c2b-4ea4-8a49-7fd65d523c94">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6ea93dfc8c9b4d418d726e1503143b00_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMy0xLTEtNjI2NDU_f5d24ae7-65a0-4624-b9ed-381f8884250f">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtNS0xLTEtNjI2NDU_2069efbc-8472-4131-ada3-99c2f2d478af">638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i433ffee4dc83441d8a68d42763e78e7d_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtOC0xLTEtNjI2NDU_3d45fae4-d6e4-4390-a7cb-4209e91a0974">805.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia021741aa8d343d79f2d259b408c46a0_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMTAtMS0xLTYyNjQ1_9899b8b4-44de-4e2f-87c2-22061e705c93">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMTItMS0xLTYyNjQ1_d1e14354-fa98-4f56-95ae-f4af0a03f135">851.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:CARESActOf2020MedicarePaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5OTQ_964ff676-069b-4c22-b2d1-61627d4b74f5">29.7</ix:nonFraction>&#160;million in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Nzc_3880ccea-773d-47b9-aaf3-d0ec48116f04" continuedAt="ic9ad9a3b3e68409198716ed914fe1aea" escape="true">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="ic9ad9a3b3e68409198716ed914fe1aea"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi0xLTEtMS0zODk2Ng_58ac01c4-3862-4688-bd98-12c39dcd66c4">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi0xLTEtMS0zNjM1OQ_db090f4b-9a37-47a5-ad54-fb40baf4ac47">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi0zLTEtMS0zNjM1OQ_e3d573a7-1e58-4138-a163-3decd24f7c11">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi01LTEtMS0zNjM1OQ_205ba9da-efa4-4fe0-bd5e-d8a829d65754">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy0xLTEtMS0zODk2Ng_e04bc85d-00e7-4fde-8f5b-85a3c6bac2dd">40.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy0xLTEtMS0zNjM1OQ_991eb38a-387e-41c2-b24d-44f6b4404437">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy0zLTEtMS0zNjM1OQ_7e2f82af-77cf-4e32-880c-40c51413e8e0">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy01LTEtMS0zNjM1OQ_8733be10-a63a-451a-bb4d-0c94bf5e33b0">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC0xLTEtMS0zODk2Ng_e4bedf0b-c428-452a-8069-9ed7e9ae16b2">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC0xLTEtMS0zNjM1OQ_66216030-f5af-4b76-b369-cccbb1fdd44e">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC0zLTEtMS0zNjM1OQ_d79e6ad7-c3b2-48e5-b3c8-7260d42dca22">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC01LTEtMS0zNjM1OQ_ae953cca-6e8c-4d31-90de-3a65dafdb778">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0xLTEtMS00ODgwMQ_a7999a2a-1f37-42cf-b117-1a24ed920115">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0zLTEtMS00ODgwOA_2319711e-49bf-45f9-94b7-c06c397a0e1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS01LTEtMS00ODgwOA_1e2dae99-ab5e-4017-9ef1-3d8e4ad150a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS03LTEtMS00ODgwOA_0752c0fe-8f7e-4b8a-97d3-926987e6dd6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0xLTEtMS0zODk2Ng_fb0da598-f7ca-4181-8d3e-a536290ce71c">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0xLTEtMS0zNjM1OQ_58ac01c4-3862-4688-bd98-12c39dcd66c4">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0zLTEtMS0zNjM1OQ_9667d6e5-f9ac-4a75-9ee8-994126a7ca43">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS01LTEtMS0zNjM1OQ_c042a4ab-2953-4bde-a293-918ae8c6de83">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of Company&#8217;s performance to date. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i374f66a5ccf748ca8bb306c0032a9d2e" continuedAt="i95a941237f434fac8e4d9e867e9141fc"><ix:continuation id="i752d02fdf4654ed1bc541fd026b61404"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2NTA5Nw_e37e9309-0bdc-4931-af1a-2eeab4b0c425">15.9</ix:nonFraction> million in revenue which resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="ief14d1a627f44e8aa55a13b03bf21cfd_D20210101-20211231" decimals="2" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2NTA4NQ_150bea30-e5be-4bcc-b649-cef0babfc404">0.15</ix:nonFraction> impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of  $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2NTExNw_f803f198-77a2-47ad-bcb4-06264dbb2798">6.8</ix:nonFraction> million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTc1NjQ_b0218e6e-b907-4353-b2b3-448b8fb88f80">9.9</ix:nonFraction> million decrease in revenue, which resulted in a $(<ix:nonFraction unitRef="usdPerShare" contextRef="i2684048ee70b4d07beca518b514fbc45_D20190701-20200630" decimals="2" sign="-" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTc2MDg_e74ed496-3950-4a85-ac46-ee7030925fb8">0.10</ix:nonFraction>) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $<ix:nonFraction unitRef="usd" contextRef="i2e458e0265a748528393f9775e33c560_I20200630" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTgyMjg_66bd743f-13e9-4c4e-94f4-07be1a6b6e1b"><ix:nonFraction unitRef="usd" contextRef="i75ba6d883e7547e7af3798c78f6badf4_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTgyMjg_938d94e9-505f-44cc-9b4f-652df34d4b9f">4.7</ix:nonFraction></ix:nonFraction> million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(<ix:nonFraction unitRef="usdPerShare" contextRef="i75ba6d883e7547e7af3798c78f6badf4_D20190701-20200630" decimals="2" sign="-" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTg1NDk_c87e2319-2480-463a-baf4-a83d85579cb7">0.05</ix:nonFraction>). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, <ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:CapitalizedContractCostGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTkwNzA_7fc16a79-6d2c-433c-b854-8f25819e9359">no</ix:nonFraction> costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i95a941237f434fac8e4d9e867e9141fc" continuedAt="i349787391ffb424eae8fe297e559c801"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjQ_8f848df7-d68d-4c4e-8399-90ba5664f1bf" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation &#8211; Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company estimates the likelihood of achievement of the performance conditions at the end of each period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="mygn:OtherIncomeExpensePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjU_8aca6eb2-c365-4de2-8838-dc385c0f41ef" continuedAt="ib0fabaf087c6444283a3ff7a94a25e9f" escape="true">Other Income (Expense)</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib0fabaf087c6444283a3ff7a94a25e9f">The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December&#160;31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2OTIyNw_dcc2d345-2eaa-46ef-9879-f77da16434ec">162.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2OTIzNA_b862252b-af92-4e00-ae3d-e49c943159df">1.0</ix:nonFraction>&#160;million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:CARESActOf2020ProviderReliefFundAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjA5NzI_e1b3b560-10ac-4e9b-aaa1-a0e9ebd4e3cc">14.6</ix:nonFraction> million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzM_2922d111-ede2-4c01-8e24-90742f99abcf" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#8217;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzI_79d34be2-8b2f-4910-bae7-94d629b75f6b" continuedAt="i9153449e25ec47978a4130b4d6a21eff" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODE_490c6457-ed0d-481d-a6ac-180f221b1439" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute <br/>&#160;&#160;&#160;&#160;basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy0xLTEtMS0zNjM1OQ_9db7b96d-beff-4c97-96c4-81fde0e6b16d">78.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy0zLTEtMS0zNjM1OQ_9f992bf5-a0c8-4db0-9c75-1a7bedb9f977">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy01LTEtMS0zNjM1OQ_ba63ee6d-cf4c-42f2-8a2a-ae9fe3ddd190">74.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy03LTEtMS0zNjM1OQ_fad35eef-f75a-4051-81c3-0a7c68d9c07b">73.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC0xLTEtMS0zNjM1OQ_1136492d-714d-453a-b372-dae1a65868f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC0zLTEtMS0zNjM1OQ_ac6c588e-976a-4ec0-afd6-746048eeecd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC01LTEtMS0zNjM1OQ_ea37f558-ab3e-45b7-a23b-0f369ae91c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC03LTEtMS0zNjM1OQ_7cf81ba3-ac4d-481f-bd96-53c55327e153">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive <br/>&#160;&#160;&#160;securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS0xLTEtMS0zNjM1OQ_af6b191a-2ca9-4a27-ae96-6198837814c9">78.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS0zLTEtMS0zNjM1OQ_fa12b354-bdb6-4fd4-9122-dc294390e200">75.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS01LTEtMS0zNjM1OQ_dd400ff7-0df0-43d3-a177-3aede806471a">74.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS03LTEtMS0zNjM1OQ_5032a190-b942-4d8e-9550-46d63344d739">76.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i349787391ffb424eae8fe297e559c801"><ix:continuation id="i9153449e25ec47978a4130b4d6a21eff"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjE_e719f458-fbee-4c59-bdf0-8b7d3eedf5ff" continuedAt="if766c44977c740b5a842f7489b29e099" escape="true">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="if766c44977c740b5a842f7489b29e099"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi0xLTEtMS0zNjM1OQ_ea8d2a9d-7a5a-415f-99ba-79cfe887373d">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi0zLTEtMS0zNjM1OQ_770b10ab-b1c7-4847-8cc5-5dd144bd4196">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi01LTEtMS0zNjM1OQ_6e2b9b78-43c9-452b-926f-19f04155f6fe">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi03LTEtMS0zNjM1OQ_3d5f20a0-09b0-4d22-a7df-477d3c4fdbae">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzQ_742a1281-1395-4613-93ac-7b3717367aad" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders&#8217; equity.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzU_b96bcaf1-5952-46e5-9613-1e6980231fe2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmIwMWJhZWZjMTk3ZDQ2NGFiNDlkNjQ0NWRhZjc4Njg0L3RhYmxlcmFuZ2U6YjAxYmFlZmMxOTdkNDY0YWI0OWQ2NDQ1ZGFmNzg2ODRfMC0xLTEtMS0zNjM1OQ_e62cf793-bb94-4083-b047-d46df46a4c11">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmIwMWJhZWZjMTk3ZDQ2NGFiNDlkNjQ0NWRhZjc4Njg0L3RhYmxlcmFuZ2U6YjAxYmFlZmMxOTdkNDY0YWI0OWQ2NDQ1ZGFmNzg2ODRfMS0xLTEtMS0zNjM1OQ_c4858c6c-9542-44ee-b9f7-abc7cd4243c7">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmIwMWJhZWZjMTk3ZDQ2NGFiNDlkNjQ0NWRhZjc4Njg0L3RhYmxlcmFuZ2U6YjAxYmFlZmMxOTdkNDY0YWI0OWQ2NDQ1ZGFmNzg2ODRfMy0xLTEtMS0zNjM1OQ_cff68f1e-ab06-4069-a54e-75ce23277493">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODQ_95f689c0-8202-432b-ad36-8fc87c234428" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNjQz_82b2aa36-2067-4d4f-9a8c-5b36254a7f1e" continuedAt="i9ae5bed64be34247a99cd5be04161631" escape="true">MARKETABLE INVESTMENT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i9ae5bed64be34247a99cd5be04161631" continuedAt="i445efc9a446e466c9724556ee57b7429"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNjQ0_2318471b-8694-4a41-9198-800e0146a061" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2021 and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMy0xLTEtMS0zOTIyMw_c2ddc3b0-9749-43b0-9aa8-2057258eb856">195.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMy03LTEtMS0zOTIyMw_95c55b73-e7af-4706-9171-bc348f444054">195.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNC0xLTEtMS0zOTIyMw_bfc93922-a185-4af8-acfb-20c0982250ea">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNC03LTEtMS0zOTIyMw_cfae94a9-813b-471c-9335-ed1521aa4197">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNS0xLTEtMS0zOTIyMw_2ef99093-7c18-421d-a92f-683a3b39356d">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNS03LTEtMS0zOTIyMw_c3b628ed-5405-4146-bf5a-885999a895cb">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy0xLTEtMS0zOTIyMw_0e95ae5c-a432-4698-b465-3291d93a3223">105.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy0zLTEtMS0zOTIyMw_6a900c76-e486-4f13-a30e-5a6fcd0b4196">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy01LTEtMS0zOTIyMw_9fe8c7fc-f0fb-444b-b46d-d2cedb1278ad">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy03LTEtMS0zOTIyMw_d771cd58-7d85-45b4-bf8f-a2fc1c6feb21">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC0xLTEtMS0zOTIyMw_aebcf62c-8047-4396-a8fa-83c02b0b8c40">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC0zLTEtMS0zOTIyMw_5ee8b0a6-2065-4343-8779-1011154e2125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC01LTEtMS0zOTIyMw_2e6e6ca4-d4df-44dd-89c9-05815c43acf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC03LTEtMS0zOTIyMw_eef71f7d-fa4e-4714-bca1-41e841d61ae7">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS0xLTEtMS0zOTIyMw_006cbc3e-36b4-4332-985e-b738e850c77c">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS0zLTEtMS0zOTIyMw_c0d9c22d-86eb-4b9b-bebb-a24fd476768a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS01LTEtMS0zOTIyMw_fbe1205a-b11d-4a17-a40c-39390855933d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS03LTEtMS0zOTIyMw_34e888c4-ff14-4cab-93ed-8dc5ddc55579">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtMS0xLTEtMzkyMjM_ad21e3e8-2936-4da7-8041-fe4f858af09d">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtMy0xLTEtMzkyMjM_d639bd92-d5ae-4922-9e7e-2172aa222c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtNS0xLTEtMzkyMjM_104249b2-ca0b-4fcb-a70f-305493d6cf4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtNy0xLTEtMzkyMjM_fce9f09c-4105-4f46-88b7-176960462102">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtMS0xLTEtMzkyMjM_d941b4a4-1f3b-427a-870a-049b9af64e62">398.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtMy0xLTEtMzkyMjM_7adad2fa-ac9e-4971-9a94-bb18949f5043">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtNS0xLTEtMzkyMjM_2b587158-b7fb-4d31-9243-faefc69e07b9">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtNy0xLTEtMzkyMjM_4432ff66-09fd-484d-907a-a3d3868a6838">398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445c0b98e214b96840337b96fa87ab1_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMy0xLTEtMS0zNjM1OQ_8570acc6-11dd-481c-a9f8-2081b363f2e0">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445c0b98e214b96840337b96fa87ab1_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMy03LTEtMS0zNjM1OQ_a56b0d2c-2369-401a-9831-ea338c6d666f">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dc0fe0c62e4eea8fd54a19e76b42e0_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNC0xLTEtMS0zNjM1OQ_781f66cd-1c70-4ab0-8231-8f1358d1e23e">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dc0fe0c62e4eea8fd54a19e76b42e0_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNC03LTEtMS0zNjM1OQ_ea3792aa-627c-43b7-9600-e9ccbbd60be6">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNS0xLTEtMS0zNjM1OQ_5d9eeed1-90bd-476f-8f20-671bbdf10f2a">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNS03LTEtMS0zNjM1OQ_6e5ed7fc-1a65-4b82-8421-88f727ac919e">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy0xLTEtMS0zNjM1OQ_f2091cc9-1b41-496a-a882-84c24f8e3a6c">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy0zLTEtMS0zNjM1OQ_d3ad5e6a-458c-4f00-9c9a-5340137d4c93">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy01LTEtMS0zNjM1OQ_41823157-20d4-4a7b-9549-b975719b20cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy03LTEtMS0zNjM1OQ_0a427c36-ef70-4243-9de9-8e48111de983">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC0xLTEtMS0zNjM1OQ_d9beda37-8f50-4c84-a859-f739b6de2779">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC0zLTEtMS0zNjM1OQ_b2aad8ad-ce7d-417f-b3bf-e24144b9c8d7">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC01LTEtMS0zNjM1OQ_bffd5391-cd70-4129-bb43-e7a836a068f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC03LTEtMS0zNjM1OQ_4424da4e-3278-4951-8aef-2dd2d0fc79d5">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS0xLTEtMS0zNjM1OQ_e66b5fc8-928a-4c4a-a01f-81baed9c70f6">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS0zLTEtMS0zNjM1OQ_7f189e7f-3c3b-4ee5-9c57-9ca91deee284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS01LTEtMS0zNjM1OQ_c4ad60c6-866b-47f2-9337-0e0d80f2051a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS03LTEtMS0zNjM1OQ_97f9e953-904f-4049-bb03-b4f842055fd0">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtMS0xLTEtMzYzNTk_821690f5-3775-41a9-b387-f69ac60028c2">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtMy0xLTEtMzYzNTk_2ff8666c-acb2-4f54-8855-08b46443db22">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtNS0xLTEtMzYzNTk_a03cd394-c6c6-4ced-815a-5f4fb8ec131e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtNy0xLTEtMzYzNTk_a308551f-e5ae-40e8-b0bb-8ae2d690e3bf">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtMS0xLTEtMzYzNTk_44f3f30b-280d-4739-a022-532efdf15d6c">170.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtMy0xLTEtMzYzNTk_013a8847-7f43-456f-b9fc-e363298f0d13">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtNS0xLTEtMzYzNTk_77812a4e-a183-4479-9e5d-466a2de764e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtNy0xLTEtMzYzNTk_4bc9e36a-f932-48c3-b911-f54533793caf">171.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNjQ1_b16aa26b-40d5-450e-8927-94aede7154f2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMS0xLTEtMS0zNjM1OQ_d88b2929-523d-4d25-bef7-ca6b1cc331c4">195.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMS0zLTEtMS0zNjM1OQ_35a08792-c7b2-44a2-8b59-2846fd2ee8a3">195.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMi0xLTEtMS0zNjM1OQ_e748b0fc-0de3-42dc-ab5c-b78e4fd14b87">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMi0zLTEtMS0zNjM1OQ_b9739a87-96a6-4bfe-9bd7-95a12973abda">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNC0xLTEtMS0zNjM1OQ_189e5706-5490-47fd-a955-24f2a63430b7">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNC0zLTEtMS0zNjM1OQ_3736189c-d0d8-4d53-9fc4-7afca9680b7e">80.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNS0xLTEtMS0zNjM1OQ_b0f72d22-bbe6-475b-8493-362ce5f2f1c0">60.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNS0zLTEtMS0zNjM1OQ_6442df21-90b8-4156-a8a5-e81fcfbb528b">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNi0xLTEtMS0zNjM1OQ_04c131e5-ccc4-4658-86bd-1c20e5fe47fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNi0zLTEtMS0zNjM1OQ_6d7dac70-64fa-43be-a3df-387b5a590000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNy0xLTEtMS0zNjM1OQ_51d896e7-ac47-4607-af4e-2496523a6bf1">398.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNy0zLTEtMS0zNjM1OQ_1e8e4182-aae3-420e-b7b7-86e9af94b041">398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="security" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNDIy_a0c7956a-a18e-4d86-8c8e-004b8cdc8f06"><ix:nonFraction unitRef="security" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNDIy_ad85775c-4864-4b38-9228-02850ce9fc83">no</ix:nonFraction></ix:nonFraction> debt securities classified as available-for-sale in a gross unrealized loss position as of December&#160;31, 2021 or December&#160;31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i445efc9a446e466c9724556ee57b7429">Additional information relating to fair value of marketable investment securities can be found in Note 3.</ix:continuation></span></div><div id="ifead9d28cda549c1af769d1d50d95807_97"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMzUyMg_065d4a77-65d6-4cd6-a8b7-bed8cb89059e" continuedAt="i424277c1beb94d03a0322a3f6c84b338" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i424277c1beb94d03a0322a3f6c84b338" continuedAt="i61298823ad8746c2a9af71edbd8cddd9"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMTY0OTI2NzQ0MjE2MDU_5ecd2169-c5a4-4b21-bd71-bc9e8c6bba7a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately <ix:nonNumeric contextRef="i247f388a3aa24cea9da562bc5232fa78_D20210101-20211231" name="mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMTg2Mg_4dc343a1-657c-4074-b8e9-418dca9a9d64">13.5</ix:nonNumeric> years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Consolidated Balance Sheets.&#160;Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMzUyMA_5492546d-816e-4af7-9a1f-ed069405acfa" continuedAt="i38dc3268c994465bb9a4b89d9f2a9808" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities that are re-measured on a regular basis:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c7a2cd0dae41d7a18fabc16b2d6351_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi0xLTEtMS00MTIyNQ_87a94792-4c66-498f-8305-a628ffb5be96">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacab91f64734e07850b1d1ccdcef519_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi0zLTEtMS00MTIyNQ_5be79192-3815-4282-921a-96f1cd3595a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d33dac4dba4cc4a2b1b2e4b46390a0_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi01LTEtMS00MTIyNQ_7c4b2e21-d3c7-44b7-a507-165eb8a9f00e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea675210e024b6c916b2862b628898c_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi03LTEtMS00MTIyNQ_4692083a-cbda-4d94-954c-addb646be1a1">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32ea39f951fe43d7bd7edbf117b03d28_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy0xLTEtMS00MTIyNQ_e72f364a-f27a-4c47-9a55-e961d0bb02a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649ff7da9f344b3594372e0db1334cf1_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy0zLTEtMS00MTIyNQ_76cb693f-3d98-4e74-9da1-10cb7e44abc6">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9950e80ecb934b8aad3038826649ece1_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy01LTEtMS00MTIyNQ_3c72ec71-dc94-4895-a95b-8bd1bc3177b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy03LTEtMS00MTIyNQ_094221fc-f83a-4837-adc6-02589bcc637c">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6caf215e4694c5297b327ebab5489f0_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC0xLTEtMS00MTIyNQ_c8ee4cf4-0b05-450f-9c82-948f10fe5f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d609efbd994ab6a4717ae77454f9c8_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC0zLTEtMS00MTIyNQ_cd51b0c2-b9de-41e4-857a-46e66e706995">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ea51262455422b9b58287df633fdba_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC01LTEtMS00MTIyNQ_741388db-3532-43d9-b631-031ee953249a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC03LTEtMS00MTIyNQ_583b902f-7af7-42e4-a16a-0a485c936a30">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc35c6df6dd437cba1f343922b27753_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS0xLTEtMS00MTIyNQ_773848d9-b977-49b3-8477-c4bec3d67afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1173e0a575429c87230088f831bd1c_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS0zLTEtMS00MTIyNQ_66cb852c-f0ce-4b10-9419-34575fc4df3d">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d46cebc1ad34bfd93e108133ea4a5a8_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS01LTEtMS00MTIyNQ_7534da30-149b-4b97-9d4e-a7374756a313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS03LTEtMS00MTIyNQ_d71204c6-1389-4143-a4f0-e6e02776b5e0">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2ac1ffa79241d7ae0a435a564bec54_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi0xLTEtMS00MTIyNQ_479910f2-b55e-48ac-85c7-602310901ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aef68764004a7ab2c3d1cafa4e6070_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi0zLTEtMS00MTIyNQ_4827f211-f71a-4e18-aae1-93cc0bf48b9d">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22dbec5ca02d419cb74d488ed87eaf6a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi01LTEtMS00MTIyNQ_85b2c6db-f2af-42f1-9076-f6de6b6fae28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi03LTEtMS00MTIyNQ_e7175de2-e77a-47ba-9db3-8b7684c54317">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ca8c5b9c4f42a7b049cd5568304428_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy0xLTEtMS00MTIyNQ_448205d0-e2ea-4f9e-aded-dd3e42b7ee76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a6e30e15d44c27a12c044d297fe0ee_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy0zLTEtMS00MTIyNQ_882d65ad-6245-4de1-9910-39c138e2d48b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a1bafe663bf4dd2af911643d8115191_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy01LTEtMS00MTIyNQ_4607f6c0-f770-4b52-8a76-d35de941833d">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i330057192ddd491eb64b21392abce0f7_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy03LTEtMS00MTIyNQ_ff36fb11-0cbc-4012-8292-8b4083827e55">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155d082ec2ff4209a45f170e667ea25c_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC0xLTEtMS00MTIyNQ_355e83a4-d8ce-42bd-8d19-8dd6fa3f0c53">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a3f606f6ce45719deb8e96cd7ddf12_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC0zLTEtMS00MTIyNQ_513bc976-87d7-450e-8c2a-df4f573295a5">140.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34fd0ce23d9465eafda8ac8e370a4d3_I20211231" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC01LTEtMS00MTIyNQ_ca58db33-de44-45f7-b174-d977d2f0a48e">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC03LTEtMS00MTIyNQ_2b3e0738-cc65-4ab8-9e2b-82f52ab8f141">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i61298823ad8746c2a9af71edbd8cddd9"><ix:continuation id="i38dc3268c994465bb9a4b89d9f2a9808"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f303592870940ab8b8f59b374e18736_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi0xLTEtMS0zNjM1OQ_fb9e581c-9249-439e-a07f-6e5d1c9f1a18">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d9ee368f974e858e239cc4f7cc09d5_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi0zLTEtMS0zNjM1OQ_1c679173-643b-4723-a2cd-6dab9e9e454e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e01d25b7bf4a20a4ae7b3bc411229b_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi01LTEtMS0zNjM1OQ_65800329-8c17-494f-a4a8-f6a9e64705b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068bcc7826fd40a29f15703667578d91_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi03LTEtMS0zNjM1OQ_af9a647b-66c1-4c62-8dd5-a1e68ba8a320">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295380b6567e4eb1b4eeb49fa5fe93d1_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy0xLTEtMS0zNjM1OQ_c5f39e79-96e0-4dd0-8658-71021fff49d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43572fc1976464398da328af82d7f20_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy0zLTEtMS0zNjM1OQ_c4481dff-bc73-47d5-93ab-d1f269790819">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5a59ec1d4d4de1ba8ba076c80e3226_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy01LTEtMS0zNjM1OQ_b90c4ca4-7549-4a96-836d-71fe67831fa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy03LTEtMS0zNjM1OQ_965f8ee7-ec2c-4774-8c87-1f99968a4e7e">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3c7d94999a4ee5a93ec6842932756b_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC0xLTEtMS0zNjM1OQ_68be33ed-ca1f-4ceb-92c7-811d7f2c1945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95aadf27c0ee42a2b79894a26f7a6303_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC0zLTEtMS0zNjM1OQ_21700935-0983-4675-992e-79054d54aed9">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a40cfd6c04ce599bbc8e4a83deadc_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC01LTEtMS0zNjM1OQ_1d6b73c8-1d3d-4853-8504-94c7780abf51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC03LTEtMS0zNjM1OQ_39a87287-5607-43ef-a80f-ce8b26701de7">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4f8a6107a54f86952fd151b5a13c08_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS0xLTEtMS0zNjM1OQ_ac7376dd-3cba-468f-b151-47d0c28bc17e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43790812a0c4238a84dddd512d335ed_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS0zLTEtMS0zNjM1OQ_91f498ec-d8e2-40c3-aae8-bbef5fa186f0">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f3fc1feaa3146ef881ca19357b23ae2_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS01LTEtMS0zNjM1OQ_b89c6f72-b65f-47a2-9013-1eb6a95b801f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS03LTEtMS0zNjM1OQ_36ce5b88-a1e4-4f31-a144-4e1181049b8c">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b9a6da1e624a6299e316b70d8feaac_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi0xLTEtMS0zNjM1OQ_776a5960-4325-4fcf-a04a-3534bc6eac7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d3ae940d944d56b1fa894aaf7ce150_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi0zLTEtMS0zNjM1OQ_ec65b450-6e31-4785-8fdd-6bbb27ccac66">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b8c164b3e1486ebec72f7e98f21e80_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi01LTEtMS0zNjM1OQ_30626fbd-a156-4a23-b719-ce612badca6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi03LTEtMS0zNjM1OQ_ec820600-7bf0-4c70-a556-0d5f64f18fbe">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e83b77ce534f3b9bd0073625848436_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy0xLTEtMS0zNjM1OQ_2e635960-d46c-48a5-a53b-1969ea351d4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f0556ba0524239b520e549288db90f_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy0zLTEtMS0zNjM1OQ_f92ae21e-39c0-4626-bb12-b49d39886e3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30c0e0850ab04139a8cc19022cb08ee3_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy01LTEtMS0zNjM1OQ_d26c7f4c-7dac-4a7d-88d9-d41a93ce3393">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ae2473b59214583a165b28061b320ce_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy03LTEtMS0zNjM1OQ_14c97e31-c443-464d-beee-c9440631c835">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c0dba4e084466d8bddadc615f6025a_I20201231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC0xLTEtMS0zNjM1OQ_3a5d2712-9f55-476d-85d6-0610dcffe116">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b398db0d1554733a657d72060893c6d_I20201231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC0zLTEtMS0zNjM1OQ_9e6ff7d6-b367-43b1-8c51-067222db04a9">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3d6ed83b23f459e9db3a9380f2701a0_I20201231" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC01LTEtMS0zNjM1OQ_2601a6bb-ba15-457e-a0a1-d07a77919b38">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC03LTEtMS0zNjM1OQ_54227045-8f48-48aa-94c4-9b38922c80f1">112.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div></ix:continuation><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMzUyMQ_17ddf6a1-99fa-426e-ba85-22adcf2968ca" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Period Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS0xLTEtMS0zOTQwOA_831a9181-7d09-446d-bf36-b6a70b37e669">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS0xLTEtMS0zNjM1OQ_3bd40705-4ea6-4601-ae01-1addb9ff26ea">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS0zLTEtMS0zNjM1OQ_29c83951-6f4e-4103-bf08-eaf4dfe018ce">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS01LTEtMS0zNjM1OQ_0a90b656-8a9f-44cf-94af-6906340055c8">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi0xLTEtMS00MTI0Nw_affd5def-dc63-414c-a516-26dd94e1a23e">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi0xLTEtMS0zNjM1OQ_fb6c0794-483c-490c-a2c2-edfc181fb998">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi0zLTEtMS0zNjM1OQ_b99fea40-1d71-4ad5-84a9-546e2b522c75">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi01LTEtMS0zNjM1OQ_f709a116-923e-48a8-91ac-d4395a2bf58c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in the statement of operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy0xLTEtMS00MTI0Nw_b85733d4-c438-4f03-a78f-c91bccb68826">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy0xLTEtMS0zNjM1OQ_652a7784-e06e-49fe-ab6b-984e680c1c07">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy0zLTEtMS0zNjM1OQ_283427f8-c8f5-4975-8a9a-aa9beab1c82e">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy01LTEtMS0zNjM1OQ_11c6da8a-3135-4fe7-9d54-c5ab4bb95181">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments recognized in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC0xLTEtMS00MTI0Nw_7307d869-ef8e-4cbe-9cd9-640647bc6d1a">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC0xLTEtMS0zNjM1OQ_d1de19e4-0825-4687-bf18-23ffe9bc1756">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC0zLTEtMS0zNjM1OQ_e71111ba-abc6-49e3-8b38-90e32367338e">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC01LTEtMS0zNjM1OQ_c379172f-0ac9-487d-a868-85ecaf38764b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS0xLTEtMS00MTI0Nw_4ca290f6-fb50-488e-ba12-e6ad93ccddbf">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS0xLTEtMS0zNjM1OQ_08e6365a-ceb8-4af4-bb53-548c480cf200">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS0zLTEtMS0zNjM1OQ_b21d5dc0-0ce3-466e-907f-90bb896c5875">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS01LTEtMS0zNjM1OQ_f2ec8291-52a3-45ec-a723-c890dff1cd55">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_100"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90ZXh0cmVnaW9uOjQ4NWE2ZWViMWE1NzRhNzg5YzJjYzhjOGE4MmRjYjNlXzI3OQ_26266fc7-d1d8-4e67-97a3-2b091a973b9e" continuedAt="ia54ebfb6d765496a8c712b27cc0ec5d2" escape="true">PROPERTY, PLANT AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="ia54ebfb6d765496a8c712b27cc0ec5d2"><div style="text-align:justify"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90ZXh0cmVnaW9uOjQ4NWE2ZWViMWE1NzRhNzg5YzJjYzhjOGE4MmRjYjNlXzI4MA_ac251f90-a1af-4518-a766-e7d084d21b88" continuedAt="ic4bd22f1242548dcafa0748cc355fc31" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c5626096e543389cd9c3f775245cfa_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzQtMS0xLTEtMzYzNTk_b9e678ab-308c-46dc-9388-02a4f5cdd5d9">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803545905c564efc93735544226e6480_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzQtMy0xLTEtMzYzNTk_0798dfca-54c5-4b0e-b68f-61ce36bade05">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ab8cfb4e2c4f0d807f2b535c421e2c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzUtMS0xLTEtMzYzNTk_98288574-27ad-45f2-824c-915272084aa5">112.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12da925d57d847f29779b2a54f0c1d8f_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzUtMy0xLTEtMzYzNTk_c1f0907c-90eb-494e-9489-25c93b939254">117.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzYtMS0xLTEtMzYzNTk_0294ec7d-c5e9-45d1-9a03-6798d21bd4c2">150.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzYtMy0xLTEtMzYzNTk_96dace15-9c92-45f4-80f0-4690908dbd67">153.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzctMS0xLTEtMzYzNTk_58287913-35c9-46c8-a13b-3ec7f3aa532d">106.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzctMy0xLTEtMzYzNTk_59599013-26d9-4cca-9251-7aea5c26ed2f">112.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzgtMS0xLTEtMzYzNTk_3146e00e-8c82-4e69-9a7f-425c28844558">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzgtMy0xLTEtMzYzNTk_709d734f-da0a-4a7d-87fb-2e5b362959e1">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $<ix:nonFraction unitRef="usd" contextRef="i76caa3c0609e438280d6a0504611599f_D20210101-20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90ZXh0cmVnaW9uOjQ4NWE2ZWViMWE1NzRhNzg5YzJjYzhjOGE4MmRjYjNlXzEwOTk1MTE2Mjg2NDE_c9c90d1b-4151-4e5b-a29f-c021e47c83ef">3.1</ix:nonFraction> million of property, plant and equipment. See Note 16 for additional information regarding these divestitures. </span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="ic4bd22f1242548dcafa0748cc355fc31"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItMS0xLTEtMzYzNTk_ab1726f5-553e-4fa3-ba7a-852f117a0a89">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItMy0xLTEtMzYzNTk_0d65ed73-5921-465e-9247-29c1ec0e5711">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItNS0xLTEtMzYzNTk_c4b80f44-8009-4389-9c54-2b1a1a581807">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItNy0xLTEtMzYzNTk_9fd94d04-130d-4f77-a91b-40e10e81c747">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1Njk_9ffc9a44-2b53-467d-9568-0948153a426f" continuedAt="i97134a92088a46d59729a0492670d7ad" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i97134a92088a46d59729a0492670d7ad" continuedAt="i92cc2ff1fef343d7bdbdb88e46dcab6d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1NzE_87e822a9-255c-4c6a-9cce-50638c2deb08" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzEtMS0xLTEtNDQwMjU_c0a55278-7bc4-489a-b573-0b74d1c5cf3b">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzMtMS0xLTEtNDQxNjc_64a3a239-65bb-4706-8815-1e746a88a721">88.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzUtMS0xLTEtNDQxNzM_f3b65e2e-af34-450e-b11f-1342bab3fe9c">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzQtMS0xLTEtNTc4NjQ_bbe1cfd6-c42e-4308-949f-f20b983559d4">239.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did <ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMyOTg1MzQ4OTQ4MjQ_2d0ef281-6850-44ab-abd3-ef9d80c7cf93"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMyOTg1MzQ4OTQ4MjQ_d02bac23-34e5-45e1-936b-e9b453c0de13"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMyOTg1MzQ4OTQ4MjQ_eaaca85c-f7cd-4035-b908-da141f3fd54a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t record an impairment of goodwill for the year ended December 31, 2021, the transition period ended December 31, 2020 or for the fiscal year ended June 30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="id6ec5554c31b4ce8828d34f1b36e247a_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzkzNQ_575ab57f-cf5f-4b0c-8459-9828d08437de">80.7</ix:nonFraction>&#160;million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended June 30, 2020, the Company also recognized a $<ix:nonFraction unitRef="usd" contextRef="i08c34d03cc5d4ce3adff6edc114a7d3d_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzEzMDQ_201a407f-af0c-4932-bd0a-91c0dec5c9cd">1.3</ix:nonFraction> million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as a non-amortizable intangible asset of in-process research and development.&#160;Due to the completion of the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, the Company's intangible assets as of December 31, 2021 consist of only purchased licenses and technologies.&#160;In connection with these sales, the Company sold $<ix:nonFraction unitRef="usd" contextRef="i2300757198c24415b7c3c129a5f3fabf_I20210913" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA3NzQ_d3cc9cfd-b428-4a9a-b4a9-fad562b5bf4b">199.1</ix:nonFraction> million in purchased licenses and technologies, $<ix:nonFraction unitRef="usd" contextRef="iba866a3cd6cf4800bbcea6f210f6455a_I20210913" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA3OTI_87f26952-1089-440f-9ade-3ed5cc595148">4.8</ix:nonFraction> million in-process research and development intangible assets, $<ix:nonFraction unitRef="usd" contextRef="i3f3b8d69d56b45199b92513424091532_I20210913" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4MDc_dfe00b35-c7f8-4687-885b-8f56503c5e50">4.7</ix:nonFraction> million in customer relationships, and $<ix:nonFraction unitRef="usd" contextRef="i275498a5a52849dea83b241134bb7e51_I20210913" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4MjI_72711e30-e642-4c27-ab01-86fc513cb02f">3.0</ix:nonFraction> million in trademarks, resulting in an aggregate decrease of intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ida1425b0bad34a70afc41eb45c93a582_I20210913" decimals="-5" name="mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4Mzk_5e801a2d-63d9-4c62-ba12-1cdcbfea3b70">120.0</ix:nonFraction> million, net of $<ix:nonFraction unitRef="usd" contextRef="ida1425b0bad34a70afc41eb45c93a582_I20210913" decimals="-5" name="mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4NTU_f71fe604-efb9-4ad4-a06d-7719e588abf9">91.6</ix:nonFraction> million in accumulated amortization. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s purchased licenses and technologies have estimated remaining useful lives between <ix:nonNumeric contextRef="ic75f471c9cdf49ab96d540192ad0b502_D20200701-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzE5MjU_c0c56281-e6fc-4726-bf80-5b7760e1fc8f">1</ix:nonNumeric> and <ix:nonNumeric contextRef="i6b9f2d157d1e4cadaae10cf7ad53658e_D20200701-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzE5MzI_4ccb6f89-f16d-4241-bc40-a174524423c6">14</ix:nonNumeric> years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets.&#160;The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI2OTM_86d429bd-3546-452b-8f1b-83d8c36d1995">17.7</ix:nonFraction> million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was <ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI5NzE_3aaf7ef5-d761-4633-96a7-0732b01cb75d"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI5NzE_b93ad04b-0d93-4799-8bbd-83d8819432fc"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI5NzE_e922bf41-f8b5-48f2-b051-b072b44bb6e6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of long-lived assets for the year ended December&#160;31, 2021, the transition period ended December 31, 2020, or for the year ended June 30, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i92cc2ff1fef343d7bdbdb88e46dcab6d"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1NzI_04c5af1e-b357-4be0-a06b-7b002c6c242b" escape="true"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1NzI_79599de9-0c2c-4379-ab70-35a52f7a4e51" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d57af1e55643e69c2cef6564b8c029_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzEtMS0xLTEtNDAxNTk_561ae847-e61d-43e5-b1e3-beb22c474402">616.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2d57af1e55643e69c2cef6564b8c029_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzEtMy0xLTEtNDAxNTk_a22adf02-e098-498e-989e-9600dc34e59f">212.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d57af1e55643e69c2cef6564b8c029_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzEtNS0xLTEtNDAxNTk_bc7d600e-f864-4703-b9e2-90ae5c4a4959">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzctMS0xLTEtNDAxNTk_ff6e07ef-d5e7-414f-bb1e-47572edd26bc">616.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzctMy0xLTEtNDAxNTk_d001f41c-968e-48f2-8de8-dd174bf330fa">212.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzctNS0xLTEtNDAxNTk_331787f4-1575-4504-8242-4b3740759ddc">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c3ca18e45c49898939a280f53e8a87_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzEtMS0xLTEtMzYzNTk_682fb30c-16d7-4d90-9803-5fad51f8b30e">818.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72c3ca18e45c49898939a280f53e8a87_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzEtMy0xLTEtMzYzNTk_69e0ab3c-e6c1-4126-8461-fbccfd002f5e">248.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c3ca18e45c49898939a280f53e8a87_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzEtNS0xLTEtMzYzNTk_64986e65-19bb-4dfa-b8d2-cfacfbb2aae3">570.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzItMS0xLTEtMzYzNTk_6b9acf99-6834-4e34-b6b1-f703987b5042">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzItMy0xLTEtMzYzNTk_13b352d3-8207-4bc1-954f-78cc659e05cc">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzItNS0xLTEtMzYzNTk_c37de50d-a53e-4bef-a464-86b866aa86e6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib683c703779c41d19954bb1ac378479f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzMtMS0xLTEtMzYzNTk_da354898-17c4-4b3a-bd12-cd18003a15a3">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib683c703779c41d19954bb1ac378479f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzMtMy0xLTEtMzYzNTk_e4c4f201-3f3a-4667-9168-632b05dbd240">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib683c703779c41d19954bb1ac378479f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzMtNS0xLTEtMzYzNTk_64e2a886-92df-4243-8e82-3f701b9827fb">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzQtMS0xLTEtMzYzNTk_ce43a2f4-65a7-4cd4-b1fd-1e39347677ba">825.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzQtMy0xLTEtMzYzNTk_7477b9b8-56e9-43ca-9a26-180e51b6c01d">254.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzQtNS0xLTEtMzYzNTk_3290377e-301b-4ecf-bdde-a9be3c4020fa">571.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4983803bd4497b2c5b4c486bbbbe6_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzUtMS0xLTEtMzYzNTk_1e684c15-6480-4529-afd6-c4ad0c50e3a5">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4983803bd4497b2c5b4c486bbbbe6_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzUtNS0xLTEtMzYzNTk_2ea312e9-2b18-45ce-b549-d724238df449">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzYtMS0xLTEtMzYzNTk_c31bfaa6-7e59-41b4-b9a7-58b15ea142f1">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzYtNS0xLTEtMzYzNTk_9835c274-b4f4-4aec-9589-6b19a4f3fbc9">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzctMS0xLTEtMzYzNTk_c9191cc6-4ac1-45de-b4a2-f3d7ac24d4ea">830.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzctMy0xLTEtMzYzNTk_55e9b0fe-2239-4666-8ca1-bfe3ea34148f">254.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzctNS0xLTEtMzYzNTk_3a87a1a4-746a-4af2-a32b-523be15e514a">576.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 the weighted average remaining amortization period for purchased licenses and technologies is approximately <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMzMzk_498bf221-572d-447d-8afd-fd3a30a0e6e6">10</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1Njc_5a9af84d-5860-4b7c-baad-e15223f7b099" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization during the respective periods for these intangible assets as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItMS0xLTEtMzYzNTk_834b72fd-d369-4281-9681-052993d5b5af">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItMy0xLTEtMzYzNTk_fa7b9171-21fc-4faa-8a2e-c2b0a1e03c75">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItNS0xLTEtMzYzNTk_b44b05a7-d399-47bb-9d3a-62fb3167291f">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItNy0xLTEtMzYzNTk_70c4b110-fd2f-4113-913f-e17f3942c4ba">59.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1Njg_c82ac7d9-6c13-4b9d-9e69-f0abd61464ba" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzEtMS0xLTEtMzYzNTk_d0d547f0-949e-4439-a922-515d5fe7457c">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzItMS0xLTEtMzYzNTk_7e0f38ce-d118-4cff-b580-aae0c84040a3">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzMtMS0xLTEtMzYzNTk_298aba96-9afb-499b-b97d-bb52733fe894">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzQtMS0xLTEtMzYzNTk_7b94e28f-7a99-4c99-9dee-b0d8543d1b2e">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzUtMS0xLTEtMzYzNTk_e0416dcf-2815-4778-9efe-6978e555decb">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzYtMS0xLTEtMzYzNTk_7b45d285-fb50-4101-af83-cd33d4e7b8a2">200.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzctMS0xLTEtMzYzNTk_7d00e07f-a468-464e-ae35-1a7c99326734">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_106"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90ZXh0cmVnaW9uOmJiN2RmM2UzMGE4ZDQ3NDhhMTBhOTUyNDkzYmU5MWMxXzI5_275600d9-e39f-41ec-b35b-6d6494764a59" continuedAt="i1f339807296c4083bb92bf3cbd925d32" escape="true">ACCRUED LIABILITIES</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i1f339807296c4083bb92bf3cbd925d32"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90ZXh0cmVnaW9uOmJiN2RmM2UzMGE4ZDQ3NDhhMTBhOTUyNDkzYmU5MWMxXzMw_00d24b49-3ee4-4b2a-b16e-ced06455718c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzItMS0xLTEtMzYzNTk_14d3fea8-7fba-4b48-a70f-5ac888026b58">52.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzItMy0xLTEtMzYzNTk_869c4dd4-7afe-4a0c-aa3d-c6a7d4df716c">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMS0xLTEtNDE0MjQ_e8cd0e65-4c53-42ab-a612-0145c0da3b07">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMy0xLTEtNDE0MzY_f35083c3-186a-43d6-b4a8-a05e82c68d9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMS0xLTEtMzYzNTk_78202db6-0ac5-4914-86bb-8eba26b3c41c">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMy0xLTEtMzYzNTk_16823dd2-3872-4425-b353-33a431b06fd7">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzUtMS0xLTEtMzYzNTk_afabb3f4-1350-4521-8326-27baac730b35">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzUtMy0xLTEtMzYzNTk_3c3351a0-a553-4b76-9f92-0b6f6f42f5e6">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzYtMS0xLTEtMzYzNTk_ee1818f0-2905-4984-9a3f-e7bdc4caec5d">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzYtMy0xLTEtMzYzNTk_12d06a87-9485-446f-8aa6-2b64717979fd">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMS0xLTEtNDE0MjQ_a934180c-554f-4023-a341-be03c6f3f16d">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMy0xLTEtNDE0MzY_db33a2db-9232-49f5-802b-200926223fa4">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMS0xLTEtMzYzNTk_cdd74db3-cfd7-48dc-aec2-3af0e2a97ea6">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMy0xLTEtMzYzNTk_8fa23660-71a9-4541-86f0-2880888b7b57">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzgtMS0xLTEtMzYzNTk_d1c60009-d6b5-489f-bc41-95b740dbdea1">156.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzgtMy0xLTEtMzYzNTk_bcee4e0f-0559-43d6-b301-1c855e96a746">79.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQ2NDA_09ba67c7-041b-4b23-888c-dbc1a27a507c" continuedAt="i81b31d0553cb4971a22afe22bb805468" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="i81b31d0553cb4971a22afe22bb805468" continuedAt="iace2553fc00e4ef191f4485aa9785caf"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to <ix:nonNumeric contextRef="iefacdace64394337b4ef1aba897012f9_D20180731-20180731" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQyMw_d2470ce2-329b-4fa7-b21f-0cfab9e38589">July 31, 2023</ix:nonNumeric> and the maximum aggregate principal commitment was increased from $<ix:nonFraction unitRef="usd" contextRef="ica35c1f0cab448d081723c1fef35a424_I20161223" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQ5Mg_e9d21d63-be6a-463d-a15c-02e846b39e9b">300.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i168fbf7f34f14b48b159064776b4fdfc_I20180731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQ5OA_68ee3e7c-819f-4221-990a-6f51809c3038">350.0</ix:nonFraction> million.&#160;&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Amended Facility, which waived the Company&#8217;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (&#8220;Modification Period&#8221;). On February 22, 2021, the Company entered into Amendment No. 3 (the "Amended Facility"), which, among other things, decreased the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="i54fc9148f3ce4861a7ad8db525b9a0a8_I20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNjgz_dfbecaaa-6044-41d9-ae3e-975f6bb78129">350.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNjk5_70575808-f957-4ae5-9fd0-eb323faba70e">300.0</ix:nonFraction>&#160;million, with a further reduction in the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzE1_fe9df11d-cc36-4c20-bbc6-67d8eef5beb2">300.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i961cf7e1f4884ffdace1af14ca9070a8_I20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzMx_645c41fd-7590-4885-94aa-01e371898ad4">250.0</ix:nonFraction>&#160;million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company's compliance with certain financial covenants through the quarter ended March 31, 2022, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. The Company's maximum aggregate principal commitment on its Amended Facility is $<ix:nonFraction unitRef="usd" contextRef="i82d39802808f4ef89f2381762fc4eb35_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzQ3_635ab3f6-00f6-43ba-a303-5764b311dfba">250.0</ix:nonFraction>&#160;million as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus <ix:nonFraction unitRef="number" contextRef="i4a989512a05b4160b8ec803a03de9836_D20200401-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIxMzc_f2296d57-e001-4097-89ce-2975238afc21">350</ix:nonFraction> basis points on drawn balances and the undrawn fee was increased to <ix:nonFraction unitRef="number" contextRef="i333e25208a214f52b7d6bdff1719f67a_D20200401-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIyMDg_549a1011-e91d-4133-b966-f43f420762f7">50</ix:nonFraction> basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR <ix:nonFraction unitRef="number" contextRef="i0c5178ceac7d4f5fbc4391a28c678d89_D20220701-20220701" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzYz_17a2bcd9-2c47-4b1a-bc80-94c484a656b3">150</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i3265f06cbffc47d085ee813629587542_D20220701-20220701" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzcz_83caf0c6-b276-47e4-9f22-22ab51498f60">250</ix:nonFraction> basis points on drawn balances and an undrawn fee ranging from <ix:nonFraction unitRef="number" contextRef="i9f99bcdbffc6436f919414c49880ae46_D20220701-20220701" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIzNzM_4fd8b885-b8ca-488e-b8d1-3235df366d83">25</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="idc6b324d8d7d49119edb7e86615e72bb_D20220701-20220701" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIzNzk_513e7bc6-b137-4cc6-9d2a-ba971a730c23">45</ix:nonFraction> basis points, in each case, based on the Company&#8217;s leverage ratio. The LIBOR floor was also increased to <ix:nonFraction unitRef="number" contextRef="i333e25208a214f52b7d6bdff1719f67a_D20200401-20220630" decimals="INF" name="mygn:DebtInstrumentLIBORFloorPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzI0NzI_8e8c47db-c23f-46c9-ba05-e6fc428010ed">1.0</ix:nonFraction>% during the Modification Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $<ix:nonFraction unitRef="usd" contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221" decimals="-5" name="mygn:DebtCovenantLiquidityCovenantMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzgz_0c4a9136-dca0-44a8-8cba-078ec5c2da9e">150.0</ix:nonFraction>&#160;million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $<ix:nonFraction unitRef="usd" contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221" decimals="-5" name="mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzk5_6475c9bd-68a9-47dd-9762-56bc89d714b7">150.0</ix:nonFraction>&#160;million, unless such borrowings are in connection with permitted acquisitions. The Company was in compliance with all applicable financial covenants at December&#160;31, 2021. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iace2553fc00e4ef191f4485aa9785caf">During the year ended December 31, 2021, the Company made principal repayments totaling $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzEwOTk1MTE2MzkzMjU_9d45ea0d-55d9-42ba-9060-25767cb03dff">226.4</ix:nonFraction> million on the Amended Facility, including a voluntary principal payment on July 30, 2021 of $<ix:nonFraction unitRef="usd" contextRef="i915c2ce66e394e6ebfd548241511f5c7_D20210730-20210730" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwODE1_c915cd57-fb59-40cb-854c-11a504aeb364">106.4</ix:nonFraction>&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had <ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwOTY0_36f0b8e0-8572-4636-90d3-bc5f09c76f95">no</ix:nonFraction> outstanding balances under the Amended Facility as of December 31, 2021. As of December 31, 2020, the Company had a long-term debt balance of $<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzEwOTk1MTE2NDEzNTI_0d7154b1-e27a-492f-a9b4-dcce1dc8ab0b">224.8</ix:nonFraction> million.</ix:continuation> </span></div><div id="ifead9d28cda549c1af769d1d50d95807_112"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90ZXh0cmVnaW9uOmI3MmU3MzAxYzk3NDQxNmRiNDYyMWE2MzVmNjhlMjM4Xzc5NA_e933958f-39a7-414b-89cf-0a5bca4ed7aa" continuedAt="i8002bb8bdbbd4b2c806d97622ce0b722" escape="true">OTHER LONG-TERM LIABILITIES</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i8002bb8bdbbd4b2c806d97622ce0b722" continuedAt="ibfdaf2cade33432f94161c8e11c708f9"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90ZXh0cmVnaW9uOmI3MmU3MzAxYzk3NDQxNmRiNDYyMWE2MzVmNjhlMjM4Xzc5NQ_af70f030-6fc3-4f7c-b35e-62781a66fcb6" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzMtMS0xLTEtMzYzNTk_67a2e222-b43e-42f9-962e-e95bd9d00b1a">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzMtMy0xLTEtMzYzNTk_15151c90-2975-4497-aad4-7dd62e496a54">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzQtMS0xLTEtMzYzNTk_dd98f0ae-8bef-4d15-96d8-496484962dab">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzQtMy0xLTEtMzYzNTk_b2c59ab0-1c0e-4547-89f2-2386d56fc4bc">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzUtMS0xLTEtMzYzNTk_d427c890-85e6-431e-a5bd-97550cbd7446">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzUtMy0xLTEtMzYzNTk_8dafd43e-7651-4ae7-bd2c-9db964571156">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibfdaf2cade33432f94161c8e11c708f9">The Company&#8217;s balance of other long-term liabilities as of December&#160;31, 2021 consists primarily of the long-term portion of contingent consideration related to the Sividon acquisition. During the prior periods the Company's portion of social security taxes that had been deferred under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") that do not have to be deposited until December 2022 were also recorded as other long-term liabilities. As of December 31, 2021 that balance has been reclassified to a current liability as it will be deposited within the next year.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE2ODc_04442c75-2336-49ca-a052-d8653de3a695" continuedAt="i8c4e0d7a655a48ab9a3f4fb2095caab4" escape="true">PREFERRED AND COMMON STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><ix:continuation id="i8c4e0d7a655a48ab9a3f4fb2095caab4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1Xzky_012d168f-c43a-4b27-b61d-1dec35d65d46"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1Xzky_1404d072-7922-4f07-b825-7ab7df94aac8">5.0</ix:nonFraction></ix:nonFraction> million shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzEzMg_5c40e6de-7106-45f5-ba98-8ea1b7696d3a"><ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzEzMg_ccaa250b-c391-493d-a20f-fcf401631b1f">0.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE1Nw_20b07d30-03e2-45e3-8790-b755e46c030f"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE1Nw_be152d27-7a0a-4db1-91ef-1a72c1ad8cbc">no</ix:nonFraction></ix:nonFraction> preferred shares outstanding at December&#160;31, 2021 and December&#160;31, 2020. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI1NA_057ed7b4-8b02-47bd-b48b-176d859291b9"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI1NA_6407d80d-9421-4bf7-ab28-6644acaa519a">150.0</ix:nonFraction></ix:nonFraction> million shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI5MQ_42c7b8d0-f23a-45ea-a511-89bc2511b225"><ix:nonFraction unitRef="usdPerShare" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI5MQ_70e974b7-0cb4-4ff0-8d69-c0d9c22a1b19">0.01</ix:nonFraction></ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzQ5NDc4MDIzMjY4MDY_6dd28bf6-be70-495c-979c-ea6cfbc01a06"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzQ5NDc4MDIzMjY4MDY_7a386753-57cd-4d8a-8455-1913f6db87be">80.0</ix:nonFraction></ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzMxNg_4e350455-abe8-47b4-ae7e-6a4a62af8a18"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzMxNg_a52f5142-8353-4e7d-b49e-57e9fecafd08">75.4</ix:nonFraction></ix:nonFraction>&#160;million shares issued and outstanding at December&#160;31, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE2ODg_e4bd6823-ee12-493c-bda6-6cd73f2d4ae2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMS0xLTEtMzYzNTk_00205760-598e-4222-bd45-3aae0cfb78bc"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMS0xLTEtMzYzNTk_bf4dfa02-7e7c-4f5d-a4de-fc77b278e349">75.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMy0xLTEtMzYzNTk_9070855a-5be7-410c-99e5-bf2816a8218c"><ix:nonFraction unitRef="shares" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMy0xLTEtMzYzNTk_ddb37f26-8d84-4fb7-913d-1939d929a62f">74.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNS0xLTEtMzYzNTk_00b05bbb-3c4d-4519-8238-c90022fa91a8"><ix:nonFraction unitRef="shares" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNS0xLTEtMzYzNTk_64734162-6015-462b-a8ba-51a0be3cc902">73.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNy0xLTEtMzYzNTk_4edc16f2-fbe8-4ebf-a4ce-f43f00509fb1"><ix:nonFraction unitRef="shares" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNy0xLTEtMzYzNTk_7015892e-eaec-4beb-824e-ad77b47d5001">70.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options and employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtMS0xLTEtMzYzNTk_42758a94-1229-4a83-8af3-8d67b10d3fa8">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtMy0xLTEtMzYzNTk_929a24a5-8615-4d73-a85d-931b8b1226db">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtNS0xLTEtMzYzNTk_69e91d52-7c02-4c5a-9b21-e333c4e2f371">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtNy0xLTEtMzYzNTk_b907b343-b619-4aeb-a761-098de334eecf">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtMS0xLTEtMzYzNTk_64d4e7f7-b716-4406-b289-c6c2eb699f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtMy0xLTEtMzYzNTk_87b766f0-8096-456e-8fc4-ddc6c858419b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtNS0xLTEtMzYzNTk_6824402f-9e14-4692-abf9-24e241f1b94e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtNy0xLTEtMzYzNTk_660f82c2-aee3-451b-8bc1-39bf482dc3d5">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending common stock issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMS0xLTEtMzYzNTk_634dd1ea-6acd-4451-a60a-249795e6a033"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMS0xLTEtMzYzNTk_e94e0af9-956e-4f38-99ab-220dad661b20">80.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMy0xLTEtMzYzNTk_14e9ca47-54af-48a5-a0e4-0ef29ae0bd6d"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMy0xLTEtMzYzNTk_d1799438-faed-45d4-80c4-d5a3fa3888d9">75.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNS0xLTEtMzYzNTk_20133038-304e-42c4-92f8-163a9a6b79c3"><ix:nonFraction unitRef="shares" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNS0xLTEtMzYzNTk_aa74fa6a-824f-4d29-a20d-3a1568580c55">74.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNy0xLTEtMzYzNTk_6626cef5-1cab-44a6-a1b2-866b236c4405"><ix:nonFraction unitRef="shares" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNy0xLTEtMzYzNTk_c7b182cb-8677-4e8d-8ac3-adaa2bde0423">73.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $<ix:nonFraction unitRef="usd" contextRef="id54bd12e649d48069a7463458d653da6_I20160630" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzU1NA_72f7b794-5c64-4f83-8cc7-fc2ed249fa26">200.0</ix:nonFraction> million of the Company&#8217;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company&#8217;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of December&#160;31, 2021, the Company has $<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzQ5NDc4MDIzMjY4MjU_3a05fd23-3cfa-4cc9-bc19-99596d6894df">110.7</ix:nonFraction> million remaining on its current share repurchase authorization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the par value method of accounting for its stock repurchases.&#160;&#160;As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to Retained earnings (accumulated deficit).&#160;&#160;During the year ended June 30, 2019, the Company used $<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzEzNzI_1a4a37fc-526f-4a9e-a624-61b35fac0530">50.0</ix:nonFraction> million to repurchase shares of the Company&#8217;s common stock as part of an accelerated share repurchase. <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="mygn:ScheduleOfCommonStockRepurchasedTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE2ODk_4a735d10-82ff-43d4-8a16-a20369b294c1" continuedAt="i7f93770aaca847bc81f84ecfeed32fbb" escape="true">The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December&#160;31, 2021, December&#160;31, 2020, June&#160;30, 2020, and June&#160;30, 2019 were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i7f93770aaca847bc81f84ecfeed32fbb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased and retired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItMS0xLTEtMzYzNTk_edade831-07dd-45b1-859f-2b37fbf0c2eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItMy0xLTEtMzYzNTk_e5761b73-8704-4461-afa6-3898c2c26821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItNS0xLTEtMzYzNTk_7c1626f7-aeb7-4911-8daf-480f53bab75b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItNy0xLTEtMzYzNTk_58784409-914d-45c0-8ffc-dad7e2cfd5f1">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in-capital reductions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtMS0xLTEtMzYzNTk_b4e0f401-430e-44ae-9ea8-4586d5159bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtMy0xLTEtMzYzNTk_ef8350f8-93ab-42b2-bcdd-28ec21090152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtNS0xLTEtMzYzNTk_8a518299-cc9a-4b42-8bbf-8f8d11faa3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtNy0xLTEtMzYzNTk_28e3082f-f885-44e0-bc81-5baf7445ff58">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges to retained earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtMS0xLTEtMzYzNTk_206b971a-a4c6-45a4-bdce-af407952bd47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtMy0xLTEtMzYzNTk_f431ca5e-bb10-499f-a821-cf41756c985a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtNS0xLTEtMzYzNTk_dd47ede0-6875-4bb0-8795-29290fa26835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtNy0xLTEtMzYzNTk_6b1c4982-003b-42f8-bd65-aa3194bcd1a4">33.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_118"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzU_7725a885-4cc0-444d-8edf-ddfc054ded73" continuedAt="iadbe00bcff2f4e53a4ec365245b2baae" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iadbe00bcff2f4e53a4ec365245b2baae" continuedAt="i87a1e223ba5f4d14a920bfaa395856a9">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2017 Plan&#8221;).&#160;&#160;The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors.&#160;Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant under the 2017 Plan. The 2017 Plan allows for issuance of up to <ix:nonFraction unitRef="shares" contextRef="i5017805749294720bfc1102605257804_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ0MA_ff35123b-256c-4b6f-af72-bda8e8753272">4.6</ix:nonFraction> million shares of common stock, with <ix:nonFraction unitRef="shares" contextRef="i5017805749294720bfc1102605257804_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEwOTk1MTE2NDUyMjI_d86cace2-e58f-4115-acf5-ff4c770d436d">3.6</ix:nonFraction> million shares available for grant as of December 31, 2021.&#160;&#160;If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they will also be available for issuance pursuant to the 2017 Plan. </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i87a1e223ba5f4d14a920bfaa395856a9" continuedAt="i00dba4acb7f2486cb80ecfc5926e71cc"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over <ix:nonNumeric contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEyMzI_e03b94e9-9520-4945-8347-ff8a0a63832b">four years</ix:nonNumeric> either on the anniversary of the date on which the RSUs were granted or during the month in which the anniversary occurs. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to our non-employee directors vest in full upon the earlier of the completion of <ix:nonNumeric contextRef="ic3842c62c98f4eff8442478a102c1f76_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEzOTI_1b64c615-5248-409f-b055-023397813fd9">one year</ix:nonNumeric> of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options generally vest ratably over service periods of <ix:nonNumeric contextRef="id019278a4e69463fa389582d302cd096_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE1MTM_6ce7e560-f794-4edd-b56e-544d109c1af9">four years</ix:nonNumeric>. Options granted generally expire <ix:nonNumeric contextRef="id019278a4e69463fa389582d302cd096_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE2NDY_70f41984-8945-4f18-a4b1-11b131c203f1">ten years</ix:nonNumeric> from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire <ix:nonNumeric contextRef="ib67b2cb2c62d457c8bfa89045a0ac26f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzMyOTg1MzQ5MDMxMjA_9321b8e1-99db-4e7a-8401-a3dcf16875af">seven years</ix:nonNumeric> from the grant date. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of RSUs awarded to certain executive officers and other senior positions that ultimately vest may be increased or reduced based on certain additional performance and market conditions. The performance and market conditions associated with awards granted during the year ended December 31, 2021 include vesting that is based <ix:nonFraction unitRef="number" contextRef="i0941bbd4ec3549fe8c0210b756b9c68d_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzIwODA_920fd529-df31-460e-851b-14bcc37254f1">50</ix:nonFraction>% on achieving certain levels of earnings per share targets, and <ix:nonFraction unitRef="number" contextRef="i0493562cfc8d469d90ebecc52d7cf045_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzIxNDY_c7681784-8b2a-4e17-adb8-95893b071c5e">50</ix:nonFraction>% based on achieving certain performance targets compared to the performance of the Nasdaq Health Care Index. The Company estimates the likelihood of achievement of performance conditions at the end of each period. During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzE_7d1f849f-e5ac-4985-8201-ff2e063a2e8d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzEtMS0xLTEtMzYzNTk_cf94fc36-cab3-4733-9546-d6b28564848c">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzEtMy0xLTEtMzYzNTk_f7e20a48-506d-4f43-84a5-744ffce825a6">23.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzItMS0xLTEtMzYzNTk_7fd15bac-c5ef-43e7-b41c-1f8dba0ff364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzItMy0xLTEtMzYzNTk_c5ef63a0-28d9-455a-a6cc-63626b3789b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzQtMS0xLTEtMzYzNTk_38028f0d-540c-45c5-82c7-8542fee6293b">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzQtMy0xLTEtMzYzNTk_a416a074-af58-4b82-a953-c2417720dc43">24.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzUtMS0xLTEtMzYzNTk_909bca5c-cbfc-4728-bc00-f18e4baeff7d">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzUtMy0xLTEtMzYzNTk_506840bd-59fc-4434-b528-aa81b871cce1">25.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzYtMS0xLTEtMzYzNTk_4dcf34dc-2631-4e60-a8da-03e13dc04a7c">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzYtMy0xLTEtMzYzNTk_e3333b5d-8a29-46cf-b7d6-8626f455d647">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzYtNS0xLTEtNTg1NTA_19f682f4-f13e-4ec6-8d75-a0a483a488dc">3.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzctMS0xLTEtMzYzNTk_a020958e-04bc-409c-be4f-a0f575ecc7ad">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzctMy0xLTEtMzYzNTk_bc747f4b-db6e-45bd-ad3e-10171900faba">23.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzctNS0xLTEtNTg1NjI_cc24e5ce-9d70-43f4-b70e-4de210f1cd68">2.09</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzgtMS0xLTEtMzYzNTk_3b3ae549-0689-4685-b3dd-6ef27dfa91c2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzgtMy0xLTEtMzYzNTk_03015eab-371f-4fc3-8952-2e0832734a48">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzgtNS0xLTEtNTg1NjI_ffeefd01-41ab-4cfd-a420-53c07dbac428">3.08</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzM4OTE_188e8124-d830-49a4-a70f-4a88b535a1a8"><ix:nonFraction unitRef="shares" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzM4OTE_a262ef6f-f01f-4579-97b7-2d6b5b51a9d0"><ix:nonFraction unitRef="shares" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzM4OTE_f2503f47-d82d-46ea-9707-91c7acd6d16d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> options granted during the years ended December&#160;31, 2021, June&#160;30, 2020, and June 30, 2019. During the transition period ended December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="id0aea44508ff4dfbb5ee1282d27b02b2_D20200701-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzMyOTg1MzQ5MDMxMjY_1bf71ccd-d49c-4255-9562-0c5e2c871807">0.7</ix:nonFraction>&#160;million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="id0aea44508ff4dfbb5ee1282d27b02b2_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzMyOTg1MzQ5MDMxMzk_842c521e-0a74-4cd1-9805-043532d90fc0">13.38</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2Njk_f84de097-2475-46e6-aca5-eb71b5e00628" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding at December&#160;31, 2021 (number of shares in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number outstanding at December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iee48b219c6314207b2b8c51e655bad7c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpjYWYwMjIxMGZjNDg0ODk2YmYzNGQwMGJiYWIzYTZhYl80_3433f998-4e26-437e-8025-33fc6597a478">13.38</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic585d4b282fa403da809d437637d7786_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItMi0xLTEtMzYzNTk_95f933b6-fec4-454d-9860-5ccb0960523e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee48b219c6314207b2b8c51e655bad7c_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItNC0xLTEtMzYzNTk_757e3576-6795-495a-a438-17f7d47e49be">5.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic585d4b282fa403da809d437637d7786_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItNi0xLTEtMzYzNTk_6afdf2f6-5d6f-4dd5-a1ff-51a7e537913a">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4aaf305cdc4c4b3783ad7772ad83b376_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjo5ODRiOGNhYTkwMTc0Y2FhYTc3OGE5OTYzYWJmMGFhOV80_0d3bf01e-62e7-49e1-9e76-cc704fc15268">23.98</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b47a20179364be1a601e6386dcdc7c0_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtMi0xLTEtMzYzNTk_77a86727-270e-4fd4-a0db-bddbc89623de">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4aaf305cdc4c4b3783ad7772ad83b376_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtNC0xLTEtMzYzNTk_e8a82550-cc51-4a6e-8b21-3432052f32d3">0.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b47a20179364be1a601e6386dcdc7c0_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtNi0xLTEtMzYzNTk_44994fca-1367-4b51-8159-3b47dc9c598a">23.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9edc8741087a458da983569f09876507_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjo4YzFiNTJkMGFhZGM0OGMwOTBiYjJhYzkxNTdkMGM1NV80_dca26e40-9ef5-467f-8f74-8139128a4754">27.07</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="i9edc8741087a458da983569f09876507_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjo4YzFiNTJkMGFhZGM0OGMwOTBiYjJhYzkxNTdkMGM1NV8xMDk5NTExNjI3ODE0_3c512125-9482-4487-95ea-e947da24e28b">36.55</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i561d9e41bc564e37b2cdadb9540775cb_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtMi0xLTEtMzYzNTk_c66bba8b-bd46-46fb-aaa8-f99128806dbb">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9edc8741087a458da983569f09876507_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtNC0xLTEtMzYzNTk_5191dd53-bbc5-4135-b117-65ac825d6956">0.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i561d9e41bc564e37b2cdadb9540775cb_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtNi0xLTEtMzYzNTk_6a9841dc-25b8-4a66-8753-5ba5e172c1e6">27.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzYtMi0xLTEtMzYzNTk_0630b24d-ca21-4494-92e5-02d1935cb5f2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzYtNC0xLTEtMzYzNTk_19f682f4-f13e-4ec6-8d75-a0a483a488dc">3.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzYtNi0xLTEtMzYzNTk_96c44423-5279-46e1-8902-fdb81fac0afd">20.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i00dba4acb7f2486cb80ecfc5926e71cc" continuedAt="i4fec85eba1a345cc860745c7405d4618"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzM_b4869643-63fd-4ffc-80e5-40726ce36e21" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzItMS0xLTEtMzYzNTk_f82323bf-8968-4ee0-a0cb-5aac0557b260">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzItMy0xLTEtMzYzNTk_d60ba26c-9fbe-44a9-8cfa-050c07346f1c">20.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzMtMS0xLTEtMzYzNTk_e536bd1d-bffe-4c8b-bef2-9da52a4a8b92">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzMtMy0xLTEtMzYzNTk_c9c82f65-7906-49f4-97a4-30d9f6251159">29.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzUtMS0xLTEtMzYzNTk_855dadf6-1166-4b09-8384-f88c504a8c61">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzUtMy0xLTEtMzYzNTk_ff22c6a3-8bf4-4b06-860d-bee98ee34bfd">21.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzYtMS0xLTEtMzYzNTk_acfd772c-d73b-411c-8beb-1297316a6791">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzYtMy0xLTEtMzYzNTk_959f3fbd-906e-4f3d-b8cf-6027254b833c">24.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab3c3decbc9b4749a615c444461f2714_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzctMS0xLTEtMzYzNTk_5e7c8645-ffe3-4359-b786-ac2df8fd202a">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab3c3decbc9b4749a615c444461f2714_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzctMy0xLTEtMzYzNTk_4c3efb9a-1246-4bed-94f8-8b6cdad2945e">24.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of restricted stock units granted during the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June&#160;30, 2020, and June&#160;30, 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ2NDQ_c9c82f65-7906-49f4-97a4-30d9f6251159">29.83</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib14d08a6c91d4a4d9a5f3397abc5c101_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ1MjQ_5070c903-6715-48da-bb1e-0e669fc1af97">13.69</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i17009626ef9e40fea086f24d4e4d938e_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ1MjA_d7b0de3b-b3e7-4d5a-aa92-14dab6fbc9a1">27.96</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i55c1d65d2fea4fb897497c39c3c543bb_D20180701-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ1MTY_8594f43e-7c9c-4ec4-a969-2015c743f04d">46.62</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock units that vested during the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June&#160;30, 2020, and June&#160;30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MTQ_e9f6d1f1-38fb-4187-8ab8-9f714246cb73">22.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib14d08a6c91d4a4d9a5f3397abc5c101_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MTA_8ad088eb-e873-4691-b881-0bc714a5dba7">29.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i17009626ef9e40fea086f24d4e4d938e_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MDY_7b614235-7322-4129-90a1-7f080b4d7850">32.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i55c1d65d2fea4fb897497c39c3c543bb_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MDI_ee04cd8e-ebed-4a47-a05a-4174d5a54d7d">27.6</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2Nzc_17684985-3072-4a81-8793-83a3cf08e7bc" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if55a0576781b4fe09cd0002c1cf57591_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItMS0xLTEtMzYzNTk_66fa4308-7c90-43e5-86c9-263993c9fd3a">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40d4e8c980d4d749c48652760c59dcb_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItMy0xLTEtMzYzNTk_02159be4-9911-4dd7-8583-723d0f89c598">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3271f5fd8d4f9cae87d273d0119cf6_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItNS0xLTEtMzYzNTk_50eadc18-0016-49e8-ac5e-6e8bd54d2267">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d82b14159db4173bec06da40fa3fba0_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItNy0xLTEtMzYzNTk_d516adcb-7b68-4078-b920-6e778ad2a9d3">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e5585fea71439f950bf077fd864a6b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtMS0xLTEtMzYzNTk_785e77b6-1d62-4245-b6c9-45fe53258024">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a7c61994bb46c687fdf99107cfd671_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtMy0xLTEtMzYzNTk_a6f2f046-4f32-48bd-9da2-5e2ae90a3a90">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c6f499764943a9b6668276c03a7dca_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtNS0xLTEtMzYzNTk_39832450-3d29-4271-a64b-286f9e43c4be">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd00bad76d24a0ba7fbe37165e9ea1e_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtNy0xLTEtMzYzNTk_49547f10-4124-4557-9821-be31233effe2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932fedfaff694d47a9c810a8ed5c652a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtMS0xLTEtMzYzNTk_0f80a3a3-40f0-4e08-97a3-9f86036b7510">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36668e3bf1614b139d53bd0dd4a1737f_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtMy0xLTEtMzYzNTk_fb6a2fef-ef9e-481a-a0fa-00bc24624d0d">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i220876603bc44dc4b5d5cba857b18a98_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtNS0xLTEtMzYzNTk_c1cb76b3-1b08-4dfd-bd60-2fd9b74be910">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fbec0d2524cbfb381bcf39f515a31_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtNy0xLTEtMzYzNTk_41578170-bb70-4892-b5f9-17064809e322">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14606df79fcb41208a7deba7ab883c8b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtMS0xLTEtMzYzNTk_abeebf95-9a97-4d7d-92a4-b2bc2ea23ab1">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id273969844de4a42b563bdd13fe471ee_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtMy0xLTEtMzYzNTk_846be8fe-9798-418c-b456-134c74edd583">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b5430845bd4bf0bdf1c90acbf50400_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtNS0xLTEtMzYzNTk_b27bc0ff-161c-415c-9a3b-6a9078a0dc04">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df27cee9a9e44d4b90685ca4d691bfe_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtNy0xLTEtMzYzNTk_4a341455-9960-4c24-83c3-3985d1cb3d31">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtMS0xLTEtMzYzNTk_177182f9-7e06-4281-bb57-2fa0e710c886">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtMy0xLTEtMzYzNTk_ae320157-fe5e-45e3-bffc-c1e4a8bc76bd">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtNS0xLTEtMzYzNTk_a9d44ba2-de2a-4475-aece-46bace785e23">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtNy0xLTEtMzYzNTk_deaff940-0fb2-4da1-b529-20825f821064">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEwOTk1MTE2NDU0ODI_25ef9201-9989-495d-9b8d-9f0b37a565e1">61.7</ix:nonFraction> million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEwOTk1MTE2NDU2MTU_d789ca7a-1113-42c6-bb8c-beba24b16b17">2.3</ix:nonNumeric> years. We expect all unvested awards to vest, and we recognize forfeitures as they occur.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzQ_eb180873-3296-49db-979c-dc325e10e6e3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo4Y2UwNTJiZTM3MTE0NGM4OTU3MWE3NGU1OWQ5MjZmYi90YWJsZXJhbmdlOjhjZTA1MmJlMzcxMTQ0Yzg5NTcxYTc0ZTU5ZDkyNmZiXzItMS0xLTEtMzYzNTk_e8afecb2-898b-4a89-98c6-dd9136f26806">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options fully vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo4Y2UwNTJiZTM3MTE0NGM4OTU3MWE3NGU1OWQ5MjZmYi90YWJsZXJhbmdlOjhjZTA1MmJlMzcxMTQ0Yzg5NTcxYTc0ZTU5ZDkyNmZiXzMtMS0xLTEtMzYzNTk_4dd26d84-e11a-4ae0-8c47-689205f46fd2">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3c3decbc9b4749a615c444461f2714_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo4Y2UwNTJiZTM3MTE0NGM4OTU3MWE3NGU1OWQ5MjZmYi90YWJsZXJhbmdlOjhjZTA1MmJlMzcxMTQ0Yzg5NTcxYTc0ZTU5ZDkyNmZiXzQtMS0xLTEtMzYzNTk_31c74716-f65d-4e86-9b69-6c5380210371">86.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i4fec85eba1a345cc860745c7405d4618"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzA_c5034b93-fea5-455e-8732-31d530a401a3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItMS0xLTEtMzYzNTk_2f239921-3306-4fa7-b662-4e9edc6146c4">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItMy0xLTEtMzYzNTk_e1e93ded-80de-4bd1-92f2-42b17afc800e">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItNS0xLTEtMzYzNTk_34a40cb8-20d6-422e-8641-828fbe170c2f">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItNy0xLTEtMzYzNTk_df48941f-2cc2-48ef-a33f-d45c33fadedb">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#8220;2012 Purchase Plan&#8221;), under which <ix:nonFraction unitRef="shares" contextRef="i8feb4bec474149ac84ceec0cbaaa45af_I20121205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzU4NzY_ae5de167-d4d3-4c11-a839-91b8ff03de39">2.0</ix:nonFraction> million shares of common stock have been authorized. On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional <ix:nonFraction unitRef="shares" contextRef="i57656916c4ad4a29bc0dda34d93091b5_D20210923-20210923" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE2NDkyNjc0NDM2NDU5_e7570879-5b37-46b1-bd80-5dd5fb35329e">2.0</ix:nonFraction>&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at <ix:nonFraction unitRef="shares" contextRef="i57656916c4ad4a29bc0dda34d93091b5_D20210923-20210923" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE2NDkyNjc0NDM2NDc0_037932a9-2f8f-43c2-b756-34f8a46c55d2">5,000</ix:nonFraction> shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At December&#160;31, 2021, a total of approximately <ix:nonFraction unitRef="shares" contextRef="i6f2deacdf28047ffa7f76605879c01a3_D20211205-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzYwMzg_171b4169-ea93-47ad-83ec-edd063257fef">2.0</ix:nonFraction> million shares of common stock had been purchased under the 2012 Purchase Plan. <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzY_facfeb04-1386-4e24-978f-2f6fc9fa5149" continuedAt="idc4bfd21bd0944bdb41c3bf7954e003d" escape="true">Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="idc4bfd21bd0944bdb41c3bf7954e003d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItMS0xLTEtMzYzNTk_a62fc6ca-6501-4fd1-9dc6-11aa680282f2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItMy0xLTEtMzYzNTk_f78496fe-dfa7-4199-912c-4122bae62123">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItNS0xLTEtMzYzNTk_828cb3c5-23dd-4b10-afd0-71a2f7fd92a5">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItNy0xLTEtMzYzNTk_520389ad-4d99-44b9-b27e-e69ce748a377">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtMS0xLTEtMzYzNTk_392d5f3f-9924-4dfe-b7f1-8fcd76e1c61e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtMy0xLTEtMzYzNTk_bbb6c869-55ac-4972-b117-b48f42ae52eb">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtNS0xLTEtMzYzNTk_1af227bf-31b0-4fe4-9455-a2cddc707860">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtNy0xLTEtMzYzNTk_73c22221-39a7-4680-8939-d5dd93880b18">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2Nzg_f0af60a9-0662-49cb-b5da-98e7e6f60e00" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black&#8209;Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItMS0xLTEtMzYzNTk_3787e0f0-62cc-4b0b-9222-9d95ce273731">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItMy0xLTEtMzYzNTk_458c9f20-a95a-4c17-a1bd-a5046a314316">0.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItNS0xLTEtMzYzNTk_c266bf4f-aa96-45df-9a85-c7c0e0fd0287">1.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItNy0xLTEtMzYzNTk_2b3caad7-0c48-4db7-8c01-09a70514f55f">2.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtMS0xLTEtMzYzNTk_da5f43e2-b253-4156-89c8-493e4e76ccc9">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtMy0xLTEtMzYzNTk_407997d3-69ec-42e3-bc12-01a13cb932bb">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtNS0xLTEtMzYzNTk_4dbecc38-e701-4540-865a-4b93af6bc7eb">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtNy0xLTEtMzYzNTk_a2bca6da-f5e3-4b1c-8eb9-df20a9cef06d">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtMS0xLTEtMzYzNTk_76b95925-3e1f-4c65-9522-83286c9958d2">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtMy0xLTEtMzYzNTk_599bc246-4e6f-4186-983d-cd277fd92f4b">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtNS0xLTEtMzYzNTk_fc6a6380-3d6e-460a-8ce7-aff2de0834dd">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtNy0xLTEtMzYzNTk_75607677-5f8a-4073-b603-ed7e7c5226ec">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtMS0xLTEtMzYzNTk_19e80f66-000a-40d6-a667-a0f484cde106">60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtMy0xLTEtMzYzNTk_65b2ea52-cb0a-425c-b9eb-09e9f117bfa0">94</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtNS0xLTEtMzYzNTk_f082c3ba-9673-4ac6-a4c4-63d02dc1f6a5">99</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtNy0xLTEtMzYzNTk_1578437c-85ca-4753-8590-3e168fe4f96c">55</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTU_883e6f99-2ff0-483d-acd8-75bcfe2dc527" continuedAt="i1c792a7974bb4c7bb442c284783f0cdc" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i1c792a7974bb4c7bb442c284783f0cdc" continuedAt="ic220f01269704fe8acb4bc2852ca2adf"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTY_3f72e3ae-871a-47a0-8538-eec0457eebe9" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtMS0xLTEtMzYzNTk_3333e8c8-0028-45a7-8c12-4cf896a6a9f9">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtMy0xLTEtMzYzNTk_9c94869b-03d2-4edd-b536-70c70cb7d5a2">75.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtNS0xLTEtMzYzNTk_a0fa89fa-426b-46b8-926b-46e0df0128aa">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtNy0xLTEtMzYzNTk_c17a58c2-b483-48ac-8526-346d80c9c29e">24.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtMS0xLTEtMzYzNTk_1037196f-4715-49af-8773-5a7a41114c15">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtMy0xLTEtMzYzNTk_88c45f87-9f51-4e3e-b1d8-f34c4d203e0d">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtNS0xLTEtMzYzNTk_1d7e3d95-4725-4a31-be2c-11af18aae50c">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtNy0xLTEtMzYzNTk_0da831bb-020d-47f3-a030-9c0490037e09">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtMS0xLTEtMzYzNTk_9d6c9280-6a95-4cf4-aba0-907b349471eb">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtMy0xLTEtMzYzNTk_c3da13d5-6673-410f-a12a-401c3da2bf38">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtNS0xLTEtMzYzNTk_1993770e-1a29-4ba4-837a-20ca59f8c3f9">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtNy0xLTEtMzYzNTk_3dcc66ff-52c5-48ef-b334-739b7a9033f6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtMS0xLTEtMzYzNTk_217253d2-8567-4da6-a253-ed7f288977d8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtMy0xLTEtMzYzNTk_42ec3b57-9562-49d5-b52c-11e5cdf69ae1">76.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtNS0xLTEtMzYzNTk_cf231271-3d26-4289-beb8-cd16e9ec0a25">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtNy0xLTEtMzYzNTk_3326f94c-9070-40bb-9b6d-aa9a38d586a9">24.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtMS0xLTEtMzYzNTk_a64b6cb5-1579-4c7c-a13a-dbe67b2ecbe8">33.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtMy0xLTEtMzYzNTk_303f8cd6-3bd2-4625-9fad-6ab6ae2ccca4">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtNS0xLTEtMzYzNTk_f8889b9e-de3d-4008-8e53-b1b0ae36870f">51.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtNy0xLTEtMzYzNTk_62d2df19-0418-4733-a07a-57b23d9e8e8c">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktMS0xLTEtMzYzNTk_1f4e2b9f-9a1b-493d-b214-39f4677a7185">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktMy0xLTEtMzYzNTk_73aaed5e-ff94-460e-931f-4ecb59081295">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktNS0xLTEtMzYzNTk_bb435dcf-fdac-45e5-82e5-b97634478303">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktNy0xLTEtMzYzNTk_9e96ef00-0a7b-497d-b7ab-e7080260b825">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTEtMS0xLTM2MzU5_217d6368-aebf-4d2d-a4c0-bd0f804868f0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTMtMS0xLTM2MzU5_4a0169c3-e851-4793-813e-c5ee523e810c">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTUtMS0xLTM2MzU5_c31da708-2f53-4cf2-bdd0-ed2ee6b79bb0">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTctMS0xLTM2MzU5_a837bff2-d5f8-4359-83fa-f3afbfb74081">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTEtMS0xLTM2MzU5_e92e48c8-c019-4bfd-93b8-0196a1022ae7">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTMtMS0xLTM2MzU5_c1bbcd98-791a-4298-874c-5ba3193fe051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTUtMS0xLTM2MzU5_c5837e3a-d399-4751-8fcd-c8b0fe47c98e">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTctMS0xLTM2MzU5_126b8903-03d3-40ca-a4b6-b8acabbac1da">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTEtMS0xLTM2MzU5_05328ec9-c972-46fc-9278-2d95202fd342">31.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTMtMS0xLTM2MzU5_72586618-12af-4512-878e-725127d72b99">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTUtMS0xLTM2MzU5_15ba58d5-43cb-4d51-b499-746da5a66003">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTctMS0xLTM2MzU5_d0194d1f-7bb0-48d8-aad6-2d7dde4595ab">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTEtMS0xLTM2MzU5_3eda28ab-9ee4-4a6a-ae33-2a15526900c3">29.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTMtMS0xLTM2MzU5_fd3ac481-b38f-4e7b-8f47-324e847bd1cf">41.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTUtMS0xLTM2MzU5_7d7a0889-11ba-4335-a91d-dc24806fe453">23.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTctMS0xLTM2MzU5_331f71d3-e0fb-4f6a-96a3-b644b0a86160">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTM_5fa4bd27-0da0-4ee3-a204-58045e1d95f1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItMS0xLTEtMzYzNTk_bb3c09ab-dc85-4727-a39c-322afe07827f">53.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItMy0xLTEtMzYzNTk_4ef5b2f3-dde0-4f14-a01b-b7c28b57c864">101.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItNS0xLTEtMzYzNTk_eef77a5c-7ca6-4068-a4ed-69c15b912607">240.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItNy0xLTEtMzYzNTk_96457948-f969-436e-9e70-b9a5dcd5ac9e">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtMS0xLTEtMzYzNTk_f6f260f0-47ac-45e2-81a8-469e0787a937">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtMy0xLTEtMzYzNTk_029427fd-b46e-4e26-8736-ecb33f21d7a4">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtNS0xLTEtMzYzNTk_ff217a8b-81d9-487d-9290-85ebe8c3da1b">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtNy0xLTEtMzYzNTk_eeffa9d7-6227-43e4-b22b-5f9b86f26aa2">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtMS0xLTEtMzYzNTk_50125b03-9372-4bcd-9b85-58e6e278e622">57.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtMy0xLTEtMzYzNTk_0649e056-4561-48b2-aa01-981114184afc">94.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtNS0xLTEtMzYzNTk_afe157a8-1fe9-4d08-9d36-7619bb70c6eb">223.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtNy0xLTEtMzYzNTk_0f44afd8-6efd-4d67-b592-e958a83ece85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="ic220f01269704fe8acb4bc2852ca2adf" continuedAt="i5b66570d3d7d40ec88b2af992f41825e"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTc_192ac97e-3250-4867-9eb8-59661eaf8c8c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at the statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMS0xLTEtMzYzNTk_84277d93-60ee-4b0a-9dcd-6e0962d46384">12.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMy0xLTEtMzYzNTk_951db345-7466-4f2f-9fec-8eee24579356">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItNS0xLTEtMzYzNTk_3e7c04bf-ff7d-4029-a020-3c688304b2ae">19.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItNy0xLTEtMzYzNTk_b275369a-942b-4eb9-b1f4-f30c1a20924f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItOS0xLTEtMzYzNTk_05530eef-4f8a-4901-b1e5-5c64e205a45a">46.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMTEtMS0xLTM2MzU5_4c123504-e508-4a29-a00e-e193e9a5edda">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMTMtMS0xLTM2MzU5_67ca1af7-560d-48bf-961e-8b5734345d96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMTUtMS0xLTM2MzU5_525dbeb2-a124-47a4-a55f-7939c3c2426d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMS0xLTEtMzYzNTk_341df10f-665d-4fec-8f68-0e379e09e710">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMy0xLTEtMzYzNTk_da0db6c1-9cfc-44df-9202-e1faaa1d5dc0">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtNS0xLTEtMzYzNTk_2b6751e3-e681-4b1c-b51b-32a57969eafc">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtNy0xLTEtMzYzNTk_b0adafc1-2364-4289-a862-8cd4a59d2a8a">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtOS0xLTEtMzYzNTk_015faaa2-584f-496e-9304-a65140debe13">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMTEtMS0xLTM2MzU5_cfc2f8af-eec8-4b7d-8d5e-65bc6012bd33">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMTMtMS0xLTM2MzU5_b0eb6394-b758-4a40-9e61-6706b6b52c87">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMTUtMS0xLTM2MzU5_791e48c9-fdd8-49b3-9883-ec2674f163be">6,422.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMS0xLTEtMzYzNTk_e5929a64-17b1-4883-a0ae-a428b25b4052">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMy0xLTEtMzYzNTk_9081c230-2dd0-452d-baf5-79d6d0dc7b1c">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtNS0xLTEtMzYzNTk_a497fb79-b854-4c40-8fbb-bb13cf620c93">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtNy0xLTEtMzYzNTk_13aeceac-6d9f-493a-8cc8-8abaf31093fb">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtOS0xLTEtMzYzNTk_33bc9fc1-73b3-479c-9384-5b9d5bf69020">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMTEtMS0xLTM2MzU5_8f607a0f-c79a-4910-aa98-81ccf8b6673a">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMTMtMS0xLTM2MzU5_634e09dc-3949-441c-a8c5-3c7b5c787cf6">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMTUtMS0xLTM2MzU5_fa5c1f15-3898-42c9-ad21-a9b759922d54">11,880.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMS0xLTEtMzYzNTk_6573e5eb-d7c0-4374-acd5-58b46965fa7f">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMy0xLTEtMzYzNTk_8bcad95d-1e94-48ec-bf1a-f33b698bf836">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtNS0xLTEtMzYzNTk_95704ce9-0178-4b5a-a0e8-ffd6171b7b09">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtNy0xLTEtMzYzNTk_3c72ca19-6853-43f8-bd77-5f54e0b5ed84">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtOS0xLTEtMzYzNTk_75e9bc16-7347-4313-a3ba-881b0561bf6f">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMTEtMS0xLTM2MzU5_23d467cc-9a0d-4bfa-b83e-04f9f46b7443">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMTMtMS0xLTM2MzU5_816b1a28-4eef-4f57-8ab7-e20d7f76ca18">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMTUtMS0xLTM2MzU5_9f51315b-aa89-4b80-9867-1c25981c22ea">13,486.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock option and employee stock purchase plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMS0xLTEtMzYzNTk_34203280-2df5-4eab-b531-8a0df15100bb">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMy0xLTEtMzYzNTk_79a721e7-eb30-45b6-9e6f-1d20afc306a4">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctNS0xLTEtMzYzNTk_3d60a9a1-6f04-44cc-a130-e8d1009aad0e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctNy0xLTEtMzYzNTk_3c3387d7-fc8e-402f-810d-7e34f4b81266">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctOS0xLTEtMzYzNTk_541ccfc4-a9fb-4ff3-a862-7985c3d7f223">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMTEtMS0xLTM2MzU5_79ef4101-c671-4f62-96b1-63b9ab7eb8d2">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMTMtMS0xLTM2MzU5_9a8e7f5e-b13d-4ffb-9269-3e81b8b1312f">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMTUtMS0xLTM2MzU5_8203ef21-420a-428c-b7a6-85f029082db9">9,954.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMS0xLTEtMzYzNTk_123ab2c2-b203-4930-af51-63fdb357667c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMy0xLTEtMzYzNTk_ceb4110a-7566-4ab3-87f8-f88d6abc8506">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtNS0xLTEtMzYzNTk_ed293181-4010-4483-9f19-978591e81062">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtNy0xLTEtMzYzNTk_0283a6de-ddcd-470c-b9dd-0cb6f36fa6ad">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtOS0xLTEtMzYzNTk_b930b4d8-8411-47d3-80bd-d7edfe5a24af">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMTEtMS0xLTM2MzU5_8e4c2ad4-61b0-4f17-beae-6b3a5f317206">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMTMtMS0xLTM2MzU5_574dc084-1fda-4e83-86c9-b1bcb196a0c9">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMTUtMS0xLTM2MzU5_de1766f8-2020-4bec-9236-ea97e18b5edf">2,568.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMS0xLTEtMzYzNTk_e2456a69-a1ac-47e5-88c5-aafa240ed7d5">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMy0xLTEtMzYzNTk_72854866-8a63-43e0-a3e5-bb7985fde8a8">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktNS0xLTEtMzYzNTk_ca4722f9-05ed-451b-bc8e-519decf61d8f">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktNy0xLTEtMzYzNTk_95fbf180-3d55-4618-a122-bf9b1e6d6008">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktOS0xLTEtMzYzNTk_da8fffb7-d426-4e1b-a5dc-2fa7efab09c5">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMTEtMS0xLTM2MzU5_04d08902-c653-4ff2-ad7e-5aad9d0f4609">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMTMtMS0xLTM2MzU5_bb104123-5d90-425c-a4a4-5313f0fbf96a">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMTUtMS0xLTM2MzU5_8b9d087b-8fed-4238-baaa-43d126bf1eef">642.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTEtMS0xLTM2MzU5_e6b37320-746a-42f1-9ba5-5bf6dbcd34b8">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationCARESAct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTMtMS0xLTM2MzU5_ae66e57c-7c07-4c11-8bf5-dfc9450b92cb">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTUtMS0xLTQwNjAw_7c141eb1-bda9-4bd0-ae7b-c5cf559ed1f8">20.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationCARESAct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTctMS0xLTQwNjAw_6a25423d-178d-4fdf-b3a3-bdf671a7ce68">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTEtMS0xLTM2MzU5_bd8a8d9f-be36-42b0-bffa-aa0367c1b49b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTMtMS0xLTM2MzU5_99b2d4dd-30f1-4e74-8dac-6a84f44b96bf">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTUtMS0xLTM2MzU5_dcacaa40-97a2-4525-9032-4067fbf156a6">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTctMS0xLTM2MzU5_354c8757-5cd6-48eb-991a-c4d8873595a5">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTktMS0xLTM2MzU5_18bf5381-acbc-4ea2-9ba4-6ea7ca2a356b">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTExLTEtMS0zNjM1OQ_b92350cc-9082-498b-bf74-0a995934da9f">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTEzLTEtMS0zNjM1OQ_72151ea0-f2fd-45c4-b986-01b84f727aa6">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTE1LTEtMS0zNjM1OQ_05dbe4cf-ce6d-4592-8396-8b44335d5a1f">4,174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTEtMS0xLTM2MzU5_cf2a9687-c17f-4815-ac38-8fe702246054">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTMtMS0xLTM2MzU5_9ec0e2ea-daf2-4a2d-9b93-10e381866a0c">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTUtMS0xLTM2MzU5_8c4bba06-6f3e-4751-8b6d-248595c0a657">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTctMS0xLTM2MzU5_c02de851-9ea2-4b51-ae67-d160828e03df">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTktMS0xLTM2MzU5_d409d4a0-2024-466e-951c-80e68dd1b9f7">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTExLTEtMS0zNjM1OQ_589d954d-786f-477b-a8a9-5fdd3556d359">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTEzLTEtMS0zNjM1OQ_6321d118-a6f5-422f-b067-b3e809df8a62">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTE1LTEtMS0zNjM1OQ_6e6cff7b-b5dc-47d3-8927-e4150ca81205">1,926.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTEtMS0xLTM2MzU5_19b95dee-a274-4268-ae26-f03d4ba3b5d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTMtMS0xLTM2MzU5_bb080b99-30e3-43dd-894f-de990233de92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTUtMS0xLTM2MzU5_9d463cdf-2b1b-4cc2-a0cc-1f8c284fbcfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTctMS0xLTM2MzU5_8a901160-68ad-4b2a-b0c5-f4bc8eaedfe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTktMS0xLTM2MzU5_276cf83f-1aa8-496a-8f1e-8ddc561ef5f0">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTExLTEtMS0zNjM1OQ_e9920c08-b89a-4950-9d54-0efce3b197f6">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTEzLTEtMS0zNjM1OQ_aac11af7-2adf-4070-8a86-113cc74301c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTE1LTEtMS0zNjM1OQ_2fe21a4b-0177-4bfc-a216-51c4b22d3edc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTEtMS0xLTM2MzU5_a3c9f4c8-ceea-491d-80c2-fbd0c873050f">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTMtMS0xLTM2MzU5_ddec444a-f9c4-41fe-a263-d6d701af5323">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTUtMS0xLTM2MzU5_2f0cbd72-f51a-412f-bbfd-c9936c10402c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTctMS0xLTM2MzU5_6fd78120-40a2-4f58-ac13-08556ed17690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTktMS0xLTM2MzU5_c3db6bc0-5503-4670-878f-3de9d2026032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTExLTEtMS0zNjM1OQ_1f0a4fa2-1bc0-4049-a47c-0a41b3fc0c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTEzLTEtMS0zNjM1OQ_ef986049-caab-4163-8da6-03b81371e860">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTE1LTEtMS0zNjM1OQ_5cf241ac-b2e3-44eb-a5af-843302899dec">6,101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, Dispositions, and Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTEtMS0xLTYxOTU0_0d61c8bc-bbde-4222-8e87-cc4a6f59cadb">23.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTMtMS0xLTYxOTU0_8c03185e-6759-42de-be8e-0cf31daa1dba">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTUtMS0xLTYxOTU0_5dd33fe1-33fd-4b04-ba3b-748774a66730">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTctMS0xLTYxOTU0_1e547786-400b-4a98-83b6-368ecbed88bf">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTktMS0xLTYxOTU0_d8fe7cca-9236-4b3e-b44d-59605bc97506">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTExLTEtMS02MTk1NA_1aad91ea-0f26-4bf6-b8cc-54e415c6dc3f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTEzLTEtMS02MTk1NA_359c635e-600f-42a5-ac73-4f73de5bba22">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTE1LTEtMS02MTk1NA_87918719-4a07-4a63-b4a4-9464046f0e6f">2,568.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method changes or tax elections</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTEtMS0xLTM2MzU5_37026ce9-65f6-406a-8ce8-7c2f158e2cca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTMtMS0xLTM2MzU5_3489aaee-34e6-496f-901a-40d1393c7a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTUtMS0xLTM2MzU5_43f41b92-0bd0-47d8-860b-c6da36527ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTctMS0xLTM2MzU5_a32de2ee-234e-4e46-b311-1a8595f28b51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTktMS0xLTM2MzU5_0e12529d-adc0-4f44-ae78-ade4be55ffc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTExLTEtMS0zNjM1OQ_5978fc79-5f7e-4100-962b-8250d0cd4661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTEzLTEtMS0zNjM1OQ_8f1c805c-bb8e-41ba-a15a-460bde26e283">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTE1LTEtMS0zNjM1OQ_fbad42ef-58d3-4230-b850-eee70bf2a3a3">2,890.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTEtMS0xLTM2MzU5_060bea99-ccee-4f65-9a26-e1419aabd2de">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTMtMS0xLTM2MzU5_a341ad52-9df8-480e-9620-d7ea7d97f7bd">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTUtMS0xLTM2MzU5_3bf77561-ee64-46f7-b999-fa2f7aa7d2d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTctMS0xLTM2MzU5_ad9d4f02-0d73-426a-8040-0ee38aa2859c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTktMS0xLTM2MzU5_e817e39a-91d4-4833-82d1-7719739ee339">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTExLTEtMS0zNjM1OQ_6c573134-23aa-4bf6-ac44-2c6d71c3b5ce">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTEzLTEtMS0zNjM1OQ_de656076-619a-4a15-8a26-18b228732052">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTE1LTEtMS0zNjM1OQ_ff07d859-93ef-464d-851b-6a2c4905a956">963.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTEtMS0xLTM2MzU5_59c71334-f21d-4d60-bdea-7b6a90dc7841">29.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTMtMS0xLTM2MzU5_be148edd-1849-45e5-a7a7-dbbf0d5817ca">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTUtMS0xLTM2MzU5_ad76c171-0c94-4d83-8960-3ffaf3687333">41.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTctMS0xLTM2MzU5_ec55947b-85ec-412c-ae37-f9238ab27048">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTktMS0xLTM2MzU5_35a2a127-af57-405e-9f2d-56a5097c9c52">23.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTExLTEtMS0zNjM1OQ_8c9f28f8-5e25-4ffc-abc3-c2eaddbb64d0">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTEzLTEtMS0zNjM1OQ_ed867682-6cd3-4116-b83a-f7b9c3bf42f5">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTE1LTEtMS0zNjM1OQ_7220402f-bd71-49c1-9ff8-3a1359cbe060">14,107.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i5b66570d3d7d40ec88b2af992f41825e" continuedAt="ie1604ecd7a24460399268bdc6fb927ff"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTg_809efcab-5ef7-4d00-99f9-6dd5ee4f78ce" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities were comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzMtMS0xLTEtMzYzNTk_dd58608d-b518-4be9-8574-f37b96ad3eb4">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzMtMy0xLTEtMzYzNTk_24129e36-cc7e-4288-a7c5-530f1b7ce413">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzQtMS0xLTEtMzYzNTk_d1c91bfb-11e1-483d-90e6-ad121fc67dea">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzQtMy0xLTEtMzYzNTk_8ee2897d-3e15-48e3-913a-8a20dfade64e">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzUtMS0xLTEtMzYzNTk_d4a6891a-64d4-4fc5-9d5e-561cf1383217">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzUtMy0xLTEtMzYzNTk_ca65165d-aa32-409d-a7c0-79d57129ea36">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzgtMS0xLTEtMzYzNTk_15b2eb9b-33bf-43bc-b115-d41db30e992e">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzgtMy0xLTEtMzYzNTk_e822072f-d963-40aa-a3a1-fa8be710072d">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:DeferredTaxAssetsLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzktMS0xLTEtMzYzNTk_683f881d-eef7-463c-8bcb-ba5d8498e42a">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:DeferredTaxAssetsLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzktMy0xLTEtMzYzNTk_cf7c2674-bfe0-455f-8c0b-cbde6b870330">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTEtMS0xLTYxOTc1_2ce35441-19dd-48ea-aa81-b5b3430a6193">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTMtMS0xLTYxOTc1_6a3e22d7-a3d4-4268-a598-8323f6da96ab">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzExLTEtMS0xLTM2MzU5_a32e4498-d8a7-437c-8e98-71afd522ec78">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzExLTMtMS0xLTM2MzU5_f663f98e-2f92-459b-a327-f1d2593dd85d">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEyLTEtMS0xLTM2MzU5_d9af5aaf-b649-4e7c-a2ae-37d14603d8d9">131.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEyLTMtMS0xLTM2MzU5_6373977b-8f32-4d07-a206-0d04c8cfc59f">145.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTEtMS0xLTM2MzU5_3b27ae57-d1c5-442f-855c-277649a2cfc4">38.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTMtMS0xLTM2MzU5_f978312f-7ead-4634-b584-74f6e7d47780">42.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE0LTEtMS0xLTM2MzU5_e05f1ef7-9bcd-425c-b05f-fa5f16ddf843">92.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE0LTMtMS0xLTM2MzU5_5ba667b3-2e98-4a50-bf78-e8fd6937ec79">103.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE2LTEtMS0xLTM2MzU5_052796d7-7d87-4dac-8bf2-d44c45685265">104.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE2LTMtMS0xLTM2MzU5_4498d0cc-255a-4ea1-9a6c-5165898c0fd3">144.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:DeferredTaxLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE3LTEtMS0xLTM2MzU5_0abf63a7-1876-47ac-956f-f21e2caa32e6">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="mygn:DeferredTaxLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE3LTMtMS0xLTM2MzU5_153a9165-5a98-49fa-ab46-d64542420090">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE4LTEtMS0xLTM2MzU5_8fb6ad31-a361-420b-8469-a128735d35dc">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE4LTMtMS0xLTM2MzU5_0159db30-431c-4907-a19d-bb50c46ddf26">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIwLTEtMS0xLTM2MzU5_cb4b830d-04f8-482d-b1fe-7e5d6f19ee64">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIwLTMtMS0xLTM2MzU5_fa454328-c069-40eb-9bdd-b385ad2e2900">174.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIxLTEtMS0xLTM2MzU5_390bb0e5-d658-4d1c-b31c-7cee79fab3d6">35.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIxLTMtMS0xLTM2MzU5_2b355db9-5626-440b-b904-f216b849a365">71.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act in 2020 made various tax law changes, including among other things (i) increased the limitation under IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest, (ii) enacted technical corrections so that qualified improvement property can be immediately expensed under IRC Section 168(k) and net operating losses arising in fiscal tax years beginning before January 1, 2018 and ending after December 31, 2017 can be carried back two years and carried forward twenty years without a taxable income limitation as opposed to carried forward indefinitely, and (iii) made modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years. As a result of the provision provided under the CARES Act, the Company was able to carry-back federal net operating losses to previous periods, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA3ODU_b5d9face-ab33-4211-8ec3-81ec2d98712a">20.7</ix:nonFraction>&#160;million tax benefit in the year ended December 31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzE0OTg_ce271f06-2564-488a-9cae-9bcd71f1a906">2.7</ix:nonFraction> million tax expense in the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized the sale of Myriad RBM, Inc., Myriad myPath, LLC, and select assets of Crescendo Biosciences, LLC (formerly known as Crescendo Biosciences, Inc. ("CBI") in the year ended December 31, 2021, which resulted in differences between book and tax treatments. This resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:DisposalGroupCapitalLossOnTaxBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MDA_b4595a69-75ab-4d4e-866d-e0111258eb5c">187.0</ix:nonFraction> million capital loss for the tax basis in the stock of Crescendo, which the Company utilized in the current year due to the $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:DisposalGroupCapitalGainOnDivestiture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MjM_0d61b6f3-7578-44c5-afed-dbea79fd24ef">282.3</ix:nonFraction>&#160;million overall capital gain from the <ix:nonFraction unitRef="divestiture" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="mygn:NumberOfDivestitures" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MzA_0ade7fa8-d4e0-41a2-b076-d7387604e925">three</ix:nonFraction> divestitures. Other consequences due to the dispositions were the removal of deferred tax assets and corresponding valuation allowances. The overall net tax benefit of the divestitures during the year ended December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="mygn:DisposalGroupNetTaxExpenseBenefitOnDivestiture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MDg_1abd1267-7606-4f26-b463-4391e6f29be7">23.4</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the economic impact of COVID-19, the Company has incurred a cumulative three-year loss. Pursuant to ASC Topic 740, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by I.R.C. Section 382 and certain jurisdictional limitations. For the year ended December 31, 2021, the Company's valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" sign="-" name="mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4NTA_3a35e242-5121-4566-be1d-38b1ac6804d3">3.5</ix:nonFraction>&#160;million, primarily due to the expiration of Utah research credits upon which a valuation allowance had been established. The Company will continue to evaluate the impact that the COVID-19 pandemic may have on its results of operations and its ability to realize its deferred tax assets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="ie1604ecd7a24460399268bdc6fb927ff"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTQ_f01091ac-d374-4c45-a22c-ea880067bc11" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to<br/>sections 382, 383</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expires<br/>beginning in year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83383bd4b0654a95842e069decbe0d94_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtMi0xLTEtMzYzNTk_9b655c5c-5fd9-423f-9a44-03b687e5d350">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d865748020e4effaae21a66a663077b_D20210101-20211231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtNC0xLTEtMzYzNTk_f17ba4a9-3392-4c98-bdf6-c36f180424f1">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dfa542a04ef4e41ac83b425d14fdea0_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtNi0xLTEtMzYzNTk_2b60fcdb-e28b-4d13-9a60-e20ca38f9996">2036</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08ceba9140e2414aa168f8323513eb92_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtOC0xLTEtMzYzNTk_ef4c1512-155c-483b-b47e-45299c3ab3eb">2037</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal capital loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb7a3dbd0394b3a98b2fa3967024ce9_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItMi0xLTEtNjIwOTE_981c3bbb-f7c3-4279-a94f-443f07ae0562">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9589f80194a941a98f9394776dc93210_D20210101-20211231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNC0xLTEtNjM1NzY_9382c0fa-6dff-43a4-9d80-1e4e62be6c26">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16e65e9f289e470e8192dacb960d4a43_D20210101-20211231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNi0xLTEtNjM1NzM_fd4b1b2c-7ce5-4b1b-8c84-cc39cd89fa1a">2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea5670d0442144a9827fb94b02527d5d_D20210101-20211231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItOC0xLTEtNjM1NzM_df69d326-fcd5-49dd-8443-49ae3a45d3ca">2026</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief421c0a8d774da3a0d3e029188f8bb1_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItMi0xLTEtMzYzNTk_876f924a-910e-409d-9ac4-c11c16f44a64">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia343da359530413f9f43cba7387074bf_D20210101-20211231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNC0xLTEtMzYzNTk_8fa460f3-5229-4afe-9c36-214f7af3081e">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3acf17d910cc465bb94c96ceb1075337_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNi0xLTEtMzYzNTk_3fd3fb9e-0b1f-41c2-bb08-e49841ee19aa">2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California net operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78965414e66747c19486ba7a6e74f9c2_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtMi0xLTEtMzYzNTk_770c181d-f249-4a49-a686-d4b31f1a3005">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfce3d729fbe4d2982bbceb25a61b887_D20210101-20211231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtNC0xLTEtMzYzNTk_46264fc0-a8e5-4049-a3c6-43b3d56c1500">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i203e33449c4d47478858a4e96feba476_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtNi0xLTEtMzYzNTk_d615e473-7a75-4f73-bed6-31195c765008">2027</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b129110cdcf40da82c792a626cb5140_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtOC0xLTEtMzYzNTk_ae9a564d-fe58-47d5-b64e-fcd4fb9ca993">2042</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other state net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc7f4bae0a24544870e68c5081d1eae_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtMi0xLTEtMzYzNTk_6d4028f8-d2a1-4d09-9e9f-5e3cc0e24397">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice0285b61cc74e72912725920fceec85_D20210101-20211231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtNC0xLTEtMzYzNTk_ea48966d-ae71-43af-a24d-a17cf20930d7">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7de9b7a4b6ea43ce99df84afe005c51f_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtNi0xLTEtMzYzNTk_754bc2d3-62c1-42dd-9cfb-bcfe954edd29">2027</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1dd974f0a354b7e918ff359564e3487_D20210101-20211231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtOC0xLTEtMzYzNTk_4f27b10b-4dd5-4aaf-b1c0-41ed4b4eee8f">2041</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating losses (various jurisdictions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e9618d910a43b3b0cf3e5ca1018738_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzUtMi0xLTEtMzYzNTk_478c8f43-617b-46ae-a2c1-9a1b484e0e94">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9ff73e805544f00a995a79e7beabfd7_D20210101-20211231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzUtNC0xLTEtMzYzNTk_4d6e657a-48af-48fb-b958-5e4f9a0dcce5">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39aada1c97204d7ba76be4c96523dd65_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtMi0xLTEtMzYzNTk_73168e66-b970-461c-81e5-53d825e620b1">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f9d97eb20794fe5ad342b5b3244164a_D20210101-20211231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtNC0xLTEtMzYzNTk_e37621cf-9317-49ea-91e9-206a322e9d26">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6a2fec96267b42df8bdcd32ac76c5bfc_D20210101-20211231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtNi0xLTEtMzYzNTk_455dc317-b7e7-47d9-be6f-0062acc00a47">2027</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13f5587e0ffc403b998eeeaf70866baa_D20210101-20211231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtOC0xLTEtMzYzNTk_a1d6defd-e790-4e5f-9f04-7516ae7e8ac7">2042</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah research credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7bfc4c89d34726b342ff9738bb6c21_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctMi0xLTEtMzYzNTk_e4a8f16c-1391-4092-a68e-ad0292bb686f">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e54383ae03647b4bdc0042c788b7d92_D20210101-20211231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctNC0xLTEtMzYzNTk_56e4b9a2-ccaa-4d12-871d-c98e64188ca9">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie2d1f694a2b246dd97539cfbc90fdaa5_D20210101-20211231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctNi0xLTEtMzYzNTk_9c75bb4d-7d10-49aa-9ec0-9d2edfc62c5b">2022</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4c32f4affc04ac8ad57b0fb12effb75_D20210101-20211231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctOC0xLTEtMzYzNTk_57f42ac7-4ab0-41f2-9c44-53954d407a77">2036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e766bbdac2412db386420a0fd67410_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzgtMi0xLTEtMzYzNTk_b624183e-028a-42c2-bd75-a2539601df3b">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37ac628246aa47a9856eff8943bb53da_D20210101-20211231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzgtNC0xLTEtMzYzNTk_d29f148a-5c93-4e0d-bcb1-c033b8524083">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consistent with the indefinite reversal criteria of ASC 740, the Company intends to continue to invest undistributed earnings of its foreign subsidiaries indefinitely. However, due to the cumulative losses that have been incurred to date in such foreign operations, the changes of the Tax Cuts and Jobs Act and the aforementioned election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company&#8217;s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December&#160;31, 2021, the Company had net unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzEwOTk1MTE2NDAxMDU_9ef2e6b1-4269-4141-a0df-09a9258ffce8">32.1</ix:nonFraction> million. <ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTI_bb95551f-c878-4308-a16e-8f71bd38890b" continuedAt="i3b4b37ea23de4d16a138d2bcd9704ee7" escape="true">The Company&#8217;s gross unrecognized tax benefits as of the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows:&#160;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i3b4b37ea23de4d16a138d2bcd9704ee7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItMS0xLTEtMzYzNTk_ef4e17d2-0f3e-4c3e-a240-8232a35cdc9d">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItMy0xLTEtMzYzNTk_12c1fa82-1495-4be6-bec3-328ee72f748e">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItNS0xLTEtMzYzNTk_9065b8af-082a-4807-af88-192300eb918a">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItNy0xLTEtMzYzNTk_62bec1f2-30e4-42f7-a028-030cd824fdb6">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtMS0xLTEtMzYzNTk_10d0bb87-553b-4b3e-9a2c-d8bd86a5e897">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtMy0xLTEtMzYzNTk_01709b7a-0b16-4e1b-9340-aa5bcbfb06dd">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtNS0xLTEtMzYzNTk_1af24363-43f0-4a1b-ae2f-e44a4e9e3156">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtNy0xLTEtMzYzNTk_3021d4d1-d0a3-4f31-976d-1179c0c832bc">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtMS0xLTEtMzYzNTk_376e9743-d991-438b-9337-4f2c62a24dcd">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtMy0xLTEtMzYzNTk_b8c04d1a-7900-47d3-bf37-2de543590e8b">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtNS0xLTEtMzYzNTk_b6e34c95-c984-4e7a-b165-8a24828078ed">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtNy0xLTEtMzYzNTk_57d1e4d8-3ea9-4cc3-b16e-f67a634e96f1">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtMS0xLTEtMzYzNTk_94043870-54b8-4a93-b10f-94fd098f7272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtMy0xLTEtMzYzNTk_7807c9a3-2325-411e-baa2-4a531f892f96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtNS0xLTEtMzYzNTk_9763b700-1c16-4fca-aa59-3c343bd48eb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtNy0xLTEtMzYzNTk_9a1e0000-f19b-4641-b464-6974db651511">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtMS0xLTEtMzYzNTk_0cbb39f7-c524-4a40-a4a4-ad991ebd3de9">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtMy0xLTEtMzYzNTk_7cdf5f31-17e0-4a22-8800-fa0082d9f530">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtNS0xLTEtMzYzNTk_3901e2fe-2ac4-444b-a2c6-499f547d29a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtNy0xLTEtMzYzNTk_bea296cf-f672-4c37-8ced-9652d6b447c2">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctMS0xLTEtMzYzNTk_8d021d13-f96f-45b0-b0d7-bd73fbe591ff">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctMy0xLTEtMzYzNTk_53d29f40-ad73-4623-af1a-fefa05897618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctNS0xLTEtMzYzNTk_7aa6e305-95ec-4977-9265-daccd759b28a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctNy0xLTEtMzYzNTk_ca58d878-80f9-40e4-b5b8-c35521e9a1a4">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - statute lapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtMS0xLTEtMzYzNTk_fddd48ef-40d9-4980-96a3-3ffcf5e2094d">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtMy0xLTEtMzYzNTk_6863bac0-26d4-4fff-b91a-efef23b65bda">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtNS0xLTEtMzYzNTk_c824d42a-5f8d-4d58-ab60-2b74b0e17542">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtNy0xLTEtMzYzNTk_b7b53756-ebe3-4bba-8bb1-9d23a939473c">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktMS0xLTEtMzYzNTk_9ef2e6b1-4269-4141-a0df-09a9258ffce8">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktMy0xLTEtMzYzNTk_5f625328-cc46-4878-b06e-6f4abc37260e">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktNS0xLTEtMzYzNTk_1ab2a1bf-ee8c-44fb-bece-06d8c134634f">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktNy0xLTEtMzYzNTk_4c7647ba-033c-4d72-860d-c1c341ce206b">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and penalties in year-end balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTEtMS0xLTM2MzU5_d9f18391-2047-4934-a626-234843fdcdb1">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTMtMS0xLTM2MzU5_ac820698-3795-435d-b4a6-8968682425d0">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTUtMS0xLTM2MzU5_e740f515-9e18-4931-9ed3-1beaeb50e4fe">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTctMS0xLTM2MzU5_d6dfd7ab-f363-4f1f-a4a5-2225eff40e42">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions are included as a component of income tax expense and all other interest and penalties are included as a component of other income (expense).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, <ix:nonNumeric contextRef="i75ab306877b54340b9ceca58fc63cf74_D20210101-20211231" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzE2NDkyNjc0NDI1NjA5_6c4462ba-9ebb-489d-ba5b-1ac442124aa1">2017</ix:nonNumeric>-<ix:nonNumeric contextRef="i40459a0ffb804202863c2399057f5faa_D20210101-20211231" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzE2NDkyNjc0NDI1NjE1_60bec8e8-d456-43b3-897f-d8eab5b2316f">2018</ix:nonNumeric>; the State of New Jersey for the years ended June 30, <ix:nonNumeric contextRef="i9ed6f2b7a99e46259c13006a1c7fb525_D20210101-20211231" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYxNzE_2c5c1189-df40-45be-a1f9-83f30da7d676">2013</ix:nonNumeric>-<ix:nonNumeric contextRef="i3720a9cb33664b36ac16fd27520f3445_D20210101-20211231" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYxODI_418ae0fe-8937-4a21-8d3d-38af528ca872">2017</ix:nonNumeric>; and Switzerland for the years ended June 30, <ix:nonNumeric contextRef="ia65ea439046741879c10f71b82d8c8af_D20210101-20211231" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYzNTE_1c125c08-2d52-47f8-8c7b-de9fdf1933b4">2015</ix:nonNumeric>-<ix:nonNumeric contextRef="i1cb51262d87a469e9b16924d435ec74e_D20210101-20211231" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYzNjI_49c2c016-498d-4934-a5b3-68f228863c36">2016</ix:nonNumeric>.&#160;&#160;Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzY3MA_f8c4d0ac-a123-494e-af69-3c21596f3d87" continuedAt="ibb29c33e8034475a90861e8c8042ee83" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ibb29c33e8034475a90861e8c8042ee83" continuedAt="i538e6ab0c78141c58b98fc479f944d24"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonable estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, our wholly-owned subsidiary, CBI, received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.&#160;&#160;On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. We have accrued $<ix:nonFraction unitRef="usd" contextRef="i26a7872b3c3e43d1a1a6e18f0a9a61eb_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzQ5NDc4MDIzMzcyODk_0c1a1c29-3fbc-4dbe-a571-dbf181afd40b">48.0</ix:nonFraction> million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend against this case, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah, against the Company, our former President and Chief Executive Officer, Mark C. Capone, and our Chief Financial Officer, R. Bryan Riggsbee (&#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added our former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. We intend to vigorously defend against this action.&#160;Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against our former President and Chief Executive Officer, Mark C. Capone, our Chief Financial Officer, R. Bryan Riggsbee, our former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of our current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding our business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i538e6ab0c78141c58b98fc479f944d24"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, a third stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock and Marcey stockholder derivative actions. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claimed negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004. The plaintiffs sought damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. As of December 31, 2021, we accrued $<ix:nonFraction unitRef="usd" contextRef="i4b60c3a470b443f8bbf026504b9c59d3_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzE1OTQyOTE4NjIwMjU1_d1adc4ca-1e91-4fe0-b8ea-cef0597eb59f">14.0</ix:nonFraction>&#160;million for a potential settlement of this lawsuit, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet as of December 31, 2021. On January 24, 2022, the Company entered into an agreement with the plaintiffs to settle the lawsuit. Pursuant to the terms of the settlement agreement, the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i971ef08a521a4060839a354e9f1482db_D20220124-20220124" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzE1OTQyOTE4NjIwMjcw_7e243792-0d11-47b2-9e08-636883e90578">14.0</ix:nonFraction>&#160;million to the plaintiffs. The settlement agreement also provides for a full release by the plaintiffs of all claims against the Company and contains no admission of liability, wrongdoing or responsibility on the part of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company&#8217;s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</span></div></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_127"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQxNzM_793474e9-f47c-4c05-9aef-5355dc655bd5" continuedAt="i84ef82efcd5b4d83be7aa4627a1f327b" escape="true">LEASES</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84ef82efcd5b4d83be7aa4627a1f327b" continuedAt="i4b1edef6212b43019018fd615e6f653c">The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4MA_466cec83-963f-4b74-b010-f7a16d9ef195">one</span> to <ix:nonNumeric contextRef="i403644c63d2f42ce9be417d4645c4d3c_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4Ng_45e23a59-1382-4799-86b7-3cf935e1f446">fourteen years</ix:nonNumeric>. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options which allows the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These optional periods have not been considered in the determination of the right-of-use-assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i4b1edef6212b43019018fd615e6f653c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the year ended December 31, 2021, the six-month transition period ended December 31, 2020 and the year ended June 30, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. As part of the adoption, the Company elected the package of practical expedients to avoid reassessing prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing right-of-use assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets. We recognize each new lease within right-of-use assets and lease liabilities once the lease commences.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2021, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQ5NDc4MDIzMjk2ODk_09dae238-f17e-49e5-b39a-59220bf7e67e">20.7</ix:nonFraction> million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQ5NDc4MDIzMjk2OTM_15572b79-a8c5-4219-a6d8-9546b9c227f1">3.2</ix:nonFraction>&#160;million was variable lease expense, which was not included in the measurement of the Company's operating right-of-use assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the transition period ended December 31, 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE2NDkyNjc0NDU5NDA_24a248d2-4ea5-4329-a879-6983b7d655a5">9.9</ix:nonFraction>&#160;million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE2NDkyNjc0NDYxMDQ_12804738-f4cf-44d8-a18a-cbbf91083fe9">1.8</ix:nonFraction> million was variable lease expense and $<ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE2NDkyNjc0NDYxMzk_c694d6d7-34cf-4426-8f71-a6547cefe247">0.1</ix:nonFraction> million was short-term lease expense, neither of which were included in the measurement of the Company's operating right-of-use assets and lease liabilities.  For the year ended June 30, 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzI5Njg_bd347815-5498-483f-8c1b-99c7d3d9f272">18.4</ix:nonFraction> million in lease costs, of which $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzI5OTY_2ffc670f-0374-4838-a8b2-3534b81773f5">2.6</ix:nonFraction>&#160;million was variable lease expense and $<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzMwMzA_3ac97c23-a723-46b3-8d08-e44172c98772">0.2</ix:nonFraction> million was short-term lease expense. Prior to the adoption of the lease guidance in ASU 2016-02, the Company's total rent expense for the year ended June 30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:OperatingLeasesRentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzMxODg_7c01a0db-b0e3-4452-94ef-892960ca96b8">19.7</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into a non-cancelable operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="idb1bf33b7a68483c99cef4bfc39ec4d0_D20211201-20211231" decimals="-3" name="mygn:LesseeOperatingLeaseAreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQ5NDc4MDIzMzA4NzE_96722359-87ec-4d9c-ad1c-a4d32b28e3fc">63,000</ix:nonFraction> square feet in South San Francisco, California, which will expire in 2033. The lease will commence in April 2023.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQxNzQ_7b72c0eb-2ad7-40c7-8ca0-a3d77a405711" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzEtMS0xLTEtMzYzNTk_5048df95-5ce3-40f2-ac34-0a3969553e44">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzItMS0xLTEtMzYzNTk_55893377-5ed1-43ac-9ffa-6f432951c71b">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzMtMS0xLTEtMzYzNTk_774262bf-35ca-485d-a383-b1d57099683b">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzQtMS0xLTEtMzYzNTk_fafaaecd-1444-4a0e-b3ad-d492c80d3e22">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzUtMS0xLTEtMzYzNTk_22afd8c7-b24b-4d42-95ef-c1f6432d5258">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzYtMS0xLTEtMzYzNTk_d595cd72-e8be-4b52-9140-4cbfd60f27fe">88.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzctMS0xLTEtMzYzNTk_13c030dc-8928-4721-bfae-47b661df15cf">179.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzgtMS0xLTEtMzYzNTk_d4b86c12-8307-4a63-86fe-32df4c9d42ad">27.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzktMS0xLTEtMzYzNTk_a50489af-c19b-43e3-a553-ef69b9ad1484">151.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: leases not yet commenced</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="mygn:OperatingLeaseLiabilityLeasesNotYetCommenced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzEwLTEtMS0xLTU0MzA2_65b65649-fc98-4f20-942b-e9cde147dadd">58.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzEwLTEtMS0xLTM2MzU5_b47c292c-1de6-41c6-8f43-53b2e21e8dbd">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzExLTEtMS0xLTM2MzU5_a035e276-150e-4dae-af62-b42895f8958e">79.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted average remaining lease term is <ix:nonNumeric contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzMzNzE_c1ab8cf7-5b7e-41c7-8ca9-ac7f69ea40f4">8.7</ix:nonNumeric> years and the weighted average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzM0NjU_2eb70ee9-1ec7-49cd-9c2f-fea8c51871bf">5.10</ix:nonFraction>%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company&#8217;s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzQ1MA_34d351a9-e2cf-47b0-ba6d-10e4a4d6c3e9" continuedAt="if9a2c67086a24baf8f0b416b1231cd7e" escape="true">EMPLOYEE DEFERRED SAVINGS PLAN</ix:nonNumeric></span></div><ix:continuation id="if9a2c67086a24baf8f0b416b1231cd7e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a deferred savings plan which qualifies under Section&#160;401(k) of the Internal Revenue Code. Substantially all of the Company&#8217;s U.S. employees are covered by the plan. The Company makes matching contributions of <ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzI2Ng_fdc03c0c-b931-4c9b-8423-736109426518">50</ix:nonFraction>% of each employee&#8217;s contribution with the employer&#8217;s contribution not to exceed <ix:nonFraction unitRef="number" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzM0OA_ed1df737-eb53-413a-a25d-aa632348641f">4</ix:nonFraction>% of the employee&#8217;s compensation. </span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzQ1MQ_1c6bff82-b117-4fbc-8c00-d9b3ece6a3d4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s recorded contributions to the plan are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred savings plan contributions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItMS0xLTEtMzYzNTk_d09e557b-25ad-49db-9070-2588ba4c3395">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItMy0xLTEtMzYzNTk_cc351468-a38b-4dad-aa5f-732b156aa321">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItNS0xLTEtMzYzNTk_da38af85-6250-4c51-af3f-6c8fd4fa3017">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItNy0xLTEtMzYzNTk_898b6c87-2ef8-46ea-98eb-d99b7deb6a5e">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_133"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90ZXh0cmVnaW9uOjI4ZTgzMzZmNmJlNTQzNTlhMDNmYzNhOTRmMTZjMTcwXzE1OTA_a6c0d48f-2c4b-42ac-8447-a32ac10be4a0" continuedAt="i3adb9bc67e3f4d729eeaff259cebbf58" escape="true">SEGMENT AND RELATED INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i3adb9bc67e3f4d729eeaff259cebbf58"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company&#8217;s previously reported other segment. The Company&#8217;s remaining operating segments have been aggregated into a single reporting segment, which primarily provides testing and collaborative development of testing that is designed to assess an individual&#8217;s risk for developing disease later in life, identify a patient&#8217;s likelihood of responding to drug therapy and guide a patient&#8217;s dosing to ensure optimal treatment, or assess a patient&#8217;s risk of disease progression, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90ZXh0cmVnaW9uOjI4ZTgzMzZmNmJlNTQzNTlhMDNmYzNhOTRmMTZjMTcwXzE1ODg_db66c862-75e5-43dd-9cfb-6352911efd84" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles assets by geographical region to total assets:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net equipment, leasehold improvements and property:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f6939f15de4b44bc5d205c498f9bb6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzMtMS0xLTEtMzYzNTk_1854d99e-688e-4840-9184-0fa26126f578">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730cf00f21e24233aa2438bc079c00fd_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzMtMy0xLTEtMzYzNTk_8aabf097-d10a-45ad-91d1-b97ecb017f81">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1693400cad7b453cbf24b4b49eaaf843_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzQtMS0xLTEtMzYzNTk_4651f039-df43-4721-b598-1776aeb23a79">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035d000528f94d29bec8473ab8e23f80_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzQtMy0xLTEtMzYzNTk_01984b96-3271-4a7e-b4c9-9c119ac69e78">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ae176a47c5401292f15f20d1f2b493_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzUtMS0xLTEtMzYzNTk_c7ebd73b-658b-4b15-a1df-cd79599bae3f">43.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a3f1dfa4a24709971fbcfbce8f1bdc_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzUtMy0xLTEtMzYzNTk_f0d829c0-d338-4d42-97d7-6db548232d39">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f6939f15de4b44bc5d205c498f9bb6_I20211231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzctMS0xLTEtMzYzNTk_65cc8b79-bb45-4d49-b069-164233203fca">870.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730cf00f21e24233aa2438bc079c00fd_I20201231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzctMy0xLTEtMzYzNTk_7c0925d5-b58d-4ccd-bb42-b5400bbcf9d1">1,190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1693400cad7b453cbf24b4b49eaaf843_I20211231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzgtMS0xLTEtMzYzNTk_d9de6d82-2e4a-48ce-9eef-cc4fd5f4da0d">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035d000528f94d29bec8473ab8e23f80_I20201231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzgtMy0xLTEtMzYzNTk_005ccdb3-cba2-48b6-89e1-06ff65d18682">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ae176a47c5401292f15f20d1f2b493_I20211231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzktMS0xLTEtMzYzNTk_2cc9bf70-662d-4ed8-b920-ef49f766af4f">921.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a3f1dfa4a24709971fbcfbce8f1bdc_I20201231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzktMy0xLTEtMzYzNTk_7bd4c9e5-916f-4e67-946a-8644f3952f68">1,247.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable investment <br/>&#160;&#160;&#160;&#160;&#160;securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzEwLTEtMS0xLTM2MzU5_fa4af01b-2a5b-4518-b500-70c62c40f184">398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzEwLTMtMS0xLTM2MzU5_138dbaaa-421b-4b36-8345-620cdbce651c">171.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzExLTEtMS0xLTM2MzU5_7d662979-327f-4b40-b0ba-fbcc668cd7e5">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzExLTMtMS0xLTM2MzU5_afa0cba1-b921-4c75-956f-be2a099822a3">1,418.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_136"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2Xzc1Ng_c859a7ed-d98d-4c75-9854-e38de36d8e4c" continuedAt="i7dfad29e52054cecb7e3058760f99172" escape="true">DIVESTITURES</ix:nonNumeric></span></div><ix:continuation id="i7dfad29e52054cecb7e3058760f99172" continuedAt="i4c4d21cfcb2e4d2a84526747082b252a"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTQ1_bc6bc574-6779-48e1-8e33-bd7e92b787fc">32.5</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528" decimals="-5" name="mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTYw_d0063b0a-5496-4a61-8c22-d2628ff09401">31.2</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTc1_468cc1fc-ebce-4774-82cc-1877502246de">1.3</ix:nonFraction>&#160;million, in Other income (expense) on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTg5_f4674677-84ca-4d8f-b227-9eab12887f45">197.0</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjE5_5eeef1ba-3ece-4ca3-a407-f67292e15719">121.0</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjA1_cadb5713-7ffe-4778-b8aa-4595921a30ff">4.8</ix:nonFraction>&#160;million, in Other income (expense) on the Company's Consolidated Statements of Operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><ix:continuation id="i4c4d21cfcb2e4d2a84526747082b252a"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjQ5_0923ab0a-49be-4a6f-bb83-aeea0c9337e7">150.0</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjY1_359302f7-9a1b-4065-937b-ea2ee77399a2">0.6</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjM1_9a6f5d6c-0e95-4b54-9650-77bdeaff1bd1">4.4</ix:nonFraction>&#160;million, in Other income (expense) on the Company's Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4Mjc5_409b323c-97d6-4f2f-91b3-ec44955b29c8">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4Mjkz_ec8e14b2-146f-43a5-a87d-07820c8fbd4c">6.5</ix:nonFraction>&#160;million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Company's Consolidated Statements of Operations for the year ended December, 2021.</span></div><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4OTEx_c9a347bf-a85e-46a4-9b05-f6c82df8170a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income for the year ended December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Myriad RBM, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860c89a3309f4862aa45108d2d164008_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzEtMS0xLTEtNDY0Mzc_a1f5a3d4-2d23-4897-b5a6-6552fe7ef336">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of the Myriad myPath, LLC laboratory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4881a7b97e68483588b542d1107dfc7d_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzItMS0xLTEtNDcxNjA_9ec1fc48-d79c-43ac-a463-38a2e391109c">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzMtMS0xLTEtNDcxNjg_2cccd134-5ff5-4d83-b9a6-a34b7610e7e0">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie93081e2cf534cd9ae7518a1f0407820_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzQtMS0xLTEtNDcxNzY_34953059-4422-4928-a37d-0b03354b705f">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzUtMS0xLTEtNDcyMDk_3efae997-0620-4af0-8812-f0eebf05d3d2">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Income</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzYtMS0xLTEtNTgyODc_cc723901-f11f-4256-86b9-9f3e9ac0d477">139.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_139"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU2OTU_470fc2b9-bd35-42df-b283-eeab1bc31539" continuedAt="i429dd687633441079770405f72ad159c" escape="true">BUSINESS ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="i429dd687633441079770405f72ad159c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counsyl</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2018, the Company completed the acquisition of Counsyl, Inc. (&#8220;Counsyl&#8221;), a leading provider of genetic testing and DNA analysis services, pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated May 25, 2018 for total consideration of $<ix:nonFraction unitRef="usd" contextRef="icd8184e7f9d64fdfa830a7580e392ea8_D20180731-20180731" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzEwOTk1MTE2NDA0NDc_d2b21b89-7cf3-4be2-ace6-a1e4c2a8179b">405.9</ix:nonFraction> million.&#160;&#160;Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a newly created wholly-owned subsidiary of the Company, was merged with and into Counsyl, with Counsyl continuing as the surviving corporation and a wholly-owned subsidiary of Myriad.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complete the purchase transaction, the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i6757f736730d439fb934901528230b15_I20180731" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU0MDQ_64b7de8f-c047-4c54-bb4b-40e6934529b4">6.8</ix:nonFraction> million of acquisition costs, which are recorded as selling, general and administrative expenses in the period incurred. For the year ended June 30, 2019, Counsyl contributed revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="iff236b6484f74a869a405f4676bd6810_D20180701-20190630" decimals="-5" name="us-gaap:BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU1OTg_209aedf0-59ee-481c-954c-fa7f5d1c5da7">104.9</ix:nonFraction> million.&#160;For the year ended June 30, 2019, operating expenses related to Counsyl were approximately $<ix:nonFraction unitRef="usd" contextRef="iff236b6484f74a869a405f4676bd6810_D20180701-20190630" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU2OTI_5d315284-371a-4732-be2d-1568e4918068">67.6</ix:nonFraction> million.</span></div></ix:continuation><div id="ifead9d28cda549c1af769d1d50d95807_142"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzEzMzE_92605bfe-a13d-4d4c-b994-490fbb363e77" continuedAt="i4222788b870a486dbd1ef782fab959ce" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4222788b870a486dbd1ef782fab959ce">In the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="ia83408ec29ac462bb67762046411429e_D20220101-20220224" decimals="-3" name="mygn:LesseeOperatingLeaseAreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzE1OTQyOTE4NjA3MDc0_4bca6936-2152-4822-871e-f9ffd6cc4a33">230,000</ix:nonFraction> square feet in Salt Lake City, Utah, which will commence in 2022, with a lease term of <ix:nonNumeric contextRef="i27de6b0d5d5e480a85e618df1ee1b0e1_I20220224" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzE1OTQyOTE4NjA3MDkx_a03a725c-2cbb-442f-9646-2f0addc10e41">15</ix:nonNumeric> years and total future lease payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i27de6b0d5d5e480a85e618df1ee1b0e1_I20220224" decimals="-5" name="mygn:LesseeOperatingLeaseEstimatedFutureLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzEwOTk1MTE2MzIwODc_bf4bb85d-7d71-4d6b-8122-9e23918e8b08">77.8</ix:nonFraction>&#160;million.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90ZXh0cmVnaW9uOmNhNWZkNTgwNzQ0YTRkNmRhMGE5OThmYjViYjg1ZGEyXzQ0_bdf477fa-e194-4a9f-b432-c6a14d3040f5" continuedAt="i46f0d2d2dcb644b7b19035b7afee9cc8" escape="true">SUPPLEMENTAL CASH FLOW INFORMATION</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i46f0d2d2dcb644b7b19035b7afee9cc8"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90ZXh0cmVnaW9uOmNhNWZkNTgwNzQ0YTRkNmRhMGE5OThmYjViYjg1ZGEyXzQ1_fc4aa149-9350-4f3e-b914-3a741593e02b" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItMS0xLTEtMzYzNTk_053ae036-2623-4f52-9f58-1d2fcd527a81">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItMy0xLTEtMzYzNTk_5201fb41-9e84-4133-91a9-94efef234615">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItNS0xLTEtMzYzNTk_e3cfd51c-3870-4fe8-aee5-c843fb9d6b5d">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItNy0xLTEtMzYzNTk_1031e268-6a60-4f8c-8f6e-010cffee0bde">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtMS0xLTEtMzYzNTk_44deedb9-4623-45b5-bdce-ea96b4c35e24">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtMy0xLTEtMzYzNTk_9613e0c7-f95b-4417-8d5e-c1192d74ef75">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtNS0xLTEtMzYzNTk_fa2a5200-a140-4227-9676-325bd9027026">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtNy0xLTEtMzYzNTk_0f1dd983-e1da-466b-aa71-360e680fd5ee">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtMS0xLTEtNjIzNDY_6ddcfa1f-ab86-4a34-9db6-090367668c68">90.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtMy0xLTEtNjIzNTM_069570db-8c85-42af-b018-29a25eb36712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtNS0xLTEtNjIzNjA_f42267b7-a7d2-43c5-a69e-55fa73813222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtNy0xLTEtNjIzNjA_867b7f3a-fd5a-4cc2-9680-dca23a5e1444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctMS0xLTEtMzYzNTk_553d0553-2dd5-4778-99b2-ce0aa1fcdaf4">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctMy0xLTEtMzYzNTk_2ffe1802-9b8f-4b93-9649-6458cfe3ccb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctNS0xLTEtMzYzNTk_d8dc4b97-7a19-455d-ad61-0b141782801a">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctNy0xLTEtMzYzNTk_e79e90b2-ed9e-41d6-851f-a74e3e65428f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtMS0xLTEtMzYzNTk_95c95dd3-c279-4fda-b586-590c3410d912">48.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtMy0xLTEtMzYzNTk_82566b1c-5b20-4b44-932a-ec918fe58ef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtNS0xLTEtMzYzNTk_5ad6553e-171d-47c4-935f-99175c3da9af">78.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtNy0xLTEtMzYzNTk_279598de-6704-408c-b661-1714c11ee8c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktMS0xLTEtMzYzNTk_fdf8b22f-0e2e-4cf4-bd69-a81e78d36091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktMy0xLTEtMzYzNTk_c0230717-1705-41fd-b63a-2dc1c4c9bb9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktNS0xLTEtMzYzNTk_2e74f98a-38b2-438d-8ce1-a6b53e47ba2b">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktNy0xLTEtMzYzNTk_471a628d-1989-4df6-8caa-5f98c57c5f5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="ifead9d28cda549c1af769d1d50d95807_151"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="mygn:TransitionPeriodComparativeDataTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90ZXh0cmVnaW9uOmZhYzU3MWNmMTc5ZjQwMTFiZjE1YTQzY2U5MjdiMjhlXzU4_6bb74d23-86bb-4278-9e74-77ccd1df8e4d" continuedAt="ie609e61a4fdc489a8ad701956cf2539b" escape="true">TRANSITION PERIOD COMPARATIVE DATA (UNAUDITED)</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="ie609e61a4fdc489a8ad701956cf2539b"><ix:nonNumeric contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231" name="mygn:ScheduleOfTransitionPeriodComparativeDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90ZXh0cmVnaW9uOmZhYzU3MWNmMTc5ZjQwMTFiZjE1YTQzY2U5MjdiMjhlXzU5_3e870bd2-0252-46c0-927d-277ae4217862" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month <br/>Period Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statement of Operations Data:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaeba814f5004cb58a2f97d102345f21_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzItMS0xLTEtMzYzNTk_0f23be1f-ff0a-4ee2-a5ff-f69c6f79341a">513.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9293cf2bcc0f4d2a920e6ccd2d4f11d1_D20190701-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzItMy0xLTEtNTA5OTc_9681d126-cccb-4a3a-8180-01b776f91700">353.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5947d8d1f246f8b9440687d0122811_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzMtMS0xLTEtMzYzNTk_e4902c0b-7b07-40b2-942f-adbb6aa8ec15">43.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123f7f47f2d641448a50320ff8fc12b3_D20190701-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzMtMy0xLTEtNTA5OTc_dc2d2a8b-840b-409d-9bb6-e766d720c76d">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzQtMS0xLTEtMzYzNTk_6b0b11c7-f8c3-4a8d-8b9b-3f79e68a0134">557.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzQtMy0xLTEtNTA5OTc_34712255-bd7a-4939-9bf9-12753efd9976">381.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaeba814f5004cb58a2f97d102345f21_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzYtMS0xLTEtMzYzNTk_84bf579f-70f2-4b26-90f5-9cba61400e38">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9293cf2bcc0f4d2a920e6ccd2d4f11d1_D20190701-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzYtMy0xLTEtNTEwNDk_2e35418a-2ed8-43ce-8b25-218abca5578c">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5947d8d1f246f8b9440687d0122811_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzctMS0xLTEtMzYzNTk_efc1d7c1-c0af-4e01-bc78-5d398d2d3475">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123f7f47f2d641448a50320ff8fc12b3_D20190701-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzctMy0xLTEtNTEwNDk_004eb122-d285-4708-abce-1d82f92bb259">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzgtMS0xLTEtMzYzNTk_0633e80e-241d-4326-8309-e1bf5e6f0284">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzgtMy0xLTEtNTEwNDk_d4b91036-9c82-4ea7-aef2-81d7af233be1">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEwLTEtMS0xLTM2MzU5_3e08d7a0-fe75-434b-88f4-03beb38c5f6b">496.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEwLTMtMS0xLTUxMDQ5_fdc4f91c-d951-4401-b7df-99c1898885b6">270.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzExLTEtMS0xLTM2MzU5_f0415e93-9e1d-4708-9e23-550e7e0dca35">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzExLTMtMS0xLTUxMDQ5_9e5fc80c-c573-408b-9fbc-5307e8353b3c">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEyLTEtMS0xLTM2MzU5_3d9a16c7-bd46-4039-b89a-0c525d4795a3">846.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEyLTMtMS0xLTUxMDQ5_83b513f8-cb7e-4525-9160-1b5b8166db2b">411.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEzLTEtMS0xLTM2MzU5_b4ac5c35-94ac-469b-acd6-d30b6e9cbfd2">289.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEzLTMtMS0xLTUxMDY2_0422a404-276f-4949-8503-bb22a215d85f">29.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE1LTEtMS0xLTM2MzU5_7ef59473-0c9c-4053-b623-ada5e1d42ba6">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE1LTMtMS0xLTUxMDU1_8a30e213-c21d-4b1d-aa6a-bc73c90e120d">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE2LTEtMS0xLTM2MzU5_b87f9e73-f4aa-4e6d-8e16-79fd5c543525">11.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE2LTMtMS0xLTUxMDY2_cc98d626-7ad9-4055-9a2e-f15ea2db922f">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE3LTEtMS0xLTM2MzU5_61476f12-801c-4f9f-87a0-2ec2b1a4d7ce">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE3LTMtMS0xLTUxMDU1_debbd126-ecab-4341-9717-6f19187a02b8">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE4LTEtMS0xLTM2MzU5_761666ec-6ab2-4ee1-806c-93c78077a138">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE4LTMtMS0xLTUxMDU1_ba93d5e4-dfa0-4738-8992-58eedcbc1ef8">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE5LTEtMS0xLTM2MzU5_d494ad72-fcf2-4662-99bb-2e3aea70be3e">283.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE5LTMtMS0xLTUxMDU1_38bcc6a8-6381-44e8-983e-ac513f7006a1">33.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIwLTEtMS0xLTM2MzU5_6e2dd308-e37a-4634-980e-e244b4bb298b">59.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIwLTMtMS0xLTUxMDU1_85fc47b9-4332-49e5-94a5-af6c42bd8b57">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIxLTEtMS0xLTM2MzU5_3b687dea-ea92-4a2c-9241-f4b3fa9ca6f2">223.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIxLTMtMS0xLTUxMDU1_85563737-1cb3-4e45-b1a1-65c6fe9f5858">28.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIyLTEtMS0xLTM2MzU5_0dcf3dc1-c2c5-4ebe-8e63-16e357f1185a">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIyLTMtMS0xLTUxMDU1_48a27ebc-6a48-40ca-a3e3-70d5898bd009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Myriad Genetics Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIzLTEtMS0xLTM2MzU5_cb909125-6b1c-48f6-a6c7-6280c1e5af7e">223.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIzLTMtMS0xLTUxMDU1_b0fb9642-8d80-43f1-b2c5-61eb9e396d93">28.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI1LTEtMS0xLTM2MzU5_edbedfec-ee54-42ec-9504-d0cd1f19ba3b">2.99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI1LTMtMS0xLTUxMDU1_6066e2be-ac24-49ba-99df-690a8de79ebd">0.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI2LTEtMS0xLTM2MzU5_e893e66c-0632-48a7-bb06-bd9ae0d5885f">2.99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI2LTMtMS0xLTUxMDgz_49e6d00b-9a96-470c-a5eb-2eacd2408722">0.39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI4LTEtMS0xLTM2MzU5_1cd3709a-f660-4df9-9639-31bbdb2dea29">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI4LTMtMS0xLTUxMDgz_28680fad-acc9-4e4b-9ab0-14e1b67ca740">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI5LTEtMS0xLTM2MzU5_f6976e21-d2fc-4cdd-921b-2cd9c032e616">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI5LTMtMS0xLTUxMDgz_62e13b07-afb1-439a-8dc5-36606c66f131">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_157"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures ("Disclosure Controls") within the meaning of Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Annual Report on Form 10-K, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December&#160;31, 2021, our Disclosure Controls were not effective due to material weaknesses in the Company's internal control over financial reporting as disclosed below.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a&#8209;15(f) and 15d&#8209;15(f) under the Exchange Act. Our internal control over financial reporting is designed to p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rovide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the preparation of the condensed consolidated quarterly financial statements as of September 30, 2021, management concluded that a material weakness in internal control over financial reporting existed related to our income tax provision process. Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the income tax provision and related accrual. While the control deficiency did not result in a misstatement of previously issued consolidated financial statements, the control deficiency could have resulted in a misstatement of the income tax related accounts or disclosures that would have resulted in a material misstatement of our consolidated financial statements that would not have been prevented or detected on a timely basis. This material weakness has not been remediated as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management also concluded that a material weakness in internal control over financial reporting exists related to general information technology controls for information systems that are relevant to the preparation of the financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, the material weakness resulted from the aggregation of control deficiencies related to systems supporting the Company's internal control processes. Our IT-dependent business process controls were also deemed ineffective because they could have been adversely impacted. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the aggregation of these deficiencies did not result in any misstatement of the consolidated financial statements, the material weakness could have resulted in a misstatement impacting account balances or disclosures that would have resulted in a material misstatement to the consolidated financial statements that would not have been prevented or detected on a timely basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021 using the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on that evaluation, management believes that our internal control over financial reporting was not effective as of December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over fina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncial reporting as of December&#160;31, 2021, has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report included elsewhere herein.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Plan to Remediate Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is committed to the remediation of the material weaknesses described above, as well as the continued improvement of our internal control over financial reporting. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have begun the process of, and we are focused on, designing and implementing effective internal control measures to improve our internal control over financial reporting and remediate the material weaknesses identified above. Our efforts include the following actions:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discrete Tax Transactions</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are continuing to take steps to design and implement enhanced controls over the review of information underlying discrete transactions in the income tax provision. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information Technology General Controls ("ITGCs")</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are implementing additional training to ensure a clear understanding of risk assessment, controls and monitoring activities related to automated processes and systems and ITGCs related to financial reporting. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are implementing improved IT policies, procedures and control activities for key systems which impact our financial reporting. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are increasing resources dedicated to monitoring ITGCs related to financial reporting, including additional personnel with the appropriate level of knowledge, experience and training, to ensure compliance with policies and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these actions and planned actions are subject to ongoing management evaluation and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles, we are committed to the continuous improvement of our internal control over financial reporting and will continue to diligently review our internal control over financial reporting for that purpose.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Remediation of Previously Reported Material Weakness</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The material weakness identified in our internal control over financial reporting in connection with the preparation of our Consolidated Financial Statements as of and for the transition period ended December 31, 2020 (the "prior material weakness") has been remediated. The prior material weakness identified related to the accounting for intercompany transactions, foreign currency exchanges and foreign currency translation related to our international subsidiaries. Specifically, as part of our financial statement close process, certain of our control activities were not sufficiently designed or operating effectively to ensure all of our policies were in compliance with generally accepted accounting principles, consistent in their application, retained in appropriate documentation and communicated to relevant parties. As a result of the prior material weakness, we recorded certain immaterial corrections to intercompany accounts, as well as foreign currency exchange and translation gains and losses, in our Consolidated Financial Statements for the transition period ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We implemented control measures to improve our internal control over financial reporting and remediated the prior material weakness. We took the following actions to remediate the prior material weakness:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We designed additional control and review procedures needed to provide more robust and comprehensive internal controls over financial reporting that address the risks of material misstatement related to the accounting for intercompany transactions, foreign currency exchanges and foreign currency translation within our business processes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We implemented additional application controls in our financial systems, implemented formal review procedures, and formally documented our newly designed processes for the identified areas.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We subjected the additional controls implemented to testing and concluded that the controls are operating effectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. &#160;&#160;&#160;&#160;Change in Internal Control over Financial </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has completed a multi-year transformation project to achieve better analytics and process efficiencies and other systematic and control improvements through the use of Oracle Fusion Cloud Services System. As of October 1, 2021, Oracle Cloud is now our primary accounting system. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than as described above, there were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Myriad Genetics, Inc.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Myriad Genetics, Inc. and subsidiaries&#8217; internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).  In our opinion, because of the effect of the material weaknesses described below on the achievement of the objectives of the control criteria, Myriad Genetics, Inc. and subsidiaries (the Company) has not maintained effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in management&#8217;s assessment. Management identified material weaknesses in controls over income taxes and information technology general controls.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Myriad Genetics, Inc. and subsidiaries as of December&#160;31, 2021 and 2020, and the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for the year ended December 31, 2021, the six month period ended December&#160;31, 2020, and each of the two years in the period ended June 30, 2020, and the related notes. These material weaknesses were considered in determining the nature, timing and extent of audit tests applied in our audit of the 2021 consolidated financial statements, and this report does not affect our report dated February&#160;25, 2022, which expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salt Lake City, UT</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</span></div><div id="ifead9d28cda549c1af769d1d50d95807_160"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_1559"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ifead9d28cda549c1af769d1d50d95807_166"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Management and Corporate Governance,&#8221; "Delinquent Section 16(a) Reports" and &#8220;Corporate Code of Conduct&#8221; in our Proxy Statement for the 2022 Annual Meeting of Stockholders to be held on June 2, 2022.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_169"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Executive Compensation,&#8221; &#8220;Management and Corporate Governance &#8211; Committees of the Board of Directors and Meetings &#8211; Compensation and Human Capital Committee Interlocks and Insider Participation,&#8221; &#8220;Compensation Committee Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;Management and Corporate Governance &#8211; Board&#8217;s Role in the Oversight of Risk Management&#8221; in our Proxy Statement for the 2022 Annual Meeting of Stockholders to be held on June 2, 2022.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_172"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive Compensation - Equity Compensation Plan Information&#8221; in our Proxy Statement for the 2022 Annual Meeting of Stockholders to be held on June 2, 2022.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_175"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Management and Corporate Governance &#8211; Director Independence&#8221; in our Proxy Statement for the 2022 Annual Meeting of Stockholders to be held </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on June 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022.</span></div><div id="ifead9d28cda549c1af769d1d50d95807_178"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto in the proposal entitled &#8220;Selection of Independent Registered Public Accounting Firm&#8221; in our Proxy Statement for the 2022 Annual Meeting of the Stockholders to be held on June 2, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ifead9d28cda549c1af769d1d50d95807_184"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Index to Consolidated Financial Statements&#8221; at Item 8 to this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules have not been included because they are not applicable, or the information is included in financial statements or notes thereto.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312511223211/dex31.htm">Restated Certificate of Incorporation, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312520269801/d102302dex31.htm">Restated By-Laws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">Specimen common stock certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 4.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992321000021/mygn-20201231xexx42.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-KT (Exhibit 4.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Agreements</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/0000927016-96-001627.txt">Lease Agreement, dated October 12, 1995, between the Registrant and Boyer Research Park Associates V, by its general partner, the Boyer Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/1996</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312516576683/d173578dex101.htm">Amendment to Phase I Lease Agreement, dated February 3, 2016, between the Registrant and HCPI/UTAH II, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/0000927356-98-001556.txt">Lease Agreement-Research Park Building Phase II, dated March 6, 1998, between the Registrant and Research Park Associated VI, by its general partner, the Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.44)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/24/1998</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312516576683/d173578dex102.htm">Amendment to Phase II Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000092735601500159/dex101.txt">Lease Agreement, dated March 31, 2001, between the Registrant and Boyer Research Park Associates VI, by its general partner, The Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/15/2001</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312516576683/d173578dex103.htm">Amendment to Phase III Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312508186392/dex1032.htm">Lease Agreement, dated March 11, 2008, between the Registrant and Boyer Research Park Associates IX, by its general partner, The Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/28/2008</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312510107257/dex104.htm">Amendment to Lease Agreement, dated February 12, 2010 between the Registrant and Boyer Research Park Associates IX, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000156459019031849/mygn-ex106_159.htm">Lease Agreement, dated January 31, 2019 between the Registrant and Boyer Research Park Associates X, L.C., by its Manager, The Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K (Exhibit 10.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreements with Executive Officers and Directors</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992321000021/mygn-20201231xexx108.htm">Non-Employee Director Compensation Policy+</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-KT (Exhibit 10.8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312509181226/dex1034.htm">Form of director and executive officer indemnification agreement+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.34)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/25/2009</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312520269801/d102302dex101.htm">Form of Severance and Change in Control Agreement+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K   (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit101-diazemploym.htm">Executive Employment Agreement between the Registrant and Paul J. Diaz dated July 24, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit102-diazpsuagre.htm">Performance-Based Restricted Stock Unit Agreement between Registrant and Paul J. Diaz dated October 8, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit103-diazrsuagre.htm">Restricted Stock Unit Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit104-diazperform.htm">Performance-Based Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit105-diaztimexba.htm">Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit106-diazformofs.htm">Form of Separation and Release Agreement between the Registrant and Paul J. Diaz+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000014/separationandconsultingagr.htm">Separation and Consulting Agreement, dated February 7, 2022, by and between Myriad Genetics, Inc. and Jerry Lanchbury</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Compensation Plans</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312516783506/d308192dex101.htm">2010 Employee, Director and Consultant Equity Incentive Plan, as amended+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/2/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312511019910/dex103.htm">Form of Stock Option Agreement under the 2010 Equity Incentive Plan+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312511019910/dex104.htm">Form of Director Stock Option Agreement under the 2010 Equity Incentive Plan+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992320000006/exhibit1012017employee.htm">2017 Employee, Director and Consultant Equity Incentive Plan, as amended+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/7/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000156459020040011/mygn-ex1011_355.htm">Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan+</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992321000090/exhibit101-amendedandresta.htm">Amended and Restated 2012 Employee Stock Purchase Plan+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/4/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000156459017024444/mygn-ex102_44.htm">2013 Executive Incentive Plan, as amended+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Agreement</span></td></tr><tr style="height:6pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992321000007/mygn-x1231earningsreleasex.htm">Amendment No. 3, dated February 22, 2021, to the Credit Agreement, dated December 23, 2016, among the Company, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, as amended July 31, 2018 and May 1, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/23/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger Agreements</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312516756511/d253869dex101.htm">Agreement and Plan of Merger among the Registrant, Myriad Merger Sub, Inc., Assurex Health, Inc. and Fortis Advisors LLC, dated as of August 3, 2016</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/2/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000156459018022312/mygn-ex1018_113.htm">Agreement and Plan of Merger among the Registrant, Cinnamon Merger Sub, Inc., a wholly owned subsidiary of Myriad, Inc., Counsyl, Inc, and Fortis Advisors, dated as of May 25, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K (Exhibit 10.18)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/24/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td></tr><tr style="height:6pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20211231ex211.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20211231xexx231.htm">Consent of Independent Registered Public Accounting Firm (Ernst &amp; Young LLP)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included in the signature page hereto)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20211231xexx311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20211231xexx312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20211231xexx32.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Myriad Genetics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii)&#160;Consolidated Statements of Comprehensive Income, (iii) Consolidated Statements of Stockholders&#8217; Equity, (iv)&#160;Consolidated Statements of Cash Flows, and (v)&#160;Notes to Consolidated Financial Statements. Inline XBRL Instance Document &#8211; Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+)&#160;&#160;&#160;&#160;Management contract or compensatory plan arrangement.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ifead9d28cda549c1af769d1d50d95807_187"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="ifead9d28cda549c1af769d1d50d95807_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February&#160;25, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MYRIAD GENETICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul J. Diaz and R. Bryan Riggsbee and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7"> of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifead9d28cda549c1af769d1d50d95807_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ R. Bryan Riggsbee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R. Bryan Riggsbee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ S. Louise Phanstiel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">S. Louise Phanstiel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Heiner Dreismann</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Heiner Dreismann, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rashmi Kumar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rashmi Kumar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dennis Langer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dennis Langer, M.D., J.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lee N. Newcomer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lee N. Newcomer, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Colleen F. Reitan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Colleen F. Reitan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel M. Skovronsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel M. Skovronsky, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel K. Spiegelman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel K. Spiegelman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>mygn-20211231ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idb3befbed5124cc8ad52c6948b8206de_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.987%"><tr><td style="width:1.0%"></td><td style="width:25.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Company Name</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Jurisdiction of Incorporation</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetic Laboratories, Inc.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Assurex Health, Inc.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Crescendo Bioscience, LLC</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Women&#8217;s Health, Inc</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad GmbH</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Services GmbH</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics Espana SL</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Spain</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics SAS</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">France</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics S.r.l.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Italy</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics GmbH </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Switzerland</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics LTD</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">United Kingdom</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics Canada Corp</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Canada</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics B.V.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Netherlands</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics Australia PTY LTD</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Australia</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad International GmbH</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Assurex Health, Ltd</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Canada</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics GK</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Japan</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1 &#8211; A wholly-owned subsidiary of Myriad Genetics, Inc., a Delaware corporation.  </font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2 &#8211; Crescendo Bioscience, LLC is owned by Myriad Genetics, Inc. and Myriad Genetics GK.</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3 &#8211; A wholly-owned subsidiary of Myriad Genetics B.V.</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4 &#8211; A wholly-owned subsidiary of Myriad Services GmbH </font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5 &#8211; A majority owned subsidiary of Assurex Health, Inc.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>mygn-20211231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i75d496475ef84e31a9440d250d950fb4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">We consent to the incorporation by reference in the following Registration Statements of Myriad Genetics, Inc.&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statement on Form S-8 (File No. 333-245718) pertaining to the Myriad Genetics, Inc. Non-Qualified Stock Option Agreement, Performance-Based Non-Qualified Stock Option Agreement, Restricted Stock Unit Agreement, and Performance-Based Restricted Stock Unit Agreement </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">Registration Statement on Form S-8 (File No. 333-222913, File No. 333-229574, File No. 333-236324, File No. 333-254337) pertaining to the Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended,</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statement on Form S-8 (File No. 333-185325) pertaining to the Myriad Genetics, Inc. 2012 Employee Stock Purchase Plan,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statements on Form S-8 (File No.&#8217;s 333-171994, 333-179281, 333-185325, 333-193767, 333-209354 and 333-215959) pertaining to the Myriad Genetics, Inc. 2010 Employee, Director and Consultant Equity Incentive Plan, as amended, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statements on Form S-8 (File No.&#8217;s 333-115409, 333-120398, 333-131653, 333-140830, 333-150792, 333-157130 and 333-164670) pertaining to the Myriad Genetics, Inc. 2003 Employee, Director and Consultant Stock Option Plan, as amended&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">of our reports dated February 25, 2022 with respect to the consolidated financial statements of Myriad Genetics, Inc. and the effectiveness of internal control over financial reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">of Myriad Genetics, Inc. included in this Annual Report (Form 10-K) of Myriad Genetics, Inc. for the year ended December 31, 2021. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Salt Lake City, UT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">February 25, 2022</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mygn-20211231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i90de63bc24da4e7e973aafa02ae8b0ab_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302 CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Diaz, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 25, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mygn-20211231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8c6436dcbc564a7fa8146dbcaa6f9da9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302 CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Bryan Riggsbee, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 25, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>mygn-20211231xexx32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib37d766b69254193a4241df51f54c386_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 25, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 25, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Bryan Riggsbee</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mygn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4990a358-c12e-4899-92d4-a6c626b561e2,g:4a66b582-ad59-47ea-a8a2-59085acc693c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mygn="http://www.myriad.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.myriad.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.myriad.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.myriad.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails">
        <link:definition>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails">
        <link:definition>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails">
        <link:definition>2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails">
        <link:definition>2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails">
        <link:definition>2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecurities" roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities">
        <link:definition>2110102 - Disclosure - Marketable Investment Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesTables" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables">
        <link:definition>2311302 - Disclosure - Marketable Investment Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
        <link:definition>2412407 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
        <link:definition>2413408 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesNarrativeDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails">
        <link:definition>2414409 - Disclosure - Marketable Investment Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.myriad.com/role/FairValueMeasurements">
        <link:definition>2115103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.myriad.com/role/FairValueMeasurementsTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2417410 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>2418411 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails">
        <link:definition>2419412 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet">
        <link:definition>2120104 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>2321304 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetBalancesDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails">
        <link:definition>2422413 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetNarrativeDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails">
        <link:definition>2423414 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetDepreciationExpenseDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails">
        <link:definition>2424415 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets">
        <link:definition>2125105 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2326305 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
        <link:definition>2427416 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2428417 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>2429418 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1">
        <link:definition>2429418 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails">
        <link:definition>2430419 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>2431420 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.myriad.com/role/AccruedLiabilities">
        <link:definition>2132106 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables">
        <link:definition>2333306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails">
        <link:definition>2434421 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.myriad.com/role/LongTermDebt">
        <link:definition>2135107 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.myriad.com/role/LongTermDebtDetails">
        <link:definition>2436422 - Disclosure - Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilities" roleURI="http://www.myriad.com/role/OtherLongTermLiabilities">
        <link:definition>2137108 - Disclosure - Other Long-Term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesTables" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables">
        <link:definition>2338307 - Disclosure - Other Long-Term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesDetails" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails">
        <link:definition>2439423 - Disclosure - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquity" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity">
        <link:definition>2140109 - Disclosure - Preferred and Common Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityTables" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables">
        <link:definition>2341308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityNarrativeDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails">
        <link:definition>2442424 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails">
        <link:definition>2443425 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityStockRepurchasesDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails">
        <link:definition>2444426 - Disclosure - Preferred and Common Stockholders' Equity - Stock Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.myriad.com/role/StockBasedCompensation">
        <link:definition>2145110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.myriad.com/role/StockBasedCompensationTables">
        <link:definition>2346309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2447427 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails">
        <link:definition>2448428 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsOutstandingDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails">
        <link:definition>2449429 - Disclosure - Stock-Based Compensation - Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>2450430 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2451431 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAggregateIntrinsicValueDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails">
        <link:definition>2452432 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationIntrinsicValueofOptionsExercisedDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails">
        <link:definition>2453433 - Disclosure - Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails">
        <link:definition>2454434 - Disclosure - Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsforESPPDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails">
        <link:definition>2455435 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.myriad.com/role/IncomeTaxes">
        <link:definition>2156111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.myriad.com/role/IncomeTaxesTables">
        <link:definition>2357310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitDetails" roleURI="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails">
        <link:definition>2458436 - Disclosure - Income Taxes - Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>2459437 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" roleURI="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails">
        <link:definition>2460438 - Disclosure - Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2461439 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.myriad.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2462440 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" roleURI="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails">
        <link:definition>2463441 - Disclosure - Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>2464442 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.myriad.com/role/CommitmentsandContingencies">
        <link:definition>2165112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2466443 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.myriad.com/role/Leases">
        <link:definition>2167113 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.myriad.com/role/LeasesTables">
        <link:definition>2368311 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.myriad.com/role/LeasesNarrativeDetails">
        <link:definition>2469444 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2470445 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2470445 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlan" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlan">
        <link:definition>2171114 - Disclosure - Employee Deferred Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlanTables" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables">
        <link:definition>2372312 - Disclosure - Employee Deferred Savings Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlanNarrativeDetails" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails">
        <link:definition>2473446 - Disclosure - Employee Deferred Savings Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlanContributionstoPlanDetails" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails">
        <link:definition>2474447 - Disclosure - Employee Deferred Savings Plan - Contributions to Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformation" roleURI="http://www.myriad.com/role/SegmentandRelatedInformation">
        <link:definition>2175115 - Disclosure - Segment and Related Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationTables" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTables">
        <link:definition>2376313 - Disclosure - Segment and Related Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationNarrativeDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails">
        <link:definition>2477448 - Disclosure - Segment and Related Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails">
        <link:definition>2478449 - Disclosure - Segment and Related Information - Assets by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.myriad.com/role/Divestitures">
        <link:definition>2179116 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.myriad.com/role/DivestituresTables">
        <link:definition>2380314 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresNarrativeDetails" roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails">
        <link:definition>2481450 - Disclosure - Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresOtherIncomeDetails" roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails">
        <link:definition>2482451 - Disclosure - Divestitures - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitions" roleURI="http://www.myriad.com/role/BusinessAcquisitions">
        <link:definition>2183117 - Disclosure - Business Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsNarrativeDetails" roleURI="http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails">
        <link:definition>2484452 - Disclosure - Business Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.myriad.com/role/SubsequentEvent">
        <link:definition>2185118 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.myriad.com/role/SubsequentEventDetails">
        <link:definition>2486453 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation">
        <link:definition>2187119 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables">
        <link:definition>2388315 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>2489454 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransitionPeriodComparativeDataUnaudited" roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited">
        <link:definition>2190120 - Disclosure - Transition Period Comparative Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransitionPeriodComparativeDataUnauditedTables" roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables">
        <link:definition>2391316 - Disclosure - Transition Period Comparative Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransitionPeriodComparativeDataUnauditedDetails" roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails">
        <link:definition>2492455 - Disclosure - Transition Period Comparative Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mygn_PharmaceuticalAndClinicalServicesMember" abstract="true" name="PharmaceuticalAndClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DeferredTaxLeaseLiability" abstract="false" name="DeferredTaxLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" abstract="false" name="EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityDivestitures" abstract="false" name="ContractWithCustomerLiabilityDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_RangeOneMember" abstract="true" name="RangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" abstract="false" name="ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_PerformanceObligationEstimatedTransactionPriceMember" abstract="true" name="PerformanceObligationEstimatedTransactionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_EmployeeStockPurchasePlanTwentyTwelveMember" abstract="true" name="EmployeeStockPurchasePlanTwentyTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" abstract="false" name="OperatingLeaseLiabilityLeasesNotYetCommenced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_NumberOfDivestitures" abstract="false" name="NumberOfDivestitures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_IntangibleAssetsLineItems" abstract="true" name="IntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_DebtCovenantLiquidityCovenantMinimum" abstract="false" name="DebtCovenantLiquidityCovenantMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" abstract="false" name="LeaseRelatedExpendituresIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticTumorProfilingMember" abstract="true" name="MolecularDiagnosticTumorProfilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MyriadAutoimmuneAssetsMember" abstract="true" name="MyriadAutoimmuneAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_PurchasedLicensesAndTechnologiesMember" abstract="true" name="PurchasedLicensesAndTechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" abstract="false" name="ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" abstract="false" name="ValuationAllowanceIncreaseDecreaseDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_LesseeOperatingLeaseAreaOfLeasedSpace" abstract="false" name="LesseeOperatingLeaseAreaOfLeasedSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" abstract="true" name="MyriadRBMIncAndMyriadAutoimmuneBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" abstract="false" name="OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadAutoimmuneReportingUnitMember" abstract="true" name="MyriadAutoimmuneReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticPrenatalTestingMember" abstract="true" name="MolecularDiagnosticPrenatalTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_SaltLakeCityLeaseMember" abstract="true" name="SaltLakeCityLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" abstract="true" name="OperatingLeaseSouthSanFranciscoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DebtInstrumentLIBORFloorPercentage" abstract="false" name="DebtInstrumentLIBORFloorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_TaxCreditCarryforwardsExpirationDate" abstract="false" name="TaxCreditCarryforwardsExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="mygn_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_NonEmployeeDirectorMember" abstract="true" name="NonEmployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_TransitionPeriodFinancialInformationLineItems" abstract="true" name="TransitionPeriodFinancialInformationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_TransitionPeriodComparativeDataTextBlock" abstract="false" name="TransitionPeriodComparativeDataTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" abstract="false" name="IncomeTaxReconciliationChangesInRevenueRecognitionMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_UnrecognizedTaxBenefitsNet" abstract="false" name="UnrecognizedTaxBenefitsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_GoodwillAndIntangibleAssetsLineItems" abstract="true" name="GoodwillAndIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" abstract="false" name="AmountOfReductionInCommonStockAsResultOfStockRepurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ClinicReportingUnitMember" abstract="true" name="ClinicReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticAutoimmuneMember" abstract="true" name="MolecularDiagnosticAutoimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" abstract="false" name="EffectiveIncomeTaxRateReconciliationAssetImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_AssetsLessCashCashEquivalentsAndInvestments" abstract="false" name="AssetsLessCashCashEquivalentsAndInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityEstablished" abstract="false" name="OperatingLeaseLiabilityEstablished" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadMyPathLLCLaboratoryMember" abstract="true" name="MyriadMyPathLLCLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLossCarryforwardsExpirationYear" abstract="false" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="mygn_DisposalGroupCapitalLossOnTaxBasis" abstract="false" name="DisposalGroupCapitalLossOnTaxBasis" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OtherStateMember" abstract="true" name="OtherStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MyriadRBMIncMember" abstract="true" name="MyriadRBMIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" abstract="false" name="DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationAssetImpairment" abstract="false" name="IncomeTaxReconciliationAssetImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOnInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticTestingMember" abstract="true" name="MolecularDiagnosticTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_MolecularDiagnosticPharmacogenomicsMember" abstract="true" name="MolecularDiagnosticPharmacogenomicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" abstract="false" name="ScheduleOfCommonStockRepurchasedTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_CostOfPharmaceuticalAndClinicalServicesMember" abstract="true" name="CostOfPharmaceuticalAndClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticOtherTestingMember" abstract="true" name="MolecularDiagnosticOtherTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CounsylIncMember" abstract="true" name="CounsylIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_RefundsPayableAndReserveCurrent" abstract="false" name="RefundsPayableAndReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_GoodwillAndIntangibleAssetsTable" abstract="true" name="GoodwillAndIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_RangeThreeMember" abstract="true" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_AmendmentToCreditAgreementMember" abstract="true" name="AmendmentToCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityPrepayments" abstract="false" name="ContractWithCustomerLiabilityPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OtherIncomeExpensePolicyPolicyTextBlock" abstract="false" name="OtherIncomeExpensePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_DeferredTaxAssetsLeaseRightOfUseAsset" abstract="false" name="DeferredTaxAssetsLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" abstract="false" name="IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationCARESAct" abstract="false" name="IncomeTaxReconciliationCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_TransitionPeriodFinancialInformationTable" abstract="true" name="TransitionPeriodFinancialInformationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mygn_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" abstract="false" name="DisposalGroupNetTaxExpenseBenefitOnDivestiture" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OptionsAndRestrictedStockUnitsMember" abstract="true" name="OptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_RangeTwoMember" abstract="true" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" abstract="false" name="ScheduleOfTransitionPeriodComparativeDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" abstract="false" name="StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" abstract="false" name="GainLossOnDispositionOfAssetsNetOfTransactionFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ScheduleOfIntangibleAssetsTable" abstract="true" name="ScheduleOfIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_CrescendoBioscienceIncMember" abstract="true" name="CrescendoBioscienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" abstract="true" name="InProcessResearchAndDevelopmentWithIndefiniteLivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DisposalGroupCapitalGainOnDivestiture" abstract="false" name="DisposalGroupCapitalGainOnDivestiture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" abstract="false" name="AmountChargedToRetainedEarningsAsResultOfStockRepurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" abstract="false" name="LesseeOperatingLeaseEstimatedFutureLeasePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_CARESActOf2020ProviderReliefFundAmount" abstract="false" name="CARESActOf2020ProviderReliefFundAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" abstract="false" name="DisposalGroupNotDiscontinuedOperationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_CARESActOf2020MedicarePaymentAmount" abstract="false" name="CARESActOf2020MedicarePaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" abstract="false" name="IncreaseDecreaseInUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationCARESAct" abstract="false" name="EffectiveIncomeTaxRateReconciliationCARESAct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" abstract="false" name="IncomeTaxReconciliationNonDeductibleLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInEarningsLossPerShare" abstract="false" name="IncreaseDecreaseInEarningsLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mygn_CostOfMolecularDiagnosticTestingMember" abstract="true" name="CostOfMolecularDiagnosticTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" abstract="false" name="IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ExecutiveOfficersAndSeniorPositionsMember" abstract="true" name="ExecutiveOfficersAndSeniorPositionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_AbelliAndPricoloMatterMember" abstract="true" name="AbelliAndPricoloMatterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticHereditaryCancerTestingMember" abstract="true" name="MolecularDiagnosticHereditaryCancerTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mygn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4990a358-c12e-4899-92d4-a6c626b561e2,g:4a66b582-ad59-47ea-a8a2-59085acc693c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_57e118ba-157c-431c-89ef-b695ba74aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_AssetsCurrent_57e118ba-157c-431c-89ef-b695ba74aebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c539a0e0-8b0b-40dd-8b85-a53d52d7b4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c539a0e0-8b0b-40dd-8b85-a53d52d7b4ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7f2d538a-9873-4b57-9693-2faf76a2c252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7f2d538a-9873-4b57-9693-2faf76a2c252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2f84d501-d8d8-4942-83a4-369ddc69d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2f84d501-d8d8-4942-83a4-369ddc69d3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d332cb4a-f6cb-4724-9341-add001ece357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d332cb4a-f6cb-4724-9341-add001ece357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d5948fcb-49d5-48f8-a7bf-2235b96b31f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_Goodwill_d5948fcb-49d5-48f8-a7bf-2235b96b31f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd85782f-2cbb-43be-8f88-2826fd465698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d17ece1b-9ba4-4301-b212-ae8b055ef7ef" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd85782f-2cbb-43be-8f88-2826fd465698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4111d62-0ce4-46e2-a791-2cbfc56971c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6cafdac2-5255-45a9-a53f-e3b109e5932d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4111d62-0ce4-46e2-a791-2cbfc56971c2" xlink:to="loc_us-gaap_CommonStockValue_6cafdac2-5255-45a9-a53f-e3b109e5932d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d7edf697-84fa-4e8d-93ce-2a2549dca2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4111d62-0ce4-46e2-a791-2cbfc56971c2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d7edf697-84fa-4e8d-93ce-2a2549dca2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3dc16a59-7acc-4ab7-abac-922d9e6a54d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4111d62-0ce4-46e2-a791-2cbfc56971c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3dc16a59-7acc-4ab7-abac-922d9e6a54d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22e4651b-4c61-4810-b2a4-119880c3b929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4111d62-0ce4-46e2-a791-2cbfc56971c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22e4651b-4c61-4810-b2a4-119880c3b929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b044b4b-7488-4ef8-b050-47bc7eae16b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b044b4b-7488-4ef8-b050-47bc7eae16b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnrecognizedTaxBenefitsNet_056ff71e-9a2b-42a6-8c7b-01999375a98b" xlink:href="mygn-20211231.xsd#mygn_UnrecognizedTaxBenefitsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:to="loc_mygn_UnrecognizedTaxBenefitsNet_056ff71e-9a2b-42a6-8c7b-01999375a98b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b34ecba1-61c1-4e26-b8c7-03dda0c7e175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b34ecba1-61c1-4e26-b8c7-03dda0c7e175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ea8a4741-e3bf-462e-b0c3-51b77b9f07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ea8a4741-e3bf-462e-b0c3-51b77b9f07e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2166c109-c69a-4116-8956-fd09a6fceab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2166c109-c69a-4116-8956-fd09a6fceab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_66334d6e-091d-4080-b77c-9ebda208e392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f55b2665-c839-438c-bd45-0512ba337904" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_66334d6e-091d-4080-b77c-9ebda208e392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41a8264f-e77b-4cbd-b7cf-22480fa484bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d095bc3f-bd65-4029-867d-e69f0c0dae7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41a8264f-e77b-4cbd-b7cf-22480fa484bf" xlink:to="loc_us-gaap_StockholdersEquity_d095bc3f-bd65-4029-867d-e69f0c0dae7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b4abb45c-f98b-4a4c-b531-c5ea4c365601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41a8264f-e77b-4cbd-b7cf-22480fa484bf" xlink:to="loc_us-gaap_MinorityInterest_b4abb45c-f98b-4a4c-b531-c5ea4c365601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae6b7cbc-34d4-4f95-81ab-02d7ebf7658a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6e36be86-c9fa-4361-9842-eee7270f4714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae6b7cbc-34d4-4f95-81ab-02d7ebf7658a" xlink:to="loc_us-gaap_Liabilities_6e36be86-c9fa-4361-9842-eee7270f4714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6d99dadf-5dba-4a0f-be9b-b0da7255c3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae6b7cbc-34d4-4f95-81ab-02d7ebf7658a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6d99dadf-5dba-4a0f-be9b-b0da7255c3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd928cca-e0d6-4097-96e8-632e9369a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae6b7cbc-34d4-4f95-81ab-02d7ebf7658a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd928cca-e0d6-4097-96e8-632e9369a1fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fb8a9f3b-c30a-4acf-881f-d9ccb06d1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_88f11479-5ad7-4940-ad53-0ed44e8a00da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fb8a9f3b-c30a-4acf-881f-d9ccb06d1039" xlink:to="loc_us-gaap_AccountsPayableCurrent_88f11479-5ad7-4940-ad53-0ed44e8a00da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8de88baa-630d-4e7a-a75c-48e0bb430c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fb8a9f3b-c30a-4acf-881f-d9ccb06d1039" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8de88baa-630d-4e7a-a75c-48e0bb430c2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6ffe977-297a-4fbf-b044-fb6f07113031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fb8a9f3b-c30a-4acf-881f-d9ccb06d1039" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6ffe977-297a-4fbf-b044-fb6f07113031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f529e8b-cb04-4b21-8583-211a07fca1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fb8a9f3b-c30a-4acf-881f-d9ccb06d1039" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f529e8b-cb04-4b21-8583-211a07fca1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3b147cb-9940-4aaf-be79-018195d3b707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3b147cb-9940-4aaf-be79-018195d3b707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f3e02f90-5616-43f6-a1ed-94fa786ff0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f3e02f90-5616-43f6-a1ed-94fa786ff0e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eba0d57a-d6fb-45ed-b5f9-e735fdb70e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eba0d57a-d6fb-45ed-b5f9-e735fdb70e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fac7c908-623d-4cf6-9cab-122161c59803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:to="loc_us-gaap_InventoryNet_fac7c908-623d-4cf6-9cab-122161c59803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_8526c29e-7509-4391-8e7c-4f16414a0e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:to="loc_us-gaap_PrepaidTaxes_8526c29e-7509-4391-8e7c-4f16414a0e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef6b484c-3f7a-405f-95af-d7a2a629a626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ab41af44-8116-462c-ba78-6b2ec86048d9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef6b484c-3f7a-405f-95af-d7a2a629a626" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_67f43ea7-5179-41f7-b9f7-e22d81634f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6e991ce1-d06e-434f-8b23-27c1f92d1c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67f43ea7-5179-41f7-b9f7-e22d81634f35" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6e991ce1-d06e-434f-8b23-27c1f92d1c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4c7923b7-8379-4864-8ed5-63ae6c1228fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67f43ea7-5179-41f7-b9f7-e22d81634f35" xlink:to="loc_us-gaap_InterestExpense_4c7923b7-8379-4864-8ed5-63ae6c1228fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_720d8d47-dc93-4562-ae38-07c2a8a3086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67f43ea7-5179-41f7-b9f7-e22d81634f35" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_720d8d47-dc93-4562-ae38-07c2a8a3086e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b0e3488-4353-4d37-a9b7-f7131178880e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8473478-6054-4bab-810a-b24b92f37510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1b0e3488-4353-4d37-a9b7-f7131178880e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8473478-6054-4bab-810a-b24b92f37510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3fa6a32c-2d62-4633-9f0c-86b41d196ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1b0e3488-4353-4d37-a9b7-f7131178880e" xlink:to="loc_us-gaap_CostsAndExpenses_3fa6a32c-2d62-4633-9f0c-86b41d196ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b7c974b1-b239-41b2-bf21-b429b061a759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6dd11bfe-5439-427c-959d-ae701eef77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b7c974b1-b239-41b2-bf21-b429b061a759" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6dd11bfe-5439-427c-959d-ae701eef77fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1f48c984-2e1e-4cd9-8a6c-cee577248758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b7c974b1-b239-41b2-bf21-b429b061a759" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1f48c984-2e1e-4cd9-8a6c-cee577248758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aeffa97b-ac39-4fcc-8fba-3aa705b27b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_11e185ff-564b-4c44-8cd0-1fb90c5663b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aeffa97b-ac39-4fcc-8fba-3aa705b27b47" xlink:to="loc_us-gaap_ProfitLoss_11e185ff-564b-4c44-8cd0-1fb90c5663b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e408a11e-09ef-49ae-b382-e992e53d7431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aeffa97b-ac39-4fcc-8fba-3aa705b27b47" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e408a11e-09ef-49ae-b382-e992e53d7431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1290fc59-3aa3-409a-9f3a-0b5870eedeab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a40aec08-a135-40dd-926f-5665ef7e3d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1290fc59-3aa3-409a-9f3a-0b5870eedeab" xlink:to="loc_us-gaap_OperatingIncomeLoss_a40aec08-a135-40dd-926f-5665ef7e3d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_038798b2-149d-4227-b0a5-0fa726be3860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1290fc59-3aa3-409a-9f3a-0b5870eedeab" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_038798b2-149d-4227-b0a5-0fa726be3860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dc1e66c8-6835-4801-ab12-81d20fb659e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_89642a9d-ad1e-4d49-a910-35974c6983ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc1e66c8-6835-4801-ab12-81d20fb659e3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_89642a9d-ad1e-4d49-a910-35974c6983ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3865c4c3-58ee-45d7-af69-6e3b9395da27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc1e66c8-6835-4801-ab12-81d20fb659e3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3865c4c3-58ee-45d7-af69-6e3b9395da27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_48d11b6e-8b2e-4e70-bdd1-ff17b7ab9bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc1e66c8-6835-4801-ab12-81d20fb659e3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_48d11b6e-8b2e-4e70-bdd1-ff17b7ab9bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_1a61ce69-ad7e-47f3-b63c-1a1d2470501b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc1e66c8-6835-4801-ab12-81d20fb659e3" xlink:to="loc_us-gaap_LitigationSettlementExpense_1a61ce69-ad7e-47f3-b63c-1a1d2470501b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_1fc8cd5e-5fd6-469b-93b4-8428059bc23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc1e66c8-6835-4801-ab12-81d20fb659e3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_1fc8cd5e-5fd6-469b-93b4-8428059bc23f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_83fde0e5-16cd-4897-b291-165e169c2be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9cc1f89e-cee5-4be6-b318-d2b9a2ef3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_83fde0e5-16cd-4897-b291-165e169c2be7" xlink:to="loc_us-gaap_NetIncomeLoss_9cc1f89e-cee5-4be6-b318-d2b9a2ef3cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8d8231c4-e425-4b1c-bf33-7069ab274b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_83fde0e5-16cd-4897-b291-165e169c2be7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8d8231c4-e425-4b1c-bf33-7069ab274b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_345e48ba-a7b6-4d6e-bf0d-9ba4daffc1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_83fde0e5-16cd-4897-b291-165e169c2be7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_345e48ba-a7b6-4d6e-bf0d-9ba4daffc1d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_45de9b4d-7f95-4290-89ef-fe568e20db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_83fde0e5-16cd-4897-b291-165e169c2be7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_45de9b4d-7f95-4290-89ef-fe568e20db1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f78814c6-8a0c-4076-a9c6-44733cefe809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f78814c6-8a0c-4076-a9c6-44733cefe809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4480a920-8aa1-4853-aaad-64e989526419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4480a920-8aa1-4853-aaad-64e989526419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1f966a7e-a3e0-4cac-bf63-210bcdc63fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1f966a7e-a3e0-4cac-bf63-210bcdc63fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_f2b9f1d6-5423-4ebe-a931-cc8e08687504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_f2b9f1d6-5423-4ebe-a931-cc8e08687504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_ca890a2a-f850-4820-ae98-fa1c8c52d61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_ca890a2a-f850-4820-ae98-fa1c8c52d61a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_bb870eac-0226-4418-8ae2-7e9935af0a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_bb870eac-0226-4418-8ae2-7e9935af0a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9cb02405-585f-4dc0-be6e-b49a4e72861e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c59b2c-f6a5-4af9-b048-acb0e4574f06" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9cb02405-585f-4dc0-be6e-b49a4e72861e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8230a93-b077-4ba2-a6d2-bf8a12449d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_1b4472b8-f110-483b-893b-77d50997d9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8230a93-b077-4ba2-a6d2-bf8a12449d51" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_1b4472b8-f110-483b-893b-77d50997d9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e4f7ca68-0d55-4979-b996-2895ab71f436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8230a93-b077-4ba2-a6d2-bf8a12449d51" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e4f7ca68-0d55-4979-b996-2895ab71f436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_d6507cb1-ae8c-45b6-b1c4-4a71569b66da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8230a93-b077-4ba2-a6d2-bf8a12449d51" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_d6507cb1-ae8c-45b6-b1c4-4a71569b66da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1a091bf2-d0e1-465e-bc15-e9380fc79cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8230a93-b077-4ba2-a6d2-bf8a12449d51" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1a091bf2-d0e1-465e-bc15-e9380fc79cb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_06ae77e8-285f-46cc-94f5-8bfbdbfefc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8230a93-b077-4ba2-a6d2-bf8a12449d51" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_06ae77e8-285f-46cc-94f5-8bfbdbfefc7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6082277-bb26-4d91-8532-222f5a3c0339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_NetIncomeLoss_a6082277-bb26-4d91-8532-222f5a3c0339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_aedb0f16-b248-494f-8711-fdc75feba533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_DepreciationAndAmortization_aedb0f16-b248-494f-8711-fdc75feba533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_14169da0-6e8e-48b4-bd90-e6b5cef5d9ae" xlink:href="mygn-20211231.xsd#mygn_NonCashInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_mygn_NonCashInterestExpense_14169da0-6e8e-48b4-bd90-e6b5cef5d9ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ef3f9306-bfc8-4172-8fa6-61a6bef44d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ef3f9306-bfc8-4172-8fa6-61a6bef44d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_882527e6-ff50-452e-a665-cfad82a2770f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_ShareBasedCompensation_882527e6-ff50-452e-a665-cfad82a2770f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0344910c-3104-46a9-8499-0d9feccf6ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0344910c-3104-46a9-8499-0d9feccf6ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_5d62a722-baa9-485b-9799-a1228776690a" xlink:href="mygn-20211231.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_5d62a722-baa9-485b-9799-a1228776690a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f451967-9def-4cfb-90c3-b868d939c975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f451967-9def-4cfb-90c3-b868d939c975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f7562af3-ea5a-492b-b5a7-0bb2c764809a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_InventoryWriteDown_f7562af3-ea5a-492b-b5a7-0bb2c764809a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_8eb27c25-2aec-43da-b7e0-993891ecaa26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_8eb27c25-2aec-43da-b7e0-993891ecaa26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_c244beda-cd67-4e22-bb8b-81a050982aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_c244beda-cd67-4e22-bb8b-81a050982aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_4d67dbf2-e2a4-4806-99bb-6aa3369e28bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_4d67dbf2-e2a4-4806-99bb-6aa3369e28bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_e54796b6-afd8-4457-9751-ff35ebbdae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_e54796b6-afd8-4457-9751-ff35ebbdae2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9d378131-6d9a-47ac-95f4-79d7f9c8266f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9d378131-6d9a-47ac-95f4-79d7f9c8266f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6621f799-3bc5-4ec2-8eeb-13fe84cbd6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6621f799-3bc5-4ec2-8eeb-13fe84cbd6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_01f28745-d04f-4c17-a9c3-52a3bd392f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_01f28745-d04f-4c17-a9c3-52a3bd392f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_570ceaa3-663e-4481-9eb8-4da5c05a4c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_570ceaa3-663e-4481-9eb8-4da5c05a4c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a0dc23c-03a8-4bc7-8091-af41e089073e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a0dc23c-03a8-4bc7-8091-af41e089073e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3e40b04c-acfc-458a-9629-587795a9a8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3e40b04c-acfc-458a-9629-587795a9a8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1c9ff2f7-df1e-4815-a65d-3c937f0f92bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46874ba3-578e-4468-83af-06808df36deb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1c9ff2f7-df1e-4815-a65d-3c937f0f92bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43d5dd50-58b2-49aa-83c5-9b2b0b3ef616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95ed24f5-1167-41ae-8f59-a20f1f4a13dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43d5dd50-58b2-49aa-83c5-9b2b0b3ef616" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95ed24f5-1167-41ae-8f59-a20f1f4a13dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_372eb35b-6442-4512-9465-2be4e81bd2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43d5dd50-58b2-49aa-83c5-9b2b0b3ef616" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_372eb35b-6442-4512-9465-2be4e81bd2d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c2f1861-9853-49a7-8edf-7bdb9763dda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43d5dd50-58b2-49aa-83c5-9b2b0b3ef616" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c2f1861-9853-49a7-8edf-7bdb9763dda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f2f5f2d-4ba3-40c9-96c7-273cefa7a0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43d5dd50-58b2-49aa-83c5-9b2b0b3ef616" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f2f5f2d-4ba3-40c9-96c7-273cefa7a0fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_951ef4ef-a9aa-49b0-8d78-ce97398e85c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3172a47c-26c3-4375-9d88-a23fa1ea53c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_951ef4ef-a9aa-49b0-8d78-ce97398e85c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3172a47c-26c3-4375-9d88-a23fa1ea53c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_140ce97b-18e4-41f3-b51e-0ae8b748a235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_951ef4ef-a9aa-49b0-8d78-ce97398e85c7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_140ce97b-18e4-41f3-b51e-0ae8b748a235" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ee258e2a-bd77-4ab8-a098-0ddf9cb2938f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1dbe942e-ff12-4b99-a1f8-e29b9230ea15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ee258e2a-bd77-4ab8-a098-0ddf9cb2938f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1dbe942e-ff12-4b99-a1f8-e29b9230ea15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_98d17c32-1c0d-4fea-8de4-249ef56e16db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ee258e2a-bd77-4ab8-a098-0ddf9cb2938f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_98d17c32-1c0d-4fea-8de4-249ef56e16db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_07694927-4227-4c2b-b016-55141b1460dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ee258e2a-bd77-4ab8-a098-0ddf9cb2938f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_07694927-4227-4c2b-b016-55141b1460dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_4ff3f884-5250-4f65-bdea-88baf209ae5e" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_39b8043c-b01a-4af2-9c40-960a891411ce" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_4ff3f884-5250-4f65-bdea-88baf209ae5e" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_39b8043c-b01a-4af2-9c40-960a891411ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_da010365-5fe0-413d-ae6b-34fbc60a4873" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_4ff3f884-5250-4f65-bdea-88baf209ae5e" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_da010365-5fe0-413d-ae6b-34fbc60a4873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_b791b846-2335-4c07-a5bd-177283992f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_4ff3f884-5250-4f65-bdea-88baf209ae5e" xlink:to="loc_us-gaap_InvestmentsAndCash_b791b846-2335-4c07-a5bd-177283992f70" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_64fe9589-bb83-4c66-b6ea-ecf6db5b2c31" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39da54ed-6987-4ad8-8055-d975e4de07d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_64fe9589-bb83-4c66-b6ea-ecf6db5b2c31" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39da54ed-6987-4ad8-8055-d975e4de07d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e6032a5b-fd79-4a43-af11-b9e7843acdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_64fe9589-bb83-4c66-b6ea-ecf6db5b2c31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e6032a5b-fd79-4a43-af11-b9e7843acdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ab54a6f7-b8d1-4dfe-b2cc-0019e065b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_64fe9589-bb83-4c66-b6ea-ecf6db5b2c31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ab54a6f7-b8d1-4dfe-b2cc-0019e065b61b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_8491f52e-e76d-4d5d-922a-0c1b912c0991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_64fe9589-bb83-4c66-b6ea-ecf6db5b2c31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_8491f52e-e76d-4d5d-922a-0c1b912c0991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_c18c5be7-88b5-44d5-8a08-465d34856134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b382413-8cbd-4bc7-a097-0f61e7e6cacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_c18c5be7-88b5-44d5-8a08-465d34856134" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b382413-8cbd-4bc7-a097-0f61e7e6cacc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_befb5181-5748-4460-9bbe-6b0e954d10c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_c18c5be7-88b5-44d5-8a08-465d34856134" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_befb5181-5748-4460-9bbe-6b0e954d10c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cd4bb25b-35ec-418d-b678-ae031a47ff74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_c18c5be7-88b5-44d5-8a08-465d34856134" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cd4bb25b-35ec-418d-b678-ae031a47ff74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_74f02c39-6a8d-4ffe-98c2-04c9f2900e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_c18c5be7-88b5-44d5-8a08-465d34856134" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_74f02c39-6a8d-4ffe-98c2-04c9f2900e0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_53116934-997d-4609-9871-ab85eeb34cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2280f97f-95c0-447c-a568-7101725dcd69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_53116934-997d-4609-9871-ab85eeb34cf0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2280f97f-95c0-447c-a568-7101725dcd69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5a5d792d-e8ef-4b65-9243-2ab3ba86aae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_53116934-997d-4609-9871-ab85eeb34cf0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5a5d792d-e8ef-4b65-9243-2ab3ba86aae9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c1699146-29ee-475b-8388-72a23568506f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_415f59bd-73a4-4381-9d00-208620caad11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c1699146-29ee-475b-8388-72a23568506f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_415f59bd-73a4-4381-9d00-208620caad11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_622b807c-fbda-409e-a2e9-028ea47b2cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c1699146-29ee-475b-8388-72a23568506f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_622b807c-fbda-409e-a2e9-028ea47b2cbd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a05880c0-7e50-4d62-b801-99c718240beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d4cf67a2-080f-4a02-87b2-bed6215c04a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a05880c0-7e50-4d62-b801-99c718240beb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d4cf67a2-080f-4a02-87b2-bed6215c04a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5b89d16a-814e-4cdd-9366-2dc252a650e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a05880c0-7e50-4d62-b801-99c718240beb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5b89d16a-814e-4cdd-9366-2dc252a650e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d54a883-9f27-46b2-ad53-97fd0b01221a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d003d86-60ea-4730-b2d1-75c0e06d8178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d54a883-9f27-46b2-ad53-97fd0b01221a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d003d86-60ea-4730-b2d1-75c0e06d8178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d5be2321-9d19-41b0-93c2-1524d2cecd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d54a883-9f27-46b2-ad53-97fd0b01221a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d5be2321-9d19-41b0-93c2-1524d2cecd5b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d1fa9a77-9948-4e46-a86d-09b6256d8d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9532c3f8-0b97-4ad1-955d-8d67ae3a216a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d1fa9a77-9948-4e46-a86d-09b6256d8d7a" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9532c3f8-0b97-4ad1-955d-8d67ae3a216a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2b25c756-9843-4ba5-a4bf-98e4c630dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d1fa9a77-9948-4e46-a86d-09b6256d8d7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2b25c756-9843-4ba5-a4bf-98e4c630dfdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_039aa4cf-9267-4d84-8619-79152a99b777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_039aa4cf-9267-4d84-8619-79152a99b777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_da6e87f8-9bc3-4c8c-99f4-9588ed1214c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_da6e87f8-9bc3-4c8c-99f4-9588ed1214c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8a544ae5-b51c-4f78-9b77-add2c135e3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8a544ae5-b51c-4f78-9b77-add2c135e3e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c6f5d74f-2c44-4fcd-b5af-02307c4f2744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c6f5d74f-2c44-4fcd-b5af-02307c4f2744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_55c187d4-3afe-42ae-8def-f632fbb122b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_55c187d4-3afe-42ae-8def-f632fbb122b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0e7bc712-4585-46a5-b3f5-9c90bdb39e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5409845d-1c80-436e-9e51-f40b725d2a8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0e7bc712-4585-46a5-b3f5-9c90bdb39e90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2022b2f6-4afe-42f4-8ca5-490796edbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2022b2f6-4afe-42f4-8ca5-490796edbc26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_05fc0ee4-d3ee-4ad3-bb57-22f3733d5f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_us-gaap_LitigationReserveCurrent_05fc0ee4-d3ee-4ad3-bb57-22f3733d5f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_1122f696-8ba9-4897-b119-4e4766c54599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_us-gaap_TaxesPayableCurrent_1122f696-8ba9-4897-b119-4e4766c54599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_a9a2039b-9b60-4b65-a7fc-c7a28f371792" xlink:href="mygn-20211231.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_a9a2039b-9b60-4b65-a7fc-c7a28f371792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fc9db56b-5936-412e-abb3-23a83902ab0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fc9db56b-5936-412e-abb3-23a83902ab0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_e4139db5-2fca-448d-be71-d85d3acef379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_e4139db5-2fca-448d-be71-d85d3acef379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79d1ec3e-2817-419b-9136-7aa14e9ea282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17498aa8-d512-4913-8915-6afc98a02a2c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79d1ec3e-2817-419b-9136-7aa14e9ea282" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7ad920b7-e333-47d0-a356-b2c77f4ca112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b58dc8f2-415f-4daa-a289-eefbcd7844d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7ad920b7-e333-47d0-a356-b2c77f4ca112" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b58dc8f2-415f-4daa-a289-eefbcd7844d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_fd0e5366-959b-4b03-a94a-d96aec779bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7ad920b7-e333-47d0-a356-b2c77f4ca112" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_fd0e5366-959b-4b03-a94a-d96aec779bac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b8e73a12-6d50-497c-b902-1fe454c447e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cb331f41-9ab3-443e-a1f6-3a57b511f7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b8e73a12-6d50-497c-b902-1fe454c447e2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cb331f41-9ab3-443e-a1f6-3a57b511f7be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cdb61a4a-5b90-435f-8b48-cbd07fb38b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b8e73a12-6d50-497c-b902-1fe454c447e2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cdb61a4a-5b90-435f-8b48-cbd07fb38b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0a1d4e0e-f032-448c-ac40-72c5e9b8c295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b8e73a12-6d50-497c-b902-1fe454c447e2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0a1d4e0e-f032-448c-ac40-72c5e9b8c295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cf945371-a375-412e-b548-5b3b36e4815f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b8e73a12-6d50-497c-b902-1fe454c447e2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cf945371-a375-412e-b548-5b3b36e4815f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_32ba2294-5049-4f9b-bc75-0f88acd57d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2124576-d57b-4914-92af-79a46f842bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_32ba2294-5049-4f9b-bc75-0f88acd57d47" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2124576-d57b-4914-92af-79a46f842bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9e037dcf-5f40-4c65-bbdd-9ec6388d54c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_32ba2294-5049-4f9b-bc75-0f88acd57d47" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9e037dcf-5f40-4c65-bbdd-9ec6388d54c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6ab32699-f63a-4cde-8fb0-7ad76dcc9385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_eaef7c22-16b0-48f0-9306-b41a4ea4f93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6ab32699-f63a-4cde-8fb0-7ad76dcc9385" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_eaef7c22-16b0-48f0-9306-b41a4ea4f93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_62a99779-ee37-4520-a01c-87e97dcfc7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6ab32699-f63a-4cde-8fb0-7ad76dcc9385" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_62a99779-ee37-4520-a01c-87e97dcfc7b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0af45092-7640-404a-9277-4930de6409f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6ab32699-f63a-4cde-8fb0-7ad76dcc9385" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0af45092-7640-404a-9277-4930de6409f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09d45286-0d6e-4df3-9b60-1d7421a168fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4fb9b753-ba4f-4cc2-951d-b3f22dc92090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09d45286-0d6e-4df3-9b60-1d7421a168fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4fb9b753-ba4f-4cc2-951d-b3f22dc92090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a9a3b4b2-d12b-4388-9a59-8335dc1b2479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09d45286-0d6e-4df3-9b60-1d7421a168fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a9a3b4b2-d12b-4388-9a59-8335dc1b2479" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c9c967b4-95d7-46e0-ae1a-b3974c518e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c9c967b4-95d7-46e0-ae1a-b3974c518e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa8cd205-10cd-495e-be56-3725c8483f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa8cd205-10cd-495e-be56-3725c8483f3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_62b399e6-c54b-46b7-bf2c-67327f30948c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_62b399e6-c54b-46b7-bf2c-67327f30948c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_c1a49f9b-2204-4ba0-bd1d-83591cfd7777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_c1a49f9b-2204-4ba0-bd1d-83591cfd7777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_5dbd6a32-6398-43e9-97fe-1a53814b66d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_5dbd6a32-6398-43e9-97fe-1a53814b66d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f1131f6d-cf08-4a19-90ed-ad7cc3529612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f1131f6d-cf08-4a19-90ed-ad7cc3529612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9c3f378d-6e4b-4937-9a54-4b100c843a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9c3f378d-6e4b-4937-9a54-4b100c843a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_2f0ff33a-03eb-4b82-b167-d3268260401f" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationCARESAct"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_2f0ff33a-03eb-4b82-b167-d3268260401f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_73a5a6fe-6aec-40ff-8af7-75cd9fcb8d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_73a5a6fe-6aec-40ff-8af7-75cd9fcb8d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_b1f5ae30-92d8-4aad-906f-1f312d26d73c" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_b1f5ae30-92d8-4aad-906f-1f312d26d73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_6d0f0c34-b641-4b92-9c08-95c1a8170dd8" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_6d0f0c34-b641-4b92-9c08-95c1a8170dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_23bbc99e-0a5b-4dfc-afbe-c6175e6a2115" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_23bbc99e-0a5b-4dfc-afbe-c6175e6a2115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_5164f515-9d88-480d-96c2-175ea32c4c8c" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_5164f515-9d88-480d-96c2-175ea32c4c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_78c447d8-b743-47ee-be61-38b3f2e6e58b" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_78c447d8-b743-47ee-be61-38b3f2e6e58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6ebbd83a-c3c0-4f20-8632-bac58203b777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8010ec1-2206-45b6-b141-e2d3a70139be" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6ebbd83a-c3c0-4f20-8632-bac58203b777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_91722317-8873-4234-8ce9-16fc5edbeb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_91722317-8873-4234-8ce9-16fc5edbeb70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fd50b00d-3d76-411e-8aed-4c054eafa5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fd50b00d-3d76-411e-8aed-4c054eafa5dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4bfc57c7-fc9b-47c2-baf0-26b2887fbb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4bfc57c7-fc9b-47c2-baf0-26b2887fbb8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_42d409a8-a46a-4d87-92d9-0c4b659c8817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_42d409a8-a46a-4d87-92d9-0c4b659c8817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_53233e3b-7fe8-4fad-a930-5216150690bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_53233e3b-7fe8-4fad-a930-5216150690bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f67eaa4e-67c2-4a02-8bc8-467207b1b730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f67eaa4e-67c2-4a02-8bc8-467207b1b730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5593050b-890e-4687-8e11-d2dc317824cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5593050b-890e-4687-8e11-d2dc317824cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationCARESAct_ca839204-f291-4807-9e3d-b1cf9c3092cc" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationCARESAct"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_mygn_IncomeTaxReconciliationCARESAct_ca839204-f291-4807-9e3d-b1cf9c3092cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_5f2bdf4d-5e2d-45bd-acc7-0b1e945126e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_5f2bdf4d-5e2d-45bd-acc7-0b1e945126e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_a061b983-e8bb-4700-8e51-4bb8ad35fc49" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_a061b983-e8bb-4700-8e51-4bb8ad35fc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAssetImpairment_645c4215-3e4f-42a0-9601-cf2df62c1661" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationAssetImpairment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_mygn_IncomeTaxReconciliationAssetImpairment_645c4215-3e4f-42a0-9601-cf2df62c1661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_b7a3c0a7-2e91-47e7-ba1c-f87949578db2" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_b7a3c0a7-2e91-47e7-ba1c-f87949578db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_42f46bcc-d3af-406b-9ff5-2f520d464c00" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_42f46bcc-d3af-406b-9ff5-2f520d464c00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_ef88fcb5-aeef-4d92-9948-612716eb6d20" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_ef88fcb5-aeef-4d92-9948-612716eb6d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b8dfab5-2507-481e-8f71-3ee315107349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2a42cbcd-b3a4-46f8-a491-3fd595bf343c" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b8dfab5-2507-481e-8f71-3ee315107349" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_610df969-fa99-4500-a47d-2b1c08911061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6ebdf8c7-35db-46d5-9c71-f46ec69ada2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_610df969-fa99-4500-a47d-2b1c08911061" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6ebdf8c7-35db-46d5-9c71-f46ec69ada2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxLeaseLiability_c0759f79-d9e9-44ab-97eb-3efbcf2692a0" xlink:href="mygn-20211231.xsd#mygn_DeferredTaxLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_610df969-fa99-4500-a47d-2b1c08911061" xlink:to="loc_mygn_DeferredTaxLeaseLiability_c0759f79-d9e9-44ab-97eb-3efbcf2692a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1e1df26d-7614-443e-93cd-5b8060ff6b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_610df969-fa99-4500-a47d-2b1c08911061" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1e1df26d-7614-443e-93cd-5b8060ff6b1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cbe2d34b-405e-4693-8e87-6b436995d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_391937fb-ed58-4f36-97c6-ab77e69c61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cbe2d34b-405e-4693-8e87-6b436995d88b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_391937fb-ed58-4f36-97c6-ab77e69c61bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8350d5d1-a737-4aa4-b28c-d20ade79277a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cbe2d34b-405e-4693-8e87-6b436995d88b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8350d5d1-a737-4aa4-b28c-d20ade79277a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bb0f0420-84b9-4578-a7e6-34e2c4911968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bb0f0420-84b9-4578-a7e6-34e2c4911968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3b2dbe83-8e7e-4be5-af66-5efec7f5fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3b2dbe83-8e7e-4be5-af66-5efec7f5fced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f160fda3-2789-4f69-abd7-52036cb24ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f160fda3-2789-4f69-abd7-52036cb24ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_77ad3c0a-c2d9-4544-aea3-7ba39070a954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_77ad3c0a-c2d9-4544-aea3-7ba39070a954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_a6e42545-4455-47cc-8ea1-6461870d43c0" xlink:href="mygn-20211231.xsd#mygn_DeferredTaxAssetsLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_a6e42545-4455-47cc-8ea1-6461870d43c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cf171089-af37-483c-86ce-7d13d5eb3a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cf171089-af37-483c-86ce-7d13d5eb3a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e3e4f8f9-cf95-47c0-a63c-ea62a9d3abcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_49725343-ae56-4af9-8db0-b509add70daf" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e3e4f8f9-cf95-47c0-a63c-ea62a9d3abcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1574dd82-e16c-4255-ab78-94254d33ef97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_38054506-56ee-4979-a83b-b142bed085a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1574dd82-e16c-4255-ab78-94254d33ef97" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_38054506-56ee-4979-a83b-b142bed085a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6949024d-9e10-4708-a3dd-adce831c94b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1574dd82-e16c-4255-ab78-94254d33ef97" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6949024d-9e10-4708-a3dd-adce831c94b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f04cd445-7e0f-4f41-a8f6-7fcf909cfa88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f04cd445-7e0f-4f41-a8f6-7fcf909cfa88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9a973322-d341-411d-ab28-b8d67e969275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9a973322-d341-411d-ab28-b8d67e969275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_24bc8c8d-69c6-46d1-844e-7e0e8d7a4728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_24bc8c8d-69c6-46d1-844e-7e0e8d7a4728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_48191e57-86b8-4cfc-958a-1d8a0a2d06e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_48191e57-86b8-4cfc-958a-1d8a0a2d06e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1a5bcf36-5a1e-429e-b49e-7a8b1ae487e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1a5bcf36-5a1e-429e-b49e-7a8b1ae487e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fdee6ad7-ec05-4983-89af-fd339ef91466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1936ddf3-5689-4504-888f-b9dd993879dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fdee6ad7-ec05-4983-89af-fd339ef91466" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1cbca40a-9818-4b05-a25a-7c124b0a888d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_12f6d8fa-c7b0-4281-8e41-f542d246ffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1cbca40a-9818-4b05-a25a-7c124b0a888d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_12f6d8fa-c7b0-4281-8e41-f542d246ffe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_aefa4f01-981f-4b01-8f6b-91604bfc4ade" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1cbca40a-9818-4b05-a25a-7c124b0a888d" xlink:to="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_aefa4f01-981f-4b01-8f6b-91604bfc4ade" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#DivestituresOtherIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3d4de99c-91aa-485d-bea9-6dd07f97dee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f8cfa171-8edd-486b-a069-3bb8df7461e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d4de99c-91aa-485d-bea9-6dd07f97dee2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f8cfa171-8edd-486b-a069-3bb8df7461e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_cf9cf698-9be6-4d53-8280-15462b0e4e7a" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d4de99c-91aa-485d-bea9-6dd07f97dee2" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_cf9cf698-9be6-4d53-8280-15462b0e4e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_f570d116-b105-4275-a1a4-060339ef1114" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d4de99c-91aa-485d-bea9-6dd07f97dee2" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_f570d116-b105-4275-a1a4-060339ef1114" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mygn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4990a358-c12e-4899-92d4-a6c626b561e2,g:4a66b582-ad59-47ea-a8a2-59085acc693c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i955b84a29d114eea891c561fc32df077_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92278080-429d-4b4b-ad44-294537bfb81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92278080-429d-4b4b-ad44-294537bfb81e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0fc4eda8-ff6d-4512-94a0-3b22a6527694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0fc4eda8-ff6d-4512-94a0-3b22a6527694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_795b5d87-749c-49b7-bb3a-8e601006b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_795b5d87-749c-49b7-bb3a-8e601006b4ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b65bee83-4947-4070-a690-e7ed0b071e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b65bee83-4947-4070-a690-e7ed0b071e2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_905d37de-b4c1-4c40-a5c7-8e91581adadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_LitigationSettlementExpense_905d37de-b4c1-4c40-a5c7-8e91581adadd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f1e75b8b-a2ff-4855-8211-9338da41a37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f1e75b8b-a2ff-4855-8211-9338da41a37b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_db354910-a6f7-4a45-a373-a04193a41f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_CostsAndExpenses_db354910-a6f7-4a45-a373-a04193a41f9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_137e717e-f7fc-47f4-94b1-4d9c12344fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_OperatingIncomeLoss_137e717e-f7fc-47f4-94b1-4d9c12344fdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_831111ad-19ba-4d6f-a5db-9812ebbfa89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_831111ad-19ba-4d6f-a5db-9812ebbfa89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a5369950-b0ec-4f32-89d4-34451d60f3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_InterestExpense_a5369950-b0ec-4f32-89d4-34451d60f3ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5ad9f525-6119-4cf6-854d-d979bec6da85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5ad9f525-6119-4cf6-854d-d979bec6da85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fcebccdf-ffc9-449d-9ef1-60fa61b111cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fcebccdf-ffc9-449d-9ef1-60fa61b111cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a39dd97d-d021-40a8-a3c6-5379539f7201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a39dd97d-d021-40a8-a3c6-5379539f7201" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_37cd2379-e71b-47b7-8794-846c10a8639c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_37cd2379-e71b-47b7-8794-846c10a8639c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_411e8b93-cd1b-42af-8aee-f8070d7d7672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_ProfitLoss_411e8b93-cd1b-42af-8aee-f8070d7d7672" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76e7e36b-9010-435d-a7b5-a61a629ee483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76e7e36b-9010-435d-a7b5-a61a629ee483" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c6cc7bb-988f-4541-99e2-f15d2fa2942e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_NetIncomeLoss_4c6cc7bb-988f-4541-99e2-f15d2fa2942e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_367964c8-7a43-4d21-9a85-dcbafd7fd241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:to="loc_us-gaap_EarningsPerShareBasic_367964c8-7a43-4d21-9a85-dcbafd7fd241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_440a13ab-4ee6-4634-99fb-2323119bbc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_440a13ab-4ee6-4634-99fb-2323119bbc4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_901de7f8-b407-4d04-85d9-be896e855a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_901de7f8-b407-4d04-85d9-be896e855a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36459792-72e2-481a-9bd8-4b342da0667b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36459792-72e2-481a-9bd8-4b342da0667b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:to="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48697284-856e-4b46-a530-ad14a3e1a8c5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:to="loc_srt_ProductsAndServicesDomain_48697284-856e-4b46-a530-ad14a3e1a8c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:to="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_23b67658-7013-44da-b5ac-d15b48756747" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_23b67658-7013-44da-b5ac-d15b48756747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_b72a64b4-717e-418b-8b34-08cb5ac6a9a1" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_b72a64b4-717e-418b-8b34-08cb5ac6a9a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i4ad5723f5b04472d80a48a0453b645c0_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5de69c3f-9035-4681-a1e1-89eab8a1c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5de69c3f-9035-4681-a1e1-89eab8a1c842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_75d0f989-6f63-47af-99a2-9f8bc03f12d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_75d0f989-6f63-47af-99a2-9f8bc03f12d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b9ddd33d-4d95-4f64-abb8-5921527e3a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b9ddd33d-4d95-4f64-abb8-5921527e3a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ff718677-785e-4dd1-bb4d-4e73c95d4e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ff718677-785e-4dd1-bb4d-4e73c95d4e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_175e19a8-1888-4ced-99ef-aaba4170a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_NetIncomeLoss_175e19a8-1888-4ced-99ef-aaba4170a84b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_43dd7412-6bef-458d-a39b-60a5c5e960fb" xlink:href="mygn-20211231.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_43dd7412-6bef-458d-a39b-60a5c5e960fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61952207-e457-4ad4-af71-135026f2f2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61952207-e457-4ad4-af71-135026f2f2dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ee200d7-ae8b-4bf7-baf3-a611ed177dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:to="loc_us-gaap_EquityComponentDomain_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:to="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7a6395ba-45da-4f77-9700-4c3eb7f10175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_CommonStockMember_7a6395ba-45da-4f77-9700-4c3eb7f10175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0af1f65b-3a0f-48b7-b7a8-410a89ec0bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0af1f65b-3a0f-48b7-b7a8-410a89ec0bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_776170fb-1ea4-4595-80dd-ef1596141e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_776170fb-1ea4-4595-80dd-ef1596141e5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ed602d1b-897a-4672-a18e-9e3e572da810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_RetainedEarningsMember_ed602d1b-897a-4672-a18e-9e3e572da810" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i75647631b2a14f6e82a06c9b2c97b520_OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:href="mygn-20211231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_30c8b61b-fd1b-4c49-af6e-88fe63956a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_30c8b61b-fd1b-4c49-af6e-88fe63956a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_568e0950-a5e2-4cad-a6d6-e1f258e160b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_568e0950-a5e2-4cad-a6d6-e1f258e160b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b410e91a-a0fb-48cf-9802-2211cdda879f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b410e91a-a0fb-48cf-9802-2211cdda879f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_eb653b1e-2a21-4b3d-8582-5f965eb38e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_eb653b1e-2a21-4b3d-8582-5f965eb38e57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d98c2b10-4a04-49bd-8397-8684a3b91f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d98c2b10-4a04-49bd-8397-8684a3b91f79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount_912f1185-8c04-40dc-877d-46ae53dc4503" xlink:href="mygn-20211231.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_CARESActOf2020MedicarePaymentAmount_912f1185-8c04-40dc-877d-46ae53dc4503" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ef8cffd1-87c1-430d-8faf-4776d10cb1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ef8cffd1-87c1-430d-8faf-4776d10cb1b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_a4a46f1f-15b2-46b0-92fa-0c6aa4bf78da" xlink:href="mygn-20211231.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_a4a46f1f-15b2-46b0-92fa-0c6aa4bf78da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_b2607da9-b82c-462c-8559-576926e2f59e" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_b2607da9-b82c-462c-8559-576926e2f59e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_789689b8-b7bd-4e36-ba4d-43a88879451d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_789689b8-b7bd-4e36-ba4d-43a88879451d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1d147dd-d09a-44a7-9735-8b3a76d30a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1d147dd-d09a-44a7-9735-8b3a76d30a73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_d8f0bcfa-2315-4779-894a-89b8553feb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_CapitalizedContractCostGross_d8f0bcfa-2315-4779-894a-89b8553feb22" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_31d9c988-3a68-4403-820d-1f7c73063b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_31d9c988-3a68-4403-820d-1f7c73063b69" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020ProviderReliefFundAmount_414816ba-08c5-4dcc-bb64-fa8d4140fcf3" xlink:href="mygn-20211231.xsd#mygn_CARESActOf2020ProviderReliefFundAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_CARESActOf2020ProviderReliefFundAmount_414816ba-08c5-4dcc-bb64-fa8d4140fcf3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:href="mygn-20211231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_80fa6c48-dec2-4482-b387-c881c5166a6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_80fa6c48-dec2-4482-b387-c881c5166a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e97a6bdf-1f01-44d1-b0b5-30f8b0d2860e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e97a6bdf-1f01-44d1-b0b5-30f8b0d2860e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_28657aee-3b7d-44a8-8583-1d1ef871f4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e97a6bdf-1f01-44d1-b0b5-30f8b0d2860e" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_28657aee-3b7d-44a8-8583-1d1ef871f4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9f7457ce-2d2b-4d42-b19f-e9768f70dd16_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:to="loc_srt_NameOfMajorCustomerDomain_9f7457ce-2d2b-4d42-b19f-e9768f70dd16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d34bdb26-884f-4c8c-a462-7ddd2055ef24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:to="loc_srt_NameOfMajorCustomerDomain_d34bdb26-884f-4c8c-a462-7ddd2055ef24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_ae95b3b8-b595-4843-b633-3d688cbbb39c" xlink:href="mygn-20211231.xsd#mygn_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d34bdb26-884f-4c8c-a462-7ddd2055ef24" xlink:to="loc_mygn_MedicareMember_ae95b3b8-b595-4843-b633-3d688cbbb39c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cd40c49e-91e5-4cc3-a450-ea182afb0448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cd40c49e-91e5-4cc3-a450-ea182afb0448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d0ac5f7-79d5-458f-afce-889e312e41bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d0ac5f7-79d5-458f-afce-889e312e41bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7b204ffa-efef-495c-8aa5-c484d0f5a086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d0ac5f7-79d5-458f-afce-889e312e41bc" xlink:to="loc_us-gaap_SalesRevenueNetMember_7b204ffa-efef-495c-8aa5-c484d0f5a086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17f24831-a65a-4a4a-9f82-d46b37cfea7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17f24831-a65a-4a4a-9f82-d46b37cfea7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aa72f69c-620a-4b2d-ad43-2c020efce661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:to="loc_us-gaap_EquipmentMember_aa72f69c-620a-4b2d-ad43-2c020efce661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0ab4c0de-82ff-4844-bc89-0001cc8f8b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0ab4c0de-82ff-4844-bc89-0001cc8f8b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_711e9c71-55b6-404e-b10b-a66cff1e41ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_711e9c71-55b6-404e-b10b-a66cff1e41ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_49b2131d-9243-474b-b229-30fb77ad5c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_49b2131d-9243-474b-b229-30fb77ad5c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_371498cd-302f-4335-aca4-661d5b66eadf" xlink:href="mygn-20211231.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_49b2131d-9243-474b-b229-30fb77ad5c28" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_371498cd-302f-4335-aca4-661d5b66eadf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_cb5c18ed-73b7-4c42-a99b-08162e82dc7a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:to="loc_srt_RestatementDomain_cb5c18ed-73b7-4c42-a99b-08162e82dc7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_115e034a-b0fd-4c70-8b1b-01228cd97707" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:to="loc_srt_RestatementDomain_115e034a-b0fd-4c70-8b1b-01228cd97707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_64761121-4f93-43c1-a946-f2f14cf52118" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_115e034a-b0fd-4c70-8b1b-01228cd97707" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_64761121-4f93-43c1-a946-f2f14cf52118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a286b84-1450-4d58-a67c-49525902cfd7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:to="loc_srt_RangeMember_5a286b84-1450-4d58-a67c-49525902cfd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:to="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dd3947f2-5c0d-440d-9ef4-d5bed578f033" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:to="loc_srt_MinimumMember_dd3947f2-5c0d-440d-9ef4-d5bed578f033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1d17c58-92b7-45ca-a5c2-46add89c5fa7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:to="loc_srt_MaximumMember_b1d17c58-92b7-45ca-a5c2-46add89c5fa7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="extended" id="i99ee8f75ab8e40bfb02cc1010ec411e0_OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8eeecd99-320a-4c9f-ad99-5a70b1d4c9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e3ee251-9c62-44af-ba80-42b206f0b1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8eeecd99-320a-4c9f-ad99-5a70b1d4c9ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e3ee251-9c62-44af-ba80-42b206f0b1a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8eeecd99-320a-4c9f-ad99-5a70b1d4c9ed" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:to="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18ebff88-551c-4559-8ca3-e95b3c3fe600_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:to="loc_srt_ProductsAndServicesDomain_18ebff88-551c-4559-8ca3-e95b3c3fe600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:to="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_a6b34be6-6b89-4fab-916a-ba54888ee34f" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_a6b34be6-6b89-4fab-916a-ba54888ee34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_9759ac8b-b089-4d3a-b6e4-aab1bf5bc712" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_9759ac8b-b089-4d3a-b6e4-aab1bf5bc712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_f01c3c5e-147d-4fbb-a714-9f24e0c77a75" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_f01c3c5e-147d-4fbb-a714-9f24e0c77a75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_4fb42aee-a205-4b55-882b-584148bb6d22" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_4fb42aee-a205-4b55-882b-584148bb6d22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_3ab02d92-30de-48a5-901d-90cc2e20e2bf" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_3ab02d92-30de-48a5-901d-90cc2e20e2bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_4e3963fd-fbad-4f15-aa9d-f5cd7fef7185" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_4e3963fd-fbad-4f15-aa9d-f5cd7fef7185" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_c4801eb5-09a0-429e-90ba-cfbc0cbf65eb" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_c4801eb5-09a0-429e-90ba-cfbc0cbf65eb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="extended" id="ied59bed51d4d476dba1280e2c988148b_OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_abea82de-c2c2-464f-b082-970760ea3534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a2d3b9-04ea-4385-933a-a6ce0e774d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_abea82de-c2c2-464f-b082-970760ea3534" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a2d3b9-04ea-4385-933a-a6ce0e774d13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_abea82de-c2c2-464f-b082-970760ea3534" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:to="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2487ffe5-44f5-46a8-9c25-aa8dc9578b46_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:to="loc_srt_SegmentGeographicalDomain_2487ffe5-44f5-46a8-9c25-aa8dc9578b46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:to="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_20cbed80-9338-4c49-b4ec-85144c6b56f9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:to="loc_country_US_20cbed80-9338-4c49-b4ec-85144c6b56f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_56ba1ac9-c43c-4853-a395-ce3fcf24c468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:to="loc_us-gaap_NonUsMember_56ba1ac9-c43c-4853-a395-ce3fcf24c468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:to="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_98c2b07d-be47-43e0-a512-a608dd0c3131_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:to="loc_srt_ProductsAndServicesDomain_98c2b07d-be47-43e0-a512-a608dd0c3131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:to="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_806fb71e-4d9f-45f9-b27f-babdb8398cad" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_806fb71e-4d9f-45f9-b27f-babdb8398cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_d51f279d-f21c-421f-9864-2392f7d0c4a9" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_d51f279d-f21c-421f-9864-2392f7d0c4a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_b3a4914a-12b5-479f-ba71-81f17bbbdc59" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_b3a4914a-12b5-479f-ba71-81f17bbbdc59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_489c088c-bd66-412e-89f7-013a4dc3ec48" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_489c088c-bd66-412e-89f7-013a4dc3ec48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_74527298-3ce8-461a-a1a6-87a5b5520b6d" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_74527298-3ce8-461a-a1a6-87a5b5520b6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_cce8bfac-b73d-421b-80c5-0079938aa2d5" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_cce8bfac-b73d-421b-80c5-0079938aa2d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_8fdee957-3929-497e-af34-55af4faf40a7" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_8fdee957-3929-497e-af34-55af4faf40a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended" id="i31a7ccfdf3544fd0831f901a1b34d41a_MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50b14f9e-2f25-4742-8474-26078ffa6b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50b14f9e-2f25-4742-8474-26078ffa6b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e604b988-3f6c-45a5-a44d-d1099e57a601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e604b988-3f6c-45a5-a44d-d1099e57a601" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd73d79f-9a40-496d-abb3-034dd517b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd73d79f-9a40-496d-abb3-034dd517b7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74634e15-064d-401c-9852-4a6bf1c9c7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74634e15-064d-401c-9852-4a6bf1c9c7d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_732cd5a9-678c-402a-b59a-106813399819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_732cd5a9-678c-402a-b59a-106813399819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc5f58a8-06fe-48c7-b729-e0c10be1ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc5f58a8-06fe-48c7-b729-e0c10be1ba60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_d64de37c-bd64-4f86-aaf7-8931c5c4c342" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_d64de37c-bd64-4f86-aaf7-8931c5c4c342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_841b8671-6208-44d9-bdbb-3b7ee38fa114" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_841b8671-6208-44d9-bdbb-3b7ee38fa114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_7185982e-0ec5-4a1e-84c2-4035cbec2179" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_7185982e-0ec5-4a1e-84c2-4035cbec2179" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_a33225da-e657-47ad-9a41-32de78dfab58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_us-gaap_InvestmentsAndCash_a33225da-e657-47ad-9a41-32de78dfab58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:to="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_37a30606-b636-4158-92e9-cfb85ba1b975_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_37a30606-b636-4158-92e9-cfb85ba1b975_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d56c527a-de88-4c0f-9169-79d1883c1a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d56c527a-de88-4c0f-9169-79d1883c1a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_3ea0779d-7e8a-494d-877d-97c61383eadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_MunicipalBondsMember_3ea0779d-7e8a-494d-877d-97c61383eadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_efe02bf9-2397-464f-8ba4-9bf9b8072d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_efe02bf9-2397-464f-8ba4-9bf9b8072d08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b3cdd76b-1420-43cf-b9be-786e12dfd185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b3cdd76b-1420-43cf-b9be-786e12dfd185" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b3e502b9-2960-4c59-b5e5-4f322714b274_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b3e502b9-2960-4c59-b5e5-4f322714b274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_85f58977-fc18-42d0-90cd-1493823ecf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:to="loc_us-gaap_CashMember_85f58977-fc18-42d0-90cd-1493823ecf8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_4a4e6237-c55e-4280-a814-9e0b1ea334df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:to="loc_us-gaap_CashEquivalentsMember_4a4e6237-c55e-4280-a814-9e0b1ea334df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended" id="ibc7086ee6548429ba543537ef05d4966_MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e3426a8-63b5-447b-adf4-0221f80f14a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e3426a8-63b5-447b-adf4-0221f80f14a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_81df25d9-1e1a-4f35-a9a8-6c241a48df26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_81df25d9-1e1a-4f35-a9a8-6c241a48df26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0fa888a5-43a2-4315-a307-d812d6593655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0fa888a5-43a2-4315-a307-d812d6593655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_268f546c-6f95-4284-b146-ea90f1407085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_268f546c-6f95-4284-b146-ea90f1407085" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_f410a13e-a33c-4c20-aec9-3893e9bd0de6" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_f410a13e-a33c-4c20-aec9-3893e9bd0de6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e459150e-4e50-4443-ad61-a21ba619754c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e459150e-4e50-4443-ad61-a21ba619754c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_97a95f3b-0485-498e-bd25-6361118a2961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_97a95f3b-0485-498e-bd25-6361118a2961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e8cc0923-9db9-486f-8867-179d8be38699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e8cc0923-9db9-486f-8867-179d8be38699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cb3ee741-7d37-45e7-9218-a48f5097fe20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cb3ee741-7d37-45e7-9218-a48f5097fe20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_fe9dae21-fea5-4996-8ee1-323c705eae57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_InvestmentsAndCash_fe9dae21-fea5-4996-8ee1-323c705eae57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_596dd470-beaa-472f-ba1f-a75b5a1ca41e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_596dd470-beaa-472f-ba1f-a75b5a1ca41e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_a2caeb85-78b6-493d-938b-a9eefbc798d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:to="loc_us-gaap_CashMember_a2caeb85-78b6-493d-938b-a9eefbc798d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_797647c1-fc1b-45b8-970e-794419089fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:to="loc_us-gaap_CashEquivalentsMember_797647c1-fc1b-45b8-970e-794419089fb5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i0ee55be401fc4e8a8b9d30a32f67631a_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8e662c74-c33b-462f-b88b-ddbf545a3ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_ac35a43d-6fd2-4805-a42d-3499a6606e8a" xlink:href="mygn-20211231.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8e662c74-c33b-462f-b88b-ddbf545a3ded" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_ac35a43d-6fd2-4805-a42d-3499a6606e8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8e662c74-c33b-462f-b88b-ddbf545a3ded" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a017bb2-7ded-4676-9173-db105f9be30c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a017bb2-7ded-4676-9173-db105f9be30c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c10d6f-63b7-418c-9505-b0a09a8deccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c10d6f-63b7-418c-9505-b0a09a8deccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_caea9b6e-558d-4370-9c31-015b7adae39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c10d6f-63b7-418c-9505-b0a09a8deccb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_caea9b6e-558d-4370-9c31-015b7adae39f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_53505532-fca7-4651-8e53-e0d65228e798_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_53505532-fca7-4651-8e53-e0d65228e798_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_17ea21b3-8f99-4cd2-b735-061858abbc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_17ea21b3-8f99-4cd2-b735-061858abbc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7a4c913c-13b1-4a67-b346-986d79f1e098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_17ea21b3-8f99-4cd2-b735-061858abbc45" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7a4c913c-13b1-4a67-b346-986d79f1e098" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="i417c982ab45b437b8920c87df8a307d0_FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a64587cb-3e48-4b7a-9159-f6f92d6a458d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a64587cb-3e48-4b7a-9159-f6f92d6a458d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_08202e0c-acb6-4d33-ae0c-41d9ebb62a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_08202e0c-acb6-4d33-ae0c-41d9ebb62a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_1eb9eb5a-3ce1-431e-a281-f8e636271dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_FairValueNetAssetLiability_1eb9eb5a-3ce1-431e-a281-f8e636271dc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b15ce4b7-7433-46f7-bf1b-d66088c88bfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b15ce4b7-7433-46f7-bf1b-d66088c88bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73b2814c-bf5f-418e-9b6c-17067572b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_73b2814c-bf5f-418e-9b6c-17067572b0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1082a8b7-a6c9-4c3a-a0c9-b93d1762edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1082a8b7-a6c9-4c3a-a0c9-b93d1762edfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_392f7065-6a20-4d49-9d9d-43d804dcd957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_392f7065-6a20-4d49-9d9d-43d804dcd957" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0a7d7236-6008-42cf-99a6-c436429895b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0a7d7236-6008-42cf-99a6-c436429895b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_adf0daac-7d14-4953-be0f-33b35541a1dc" xlink:href="mygn-20211231.xsd#mygn_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0a7d7236-6008-42cf-99a6-c436429895b5" xlink:to="loc_mygn_ContingentConsiderationMember_adf0daac-7d14-4953-be0f-33b35541a1dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f0fd14a9-473f-4d51-817e-2bbce76fd2fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f0fd14a9-473f-4d51-817e-2bbce76fd2fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fbc08453-c725-4b03-b9fd-9a71cbb56e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fbc08453-c725-4b03-b9fd-9a71cbb56e5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_149f48bc-2c70-422e-862e-5b672c6e769f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_149f48bc-2c70-422e-862e-5b672c6e769f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_6e3b8467-cb5e-4b2c-8c98-04e3de547cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_MunicipalBondsMember_6e3b8467-cb5e-4b2c-8c98-04e3de547cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_347a4194-f031-4cdb-b317-d0bd8930d3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_347a4194-f031-4cdb-b317-d0bd8930d3ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9799ca9e-5f6a-4c72-a515-4435e29d5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9799ca9e-5f6a-4c72-a515-4435e29d5e2e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended" id="icabcc637ffb84f6291223f159823a4a0_PropertyPlantandEquipmentNetBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dc7ffcdb-d067-4933-9c6e-5f29512cc9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dc7ffcdb-d067-4933-9c6e-5f29512cc9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b18b87e5-3d35-4285-aa0e-3657c3e3f48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b18b87e5-3d35-4285-aa0e-3657c3e3f48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72a3418b-e8cf-47ab-ba14-aa44625ca8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72a3418b-e8cf-47ab-ba14-aa44625ca8e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4f0d1f02-aaca-4ac6-bffc-8cebe200b422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4f0d1f02-aaca-4ac6-bffc-8cebe200b422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fde4f371-dc96-4c84-aff8-e8f5bbaec8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:to="loc_us-gaap_EquipmentMember_fde4f371-dc96-4c84-aff8-e8f5bbaec8a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="extended" id="i3691649657f747e8b7eb4720885f50aa_PropertyPlantandEquipmentNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a9be860-84f4-424b-82a0-8a91d997f4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_62c6b548-ebb3-4136-b9b2-9a0a4e5ae5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a9be860-84f4-424b-82a0-8a91d997f4c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_62c6b548-ebb3-4136-b9b2-9a0a4e5ae5fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a9be860-84f4-424b-82a0-8a91d997f4c3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_beefab26-74d8-41be-8c58-cdf5d7b3b89d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_beefab26-74d8-41be-8c58-cdf5d7b3b89d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68cce006-84d7-43ee-a0cc-69dfba7269ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68cce006-84d7-43ee-a0cc-69dfba7269ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_6148e776-4bc5-40c0-ad6b-a64e92a7a5a6" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68cce006-84d7-43ee-a0cc-69dfba7269ff" xlink:to="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_6148e776-4bc5-40c0-ad6b-a64e92a7a5a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="idd87524c38744d1eb6afd2aa66eb2a9c_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:href="mygn-20211231.xsd#mygn_GoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4b7ee42a-5852-4bd8-8c64-0be3eb2f3437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4b7ee42a-5852-4bd8-8c64-0be3eb2f3437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_de60d387-f7aa-4135-8482-173d1dbe8154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_de60d387-f7aa-4135-8482-173d1dbe8154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_4f5f2a75-66e7-49f2-937d-cfba06bb6eaa" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_4f5f2a75-66e7-49f2-937d-cfba06bb6eaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_d831ed66-0a2e-4632-bcaa-1486de41bd1d" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_d831ed66-0a2e-4632-bcaa-1486de41bd1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_32fa3ce0-8831-428d-ace5-9f500d600072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_32fa3ce0-8831-428d-ace5-9f500d600072" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4c70b303-6151-4032-b7d2-b5267cbfba18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4c70b303-6151-4032-b7d2-b5267cbfba18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b0a08613-70fc-42c8-bb23-70b4f83d063c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b0a08613-70fc-42c8-bb23-70b4f83d063c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:href="mygn-20211231.xsd#mygn_GoodwillAndIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_8394e36a-ca40-43be-a821-d10c5ce7b181_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:to="loc_us-gaap_ReportingUnitDomain_8394e36a-ca40-43be-a821-d10c5ce7b181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:to="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneReportingUnitMember_c05c0134-a73f-4b6c-8081-146a1428fde0" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:to="loc_mygn_MyriadAutoimmuneReportingUnitMember_c05c0134-a73f-4b6c-8081-146a1428fde0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ClinicReportingUnitMember_07117d71-fb72-4aa7-95b8-ce9a6413b09a" xlink:href="mygn-20211231.xsd#mygn_ClinicReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:to="loc_mygn_ClinicReportingUnitMember_07117d71-fb72-4aa7-95b8-ce9a6413b09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_90879077-a0f7-48ba-96c2-a351f15d6bea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_90879077-a0f7-48ba-96c2-a351f15d6bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01849078-a456-436f-8d6a-4d2797505ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01849078-a456-436f-8d6a-4d2797505ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_72c46854-8778-488c-88e6-b2ce7194366b" xlink:href="mygn-20211231.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01849078-a456-436f-8d6a-4d2797505ded" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_72c46854-8778-488c-88e6-b2ce7194366b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_56177104-e118-42dc-83d1-5b7aac6a6003" xlink:href="mygn-20211231.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_56177104-e118-42dc-83d1-5b7aac6a6003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_401fec93-4b01-482a-a838-e6ef6a51fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:to="loc_us-gaap_CustomerRelationshipsMember_401fec93-4b01-482a-a838-e6ef6a51fec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_56dccd18-8f60-48e6-836d-0f94c77ee4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:to="loc_us-gaap_TrademarksMember_56dccd18-8f60-48e6-836d-0f94c77ee4d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7531e73-8c04-4fee-b4d4-7327b4f6feb4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:to="loc_srt_RangeMember_a7531e73-8c04-4fee-b4d4-7327b4f6feb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:to="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4fd550a-db0f-4fb7-9795-06657114dcf7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:to="loc_srt_MinimumMember_a4fd550a-db0f-4fb7-9795-06657114dcf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eaebf57d-8431-4700-bb49-48b0df53ed9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:to="loc_srt_MaximumMember_eaebf57d-8431-4700-bb49-48b0df53ed9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8e44ea48-ad22-455e-85bc-23c68dd71010_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8e44ea48-ad22-455e-85bc-23c68dd71010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0efc9804-29e9-4c38-8523-704c1349f9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0efc9804-29e9-4c38-8523-704c1349f9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63dd60fb-96bf-49fc-a9d3-4ba463969ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0efc9804-29e9-4c38-8523-704c1349f9f5" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63dd60fb-96bf-49fc-a9d3-4ba463969ef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0ea77245-140c-4638-975e-f0a7cc568553_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0ea77245-140c-4638-975e-f0a7cc568553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77ef04a6-b775-4445-81f0-ae9d626ec9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77ef04a6-b775-4445-81f0-ae9d626ec9bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_13659b9c-8c81-4dfa-8673-a18b531cfafc" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77ef04a6-b775-4445-81f0-ae9d626ec9bd" xlink:to="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_13659b9c-8c81-4dfa-8673-a18b531cfafc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="i866fc72a84974c3e8a1e21f8c90ef820_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:href="mygn-20211231.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bea6ad2-debf-499e-ac59-ef31519f55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bea6ad2-debf-499e-ac59-ef31519f55d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37fff5b3-2bf3-4efb-9c9c-74659c811a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37fff5b3-2bf3-4efb-9c9c-74659c811a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f012335d-19b5-4bc2-b7a7-e49eeb41df39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f012335d-19b5-4bc2-b7a7-e49eeb41df39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e321f4e-f667-4e2d-8b1d-633b45cbcd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e321f4e-f667-4e2d-8b1d-633b45cbcd15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5c099d3f-4521-418c-b103-f0994c48ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5c099d3f-4521-418c-b103-f0994c48ed99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2e0a5ba0-72e6-4338-af15-cf8b8612ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2e0a5ba0-72e6-4338-af15-cf8b8612ce0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7721095-16a9-4fce-ae09-643761d16ed7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7721095-16a9-4fce-ae09-643761d16ed7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3594fa46-e514-4535-95ac-94600af477c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3594fa46-e514-4535-95ac-94600af477c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_4f7edaff-e9b5-4167-b412-b0c8941a3df3" xlink:href="mygn-20211231.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3594fa46-e514-4535-95ac-94600af477c8" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_4f7edaff-e9b5-4167-b412-b0c8941a3df3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_6f01b780-129a-4494-bc2d-b26fecdfe828" xlink:href="mygn-20211231.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_6f01b780-129a-4494-bc2d-b26fecdfe828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1fd09bec-49cb-480a-bc6b-adeb13590e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1fd09bec-49cb-480a-bc6b-adeb13590e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_48aa4b4e-f234-4373-8fff-ccfc3fc73314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:to="loc_us-gaap_TrademarksMember_48aa4b4e-f234-4373-8fff-ccfc3fc73314" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#LongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="extended" id="id9dae93424f147a39211cac9998eec0c_LongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_59c7fe46-7663-48d8-9df6-765655eec639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_59c7fe46-7663-48d8-9df6-765655eec639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_97788fef-755c-4bf2-be51-d4f9704430c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_97788fef-755c-4bf2-be51-d4f9704430c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_111c69c2-aa7c-41c2-9fbb-2f557483c156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_111c69c2-aa7c-41c2-9fbb-2f557483c156" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_39f8c1cc-495a-4530-a4ea-bab1f34b9fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_39f8c1cc-495a-4530-a4ea-bab1f34b9fd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage_ee2f91d4-7cca-449f-af61-e6f1e3c4daf8" xlink:href="mygn-20211231.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_mygn_DebtInstrumentLIBORFloorPercentage_ee2f91d4-7cca-449f-af61-e6f1e3c4daf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_e0f36595-05d2-4b11-bca3-fbafe1ebe3f1" xlink:href="mygn-20211231.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_e0f36595-05d2-4b11-bca3-fbafe1ebe3f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_c0713c6e-7bc6-4a46-8d22-98be0cc6ab47" xlink:href="mygn-20211231.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_c0713c6e-7bc6-4a46-8d22-98be0cc6ab47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_205b8b50-1964-42a7-af39-a57b9621d027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_205b8b50-1964-42a7-af39-a57b9621d027" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1e7705c-c6ca-4c67-95d3-e907f675b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_LongTermDebt_a1e7705c-c6ca-4c67-95d3-e907f675b68a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6c242925-bd04-44d7-8cb9-808e6469bba8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:to="loc_us-gaap_CreditFacilityDomain_6c242925-bd04-44d7-8cb9-808e6469bba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2bfbe98-7658-4682-ac3f-3cbdc9302258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:to="loc_us-gaap_CreditFacilityDomain_e2bfbe98-7658-4682-ac3f-3cbdc9302258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bf88c941-e931-45cb-8116-b8bbf9b2724d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e2bfbe98-7658-4682-ac3f-3cbdc9302258" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bf88c941-e931-45cb-8116-b8bbf9b2724d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_511a1451-0c6c-45b1-8901-f577f9433d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_511a1451-0c6c-45b1-8901-f577f9433d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_81e8785b-fab0-4d26-a305-5958f2e2333b" xlink:href="mygn-20211231.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_511a1451-0c6c-45b1-8901-f577f9433d40" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_81e8785b-fab0-4d26-a305-5958f2e2333b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_862217e8-366b-48de-afd5-cc14e0bbf06c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:to="loc_us-gaap_VariableRateDomain_862217e8-366b-48de-afd5-cc14e0bbf06c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21709740-c1d3-43eb-90cd-438b50447402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:to="loc_us-gaap_VariableRateDomain_21709740-c1d3-43eb-90cd-438b50447402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7e95485e-ce65-449f-b165-6c0adb09d953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_21709740-c1d3-43eb-90cd-438b50447402" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7e95485e-ce65-449f-b165-6c0adb09d953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d67a376b-7530-4f72-9812-bc95ec2afd14_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d67a376b-7530-4f72-9812-bc95ec2afd14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e24f0d56-5434-42fb-a457-0528d2b4c2d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e24f0d56-5434-42fb-a457-0528d2b4c2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0a419259-b125-40a0-a5a5-047c57c609a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e24f0d56-5434-42fb-a457-0528d2b4c2d5" xlink:to="loc_srt_ScenarioForecastMember_0a419259-b125-40a0-a5a5-047c57c609a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46dff362-4d75-48ef-af51-dcf598542cd6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:to="loc_srt_RangeMember_46dff362-4d75-48ef-af51-dcf598542cd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:to="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aed8ca2a-353b-466b-99f5-86d55ac5ed89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:to="loc_srt_MinimumMember_aed8ca2a-353b-466b-99f5-86d55ac5ed89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99bc5872-9251-4c90-aa14-9ed3c7892c62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:to="loc_srt_MaximumMember_99bc5872-9251-4c90-aa14-9ed3c7892c62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i91c342d87eb7400e9b9815ec29d0a128_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4348f3f-92c3-4845-b898-de82be4504e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4348f3f-92c3-4845-b898-de82be4504e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_679e80a3-ea40-41be-b1cd-5730427efd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_679e80a3-ea40-41be-b1cd-5730427efd48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffa0835e-24cb-41d6-970a-5135655fc11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffa0835e-24cb-41d6-970a-5135655fc11a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ed587ca-1724-47dc-923e-3be110d9450d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ed587ca-1724-47dc-923e-3be110d9450d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cdbc2715-b761-4b0e-833e-e84364bd9457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cdbc2715-b761-4b0e-833e-e84364bd9457" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98176f9a-7053-4902-885b-1f91003f2acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98176f9a-7053-4902-885b-1f91003f2acc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff571c62-6d0c-42cb-8c34-a3af48b32d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff571c62-6d0c-42cb-8c34-a3af48b32d2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ce43cad6-f614-48a1-be72-e29d8f813bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ce43cad6-f614-48a1-be72-e29d8f813bd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2d7b8408-39c6-45d0-a3b8-02cd70c41560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2d7b8408-39c6-45d0-a3b8-02cd70c41560" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_403efcb6-9211-472e-84db-75b53c148006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_403efcb6-9211-472e-84db-75b53c148006" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a1903cb-f77d-4970-b79b-1f46a101c061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a1903cb-f77d-4970-b79b-1f46a101c061" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_573acce0-843c-4646-ae06-49336207b717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_573acce0-843c-4646-ae06-49336207b717" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_5118c807-0a8c-4600-808c-981917932221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_5118c807-0a8c-4600-808c-981917932221" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_44f63828-1b44-47d3-97fe-d5184df0b3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_44f63828-1b44-47d3-97fe-d5184df0b3c4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a059f23e-122c-43c0-a7f2-63e71c618b58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a059f23e-122c-43c0-a7f2-63e71c618b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd745c06-bda6-43b4-a40d-6e49766de8db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd745c06-bda6-43b4-a40d-6e49766de8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:href="mygn-20211231.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd745c06-bda6-43b4-a40d-6e49766de8db" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_79efff2b-c131-4d7e-9bfc-1eedcd303969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_79efff2b-c131-4d7e-9bfc-1eedcd303969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9dd3f23f-af0f-4f10-a234-22df12e0c0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9dd3f23f-af0f-4f10-a234-22df12e0c0a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e42aa52-44f6-4323-8d54-ab911b324d1a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e42aa52-44f6-4323-8d54-ab911b324d1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_84a4f87a-6653-4bdb-bf95-49e7af9f4878" xlink:href="mygn-20211231.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:to="loc_mygn_NonEmployeeDirectorMember_84a4f87a-6653-4bdb-bf95-49e7af9f4878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_64997f58-fdb3-42fd-9ad4-23e73cfbfb28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:to="loc_srt_ChiefExecutiveOfficerMember_64997f58-fdb3-42fd-9ad4-23e73cfbfb28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ExecutiveOfficersAndSeniorPositionsMember_313ce21b-3bb3-4494-b5cc-90f743026137" xlink:href="mygn-20211231.xsd#mygn_ExecutiveOfficersAndSeniorPositionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:to="loc_mygn_ExecutiveOfficersAndSeniorPositionsMember_313ce21b-3bb3-4494-b5cc-90f743026137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8f11d980-e107-4142-8cb9-62a882e05044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:to="loc_us-gaap_VestingDomain_8f11d980-e107-4142-8cb9-62a882e05044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:to="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_67f2b98e-34ed-48c6-bc32-4ef03af914ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_67f2b98e-34ed-48c6-bc32-4ef03af914ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_67a9ed88-9dd8-4f61-8592-8d6bba45d931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_67a9ed88-9dd8-4f61-8592-8d6bba45d931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_18a3c569-c906-491d-be58-6715e77019ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:to="loc_us-gaap_PlanNameDomain_18a3c569-c906-491d-be58-6715e77019ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:to="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_2b3d8220-6b46-4bce-9fd5-e0923d9b12f2" xlink:href="mygn-20211231.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_2b3d8220-6b46-4bce-9fd5-e0923d9b12f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0530c557-fca8-4317-ae7f-636a79e221ba" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0530c557-fca8-4317-ae7f-636a79e221ba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails" xlink:type="extended" id="i755c5d714d744d0ca6e20f1cbad3ee4b_StockBasedCompensationStockOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_72c4d599-52cb-47e7-b3c6-4ec35e028123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_72c4d599-52cb-47e7-b3c6-4ec35e028123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c9514e57-afb4-4a28-bb6c-cbeedfad642d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c9514e57-afb4-4a28-bb6c-cbeedfad642d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1afc9b36-6a21-4bed-960d-fd5374fc0db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1afc9b36-6a21-4bed-960d-fd5374fc0db5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_96c515d5-5bef-47c1-9097-d3e47857bae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_96c515d5-5bef-47c1-9097-d3e47857bae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_908e2625-87a8-4773-b13e-dd3143345bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_908e2625-87a8-4773-b13e-dd3143345bcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8e37dcd7-32f3-46f2-9d82-dd59de5755a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8e37dcd7-32f3-46f2-9d82-dd59de5755a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeOneMember_b158ae8e-cbfa-427f-9720-7234e3454efa" xlink:href="mygn-20211231.xsd#mygn_RangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:to="loc_mygn_RangeOneMember_b158ae8e-cbfa-427f-9720-7234e3454efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeTwoMember_103e5a23-b483-43aa-8ad8-ee591d1e2ff7" xlink:href="mygn-20211231.xsd#mygn_RangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:to="loc_mygn_RangeTwoMember_103e5a23-b483-43aa-8ad8-ee591d1e2ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeThreeMember_0e9ed508-d937-42cd-aaf7-061aaaa9be6b" xlink:href="mygn-20211231.xsd#mygn_RangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:to="loc_mygn_RangeThreeMember_0e9ed508-d937-42cd-aaf7-061aaaa9be6b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="iddf2bd0a1bac4d7198ec9d88430c1f66_StockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ceb0d95-cf79-4f5d-9452-e27679abebd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ceb0d95-cf79-4f5d-9452-e27679abebd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9c5c2d8e-3bdc-4293-ac9d-7d7a0a72f1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9c5c2d8e-3bdc-4293-ac9d-7d7a0a72f1ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_96910d16-2ea5-423e-a526-f36f2963751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_96910d16-2ea5-423e-a526-f36f2963751f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be45ac04-1429-4fcb-ac34-7c63e31be34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be45ac04-1429-4fcb-ac34-7c63e31be34f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a0ac18c5-cd33-41c7-9c27-3462df01d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6e5987b0-3101-4e37-a7af-7fd94da0e0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6e5987b0-3101-4e37-a7af-7fd94da0e0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2179d41a-24ac-436c-bcd0-1e455c662306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2179d41a-24ac-436c-bcd0-1e455c662306" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ddb17db-2d57-4a65-99a6-91c20f69012a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ddb17db-2d57-4a65-99a6-91c20f69012a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_83e59e80-7f21-4b46-a04f-fc003005bcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_83e59e80-7f21-4b46-a04f-fc003005bcd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_960efca9-1234-49bd-a516-a931128a7138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:to="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4aba39d2-e0fb-4baa-ad5f-239d6befd696_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4aba39d2-e0fb-4baa-ad5f-239d6befd696_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d7217c9-19af-4508-94a6-90f21943de99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d7217c9-19af-4508-94a6-90f21943de99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1f69d93a-37d5-4cd4-af83-bc168fcbdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d7217c9-19af-4508-94a6-90f21943de99" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1f69d93a-37d5-4cd4-af83-bc168fcbdcd4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i50071b29ef5c4852806cc742b1fefc54_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37cac3fe-a8ad-48a4-b812-b46939a64f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5e5df307-1f22-4f7e-a481-d2c5870f4903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37cac3fe-a8ad-48a4-b812-b46939a64f4e" xlink:to="loc_us-gaap_ShareBasedCompensation_5e5df307-1f22-4f7e-a481-d2c5870f4903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37cac3fe-a8ad-48a4-b812-b46939a64f4e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember_bacbbdf3-4ef5-4fe0-8461-5f8342a5e7b4" xlink:href="mygn-20211231.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_mygn_CostOfMolecularDiagnosticTestingMember_bacbbdf3-4ef5-4fe0-8461-5f8342a5e7b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_7681f636-a679-46f8-807e-5de156ac174a" xlink:href="mygn-20211231.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_7681f636-a679-46f8-807e-5de156ac174a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_05994357-6030-4b49-807f-4541990b9591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_05994357-6030-4b49-807f-4541990b9591" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2403d9f1-4f74-428b-a1c5-e72d97db3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2403d9f1-4f74-428b-a1c5-e72d97db3c75" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationAggregateIntrinsicValueDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="extended" id="i62ea31ac2f214614a8c4974dcd1da68a_StockBasedCompensationAggregateIntrinsicValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7412a58f-6e7e-4e85-91b8-f52899075e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7412a58f-6e7e-4e85-91b8-f52899075e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9cf0969d-7380-45f0-a532-20bcf78703d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9cf0969d-7380-45f0-a532-20bcf78703d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_ab772c81-d2f9-49d4-a25d-8e969eb63ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_ab772c81-d2f9-49d4-a25d-8e969eb63ac3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:to="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c93945c-a9b8-498c-95c4-ea2e2c37ce11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c93945c-a9b8-498c-95c4-ea2e2c37ce11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbcb6f82-5a6f-478b-b70f-cdd8294332e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbcb6f82-5a6f-478b-b70f-cdd8294332e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_382ca739-4466-4a57-ace7-d00efce986b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbcb6f82-5a6f-478b-b70f-cdd8294332e2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_382ca739-4466-4a57-ace7-d00efce986b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="extended" id="i3e057558c3944230a416ab376cc9acd9_StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_d5fbc065-8387-497f-b4f6-365bc0dfccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_d5fbc065-8387-497f-b4f6-365bc0dfccdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_8118b7f2-d3fd-4d7c-956e-16f9b223fe02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_8118b7f2-d3fd-4d7c-956e-16f9b223fe02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:to="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6fb1dc2a-27bd-4bc6-9429-303deee71329_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:to="loc_us-gaap_PlanNameDomain_6fb1dc2a-27bd-4bc6-9429-303deee71329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_415a0110-0b04-411e-b9b5-7f14db4eec6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:to="loc_us-gaap_PlanNameDomain_415a0110-0b04-411e-b9b5-7f14db4eec6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_5475edcd-28cf-4504-8250-26a6f65303bc" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_415a0110-0b04-411e-b9b5-7f14db4eec6a" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_5475edcd-28cf-4504-8250-26a6f65303bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationValuationAssumptionsforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="extended" id="i5b73052848414625a9bb28ea2e2a03f7_StockBasedCompensationValuationAssumptionsforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f479f06e-627c-42fa-bbdf-d3f352e30b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f479f06e-627c-42fa-bbdf-d3f352e30b07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cf8f2c88-ceba-4ae9-ae16-9219949802c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cf8f2c88-ceba-4ae9-ae16-9219949802c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_da1a9efc-e3cd-46e7-aab8-e4a48f6979f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_da1a9efc-e3cd-46e7-aab8-e4a48f6979f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64e26a0f-30a2-4cc2-b6f7-5efb07a57c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64e26a0f-30a2-4cc2-b6f7-5efb07a57c79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_55bbc4cd-92fc-4e1b-8139-472f4c0a977f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_55bbc4cd-92fc-4e1b-8139-472f4c0a977f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f479f06e-627c-42fa-bbdf-d3f352e30b07" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:to="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_479a37c5-60e7-408c-b713-884101a58785_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:to="loc_us-gaap_PlanNameDomain_479a37c5-60e7-408c-b713-884101a58785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9dd1b101-953d-435c-8496-63d3c4ae0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:to="loc_us-gaap_PlanNameDomain_9dd1b101-953d-435c-8496-63d3c4ae0f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0e4e8abf-ea47-4440-a6d6-fec8bafe7017" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9dd1b101-953d-435c-8496-63d3c4ae0f63" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0e4e8abf-ea47-4440-a6d6-fec8bafe7017" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i6f004e07316d458db5ef7a6f5f5077ec_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_f2306c91-89de-4a44-9eec-f192283584b3" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_f2306c91-89de-4a44-9eec-f192283584b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupCapitalLossOnTaxBasis_816adc36-ce77-40d8-b786-768e0fc35c3d" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupCapitalLossOnTaxBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_DisposalGroupCapitalLossOnTaxBasis_816adc36-ce77-40d8-b786-768e0fc35c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupCapitalGainOnDivestiture_9905d757-c4dc-448c-95ce-cae2f62d8a49" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupCapitalGainOnDivestiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_DisposalGroupCapitalGainOnDivestiture_9905d757-c4dc-448c-95ce-cae2f62d8a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NumberOfDivestitures_42e0274b-b778-48b5-bda7-d9598f1b0998" xlink:href="mygn-20211231.xsd#mygn_NumberOfDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_NumberOfDivestitures_42e0274b-b778-48b5-bda7-d9598f1b0998" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_06edc429-d2d6-4424-a9dd-d02e2a8c2f56" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_06edc429-d2d6-4424-a9dd-d02e2a8c2f56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_6bbc66e4-e819-46ba-8d45-9f9bfab1e7ac" xlink:href="mygn-20211231.xsd#mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_6bbc66e4-e819-46ba-8d45-9f9bfab1e7ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_abff445d-bb38-4f2c-beb1-6875453872ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_abff445d-bb38-4f2c-beb1-6875453872ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_750acb95-7cb9-4a0a-b39a-ea04d1cc3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_750acb95-7cb9-4a0a-b39a-ea04d1cc3bb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f1c2bc63-ce5a-4463-b319-84219e6f63b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f1c2bc63-ce5a-4463-b319-84219e6f63b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e7655d66-4bdd-436b-b034-7be1d3f8a7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:to="loc_us-gaap_ForeignCountryMember_e7655d66-4bdd-436b-b034-7be1d3f8a7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e3009b95-d455-45d9-883e-c71d00b381e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e3009b95-d455-45d9-883e-c71d00b381e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_f04a8a5b-ade8-4fd0-adda-d4d0f9388d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_f04a8a5b-ade8-4fd0-adda-d4d0f9388d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_4bc43ead-e838-48ed-94f3-50d180fe4444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_4bc43ead-e838-48ed-94f3-50d180fe4444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_017a79db-f1be-4c6b-ace6-89ea59e2c66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_017a79db-f1be-4c6b-ace6-89ea59e2c66d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:to="loc_us-gaap_TaxPeriodDomain_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:to="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_869e5d0d-8be6-4677-8b31-05282dbe9865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:to="loc_us-gaap_EarliestTaxYearMember_869e5d0d-8be6-4677-8b31-05282dbe9865" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_3fbb5e15-8f8f-4d89-a390-835943462a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:to="loc_us-gaap_LatestTaxYearMember_3fbb5e15-8f8f-4d89-a390-835943462a2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="extended" id="i886f1a1856444cbca4ab20fe5dd3cea5_IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_84af3704-27a1-4092-aaea-8d1983b0bda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_84af3704-27a1-4092-aaea-8d1983b0bda8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_69c02d0d-ca2b-4296-85fe-f60dd746597c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_69c02d0d-ca2b-4296-85fe-f60dd746597c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_503ec46b-66d3-42b5-8b5f-80d71e7dff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_503ec46b-66d3-42b5-8b5f-80d71e7dff4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_22cbb515-f372-45a1-bbc3-e56e102dd868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_22cbb515-f372-45a1-bbc3-e56e102dd868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLossCarryforwardsExpirationYear_cb84e688-80d2-4a03-a75e-ea97a256e513" xlink:href="mygn-20211231.xsd#mygn_OperatingLossCarryforwardsExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_mygn_OperatingLossCarryforwardsExpirationYear_cb84e688-80d2-4a03-a75e-ea97a256e513" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TaxCreditCarryforwardsExpirationDate_73f1a3ba-b183-4280-af38-7ca8e41a673a" xlink:href="mygn-20211231.xsd#mygn_TaxCreditCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_mygn_TaxCreditCarryforwardsExpirationDate_73f1a3ba-b183-4280-af38-7ca8e41a673a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5a238ff1-f327-46f0-8c0d-25173310ae48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5a238ff1-f327-46f0-8c0d-25173310ae48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8a91517d-a966-4d85-b58e-2faf693d4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:to="loc_us-gaap_DomesticCountryMember_8a91517d-a966-4d85-b58e-2faf693d4d2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_200c0265-3e6e-48b0-9ffa-0d844cb11f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_200c0265-3e6e-48b0-9ffa-0d844cb11f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_265f45af-4e00-499b-951c-58a96229eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:to="loc_us-gaap_ForeignCountryMember_265f45af-4e00-499b-951c-58a96229eb2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_6d6b27db-6f36-45a9-a2c5-48796bc22f8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_6d6b27db-6f36-45a9-a2c5-48796bc22f8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_bedc577c-5baa-4d4d-823f-5be8f41923f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_bedc577c-5baa-4d4d-823f-5be8f41923f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_UT_ebd7730e-00db-4742-9323-62a37c3548c6" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_UT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_stpr_UT_ebd7730e-00db-4742-9323-62a37c3548c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_93792258-3020-414c-8810-f02aa12d1ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_93792258-3020-414c-8810-f02aa12d1ce7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherStateMember_964f3148-a753-4b7d-a3b0-3c849b3c1078" xlink:href="mygn-20211231.xsd#mygn_OtherStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_mygn_OtherStateMember_964f3148-a753-4b7d-a3b0-3c849b3c1078" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_9734091c-0667-4d0b-b15b-23977709f739_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_9734091c-0667-4d0b-b15b-23977709f739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_b5a0f70b-2305-4b55-a8b1-2dba029a6dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_b5a0f70b-2305-4b55-a8b1-2dba029a6dcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_1c666e1f-c5b2-4fa8-bb1b-08c1e6f38528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:to="loc_us-gaap_ResearchMember_1c666e1f-c5b2-4fa8-bb1b-08c1e6f38528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da5823d6-4692-4e26-9191-9ad26c914fa7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:to="loc_srt_RangeMember_da5823d6-4692-4e26-9191-9ad26c914fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:to="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_525e80cc-8edf-469f-8881-f0c1eb217754" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:to="loc_srt_MinimumMember_525e80cc-8edf-469f-8881-f0c1eb217754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d22eae3-7f70-41f3-b59f-a97d1684083e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:to="loc_srt_MaximumMember_2d22eae3-7f70-41f3-b59f-a97d1684083e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ib9f3cdc557594397aebac41267da26fc_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_e5ca8d68-3856-4f5c-b984-d1c52f84e193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:to="loc_us-gaap_LitigationReserveCurrent_e5ca8d68-3856-4f5c-b984-d1c52f84e193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_01c70f09-2d19-4ed1-abbe-d8cb58b53bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_01c70f09-2d19-4ed1-abbe-d8cb58b53bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:to="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:to="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d6a14f6b-dd25-464a-b881-fac5b31c9e61_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:to="loc_srt_LitigationCaseTypeDomain_d6a14f6b-dd25-464a-b881-fac5b31c9e61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:to="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CrescendoBioscienceIncMember_881d3766-6f09-4ec1-8740-dea8cda59cc4" xlink:href="mygn-20211231.xsd#mygn_CrescendoBioscienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:to="loc_mygn_CrescendoBioscienceIncMember_881d3766-6f09-4ec1-8740-dea8cda59cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AbelliAndPricoloMatterMember_dbc52f03-e233-4857-bb9a-8f17a34974f6" xlink:href="mygn-20211231.xsd#mygn_AbelliAndPricoloMatterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:to="loc_mygn_AbelliAndPricoloMatterMember_dbc52f03-e233-4857-bb9a-8f17a34974f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5c97ad94-36d9-4e5b-8c2c-d824f0813348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5c97ad94-36d9-4e5b-8c2c-d824f0813348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4f581009-75ca-4342-9e35-bb9fadf706aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5c97ad94-36d9-4e5b-8c2c-d824f0813348" xlink:to="loc_us-gaap_SubsequentEventMember_4f581009-75ca-4342-9e35-bb9fadf706aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i0e0418d8c0c84f0fbe7f1faf405e812e_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ab199739-4904-40bc-99d4-6d5de4f69b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ab199739-4904-40bc-99d4-6d5de4f69b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a64e6270-ce6f-4766-9681-e99d62bf8e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_LeaseCost_a64e6270-ce6f-4766-9681-e99d62bf8e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_db5301ef-06ee-4d6b-ba58-d39960982464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_VariableLeaseCost_db5301ef-06ee-4d6b-ba58-d39960982464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_75756ce2-7742-4d94-9927-9ef0bd24bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_ShortTermLeaseCost_75756ce2-7742-4d94-9927-9ef0bd24bbed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_c4ebc6c1-c84d-4df8-bb91-4772493db5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_c4ebc6c1-c84d-4df8-bb91-4772493db5e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_e0c79cdd-c30e-4751-b97a-bb754d8b058d" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_e0c79cdd-c30e-4751-b97a-bb754d8b058d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_28fe867f-616d-4491-abf2-50d4998f6069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_28fe867f-616d-4491-abf2-50d4998f6069" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6240b6d8-9005-460f-ac93-e24d08202305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6240b6d8-9005-460f-ac93-e24d08202305" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:to="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e061fda-cf5e-40be-acb5-a7d48b46cc12_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:to="loc_srt_RangeMember_5e061fda-cf5e-40be-acb5-a7d48b46cc12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:to="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_682bca4b-e731-4fff-9044-1789b6b49228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:to="loc_srt_MinimumMember_682bca4b-e731-4fff-9044-1789b6b49228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19025076-28f0-427b-80b0-a3e89d6bf599" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:to="loc_srt_MaximumMember_19025076-28f0-427b-80b0-a3e89d6bf599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:to="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_a0e13c41-29ad-4022-b56d-ae5f2604c42b_default" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:to="loc_mygn_LeaseArrangementDomain_a0e13c41-29ad-4022-b56d-ae5f2604c42b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_1c26948a-cc96-43ba-ba69-c99ff52bc133" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:to="loc_mygn_LeaseArrangementDomain_1c26948a-cc96-43ba-ba69-c99ff52bc133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_ae61e7b2-2867-45ea-9f01-1c41dee9e56e" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_LeaseArrangementDomain_1c26948a-cc96-43ba-ba69-c99ff52bc133" xlink:to="loc_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_ae61e7b2-2867-45ea-9f01-1c41dee9e56e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="extended" id="if485d7f9ef0246a7861ceec047ea60e5_SegmentandRelatedInformationAssetsbyGeographicalRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_772462b0-ba26-4bce-853c-b0307efb50a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_772462b0-ba26-4bce-853c-b0307efb50a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_cae5499a-d494-40c3-ad35-3ace427e3d51" xlink:href="mygn-20211231.xsd#mygn_AssetsLessCashCashEquivalentsAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_cae5499a-d494-40c3-ad35-3ace427e3d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_004358c5-2332-460a-bf98-d4ad81b965cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_004358c5-2332-460a-bf98-d4ad81b965cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0ff18eee-18e7-49cb-985b-714b9441eaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_Assets_0ff18eee-18e7-49cb-985b-714b9441eaa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:to="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e9a32ef1-f636-411b-a45a-48246a7f9287_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:to="loc_srt_ConsolidationItemsDomain_e9a32ef1-f636-411b-a45a-48246a7f9287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_80a8cf2f-d9e9-4d1d-b846-74678427971f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:to="loc_srt_ConsolidationItemsDomain_80a8cf2f-d9e9-4d1d-b846-74678427971f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_abd1df05-702b-4a21-9f48-b8025a92af33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_80a8cf2f-d9e9-4d1d-b846-74678427971f" xlink:to="loc_srt_ReportableGeographicalComponentsMember_abd1df05-702b-4a21-9f48-b8025a92af33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:to="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:to="loc_srt_SegmentGeographicalDomain_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:to="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_65dd9e53-f7c1-4112-97ac-fe4471540209" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:to="loc_country_US_65dd9e53-f7c1-4112-97ac-fe4471540209" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2c856bab-2d2f-442d-82a6-ea70f7b80031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:to="loc_us-gaap_NonUsMember_2c856bab-2d2f-442d-82a6-ea70f7b80031" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#DivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="extended" id="id80c9f929f7d483da3abdbbc8cca9213_DivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4ab15221-09cf-4597-8b42-a9fc19fe1d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4ab15221-09cf-4597-8b42-a9fc19fe1d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_79ffdee6-3aaf-4e75-a9f5-fc310a5a0b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_79ffdee6-3aaf-4e75-a9f5-fc310a5a0b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_adaca6a3-ccf4-4a19-9c0b-fd886f1f15ba" xlink:href="mygn-20211231.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_adaca6a3-ccf4-4a19-9c0b-fd886f1f15ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5b34094a-4177-447b-b91a-aaada0837814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5b34094a-4177-447b-b91a-aaada0837814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_67724ad4-ecfe-4a0f-bd59-75729577cd3e" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_67724ad4-ecfe-4a0f-bd59-75729577cd3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_0ee7950b-296b-4165-8cfc-08f0fdbb435f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_0ee7950b-296b-4165-8cfc-08f0fdbb435f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_90879135-1a60-46eb-be53-62470a8943f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_InventoryWriteDown_90879135-1a60-46eb-be53-62470a8943f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f9d85d34-9983-481e-a3fe-b85153fdc77d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f9d85d34-9983-481e-a3fe-b85153fdc77d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0ede8233-5b47-4eae-b7e9-edb53783f963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0ede8233-5b47-4eae-b7e9-edb53783f963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a828d8a6-e236-4187-9fc7-1a4eb3fda8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0ede8233-5b47-4eae-b7e9-edb53783f963" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a828d8a6-e236-4187-9fc7-1a4eb3fda8b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_791d006b-e3cd-4517-b649-d19941e46278_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_791d006b-e3cd-4517-b649-d19941e46278_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_4429745b-7d25-46ba-a0be-ff655973f718" xlink:href="mygn-20211231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_4429745b-7d25-46ba-a0be-ff655973f718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_4a69ea6c-2929-4694-8a5b-e72e4fb294a5" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:to="loc_mygn_MyriadRBMIncMember_4a69ea6c-2929-4694-8a5b-e72e4fb294a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_cb53d06c-7032-4c72-9be7-e69b9c6ff01b" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_cb53d06c-7032-4c72-9be7-e69b9c6ff01b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#DivestituresOtherIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended" id="i2992e0dec47c414083089aec117fbf59_DivestituresOtherIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f1684332-7513-4915-b1e4-e62a542a32e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f1684332-7513-4915-b1e4-e62a542a32e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_209ffeaa-444c-4c4f-9432-a2863e0c7e35" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_209ffeaa-444c-4c4f-9432-a2863e0c7e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_6655903e-e8ed-4495-8a97-37ad66954b42" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_6655903e-e8ed-4495-8a97-37ad66954b42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_06c07a13-3b04-4381-93b4-8aedd42ad0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_06c07a13-3b04-4381-93b4-8aedd42ad0a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_58434d7e-ab42-4ad2-804b-0dfdc2c9feba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_58434d7e-ab42-4ad2-804b-0dfdc2c9feba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_fa7aae97-d2e6-46f1-a3fb-e45293000841" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:to="loc_mygn_MyriadRBMIncMember_fa7aae97-d2e6-46f1-a3fb-e45293000841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_a1a7be81-6287-4ea5-affe-a5563b05c6fc" xlink:href="mygn-20211231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_a1a7be81-6287-4ea5-affe-a5563b05c6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_35f564ec-4318-475a-9cce-b41773773f9b" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_35f564ec-4318-475a-9cce-b41773773f9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9ea857d7-44fd-4476-8b9d-29d97ef47357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9ea857d7-44fd-4476-8b9d-29d97ef47357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1dc4fe20-a26b-4cc9-8544-68382f33bffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1dc4fe20-a26b-4cc9-8544-68382f33bffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e8143420-37f1-4369-8481-410f3eebeb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1dc4fe20-a26b-4cc9-8544-68382f33bffc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e8143420-37f1-4369-8481-410f3eebeb12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#BusinessAcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="extended" id="ic434488bae394e69aa39e9f4980060fe_BusinessAcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_14414c62-b2b4-45a6-843a-1658bad92f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_14414c62-b2b4-45a6-843a-1658bad92f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c0d902d9-9c28-46a1-9da6-a3c64594de44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c0d902d9-9c28-46a1-9da6-a3c64594de44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_63d509af-6843-4207-ae7d-2218e55950ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_63d509af-6843-4207-ae7d-2218e55950ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_db44bdd0-bb26-4f6a-9ad4-1e79049d453d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_OperatingExpenses_db44bdd0-bb26-4f6a-9ad4-1e79049d453d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697d00fd-6271-4920-b20e-6fe1816c9a80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697d00fd-6271-4920-b20e-6fe1816c9a80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a98931d5-56ef-4721-9b2d-fe9dbdb2a92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a98931d5-56ef-4721-9b2d-fe9dbdb2a92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CounsylIncMember_fd7d8c8d-532f-430a-9c9a-f2e0c44df842" xlink:href="mygn-20211231.xsd#mygn_CounsylIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a98931d5-56ef-4721-9b2d-fe9dbdb2a92b" xlink:to="loc_mygn_CounsylIncMember_fd7d8c8d-532f-430a-9c9a-f2e0c44df842" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/SubsequentEventDetails" xlink:type="extended" id="i1ed50d6009714b1b8bcd6508d4c2a369_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_1db74b2d-45bc-43a5-b5e2-f56c8ccc6cc7" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_1db74b2d-45bc-43a5-b5e2-f56c8ccc6cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_4f7724ed-369e-4fe1-a9b3-719f8d8f15da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_4f7724ed-369e-4fe1-a9b3-719f8d8f15da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_2ae49f99-df28-4ed1-9d33-2892e38ac27d" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_2ae49f99-df28-4ed1-9d33-2892e38ac27d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7f2f6d2b-5e3d-4080-9f42-366580d25889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7f2f6d2b-5e3d-4080-9f42-366580d25889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_414bea33-4954-40bd-9706-9d46d287d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_414bea33-4954-40bd-9706-9d46d287d01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a1ee5192-da7e-40ae-9de0-81c3bb6e3314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_414bea33-4954-40bd-9706-9d46d287d01e" xlink:to="loc_us-gaap_SubsequentEventMember_a1ee5192-da7e-40ae-9de0-81c3bb6e3314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:to="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_3b233bf6-eb8a-4ae3-b776-bf05d06946ea_default" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:to="loc_mygn_LeaseArrangementDomain_3b233bf6-eb8a-4ae3-b776-bf05d06946ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_32ad51a9-2944-452c-b411-44ea827b472e" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:to="loc_mygn_LeaseArrangementDomain_32ad51a9-2944-452c-b411-44ea827b472e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SaltLakeCityLeaseMember_0d809dfa-9be0-4f86-bcbb-29c32304de5c" xlink:href="mygn-20211231.xsd#mygn_SaltLakeCityLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_LeaseArrangementDomain_32ad51a9-2944-452c-b411-44ea827b472e" xlink:to="loc_mygn_SaltLakeCityLeaseMember_0d809dfa-9be0-4f86-bcbb-29c32304de5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#TransitionPeriodComparativeDataUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails" xlink:type="extended" id="i60200ac3c6814989bee3746069838d4b_TransitionPeriodComparativeDataUnauditedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodFinancialInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bdfc872-3cdd-42b0-8ae1-a2161af33757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bdfc872-3cdd-42b0-8ae1-a2161af33757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6e09e511-c176-44b4-802e-07c5f74cd226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6e09e511-c176-44b4-802e-07c5f74cd226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aafe7edf-b214-4e43-982c-80d909f559e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aafe7edf-b214-4e43-982c-80d909f559e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0324304-bc55-4dc6-8e9b-2fef5519b818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0324304-bc55-4dc6-8e9b-2fef5519b818" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6f122624-ab16-4c7d-8231-378ab06fbf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6f122624-ab16-4c7d-8231-378ab06fbf64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_caa4ad05-1d2b-4528-966a-8b865ae2dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_CostsAndExpenses_caa4ad05-1d2b-4528-966a-8b865ae2dd5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1fc16940-d5a3-437e-a04f-2b44963c9e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_OperatingIncomeLoss_1fc16940-d5a3-437e-a04f-2b44963c9e89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fecfefdc-497e-4ba6-997a-6fc407bf07fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fecfefdc-497e-4ba6-997a-6fc407bf07fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ef801c3f-f3f9-43c2-b6b0-457d10d07616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_InterestExpense_ef801c3f-f3f9-43c2-b6b0-457d10d07616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61d2245a-1f8f-4044-bd17-0a27108aa799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61d2245a-1f8f-4044-bd17-0a27108aa799" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2c972151-60da-4a58-ac10-44c81a93f8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2c972151-60da-4a58-ac10-44c81a93f8e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d286b5e-c026-418d-b54b-8d69c1583838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d286b5e-c026-418d-b54b-8d69c1583838" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a87a09b6-37ff-4f3b-b207-f039cad6ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a87a09b6-37ff-4f3b-b207-f039cad6ef36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_be822d4e-e44b-4cb1-89f8-5798cc7bb411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_ProfitLoss_be822d4e-e44b-4cb1-89f8-5798cc7bb411" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d54609ad-1791-4218-b0b3-d713f1216d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d54609ad-1791-4218-b0b3-d713f1216d62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8086032d-6881-4f57-90ad-2a3bc4b334ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_NetIncomeLoss_8086032d-6881-4f57-90ad-2a3bc4b334ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e676de1-ec7a-40e4-85a0-7f2590f6f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e676de1-ec7a-40e4-85a0-7f2590f6f9df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5ebca9b2-efdc-45b0-b543-0067411c9f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5ebca9b2-efdc-45b0-b543-0067411c9f0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c7bf3af-6c95-4e8b-a3e0-5b3f08c06a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c7bf3af-6c95-4e8b-a3e0-5b3f08c06a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90751e84-9734-4dd4-934c-f9fcc1f45b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90751e84-9734-4dd4-934c-f9fcc1f45b1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodFinancialInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:to="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_60dd2ff6-cc59-499a-9916-da2bbcbfbda0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:to="loc_srt_ProductsAndServicesDomain_60dd2ff6-cc59-499a-9916-da2bbcbfbda0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:to="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_7a4c602f-8b60-4f88-a71b-456a6ed9844e" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_7a4c602f-8b60-4f88-a71b-456a6ed9844e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_3871cfa4-156f-45af-85ce-d516665f2cf2" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_3871cfa4-156f-45af-85ce-d516665f2cf2" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mygn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4990a358-c12e-4899-92d4-a6c626b561e2,g:4a66b582-ad59-47ea-a8a2-59085acc693c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_feb7c2cc-5220-46e1-a74d-b7316bf63e66_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationCARESAct_df595e71-eca5-4dfd-a613-b56367b76597_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationCARESAct_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation CARES Act</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationCARESAct_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationCARESAct" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationCARESAct" xlink:to="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_84a5717b-97bf-44c5-a975-c8512093327c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_0f26215d-2b4d-4c91-bf0d-6a5c10411a8d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_76eb2454-4f48-4f63-8c03-f983a296f6d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense at the statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_95ceb06d-0bcc-44ae-948a-f8f4828bc3ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b8daa255-e4e0-4ff9-a955-df24794f9830_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_35705b24-39a6-493a-bfe1-49a299f0b135_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4185413-10da-4771-bcf5-e42d81dfafb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2580be4a-3092-444b-a534-92ccaeba7170_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_fc255ece-173a-4a46-be84-d11dbc514095_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f75d5ff5-75fc-4068-a618-836e2cc9245e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1a3e403-a1d4-4074-aee9-2808c2da0c10_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TransitionPeriodFinancialInformationTable_ece3e14c-1e23-4bd9-bcbc-462e0453b332_terseLabel_en-US" xlink:label="lab_mygn_TransitionPeriodFinancialInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Financial Information [Table]</link:label>
    <link:label id="lab_mygn_TransitionPeriodFinancialInformationTable_label_en-US" xlink:label="lab_mygn_TransitionPeriodFinancialInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Financial Information [Table]</link:label>
    <link:label id="lab_mygn_TransitionPeriodFinancialInformationTable_documentation_en-US" xlink:label="lab_mygn_TransitionPeriodFinancialInformationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodFinancialInformationTable" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodFinancialInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TransitionPeriodFinancialInformationTable" xlink:to="lab_mygn_TransitionPeriodFinancialInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_39629edb-8cb9-4abe-90da-8d418f678d2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c80154f2-8967-4e36-ad86-692bce7dd981_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b84e3128-9df2-4faa-a1d5-57189b1b62e8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_59116e24-5b2b-4e65-9442-c92e48d20ea9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0d90ed8f-f03a-45ac-b6a9-cb4798ba032c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ca31b32c-dd70-4e68-ac7f-bb16faea5abd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_87dba24f-a442-4fc1-9dfa-5633a47f7a85_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3066c8ad-f9d6-41d6-835c-d64d4861a25c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseArrangementAxis_c8ba4355-0936-4b98-906a-7ae964648d73_terseLabel_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_mygn_LeaseArrangementAxis_label_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_mygn_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseArrangementAxis" xlink:to="lab_mygn_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1bd8cd03-a197-4830-b302-d8eedf383051_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_770b8f16-3345-4889-ae78-8ac5e4799812_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_21bb4373-36fd-48de-a3e7-95a23f29082d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_ff0df1f8-9214-45dc-a2e7-37f9d44fa788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per participant per offering period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5bb20860-f850-4bfb-8794-684184979ba8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_70b437cb-cc84-40db-9b03-7a9eea707741_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration recognized at acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f3f6d33b-ed8e-496e-abf3-12174e996bda_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c4feea17-442d-4d30-8bd1-7c8b6d3e2214_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9c8c7e81-c699-44f9-a335-f5ac70b33389_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_977636ab-6e99-4229-80bb-c29ab4b7ca65_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_91a7496b-b8c2-459c-ac8f-de26bd87e906_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_9c95d7e1-d911-4d30-94e9-6c3d5128f184_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d464865b-500e-4d31-8264-aec613f48e07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfc08d06-9129-4e75-adf9-19ed2e9d440a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_79791b0c-0229-43d7-9fc3-a8c6cf185551_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_b69865d6-276a-4ddb-a098-d15d8da8786f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_994557b0-5cd3-4455-8d7b-1ce7deda683b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TaxCreditCarryforwardsExpirationDate_b834b5e1-242e-412e-99d4-51ec9151fd72_terseLabel_en-US" xlink:label="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit, expiration in year</link:label>
    <link:label id="lab_mygn_TaxCreditCarryforwardsExpirationDate_label_en-US" xlink:label="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforwards Expiration Date</link:label>
    <link:label id="lab_mygn_TaxCreditCarryforwardsExpirationDate_documentation_en-US" xlink:label="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforwards Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TaxCreditCarryforwardsExpirationDate" xlink:href="mygn-20211231.xsd#mygn_TaxCreditCarryforwardsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TaxCreditCarryforwardsExpirationDate" xlink:to="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7fac95c9-138a-43ef-95de-cd5908ae9cc4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a3e74bf9-fe48-41f7-83d0-5dd59d7c5e71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_221f31f7-065c-442b-93bb-5e0dbe04ffaf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a14a1dd-8f66-4b14-b7bd-7fb351ecf9d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based payment expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6bdda69e-a195-4d8a-8fb6-72299c917e51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a40f2ad-3b68-4101-8277-b57cbbaaf765_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2d4ad0e8-8802-41f3-bcce-5c7e5f613ff1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recognized in the statement of operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_df242667-f687-434e-b4fa-f3afae8e22d5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c914dc46-6621-44b4-830f-a422641ef5cc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_26cb341c-da87-4f55-b893-b23002d802ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of exercise prices, minimum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_5122614b-cc75-42c9-9f30-410c721d40f2_terseLabel_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of pharmaceutical and clinical services</link:label>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_label_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Pharmaceutical And Clinical Services [Member]</link:label>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_documentation_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:href="mygn-20211231.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:to="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9436fe69-00f8-423a-87e4-f34cae689975_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_96642d50-ab74-413d-9b6e-2237a204339e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_7cba2da0-2b21-45b8-9b66-9dbf87fba0eb_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges pending settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9325bba2-43b2-4cea-9a38-d02a81e434ab_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e2fac199-cbd5-4f3a-9b5f-7358f2bc1165_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a9d30380-dcd1-47c8-be0f-87765012498b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_5c1aaffd-c423-47a9-8891-421be3977929_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a5f040a6-28b7-467c-a033-66515bcf5967_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_728dfc6c-ce79-4308-b98a-864eca7ecd91_terseLabel_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease area (sq ft)</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_label_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Leased Space</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_documentation_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Leased Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:to="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9b6f0338-55f8-4e42-af84-66b0e7a4a2e8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive options and RSUs excluded from EPS computation</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b93fd2f6-dcd9-45e4-ae9f-459c7ca4326a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_14427ace-77f3-4848-a99c-d2d5a79468f7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_0f699051-57a9-4074-bce9-2c4e5d7a2dbe_terseLabel_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad myPath LLC laboratory</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_label_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad My Path LLC Laboratory [Member]</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_documentation_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad My Path LLC Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember" xlink:href="mygn-20211231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadMyPathLLCLaboratoryMember" xlink:to="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_e641b363-49da-4eac-af26-6aca437a7a1a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_cda17661-6a79-4a9e-82b8-12bd1b74f0cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a15b7b19-1000-4bc0-a711-9379a201f42e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted stock units that vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_03e85ce7-01af-4bd1-a6e8-63694afd97a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e80dee87-be10-433c-8a5a-f74a56329dda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_2a0cb61d-a321-4e30-a1fb-812a809c20f9_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_abdcb2cb-9d3d-4d7b-b605-ddffa2217ab4_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_433689b1-cf50-4ac9-a00e-6b9ceab7def6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d67b72e-4fe2-40cb-8f54-9c1df5ed34ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_c75e0ce2-7c07-420c-8bdf-63902d40a310_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b40ff971-2da0-4cb9-a0c4-d16df7c4063b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_bb2716b8-f1f5-4a5a-9f87-01ec102d92f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of RSUs outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c756ae-c48a-4886-9264-10ba32b5a66f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5082f601-5c98-447f-8629-8a7d4cc385c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f243b1f6-6473-4609-b698-502db45926f5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1eb27877-edd4-4e10-bba0-c0774b0dd680_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_7add6bc6-8008-4288-b74e-62e1d740f5a9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4be14c56-ed58-4fd2-b4e9-0a097bcb4f1d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_4617b3b0-2d17-43bf-9069-cbd70b090a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_dbf1d47c-d998-4624-901f-d5c717062f4d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and long-lived asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_88a0918b-ed96-4b4b-aa4e-965384804bc4_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill and long-lived assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2c2dc0ee-d9c6-455d-825e-51430e41c2a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_3a459351-833e-4e18-8ebc-e774a407cd9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1b226ab6-1605-4d7d-bb7f-3a0e264168d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_fab8fdcb-b29a-44a4-844f-5ec9e82fe627_negatedLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:to="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7b26d6b8-bc55-43e5-a8d9-b79b089923d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_24fbc64e-6fa6-478e-aa96-507aac8b3693_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7641fd54-1d8a-4d61-a351-c763f8b9ba3c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b4e4cf7-8025-4303-8e36-4e0e93cef66a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_5625ba22-cd4d-4a00-80f5-f013c626cd3e_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_eed63db3-6ed7-4b19-90d1-355e4cd1d932_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_8a3a39ea-fd9f-47d8-9b3b-f550cf17cb3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_bbc1196c-3d6d-407f-ba8f-dd3985495931_negatedTerseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Divestitures</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityDivestitures" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerLiabilityDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityDivestitures" xlink:to="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_571a319a-8942-429e-91f1-cae4a97743cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8c512a2e-9953-4b19-8e86-2177ade5f843_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b7f2dbed-9d09-4dba-ad10-6d642e287acd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d51ce12-9253-4c0a-9fd2-6d723b850090_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NumberOfDivestitures_8c8b5401-abe1-4cb6-8041-808660850a94_terseLabel_en-US" xlink:label="lab_mygn_NumberOfDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of divestitures</link:label>
    <link:label id="lab_mygn_NumberOfDivestitures_label_en-US" xlink:label="lab_mygn_NumberOfDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Divestitures</link:label>
    <link:label id="lab_mygn_NumberOfDivestitures_documentation_en-US" xlink:label="lab_mygn_NumberOfDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NumberOfDivestitures" xlink:href="mygn-20211231.xsd#mygn_NumberOfDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NumberOfDivestitures" xlink:to="lab_mygn_NumberOfDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_37150159-ae11-4fd5-a07b-0dca022a03ac_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ea13fa84-2c3d-4547-9b2b-a3d3d8576dfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e6603260-c86d-4a4b-ac6d-a978d5187c0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_e2b4d4e0-c93a-4c67-830d-b71f656c22a0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_cfe2f48f-fbdc-4661-bc6c-7fcc9678cac7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9108d277-3993-4399-b2e8-42def3b040bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_528f901f-4b71-4443-ac01-bca69fb0b364_verboseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period translation adjustments</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_5cebcb8d-c362-4b4c-85d5-91204f453e3d_terseLabel_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation estimate</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_label_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price [Member]</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_documentation_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:href="mygn-20211231.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:to="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_55164b4d-e0b8-4d4f-a818-7853a605f9b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue contributed by acquired entity</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Revenue Reported by Acquired Entity for Last Annual Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod" xlink:to="lab_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_72d38297-23e8-447f-8c98-7cf5fd70eee2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_020f0e4a-859b-49af-880f-f771729a7133_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Dispositions, and Contingent Consideration</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_fb8e3239-a17f-44a7-a662-e90ba369f24d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0168675d-1866-4d06-8a5b-4c354f8be0b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets by Geographical Region</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_85c5ad4b-53bd-462b-a024-1acce473817b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_8d3158a5-8d8e-4bdd-a80d-447ba4494048_negatedTerseLabel_en-US" xlink:label="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_label_en-US" xlink:label="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Increase (Decrease) During Period</link:label>
    <link:label id="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_documentation_en-US" xlink:label="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Increase (Decrease) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:href="mygn-20211231.xsd#mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:to="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3bf2bb11-bde7-4b54-b6fd-05b112b41e53_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_773156ee-5c27-423e-9b82-e6464a48cce5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_b5f4ff2d-f202-4c6a-b250-7fdc9abfc0ee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_09c26b7f-ee71-4a86-8412-8a963999cf0f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_738f508e-fcc3-4931-bff3-e20bd9b8beb2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting weight (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_2d4533b3-86ec-4455-bfb5-b46495d5e002_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d9fb772c-5e63-4a0a-9854-8a1d0d5e3c01_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CARESActOf2020ProviderReliefFundAmount_c685d019-5829-4e1c-9059-86bbc901b536_terseLabel_en-US" xlink:label="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider fund relief under CARES Act</link:label>
    <link:label id="lab_mygn_CARESActOf2020ProviderReliefFundAmount_label_en-US" xlink:label="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C A R E S Act Of2020 Provider Relief Fund Amount</link:label>
    <link:label id="lab_mygn_CARESActOf2020ProviderReliefFundAmount_documentation_en-US" xlink:label="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act of 2020 Provider Relief Fund amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:href="mygn-20211231.xsd#mygn_CARESActOf2020ProviderReliefFundAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:to="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36a9ed27-102a-400f-b4fa-c57d5800d033_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_77de8a25-2347-44a5-a006-8f59e76a371c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_dab8311a-9216-4a62-afa0-23eab0d72ea7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7f4eb4b5-d37a-4486-badf-4a2f6a230c71_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immaterial prior period Medicare claims</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_1773e959-f468-455a-8c84-ea915cf9d58f_terseLabel_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_label_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_documentation_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:href="mygn-20211231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_998d36d1-900b-469d-aa2c-523d381d947a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_29cd184b-0fa0-4271-832a-3f748327debd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d0125ec2-c0fc-4c83-b016-9225e1a94734_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_c5abb424-959b-401a-b513-4a82a1c0b965_terseLabel_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets adjusted for transaction fees</link:label>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_label_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</link:label>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_documentation_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:href="mygn-20211231.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:to="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bc5e47a9-d450-41ea-9a78-7ed9657b5157_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_c2a28462-ff2a-4f9c-b20b-8b519273692d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal agency issues</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_57b2305f-2323-45f3-ac68-004940cbc353_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_49bbb58e-ebe0-4267-90fb-25dfdc6bcd95_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of business and assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LatestTaxYearMember_72f0b0e1-28d9-4644-ad6c-ce0ed82ade7c_terseLabel_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest tax years</link:label>
    <link:label id="lab_us-gaap_LatestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6d3c9b4b-8fe1-4cdd-b956-88a91ad68f10_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a380ba54-d633-4dff-96b8-835c0e7fb37c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7074619d-29c2-449c-b53d-0707a590eac9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2c18c3a-b733-41d1-9aef-7a87b74a2bc7_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2e451c75-66ff-4aa7-ba03-fbe6a46acdf3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CrescendoBioscienceIncMember_bf5710f9-bea7-46b4-9c29-0076636a54bb_terseLabel_en-US" xlink:label="lab_mygn_CrescendoBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CBI</link:label>
    <link:label id="lab_mygn_CrescendoBioscienceIncMember_label_en-US" xlink:label="lab_mygn_CrescendoBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crescendo Bioscience, Inc [Member]</link:label>
    <link:label id="lab_mygn_CrescendoBioscienceIncMember_documentation_en-US" xlink:label="lab_mygn_CrescendoBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crescendo Bioscience, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CrescendoBioscienceIncMember" xlink:href="mygn-20211231.xsd#mygn_CrescendoBioscienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CrescendoBioscienceIncMember" xlink:to="lab_mygn_CrescendoBioscienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_bf4a346c-d11b-49dd-93b5-bd412bc525d2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_5771135e-3ac0-41c0-9bdb-abf4ef62c3e0_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation CARES Act</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RangeOneMember_843c4768-0af3-4e25-b900-15f585959f06_terseLabel_en-US" xlink:label="lab_mygn_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$ 13.38</link:label>
    <link:label id="lab_mygn_RangeOneMember_label_en-US" xlink:label="lab_mygn_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_mygn_RangeOneMember_documentation_en-US" xlink:label="lab_mygn_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeOneMember" xlink:href="mygn-20211231.xsd#mygn_RangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RangeOneMember" xlink:to="lab_mygn_RangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2134c01d-0a12-4273-8849-066966cffce8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_c4970c5c-978b-4000-a322-557f3d46d798_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_f5788e4f-88a6-4b63-8bee-a0e848ab7ebe_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b19334d-91d6-4fab-a428-f87bfcf45d97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_87f34b14-7242-43b5-9dce-8b28a18c512e_terseLabel_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended facility</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_label_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment To Credit Agreement [Member]</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_documentation_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment to Credit Agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember" xlink:href="mygn-20211231.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AmendmentToCreditAgreementMember" xlink:to="lab_mygn_AmendmentToCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_6129eef2-e581-48bf-a321-be4828685785_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1283080d-d5ac-41f5-9b9d-c0d4fe03ee27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_a451cbb4-6dea-461c-abd1-79902dd941bc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock option and employee stock purchase plan expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0623a44c-8f51-4f7f-abbf-195041f0b160_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_0f0d7092-2be8-406b-b076-dbf24f7eb84c_negatedTerseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross unrealized holding gains</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_860c8ee2-0a5c-4efe-a904-b530ba81bd0f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_df384c3d-3141-4726-96ba-7ff277cffac9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d54e9f9e-af44-4b25-8d62-ffd66768dc16_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_f6124a8c-3c45-4f07-83af-2ff80204cef0_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_474a1634-191f-47bb-8571-8376e3d91595_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_20e33c2c-8ce3-4be7-9a4a-0191cb2baceb_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible officer compensation</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Officers Compensation</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense officers compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_923f1c8d-53c6-4de1-b9ad-e12bc06e06dc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_99eafb25-80e4-4aab-bc26-5270e2a988ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c9fe6826-7623-4143-ac34-c55856c7152d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5f79ef3d-c290-4124-b342-7e3720c55d5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77d412e-6a94-413e-8c37-ba94ec065c9c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dd7af740-4f56-45c2-90c0-85bcade126dc_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7ef0cece-0968-4030-8f7e-bc6b39cdc070_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charge</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_723eec64-ecf5-4195-b3f7-18e0c5d8313c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_05d94c07-2501-45b5-b802-b7c6a0d6ebb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_786b01d6-a13f-48ad-afdc-f549a39e84a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d7918252-925c-4cfb-8846-156fbb7e90fb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bb51e7fe-ac99-4fee-94bc-3cfcaa9e65b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_82770664-c8f5-4423-90d0-b3f14d1b0b26_terseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Select operating assets and intellectual property of Myriad Autoimmune business unit</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_e9ef516f-b9e0-40a6-b101-62eaacbfc35e_verboseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune assets</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_label_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets [Member]</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_documentation_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadAutoimmuneAssetsMember" xlink:to="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_da88887f-c796-4eb2-9a66-f544a7d347ae_terseLabel_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of molecular diagnostic testing</link:label>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_label_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Molecular Diagnostic Testing [Member]</link:label>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_documentation_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember" xlink:href="mygn-20211231.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfMolecularDiagnosticTestingMember" xlink:to="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d6423a84-7738-4d46-b222-9e16c97e9bb9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_45ac6011-f162-4227-953b-4041a034b83c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a3bc2ea8-1e4a-473a-9913-b4929136e660_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_27072cfe-2484-42c7-bc32-2cf8effe41e4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liability for Medicare refund</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_f3a18526-ab02-40f2-8610-08ace85865b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_89c1b213-78ff-47f6-8598-71981e06c1a7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_669efa6f-7316-45ad-987d-5e181fe93bc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement levels based on EPS targets</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9501a91d-d4c0-4821-b00b-0cd1ed0ba8ba_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_afd9eb24-9b62-47f5-b76c-38caef7c9c12_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1879e44b-745d-4774-8ef1-11d4faf25da2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_eee3497f-22a9-4c8f-96e4-9db35cce9232_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_9a98f734-d8f1-4982-82a5-221718ac1d2e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock option and employee stock purchase plan expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_fff1fd7a-9566-4268-95ae-45b0fac950d5_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_85013a1c-70b4-4780-9746-dd00e1b64186_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_85f40fb7-1fb8-4aae-bebe-4e851c2a6495_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_8a3c7537-e934-441f-ba17-53de9a49590f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_bc8ffcea-0f74-456a-9bed-119b6145bcd8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_f4a6943f-b0ea-4a28-a057-ede6d65f5ea2_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible legal settlement</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Non Deductible Legal Settlements</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation non deductible legal settlements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b18837b5-c396-46af-b79f-b5a1493e80cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_af91654c-4636-4481-b55d-73f9b758338f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_b6a57785-29f7-43b0-a76f-a44cca58c805_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_96d41b94-5760-483a-b11a-db8577d99697_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_92f041ea-6cbf-4900-ae7a-da4ddf7193e7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e2129bcd-f472-4a4e-915f-673e69f969ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0409fb38-2dbc-4baf-90e8-60b7c27af31b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_73f465e0-6078-4a99-ad6f-65b30727aee6_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1ec0c710-d229-4609-8cd4-534c0ca32cd9_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases - settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_90053353-34ff-4204-94a8-bd599ed01905_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_2ab1ff07-8fb4-4439-9812-607a491761be_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b43cfc3b-4387-4170-b5a8-530d0c88170d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56c63a1a-316c-4810-ba6a-30ba64968ad8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d7855a83-e666-4f74-808b-224ef14ea749_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0b98645d-5ca1-4157-bf39-b79e2a65b8d9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_33a64070-e040-487d-b407-038c880ba21d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b7eb4872-3d87-47b1-b485-49838d80a985_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_d2190162-5e0d-4ca2-8820-af851f493b49_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible meals and entertainment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases_e2238879-2f61-460b-aa12-771d37da9c7e_terseLabel_en-US" xlink:label="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges to retained earnings</link:label>
    <link:label id="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases_label_en-US" xlink:label="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Charged To Retained Earnings As Result Of Stock Repurchases</link:label>
    <link:label id="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases_documentation_en-US" xlink:label="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount charged to retained earnings as a result of stock repurchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" xlink:href="mygn-20211231.xsd#mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" xlink:to="lab_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_56e54826-f5bf-4735-9040-bd1db42e7554_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a72da813-084d-4b96-b437-81c5318386f8_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_4dd5f0fc-9006-43ba-8afe-fd44a748b39f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d9d2a7d0-8036-4f46-8b04-9fbdb49ad164_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5389a76e-6cc3-4ce8-b828-e28738bae3d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at the beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_653cf281-68ee-4d63-9176-4e7573c80538_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c6c4c206-e34c-4805-a1cb-f8a522f7d4d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_49b9ae57-ed68-4852-8301-8f2d9e565c1e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_b2664c93-9978-41d2-a212-c03862f94359_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_082167b3-206c-48ea-830e-f34dda39a7e1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_39e7374c-efb8-47b5-a444-5d3b9d18ba05_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadRBMIncMember_ef70fb58-4cf3-4262-96e3-bf7eb5558cd8_terseLabel_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc.</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_label_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc [Member]</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_documentation_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadRBMIncMember" xlink:to="lab_mygn_MyriadRBMIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_5b591e55-eede-4c8e-bbaa-18d1201fe81f_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a5096dc-9530-464a-819c-59240653fa6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_ae49d32a-c42c-4ef9-bab6-e9fac9f7d04e_terseLabel_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_label_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Estimated Future Lease Payments</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_documentation_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Estimated Future Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" xlink:to="lab_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d3a9a974-16b2-4cbd-8cc8-fe57fcc5789a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_75a7c2dd-7d0c-43ce-9868-e3879795a0b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_200b3b8c-81ac-43d3-9740-c73e44a1bfaa_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_d3aebc4e-496a-430f-b8a5-8bcdca42391c_negatedLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_e79a32cd-7fcd-4ed8-b627-ab231ef137c5_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_31168106-b822-453b-b3d6-2178a8ab0c52_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c539f41d-25f5-46bf-9a2f-6b95fd9110e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_4125beda-d264-4228-a1b8-23df5b68fa94_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for income tax receivables</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2bd81ea6-f598-4f8d-af7b-90a7a3a3e925_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6eedaaef-b157-42d0-b2ae-d70b1516b1a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0a4ddde1-0dd2-4103-ad8c-075d708c396f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c3b39b0a-3a7b-49d7-9f9e-cca43d924fac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1403dd2a-f73e-4055-9d4b-451bccdbdad7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_60758569-7b3e-42a8-9d14-45922367fca9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties in year-end balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_12a86cdd-e5ee-4f13-a74e-7049aec8ef1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_ec310a6b-0931-4fac-8753-8a3e7177cd66_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_87bd60b4-4c9a-4fa3-92fc-4e0275d9d1e6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9439e134-8ca5-46e1-8be2-66b364c02bb4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_14955d40-bce8-407f-9837-fa2d69374ac7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of foreign currency transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7f5e108f-2c86-48b1-a9a4-cab63e4f1ad2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 80.0 and 75.4 shares outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a562f6a3-9ecf-459d-be9a-f61b2b93da0c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c22e1b78-bcbc-46c1-80de-218e189e0658_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6dbc2f7-81e3-4d0d-80a7-9fcce6b3055f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ClinicReportingUnitMember_b451d8ea-ec9a-4046-9422-e0c7e58049d5_terseLabel_en-US" xlink:label="lab_mygn_ClinicReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinic reporting unit</link:label>
    <link:label id="lab_mygn_ClinicReportingUnitMember_label_en-US" xlink:label="lab_mygn_ClinicReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinic Reporting Unit [Member]</link:label>
    <link:label id="lab_mygn_ClinicReportingUnitMember_documentation_en-US" xlink:label="lab_mygn_ClinicReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinic Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ClinicReportingUnitMember" xlink:href="mygn-20211231.xsd#mygn_ClinicReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ClinicReportingUnitMember" xlink:to="lab_mygn_ClinicReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f4afb267-e510-4499-bc93-62dca68fbcd3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, beginning (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b3307e4-ce0b-43d7-8ea0-85d30ec2c27b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, ending (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dee834ce-3f3e-47cc-869e-8b7c3e917ac4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c7518e57-bcb1-4ee5-a312-bdae161e37bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_3b18ce65-0062-4f7a-9164-c673792f7cc2_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Pharmacogenomics</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Pharmacogenomics [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Pharmacogenomics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:to="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TransitionPeriodFinancialInformationLineItems_e486bb52-f30b-4a85-ba2f-bbf66f4dbe87_terseLabel_en-US" xlink:label="lab_mygn_TransitionPeriodFinancialInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Financial Information [Line Items]</link:label>
    <link:label id="lab_mygn_TransitionPeriodFinancialInformationLineItems_label_en-US" xlink:label="lab_mygn_TransitionPeriodFinancialInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Financial Information [Line Items]</link:label>
    <link:label id="lab_mygn_TransitionPeriodFinancialInformationLineItems_documentation_en-US" xlink:label="lab_mygn_TransitionPeriodFinancialInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodFinancialInformationLineItems" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodFinancialInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems" xlink:to="lab_mygn_TransitionPeriodFinancialInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock_ea78dfc6-3b36-4311-9753-cd28e9e764ba_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transition Period Comparative Data</link:label>
    <link:label id="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock_label_en-US" xlink:label="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Transition Period Comparative Data [Table Text Block]</link:label>
    <link:label id="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock_documentation_en-US" xlink:label="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Transition Period Comparative Data</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" xlink:to="lab_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5ae023e8-2e40-41c8-af03-24ec91a6af23_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_86c585e0-4588-497d-9c41-e3b6af2491ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c7fa292-53e5-42b3-93bc-c4976f003c28_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_31e0771d-6ef3-447e-b107-85159fe3a50e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_04a75642-d7d5-4b15-a250-3e464c5f0888_terseLabel_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds payable and reserves</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_label_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_documentation_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent" xlink:href="mygn-20211231.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RefundsPayableAndReserveCurrent" xlink:to="lab_mygn_RefundsPayableAndReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_4c2fde65-74c3-4f60-8cc1-1dcb67faaf64_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_22d80ef1-d5f0-4ee1-a861-9e510ffcc4f5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MedicareMember_03e4aff3-3a54-460d-a2fd-73689c060e6e_terseLabel_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_mygn_MedicareMember_label_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_mygn_MedicareMember_documentation_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember" xlink:href="mygn-20211231.xsd#mygn_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MedicareMember" xlink:to="lab_mygn_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_ccdaf22e-de36-49eb-a693-f815dcde63e2_terseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:label id="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_label_en-US" xlink:label="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, South San Francisco California [Member]</link:label>
    <link:label id="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, South San Francisco California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" xlink:to="lab_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_eeed8ba9-5279-491c-9e48-c95a258adef3_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Deferred Savings Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLossCarryforwardsExpirationYear_9cd9ebd1-8ad7-48e7-be0a-8686769267b5_terseLabel_en-US" xlink:label="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss, expiration in year</link:label>
    <link:label id="lab_mygn_OperatingLossCarryforwardsExpirationYear_label_en-US" xlink:label="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label id="lab_mygn_OperatingLossCarryforwardsExpirationYear_documentation_en-US" xlink:label="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLossCarryforwardsExpirationYear" xlink:href="mygn-20211231.xsd#mygn_OperatingLossCarryforwardsExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1d2a411e-78cd-4b2e-a84a-0d5291c64e50_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_3dec283c-b6d3-420f-a407-a72ff8235708_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_57eccded-9709-4608-9acc-838bc7ca7746_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_97d18330-7cbb-4e71-a0fd-db76cd6c1f0f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_60e84e48-4011-4b08-bd7a-b9d25bc659db_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_84d02d80-e9e7-4322-a756-219d5c6f1739_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7d3650f7-2b4a-4deb-bae7-5cc0e3981c65_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_474f8912-0b52-47ef-8a96-9ade9ad36bd5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in pension liability</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_19ff603e-7ee4-4e7b-8f85-a74fba93fc5e_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e1ab55c1-85bf-47ec-be3e-b07dec4a7607_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CounsylIncMember_a7466791-3dd8-4353-bbff-7e151c56a9ce_terseLabel_en-US" xlink:label="lab_mygn_CounsylIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counsyl Inc</link:label>
    <link:label id="lab_mygn_CounsylIncMember_label_en-US" xlink:label="lab_mygn_CounsylIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counsyl Inc [Member]</link:label>
    <link:label id="lab_mygn_CounsylIncMember_documentation_en-US" xlink:label="lab_mygn_CounsylIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counsyl Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CounsylIncMember" xlink:href="mygn-20211231.xsd#mygn_CounsylIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CounsylIncMember" xlink:to="lab_mygn_CounsylIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_67a6e59e-709f-4124-93bd-9812c37b7e73_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_276f8f3e-9292-4d39-ae4c-e093663b395a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographical Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_bd202c27-aafd-459f-90aa-ed330744567b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Investment Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b2d19af9-1c31-4212-8d74-6811a8c59210_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsTable_7a4be56f-0d8c-461b-8ca5-98c5a1f7902d_terseLabel_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsTable_label_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsTable_documentation_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsTable" xlink:href="mygn-20211231.xsd#mygn_GoodwillAndIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable" xlink:to="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d543133d-b0ab-424f-b82e-238b335dc018_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2998ae52-e401-408f-bda5-fadde6921cad_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DeferredTaxLeaseLiability_d388a51b-7612-4c6d-9b1f-95e8bb129094_terseLabel_en-US" xlink:label="lab_mygn_DeferredTaxLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_mygn_DeferredTaxLeaseLiability_label_en-US" xlink:label="lab_mygn_DeferredTaxLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Lease Liability</link:label>
    <link:label id="lab_mygn_DeferredTaxLeaseLiability_documentation_en-US" xlink:label="lab_mygn_DeferredTaxLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxLeaseLiability" xlink:href="mygn-20211231.xsd#mygn_DeferredTaxLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DeferredTaxLeaseLiability" xlink:to="lab_mygn_DeferredTaxLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_4f0050ad-d28c-4320-a3f5-62023ecbceb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_4b72f533-e13c-49b2-a3b9-f56e01a6a4f7_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_fe45b265-5410-4d04-8d50-e9fbde624b17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_421ffa96-7858-423f-b6f2-bca134889b06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased under the plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments_dc35ed5c-c5d6-423c-ae06-7f2b5927c85b_verboseLabel_en-US" xlink:label="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments_label_en-US" xlink:label="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Less Cash, Cash Equivalents, And Investments</link:label>
    <link:label id="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments_documentation_en-US" xlink:label="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Less Cash, Cash Equivalents, And Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:href="mygn-20211231.xsd#mygn_AssetsLessCashCashEquivalentsAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:to="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_c6cc0182-362a-413b-94e2-0f92f1809aef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_181b83b3-7b62-47ec-8fdb-c1d2b56b67c3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_2e8423e5-46ef-4920-9a5d-bc051c88504c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_06879b9d-5af1-45b1-ab97-6d611b50a058_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d172131c-79c4-417d-99f2-65babf2ea935_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f70e75d3-2918-4eb9-afa5-b8ae41f228ca_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec940b4e-d0f5-4417-980d-fb3258d1c012_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_003a3000-f166-46cc-9cad-b569d86c4f29_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_760eb249-ad94-4204-b36c-8a62634b6954_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_99925992-2e5d-48f9-ba0e-70aad557ca0b_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Intrinsic Value</link:label>
    <link:label id="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_label_en-US" xlink:label="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value [Table Text Block]</link:label>
    <link:label id="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_documentation_en-US" xlink:label="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:to="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_a386e988-675b-41dc-9c29-66f7a62c6777_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7b8c155f-ca8f-4a47-b63f-0e1b589272b2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_1c40d800-f437-4924-af63-a06f4ccdb137_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on inventory</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_315b8412-989e-4d68-a786-6965c44da7cc_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Method changes or tax elections</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Changes In Revenue Recognition Method</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation changes in revenue recognition method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" xlink:to="lab_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3a0e2f77-f492-4e4a-9c7d-c49ad8404757_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a00e6e85-c269-40ce-b8a5-03d038741643_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7d358315-5dda-4f09-b9fe-5b550573a968_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_ad678748-032c-4930-baec-4314cc81407a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_898839ac-f3fd-4402-b961-0177c1666122_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffc41194-7ceb-4da5-9eaf-5227c47dcb0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a4ac0656-4d51-4995-a691-2db5db92a478_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_1e7cc6bb-93da-44d6-acec-834a6c9284d3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_0f35c5c3-d0a9-4f94-bd65-7d25a46f9906_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_61ecbc6c-f7cb-44e5-8c55-6eb0544cbba0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_05e752b9-1384-4604-ab96-ac01c15cd408_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_77eb53c1-f2fd-40ea-bb5a-ee83ae675588_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_e0b19c5a-d2af-40a8-80d6-789db598b45e_terseLabel_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Medicare payments to provide relief from economic impacts of COVID-19</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_label_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Of 2020 Medicare Payment Amount</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_documentation_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act of 2020 medicare payment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:href="mygn-20211231.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:to="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_745d9bbc-8e21-450c-b514-5b8283fd1ece_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2feb0f6f-8e91-4cfb-826e-23ba386ebf8f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Related Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_abb27f3c-118f-4c5a-9afd-7f99bd5404e8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_e5c2a621-48bf-499f-a749-36ed7a1ce8f5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred savings plan contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aedee1f2-dcec-4b9a-bc29-d84c79c40f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d2cea63-3961-4030-b3a7-f7edfd96e615_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c4718221-e6ac-49e4-9fd4-176e5a661b90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_da271ac2-3c04-4832-acc4-8418204efa7a_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1c0d0914-9e51-4700-b171-2f9aee60ee92_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_88e1325a-687f-4bd8-ab3e-a0d8c7b39deb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_aecf2611-4ef7-4ee1-95a8-881e305add6e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f886ea44-4920-4efc-aeb6-5b51aee1480b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_be80048b-f40c-49db-8fd4-7a8c8ac6e4d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_40ce73aa-119e-4938-b9d2-e82051c46042_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_055acfaa-4224-4bda-ae10-07225ce2cd09_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_3ecdad02-2294-4466-94f8-ff257b0b8b47_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_40629184-2357-4a4d-af47-c6a5dd176e06_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_ac464a60-5f3d-4aa8-b0ec-ae54e8899d3b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a4ad414d-a6ef-44b0-aac8-9765c706f654_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3f3d7c7f-14f5-4f56-b6bb-c8b2a28cba09_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_0c2c3189-99c1-4516-9ab0-d8e2a85c3d01_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_46e38798-8dc1-4b94-81d6-a2d67933c477_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6c60c15-e954-4652-8958-9ac71f8612f3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42a190ec-9e3a-4aa2-98fa-9c93df07417b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3bfa6a54-e4b2-4299-b4e6-1e23d3468fb2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b519e35f-57b6-41b7-acaf-e344dc5de35c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_a8408daf-e4b8-4de6-8c5b-78a96b9cb065_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees associated with refinancing of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TransitionPeriodComparativeDataTextBlock_109c67f2-b2e6-422a-b113-a082e3db4d4a_terseLabel_en-US" xlink:label="lab_mygn_TransitionPeriodComparativeDataTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Comparative Data (Unaudited)</link:label>
    <link:label id="lab_mygn_TransitionPeriodComparativeDataTextBlock_label_en-US" xlink:label="lab_mygn_TransitionPeriodComparativeDataTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Comparative Data [Text Block]</link:label>
    <link:label id="lab_mygn_TransitionPeriodComparativeDataTextBlock_documentation_en-US" xlink:label="lab_mygn_TransitionPeriodComparativeDataTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period Comparative Data</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodComparativeDataTextBlock" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodComparativeDataTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TransitionPeriodComparativeDataTextBlock" xlink:to="lab_mygn_TransitionPeriodComparativeDataTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_241dc024-c4a2-4a80-a197-5222f5e1e3ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f6f68be1-dc2e-47cf-ab73-8f0a527be2cc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0f3aa468-261c-4b0f-b35b-045d7dcca15b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_0744c167-1527-4485-ad38-eb3656655c0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_4207f447-cb54-4ec6-9bbb-0356c2463ee8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total:</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract" xlink:to="lab_us-gaap_InvestmentsAndCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_f4d9000e-9e97-4312-82b2-f468be7b8e83_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_f27c6bc0-f43d-420a-8dbc-78d231481083_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Prenatal</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Prenatal Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic Prenatal testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:to="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6b62b6dd-c2e1-4fe3-bc23-1b8feb6b7b35_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7fbc6ce0-79af-4966-a7c0-4cdaa59fb046_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other Income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_57f42f6a-44dc-4098-8a33-4ff50fe3dbf1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_e0b20415-0488-4e11-aca5-5f6296ab4ade_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased and retired</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_2693b25f-9b7c-4d50-adec-730a96fb352c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_8002c196-8cbb-42b4-bcb7-4e5afb486c0f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_49803582-8b34-41e7-9d47-d0ed7958ec3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ac9a9475-4b27-499f-a3e2-df1a6b15789c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c2dc00d8-62ae-4f08-91f0-ec55c91e37df_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20a9eb96-14e2-4d5b-ba57-274b104b30f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_f5516d62-aed5-4b2e-bef9-f8bf91e0c186_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense (prior to adoption of ASU 2016-02)</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9242e038-8a97-4e3c-aefd-b323cf6bd824_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_280be850-e05a-4632-acb2-538bffccb72b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to the Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f0e48b4a-31de-493c-bec4-949e67a1393c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationAssetImpairment_6bd7cd9e-2d93-46df-89d9-86e266135c9c_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAssetImpairment_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Asset Impairment</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAssetImpairment_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation asset impairment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAssetImpairment" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationAssetImpairment" xlink:to="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2629fd9a-8a92-4026-acf3-665b85d48b88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_84f592a2-e47b-468a-8859-aa1e4d5b1399_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_55f9c2bf-b722-4217-a769-9ce96ec56417_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b4d83f67-fb75-405b-9972-5172238e825f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a1e1d75-e783-4a78-96e8-5ab760c9d98e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_293b68c7-09e7-46a9-b6e1-07000af14771_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_b80d222e-cf2d-4c55-b060-24ff50f35a95_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan compensation expense</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_635181f2-d812-45d7-9f33-033b03685abb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_0051dc7e-b750-465b-9fa8-02a50cb8d1fd_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_07df30a2-bd2c-4d79-a510-78ffacac8aa4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c8d0f604-96fb-4048-a893-18f60fa944b4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Myriad Genetics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_945be164-d7f5-4429-8cff-a9ee88336c56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fdc6b8e4-6b01-4182-94ed-dc1da5b165b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d8d8dffd-cfa1-4024-97e7-c4a8586a3e06_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_103cfac6-18ba-4b96-94e4-bf8edbde30fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b57b33f3-931a-45c3-96e9-4a15fb1db946_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b39ad15e-ea72-410c-9eb7-e642d3edf9fb_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_0cb2cc5b-6dea-4865-aaca-83a5841d4c5b_negatedLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:href="mygn-20211231.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:to="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_455443a2-d677-436a-9a1d-20b5a04a4456_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options fully vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_926cad62-1e0a-4bc0-9109-2068a00a428a_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized due to expanded local coverage determination for which revenue was previously constrained</link:label>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_label_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</link:label>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:to="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_66648432-2bd9-4ef4-9832-bdee8a945ddc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a83d4179-af0c-4eb7-8794-7bec514aac64_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_4509bccd-b0b0-4ee1-965c-7ef102a824e5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_546a3be0-b729-4256-85f0-2682292d7725_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_615702e9-8071-448b-af2f-53edd85434d6_terseLabel_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee director</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_label_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_documentation_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee director.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember" xlink:href="mygn-20211231.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonEmployeeDirectorMember" xlink:to="lab_mygn_NonEmployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2a8c9416-eafd-4c56-858b-058c0298a1de_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_507ce407-1713-449d-bf35-54b5e4650ac2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of Company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1cf51347-7559-4915-b475-29f839864cf3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_d29b816c-e39b-4b05-9939-8924a69dd471_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Tumor Profiling</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Tumor Profiling [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Tumor Profiling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticTumorProfilingMember" xlink:to="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_c26f4247-b7f0-48d8-b982-01ff21c9f834_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_092714e6-7697-412c-890a-ae642ccedfb4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AbelliAndPricoloMatterMember_49d86412-f3b8-4092-825f-cadd1266cdbc_terseLabel_en-US" xlink:label="lab_mygn_AbelliAndPricoloMatterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abelli and Pricolo</link:label>
    <link:label id="lab_mygn_AbelliAndPricoloMatterMember_label_en-US" xlink:label="lab_mygn_AbelliAndPricoloMatterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abelli And Pricolo Matter [Member]</link:label>
    <link:label id="lab_mygn_AbelliAndPricoloMatterMember_documentation_en-US" xlink:label="lab_mygn_AbelliAndPricoloMatterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abelli And Pricolo Matter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AbelliAndPricoloMatterMember" xlink:href="mygn-20211231.xsd#mygn_AbelliAndPricoloMatterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AbelliAndPricoloMatterMember" xlink:to="lab_mygn_AbelliAndPricoloMatterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_95d2e925-2581-43f6-b7eb-55c9ed9f4174_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b44936c3-8acc-4b16-81d0-c3fea559e094_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_be790dbb-d90b-4c24-a0ab-9c2e39b2ff9d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of subsidiary</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6ee93a63-dd3f-4671-a499-462040846fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_ac1a4802-0b5a-4054-8de3-d10084bef36f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_cf5da0e8-041a-4598-b2eb-f2e024e25d59_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4689f7a0-d600-40f6-a683-5c06d173927e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_4a3e8743-261b-48ce-b1d7-c8d848e97dcb_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6e260c9c-66d2-4074-96f4-7bf21d6ff72e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_12d2bff1-cde8-4f63-ab8c-a940339b9d99_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - acquisitions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2dec1d58-83ba-4cc3-9467-5112b5033ca7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_68ce20f7-be91-464d-b54d-9dba6433637a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment sold and deconsolidated</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6b43060e-c9c2-4185-b404-8e166139bd00_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_2e032a66-60f6-4fc3-a89e-9eb36a4f1106_terseLabel_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased licenses and technologies</link:label>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_label_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Licenses And Technologies [Member]</link:label>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_documentation_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased licenses and technologies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember" xlink:href="mygn-20211231.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PurchasedLicensesAndTechnologiesMember" xlink:to="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_42f74f37-032d-41fa-9e9b-ec8ccd4336c6_terseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross unrealized holding gains</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a96013ab-3822-46a9-9b56-081c6c04abcb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_d4fb6810-8418-40ae-a34b-7748957b4a06_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e68cb9cc-aeac-4f6a-b067-4d19db2dd809_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_71a2c601-80bc-487e-9ba3-767f7cdf26f5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_a7958192-bff7-471f-9cac-03d0af072bad_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a8092513-2001-4d1d-aa43-886f3c998112_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_c1131e6f-5120-467f-9aed-4d67d465841e_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dd59c21a-0995-4d1f-8b34-51bb9108bf53_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6a25601f-e80d-4faf-b84e-7a8531d41afa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_d28656a1-0ac0-4780-a275-3b8e7ed6f227_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company matching contribution as percentage of employee contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d608ba55-88f8-4636-a598-8feff4197899_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_85b202e5-4d9d-414a-8bf9-39fba2e35cb2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_dca1f7c5-469f-429f-9e67-08c05bd19d33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary impairments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6b50b8f9-72c2-4531-b146-976d475d113c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c972ade4-a180-4804-ae71-1a43c95f2396_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance based on Nasdaq Healthcare Provider Index</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_c55d38c5-1459-40c9-9e0b-5730d05fda5a_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (benefit) related to operating loss carryback, CARES Act</link:label>
    <link:label id="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_label_en-US" xlink:label="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Operating Loss Carryback, CARES Act</link:label>
    <link:label id="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_documentation_en-US" xlink:label="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Operating Loss Carryback, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" xlink:to="lab_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bf774935-1dcf-49d8-9259-175e82c82a0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5bb9c9dd-9017-4dd7-9eaa-a52096963ddc_verboseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_f80a3364-ab8c-4a48-815d-5f15b18a8860_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Purchased and Compensation Expenses for ESPP</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e8c359bc-1de0-4922-9005-e56d13c0c314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_6d7f1162-4b6d-4c01-9821-f05b69218e7b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_58d64208-dfce-4b4f-9d3e-09ac8f226303_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0552e6c2-8d52-4b4a-a1d0-d293e01fc594_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-amortizable</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_754419c4-b35f-4b42-9122-e5c75c56e7dd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized software costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_c2d005ab-9dd4-412b-9931-4b9f213c6dcb_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_label_en-US" xlink:label="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustment Summary [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CumulativeTranslationAdjustmentSummaryRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:to="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_7e9d1527-e809-4d4d-ba54-a1dc4ae09c2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ffe984e6-6910-46d0-9f47-593776b00b92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_781915cb-afd0-4ca3-84d9-7c489367b0ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c8007c66-9606-4261-8372-8fc1a1e5ea4e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46dcb4cc-9623-4239-9519-885b34955c04_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0190e5e1-b471-4431-93e9-ab5957c9432a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35298856-26e4-4ff5-8a19-44d903150540_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d19920a0-7e1a-4a6a-bd95-d00a81b02bd7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a5dd04c8-7b6a-401e-86ce-4437ad9770aa_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_7aa27b54-1125-40a0-8c1d-2ded2da79d6a_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Autoimmune</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Autoimmune [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Autoimmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticAutoimmuneMember" xlink:to="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4427be78-3e2c-43a6-bdf4-50ae9bc48f07_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3595cfb8-231f-4d90-a966-cc1f62ccbc73_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_758899be-c295-479c-81cf-3f002e6c97a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_dbfb8fa4-ef01-4417-a0dd-160d35a0d891_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_35341031-5dda-4469-95b0-91f1d63379f4_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_38adee32-1a95-4b0f-b502-87f9a14093ea_terseLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in earnings (loss) per share (dollars per share)</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Earnings Loss Per Share</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in earnings (loss) per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:href="mygn-20211231.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:to="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b7645227-4080-4f0e-9208-0db09573e4bc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ed4db33-b569-42f3-b857-cd70f85e90ab_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d7a88f9a-e1df-4835-84fd-41f2001da63d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5f55eff9-3a1c-4ec2-8269-e9a10e140c76_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24c5a9e2-a9f6-42ca-bead-13d5cced7889_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ac856db5-79e6-40cd-9704-8b4e6d327d80_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_92b932c3-e020-45d9-9993-0db20ff7d248_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_7c43ae61-53c6-4164-8d01-5da077207c7e_negatedTerseLabel_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization on intangible assets included in sale</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_label_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Noncurrent</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_documentation_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as accumulated amortization of intangible assets attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:to="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_3c9ae731-6203-46b6-bd70-79fb26c614fe_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:href="mygn-20211231.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:to="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8bcd3520-6dd3-45ea-96e5-608de1b4605c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Payment Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_df273b82-09c8-4909-992c-04ad43fc1211_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b7f5900b-4acb-432b-874e-16346adebd12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a44a1673-7cf4-400b-9d44-1ad3dd07af76_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f267a01a-cf90-4396-922b-dedd1dfa44c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0e2cb4e8-e4c3-40f5-aa4f-f18f0ec3e5b2_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_47960daa-4847-4f34-9d3b-a175a5f934c1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3ae98d70-4264-4073-b521-6a0f47095cbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6738f41c-f41b-40c5-bd78-2e25a8cca212_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_737a9776-dfc9-4474-b0c6-903411325f39_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_70a9b7da-5d19-4bfa-bc4d-6a589181aaed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_5e32127a-8b38-44f1-b6e7-925c08ecb23a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f9f65d27-c014-4a3a-b14f-fc85a272d51a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_cfbde537-7211-4e83-8fd4-40bcbda28fe9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_428068c5-08e7-43a4-9cbd-fa68fbc5d137_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:to="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_49d29dab-93e0-4f45-8194-5b8e92cdbd70_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_b3a916b2-3908-4fea-b526-e36288df3001_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_da207141-3b82-4463-b1ad-a070b77ee628_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ae8a4e14-e297-475e-818b-55e1a04ddc92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_616fc2d0-a882-4f16-9695-115c177c1a55_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_2b55acd7-54ab-4795-b383-c99f9a78e7e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_68260166-3316-479f-b282-ecafa26b23dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8e3614de-4429-489d-9498-3d88a15a21c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2be920e3-d0e4-4bee-a342-0fe533dbfb5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbad6467-7d3a-4406-b481-6a518dc64a6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_4773319b-049e-4301-ab4b-a147372f757e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_bd53bdd6-5c4b-4724-9ec2-5150f38facb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_SaltLakeCityLeaseMember_ee4b6a60-933e-4da8-8a44-8258bb7890f6_terseLabel_en-US" xlink:label="lab_mygn_SaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salt Lake City</link:label>
    <link:label id="lab_mygn_SaltLakeCityLeaseMember_label_en-US" xlink:label="lab_mygn_SaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salt Lake City Lease [Member]</link:label>
    <link:label id="lab_mygn_SaltLakeCityLeaseMember_documentation_en-US" xlink:label="lab_mygn_SaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salt Lake City Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SaltLakeCityLeaseMember" xlink:href="mygn-20211231.xsd#mygn_SaltLakeCityLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_SaltLakeCityLeaseMember" xlink:to="lab_mygn_SaltLakeCityLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_e48be6d1-a6ec-4691-b218-7d4617e55a82_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5815f9b5-ca9f-41a6-b862-aa44a3f04a28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aae96a58-97ab-447c-982c-d8d4528a4a7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_d075041a-a439-414c-9e97-0604f56e7f7a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of businesses and assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_56c0eb8d-1d84-4aac-a288-d3fc5714e0f2_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d5891d40-9d37-40b9-be0f-902b63d5793b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_473f1707-049f-4be0-b739-ca8a6ffef69f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupCapitalLossOnTaxBasis_1bcc81b0-c42d-4b29-9642-aaee4f767b7c_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupCapitalLossOnTaxBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss for the tax basis on stock</link:label>
    <link:label id="lab_mygn_DisposalGroupCapitalLossOnTaxBasis_label_en-US" xlink:label="lab_mygn_DisposalGroupCapitalLossOnTaxBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Capital Loss On Tax Basis</link:label>
    <link:label id="lab_mygn_DisposalGroupCapitalLossOnTaxBasis_documentation_en-US" xlink:label="lab_mygn_DisposalGroupCapitalLossOnTaxBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Capital Loss On Tax Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupCapitalLossOnTaxBasis" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupCapitalLossOnTaxBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupCapitalLossOnTaxBasis" xlink:to="lab_mygn_DisposalGroupCapitalLossOnTaxBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c37df879-24ec-426a-a6d8-964ae6086e45_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9078eb1a-3a7c-4b22-b011-b3fe42431efb_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_263c9f42-a3c6-46d5-ac57-9081f8729080_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9d4ec647-cb60-49a4-b56c-00ab98b8bfee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_58c1b204-a66f-420d-b9a1-ba9b58397ab6_terseLabel_en-US" xlink:label="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_label_en-US" xlink:label="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development With Indefinite Lives [Member]</link:label>
    <link:label id="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_documentation_en-US" xlink:label="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development with indefinite lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:href="mygn-20211231.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:to="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_bdc06dfb-39c8-45a7-8bfe-43a705cf532d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on non-cancelable purchase commitment</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5dcfaf00-73e6-49bf-9e79-d7e5403a45e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a4c29df2-7460-4277-90e1-b0e0a63b2531_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c98045a2-cea1-43ad-ad4f-1165314f83e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_5bc47d91-539d-4421-8565-278c55a47283_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_046a0beb-5d06-46ce-a564-794c0e642147_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Other</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Other Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic other testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticOtherTestingMember" xlink:to="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8e1eeafb-080e-432f-8941-9ef8701699e0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_090aadf6-76a9-4c21-9297-78fbd8617718_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_31c764af-2f84-49ea-9ed8-f6222d573cf2_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) Other</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d4b913b4-64f7-4f56-b840-6b364c3c73e0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adcc25fb-0703-4f8d-a649-ae791789751b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2ecc1721-4520-421e-8743-0a599ba51221_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_77459d28-304e-4d6b-ac4e-fea355c32229_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_2249f8b4-b5d1-4d50-850d-514e01727cff_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1b229b21-9492-4454-a701-e5e4f350ebe1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_27296662-083e-4a30-acf7-4ddf8ab984a7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_dc04ceed-91a5-47f5-a8e9-21a0e1f63b28_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_73a28314-9a0e-4f51-8814-23a32cabbeac_terseLabel_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_label_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems" xlink:href="mygn-20211231.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IntangibleAssetsLineItems" xlink:to="lab_mygn_IntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f6adc06f-6046-4d17-8d5b-ed84321a17f7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f463919-0b9a-48fd-8243-a7ec0f6eac9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_dd62b3cf-c0f6-4bec-9161-c7e842470abd_terseLabel_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase Plan</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_label_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_documentation_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:to="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1d301a85-fa51-4930-a269-5083c97cfa99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_dcbb543a-92d1-4dd4-9996-74fcde698e06_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83ef3760-310f-44e5-a7cd-2680a884eaeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_584fa65e-a31b-448e-ab4c-be0275662ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_8cdd6caa-d4ae-4347-b99e-0ecdba009036_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_809b3d47-028b-4276-b8f2-eb546d00950c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_85b5ad3a-34ce-4cdb-9268-40f54aac4528_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_a74a0368-fa3f-4515-9576-f0c72e0aed07_terseLabel_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_label_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen employee director and consultant equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:href="mygn-20211231.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:to="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a77ad89e-35f5-4c95-ab1a-fd3c781d13ef_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_762408a8-1613-4ba7-840c-e2718ad2310e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationYearUnderExamination_a5bec47f-c080-4820-b6be-bf9bf7cc8e0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax year being audited in income tax examination</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationYearUnderExamination_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Year under Examination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cf01cb2b-0a1e-428e-b29c-8dbf15e6aea4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_e7cb4b65-4664-4208-8027-11aeb36fb2c2_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cde84d03-15a5-4139-98f5-372390d29bd9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6a8ee52a-f684-4012-83dc-cd2c87cb38aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_849fcc7d-d754-4654-b0ad-c392dbcae984_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b587d7d6-6ecf-41e6-a5d3-b45e38b990cc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_28cabedb-cbc1-4515-95bf-b9df8b842b6a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f9df0bfa-8d0b-4e18-989e-32d241d1fd1c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d649d336-aa81-4c21-add9-5d851b128ef3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContingentConsiderationMember_82ec851e-58ef-48b7-8569-81156b407915_terseLabel_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_label_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember" xlink:href="mygn-20211231.xsd#mygn_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContingentConsiderationMember" xlink:to="lab_mygn_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9991639d-4b60-4f5a-91ad-47f09f3601b7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c5861634-2e28-47ad-b742-cfb5c895b4aa_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_2e33890a-2919-472f-a502-2425fedb64a5_totalLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Amortized cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:to="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases_0bda9004-0c24-4491-813e-e322c9443f72_terseLabel_en-US" xlink:label="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in-capital reductions</link:label>
    <link:label id="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases_label_en-US" xlink:label="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Reduction In Common Stock As Result Of Stock Repurchases</link:label>
    <link:label id="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases_documentation_en-US" xlink:label="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of reduction in common stock as a result of stock repurchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" xlink:href="mygn-20211231.xsd#mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" xlink:to="lab_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b53a4aaf-8ae3-4c7c-a1b6-436e1bda1a92_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5115c7f-f894-4cef-8d95-19f149da54a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc214c6b-bb20-463a-b4bb-9007e721c96f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_650ec7f2-c65c-420c-b9a6-4499f5c464eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_90a066fb-46c2-49d6-b22d-c0215567dafe_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_94817a19-239e-47aa-b05d-22bba8081e0a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_4a5f4474-82d0-4ea9-a63a-350fcdc66e13_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d39d6cca-910a-41ca-b321-c2a39c3ad54d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_860b0643-3602-4e3e-b60e-c70849cfb262_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0f23c457-9a69-4ee9-99ed-03be436871d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2c5e30fc-8fb1-4e30-b270-5c8b199ce46d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_c7fdfb17-74e8-4527-956e-30e856ba8f69_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6cc0491b-e98a-4c50-b9f8-93ffef1dbda2_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_c9c3f24a-528b-44e5-8439-5fe0ef08c913_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_329c2019-cea6-473f-a77d-4bca09912127_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (weighted average shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1565e2f5-a63b-4ec0-8251-1aa5355fe4c6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute basic EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c28a61d2-7c0e-45ed-84f5-280371138183_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_92a3b1d2-052e-42ac-8985-5cde5911d764_verboseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local jurisdictions</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_541b0380-573f-423e-8e9e-fef962e29031_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_986722fa-087c-427d-a0f7-9ecb53fee8be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_6e577339-c11c-4793-9ccb-cd0c8c209039_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac22b1c6-7bbb-4cf9-982f-1630dfa56a5b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive stock options</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock_d1706d1d-132f-4d34-967c-14c0a8e9b242_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Repurchases</link:label>
    <link:label id="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock_label_en-US" xlink:label="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Repurchased Table [Table Text Block]</link:label>
    <link:label id="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock_documentation_en-US" xlink:label="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of common stock repurchased table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" xlink:to="lab_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock_abb3f01e-bbac-42ff-8ced-ef29fda9f951_terseLabel_en-US" xlink:label="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock_label_en-US" xlink:label="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense) Policy [Policy Text Block]</link:label>
    <link:label id="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income policy text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:href="mygn-20211231.xsd#mygn_OtherIncomeExpensePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:to="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_e508b7d2-627d-4acb-9f41-c9ff6a0734a0_terseLabel_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period for earn out liability</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_label_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_documentation_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:href="mygn-20211231.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:to="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_0714c0ad-c6be-4e7f-983a-5859a1c76407_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_5044c82f-50d1-4d17-8d00-2e00e16c93f0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs incurred to obtain or fulfill contract</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_541a53d7-3a2a-400f-9639-fe7c9b2ee61b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b8d01c7b-bc75-429f-a088-70463016ba96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_104c6ff0-fc8c-459e-aa45-0a5183cb545f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recorded Amortization for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_24c37c97-6fa9-47ba-bcd1-d190f06785a4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c20fde1e-dd54-433c-987a-33b1490eb84c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f489f83f-bf57-4f02-b0c8-33d91f1ef9de_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_e78c4d41-e3f3-4686-b045-99761aba3c7f_negatedTerseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: leases not yet commenced</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Leases Not Yet Commenced</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Leases Not Yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityLeasesNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:to="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c0f8048-dfdf-43d3-a96e-199503a8cd0f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_4d44d780-606f-44ad-986c-b6e5d224cc65_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_c0a8defe-a746-45b3-9d16-53d06b9e8a95_negatedTerseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overall net tax benefit of divestitures</link:label>
    <link:label id="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_label_en-US" xlink:label="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Net Tax Expense (Benefit) On Divestiture</link:label>
    <link:label id="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Net Tax Expense (Benefit) On Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" xlink:to="lab_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1ce7c894-93e9-4b6e-a9b5-4fd9b7a1d7f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for award vesting (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5aec7a81-c648-41b1-ab94-bf576a22d737_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadAutoimmuneReportingUnitMember_1f1f741e-b0bb-4447-830b-4a455c45385d_terseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune reporting unit</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneReportingUnitMember_label_en-US" xlink:label="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Reporting Unit [Member]</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneReportingUnitMember_documentation_en-US" xlink:label="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneReportingUnitMember" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadAutoimmuneReportingUnitMember" xlink:to="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupCapitalGainOnDivestiture_87e3289f-0974-43a5-9b02-df639b6c2dd2_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupCapitalGainOnDivestiture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overall capital gain on divestitures</link:label>
    <link:label id="lab_mygn_DisposalGroupCapitalGainOnDivestiture_label_en-US" xlink:label="lab_mygn_DisposalGroupCapitalGainOnDivestiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Capital Gain On Divestiture</link:label>
    <link:label id="lab_mygn_DisposalGroupCapitalGainOnDivestiture_documentation_en-US" xlink:label="lab_mygn_DisposalGroupCapitalGainOnDivestiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Capital Gain On Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupCapitalGainOnDivestiture" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupCapitalGainOnDivestiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupCapitalGainOnDivestiture" xlink:to="lab_mygn_DisposalGroupCapitalGainOnDivestiture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_916c8faf-156d-4948-9673-1dd6ec87948b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7218daf5-5725-4e45-a0d0-64eef15cbd87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_154ac9b6-1e7d-47c9-b1ae-34b06030d4ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_084c0a1d-f47e-44f6-a14e-61fa7e22f2dd_terseLabel_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical and clinical services</link:label>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_label_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical And Clinical Services [Member]</link:label>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_documentation_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical and clinical services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PharmaceuticalAndClinicalServicesMember" xlink:to="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_949ff2b0-57ef-4641-9d4d-a0eee571d621_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash and cash equivalents threshold per covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:href="mygn-20211231.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:to="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e0ed1ebf-5d4d-4e87-a2a1-007715015ef0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_2d160010-4480-4495-983c-3765abc2d0b9_terseLabel_en-US" xlink:label="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease right-of-use asset</link:label>
    <link:label id="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Right Of Use Asset</link:label>
    <link:label id="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets lease right-of-use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:href="mygn-20211231.xsd#mygn_DeferredTaxAssetsLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:to="lab_mygn_DeferredTaxAssetsLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6faad70f-0486-4e99-8cd5-4d1582cda3bb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonCashInterestExpense_68ebea25-07d2-4e6c-a406-cb0d3a66aab1_terseLabel_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_label_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_documentation_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense" xlink:href="mygn-20211231.xsd#mygn_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonCashInterestExpense" xlink:to="lab_mygn_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0542b34c-f23c-434a-bae6-45a1abfb1f98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_b4dce20d-4580-47c9-b3d1-fb9d36ea9649_terseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future lease payments</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Including Leases Not Yet Commenced</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Including Leases Not Yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:to="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_510c4e11-8dce-446a-bd11-476538a08503_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_7fc0659d-0102-4b64-baf0-9093e415a7cf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges pending settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_0240e323-936e-47c9-9dec-e68e9229282e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4d2866fb-483d-4cbf-ace8-92e6742aefa6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_57ee08c0-4bc6-4e68-a8d2-0b6475f1da0b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_fa255aec-add3-4447-bb78-2720a7ed8ab4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_09096a39-cc08-423d-9556-3de9693afe85_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_273cbb19-30e6-4a31-baae-f711d839318e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1812997e-6f05-4374-8036-06580127ef17_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending common stock outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_40c6d354-a194-4749-95b5-0a614ae34662_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible officer compensation</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Non Deductible Officer Compensation</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation non-deductible officer compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c3554a0b-e07d-4176-8c4e-051ba8d60c77_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6e3419bc-7447-4b6d-b3bd-190156a9333e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_18ace502-bcbf-4326-81cb-ff8c094293e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_20e25337-79fe-44fa-b934-4da2d855fad8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fb2df67e-bb6c-4f39-8cbd-8ac7df5f1b10_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8d676543-e251-4eab-8b60-917286ea3432_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d5010b84-6177-4c77-b387-c32c7ea26863_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_f1496f70-4730-483a-a0b3-cef3ff593aec_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_cc753058-d141-4fbe-9634-648b396dcd50_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Consolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_670a8096-c3d5-46b4-b111-7c8ff6d3b8d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_1e4dfa65-821f-41cb-94ef-d6c6e0b86308_terseLabel_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and Restricted Stock Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:href="mygn-20211231.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:to="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9b03f7e6-dba2-47fb-a4a7-7400dc143395_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_84492ac4-37d2-4210-9dcf-2f6147f78a45_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_405b01af-3b94-4e1f-8564-4823f852f37d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of Subsidiary [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_8c12bf1f-0944-4020-87da-366abaf87080_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1a8b1ca8-540c-42ff-9dc1-fb90558f7e49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_dc829bb3-92be-444d-9321-f33af496af0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_b4ab795e-9c17-42b4-bae7-b36bbf1947d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of exercise prices, maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_426b687a-4428-41ae-8d1c-6ac161c8fb8b_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases - prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_1c34ef8a-9f33-41b7-bbe6-7efac3b18ece_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5ceeb720-da4e-48e3-9790-be81c6555996_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares available for future grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsLineItems_358c428d-f664-4c72-9fc3-1b67c3dcd1fe_terseLabel_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsLineItems_label_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:href="mygn-20211231.xsd#mygn_GoodwillAndIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:to="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_89b1442b-0f8c-44be-8098-f21b102b64c8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0643f3ec-7ecd-4723-b992-70498ce87b98_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_4864738a-a926-49e1-b6cd-81c0cc56a71a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a8a73a6d-13d9-4937-9e9c-300a298966ed_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_182fd8d8-2ddd-4b7b-884c-c4eb1ac887cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b932b641-313f-4fac-83ee-33d7774cc032_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_07705cca-f04b-4af7-a2ce-636a1a0be088_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net equipment, leasehold improvements and property</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cb323ad1-d41f-494e-933d-170ee52f3b76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to acquired entity</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_aae25aa2-2598-41b8-8a78-b2894f392680_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Dispositions, and Contingent Consideration</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:to="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228f3f8-b374-482b-af2d-31f7fe4b2ae3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_98c3327f-8e26-4e86-86cc-7a5de460c15b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b5003576-0b22-4632-9f75-8f8a31d94c2d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_95674618-92dc-496f-9820-9448a16b3691_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_b31a901e-08fd-4184-9b73-c98e5f4e6ded_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b4184c7a-2bac-4f43-8ab2-a9161aa18d30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f945ab59-51c9-4ae8-950c-2e8106b9b010_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d99aded7-6a5b-4db9-b82a-bcb781e24bc8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b97a3799-6420-445b-b172-833cfe96427a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_UT_d2b9143b-65b8-4e99-b362-ad035d049b28_terseLabel_en-US" xlink:label="lab_stpr_UT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utah</link:label>
    <link:label id="lab_stpr_UT_label_en-US" xlink:label="lab_stpr_UT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UTAH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_UT" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_UT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_UT" xlink:to="lab_stpr_UT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_971e6935-cfd8-463c-b6d6-76f97a6cc4ec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d640110b-e574-491d-8493-ab4f8ce16a7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_16ba4a25-aad9-4a86-882e-582f815689af_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_c6cce2b2-655c-473b-82c9-64bfda288142_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1e893cca-d6b2-42d0-b264-3396381cc515_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_9c57c453-009f-4de3-a277-7a616275efe0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f5d7fadf-ba92-49d1-9621-d2519fefd07d_terseLabel_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_label_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_documentation_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:href="mygn-20211231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_8952a33a-fbec-4e7d-ac48-2402bf0a247b_terseLabel_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR floor (percent)</link:label>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_label_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, LIBOR Floor, Percentage</link:label>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_documentation_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, LIBOR Floor, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage" xlink:href="mygn-20211231.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtInstrumentLIBORFloorPercentage" xlink:to="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1e48112-4988-455f-a1e7-c275d1a3e69e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a033df6-eda8-4df4-be76-a732c168c93a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_07440c3a-040e-477f-beac-611aeb95897d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c0ccdc0e-792a-4048-a92c-aa7bd3531db2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_7f4832f5-d2c9-4d61-8841-fc0df9628b94_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_9bbd3b50-1e9c-4cd3-9d9e-cce1c593608f_terseLabel_en-US" xlink:label="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other long-term liabilities</link:label>
    <link:label id="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Related Expenditures Incurred But Not Yet Paid</link:label>
    <link:label id="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Related Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:href="mygn-20211231.xsd#mygn_LeaseRelatedExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:to="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_5387da4d-a97e-40a5-a51c-14fd790f84be_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in intangible assets due to sale</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_label_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Net, Noncurrent</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_documentation_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as intangible assets, net of accumulated amortization, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:to="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_e696d55c-2259-4e85-a687-5aba66649790_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Hereditary Cancer</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Hereditary Cancer Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic hereditary cancer testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:to="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dd7e51c8-00af-48cb-abba-9f20e23e4368_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_97120c9a-460f-4432-a6e0-ebf1c9825bef_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_82479ece-e960-43d3-af86-248598d6ffbb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86278dfd-0c09-4c73-a437-fe7c18767a8a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9cc73a17-e4f1-417c-98f5-d4c16338de47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_eaec8dca-1b36-4ac3-bb5c-3fb602b5c081_terseLabel_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_label_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss Federal Tax Administration (FTA) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:to="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_85e34bb4-4804-4fe4-a2ee-eafcd456a348_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_71d3a861-10a6-49a0-94c3-88621e506056_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_706fd31a-4cf4-4f27-bfb3-30ae49f30dcb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7479711b-dcc1-4978-b192-b54200595ccb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0182586c-ec9d-4cbc-895f-454a0fbdd4a8_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0e177eb7-24dc-4c79-9f94-9c0ba78bbd15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fae9209-75b8-45bb-9d6e-7c2cde17bc76_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ab69f5e-5059-4edb-8b13-57c1e0680a36_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_de114127-cf10-4511-b37a-6eb43e3b76ba_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_2891ed80-2067-4a99-bca9-ccf4a253b4e6_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_503993f3-b357-4ff7-ab56-bb439d650978_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_607688ac-9625-48cb-b687-599d97caacdb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d515f575-8e1a-4818-91d1-7d47051a79a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_76443fd3-29bd-4579-b075-aac972271cb2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_1c6cd3ad-5c77-40f0-87c5-a7fb5f9d4550_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible legal settlement</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Non Deductible Legal Settlement</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation non-deductible legal settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:to="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4d4532e4-153a-4ede-ac7d-a8864a7696b8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_48b3c7ca-7daf-4cfb-ac38-5667808ff401_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dd95515d-9110-45e8-aace-41c9f8f442b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c9f25024-8711-43a8-bfdc-4c3592ba8232_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_1edbb756-34e3-4475-925f-2ce4e190b548_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_54fcdeaf-c75f-4a94-af23-d5086cb9d714_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_ce351b78-8ceb-455e-98f7-99d1bfe4a94a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_be65c2c5-03b7-4a77-b735-77176d0bd92a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_d303ec6b-65a2-46a1-86e4-cb7dc8731f06_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_73d45ebf-2f81-4827-b668-bc1cd27a2c3e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_583474c8-93dc-4f47-96db-613b8657b27d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_46b35c98-bb22-487b-b45f-a5cb12506e0f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d64c4aa8-b8cb-4a11-b9db-23f328c47f7a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48cbf89f-ff0a-473c-9328-b3d4dd386c9e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_481a62b3-6533-49e8-9943-992c40cad6bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_UnrecognizedTaxBenefitsNet_b815893d-cc03-422c-9c9c-6076053baa3d_terseLabel_en-US" xlink:label="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_mygn_UnrecognizedTaxBenefitsNet_label_en-US" xlink:label="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:label id="lab_mygn_UnrecognizedTaxBenefitsNet_documentation_en-US" xlink:label="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnrecognizedTaxBenefitsNet" xlink:href="mygn-20211231.xsd#mygn_UnrecognizedTaxBenefitsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_UnrecognizedTaxBenefitsNet" xlink:to="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_697977fd-4db6-4a14-9489-06cfda904651_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (weighted average shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f54faa4-a87d-4ed5-98b0-c149e7d92026_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d7996ab2-68fe-4577-9eab-e4ea9f3a086d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f8d9d1ab-2282-4916-be28-a71fe3aa80ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_2a9d08ea-4320-4a77-9516-2f3453e17ca5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets included in sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_f4603ed8-2fc9-4a40-b738-8607c2aa6cc0_terseLabel_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest tax year</link:label>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_38704d6d-330f-4c08-9a34-e4d0af7b9c99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_5419f943-0cbb-4481-8720-17adc8451343_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable investment securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bea3fc02-1da9-412d-81e8-241007b06643_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_c1870c17-e0fd-4549-aafc-43133dab0b5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RangeTwoMember_089777d0-dd36-4c53-bd60-e6a18946fb01_terseLabel_en-US" xlink:label="lab_mygn_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$ 23.98</link:label>
    <link:label id="lab_mygn_RangeTwoMember_label_en-US" xlink:label="lab_mygn_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_mygn_RangeTwoMember_documentation_en-US" xlink:label="lab_mygn_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeTwoMember" xlink:href="mygn-20211231.xsd#mygn_RangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RangeTwoMember" xlink:to="lab_mygn_RangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7cadc75-4aa3-4d0f-b101-54208221b687_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_099fc754-70aa-4693-9bc6-006e22c885f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred and Common Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b2bee674-2a54-41e9-a587-77fe7e50dbfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_b5fd2a41-78d9-4562-9678-1f42202165e0_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases - statute lapse</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5201828d-a5b1-4b34-8870-6f1d7c2aa5d8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_921c6c69-10f1-48ff-8a1e-6129a5e4ad73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Common Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_173a88d3-8708-456c-af53-630713e0bd1a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f6e72789-949b-498e-bf33-7ce9e34ea3bb_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c96738a7-dc42-449f-a232-210730850d1c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_b4f68940-2248-4a92-8d8b-21a094c65784_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Asset Impairment</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation asset impairment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_ddde3559-67da-4bef-8e3f-8a0c3d80bf2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intrinsic Value of Options Exercised</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RangeThreeMember_d6710b13-5e23-4ca3-bd46-72d157e3b2a1_terseLabel_en-US" xlink:label="lab_mygn_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$ 27.07 - 36.55</link:label>
    <link:label id="lab_mygn_RangeThreeMember_label_en-US" xlink:label="lab_mygn_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label id="lab_mygn_RangeThreeMember_documentation_en-US" xlink:label="lab_mygn_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeThreeMember" xlink:href="mygn-20211231.xsd#mygn_RangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RangeThreeMember" xlink:to="lab_mygn_RangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_df607fca-3add-483e-914b-f8139bd698e9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89c43bf1-6b7f-44bd-8c99-35c292363a11_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2bd861a1-804d-4406-b31f-9fd453bd4955_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_87bd9f91-8b00-4346-be81-ff504a81424f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d24fe82-3ffe-446c-b754-15f0f44259d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a265b7ac-92dc-4ce4-bb5c-29558d74d3e1_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c4161cf4-e8b6-4a36-b6fa-6aebf85325e6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_086071cf-82f2-4f04-832d-6b8f8c268d88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9df559d-4be4-4c44-8d05-1b571ace6499_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_37b37e2d-0c5d-4986-ab73-43872ca45752_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember_a89a4413-887c-4d82-b192-4dc91fa94f35_terseLabel_en-US" xlink:label="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain executive officers and other senior positions</link:label>
    <link:label id="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember_label_en-US" xlink:label="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officers And Senior Positions [Member]</link:label>
    <link:label id="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember_documentation_en-US" xlink:label="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officers And Senior Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ExecutiveOfficersAndSeniorPositionsMember" xlink:href="mygn-20211231.xsd#mygn_ExecutiveOfficersAndSeniorPositionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ExecutiveOfficersAndSeniorPositionsMember" xlink:to="lab_mygn_ExecutiveOfficersAndSeniorPositionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6a8411e6-586f-4b37-867d-957d25ece559_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0fc661e0-7660-4fd5-99cb-9030805164be_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dd2520bd-8c82-4b5e-8b6a-ccdbd6646c37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tax withheld for common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AuditInformationAbstract_label_en-US" xlink:label="lab_mygn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mygn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mygn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AuditInformationAbstract" xlink:href="mygn-20211231.xsd#mygn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AuditInformationAbstract" xlink:to="lab_mygn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_37be1cb3-b8c3-4edb-89f6-887058eaa9a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of operating lease right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_08abdb36-de53-433c-a4b6-a35f0a0112c8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate principal commitment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_3009c520-6f4d-4699-9fa3-123b1d3fdd24_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6a1cbdf6-8be7-49a3-9cc3-3425a9674532_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_d36d09dd-fec1-4142-b0fb-12b0c799d040_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b7c8ed94-0e28-475b-a623-e5ce772f525d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_03bedf50-803c-47f9-bb2d-8c25b05a931c_verboseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_8596c075-f51f-43f8-a682-e4020ed9de8e_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_label_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_documentation_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:to="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_39acc192-cf96-4acc-8308-7973ee71e8d9_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e7978f22-b1b0-4ae0-8fa8-b210bd94f667_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_ebecb8a1-c310-4946-b0a2-d9a06ab48d76_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government contracts concentration risk</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_48462fcd-098f-4cf5-a79e-1940e7d36de0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_abfbebfc-de0e-437a-9205-ba70d31465ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1b94ee1b-20be-42b4-a689-1c76c4649693_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_30e98f3b-24c7-4eeb-a36a-1f99a615d0b8_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_73f024ff-7489-45bb-b661-dc8c985cc67c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c74b417e-5dd9-43d2-802c-4a6f36c436be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_7d2f4c53-7235-4112-91d0-0012df680954_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OtherStateMember_06b3eda1-f84d-474c-b9cd-d3c12fece272_terseLabel_en-US" xlink:label="lab_mygn_OtherStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mygn_OtherStateMember_label_en-US" xlink:label="lab_mygn_OtherStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State [Member]</link:label>
    <link:label id="lab_mygn_OtherStateMember_documentation_en-US" xlink:label="lab_mygn_OtherStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherStateMember" xlink:href="mygn-20211231.xsd#mygn_OtherStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OtherStateMember" xlink:to="lab_mygn_OtherStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ed2794df-6569-47c2-963b-0a210048f8fe_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ce09b323-5f45-42f9-b0f2-41825091d614_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_44d80023-75d7-45aa-ad83-2c14f84820e6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_bf410661-f435-42f9-aa5e-9c0572db8cf3_terseLabel_en-US" xlink:label="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc. and Myriad Autoimmune business</link:label>
    <link:label id="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_label_en-US" xlink:label="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc. And Myriad Autoimmune Business [Member]</link:label>
    <link:label id="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_documentation_en-US" xlink:label="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc. And Myriad Autoimmune Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:to="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f0383a3a-4023-4e75-98ac-4d3cae098255_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fab5764c-9cb6-48e8-855c-089a777eef6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense at the statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_f3fab951-8c1e-465b-8b90-05e33972f9d4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit subject to sections 382,383</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_27f8deb8-b623-4c3f-b933-2a6a3b259889_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, net, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_98d092d3-831b-4b42-87af-6bd5d2272859_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_d15b8afb-0b65-472e-8b94-4c0c6851cc3f_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_8ef51652-669f-446c-8942-a9a5ed5f60ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount at end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_6dd9f297-cc8e-4d1b-8ca0-66fef9e61f0e_terseLabel_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</link:label>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</link:label>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:href="mygn-20211231.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:to="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_dd4c468d-2bef-4029-8562-6e7945bc2b04_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_39656b63-8a96-491c-9e13-d761ac0bafe4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_28234825-beff-44f9-ab2e-15d466763119_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_ee0749f2-e01a-40f5-88f2-780f16f78c24_terseLabel_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of options and employee stock plans</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:href="mygn-20211231.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:to="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_d685c8fc-01d4-4f34-953f-770f1e4aa659_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss subject to sections 382,383</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_7e134258-6e9b-4feb-ae95-b76e70385467_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Method changes or tax elections</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Changes In Revenue Recognition Method</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, changes in revenue recognition/method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_39566b26-3739-442d-a9da-977806f5514c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_620db114-9605-4b82-890f-5ad1df4472ba_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2c5d3881-0cbb-4745-8fee-24d929233977_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5b907eab-cd45-4ece-958f-753244d306e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb7888ba-c967-4705-94df-7ac80b03c930_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6b57651d-b329-4df8-b9d9-5c0fe8006882_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_765c0bd6-ec4a-4fa2-ab65-501a171f9ec0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseArrangementDomain_a1b6099a-d054-4ec3-966f-d4a03e1304ea_terseLabel_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_mygn_LeaseArrangementDomain_label_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_mygn_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseArrangementDomain" xlink:to="lab_mygn_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_74643bb4-5a18-4620-9120-4e39f57b716c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c8ce53bb-9913-45b3-b0f4-72bb794f6af8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_0b38ab4d-b41e-4c9a-82ba-f86e35cdbf51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Shares Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_b0afb1f6-7474-4b69-9aff-dd698c31aa6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_60143aa5-8720-4ce3-8475-274aed623526_terseLabel_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable geographical components</link:label>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_label_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember" xlink:to="lab_srt_ReportableGeographicalComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_6620c9bc-8a6e-4bdc-9f14-cf03a0de71fc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company matching contribution, maximum as percentage of employee compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8e0c0798-45aa-4a72-9b8a-9c292576f536_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_d674127e-4c3f-4542-bfdd-ab795b614e40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions for ESPP</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_1c3259f6-9ddb-46b3-978c-f793c4a103b1_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic revenues</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticTestingMember" xlink:to="lab_mygn_MolecularDiagnosticTestingMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mygn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4990a358-c12e-4899-92d4-a6c626b561e2,g:4a66b582-ad59-47ea-a8a2-59085acc693c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/Cover" xlink:type="simple" xlink:href="mygn-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5e12b3d1-61bd-432e-a36d-a1253ff47132" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentType_5e12b3d1-61bd-432e-a36d-a1253ff47132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b814a73d-3a9d-4a7e-bc75-e0859ab7f2a6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentAnnualReport_b814a73d-3a9d-4a7e-bc75-e0859ab7f2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_43bd7c87-06f5-434e-9872-f6f3f0aafcc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentPeriodEndDate_43bd7c87-06f5-434e-9872-f6f3f0aafcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b65181ac-9e0b-4bcc-af0b-262b7de6acd1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_CurrentFiscalYearEndDate_b65181ac-9e0b-4bcc-af0b-262b7de6acd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_296aa1c8-fc35-4d38-bd1a-3e460022b1a0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentTransitionReport_296aa1c8-fc35-4d38-bd1a-3e460022b1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e1dfab30-6fd4-4557-9014-d3a834b5d780" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityFileNumber_e1dfab30-6fd4-4557-9014-d3a834b5d780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_979681ed-7a16-4417-be34-876add55efeb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityRegistrantName_979681ed-7a16-4417-be34-876add55efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_30a4c843-d2de-49e7-9a13-970498bcc74e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_30a4c843-d2de-49e7-9a13-970498bcc74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a01d35c5-8594-4868-ae80-2c4f45510457" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityTaxIdentificationNumber_a01d35c5-8594-4868-ae80-2c4f45510457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e13a8340-63e4-494e-b361-975193675061" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityAddressAddressLine1_e13a8340-63e4-494e-b361-975193675061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9f744133-78d5-4ec6-b6e0-7ed69c0a088a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityAddressCityOrTown_9f744133-78d5-4ec6-b6e0-7ed69c0a088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d8bfad00-a5a6-4a83-a366-b1bfffc5a2b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityAddressStateOrProvince_d8bfad00-a5a6-4a83-a366-b1bfffc5a2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_082a3791-0bc2-4855-9917-8580f1f7effa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityAddressPostalZipCode_082a3791-0bc2-4855-9917-8580f1f7effa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e4cb8159-48b5-437b-8fa5-6839d9191c0b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_CityAreaCode_e4cb8159-48b5-437b-8fa5-6839d9191c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cc327a5d-0899-42cd-ae6a-45fd50991241" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_LocalPhoneNumber_cc327a5d-0899-42cd-ae6a-45fd50991241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_50ca719d-77e5-40c8-a800-247103930471" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_Security12bTitle_50ca719d-77e5-40c8-a800-247103930471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8b3e210b-eed3-4fd3-b33e-013a52122133" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_TradingSymbol_8b3e210b-eed3-4fd3-b33e-013a52122133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_567b6490-3876-46e9-9308-7f6e3798f64a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_SecurityExchangeName_567b6490-3876-46e9-9308-7f6e3798f64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8fac477b-6418-4828-86c4-85c3e5554798" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8fac477b-6418-4828-86c4-85c3e5554798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d04e3c14-4cc2-41d4-b91e-8ca1667ea630" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityVoluntaryFilers_d04e3c14-4cc2-41d4-b91e-8ca1667ea630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3f83697d-b3b8-43f0-ba0d-9ed7eadab9d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityCurrentReportingStatus_3f83697d-b3b8-43f0-ba0d-9ed7eadab9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e405a053-c7e0-43e0-8c7a-8fd67c4457c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityInteractiveDataCurrent_e405a053-c7e0-43e0-8c7a-8fd67c4457c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0dc16c9f-22fd-45b6-80f0-a6a1c4f8ca4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityFilerCategory_0dc16c9f-22fd-45b6-80f0-a6a1c4f8ca4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6e7475a9-1a46-4513-9cd6-c62e4f40457e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntitySmallBusiness_6e7475a9-1a46-4513-9cd6-c62e4f40457e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_02575fb1-2a81-4c8b-aaf4-0ef94e82e16b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityEmergingGrowthCompany_02575fb1-2a81-4c8b-aaf4-0ef94e82e16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_dca0c871-3e05-40bf-b04f-d812c43f39ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_IcfrAuditorAttestationFlag_dca0c871-3e05-40bf-b04f-d812c43f39ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6cafae0e-4c7f-446d-ab45-c52d7835410a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityShellCompany_6cafae0e-4c7f-446d-ab45-c52d7835410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_3117b53d-1e90-4ec8-965b-4974872eb155" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityPublicFloat_3117b53d-1e90-4ec8-965b-4974872eb155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4c260749-ab52-4fb7-8ef0-e1da169da392" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4c260749-ab52-4fb7-8ef0-e1da169da392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_335df1a6-6f0d-43c1-99d8-09109db2360e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_EntityCentralIndexKey_335df1a6-6f0d-43c1-99d8-09109db2360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6bb02a46-6388-4942-8ab2-37533f051518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentFiscalYearFocus_6bb02a46-6388-4942-8ab2-37533f051518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_526182f3-c109-4d89-b38f-1b1a4ad1dc1e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_526182f3-c109-4d89-b38f-1b1a4ad1dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7d077b79-631f-4f03-939a-b9605c3fd001" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_AmendmentFlag_7d077b79-631f-4f03-939a-b9605c3fd001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a6dd1b99-8341-4e53-93b3-92c337c1e2a5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90b111fb-0dbd-4731-9c9d-052459f64ca8" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a6dd1b99-8341-4e53-93b3-92c337c1e2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AuditInformation" xlink:type="simple" xlink:href="mygn-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AuditInformationAbstract_c38e6e98-272b-4cc9-9243-0322decb09b1" xlink:href="mygn-20211231.xsd#mygn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_26e82677-6d54-4a0b-8340-2842b02d6fb1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_AuditInformationAbstract_c38e6e98-272b-4cc9-9243-0322decb09b1" xlink:to="loc_dei_AuditorName_26e82677-6d54-4a0b-8340-2842b02d6fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_8a042b5f-839e-49d1-bfd4-b7adf5367368" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_AuditInformationAbstract_c38e6e98-272b-4cc9-9243-0322decb09b1" xlink:to="loc_dei_AuditorLocation_8a042b5f-839e-49d1-bfd4-b7adf5367368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_86eafe0a-cb97-4302-b375-1f936f4424a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_AuditInformationAbstract_c38e6e98-272b-4cc9-9243-0322decb09b1" xlink:to="loc_dei_AuditorFirmId_86eafe0a-cb97-4302-b375-1f936f4424a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1acf869a-6b1a-4aeb-be51-fdd3e839d324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1acf869a-6b1a-4aeb-be51-fdd3e839d324" xlink:to="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9567065-120b-4e6e-931d-2958a5404cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9567065-120b-4e6e-931d-2958a5404cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2b0f73c0-f798-484e-ab7f-f74f7a78d131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2b0f73c0-f798-484e-ab7f-f74f7a78d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_86ec8101-b222-423c-8906-de2840c49a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_86ec8101-b222-423c-8906-de2840c49a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d9f05277-fd38-4262-bfac-8c33a36ca4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_InventoryNet_d9f05277-fd38-4262-bfac-8c33a36ca4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_d1ddb687-a9f3-4f6d-b046-49520b0ecf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_PrepaidTaxes_d1ddb687-a9f3-4f6d-b046-49520b0ecf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa358e9a-a2f4-44bc-b97e-1a1f5e8ad197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa358e9a-a2f4-44bc-b97e-1a1f5e8ad197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_93c3cced-aa98-472d-8a35-f1695972eede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9668c5e0-f141-4c85-8368-823e13c98990" xlink:to="loc_us-gaap_AssetsCurrent_93c3cced-aa98-472d-8a35-f1695972eede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_30ed6eda-b3f2-4043-8cbb-8e2c5114d83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_30ed6eda-b3f2-4043-8cbb-8e2c5114d83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1c79d184-24f0-4e12-80ed-3a6faa243d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1c79d184-24f0-4e12-80ed-3a6faa243d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b5be323-c2cb-42fc-88a9-d42565167d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b5be323-c2cb-42fc-88a9-d42565167d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_81070ce1-3da2-457c-969e-02b0c87a9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_81070ce1-3da2-457c-969e-02b0c87a9bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_393ce5fa-b6e0-4933-97d2-0c0450093ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_Goodwill_393ce5fa-b6e0-4933-97d2-0c0450093ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ca6e2b79-9321-4583-86df-767346da125e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ca6e2b79-9321-4583-86df-767346da125e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_65bd8af6-4a2b-49bf-a055-9f2140a74aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c7e7e38f-acd4-48c9-9097-9d3dfdaf480a" xlink:to="loc_us-gaap_Assets_65bd8af6-4a2b-49bf-a055-9f2140a74aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1acf869a-6b1a-4aeb-be51-fdd3e839d324" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_09e93cc8-8f8d-4e5c-a5a8-b8e64187b127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:to="loc_us-gaap_AccountsPayableCurrent_09e93cc8-8f8d-4e5c-a5a8-b8e64187b127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_689086ff-fe6d-4d80-837b-887762b96bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_689086ff-fe6d-4d80-837b-887762b96bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_033ae6d8-bd42-4f43-acd1-29036b5b5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_033ae6d8-bd42-4f43-acd1-29036b5b5d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc110b5d-8da1-4f3e-a97a-ec108827b037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc110b5d-8da1-4f3e-a97a-ec108827b037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4c1ffe87-d223-40c3-a1d0-a3fd26eaf2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a7819aed-4e05-4609-8d12-22686223e890" xlink:to="loc_us-gaap_LiabilitiesCurrent_4c1ffe87-d223-40c3-a1d0-a3fd26eaf2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnrecognizedTaxBenefitsNet_484d1c2f-e73c-4af2-9c9f-7ad43cd8f29e" xlink:href="mygn-20211231.xsd#mygn_UnrecognizedTaxBenefitsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_mygn_UnrecognizedTaxBenefitsNet_484d1c2f-e73c-4af2-9c9f-7ad43cd8f29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7d9751e0-3aaf-4bd9-af56-61bf9b73cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7d9751e0-3aaf-4bd9-af56-61bf9b73cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4fc34be0-da85-4be4-9bd8-26fd3a45335c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4fc34be0-da85-4be4-9bd8-26fd3a45335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b6a89e7f-c9cc-46d2-a1ba-b11d055eb777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b6a89e7f-c9cc-46d2-a1ba-b11d055eb777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_62be72da-7b2e-4747-9cd0-99f0b5916b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_62be72da-7b2e-4747-9cd0-99f0b5916b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_431fe8eb-1684-48d8-935e-1503dd3d1c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_Liabilities_431fe8eb-1684-48d8-935e-1503dd3d1c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_98b35c88-5461-4e20-89ea-d982b2ddd315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_CommitmentsAndContingencies_98b35c88-5461-4e20-89ea-d982b2ddd315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_53eadbbd-7f5c-4f26-a56b-cb1e057b02f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_CommonStockValue_53eadbbd-7f5c-4f26-a56b-cb1e057b02f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d7cd11ca-8f13-4aa5-8881-0fbf4ee6d4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d7cd11ca-8f13-4aa5-8881-0fbf4ee6d4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_410d1db7-d190-433d-abbb-2392d0e2974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_410d1db7-d190-433d-abbb-2392d0e2974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9cc7ca93-1881-46d9-9fe5-6c0fc591505f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9cc7ca93-1881-46d9-9fe5-6c0fc591505f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5afe2aa6-3a57-49b0-afcc-90b840d32061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_StockholdersEquity_5afe2aa6-3a57-49b0-afcc-90b840d32061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b6a01908-9aad-4949-a5b0-e6ae73f00185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_MinorityInterest_b6a01908-9aad-4949-a5b0-e6ae73f00185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b0c5116-d41c-4d49-b6dd-b4c4ca99cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f964e878-b89d-4ab3-a7d7-988ed3d7e1bf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b0c5116-d41c-4d49-b6dd-b4c4ca99cad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37c9b5d6-4c76-4f1d-9341-365d2d0fc43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81926b07-bf7f-469a-9739-1c56478d7487" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37c9b5d6-4c76-4f1d-9341-365d2d0fc43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_59b1c026-2326-4f5d-994d-0d2be9d775b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2274eef6-d03c-49ca-8e5a-d8a56ab4d6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59b1c026-2326-4f5d-994d-0d2be9d775b4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2274eef6-d03c-49ca-8e5a-d8a56ab4d6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2c6409b8-7e71-48ea-8dd0-39e23f19e760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59b1c026-2326-4f5d-994d-0d2be9d775b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2c6409b8-7e71-48ea-8dd0-39e23f19e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8b37e777-a90e-42c0-9e09-e8591b0fe33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b37e777-a90e-42c0-9e09-e8591b0fe33d" xlink:to="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:to="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_48697284-856e-4b46-a530-ad14a3e1a8c5" xlink:to="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_23b67658-7013-44da-b5ac-d15b48756747" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_23b67658-7013-44da-b5ac-d15b48756747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_b72a64b4-717e-418b-8b34-08cb5ac6a9a1" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46afda7b-6402-4dc6-b41d-36f60828248e" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_b72a64b4-717e-418b-8b34-08cb5ac6a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d478e94-7fce-4295-9fa4-585e8ac00752" xlink:to="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92278080-429d-4b4b-ad44-294537bfb81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92278080-429d-4b4b-ad44-294537bfb81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0fc4eda8-ff6d-4512-94a0-3b22a6527694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0fc4eda8-ff6d-4512-94a0-3b22a6527694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_795b5d87-749c-49b7-bb3a-8e601006b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_795b5d87-749c-49b7-bb3a-8e601006b4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b65bee83-4947-4070-a690-e7ed0b071e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b65bee83-4947-4070-a690-e7ed0b071e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_905d37de-b4c1-4c40-a5c7-8e91581adadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_LitigationSettlementExpense_905d37de-b4c1-4c40-a5c7-8e91581adadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f1e75b8b-a2ff-4855-8211-9338da41a37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f1e75b8b-a2ff-4855-8211-9338da41a37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_db354910-a6f7-4a45-a373-a04193a41f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_91b46f69-8ceb-4eb2-bcdb-06958f1d699b" xlink:to="loc_us-gaap_CostsAndExpenses_db354910-a6f7-4a45-a373-a04193a41f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_137e717e-f7fc-47f4-94b1-4d9c12344fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_OperatingIncomeLoss_137e717e-f7fc-47f4-94b1-4d9c12344fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_831111ad-19ba-4d6f-a5db-9812ebbfa89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_831111ad-19ba-4d6f-a5db-9812ebbfa89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a5369950-b0ec-4f32-89d4-34451d60f3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_InterestExpense_a5369950-b0ec-4f32-89d4-34451d60f3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5ad9f525-6119-4cf6-854d-d979bec6da85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5ad9f525-6119-4cf6-854d-d979bec6da85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fcebccdf-ffc9-449d-9ef1-60fa61b111cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7e974ff-c114-454c-bbf5-bcd9d646f0f3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fcebccdf-ffc9-449d-9ef1-60fa61b111cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a39dd97d-d021-40a8-a3c6-5379539f7201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a39dd97d-d021-40a8-a3c6-5379539f7201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_37cd2379-e71b-47b7-8794-846c10a8639c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_37cd2379-e71b-47b7-8794-846c10a8639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_411e8b93-cd1b-42af-8aee-f8070d7d7672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_ProfitLoss_411e8b93-cd1b-42af-8aee-f8070d7d7672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76e7e36b-9010-435d-a7b5-a61a629ee483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76e7e36b-9010-435d-a7b5-a61a629ee483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c6cc7bb-988f-4541-99e2-f15d2fa2942e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_NetIncomeLoss_4c6cc7bb-988f-4541-99e2-f15d2fa2942e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_367964c8-7a43-4d21-9a85-dcbafd7fd241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:to="loc_us-gaap_EarningsPerShareBasic_367964c8-7a43-4d21-9a85-dcbafd7fd241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_440a13ab-4ee6-4634-99fb-2323119bbc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0d3f574-afe0-47fd-9994-f8b14177b55b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_440a13ab-4ee6-4634-99fb-2323119bbc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_50702ce7-11ef-454b-ab7c-b9e7e27db294" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_901de7f8-b407-4d04-85d9-be896e855a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_901de7f8-b407-4d04-85d9-be896e855a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36459792-72e2-481a-9bd8-4b342da0667b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_66f7fc65-8f3f-4e92-9b79-41b7ea0e1286" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36459792-72e2-481a-9bd8-4b342da0667b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3843ad0b-1c4b-4364-93d4-3d1e4ef676e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_874ee421-237c-4738-aaf3-501a5afdceae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3843ad0b-1c4b-4364-93d4-3d1e4ef676e5" xlink:to="loc_us-gaap_NetIncomeLoss_874ee421-237c-4738-aaf3-501a5afdceae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ee23f5e4-484f-4291-834b-2a4a863675a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3843ad0b-1c4b-4364-93d4-3d1e4ef676e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ee23f5e4-484f-4291-834b-2a4a863675a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_7cd9effe-e099-4f89-87da-467c319025ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3843ad0b-1c4b-4364-93d4-3d1e4ef676e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_7cd9effe-e099-4f89-87da-467c319025ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c9602321-431a-465f-8450-fbf8d6407d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3843ad0b-1c4b-4364-93d4-3d1e4ef676e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c9602321-431a-465f-8450-fbf8d6407d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd822685-6971-4b1e-b41a-c9d34f39d231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3843ad0b-1c4b-4364-93d4-3d1e4ef676e5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd822685-6971-4b1e-b41a-c9d34f39d231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5aa0824c-d65c-4a7b-bd09-77d29b3b34de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5aa0824c-d65c-4a7b-bd09-77d29b3b34de" xlink:to="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22bbed19-b8ee-42ad-8796-f8f4ee75f2bd" xlink:to="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7a6395ba-45da-4f77-9700-4c3eb7f10175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_CommonStockMember_7a6395ba-45da-4f77-9700-4c3eb7f10175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0af1f65b-3a0f-48b7-b7a8-410a89ec0bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0af1f65b-3a0f-48b7-b7a8-410a89ec0bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_776170fb-1ea4-4595-80dd-ef1596141e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_776170fb-1ea4-4595-80dd-ef1596141e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ed602d1b-897a-4672-a18e-9e3e572da810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99c86957-95d0-46a8-8ea7-fa079e397893" xlink:to="loc_us-gaap_RetainedEarningsMember_ed602d1b-897a-4672-a18e-9e3e572da810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99e88dc0-0afb-4459-afe1-7a586f2f172b" xlink:to="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5de69c3f-9035-4681-a1e1-89eab8a1c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5de69c3f-9035-4681-a1e1-89eab8a1c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_75d0f989-6f63-47af-99a2-9f8bc03f12d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_75d0f989-6f63-47af-99a2-9f8bc03f12d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b9ddd33d-4d95-4f64-abb8-5921527e3a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b9ddd33d-4d95-4f64-abb8-5921527e3a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ff718677-785e-4dd1-bb4d-4e73c95d4e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_ff718677-785e-4dd1-bb4d-4e73c95d4e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_175e19a8-1888-4ced-99ef-aaba4170a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_NetIncomeLoss_175e19a8-1888-4ced-99ef-aaba4170a84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_43dd7412-6bef-458d-a39b-60a5c5e960fb" xlink:href="mygn-20211231.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_43dd7412-6bef-458d-a39b-60a5c5e960fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61952207-e457-4ad4-af71-135026f2f2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61952207-e457-4ad4-af71-135026f2f2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ee200d7-ae8b-4bf7-baf3-a611ed177dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873c1bf7-0787-4acb-92cf-04f8f1742d58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ee200d7-ae8b-4bf7-baf3-a611ed177dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d89fb9bd-c645-4cc5-a351-20b37c14caff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d89fb9bd-c645-4cc5-a351-20b37c14caff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_27ddef66-6e0c-47b6-a1ce-074af63b94eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d89fb9bd-c645-4cc5-a351-20b37c14caff" xlink:to="loc_us-gaap_NetIncomeLoss_27ddef66-6e0c-47b6-a1ce-074af63b94eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d89fb9bd-c645-4cc5-a351-20b37c14caff" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_4f5e142e-a94d-4bc1-a19e-1d4ad23e4066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_DepreciationAndAmortization_4f5e142e-a94d-4bc1-a19e-1d4ad23e4066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_968347cf-db31-4bb3-aafc-0f4644bc5ab3" xlink:href="mygn-20211231.xsd#mygn_NonCashInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_mygn_NonCashInterestExpense_968347cf-db31-4bb3-aafc-0f4644bc5ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9eeff7bd-98bb-4ee3-a5fa-109a297a0edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9eeff7bd-98bb-4ee3-a5fa-109a297a0edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_602addf5-90ac-4e60-92f6-32cbcba6c9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_ShareBasedCompensation_602addf5-90ac-4e60-92f6-32cbcba6c9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f31696f5-ae5d-4b51-84ef-af4d4130fa90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f31696f5-ae5d-4b51-84ef-af4d4130fa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_4f3e20e8-8ff5-4397-9921-35366663d7d0" xlink:href="mygn-20211231.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_4f3e20e8-8ff5-4397-9921-35366663d7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_92396365-1800-4750-8c27-ec55aa9f50b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_92396365-1800-4750-8c27-ec55aa9f50b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_52444294-5aa4-4605-a20b-02d8e5d03ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_InventoryWriteDown_52444294-5aa4-4605-a20b-02d8e5d03ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_2ccf30d0-1637-4418-a3c7-178bab4a303e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_2ccf30d0-1637-4418-a3c7-178bab4a303e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_a09f4aef-c3ab-42e1-81ac-f17bfa8d25e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_a09f4aef-c3ab-42e1-81ac-f17bfa8d25e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_07c4c809-6fea-48f3-ad76-b92a1de18901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_07c4c809-6fea-48f3-ad76-b92a1de18901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d8f5b82-82ce-4814-aad0-741d6d1edf4a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_a1839848-872e-4047-b65b-1db6f6d85d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_a1839848-872e-4047-b65b-1db6f6d85d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b6e9e29-4e45-4da9-ae13-033cce09191b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b6e9e29-4e45-4da9-ae13-033cce09191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ebcf5cd2-452f-47f2-beaf-8d79dddfafc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ebcf5cd2-452f-47f2-beaf-8d79dddfafc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_d74bf925-de5d-4dd3-8197-5c7d0f716c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_d74bf925-de5d-4dd3-8197-5c7d0f716c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0df6fd31-e701-4b89-ae40-5c06b4df48bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0df6fd31-e701-4b89-ae40-5c06b4df48bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d30be471-5d48-474d-9ffc-1713d605ef0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d30be471-5d48-474d-9ffc-1713d605ef0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f6eaffbc-4b1b-4cc1-bb28-848d9f9f530c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f6eaffbc-4b1b-4cc1-bb28-848d9f9f530c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_484ef1fe-e492-4b02-86b2-8160c6d10e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfabfb4f-4eb1-443b-8128-d619b5f00686" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_484ef1fe-e492-4b02-86b2-8160c6d10e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dad52512-92be-4b82-99d8-89ffafdfb9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d89fb9bd-c645-4cc5-a351-20b37c14caff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dad52512-92be-4b82-99d8-89ffafdfb9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_f9d58415-7b7b-4f21-8b12-0a26599eaccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_f9d58415-7b7b-4f21-8b12-0a26599eaccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_69a9ba70-b0a6-4006-9d0d-58dd3f669a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_69a9ba70-b0a6-4006-9d0d-58dd3f669a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_4665cd36-f167-4e66-8272-a81568e87ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_4665cd36-f167-4e66-8272-a81568e87ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8d3bc715-8807-4536-b9db-e5441e267275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8d3bc715-8807-4536-b9db-e5441e267275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_51291dad-213b-4bcc-a382-cf026781b58c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_51291dad-213b-4bcc-a382-cf026781b58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e0c481d6-248a-4b1d-8e60-79db4219050d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e030937-6c59-447b-88cc-6f9d44c3e0d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e0c481d6-248a-4b1d-8e60-79db4219050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_15a74eb1-28c6-4e50-8a26-2e5355372cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_15a74eb1-28c6-4e50-8a26-2e5355372cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d895399e-8672-44ed-8a20-4d0e03d6b3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d895399e-8672-44ed-8a20-4d0e03d6b3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3afdd74d-c268-43ba-ab2c-3791e8e7fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3afdd74d-c268-43ba-ab2c-3791e8e7fdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_9b4a8a82-3cde-4a69-830d-375e93b05ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_9b4a8a82-3cde-4a69-830d-375e93b05ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_653f4539-1e38-4a52-b375-4cea583d2bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_653f4539-1e38-4a52-b375-4cea583d2bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_97af457d-7229-4ecb-b60d-98d3aa677ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_97af457d-7229-4ecb-b60d-98d3aa677ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ade2867c-ea2b-43d2-9f1d-a4b86cf91fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ade2867c-ea2b-43d2-9f1d-a4b86cf91fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfc92647-1337-4226-afd3-cd04ff7375ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d8174a3-59be-403b-b338-e8fafe284ce1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfc92647-1337-4226-afd3-cd04ff7375ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05a71a78-b120-4285-933e-862c16697acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05a71a78-b120-4285-933e-862c16697acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b61b5507-7af5-4137-93e1-24abc647e9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b61b5507-7af5-4137-93e1-24abc647e9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac2a63e2-afb3-4752-b27b-070b8c02c251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac2a63e2-afb3-4752-b27b-070b8c02c251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_85292d4e-49a5-492b-8c44-34aba4330174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_06b180e4-dae7-42fe-922c-46cfeede9d14" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_85292d4e-49a5-492b-8c44-34aba4330174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d1da4fac-bed8-4626-bcf8-b9c049c73baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_e426e6d7-c63a-4d21-ae5f-96ef32714680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d1da4fac-bed8-4626-bcf8-b9c049c73baf" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_e426e6d7-c63a-4d21-ae5f-96ef32714680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_66deb3b5-08c1-4009-8ae2-0186d48e616a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_66deb3b5-08c1-4009-8ae2-0186d48e616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0e7ba108-720a-4e9a-88d4-f25a9d3b7021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_UseOfEstimates_0e7ba108-720a-4e9a-88d4-f25a9d3b7021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8cefd11a-f1c3-4be1-bed3-af923c488b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8cefd11a-f1c3-4be1-bed3-af923c488b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c3792e3a-70ac-4049-800a-63a14af82ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c3792e3a-70ac-4049-800a-63a14af82ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d67967d8-2445-44c5-8923-739e48e7fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d67967d8-2445-44c5-8923-739e48e7fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_720fc7ed-582d-4745-bb22-cd7cd05b567f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_720fc7ed-582d-4745-bb22-cd7cd05b567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7ab29584-5d9b-4ffc-8e58-8500bef1c6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7ab29584-5d9b-4ffc-8e58-8500bef1c6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_0bcaf560-88af-4e30-b370-accbc7f517c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_0bcaf560-88af-4e30-b370-accbc7f517c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8ab5d665-8da2-4a56-8d27-3c4958e4d843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8ab5d665-8da2-4a56-8d27-3c4958e4d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_d310d594-6e2e-42c5-ae48-46f16f0f5037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_d310d594-6e2e-42c5-ae48-46f16f0f5037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_512b7539-20e9-4b07-b81c-88067237c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_512b7539-20e9-4b07-b81c-88067237c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0202dd72-1359-42be-8d61-95b1c07a7333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0202dd72-1359-42be-8d61-95b1c07a7333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_55f47b5f-c5e0-4ef4-8d3e-8f465111a254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_55f47b5f-c5e0-4ef4-8d3e-8f465111a254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock_24651eab-ce1e-45a0-9c1f-9a468d711642" xlink:href="mygn-20211231.xsd#mygn_OtherIncomeExpensePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock_24651eab-ce1e-45a0-9c1f-9a468d711642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f21f141d-245a-42ad-90b2-f1c25cc54679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f21f141d-245a-42ad-90b2-f1c25cc54679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7c828493-a975-4dfe-b96b-2b7208cf4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7c828493-a975-4dfe-b96b-2b7208cf4be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_914d93a7-86cf-4e44-b657-bbe0b2c2aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_914d93a7-86cf-4e44-b657-bbe0b2c2aba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_563d79ea-a06b-4709-af78-12cad21ad6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_563d79ea-a06b-4709-af78-12cad21ad6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_190e004d-c032-4c89-8057-584ff847058b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb7f3ad5-074b-44ac-bf19-74ab6b8963f2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_190e004d-c032-4c89-8057-584ff847058b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d06cdc3b-592e-404a-a08d-b618168d1e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d06cdc3b-592e-404a-a08d-b618168d1e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9f5ee552-404f-40d1-99a4-fb1a86e895e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9f5ee552-404f-40d1-99a4-fb1a86e895e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8da57594-f8ab-4798-b245-a644898b377e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8da57594-f8ab-4798-b245-a644898b377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_2a095b63-5696-40d0-9248-5a388203ff30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_2a095b63-5696-40d0-9248-5a388203ff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9bf3e380-f600-4ce5-b735-455cb7db0fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9bf3e380-f600-4ce5-b735-455cb7db0fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_126ba6a5-0213-4e18-b72f-d1f1bb5f7e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c8a011-f051-44ba-8ca8-86246cbf42ae" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_126ba6a5-0213-4e18-b72f-d1f1bb5f7e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d16d4a0-3b73-4bdb-af0e-813cad5bdb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:href="mygn-20211231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d16d4a0-3b73-4bdb-af0e-813cad5bdb5e" xlink:to="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e97a6bdf-1f01-44d1-b0b5-30f8b0d2860e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80fa6c48-dec2-4482-b387-c881c5166a6f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e97a6bdf-1f01-44d1-b0b5-30f8b0d2860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_28657aee-3b7d-44a8-8583-1d1ef871f4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e97a6bdf-1f01-44d1-b0b5-30f8b0d2860e" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_28657aee-3b7d-44a8-8583-1d1ef871f4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d34bdb26-884f-4c8c-a462-7ddd2055ef24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9f7457ce-2d2b-4d42-b19f-e9768f70dd16" xlink:to="loc_srt_NameOfMajorCustomerDomain_d34bdb26-884f-4c8c-a462-7ddd2055ef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_ae95b3b8-b595-4843-b633-3d688cbbb39c" xlink:href="mygn-20211231.xsd#mygn_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d34bdb26-884f-4c8c-a462-7ddd2055ef24" xlink:to="loc_mygn_MedicareMember_ae95b3b8-b595-4843-b633-3d688cbbb39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d0ac5f7-79d5-458f-afce-889e312e41bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd40c49e-91e5-4cc3-a450-ea182afb0448" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d0ac5f7-79d5-458f-afce-889e312e41bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7b204ffa-efef-495c-8aa5-c484d0f5a086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8d0ac5f7-79d5-458f-afce-889e312e41bc" xlink:to="loc_us-gaap_SalesRevenueNetMember_7b204ffa-efef-495c-8aa5-c484d0f5a086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f24831-a65a-4a4a-9f82-d46b37cfea7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aa72f69c-620a-4b2d-ad43-2c020efce661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:to="loc_us-gaap_EquipmentMember_aa72f69c-620a-4b2d-ad43-2c020efce661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0ab4c0de-82ff-4844-bc89-0001cc8f8b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a40fccf7-d866-4634-8d26-5183821f147a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0ab4c0de-82ff-4844-bc89-0001cc8f8b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_49b2131d-9243-474b-b229-30fb77ad5c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_711e9c71-55b6-404e-b10b-a66cff1e41ef" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_49b2131d-9243-474b-b229-30fb77ad5c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_371498cd-302f-4335-aca4-661d5b66eadf" xlink:href="mygn-20211231.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_49b2131d-9243-474b-b229-30fb77ad5c28" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_371498cd-302f-4335-aca4-661d5b66eadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_115e034a-b0fd-4c70-8b1b-01228cd97707" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_cb5c18ed-73b7-4c42-a99b-08162e82dc7a" xlink:to="loc_srt_RestatementDomain_115e034a-b0fd-4c70-8b1b-01228cd97707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_64761121-4f93-43c1-a946-f2f14cf52118" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_115e034a-b0fd-4c70-8b1b-01228cd97707" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_64761121-4f93-43c1-a946-f2f14cf52118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a286b84-1450-4d58-a67c-49525902cfd7" xlink:to="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dd3947f2-5c0d-440d-9ef4-d5bed578f033" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:to="loc_srt_MinimumMember_dd3947f2-5c0d-440d-9ef4-d5bed578f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1d17c58-92b7-45ca-a5c2-46add89c5fa7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4f4bf737-d137-4f29-9cd0-b767674f2b74" xlink:to="loc_srt_MaximumMember_b1d17c58-92b7-45ca-a5c2-46add89c5fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:href="mygn-20211231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_f9d02ad1-8423-46ea-839d-17ee271bbc40" xlink:to="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_30c8b61b-fd1b-4c49-af6e-88fe63956a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_30c8b61b-fd1b-4c49-af6e-88fe63956a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_568e0950-a5e2-4cad-a6d6-e1f258e160b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_568e0950-a5e2-4cad-a6d6-e1f258e160b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b410e91a-a0fb-48cf-9802-2211cdda879f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b410e91a-a0fb-48cf-9802-2211cdda879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_eb653b1e-2a21-4b3d-8582-5f965eb38e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_eb653b1e-2a21-4b3d-8582-5f965eb38e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d98c2b10-4a04-49bd-8397-8684a3b91f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d98c2b10-4a04-49bd-8397-8684a3b91f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount_912f1185-8c04-40dc-877d-46ae53dc4503" xlink:href="mygn-20211231.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_CARESActOf2020MedicarePaymentAmount_912f1185-8c04-40dc-877d-46ae53dc4503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ef8cffd1-87c1-430d-8faf-4776d10cb1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ef8cffd1-87c1-430d-8faf-4776d10cb1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_a4a46f1f-15b2-46b0-92fa-0c6aa4bf78da" xlink:href="mygn-20211231.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_a4a46f1f-15b2-46b0-92fa-0c6aa4bf78da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_b2607da9-b82c-462c-8559-576926e2f59e" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_b2607da9-b82c-462c-8559-576926e2f59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_789689b8-b7bd-4e36-ba4d-43a88879451d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_789689b8-b7bd-4e36-ba4d-43a88879451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1d147dd-d09a-44a7-9735-8b3a76d30a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1d147dd-d09a-44a7-9735-8b3a76d30a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_d8f0bcfa-2315-4779-894a-89b8553feb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_CapitalizedContractCostGross_d8f0bcfa-2315-4779-894a-89b8553feb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_31d9c988-3a68-4403-820d-1f7c73063b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_31d9c988-3a68-4403-820d-1f7c73063b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020ProviderReliefFundAmount_414816ba-08c5-4dcc-bb64-fa8d4140fcf3" xlink:href="mygn-20211231.xsd#mygn_CARESActOf2020ProviderReliefFundAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_9c1ea6d6-aa24-4554-8a25-88a16f372f3c" xlink:to="loc_mygn_CARESActOf2020ProviderReliefFundAmount_414816ba-08c5-4dcc-bb64-fa8d4140fcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_729bd113-9edd-4dc7-bdc5-4a614b5e4622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_729bd113-9edd-4dc7-bdc5-4a614b5e4622" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:to="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_18ebff88-551c-4559-8ca3-e95b3c3fe600" xlink:to="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_a6b34be6-6b89-4fab-916a-ba54888ee34f" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_a6b34be6-6b89-4fab-916a-ba54888ee34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_9759ac8b-b089-4d3a-b6e4-aab1bf5bc712" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_9759ac8b-b089-4d3a-b6e4-aab1bf5bc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_f01c3c5e-147d-4fbb-a714-9f24e0c77a75" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_f01c3c5e-147d-4fbb-a714-9f24e0c77a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_4fb42aee-a205-4b55-882b-584148bb6d22" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_4fb42aee-a205-4b55-882b-584148bb6d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_3ab02d92-30de-48a5-901d-90cc2e20e2bf" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_3ab02d92-30de-48a5-901d-90cc2e20e2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_4e3963fd-fbad-4f15-aa9d-f5cd7fef7185" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1dba7341-25f6-4296-ab52-46f837a9a2cc" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_4e3963fd-fbad-4f15-aa9d-f5cd7fef7185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_c4801eb5-09a0-429e-90ba-cfbc0cbf65eb" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ce7b3ed2-366f-4bef-8dc2-7663b8f65cb0" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_c4801eb5-09a0-429e-90ba-cfbc0cbf65eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8eeecd99-320a-4c9f-ad99-5a70b1d4c9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_04fff4fe-e848-429c-90c7-6c8e04eb1cb6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8eeecd99-320a-4c9f-ad99-5a70b1d4c9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e3ee251-9c62-44af-ba80-42b206f0b1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8eeecd99-320a-4c9f-ad99-5a70b1d4c9ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e3ee251-9c62-44af-ba80-42b206f0b1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0b6e7db-eae0-405d-a377-406504293a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0b6e7db-eae0-405d-a377-406504293a64" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:to="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2487ffe5-44f5-46a8-9c25-aa8dc9578b46" xlink:to="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_20cbed80-9338-4c49-b4ec-85144c6b56f9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:to="loc_country_US_20cbed80-9338-4c49-b4ec-85144c6b56f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_56ba1ac9-c43c-4853-a395-ce3fcf24c468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c409072a-28ec-4862-87cd-ac85e0a7d7af" xlink:to="loc_us-gaap_NonUsMember_56ba1ac9-c43c-4853-a395-ce3fcf24c468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:to="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_98c2b07d-be47-43e0-a512-a608dd0c3131" xlink:to="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_806fb71e-4d9f-45f9-b27f-babdb8398cad" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_806fb71e-4d9f-45f9-b27f-babdb8398cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_d51f279d-f21c-421f-9864-2392f7d0c4a9" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_d51f279d-f21c-421f-9864-2392f7d0c4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_b3a4914a-12b5-479f-ba71-81f17bbbdc59" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_b3a4914a-12b5-479f-ba71-81f17bbbdc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_489c088c-bd66-412e-89f7-013a4dc3ec48" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_489c088c-bd66-412e-89f7-013a4dc3ec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_74527298-3ce8-461a-a1a6-87a5b5520b6d" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_74527298-3ce8-461a-a1a6-87a5b5520b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_cce8bfac-b73d-421b-80c5-0079938aa2d5" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_1b39822e-287f-4a50-81ac-8a4d0b435a56" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_cce8bfac-b73d-421b-80c5-0079938aa2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_8fdee957-3929-497e-af34-55af4faf40a7" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_30a3b39f-08de-4c10-890e-e39bcc4295fa" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_8fdee957-3929-497e-af34-55af4faf40a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_abea82de-c2c2-464f-b082-970760ea3534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c068ad8-ba67-4e2d-b501-560c06f68642" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_abea82de-c2c2-464f-b082-970760ea3534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a2d3b9-04ea-4385-933a-a6ce0e774d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_abea82de-c2c2-464f-b082-970760ea3534" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a2d3b9-04ea-4385-933a-a6ce0e774d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_de93d2aa-aee3-49b7-b865-40b2a1d6bbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_de93d2aa-aee3-49b7-b865-40b2a1d6bbc4" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_03548f3c-0ecf-4a31-9d00-5365ccc0532e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_03548f3c-0ecf-4a31-9d00-5365ccc0532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_37a523cb-c502-4c1c-8bf8-36cb97027687" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:to="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_37a523cb-c502-4c1c-8bf8-36cb97027687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments_bff2e1da-92e9-4bc7-a71e-2288fd4f5716" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:to="loc_mygn_ContractWithCustomerLiabilityPrepayments_bff2e1da-92e9-4bc7-a71e-2288fd4f5716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityDivestitures_cbb0636e-fa4b-4bbf-af31-4bec89fce7aa" xlink:href="mygn-20211231.xsd#mygn_ContractWithCustomerLiabilityDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:to="loc_mygn_ContractWithCustomerLiabilityDivestitures_cbb0636e-fa4b-4bbf-af31-4bec89fce7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_805c62b9-1490-4950-90c5-a5be08399a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ef3f1042-6a3a-424f-8d6c-60c40925e9c2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_805c62b9-1490-4950-90c5-a5be08399a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d45cbe34-f1d4-4831-b006-418055cb076a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2aaa124a-6cc4-4f53-bb37-e3d2aea24a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d45cbe34-f1d4-4831-b006-418055cb076a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2aaa124a-6cc4-4f53-bb37-e3d2aea24a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dc87acf2-bb1d-4439-8f44-e01bfe431111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d45cbe34-f1d4-4831-b006-418055cb076a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dc87acf2-bb1d-4439-8f44-e01bfe431111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80e09f93-723d-458e-9806-95d0c920e954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d45cbe34-f1d4-4831-b006-418055cb076a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80e09f93-723d-458e-9806-95d0c920e954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_49095b36-fb64-480a-9cc8-5b78ffd0b0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d45cbe34-f1d4-4831-b006-418055cb076a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_49095b36-fb64-480a-9cc8-5b78ffd0b0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9a71fda2-4e3b-4f5d-a9e2-4028b93ac556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_4fdf3c84-5daf-4440-aa3a-3c7ad0005301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CumulativeTranslationAdjustmentSummaryRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a71fda2-4e3b-4f5d-a9e2-4028b93ac556" xlink:to="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_4fdf3c84-5daf-4440-aa3a-3c7ad0005301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_c9dcbbed-bf59-4225-86bf-00c7607a7dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_4fdf3c84-5daf-4440-aa3a-3c7ad0005301" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_c9dcbbed-bf59-4225-86bf-00c7607a7dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_2b0cc499-2171-4d5e-ab1d-a4537988f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_4fdf3c84-5daf-4440-aa3a-3c7ad0005301" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_2b0cc499-2171-4d5e-ab1d-a4537988f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0b82aa42-b9cf-4ac3-b392-44bca83fccf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_4fdf3c84-5daf-4440-aa3a-3c7ad0005301" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0b82aa42-b9cf-4ac3-b392-44bca83fccf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecurities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_713de11b-6bca-4dc5-9165-02f9afda96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_dc24e09d-ad41-46fa-acb9-38afbe5343f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_713de11b-6bca-4dc5-9165-02f9afda96f5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_dc24e09d-ad41-46fa-acb9-38afbe5343f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3f1270f-296a-4df1-b95e-b5677b725f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_0e24c66c-42e5-459a-b1a3-a3f1758016c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3f1270f-296a-4df1-b95e-b5677b725f74" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_0e24c66c-42e5-459a-b1a3-a3f1758016c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a0891f8a-687a-4462-8516-3c0e96895f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3f1270f-296a-4df1-b95e-b5677b725f74" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a0891f8a-687a-4462-8516-3c0e96895f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d804c22e-efb4-4b4f-afd9-cefaa99eaf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d804c22e-efb4-4b4f-afd9-cefaa99eaf10" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:to="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_37a30606-b636-4158-92e9-cfb85ba1b975" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d56c527a-de88-4c0f-9169-79d1883c1a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d56c527a-de88-4c0f-9169-79d1883c1a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_3ea0779d-7e8a-494d-877d-97c61383eadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_MunicipalBondsMember_3ea0779d-7e8a-494d-877d-97c61383eadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_efe02bf9-2397-464f-8ba4-9bf9b8072d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_efe02bf9-2397-464f-8ba4-9bf9b8072d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b3cdd76b-1420-43cf-b9be-786e12dfd185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de19bc1a-dcdf-4acf-a6de-fc0fa62fb7a0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b3cdd76b-1420-43cf-b9be-786e12dfd185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b3e502b9-2960-4c59-b5e5-4f322714b274" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_85f58977-fc18-42d0-90cd-1493823ecf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:to="loc_us-gaap_CashMember_85f58977-fc18-42d0-90cd-1493823ecf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_4a4e6237-c55e-4280-a814-9e0b1ea334df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a159b44-87a5-4bcc-8a63-aa43c3654f49" xlink:to="loc_us-gaap_CashEquivalentsMember_4a4e6237-c55e-4280-a814-9e0b1ea334df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8632131f-a6bc-49f2-ae83-0226626decbb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50b14f9e-2f25-4742-8474-26078ffa6b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50b14f9e-2f25-4742-8474-26078ffa6b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e604b988-3f6c-45a5-a44d-d1099e57a601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_74f60e0a-b14f-40d7-b852-6fc7d29b9754" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e604b988-3f6c-45a5-a44d-d1099e57a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd73d79f-9a40-496d-abb3-034dd517b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd73d79f-9a40-496d-abb3-034dd517b7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74634e15-064d-401c-9852-4a6bf1c9c7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74634e15-064d-401c-9852-4a6bf1c9c7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_732cd5a9-678c-402a-b59a-106813399819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_732cd5a9-678c-402a-b59a-106813399819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc5f58a8-06fe-48c7-b729-e0c10be1ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5cf2cadb-814a-4ffc-a722-3b909be4e212" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc5f58a8-06fe-48c7-b729-e0c10be1ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7f32e1a2-a9b1-47f2-8d49-fadca04eff8c" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_d64de37c-bd64-4f86-aaf7-8931c5c4c342" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_d64de37c-bd64-4f86-aaf7-8931c5c4c342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_841b8671-6208-44d9-bdbb-3b7ee38fa114" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_841b8671-6208-44d9-bdbb-3b7ee38fa114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_7185982e-0ec5-4a1e-84c2-4035cbec2179" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_7185982e-0ec5-4a1e-84c2-4035cbec2179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_a33225da-e657-47ad-9a41-32de78dfab58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_bddd4d73-279e-4e8f-a9e2-1d83e0930067" xlink:to="loc_us-gaap_InvestmentsAndCash_a33225da-e657-47ad-9a41-32de78dfab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c63ac34a-ee5c-40b5-8d41-d12384b1b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c63ac34a-ee5c-40b5-8d41-d12384b1b8b0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_596dd470-beaa-472f-ba1f-a75b5a1ca41e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_a2caeb85-78b6-493d-938b-a9eefbc798d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:to="loc_us-gaap_CashMember_a2caeb85-78b6-493d-938b-a9eefbc798d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_797647c1-fc1b-45b8-970e-794419089fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc7e2ff8-693f-43ba-b61a-5a3ae30bd2e0" xlink:to="loc_us-gaap_CashEquivalentsMember_797647c1-fc1b-45b8-970e-794419089fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c544a997-a0a5-4c1b-a810-14ee690c4099" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e3426a8-63b5-447b-adf4-0221f80f14a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e3426a8-63b5-447b-adf4-0221f80f14a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_81df25d9-1e1a-4f35-a9a8-6c241a48df26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_81df25d9-1e1a-4f35-a9a8-6c241a48df26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0fa888a5-43a2-4315-a307-d812d6593655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0fa888a5-43a2-4315-a307-d812d6593655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_268f546c-6f95-4284-b146-ea90f1407085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_268f546c-6f95-4284-b146-ea90f1407085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_f410a13e-a33c-4c20-aec9-3893e9bd0de6" xlink:href="mygn-20211231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_0319786c-5759-454a-8fc8-88bd188fec3f" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_f410a13e-a33c-4c20-aec9-3893e9bd0de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_62b3b89b-e976-43a2-a6dd-7562c2003530" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e459150e-4e50-4443-ad61-a21ba619754c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e459150e-4e50-4443-ad61-a21ba619754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_97a95f3b-0485-498e-bd25-6361118a2961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_97a95f3b-0485-498e-bd25-6361118a2961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e8cc0923-9db9-486f-8867-179d8be38699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e8cc0923-9db9-486f-8867-179d8be38699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cb3ee741-7d37-45e7-9218-a48f5097fe20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cb3ee741-7d37-45e7-9218-a48f5097fe20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_fe9dae21-fea5-4996-8ee1-323c705eae57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d73fc175-6b45-4cfa-aaf7-ba598c19dc38" xlink:to="loc_us-gaap_InvestmentsAndCash_fe9dae21-fea5-4996-8ee1-323c705eae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#MarketableInvestmentSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_febe87a5-f462-40e8-b36a-125042fa0f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7bda2ef9-c92f-4d93-8e2b-c5c3a9acf2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_febe87a5-f462-40e8-b36a-125042fa0f9b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7bda2ef9-c92f-4d93-8e2b-c5c3a9acf2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_abb5c475-30c7-4b9b-b1d2-36058b40042d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ef17cf77-4526-489e-8b0f-af6ad8ba18df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_abb5c475-30c7-4b9b-b1d2-36058b40042d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ef17cf77-4526-489e-8b0f-af6ad8ba18df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_715a4fb3-a5d8-4931-8ff5-9c1c59949b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_277c6ef8-7bda-4a51-98fa-880595464eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_715a4fb3-a5d8-4931-8ff5-9c1c59949b48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_277c6ef8-7bda-4a51-98fa-880595464eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4658960f-bb01-41ea-9478-1c47e450f22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_715a4fb3-a5d8-4931-8ff5-9c1c59949b48" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4658960f-bb01-41ea-9478-1c47e450f22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_97ab7145-7257-4503-978e-e590b837f4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_97ab7145-7257-4503-978e-e590b837f4fc" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c10d6f-63b7-418c-9505-b0a09a8deccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a017bb2-7ded-4676-9173-db105f9be30c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c10d6f-63b7-418c-9505-b0a09a8deccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_caea9b6e-558d-4370-9c31-015b7adae39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c10d6f-63b7-418c-9505-b0a09a8deccb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_caea9b6e-558d-4370-9c31-015b7adae39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_17ea21b3-8f99-4cd2-b735-061858abbc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_53505532-fca7-4651-8e53-e0d65228e798" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_17ea21b3-8f99-4cd2-b735-061858abbc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7a4c913c-13b1-4a67-b346-986d79f1e098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_17ea21b3-8f99-4cd2-b735-061858abbc45" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7a4c913c-13b1-4a67-b346-986d79f1e098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8e662c74-c33b-462f-b88b-ddbf545a3ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_734a5ae5-a98c-40e3-8970-1efb818d0e5f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8e662c74-c33b-462f-b88b-ddbf545a3ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_ac35a43d-6fd2-4805-a42d-3499a6606e8a" xlink:href="mygn-20211231.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8e662c74-c33b-462f-b88b-ddbf545a3ded" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_ac35a43d-6fd2-4805-a42d-3499a6606e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f2d63099-e98c-4a41-b7d2-d83427ab7f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2d63099-e98c-4a41-b7d2-d83427ab7f82" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b15ce4b7-7433-46f7-bf1b-d66088c88bfc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73b2814c-bf5f-418e-9b6c-17067572b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_73b2814c-bf5f-418e-9b6c-17067572b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1082a8b7-a6c9-4c3a-a0c9-b93d1762edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1082a8b7-a6c9-4c3a-a0c9-b93d1762edfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_392f7065-6a20-4d49-9d9d-43d804dcd957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b31aa4f-849b-4f02-9644-ac22d80b2995" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_392f7065-6a20-4d49-9d9d-43d804dcd957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0a7d7236-6008-42cf-99a6-c436429895b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_07f39a4f-ef98-4f2c-9df0-2c43cd457bc8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0a7d7236-6008-42cf-99a6-c436429895b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_adf0daac-7d14-4953-be0f-33b35541a1dc" xlink:href="mygn-20211231.xsd#mygn_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0a7d7236-6008-42cf-99a6-c436429895b5" xlink:to="loc_mygn_ContingentConsiderationMember_adf0daac-7d14-4953-be0f-33b35541a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f0fd14a9-473f-4d51-817e-2bbce76fd2fd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fbc08453-c725-4b03-b9fd-9a71cbb56e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fbc08453-c725-4b03-b9fd-9a71cbb56e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_149f48bc-2c70-422e-862e-5b672c6e769f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_149f48bc-2c70-422e-862e-5b672c6e769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_6e3b8467-cb5e-4b2c-8c98-04e3de547cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_MunicipalBondsMember_6e3b8467-cb5e-4b2c-8c98-04e3de547cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_347a4194-f031-4cdb-b317-d0bd8930d3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_347a4194-f031-4cdb-b317-d0bd8930d3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9799ca9e-5f6a-4c72-a515-4435e29d5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7cbc523a-3de7-4b97-a0ee-687db64cdd6b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9799ca9e-5f6a-4c72-a515-4435e29d5e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15114f7f-a0ed-4de2-a2da-bc114f6465ae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a64587cb-3e48-4b7a-9159-f6f92d6a458d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a64587cb-3e48-4b7a-9159-f6f92d6a458d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_08202e0c-acb6-4d33-ae0c-41d9ebb62a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_08202e0c-acb6-4d33-ae0c-41d9ebb62a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_1eb9eb5a-3ce1-431e-a281-f8e636271dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78769154-44f9-4a72-9eef-8014d8623cc2" xlink:to="loc_us-gaap_FairValueNetAssetLiability_1eb9eb5a-3ce1-431e-a281-f8e636271dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a0c4e22c-016f-454f-ade2-216c264e850c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a0c4e22c-016f-454f-ade2-216c264e850c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5fa0fc84-c1cb-41c1-a951-5e9b43a95a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5fa0fc84-c1cb-41c1-a951-5e9b43a95a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_13d44c7f-3afa-4071-85a2-653ad9bb1bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_13d44c7f-3afa-4071-85a2-653ad9bb1bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_df23d52f-66ad-4192-b5eb-883443c57e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_df23d52f-66ad-4192-b5eb-883443c57e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_00b85ede-50f6-4821-aebe-04468ae5c59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_00b85ede-50f6-4821-aebe-04468ae5c59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_acbe2da8-67ad-447a-82bc-63293a12350f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7e069e86-f627-456e-be2d-0e9d8989d9e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_acbe2da8-67ad-447a-82bc-63293a12350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4633b92f-490c-49f6-8c2f-12353743d550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2135fb67-1f22-46b1-b5eb-d14778b5b342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4633b92f-490c-49f6-8c2f-12353743d550" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2135fb67-1f22-46b1-b5eb-d14778b5b342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bc584cf3-2453-4990-bfae-151628575265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bb2fa965-c3f5-437b-84d3-927358bf2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bc584cf3-2453-4990-bfae-151628575265" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bb2fa965-c3f5-437b-84d3-927358bf2ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33658e75-9ef5-4535-95fd-4ca4b65a2d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33658e75-9ef5-4535-95fd-4ca4b65a2d85" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d0f71b6-3825-4d6a-9c56-13e0a0a00b3f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4f0d1f02-aaca-4ac6-bffc-8cebe200b422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4f0d1f02-aaca-4ac6-bffc-8cebe200b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fde4f371-dc96-4c84-aff8-e8f5bbaec8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aee7d56a-f9dd-43c0-a4b8-7b698f8fd44b" xlink:to="loc_us-gaap_EquipmentMember_fde4f371-dc96-4c84-aff8-e8f5bbaec8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8fa6d2e-83e1-4a5f-8b6f-99a74dd0d8e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dc7ffcdb-d067-4933-9c6e-5f29512cc9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dc7ffcdb-d067-4933-9c6e-5f29512cc9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b18b87e5-3d35-4285-aa0e-3657c3e3f48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b18b87e5-3d35-4285-aa0e-3657c3e3f48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72a3418b-e8cf-47ab-ba14-aa44625ca8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b76b09e2-9357-4641-bb4a-c69ab86beefa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72a3418b-e8cf-47ab-ba14-aa44625ca8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_69ce313c-3be0-435c-88da-2358f3576daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_69ce313c-3be0-435c-88da-2358f3576daa" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68cce006-84d7-43ee-a0cc-69dfba7269ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beefab26-74d8-41be-8c58-cdf5d7b3b89d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68cce006-84d7-43ee-a0cc-69dfba7269ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_6148e776-4bc5-40c0-ad6b-a64e92a7a5a6" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68cce006-84d7-43ee-a0cc-69dfba7269ff" xlink:to="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_6148e776-4bc5-40c0-ad6b-a64e92a7a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a9be860-84f4-424b-82a0-8a91d997f4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d2fa2bf-ab4f-43b1-b9c8-20a7eb6fc585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a9be860-84f4-424b-82a0-8a91d997f4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_62c6b548-ebb3-4136-b9b2-9a0a4e5ae5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a9be860-84f4-424b-82a0-8a91d997f4c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_62c6b548-ebb3-4136-b9b2-9a0a4e5ae5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PropertyPlantandEquipmentNetDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_89f79c52-3fcf-4f06-b7fe-c10557006532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a6945551-3996-4fdc-a0c3-af94ba5470dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_89f79c52-3fcf-4f06-b7fe-c10557006532" xlink:to="loc_us-gaap_Depreciation_a6945551-3996-4fdc-a0c3-af94ba5470dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59b254c1-8bf9-4225-84c3-e33fa2f6bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_873ac53f-dd8c-4b32-a11a-1678aae5d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59b254c1-8bf9-4225-84c3-e33fa2f6bd77" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_873ac53f-dd8c-4b32-a11a-1678aae5d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3cbad97-2f48-4736-8a01-6262c6633314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_a97e278d-875b-4c60-94be-43e7bde6bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3cbad97-2f48-4736-8a01-6262c6633314" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_a97e278d-875b-4c60-94be-43e7bde6bd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6573388a-0981-46a2-883d-10a1457cff70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3cbad97-2f48-4736-8a01-6262c6633314" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6573388a-0981-46a2-883d-10a1457cff70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_04b5f619-a470-4ee8-a4b5-e73cd0bca2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3cbad97-2f48-4736-8a01-6262c6633314" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_04b5f619-a470-4ee8-a4b5-e73cd0bca2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_dc52287d-bc69-4237-a698-f009999af9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3cbad97-2f48-4736-8a01-6262c6633314" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_dc52287d-bc69-4237-a698-f009999af9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8a101786-0ea5-4a0c-91f5-f7727ca05e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3cbad97-2f48-4736-8a01-6262c6633314" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8a101786-0ea5-4a0c-91f5-f7727ca05e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c96d7d3e-0c19-4439-92ea-f4710e46e6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_34741df6-adc8-4fcb-a137-f6c2f2e5835d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c96d7d3e-0c19-4439-92ea-f4710e46e6bd" xlink:to="loc_us-gaap_GoodwillRollForward_34741df6-adc8-4fcb-a137-f6c2f2e5835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5c4349c5-87d9-4e60-8c49-6cedbdf4d5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_34741df6-adc8-4fcb-a137-f6c2f2e5835d" xlink:to="loc_us-gaap_Goodwill_5c4349c5-87d9-4e60-8c49-6cedbdf4d5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_2662e6b5-4131-486c-bdd3-bc4e33aac2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_34741df6-adc8-4fcb-a137-f6c2f2e5835d" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_2662e6b5-4131-486c-bdd3-bc4e33aac2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a8c3391b-b798-43e3-b9bb-bae713e0f53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_34741df6-adc8-4fcb-a137-f6c2f2e5835d" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a8c3391b-b798-43e3-b9bb-bae713e0f53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_32042b14-ca96-434e-9a7f-b054db553e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_34741df6-adc8-4fcb-a137-f6c2f2e5835d" xlink:to="loc_us-gaap_Goodwill_32042b14-ca96-434e-9a7f-b054db553e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b66e3b67-04dc-4324-8159-3506e7a0aa33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:href="mygn-20211231.xsd#mygn_GoodwillAndIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b66e3b67-04dc-4324-8159-3506e7a0aa33" xlink:to="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_8394e36a-ca40-43be-a821-d10c5ce7b181" xlink:to="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneReportingUnitMember_c05c0134-a73f-4b6c-8081-146a1428fde0" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:to="loc_mygn_MyriadAutoimmuneReportingUnitMember_c05c0134-a73f-4b6c-8081-146a1428fde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ClinicReportingUnitMember_07117d71-fb72-4aa7-95b8-ce9a6413b09a" xlink:href="mygn-20211231.xsd#mygn_ClinicReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_596b5f82-315a-4904-9767-feb8717451c4" xlink:to="loc_mygn_ClinicReportingUnitMember_07117d71-fb72-4aa7-95b8-ce9a6413b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01849078-a456-436f-8d6a-4d2797505ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90879077-a0f7-48ba-96c2-a351f15d6bea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01849078-a456-436f-8d6a-4d2797505ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_72c46854-8778-488c-88e6-b2ce7194366b" xlink:href="mygn-20211231.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01849078-a456-436f-8d6a-4d2797505ded" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_72c46854-8778-488c-88e6-b2ce7194366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad0f17c9-7f7b-4548-9dc1-eb90c314dba9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_56177104-e118-42dc-83d1-5b7aac6a6003" xlink:href="mygn-20211231.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_56177104-e118-42dc-83d1-5b7aac6a6003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_401fec93-4b01-482a-a838-e6ef6a51fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:to="loc_us-gaap_CustomerRelationshipsMember_401fec93-4b01-482a-a838-e6ef6a51fec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_56dccd18-8f60-48e6-836d-0f94c77ee4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_df7320ba-01b5-4c09-85e7-cce2f252af19" xlink:to="loc_us-gaap_TrademarksMember_56dccd18-8f60-48e6-836d-0f94c77ee4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a7531e73-8c04-4fee-b4d4-7327b4f6feb4" xlink:to="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4fd550a-db0f-4fb7-9795-06657114dcf7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:to="loc_srt_MinimumMember_a4fd550a-db0f-4fb7-9795-06657114dcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eaebf57d-8431-4700-bb49-48b0df53ed9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b9f6003-12c9-45ba-9cba-9d4f41b9a628" xlink:to="loc_srt_MaximumMember_eaebf57d-8431-4700-bb49-48b0df53ed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0efc9804-29e9-4c38-8523-704c1349f9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8e44ea48-ad22-455e-85bc-23c68dd71010" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0efc9804-29e9-4c38-8523-704c1349f9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63dd60fb-96bf-49fc-a9d3-4ba463969ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0efc9804-29e9-4c38-8523-704c1349f9f5" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63dd60fb-96bf-49fc-a9d3-4ba463969ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77ef04a6-b775-4445-81f0-ae9d626ec9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ea77245-140c-4638-975e-f0a7cc568553" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77ef04a6-b775-4445-81f0-ae9d626ec9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_13659b9c-8c81-4dfa-8673-a18b531cfafc" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77ef04a6-b775-4445-81f0-ae9d626ec9bd" xlink:to="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_13659b9c-8c81-4dfa-8673-a18b531cfafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:href="mygn-20211231.xsd#mygn_GoodwillAndIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_85dd8270-85bf-4433-a612-33d3f53622da" xlink:to="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4b7ee42a-5852-4bd8-8c64-0be3eb2f3437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4b7ee42a-5852-4bd8-8c64-0be3eb2f3437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_de60d387-f7aa-4135-8482-173d1dbe8154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_de60d387-f7aa-4135-8482-173d1dbe8154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_4f5f2a75-66e7-49f2-937d-cfba06bb6eaa" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_4f5f2a75-66e7-49f2-937d-cfba06bb6eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_d831ed66-0a2e-4632-bcaa-1486de41bd1d" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_d831ed66-0a2e-4632-bcaa-1486de41bd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_32fa3ce0-8831-428d-ace5-9f500d600072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_32fa3ce0-8831-428d-ace5-9f500d600072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4c70b303-6151-4032-b7d2-b5267cbfba18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4c70b303-6151-4032-b7d2-b5267cbfba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b0a08613-70fc-42c8-bb23-70b4f83d063c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_611eace3-984c-4860-a3e1-4ef248dbe909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b0a08613-70fc-42c8-bb23-70b4f83d063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0acd233c-e957-4a81-9c0a-0d6f6191df04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0acd233c-e957-4a81-9c0a-0d6f6191df04" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3594fa46-e514-4535-95ac-94600af477c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d7721095-16a9-4fce-ae09-643761d16ed7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3594fa46-e514-4535-95ac-94600af477c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_4f7edaff-e9b5-4167-b412-b0c8941a3df3" xlink:href="mygn-20211231.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3594fa46-e514-4535-95ac-94600af477c8" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_4f7edaff-e9b5-4167-b412-b0c8941a3df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bf15a4f-c8e8-4b43-a56f-20fb6cf58e60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_6f01b780-129a-4494-bc2d-b26fecdfe828" xlink:href="mygn-20211231.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_6f01b780-129a-4494-bc2d-b26fecdfe828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1fd09bec-49cb-480a-bc6b-adeb13590e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1fd09bec-49cb-480a-bc6b-adeb13590e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_48aa4b4e-f234-4373-8fff-ccfc3fc73314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bf43ce7-9ac8-4f7d-b982-00cf74621c0f" xlink:to="loc_us-gaap_TrademarksMember_48aa4b4e-f234-4373-8fff-ccfc3fc73314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:href="mygn-20211231.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_1cfb1647-9811-496d-8fe0-2db0410e294a" xlink:to="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bea6ad2-debf-499e-ac59-ef31519f55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0bea6ad2-debf-499e-ac59-ef31519f55d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37fff5b3-2bf3-4efb-9c9c-74659c811a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37fff5b3-2bf3-4efb-9c9c-74659c811a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f012335d-19b5-4bc2-b7a7-e49eeb41df39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f012335d-19b5-4bc2-b7a7-e49eeb41df39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e321f4e-f667-4e2d-8b1d-633b45cbcd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e321f4e-f667-4e2d-8b1d-633b45cbcd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5c099d3f-4521-418c-b103-f0994c48ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5c099d3f-4521-418c-b103-f0994c48ed99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2e0a5ba0-72e6-4338-af15-cf8b8612ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_1fc025da-423f-4d69-b87c-e0fa23a3b02d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2e0a5ba0-72e6-4338-af15-cf8b8612ce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1dcb1ee-3920-4158-b63e-5c49fd7b2cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5c0f9af7-fca5-4b03-9653-3be124b9274a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1dcb1ee-3920-4158-b63e-5c49fd7b2cc8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5c0f9af7-fca5-4b03-9653-3be124b9274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_4f897690-1df2-4f2e-a54e-7c17fd9ebb71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_4f897690-1df2-4f2e-a54e-7c17fd9ebb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2ca7016e-02f0-4ecd-8ec2-b17a0c866bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2ca7016e-02f0-4ecd-8ec2-b17a0c866bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_910c94ce-871b-44d0-913d-eb40e4a0176a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_910c94ce-871b-44d0-913d-eb40e4a0176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3001e067-6397-41dc-bf25-2a77167dc259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3001e067-6397-41dc-bf25-2a77167dc259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1d3ac3a0-48d7-4400-ac02-26b624dbd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1d3ac3a0-48d7-4400-ac02-26b624dbd75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c1009d5f-031c-4f17-a5d9-71773f856330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c1009d5f-031c-4f17-a5d9-71773f856330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_de1f4cb4-9b34-44b2-bd1b-c39ddf2a97a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_de1f4cb4-9b34-44b2-bd1b-c39ddf2a97a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_26298ac9-94f9-48b4-ad50-0254f65aebf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_689f58c8-e83b-4e72-837c-5a3a48ab0d3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_26298ac9-94f9-48b4-ad50-0254f65aebf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="mygn-20211231.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bb8dc6e2-4fb5-42f1-b1d3-effcca3d5cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7610165e-b895-4849-a892-ddddc1a12897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bb8dc6e2-4fb5-42f1-b1d3-effcca3d5cf2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7610165e-b895-4849-a892-ddddc1a12897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a072a473-787c-458e-b69a-fe7c22aa02b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f5064ecd-9cbc-46f1-86a4-01628a948fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a072a473-787c-458e-b69a-fe7c22aa02b2" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f5064ecd-9cbc-46f1-86a4-01628a948fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_94b55392-39f6-41b5-a5cc-787bd301fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_94b55392-39f6-41b5-a5cc-787bd301fd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_791a6b1b-b9de-4d20-818d-75c5cdbe6914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_LitigationReserveCurrent_791a6b1b-b9de-4d20-818d-75c5cdbe6914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_64e0826a-bb32-4266-8f33-81c0e2019df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_TaxesPayableCurrent_64e0826a-bb32-4266-8f33-81c0e2019df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_8ce8a838-69ce-4df2-ac98-13dfbf22c9e8" xlink:href="mygn-20211231.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_8ce8a838-69ce-4df2-ac98-13dfbf22c9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e3c8d05c-aeae-4641-9237-2656ccefed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e3c8d05c-aeae-4641-9237-2656ccefed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_954abd9e-95bc-4316-9706-8d9a40129a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_954abd9e-95bc-4316-9706-8d9a40129a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e6e4029a-cb6b-449c-bcf8-95d4c0661403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e6e4029a-cb6b-449c-bcf8-95d4c0661403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_385cd415-1615-46c0-a5ac-f6c4df1a56b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_57ff8c2c-d429-41d1-99d1-a31041164b05" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_385cd415-1615-46c0-a5ac-f6c4df1a56b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebt" xlink:type="simple" xlink:href="mygn-20211231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f16f9c2c-37c4-4a25-9ce5-1d079aef5692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d8f3ae89-85bd-4e2f-84ae-d9fd285884ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f16f9c2c-37c4-4a25-9ce5-1d079aef5692" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d8f3ae89-85bd-4e2f-84ae-d9fd285884ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#LongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d41733e1-8964-4896-b6dc-95f3ae285d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d41733e1-8964-4896-b6dc-95f3ae285d06" xlink:to="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2bfbe98-7658-4682-ac3f-3cbdc9302258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6c242925-bd04-44d7-8cb9-808e6469bba8" xlink:to="loc_us-gaap_CreditFacilityDomain_e2bfbe98-7658-4682-ac3f-3cbdc9302258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bf88c941-e931-45cb-8116-b8bbf9b2724d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e2bfbe98-7658-4682-ac3f-3cbdc9302258" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bf88c941-e931-45cb-8116-b8bbf9b2724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_511a1451-0c6c-45b1-8901-f577f9433d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1872fb8d-6a6c-4a7e-8f11-2f341b7cd562" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_511a1451-0c6c-45b1-8901-f577f9433d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_81e8785b-fab0-4d26-a305-5958f2e2333b" xlink:href="mygn-20211231.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_511a1451-0c6c-45b1-8901-f577f9433d40" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_81e8785b-fab0-4d26-a305-5958f2e2333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21709740-c1d3-43eb-90cd-438b50447402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_862217e8-366b-48de-afd5-cc14e0bbf06c" xlink:to="loc_us-gaap_VariableRateDomain_21709740-c1d3-43eb-90cd-438b50447402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7e95485e-ce65-449f-b165-6c0adb09d953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_21709740-c1d3-43eb-90cd-438b50447402" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7e95485e-ce65-449f-b165-6c0adb09d953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e24f0d56-5434-42fb-a457-0528d2b4c2d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d67a376b-7530-4f72-9812-bc95ec2afd14" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e24f0d56-5434-42fb-a457-0528d2b4c2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0a419259-b125-40a0-a5a5-047c57c609a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e24f0d56-5434-42fb-a457-0528d2b4c2d5" xlink:to="loc_srt_ScenarioForecastMember_0a419259-b125-40a0-a5a5-047c57c609a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46dff362-4d75-48ef-af51-dcf598542cd6" xlink:to="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aed8ca2a-353b-466b-99f5-86d55ac5ed89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:to="loc_srt_MinimumMember_aed8ca2a-353b-466b-99f5-86d55ac5ed89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99bc5872-9251-4c90-aa14-9ed3c7892c62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ca0e0512-33db-4b91-ae1f-6f03eb3fc424" xlink:to="loc_srt_MaximumMember_99bc5872-9251-4c90-aa14-9ed3c7892c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e92ff3b9-c37a-487b-996b-2ac4844c01a7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_59c7fe46-7663-48d8-9df6-765655eec639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_59c7fe46-7663-48d8-9df6-765655eec639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_97788fef-755c-4bf2-be51-d4f9704430c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_97788fef-755c-4bf2-be51-d4f9704430c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_111c69c2-aa7c-41c2-9fbb-2f557483c156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_111c69c2-aa7c-41c2-9fbb-2f557483c156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_39f8c1cc-495a-4530-a4ea-bab1f34b9fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_39f8c1cc-495a-4530-a4ea-bab1f34b9fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage_ee2f91d4-7cca-449f-af61-e6f1e3c4daf8" xlink:href="mygn-20211231.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_mygn_DebtInstrumentLIBORFloorPercentage_ee2f91d4-7cca-449f-af61-e6f1e3c4daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_e0f36595-05d2-4b11-bca3-fbafe1ebe3f1" xlink:href="mygn-20211231.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_e0f36595-05d2-4b11-bca3-fbafe1ebe3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_c0713c6e-7bc6-4a46-8d22-98be0cc6ab47" xlink:href="mygn-20211231.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_c0713c6e-7bc6-4a46-8d22-98be0cc6ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_205b8b50-1964-42a7-af39-a57b9621d027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_205b8b50-1964-42a7-af39-a57b9621d027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1e7705c-c6ca-4c67-95d3-e907f675b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77e47f62-f50c-4c88-a5cc-baa143163a33" xlink:to="loc_us-gaap_LongTermDebt_a1e7705c-c6ca-4c67-95d3-e907f675b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="simple" xlink:href="mygn-20211231.xsd#OtherLongTermLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e4c7c228-1fdc-42ae-bf67-3ceb1c0dd9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_23e02169-7af6-4041-badf-67a9408dec48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e4c7c228-1fdc-42ae-bf67-3ceb1c0dd9b6" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_23e02169-7af6-4041-badf-67a9408dec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#OtherLongTermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a6df02d2-49f6-4200-937f-a34ff1f96bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2dc1494d-349f-4dd5-8bba-969c1ab00fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a6df02d2-49f6-4200-937f-a34ff1f96bc5" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2dc1494d-349f-4dd5-8bba-969c1ab00fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2331197a-93e0-4f25-8728-e4bdbccc0a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8bfd10ad-d3e4-45ed-ba83-fbe22df764cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2331197a-93e0-4f25-8728-e4bdbccc0a07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8bfd10ad-d3e4-45ed-ba83-fbe22df764cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_977fa31f-affe-4582-b587-984aeb12c38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2331197a-93e0-4f25-8728-e4bdbccc0a07" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_977fa31f-affe-4582-b587-984aeb12c38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f5294d39-0fe0-450a-ad5c-b72881450550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2331197a-93e0-4f25-8728-e4bdbccc0a07" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f5294d39-0fe0-450a-ad5c-b72881450550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="simple" xlink:href="mygn-20211231.xsd#PreferredandCommonStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6484868b-30cd-4ef2-93e2-137c8b703877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7461b48b-4edb-4420-a6ec-882390cabb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6484868b-30cd-4ef2-93e2-137c8b703877" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7461b48b-4edb-4420-a6ec-882390cabb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#PreferredandCommonStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_290fe963-c606-47b6-8fdf-714acce634f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_5f8e9f60-c627-407e-b240-85ba6278e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_290fe963-c606-47b6-8fdf-714acce634f3" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_5f8e9f60-c627-407e-b240-85ba6278e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock_b5ad7bd0-0576-47e1-8299-f6a9c818b31a" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_290fe963-c606-47b6-8fdf-714acce634f3" xlink:to="loc_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock_b5ad7bd0-0576-47e1-8299-f6a9c818b31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PreferredandCommonStockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_49a5ed86-f13b-45c9-88d0-b4667a18c06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_49a5ed86-f13b-45c9-88d0-b4667a18c06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0376c2a1-83d5-4f69-a697-d8c725b42e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0376c2a1-83d5-4f69-a697-d8c725b42e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4677e13d-d549-49db-8f7e-488ded936c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4677e13d-d549-49db-8f7e-488ded936c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fdd56c7b-33e3-41b1-9f77-1b9d998ad19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fdd56c7b-33e3-41b1-9f77-1b9d998ad19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_689d6bb1-96fc-455f-8d15-ab17278611b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_689d6bb1-96fc-455f-8d15-ab17278611b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_961ed832-a1b7-4b21-b2df-95c766465eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_961ed832-a1b7-4b21-b2df-95c766465eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3bf05459-1c46-49b5-895f-566966658eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3bf05459-1c46-49b5-895f-566966658eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9d185755-9d19-4113-94f1-1700b1e26bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9d185755-9d19-4113-94f1-1700b1e26bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4a70e393-9134-4e38-9791-ae4fdc78134b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4a70e393-9134-4e38-9791-ae4fdc78134b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f9e96019-9ae3-4c51-bcf2-85b951d56d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c77e98ef-6657-46c0-bfce-17121c5af8d8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f9e96019-9ae3-4c51-bcf2-85b951d56d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c24d02b8-0feb-4fe0-8bd3-0c8f7e5d6d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c24d02b8-0feb-4fe0-8bd3-0c8f7e5d6d47" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_486b2774-da4c-40d9-bbd8-988bad106f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:to="loc_us-gaap_CommonStockSharesIssued_486b2774-da4c-40d9-bbd8-988bad106f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_563c5a77-b390-468e-a642-115382da05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_563c5a77-b390-468e-a642-115382da05c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_26ae0c6d-1f7c-457d-92cc-fad02ca66b84" xlink:href="mygn-20211231.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:to="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_26ae0c6d-1f7c-457d-92cc-fad02ca66b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c5efd67a-d3a7-4202-b72c-0790e644a653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c5efd67a-d3a7-4202-b72c-0790e644a653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0f11746e-9066-4cf9-98d0-a9b396ff71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:to="loc_us-gaap_CommonStockSharesIssued_0f11746e-9066-4cf9-98d0-a9b396ff71b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eb3df8eb-0949-4b16-a19d-6206519df8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0b02686f-67da-4f9e-a6a4-c0502125f733" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eb3df8eb-0949-4b16-a19d-6206519df8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#PreferredandCommonStockholdersEquityStockRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2701c4b4-7ecd-4c5c-a6bb-e0a44ad3cbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d5d1a014-10bd-48b0-8bee-4cc14ea27d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2701c4b4-7ecd-4c5c-a6bb-e0a44ad3cbb0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d5d1a014-10bd-48b0-8bee-4cc14ea27d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases_791aadd8-d806-4a0d-ba23-a67e81435235" xlink:href="mygn-20211231.xsd#mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2701c4b4-7ecd-4c5c-a6bb-e0a44ad3cbb0" xlink:to="loc_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases_791aadd8-d806-4a0d-ba23-a67e81435235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases_fa2df9a6-a799-4975-8c78-1f34c7468807" xlink:href="mygn-20211231.xsd#mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2701c4b4-7ecd-4c5c-a6bb-e0a44ad3cbb0" xlink:to="loc_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases_fa2df9a6-a799-4975-8c78-1f34c7468807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eb9dd1f4-cddf-482c-8f7f-00fee79fcdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2701c4b4-7ecd-4c5c-a6bb-e0a44ad3cbb0" xlink:to="loc_us-gaap_CommonStockSharesIssued_eb9dd1f4-cddf-482c-8f7f-00fee79fcdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d08f82ae-6435-45e9-8253-a9386e857a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a1171d1-2d92-46ba-a02e-0d2c8ae05ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d08f82ae-6435-45e9-8253-a9386e857a0d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a1171d1-2d92-46ba-a02e-0d2c8ae05ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0d116c6d-2e80-4e1f-85ee-9e1e1c40ad26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0d116c6d-2e80-4e1f-85ee-9e1e1c40ad26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_b06c0428-9714-4755-bd41-fffb2c0bcb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_b06c0428-9714-4755-bd41-fffb2c0bcb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_70094bd1-8a77-4a63-943c-5cde0eb5bbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_70094bd1-8a77-4a63-943c-5cde0eb5bbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8f3fa8a5-c472-4a3d-8de1-4c84dcc593b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8f3fa8a5-c472-4a3d-8de1-4c84dcc593b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_62fa8941-8044-45ff-adef-6781f8218e56" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_62fa8941-8044-45ff-adef-6781f8218e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_a8de7b8b-69cc-4466-b487-e67b915c3306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_a8de7b8b-69cc-4466-b487-e67b915c3306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_85b242c7-2db7-49d2-8a82-202a3acf84e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_85b242c7-2db7-49d2-8a82-202a3acf84e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_16944d51-4eba-45ba-abfb-27cf0f5d2104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86dabb6-2dfb-4623-85e1-4ba5730c3c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_16944d51-4eba-45ba-abfb-27cf0f5d2104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38d50ad7-9a5f-4b74-a9f4-422b861ed90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38d50ad7-9a5f-4b74-a9f4-422b861ed90d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd745c06-bda6-43b4-a40d-6e49766de8db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a059f23e-122c-43c0-a7f2-63e71c618b58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd745c06-bda6-43b4-a40d-6e49766de8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:href="mygn-20211231.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd745c06-bda6-43b4-a40d-6e49766de8db" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_79efff2b-c131-4d7e-9bfc-1eedcd303969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_79efff2b-c131-4d7e-9bfc-1eedcd303969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9dd3f23f-af0f-4f10-a234-22df12e0c0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_0e825db6-0f1a-4935-a7bb-e85fbc148ba2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9dd3f23f-af0f-4f10-a234-22df12e0c0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_9e42aa52-44f6-4323-8d54-ab911b324d1a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_84a4f87a-6653-4bdb-bf95-49e7af9f4878" xlink:href="mygn-20211231.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:to="loc_mygn_NonEmployeeDirectorMember_84a4f87a-6653-4bdb-bf95-49e7af9f4878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_64997f58-fdb3-42fd-9ad4-23e73cfbfb28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:to="loc_srt_ChiefExecutiveOfficerMember_64997f58-fdb3-42fd-9ad4-23e73cfbfb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ExecutiveOfficersAndSeniorPositionsMember_313ce21b-3bb3-4494-b5cc-90f743026137" xlink:href="mygn-20211231.xsd#mygn_ExecutiveOfficersAndSeniorPositionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85f05bfa-e639-4c08-9dd4-fd43cfaafbeb" xlink:to="loc_mygn_ExecutiveOfficersAndSeniorPositionsMember_313ce21b-3bb3-4494-b5cc-90f743026137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_8f11d980-e107-4142-8cb9-62a882e05044" xlink:to="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_67f2b98e-34ed-48c6-bc32-4ef03af914ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_67f2b98e-34ed-48c6-bc32-4ef03af914ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_67a9ed88-9dd8-4f61-8592-8d6bba45d931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_05c17721-7b20-4280-b478-5818d8fc7e1d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_67a9ed88-9dd8-4f61-8592-8d6bba45d931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_18a3c569-c906-491d-be58-6715e77019ec" xlink:to="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_2b3d8220-6b46-4bce-9fd5-e0923d9b12f2" xlink:href="mygn-20211231.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_2b3d8220-6b46-4bce-9fd5-e0923d9b12f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0530c557-fca8-4317-ae7f-636a79e221ba" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_15046cdd-5576-47a5-b776-2888b4e549fe" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0530c557-fca8-4317-ae7f-636a79e221ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d9b6846-513f-46e9-852d-d5cbfd91a40c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4348f3f-92c3-4845-b898-de82be4504e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4348f3f-92c3-4845-b898-de82be4504e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_679e80a3-ea40-41be-b1cd-5730427efd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_679e80a3-ea40-41be-b1cd-5730427efd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffa0835e-24cb-41d6-970a-5135655fc11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffa0835e-24cb-41d6-970a-5135655fc11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ed587ca-1724-47dc-923e-3be110d9450d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ed587ca-1724-47dc-923e-3be110d9450d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cdbc2715-b761-4b0e-833e-e84364bd9457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cdbc2715-b761-4b0e-833e-e84364bd9457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98176f9a-7053-4902-885b-1f91003f2acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98176f9a-7053-4902-885b-1f91003f2acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff571c62-6d0c-42cb-8c34-a3af48b32d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff571c62-6d0c-42cb-8c34-a3af48b32d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ce43cad6-f614-48a1-be72-e29d8f813bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ce43cad6-f614-48a1-be72-e29d8f813bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2d7b8408-39c6-45d0-a3b8-02cd70c41560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2d7b8408-39c6-45d0-a3b8-02cd70c41560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_403efcb6-9211-472e-84db-75b53c148006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_403efcb6-9211-472e-84db-75b53c148006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a1903cb-f77d-4970-b79b-1f46a101c061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a1903cb-f77d-4970-b79b-1f46a101c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_573acce0-843c-4646-ae06-49336207b717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_573acce0-843c-4646-ae06-49336207b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_5118c807-0a8c-4600-808c-981917932221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_5118c807-0a8c-4600-808c-981917932221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_44f63828-1b44-47d3-97fe-d5184df0b3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0805bbc4-1d90-404e-8825-43a5d23794a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_44f63828-1b44-47d3-97fe-d5184df0b3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e63d28a-c57a-4930-84a2-0ad5990a7bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e63d28a-c57a-4930-84a2-0ad5990a7bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8ef0526-6c14-4807-ba17-f6f8c4d74c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8ef0526-6c14-4807-ba17-f6f8c4d74c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fbdb2a1-fda4-42cf-aa57-ee7f370e508f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fbdb2a1-fda4-42cf-aa57-ee7f370e508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_954c1cf9-d5d4-4938-8979-0881eaa7c980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_954c1cf9-d5d4-4938-8979-0881eaa7c980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d7c2686-ff29-46bd-8cf8-9af635b0c631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b2e23b-6d24-4881-8335-8ea09efc3fc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d7c2686-ff29-46bd-8cf8-9af635b0c631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c5bca8a1-ecf5-4929-ad86-906c18d409ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c5bca8a1-ecf5-4929-ad86-906c18d409ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_946726bc-3c0d-4708-bbed-47d765aebe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_946726bc-3c0d-4708-bbed-47d765aebe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e9ec96b4-f80a-4897-a977-b54d64ac6e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e9ec96b4-f80a-4897-a977-b54d64ac6e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b574429b-7376-4fb7-a292-a9cb1518bf33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b574429b-7376-4fb7-a292-a9cb1518bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_45f6a5c7-9253-4461-80c5-611e6ba4997e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_45f6a5c7-9253-4461-80c5-611e6ba4997e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4221574b-2510-424c-8314-c369869263af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4221574b-2510-424c-8314-c369869263af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb13f8f8-f8e2-4d28-9f98-6e6e89050e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4ebaa5e-74b9-428e-aa2b-36e943f65638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb13f8f8-f8e2-4d28-9f98-6e6e89050e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eae3f56-2af8-4299-b042-088ec5e75b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eae3f56-2af8-4299-b042-088ec5e75b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_39bfe160-e96e-4cf0-bce5-52e289d5e1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_39bfe160-e96e-4cf0-bce5-52e289d5e1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_caebeaed-846a-4fe8-9b2d-1d5a4dfe0846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37db246e-625d-4622-b24e-6c9d5bc6c1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_caebeaed-846a-4fe8-9b2d-1d5a4dfe0846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_d89e6b30-564b-4d29-b18b-55f693add752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_caebeaed-846a-4fe8-9b2d-1d5a4dfe0846" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_d89e6b30-564b-4d29-b18b-55f693add752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d61df79f-a000-489d-a406-e9d0a8e91dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_caebeaed-846a-4fe8-9b2d-1d5a4dfe0846" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d61df79f-a000-489d-a406-e9d0a8e91dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_2652f9a1-72f1-499c-9906-f74577ae962a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_caebeaed-846a-4fe8-9b2d-1d5a4dfe0846" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_2652f9a1-72f1-499c-9906-f74577ae962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b61f711-3bd8-4c9b-9162-6ed20a1b1a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b61f711-3bd8-4c9b-9162-6ed20a1b1a51" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e37dcd7-32f3-46f2-9d82-dd59de5755a9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeOneMember_b158ae8e-cbfa-427f-9720-7234e3454efa" xlink:href="mygn-20211231.xsd#mygn_RangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:to="loc_mygn_RangeOneMember_b158ae8e-cbfa-427f-9720-7234e3454efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeTwoMember_103e5a23-b483-43aa-8ad8-ee591d1e2ff7" xlink:href="mygn-20211231.xsd#mygn_RangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:to="loc_mygn_RangeTwoMember_103e5a23-b483-43aa-8ad8-ee591d1e2ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RangeThreeMember_0e9ed508-d937-42cd-aaf7-061aaaa9be6b" xlink:href="mygn-20211231.xsd#mygn_RangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ac4f6a9a-789f-47d6-b089-07abd762ada1" xlink:to="loc_mygn_RangeThreeMember_0e9ed508-d937-42cd-aaf7-061aaaa9be6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9a3d6aed-e518-4f86-bd53-75687339078f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_72c4d599-52cb-47e7-b3c6-4ec35e028123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_72c4d599-52cb-47e7-b3c6-4ec35e028123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c9514e57-afb4-4a28-bb6c-cbeedfad642d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c9514e57-afb4-4a28-bb6c-cbeedfad642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1afc9b36-6a21-4bed-960d-fd5374fc0db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1afc9b36-6a21-4bed-960d-fd5374fc0db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_96c515d5-5bef-47c1-9097-d3e47857bae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_96c515d5-5bef-47c1-9097-d3e47857bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_908e2625-87a8-4773-b13e-dd3143345bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_4f99cf64-7336-4a7e-95b6-f08200ad61dd" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_908e2625-87a8-4773-b13e-dd3143345bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_319dfe79-9e7a-4ece-9e0f-5daf9cdd6913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_319dfe79-9e7a-4ece-9e0f-5daf9cdd6913" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:to="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d7217c9-19af-4508-94a6-90f21943de99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4aba39d2-e0fb-4baa-ad5f-239d6befd696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d7217c9-19af-4508-94a6-90f21943de99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1f69d93a-37d5-4cd4-af83-bc168fcbdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d7217c9-19af-4508-94a6-90f21943de99" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1f69d93a-37d5-4cd4-af83-bc168fcbdcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fe57530-311b-4d82-8cd9-f0cfa0f0209a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ceb0d95-cf79-4f5d-9452-e27679abebd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ceb0d95-cf79-4f5d-9452-e27679abebd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9c5c2d8e-3bdc-4293-ac9d-7d7a0a72f1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9c5c2d8e-3bdc-4293-ac9d-7d7a0a72f1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_96910d16-2ea5-423e-a526-f36f2963751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_96910d16-2ea5-423e-a526-f36f2963751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be45ac04-1429-4fcb-ac34-7c63e31be34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be45ac04-1429-4fcb-ac34-7c63e31be34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a0ac18c5-cd33-41c7-9c27-3462df01d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0147db2e-b78b-42ae-b65f-8dfe23d92046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a0ac18c5-cd33-41c7-9c27-3462df01d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5c83c04-fb9b-4f2b-a710-4bc74dc7e2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6e5987b0-3101-4e37-a7af-7fd94da0e0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6e5987b0-3101-4e37-a7af-7fd94da0e0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2179d41a-24ac-436c-bcd0-1e455c662306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2179d41a-24ac-436c-bcd0-1e455c662306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ddb17db-2d57-4a65-99a6-91c20f69012a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ddb17db-2d57-4a65-99a6-91c20f69012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_83e59e80-7f21-4b46-a04f-fc003005bcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_83e59e80-7f21-4b46-a04f-fc003005bcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_960efca9-1234-49bd-a516-a931128a7138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a24f13d-f748-4562-9145-05191f724383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_960efca9-1234-49bd-a516-a931128a7138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12b10c8f-3bab-4784-b0b5-44233cbebf41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12b10c8f-3bab-4784-b0b5-44233cbebf41" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94fafdc8-ea35-46b4-b64e-d7dc6ab19c63" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember_bacbbdf3-4ef5-4fe0-8461-5f8342a5e7b4" xlink:href="mygn-20211231.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_mygn_CostOfMolecularDiagnosticTestingMember_bacbbdf3-4ef5-4fe0-8461-5f8342a5e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_7681f636-a679-46f8-807e-5de156ac174a" xlink:href="mygn-20211231.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_7681f636-a679-46f8-807e-5de156ac174a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_05994357-6030-4b49-807f-4541990b9591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_05994357-6030-4b49-807f-4541990b9591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2403d9f1-4f74-428b-a1c5-e72d97db3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44a6bfab-db90-4dd7-b3d9-62b85a0140fd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2403d9f1-4f74-428b-a1c5-e72d97db3c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37cac3fe-a8ad-48a4-b812-b46939a64f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_750aae1f-3cac-45b5-8d71-39c5a0ac5881" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37cac3fe-a8ad-48a4-b812-b46939a64f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5e5df307-1f22-4f7e-a481-d2c5870f4903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37cac3fe-a8ad-48a4-b812-b46939a64f4e" xlink:to="loc_us-gaap_ShareBasedCompensation_5e5df307-1f22-4f7e-a481-d2c5870f4903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationAggregateIntrinsicValueDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef6c0489-89d1-46ed-9ccd-666e10cc4f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef6c0489-89d1-46ed-9ccd-666e10cc4f10" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:to="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbcb6f82-5a6f-478b-b70f-cdd8294332e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c93945c-a9b8-498c-95c4-ea2e2c37ce11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbcb6f82-5a6f-478b-b70f-cdd8294332e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_382ca739-4466-4a57-ace7-d00efce986b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbcb6f82-5a6f-478b-b70f-cdd8294332e2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_382ca739-4466-4a57-ace7-d00efce986b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5d886b8-868c-44d6-b3f0-61e140728c04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7412a58f-6e7e-4e85-91b8-f52899075e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7412a58f-6e7e-4e85-91b8-f52899075e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9cf0969d-7380-45f0-a532-20bcf78703d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9cf0969d-7380-45f0-a532-20bcf78703d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_ab772c81-d2f9-49d4-a25d-8e969eb63ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc5c34ba-62e8-4ae3-a6d8-ceaa6dc02035" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_ab772c81-d2f9-49d4-a25d-8e969eb63ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationIntrinsicValueofOptionsExercisedDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd85941d-cb7e-4ee3-bd83-4a316177e595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2bd3e6d7-75a9-4a57-99e8-82212df50cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd85941d-cb7e-4ee3-bd83-4a316177e595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2bd3e6d7-75a9-4a57-99e8-82212df50cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5971e65a-4d39-4596-ac76-42cfc5543499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5971e65a-4d39-4596-ac76-42cfc5543499" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:to="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_415a0110-0b04-411e-b9b5-7f14db4eec6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6fb1dc2a-27bd-4bc6-9429-303deee71329" xlink:to="loc_us-gaap_PlanNameDomain_415a0110-0b04-411e-b9b5-7f14db4eec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_5475edcd-28cf-4504-8250-26a6f65303bc" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_415a0110-0b04-411e-b9b5-7f14db4eec6a" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_5475edcd-28cf-4504-8250-26a6f65303bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c438b22c-5b83-4088-971f-c6356f016a87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_d5fbc065-8387-497f-b4f6-365bc0dfccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_d5fbc065-8387-497f-b4f6-365bc0dfccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_8118b7f2-d3fd-4d7c-956e-16f9b223fe02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b6dcb44-18bf-47d6-94c4-21e0c4f3ec28" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_8118b7f2-d3fd-4d7c-956e-16f9b223fe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#StockBasedCompensationValuationAssumptionsforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aba0a381-adc1-4b0d-b47b-5b0bd23a8136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aba0a381-adc1-4b0d-b47b-5b0bd23a8136" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:to="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9dd1b101-953d-435c-8496-63d3c4ae0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_479a37c5-60e7-408c-b713-884101a58785" xlink:to="loc_us-gaap_PlanNameDomain_9dd1b101-953d-435c-8496-63d3c4ae0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0e4e8abf-ea47-4440-a6d6-fec8bafe7017" xlink:href="mygn-20211231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9dd1b101-953d-435c-8496-63d3c4ae0f63" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_0e4e8abf-ea47-4440-a6d6-fec8bafe7017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f479f06e-627c-42fa-bbdf-d3f352e30b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_566cb82f-a84f-4c55-a7d8-3a35bb47990d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f479f06e-627c-42fa-bbdf-d3f352e30b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f479f06e-627c-42fa-bbdf-d3f352e30b07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cf8f2c88-ceba-4ae9-ae16-9219949802c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cf8f2c88-ceba-4ae9-ae16-9219949802c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_da1a9efc-e3cd-46e7-aab8-e4a48f6979f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_da1a9efc-e3cd-46e7-aab8-e4a48f6979f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64e26a0f-30a2-4cc2-b6f7-5efb07a57c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_64e26a0f-30a2-4cc2-b6f7-5efb07a57c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_55bbc4cd-92fc-4e1b-8139-472f4c0a977f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_fb66cc2c-f02f-481f-ac39-0a0bc7d0b88b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_55bbc4cd-92fc-4e1b-8139-472f4c0a977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d54ad958-8367-437a-8898-f896aa986eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_937fd56b-2eb7-4eda-85f0-222fe8033fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d54ad958-8367-437a-8898-f896aa986eb1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_937fd56b-2eb7-4eda-85f0-222fe8033fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_70b20d64-4339-481f-81a1-892f4df09538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_70b20d64-4339-481f-81a1-892f4df09538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_148ed010-921a-4a34-9a02-84fb51ccf41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_148ed010-921a-4a34-9a02-84fb51ccf41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_10e80fb5-27e8-487b-b376-d7496f39d274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_10e80fb5-27e8-487b-b376-d7496f39d274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cfccf118-b3b6-4843-8938-a3ba9321cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cfccf118-b3b6-4843-8938-a3ba9321cb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_c0c2a80d-e757-4583-aba8-6b5079f3d769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_c0c2a80d-e757-4583-aba8-6b5079f3d769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_aff43b56-3ac2-4244-9127-17c97d223c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99cfbb2b-a13f-4d90-8e4c-c3eb3318f4ab" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_aff43b56-3ac2-4244-9127-17c97d223c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_afbff13c-2de5-4115-9a2b-4d296a1cc381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a99e499-cdc3-4eec-872a-5ea0b7af6d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afbff13c-2de5-4115-9a2b-4d296a1cc381" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a99e499-cdc3-4eec-872a-5ea0b7af6d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ac92170c-1c0d-41d9-aa66-74f5a9db5dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a99e499-cdc3-4eec-872a-5ea0b7af6d22" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ac92170c-1c0d-41d9-aa66-74f5a9db5dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_66582a1f-2b68-4c1d-9e1d-2d88d2903c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a99e499-cdc3-4eec-872a-5ea0b7af6d22" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_66582a1f-2b68-4c1d-9e1d-2d88d2903c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3f227ebf-9fea-4951-8db8-86d2bbcf110f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a99e499-cdc3-4eec-872a-5ea0b7af6d22" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3f227ebf-9fea-4951-8db8-86d2bbcf110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c88f5316-7d9e-4bd7-b0e0-af921052c050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a99e499-cdc3-4eec-872a-5ea0b7af6d22" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c88f5316-7d9e-4bd7-b0e0-af921052c050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afbff13c-2de5-4115-9a2b-4d296a1cc381" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0323b33d-fa8c-4619-a64d-8b9903f2da11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0323b33d-fa8c-4619-a64d-8b9903f2da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7054f212-545c-4c5d-9266-5e232411c8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7054f212-545c-4c5d-9266-5e232411c8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_dc62eb3e-9dac-4815-bc77-a010861d593a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_dc62eb3e-9dac-4815-bc77-a010861d593a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_10747406-68ea-460d-baf1-ced129b9cf56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_10747406-68ea-460d-baf1-ced129b9cf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ce9b41e1-71f2-42e4-aae2-814c5ef31f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_05fbaee1-dbc4-44a8-95ec-00d474e3f320" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ce9b41e1-71f2-42e4-aae2-814c5ef31f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2bc5c395-f5ed-4c2e-bc44-973108c25ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afbff13c-2de5-4115-9a2b-4d296a1cc381" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2bc5c395-f5ed-4c2e-bc44-973108c25ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e6ba76ee-4bfb-4b8d-9192-a59d9ca3130d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_bac691b7-2b73-4c9c-a6a2-c7a4ebafbbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e6ba76ee-4bfb-4b8d-9192-a59d9ca3130d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_bac691b7-2b73-4c9c-a6a2-c7a4ebafbbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_db23f18d-3e32-4bfb-8519-58792f6e9d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_bac691b7-2b73-4c9c-a6a2-c7a4ebafbbc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_db23f18d-3e32-4bfb-8519-58792f6e9d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_819eb781-f160-43d6-b7c1-1e6b725e9e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_bac691b7-2b73-4c9c-a6a2-c7a4ebafbbc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_819eb781-f160-43d6-b7c1-1e6b725e9e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_859447f8-6188-4720-aa67-6f91b39a7f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_bac691b7-2b73-4c9c-a6a2-c7a4ebafbbc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_859447f8-6188-4720-aa67-6f91b39a7f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5f1678e4-2814-4f55-b579-ed677ca416ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f1678e4-2814-4f55-b579-ed677ca416ff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_512d6093-40b1-4f1d-ab88-405ac5d3b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_512d6093-40b1-4f1d-ab88-405ac5d3b1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d93f2df4-8baa-4f30-8a99-9e1238b2d266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d93f2df4-8baa-4f30-8a99-9e1238b2d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_fcfdcd9b-adfd-4f62-aa02-2499e0df295a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_fcfdcd9b-adfd-4f62-aa02-2499e0df295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_b33ed179-5c35-48f3-94bd-a285280a8dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_b33ed179-5c35-48f3-94bd-a285280a8dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2be4dd10-c538-44b9-8032-3ca3e9c6e19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2be4dd10-c538-44b9-8032-3ca3e9c6e19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_c15781f5-dbfd-4743-a97d-eef7df8537fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_c15781f5-dbfd-4743-a97d-eef7df8537fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d24660e5-faaa-4b24-8b80-652a14575dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d24660e5-faaa-4b24-8b80-652a14575dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationCARESAct_8cef0033-5650-4cec-8585-3258dd6c07a5" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationCARESAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_mygn_IncomeTaxReconciliationCARESAct_8cef0033-5650-4cec-8585-3258dd6c07a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_1b15e242-1b05-45b3-936a-5533abe2161f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_1b15e242-1b05-45b3-936a-5533abe2161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_eae85cb1-cd89-4edc-ab25-4d402fafde47" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_eae85cb1-cd89-4edc-ab25-4d402fafde47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAssetImpairment_9a68446a-0dde-4943-8da8-b8aa3e09c0c9" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationAssetImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_mygn_IncomeTaxReconciliationAssetImpairment_9a68446a-0dde-4943-8da8-b8aa3e09c0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_dfaa1c11-b95e-4999-b560-2b720f22cd80" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_dfaa1c11-b95e-4999-b560-2b720f22cd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_ea1bc980-9b81-4a15-8c78-1b5e2e2d43c6" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_ea1bc980-9b81-4a15-8c78-1b5e2e2d43c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_f02237d9-3d51-4787-85a2-1b2c70110db5" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod_f02237d9-3d51-4787-85a2-1b2c70110db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_e288de84-7a86-4f91-bee2-b64a801ce4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_e288de84-7a86-4f91-bee2-b64a801ce4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5567476e-fff3-4d5a-a0f3-8a47e502b328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70dc689a-5707-4688-9735-8457698888ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5567476e-fff3-4d5a-a0f3-8a47e502b328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f1678e4-2814-4f55-b579-ed677ca416ff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_873933e6-b07a-4188-a1e8-57d9c8eaa5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_873933e6-b07a-4188-a1e8-57d9c8eaa5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7f83a9b1-7e3d-47c6-8c30-de5d79870819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7f83a9b1-7e3d-47c6-8c30-de5d79870819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d0319085-c2a0-448b-a9e7-7a5309dd1424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d0319085-c2a0-448b-a9e7-7a5309dd1424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_21051c8b-88a1-4442-8fa8-23c936aaeaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_21051c8b-88a1-4442-8fa8-23c936aaeaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_6604de40-2115-476c-983c-18292f96a88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_6604de40-2115-476c-983c-18292f96a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2be30e8a-b9b8-45b1-a0cc-d408bb6081e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2be30e8a-b9b8-45b1-a0cc-d408bb6081e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2593243a-6e17-410c-abd8-eb7e1a876977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2593243a-6e17-410c-abd8-eb7e1a876977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_65bab711-edbc-46ef-b17a-501924a723a8" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationCARESAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_65bab711-edbc-46ef-b17a-501924a723a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_405c442d-59c2-4160-bba2-fe7291d57265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_405c442d-59c2-4160-bba2-fe7291d57265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_1e440dc4-6ae2-437a-b2f2-443d2fbe1f51" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_1e440dc4-6ae2-437a-b2f2-443d2fbe1f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_d06d3470-bc89-43e7-b605-7dd03b6f8850" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_d06d3470-bc89-43e7-b605-7dd03b6f8850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_727f9a8c-9730-42d4-b7e9-0285b159b1f6" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_727f9a8c-9730-42d4-b7e9-0285b159b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_990df2bf-100c-4aff-a36a-a1cbbd7923b5" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_990df2bf-100c-4aff-a36a-a1cbbd7923b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_23eedb68-14ce-4228-aed9-f68e4ea15311" xlink:href="mygn-20211231.xsd#mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod_23eedb68-14ce-4228-aed9-f68e4ea15311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_acaa825d-9e22-418c-8279-0d3d284c2377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_acaa825d-9e22-418c-8279-0d3d284c2377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9ec2de86-f303-457b-a395-e9a137167a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_aebad4fe-a8d2-41a0-a062-46fe215fd7e6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9ec2de86-f303-457b-a395-e9a137167a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c16e16ac-5882-48ee-8ce9-9e74483c7544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c16e16ac-5882-48ee-8ce9-9e74483c7544" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d11ee4fb-f767-4d98-97e1-049ad61bb752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d11ee4fb-f767-4d98-97e1-049ad61bb752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_28adde28-4440-4ca3-b1e4-ea26b2536755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_28adde28-4440-4ca3-b1e4-ea26b2536755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0ba1f391-26a7-47c1-baef-205abdf2d5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0ba1f391-26a7-47c1-baef-205abdf2d5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_32698064-be6f-463b-a017-9fad6f05e006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_32698064-be6f-463b-a017-9fad6f05e006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_9732cf5b-086a-43a6-be8b-0ad7e3596b6d" xlink:href="mygn-20211231.xsd#mygn_DeferredTaxAssetsLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_mygn_DeferredTaxAssetsLeaseRightOfUseAsset_9732cf5b-086a-43a6-be8b-0ad7e3596b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d99f752c-f40d-4bcf-a23c-b34bae76d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d99f752c-f40d-4bcf-a23c-b34bae76d75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2331cc93-c4b7-4bcf-ac3a-ac6cef22fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2331cc93-c4b7-4bcf-ac3a-ac6cef22fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2d131239-347b-484f-88e8-f44ffc93306a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2d131239-347b-484f-88e8-f44ffc93306a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a7be0a19-5c81-4434-9ce9-19b58a6b4631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a7be0a19-5c81-4434-9ce9-19b58a6b4631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1e72abbe-3f5f-44d0-aec4-9c6bce0260ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10ed35ec-e364-497e-b8aa-d24622eb29c1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1e72abbe-3f5f-44d0-aec4-9c6bce0260ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c16e16ac-5882-48ee-8ce9-9e74483c7544" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e0bed5a6-c1ef-48ae-8d43-c0ad79795f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e0bed5a6-c1ef-48ae-8d43-c0ad79795f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxLeaseLiability_e26d0dad-1a2d-45df-a602-ed15ca3e87df" xlink:href="mygn-20211231.xsd#mygn_DeferredTaxLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:to="loc_mygn_DeferredTaxLeaseLiability_e26d0dad-1a2d-45df-a602-ed15ca3e87df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_191321c6-0707-4f1f-a948-3979b3493391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_191321c6-0707-4f1f-a948-3979b3493391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ae50c383-c1f8-4da5-9127-f5789084d138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ae50c383-c1f8-4da5-9127-f5789084d138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_889b9404-3e33-41e4-8534-c4d4a7140368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db3429b-9890-4f28-a832-efab70a9e91c" xlink:to="loc_us-gaap_DeferredTaxLiabilities_889b9404-3e33-41e4-8534-c4d4a7140368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_da401102-5fe3-4a5e-8144-f820c0946aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da401102-5fe3-4a5e-8144-f820c0946aeb" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f1f74b86-3e7e-4a11-a9ea-c6cfb8ae8d95" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f1c2bc63-ce5a-4463-b319-84219e6f63b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f1c2bc63-ce5a-4463-b319-84219e6f63b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e7655d66-4bdd-436b-b034-7be1d3f8a7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_adb51adf-0fd3-492a-819f-941f5dcbc564" xlink:to="loc_us-gaap_ForeignCountryMember_e7655d66-4bdd-436b-b034-7be1d3f8a7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e3009b95-d455-45d9-883e-c71d00b381e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_f04a8a5b-ade8-4fd0-adda-d4d0f9388d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_f04a8a5b-ade8-4fd0-adda-d4d0f9388d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_4bc43ead-e838-48ed-94f3-50d180fe4444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_4bc43ead-e838-48ed-94f3-50d180fe4444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_017a79db-f1be-4c6b-ace6-89ea59e2c66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a9b64495-fe42-4bef-989b-0950bc908b39" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_017a79db-f1be-4c6b-ace6-89ea59e2c66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_4e1645dd-3f12-4cbc-b831-0de8bc83c8a6" xlink:to="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_869e5d0d-8be6-4677-8b31-05282dbe9865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:to="loc_us-gaap_EarliestTaxYearMember_869e5d0d-8be6-4677-8b31-05282dbe9865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_3fbb5e15-8f8f-4d89-a390-835943462a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_ab60118a-b804-4ee3-a835-1caa3fbcd32b" xlink:to="loc_us-gaap_LatestTaxYearMember_3fbb5e15-8f8f-4d89-a390-835943462a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a234b5f0-5040-43c8-aba0-3d810624a070" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_f2306c91-89de-4a44-9eec-f192283584b3" xlink:href="mygn-20211231.xsd#mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct_f2306c91-89de-4a44-9eec-f192283584b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupCapitalLossOnTaxBasis_816adc36-ce77-40d8-b786-768e0fc35c3d" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupCapitalLossOnTaxBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_DisposalGroupCapitalLossOnTaxBasis_816adc36-ce77-40d8-b786-768e0fc35c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupCapitalGainOnDivestiture_9905d757-c4dc-448c-95ce-cae2f62d8a49" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupCapitalGainOnDivestiture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_DisposalGroupCapitalGainOnDivestiture_9905d757-c4dc-448c-95ce-cae2f62d8a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NumberOfDivestitures_42e0274b-b778-48b5-bda7-d9598f1b0998" xlink:href="mygn-20211231.xsd#mygn_NumberOfDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_NumberOfDivestitures_42e0274b-b778-48b5-bda7-d9598f1b0998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_06edc429-d2d6-4424-a9dd-d02e2a8c2f56" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture_06edc429-d2d6-4424-a9dd-d02e2a8c2f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_6bbc66e4-e819-46ba-8d45-9f9bfab1e7ac" xlink:href="mygn-20211231.xsd#mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_6bbc66e4-e819-46ba-8d45-9f9bfab1e7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_abff445d-bb38-4f2c-beb1-6875453872ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_abff445d-bb38-4f2c-beb1-6875453872ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_750acb95-7cb9-4a0a-b39a-ea04d1cc3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_00617cdf-2d3c-4b24-952b-a3a98ea0c4f7" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_750acb95-7cb9-4a0a-b39a-ea04d1cc3bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29ec8459-d6db-4007-b7dd-32cb764d34ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29ec8459-d6db-4007-b7dd-32cb764d34ab" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5a238ff1-f327-46f0-8c0d-25173310ae48" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8a91517d-a966-4d85-b58e-2faf693d4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:to="loc_us-gaap_DomesticCountryMember_8a91517d-a966-4d85-b58e-2faf693d4d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_200c0265-3e6e-48b0-9ffa-0d844cb11f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_200c0265-3e6e-48b0-9ffa-0d844cb11f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_265f45af-4e00-499b-951c-58a96229eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bad772a7-172f-4165-a186-bcd6683c8d5a" xlink:to="loc_us-gaap_ForeignCountryMember_265f45af-4e00-499b-951c-58a96229eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d6b27db-6f36-45a9-a2c5-48796bc22f8f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_bedc577c-5baa-4d4d-823f-5be8f41923f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_bedc577c-5baa-4d4d-823f-5be8f41923f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_UT_ebd7730e-00db-4742-9323-62a37c3548c6" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_UT"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_stpr_UT_ebd7730e-00db-4742-9323-62a37c3548c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_93792258-3020-414c-8810-f02aa12d1ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_93792258-3020-414c-8810-f02aa12d1ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherStateMember_964f3148-a753-4b7d-a3b0-3c849b3c1078" xlink:href="mygn-20211231.xsd#mygn_OtherStateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_db942a66-dd8c-467d-84c0-3ba9a232fd14" xlink:to="loc_mygn_OtherStateMember_964f3148-a753-4b7d-a3b0-3c849b3c1078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_9734091c-0667-4d0b-b15b-23977709f739" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_b5a0f70b-2305-4b55-a8b1-2dba029a6dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_b5a0f70b-2305-4b55-a8b1-2dba029a6dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_1c666e1f-c5b2-4fa8-bb1b-08c1e6f38528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_e621f1a5-9e78-4b31-953d-4e6a15081d37" xlink:to="loc_us-gaap_ResearchMember_1c666e1f-c5b2-4fa8-bb1b-08c1e6f38528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da5823d6-4692-4e26-9191-9ad26c914fa7" xlink:to="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_525e80cc-8edf-469f-8881-f0c1eb217754" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:to="loc_srt_MinimumMember_525e80cc-8edf-469f-8881-f0c1eb217754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d22eae3-7f70-41f3-b59f-a97d1684083e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4fe6e6d0-8380-48b7-9a28-fa5505869490" xlink:to="loc_srt_MaximumMember_2d22eae3-7f70-41f3-b59f-a97d1684083e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0e83583a-5a57-4731-bb96-0860480d54f3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_84af3704-27a1-4092-aaea-8d1983b0bda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_84af3704-27a1-4092-aaea-8d1983b0bda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_69c02d0d-ca2b-4296-85fe-f60dd746597c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_69c02d0d-ca2b-4296-85fe-f60dd746597c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_503ec46b-66d3-42b5-8b5f-80d71e7dff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_503ec46b-66d3-42b5-8b5f-80d71e7dff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_22cbb515-f372-45a1-bbc3-e56e102dd868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_22cbb515-f372-45a1-bbc3-e56e102dd868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLossCarryforwardsExpirationYear_cb84e688-80d2-4a03-a75e-ea97a256e513" xlink:href="mygn-20211231.xsd#mygn_OperatingLossCarryforwardsExpirationYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_mygn_OperatingLossCarryforwardsExpirationYear_cb84e688-80d2-4a03-a75e-ea97a256e513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TaxCreditCarryforwardsExpirationDate_73f1a3ba-b183-4280-af38-7ca8e41a673a" xlink:href="mygn-20211231.xsd#mygn_TaxCreditCarryforwardsExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_47b5e8e4-3b43-46bd-a67a-b169e2c06a6b" xlink:to="loc_mygn_TaxCreditCarryforwardsExpirationDate_73f1a3ba-b183-4280-af38-7ca8e41a673a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_946dd17a-e53e-401b-a822-8230d6cd30ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_946dd17a-e53e-401b-a822-8230d6cd30ae" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_577f66c2-33d1-4d46-aadb-86824ee8d2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_577f66c2-33d1-4d46-aadb-86824ee8d2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_59781f98-95c4-4396-957e-f1cb9169c9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_59781f98-95c4-4396-957e-f1cb9169c9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15124fc6-321e-43cd-bb74-a72dc6c6783a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15124fc6-321e-43cd-bb74-a72dc6c6783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_7cc1e4eb-7d6a-4266-a90d-e0190538d642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_7cc1e4eb-7d6a-4266-a90d-e0190538d642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_997b86a4-d7ab-43a2-a8a9-a0373bf87743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_997b86a4-d7ab-43a2-a8a9-a0373bf87743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f5d67479-c58b-4dda-9d1e-bf92c845531c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f5d67479-c58b-4dda-9d1e-bf92c845531c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_30807d51-f974-4ac9-9df9-80e03fb621ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_30807d51-f974-4ac9-9df9-80e03fb621ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_156b9c61-4c2f-42d5-bb9f-4b29063ff720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c776d62-7737-40f4-997a-3386030c687a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_156b9c61-4c2f-42d5-bb9f-4b29063ff720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_de9b3317-0c1c-42a7-8ab2-e888bcfd4d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_946dd17a-e53e-401b-a822-8230d6cd30ae" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_de9b3317-0c1c-42a7-8ab2-e888bcfd4d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mygn-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d5aa4af-3253-448a-b42e-8d22c8927313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a2cd29a8-8417-4490-be7e-4aba944496e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d5aa4af-3253-448a-b42e-8d22c8927313" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a2cd29a8-8417-4490-be7e-4aba944496e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f953a9b2-de07-4574-b2bf-9aacbb922544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f953a9b2-de07-4574-b2bf-9aacbb922544" xlink:to="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:to="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d6a14f6b-dd25-464a-b881-fac5b31c9e61" xlink:to="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CrescendoBioscienceIncMember_881d3766-6f09-4ec1-8740-dea8cda59cc4" xlink:href="mygn-20211231.xsd#mygn_CrescendoBioscienceIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:to="loc_mygn_CrescendoBioscienceIncMember_881d3766-6f09-4ec1-8740-dea8cda59cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AbelliAndPricoloMatterMember_dbc52f03-e233-4857-bb9a-8f17a34974f6" xlink:href="mygn-20211231.xsd#mygn_AbelliAndPricoloMatterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_84f007b9-4018-41ee-992a-4fb4800f0ddb" xlink:to="loc_mygn_AbelliAndPricoloMatterMember_dbc52f03-e233-4857-bb9a-8f17a34974f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5c97ad94-36d9-4e5b-8c2c-d824f0813348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2c9f5f2e-a7c1-4b57-ad33-d7b0307b479c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5c97ad94-36d9-4e5b-8c2c-d824f0813348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4f581009-75ca-4342-9e35-bb9fadf706aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5c97ad94-36d9-4e5b-8c2c-d824f0813348" xlink:to="loc_us-gaap_SubsequentEventMember_4f581009-75ca-4342-9e35-bb9fadf706aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_74d5b969-3954-4627-a83e-3b38b4a0bbbe" xlink:to="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_e5ca8d68-3856-4f5c-b984-d1c52f84e193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:to="loc_us-gaap_LitigationReserveCurrent_e5ca8d68-3856-4f5c-b984-d1c52f84e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_01c70f09-2d19-4ed1-abbe-d8cb58b53bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_344bdb5d-0347-4358-8650-7b7b4ad4a3b8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_01c70f09-2d19-4ed1-abbe-d8cb58b53bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Leases" xlink:type="simple" xlink:href="mygn-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b26791a9-5d78-463f-9d02-778b085ae070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7a1457b4-23ca-401f-a06c-530dcc0a6f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b26791a9-5d78-463f-9d02-778b085ae070" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7a1457b4-23ca-401f-a06c-530dcc0a6f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_90578787-8db5-40de-9e30-467ad93c8d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_032e12c3-5617-4aa9-b20b-34af3bf236e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90578787-8db5-40de-9e30-467ad93c8d22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_032e12c3-5617-4aa9-b20b-34af3bf236e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2dfea877-95f2-429d-a6c5-4e4f9732644f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2dfea877-95f2-429d-a6c5-4e4f9732644f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:to="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5e061fda-cf5e-40be-acb5-a7d48b46cc12" xlink:to="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_682bca4b-e731-4fff-9044-1789b6b49228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:to="loc_srt_MinimumMember_682bca4b-e731-4fff-9044-1789b6b49228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19025076-28f0-427b-80b0-a3e89d6bf599" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37ad6239-cfca-45b5-bc9c-29bd641b5a2e" xlink:to="loc_srt_MaximumMember_19025076-28f0-427b-80b0-a3e89d6bf599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:to="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_1c26948a-cc96-43ba-ba69-c99ff52bc133" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementAxis_a0e13c41-29ad-4022-b56d-ae5f2604c42b" xlink:to="loc_mygn_LeaseArrangementDomain_1c26948a-cc96-43ba-ba69-c99ff52bc133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_ae61e7b2-2867-45ea-9f01-1c41dee9e56e" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementDomain_1c26948a-cc96-43ba-ba69-c99ff52bc133" xlink:to="loc_mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember_ae61e7b2-2867-45ea-9f01-1c41dee9e56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2b31cfa0-cd6f-41d0-a5b8-4a985922bea0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ab199739-4904-40bc-99d4-6d5de4f69b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ab199739-4904-40bc-99d4-6d5de4f69b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a64e6270-ce6f-4766-9681-e99d62bf8e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_LeaseCost_a64e6270-ce6f-4766-9681-e99d62bf8e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_db5301ef-06ee-4d6b-ba58-d39960982464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_VariableLeaseCost_db5301ef-06ee-4d6b-ba58-d39960982464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_75756ce2-7742-4d94-9927-9ef0bd24bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_ShortTermLeaseCost_75756ce2-7742-4d94-9927-9ef0bd24bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_c4ebc6c1-c84d-4df8-bb91-4772493db5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_c4ebc6c1-c84d-4df8-bb91-4772493db5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_e0c79cdd-c30e-4751-b97a-bb754d8b058d" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_e0c79cdd-c30e-4751-b97a-bb754d8b058d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_28fe867f-616d-4491-abf2-50d4998f6069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_28fe867f-616d-4491-abf2-50d4998f6069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6240b6d8-9005-460f-ac93-e24d08202305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_25c5a57c-6b07-4261-a05b-537faee67463" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6240b6d8-9005-460f-ac93-e24d08202305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cfb314af-0bfb-4ce2-b039-21c6cf87502d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfb314af-0bfb-4ce2-b039-21c6cf87502d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b0047155-3f9a-4648-89bd-d9152480b156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b0047155-3f9a-4648-89bd-d9152480b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e5946c7f-6ac6-4547-8a0d-8b660abd0a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e5946c7f-6ac6-4547-8a0d-8b660abd0a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f9763a00-4ab9-4c48-80b8-4def49f7b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f9763a00-4ab9-4c48-80b8-4def49f7b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2069afa0-aa1d-4e06-ace0-1ea1e9db1d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2069afa0-aa1d-4e06-ace0-1ea1e9db1d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f99b09a4-bddf-4125-9d48-3e5838e345b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f99b09a4-bddf-4125-9d48-3e5838e345b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a72b155f-9ff2-4874-a3e7-7f765645aab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a72b155f-9ff2-4874-a3e7-7f765645aab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12a80c93-6532-43a8-8141-f48b6386faa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12a80c93-6532-43a8-8141-f48b6386faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c0e8778-0995-487f-ba50-701dccf6ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c0e8778-0995-487f-ba50-701dccf6ced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_98b475bb-5881-4afa-872c-6853781914f2" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_98b475bb-5881-4afa-872c-6853781914f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_bfc3efc3-732b-49eb-8168-cf31246c6b73" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityLeasesNotYetCommenced"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_bfc3efc3-732b-49eb-8168-cf31246c6b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a77fab8-b83e-4b1d-a9ab-807a12df1620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a77fab8-b83e-4b1d-a9ab-807a12df1620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2b8702f-9bc4-4018-9ad1-18fd332884bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c8ee11ca-b1b1-40b1-9a30-276084b1d9f4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2b8702f-9bc4-4018-9ad1-18fd332884bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mygn-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlan" xlink:type="simple" xlink:href="mygn-20211231.xsd#EmployeeDeferredSavingsPlan"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7620c59-9719-48cc-bd80-f7c6d0b27715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_7200352d-37a3-404b-b917-a1ac779a2b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7620c59-9719-48cc-bd80-f7c6d0b27715" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_7200352d-37a3-404b-b917-a1ac779a2b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#EmployeeDeferredSavingsPlanTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60da43bb-2b23-40a5-b518-654b4b72342d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_dc88075c-6aa7-4a04-825a-659d32f8fc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60da43bb-2b23-40a5-b518-654b4b72342d" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_dc88075c-6aa7-4a04-825a-659d32f8fc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#EmployeeDeferredSavingsPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a062ae2-15cf-476f-863e-2c97785e29d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_f57279dd-13c5-43c5-b094-06e7434782c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a062ae2-15cf-476f-863e-2c97785e29d6" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_f57279dd-13c5-43c5-b094-06e7434782c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_d3b4a3b6-9d89-49a6-8aa4-72dc64836406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a062ae2-15cf-476f-863e-2c97785e29d6" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_d3b4a3b6-9d89-49a6-8aa4-72dc64836406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#EmployeeDeferredSavingsPlanContributionstoPlanDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_825924c2-b821-4e98-9668-216bea26749c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1b3b4769-43d0-4fb0-b981-1fed97304f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_825924c2-b821-4e98-9668-216bea26749c" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1b3b4769-43d0-4fb0-b981-1fed97304f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformation" xlink:type="simple" xlink:href="mygn-20211231.xsd#SegmentandRelatedInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c0089088-b718-4937-8fb2-bc41287e3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2f535434-dc2c-4030-a9e2-f82359f8a32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0089088-b718-4937-8fb2-bc41287e3c88" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_2f535434-dc2c-4030-a9e2-f82359f8a32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#SegmentandRelatedInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a273ffa9-a86d-47d4-941b-7d45fc4d58e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_ccdf0a7d-db91-46fe-85b3-2a9efa4dd6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a273ffa9-a86d-47d4-941b-7d45fc4d58e2" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_ccdf0a7d-db91-46fe-85b3-2a9efa4dd6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#SegmentandRelatedInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_079e548b-b85c-418b-a5de-41102629b2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e1339316-16ac-4f13-81ba-74fd6e125468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_079e548b-b85c-418b-a5de-41102629b2f6" xlink:to="loc_us-gaap_NumberOfReportableSegments_e1339316-16ac-4f13-81ba-74fd6e125468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f232558f-0317-4074-a98b-1ca968e7c707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f232558f-0317-4074-a98b-1ca968e7c707" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:to="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_80a8cf2f-d9e9-4d1d-b846-74678427971f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e9a32ef1-f636-411b-a45a-48246a7f9287" xlink:to="loc_srt_ConsolidationItemsDomain_80a8cf2f-d9e9-4d1d-b846-74678427971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_abd1df05-702b-4a21-9f48-b8025a92af33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_80a8cf2f-d9e9-4d1d-b846-74678427971f" xlink:to="loc_srt_ReportableGeographicalComponentsMember_abd1df05-702b-4a21-9f48-b8025a92af33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:to="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9914ca79-70e7-4f8a-88b4-ffbc08ea1aea" xlink:to="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_65dd9e53-f7c1-4112-97ac-fe4471540209" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:to="loc_country_US_65dd9e53-f7c1-4112-97ac-fe4471540209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2c856bab-2d2f-442d-82a6-ea70f7b80031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6170c2d-bedb-4bc2-a4b8-2bc3ae476c11" xlink:to="loc_us-gaap_NonUsMember_2c856bab-2d2f-442d-82a6-ea70f7b80031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_836f0752-742d-48a1-9513-801c3fc2a991" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_772462b0-ba26-4bce-853c-b0307efb50a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_772462b0-ba26-4bce-853c-b0307efb50a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_cae5499a-d494-40c3-ad35-3ace427e3d51" xlink:href="mygn-20211231.xsd#mygn_AssetsLessCashCashEquivalentsAndInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_cae5499a-d494-40c3-ad35-3ace427e3d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_004358c5-2332-460a-bf98-d4ad81b965cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_004358c5-2332-460a-bf98-d4ad81b965cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0ff18eee-18e7-49cb-985b-714b9441eaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3380a2d-b8d0-43ac-af4d-2a68c0fadd54" xlink:to="loc_us-gaap_Assets_0ff18eee-18e7-49cb-985b-714b9441eaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Divestitures" xlink:type="simple" xlink:href="mygn-20211231.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3350a5fb-0acd-4aa2-9fa8-7aca2f692aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_32c8d43a-8e91-4253-b1e0-0faeb797bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3350a5fb-0acd-4aa2-9fa8-7aca2f692aa4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_32c8d43a-8e91-4253-b1e0-0faeb797bcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#DivestituresTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_212462ac-fc93-4067-b01b-4e3bae1b246c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_70d0e776-85fc-4cdb-82bd-1ee99a226376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_212462ac-fc93-4067-b01b-4e3bae1b246c" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_70d0e776-85fc-4cdb-82bd-1ee99a226376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#DivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_67799c1b-6a8f-4607-959a-5bdb6df16210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_67799c1b-6a8f-4607-959a-5bdb6df16210" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0ede8233-5b47-4eae-b7e9-edb53783f963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f9d85d34-9983-481e-a3fe-b85153fdc77d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0ede8233-5b47-4eae-b7e9-edb53783f963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a828d8a6-e236-4187-9fc7-1a4eb3fda8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0ede8233-5b47-4eae-b7e9-edb53783f963" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a828d8a6-e236-4187-9fc7-1a4eb3fda8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_791d006b-e3cd-4517-b649-d19941e46278" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_4429745b-7d25-46ba-a0be-ff655973f718" xlink:href="mygn-20211231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_4429745b-7d25-46ba-a0be-ff655973f718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_4a69ea6c-2929-4694-8a5b-e72e4fb294a5" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:to="loc_mygn_MyriadRBMIncMember_4a69ea6c-2929-4694-8a5b-e72e4fb294a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_cb53d06c-7032-4c72-9be7-e69b9c6ff01b" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f8730adb-ce18-4715-874e-b0f85c204630" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_cb53d06c-7032-4c72-9be7-e69b9c6ff01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77b74ec4-6fbf-4378-b750-94f8f1c339a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4ab15221-09cf-4597-8b42-a9fc19fe1d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4ab15221-09cf-4597-8b42-a9fc19fe1d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_79ffdee6-3aaf-4e75-a9f5-fc310a5a0b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_79ffdee6-3aaf-4e75-a9f5-fc310a5a0b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_adaca6a3-ccf4-4a19-9c0b-fd886f1f15ba" xlink:href="mygn-20211231.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_adaca6a3-ccf4-4a19-9c0b-fd886f1f15ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5b34094a-4177-447b-b91a-aaada0837814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5b34094a-4177-447b-b91a-aaada0837814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_67724ad4-ecfe-4a0f-bd59-75729577cd3e" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_67724ad4-ecfe-4a0f-bd59-75729577cd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_0ee7950b-296b-4165-8cfc-08f0fdbb435f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_0ee7950b-296b-4165-8cfc-08f0fdbb435f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_90879135-1a60-46eb-be53-62470a8943f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1b24d7c-e5f5-4696-b49e-aa369107f72d" xlink:to="loc_us-gaap_InventoryWriteDown_90879135-1a60-46eb-be53-62470a8943f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#DivestituresOtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dc1c4cf3-c4e8-4431-a416-d97ed2c84ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dc1c4cf3-c4e8-4431-a416-d97ed2c84ba6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_58434d7e-ab42-4ad2-804b-0dfdc2c9feba" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_fa7aae97-d2e6-46f1-a3fb-e45293000841" xlink:href="mygn-20211231.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:to="loc_mygn_MyriadRBMIncMember_fa7aae97-d2e6-46f1-a3fb-e45293000841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_a1a7be81-6287-4ea5-affe-a5563b05c6fc" xlink:href="mygn-20211231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_a1a7be81-6287-4ea5-affe-a5563b05c6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_35f564ec-4318-475a-9cce-b41773773f9b" xlink:href="mygn-20211231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47e1a823-3ffe-41e0-bf4d-e89ca0420d1f" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_35f564ec-4318-475a-9cce-b41773773f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1dc4fe20-a26b-4cc9-8544-68382f33bffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9ea857d7-44fd-4476-8b9d-29d97ef47357" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1dc4fe20-a26b-4cc9-8544-68382f33bffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e8143420-37f1-4369-8481-410f3eebeb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1dc4fe20-a26b-4cc9-8544-68382f33bffc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e8143420-37f1-4369-8481-410f3eebeb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_af3e0753-fdf9-4361-80c6-297b560f0dc4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f1684332-7513-4915-b1e4-e62a542a32e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f1684332-7513-4915-b1e4-e62a542a32e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_209ffeaa-444c-4c4f-9432-a2863e0c7e35" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_209ffeaa-444c-4c4f-9432-a2863e0c7e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_6655903e-e8ed-4495-8a97-37ad66954b42" xlink:href="mygn-20211231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_6655903e-e8ed-4495-8a97-37ad66954b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_06c07a13-3b04-4381-93b4-8aedd42ad0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c7192523-41e3-4a1c-849b-c9f5b5c99685" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_06c07a13-3b04-4381-93b4-8aedd42ad0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitions" xlink:type="simple" xlink:href="mygn-20211231.xsd#BusinessAcquisitions"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f75fefd1-1260-44c3-afc4-9090a41dca22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_145f55e6-6d48-4274-8b46-577f27335512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f75fefd1-1260-44c3-afc4-9090a41dca22" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_145f55e6-6d48-4274-8b46-577f27335512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#BusinessAcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8e4e744f-a342-4fba-b7af-457086a680d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8e4e744f-a342-4fba-b7af-457086a680d7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a98931d5-56ef-4721-9b2d-fe9dbdb2a92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_697d00fd-6271-4920-b20e-6fe1816c9a80" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a98931d5-56ef-4721-9b2d-fe9dbdb2a92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CounsylIncMember_fd7d8c8d-532f-430a-9c9a-f2e0c44df842" xlink:href="mygn-20211231.xsd#mygn_CounsylIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a98931d5-56ef-4721-9b2d-fe9dbdb2a92b" xlink:to="loc_mygn_CounsylIncMember_fd7d8c8d-532f-430a-9c9a-f2e0c44df842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6af43b87-401f-4c7a-b99e-54c60f57e290" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_14414c62-b2b4-45a6-843a-1658bad92f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_14414c62-b2b4-45a6-843a-1658bad92f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c0d902d9-9c28-46a1-9da6-a3c64594de44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c0d902d9-9c28-46a1-9da6-a3c64594de44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_63d509af-6843-4207-ae7d-2218e55950ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_63d509af-6843-4207-ae7d-2218e55950ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_db44bdd0-bb26-4f6a-9ad4-1e79049d453d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b82a19b-3149-4acf-b513-aba00866fbe7" xlink:to="loc_us-gaap_OperatingExpenses_db44bdd0-bb26-4f6a-9ad4-1e79049d453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEvent" xlink:type="simple" xlink:href="mygn-20211231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5eee0cc8-267a-47ca-95b0-2c5020cf2fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_8428e5e1-5e66-4cd0-a3ab-1d2299d895f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5eee0cc8-267a-47ca-95b0-2c5020cf2fbe" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_8428e5e1-5e66-4cd0-a3ab-1d2299d895f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1711e39c-385f-4f39-b919-dd87da97c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1711e39c-385f-4f39-b919-dd87da97c1ed" xlink:to="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_414bea33-4954-40bd-9706-9d46d287d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7f2f6d2b-5e3d-4080-9f42-366580d25889" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_414bea33-4954-40bd-9706-9d46d287d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a1ee5192-da7e-40ae-9de0-81c3bb6e3314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_414bea33-4954-40bd-9706-9d46d287d01e" xlink:to="loc_us-gaap_SubsequentEventMember_a1ee5192-da7e-40ae-9de0-81c3bb6e3314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:to="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_32ad51a9-2944-452c-b411-44ea827b472e" xlink:href="mygn-20211231.xsd#mygn_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementAxis_3b233bf6-eb8a-4ae3-b776-bf05d06946ea" xlink:to="loc_mygn_LeaseArrangementDomain_32ad51a9-2944-452c-b411-44ea827b472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SaltLakeCityLeaseMember_0d809dfa-9be0-4f86-bcbb-29c32304de5c" xlink:href="mygn-20211231.xsd#mygn_SaltLakeCityLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementDomain_32ad51a9-2944-452c-b411-44ea827b472e" xlink:to="loc_mygn_SaltLakeCityLeaseMember_0d809dfa-9be0-4f86-bcbb-29c32304de5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_87e24639-0126-4788-9493-6caa332e68df" xlink:to="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_1db74b2d-45bc-43a5-b5e2-f56c8ccc6cc7" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_1db74b2d-45bc-43a5-b5e2-f56c8ccc6cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_4f7724ed-369e-4fe1-a9b3-719f8d8f15da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_4f7724ed-369e-4fe1-a9b3-719f8d8f15da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_2ae49f99-df28-4ed1-9d33-2892e38ac27d" xlink:href="mygn-20211231.xsd#mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_650b823f-1d39-4baf-871d-75d31443be38" xlink:to="loc_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments_2ae49f99-df28-4ed1-9d33-2892e38ac27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="mygn-20211231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_75a6b1ff-cdd2-43a7-ab2e-f3e32d769281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_0d386704-1348-40d1-835b-bdca6e25e540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_75a6b1ff-cdd2-43a7-ab2e-f3e32d769281" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_0d386704-1348-40d1-835b-bdca6e25e540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_2167feaa-f971-44a2-9dbf-d62bdace94bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_aec3c4fc-b2a1-417e-90c9-90b698b6a156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_2167feaa-f971-44a2-9dbf-d62bdace94bf" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_aec3c4fc-b2a1-417e-90c9-90b698b6a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_006c7334-363a-42c0-b473-f3187b6c4b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_c24bd5ef-71bb-4bce-bc88-192ad286d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_006c7334-363a-42c0-b473-f3187b6c4b7e" xlink:to="loc_us-gaap_IncomeTaxesPaid_c24bd5ef-71bb-4bce-bc88-192ad286d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cc6b6221-14bd-4252-a382-a686878e0625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_006c7334-363a-42c0-b473-f3187b6c4b7e" xlink:to="loc_us-gaap_InterestPaidNet_cc6b6221-14bd-4252-a382-a686878e0625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_9745b7f2-5951-4d64-aae3-2b6edbe44513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_006c7334-363a-42c0-b473-f3187b6c4b7e" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_9745b7f2-5951-4d64-aae3-2b6edbe44513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d38a8f-9784-4414-8ea3-8667ab2ca542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_006c7334-363a-42c0-b473-f3187b6c4b7e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d38a8f-9784-4414-8ea3-8667ab2ca542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5f420ad3-0fd0-4b54-9f1d-6df7200d3782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d38a8f-9784-4414-8ea3-8667ab2ca542" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5f420ad3-0fd0-4b54-9f1d-6df7200d3782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2830e016-fb37-4e6f-85a5-7d8ca7e8ba22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5f420ad3-0fd0-4b54-9f1d-6df7200d3782" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2830e016-fb37-4e6f-85a5-7d8ca7e8ba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished_ea2b857c-7665-4e11-af89-f3e70e351ebd" xlink:href="mygn-20211231.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5f420ad3-0fd0-4b54-9f1d-6df7200d3782" xlink:to="loc_mygn_OperatingLeaseLiabilityEstablished_ea2b857c-7665-4e11-af89-f3e70e351ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_e0380690-9f2f-4526-a091-932703055ea1" xlink:href="mygn-20211231.xsd#mygn_LeaseRelatedExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5f420ad3-0fd0-4b54-9f1d-6df7200d3782" xlink:to="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_e0380690-9f2f-4526-a091-932703055ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited" xlink:type="simple" xlink:href="mygn-20211231.xsd#TransitionPeriodComparativeDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22f13988-0ca0-4c92-b294-5cc750a81e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodComparativeDataTextBlock_48c94596-efd3-47d2-a942-84eb42ae89a5" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodComparativeDataTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22f13988-0ca0-4c92-b294-5cc750a81e22" xlink:to="loc_mygn_TransitionPeriodComparativeDataTextBlock_48c94596-efd3-47d2-a942-84eb42ae89a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables" xlink:type="simple" xlink:href="mygn-20211231.xsd#TransitionPeriodComparativeDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5dfb6cc-4be9-4745-bcd0-cbb699c4e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock_09c91b78-c5d8-49e5-9f02-48b08ff2c89b" xlink:href="mygn-20211231.xsd#mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5dfb6cc-4be9-4745-bcd0-cbb699c4e2c5" xlink:to="loc_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock_09c91b78-c5d8-49e5-9f02-48b08ff2c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails" xlink:type="simple" xlink:href="mygn-20211231.xsd#TransitionPeriodComparativeDataUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f697d7-b966-4de8-b349-a4410d34b121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodFinancialInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f697d7-b966-4de8-b349-a4410d34b121" xlink:to="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:to="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60dd2ff6-cc59-499a-9916-da2bbcbfbda0" xlink:to="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_7a4c602f-8b60-4f88-a71b-456a6ed9844e" xlink:href="mygn-20211231.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_7a4c602f-8b60-4f88-a71b-456a6ed9844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_3871cfa4-156f-45af-85ce-d516665f2cf2" xlink:href="mygn-20211231.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7dcc48e-91e7-4ae4-8063-042c5dbc4db1" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_3871cfa4-156f-45af-85ce-d516665f2cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:href="mygn-20211231.xsd#mygn_TransitionPeriodFinancialInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationTable_f35aef56-5e39-4fe9-ba86-99bbb34e6913" xlink:to="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bdfc872-3cdd-42b0-8ae1-a2161af33757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bdfc872-3cdd-42b0-8ae1-a2161af33757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6e09e511-c176-44b4-802e-07c5f74cd226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6e09e511-c176-44b4-802e-07c5f74cd226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aafe7edf-b214-4e43-982c-80d909f559e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aafe7edf-b214-4e43-982c-80d909f559e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0324304-bc55-4dc6-8e9b-2fef5519b818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0324304-bc55-4dc6-8e9b-2fef5519b818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6f122624-ab16-4c7d-8231-378ab06fbf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6f122624-ab16-4c7d-8231-378ab06fbf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_caa4ad05-1d2b-4528-966a-8b865ae2dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_449b7558-dbfd-4d2e-ba13-ac8654ee417c" xlink:to="loc_us-gaap_CostsAndExpenses_caa4ad05-1d2b-4528-966a-8b865ae2dd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1fc16940-d5a3-437e-a04f-2b44963c9e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_OperatingIncomeLoss_1fc16940-d5a3-437e-a04f-2b44963c9e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fecfefdc-497e-4ba6-997a-6fc407bf07fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fecfefdc-497e-4ba6-997a-6fc407bf07fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ef801c3f-f3f9-43c2-b6b0-457d10d07616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_InterestExpense_ef801c3f-f3f9-43c2-b6b0-457d10d07616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61d2245a-1f8f-4044-bd17-0a27108aa799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61d2245a-1f8f-4044-bd17-0a27108aa799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2c972151-60da-4a58-ac10-44c81a93f8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_75b5b3f0-7bf4-45a1-9af0-234208849e80" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2c972151-60da-4a58-ac10-44c81a93f8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d286b5e-c026-418d-b54b-8d69c1583838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d286b5e-c026-418d-b54b-8d69c1583838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a87a09b6-37ff-4f3b-b207-f039cad6ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a87a09b6-37ff-4f3b-b207-f039cad6ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_be822d4e-e44b-4cb1-89f8-5798cc7bb411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_ProfitLoss_be822d4e-e44b-4cb1-89f8-5798cc7bb411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d54609ad-1791-4218-b0b3-d713f1216d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d54609ad-1791-4218-b0b3-d713f1216d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8086032d-6881-4f57-90ad-2a3bc4b334ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_NetIncomeLoss_8086032d-6881-4f57-90ad-2a3bc4b334ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e676de1-ec7a-40e4-85a0-7f2590f6f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e676de1-ec7a-40e4-85a0-7f2590f6f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5ebca9b2-efdc-45b0-b543-0067411c9f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_86d26885-851c-4a2f-b50d-83677baa50b8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5ebca9b2-efdc-45b0-b543-0067411c9f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TransitionPeriodFinancialInformationLineItems_9a0460db-4c50-43a3-8b04-a9b381e6688d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c7bf3af-6c95-4e8b-a3e0-5b3f08c06a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c7bf3af-6c95-4e8b-a3e0-5b3f08c06a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90751e84-9734-4dd4-934c-f9fcc1f45b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8f404a63-fcbb-484d-86ea-286b4c7c4a02" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90751e84-9734-4dd4-934c-f9fcc1f45b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mygn-20211231_g1.gif
<TEXT>
begin 644 mygn-20211231_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M E:C9:='R?GJ41'II&^J*=[D990)AAEV4+)^LCX(\:[[[W%%(Y ^O-,CFL;
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M ]'E]*S>$''X.>;[L!9AN<_[INB\+9H1A3>CFMNE;M&HB5V!_SR:DM*Q'.L
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MK1-:CVE]BE.9J%QXD9Q=R,DHUV2H7_-3)D-\@2Y[<<MV=_D9@@@!R8$-L,J
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M;,(EQ+;[R[^H"HQ@&*5[ HPHI$*.$0;_8P?- 4 "),!Y.,!E ;6,&8EO0*'
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MTF'.HD,9BMR[KDD=9?"(FXN8&7&*:E$SGUR[!(0SR2Q  8Q'T/^[3%N$.WK
M'Y82"C<R/MMD/XU ( "BI3?) 4KHH;!<F%"!B_^*++=$+?=\2PXA/_ET-Q\2
MP\KQO)J\24P<*>I(3M+Q!0^<H?,:3-)AE/-B3L2:R.<$BIXP3*W!&WI8ANI,
MKDVI/=I+"+JIIH!:M9*Y2 "M"/#8"B6QCT<AAJHP*(:)BV(JH+J$T;=:B=^(
M!D?!BD<Y#L5XQ.USNFG;JP)L%IOTN<*(%O3,*AQQ)1SI4-["4AGJ"6[)A BU
M)K_;EJRBN$7)4'\ZTT49!E  4>E$B\6T0<KR#B3+A%X@#TVPTV&@G1\5"SER
M&6Y:3251C7A24CX]R6AX%(_CHO9SMMW_N,%(E,D&S,N3J,DH=::1XL)AR#.2
M>4.5(AT07#U]FXYZ0)V=P!H0+-/TXM -0SH[[= 6_< L-1DW@D/F+-/)X%"_
M$[>OJ9T:.B-L4<XR[05->#5#/8HJ0R 1*PZLH ])T31C)<1'U0F74U2WI*Y#
M>[<BD=0"I$?,F4K $D!-Y<I66TX,-<R<>]9ZJ(?4(1R>T)]PLU,W>DZ409D(
MI5>C$]-@U#-%Z;N)G$A_JJ95=:,]&XKV-%;-\],?N"A(@U8^W8C\!*!X,E%-
M<] $!<ARA)8L'#VM7$_$<B5Q0]>)"-G,(%41#4S#N0P0Q-!YK0Q^?<ZL4A3]
M@=4+K5,VNE)KBDHZ'PW0ETPM G*;_#"[D&W8H-J-C0 V)J&$!<N3[:N<A3/%
M5:3"7M!4-@J*HEO1@=*\$2'9M1$;GN")8.26&ZG:_&$4_"G8H=T5B\A:M#7&
M=C*B1ZLO4\NU,4305NS$320,$])8F]70\E EK3F_)'I).N&G=:T=$/5:.*2A
MB]!9L*N7&$R,0Y$2^/]@6W[C$+$JM#-+OV4!"?GK*^O@N=$37:K]-A8%"F((
MW,&-ULKMO@Y2TK5E7?.1UH8 I[=MH$)EB(YPA_BSCG_<!= ;!DP@S45YSEDE
MUIB,O,,+CL;M#*806MN,-1^,O@&)W1^D"T@-.DC%)M^@#7N9C=TH*'B""B%M
M,R%T4GNDPJJ4!'$=7@]$.HM<O><%)MBMWOHM%I.ZWIKAODLA7PG4"2/:)4)U
ML].JIY"0A!1B$> EW5S]B6%-.B:SWPB6X!]QHDX2DJ)PI^+(@:3:#^H(M?0-
MB:G-JG\BOFP!58.=X!168>&HI#M!"A3^D5(+A871S<S[1CSSO .V0DWU4C3_
M7=48HB'Y7>$A)N+8J*1T@>$1V8M';(DQ"*1T>A]-E80KQ 1>$-Y6(QTO)3[
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M#+5,2@7R2WG'(+/P).QC3>7D$(OIH("',L!%!L+0^PB/IU!R!&(R7X0()<=
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8^?.FKY 7N9$?.9(G";F2+SF30UE    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438159624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MYRIAD GENETICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0494517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">320 Wakara Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">584-3600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MYGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,376,886,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,022,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:&#160;&#160;Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December&#160;31, 2021, for the Annual Meeting of Stockholders to be held on June 2, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438702952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Salt Lake City, UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435497432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 258.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable investment securities</a></td>
<td class="nump">81.4<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">91.3<span></span>
</td>
<td class="nump">89.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">108.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">484.8<span></span>
</td>
<td class="nump">389.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">81.8<span></span>
</td>
<td class="nump">59.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable investment securities</a></td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">404.1<span></span>
</td>
<td class="nump">576.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">239.2<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,320.7<span></span>
</td>
<td class="nump">1,418.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">156.5<span></span>
</td>
<td class="nump">79.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">204.3<span></span>
</td>
<td class="nump">145.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_UnrecognizedTaxBenefitsNet', window );">Unrecognized tax benefits</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Long-term deferred taxes</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">71.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">224.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">79.3<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">352.9<span></span>
</td>
<td class="nump">537.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 80.0 and 75.4 shares outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,226.3<span></span>
</td>
<td class="nump">1,109.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(254.2)<span></span>
</td>
<td class="num">(227.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Myriad Genetics, Inc. stockholders' equity</a></td>
<td class="nump">967.8<span></span>
</td>
<td class="nump">881.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">967.8<span></span>
</td>
<td class="nump">881.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,320.7<span></span>
</td>
<td class="nump">$ 1,418.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_UnrecognizedTaxBenefitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_UnrecognizedTaxBenefitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438291976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431182984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
<td class="nump">$ 851.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
<td class="nump">85.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">260.4<span></span>
</td>
<td class="nump">537.8<span></span>
</td>
<td class="nump">507.3<span></span>
</td>
<td class="nump">556.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal charges pending settlement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">387.6<span></span>
</td>
<td class="nump">881.1<span></span>
</td>
<td class="nump">870.3<span></span>
</td>
<td class="nump">843.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(87.8)<span></span>
</td>
<td class="num">(190.5)<span></span>
</td>
<td class="num">(231.7)<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">139.3<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">133.4<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax</a></td>
<td class="num">(94.1)<span></span>
</td>
<td class="num">(57.1)<span></span>
</td>
<td class="num">(223.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">(29.9)<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(53.1)<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="num">(199.6)<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (weighted average shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (weighted average shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 279.6<span></span>
</td>
<td class="nump">$ 666.4<span></span>
</td>
<td class="nump">$ 586.9<span></span>
</td>
<td class="nump">$ 789.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs and expenses</a></td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
<td class="nump">157.5<span></span>
</td>
<td class="nump">168.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">61.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs and expenses</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 28.6<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436818632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in pension liability</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustment, net of tax</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (50.2)<span></span>
</td>
<td class="num">$ (30.0)<span></span>
</td>
<td class="num">$ (199.4)<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438258376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings (accumulated deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2018</a></td>
<td class="nump">$ 966.1<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 915.4<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="nump">$ 54.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">1,088.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,068.0<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(199.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(199.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary', window );">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">918.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,096.6<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(173.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(53.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">881.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,109.5<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(227.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(27.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 967.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1,226.3<span></span>
</td>
<td class="num">$ (5.1)<span></span>
</td>
<td class="num">$ (254.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432321192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (28.9)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (223.6)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Non-cash impact of foreign currency transactions</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Loss on inventory</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill and long-lived assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of businesses and assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment of contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(21.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="num">(18.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="num">(108.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="num">(25.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(73.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(278.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale of business and assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable investment securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60.8)<span></span>
</td>
<td class="num">(78.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable investment securities</a></td>
<td class="nump">35.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
<td class="num">(286.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of tax withheld for common stock issued under stock-based compensation plans</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration recognized at acquisition</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">340.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Fees associated with refinancing of revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(115.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and retirement of common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">182.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(46.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.5<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">163.7<span></span>
</td>
<td class="nump">$ 93.2<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
<td class="nump">110.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="nump">$ 163.7<span></span>
</td>
<td class="nump">$ 93.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438617208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Financial Statement Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and subsidiaries (collectively, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties.&#160;The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.&#160;The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of the COVID-19 outbreak continues to evolve and its future impacts remain uncertain and unpredictable. The Omicron variant, which has become the most common form of the virus circulating throughout the world and appears to be more transmissible than other variants to date, is causing significant uncertainty. The impact of the Omicron variant and other variants that may emerge cannot be predicted at this time and could depend on numerous factors, including, but not limited to, vaccination rates among the population, the effectiveness of COVID-19 vaccinations against emerging variants, and any new measures that may be introduced by governments or other parties in response to an increase in COVID-19 cases. Management is actively monitoring the impact of the global situation on the Company&#8217;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17%, 16%, 15% and 14% of total revenue for the year ended December 31, 2021, the six-month transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No customer accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Investment Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#8217;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#8217;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December&#160;31, 2020 or during the years ended June 30, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#8217;s assessment of current and expected orders from the Company&#8217;s customers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f">five</span> to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b">one</span> to seven years. Repairs and maintenance costs are charged to expense as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company&#8217;s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $6.7 million and $2.3 million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $0.2 million. There was no capitalized software amortization expense for the remaining periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">466.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">789.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">805.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $29.7&#160;million in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of Company&#8217;s performance to date. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of  $6.8 million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(0.05). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation &#8211; Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company estimates the likelihood of achievement of the performance conditions at the end of each period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December&#160;31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $162.0 million and $1.0&#160;million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $14.6 million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#8217;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute <br/>&#160;&#160;&#160;&#160;basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive <br/>&#160;&#160;&#160;securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438558408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Investment Securities</a></td>
<td class="text">MARKETABLE INVESTMENT SECURITIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2021 and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no debt securities classified as available-for-sale in a gross unrealized loss position as of December&#160;31, 2021 or December&#160;31, 2020.</span></div>Additional information relating to fair value of marketable investment securities can be found in Note 3.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451442581320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately 13.5 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Consolidated Balance Sheets.&#160;Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities that are re-measured on a regular basis:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Period Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in the statement of operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments recognized in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436081224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT, NET<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $3.1 million of property, plant and equipment. See Note 16 for additional information regarding these divestitures. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438472840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did not record an impairment of goodwill for the year ended December 31, 2021, the transition period ended December 31, 2020 or for the fiscal year ended June 30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $80.7&#160;million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended June 30, 2020, the Company also recognized a $1.3 million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as a non-amortizable intangible asset of in-process research and development.&#160;Due to the completion of the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, the Company's intangible assets as of December 31, 2021 consist of only purchased licenses and technologies.&#160;In connection with these sales, the Company sold $199.1 million in purchased licenses and technologies, $4.8 million in-process research and development intangible assets, $4.7 million in customer relationships, and $3.0 million in trademarks, resulting in an aggregate decrease of intangible assets of $120.0 million, net of $91.6 million in accumulated amortization. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s purchased licenses and technologies have estimated remaining useful lives between 1 and 14 years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets.&#160;The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $17.7 million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was no impairment of long-lived assets for the year ended December&#160;31, 2021, the transition period ended December 31, 2020, or for the year ended June 30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 the weighted average remaining amortization period for purchased licenses and technologies is approximately 10 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization during the respective periods for these intangible assets as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438607736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">ACCRUED LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438531672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">LONG-TERM DEBT<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Amended Facility, which waived the Company&#8217;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (&#8220;Modification Period&#8221;). On February 22, 2021, the Company entered into Amendment No. 3 (the "Amended Facility"), which, among other things, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company's compliance with certain financial covenants through the quarter ended March 31, 2022, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0&#160;million as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company&#8217;s leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0&#160;million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0&#160;million, unless such borrowings are in connection with permitted acquisitions. The Company was in compliance with all applicable financial covenants at December&#160;31, 2021. </span></div>During the year ended December 31, 2021, the Company made principal repayments totaling $226.4 million on the Amended Facility, including a voluntary principal payment on July 30, 2021 of $106.4&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of December 31, 2021. As of December 31, 2020, the Company had a long-term debt balance of $224.8 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438471752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Long-Term Liabilities</a></td>
<td class="text">OTHER LONG-TERM LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The Company&#8217;s balance of other long-term liabilities as of December&#160;31, 2021 consists primarily of the long-term portion of contingent consideration related to the Sividon acquisition. During the prior periods the Company's portion of social security taxes that had been deferred under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") that do not have to be deposited until December 2022 were also recorded as other long-term liabilities. As of December 31, 2021 that balance has been reclassified to a current liability as it will be deposited within the next year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438476408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Preferred and Common Stockholders' Equity</a></td>
<td class="text">PREFERRED AND COMMON STOCKHOLDERS' EQUITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share.&#160;There were no preferred shares outstanding at December&#160;31, 2021 and December&#160;31, 2020. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 80.0&#160;million and 75.4&#160;million shares issued and outstanding at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options and employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending common stock issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#8217;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company&#8217;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of December&#160;31, 2021, the Company has $110.7 million remaining on its current share repurchase authorization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the par value method of accounting for its stock repurchases.&#160;&#160;As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to Retained earnings (accumulated deficit).&#160;&#160;During the year ended June 30, 2019, the Company used $50.0 million to repurchase shares of the Company&#8217;s common stock as part of an accelerated share repurchase. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December&#160;31, 2021, December&#160;31, 2020, June&#160;30, 2020, and June&#160;30, 2019 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased and retired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in-capital reductions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges to retained earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438484216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATIONOn November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2017 Plan&#8221;).&#160;&#160;The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors.&#160;Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant under the 2017 Plan. The 2017 Plan allows for issuance of up to 4.6 million shares of common stock, with 3.6 million shares available for grant as of December 31, 2021.&#160;&#160;If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they will also be available for issuance pursuant to the 2017 Plan. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which the anniversary occurs. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to our non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options generally vest ratably over service periods of four years. Options granted generally expire ten years from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of RSUs awarded to certain executive officers and other senior positions that ultimately vest may be increased or reduced based on certain additional performance and market conditions. The performance and market conditions associated with awards granted during the year ended December 31, 2021 include vesting that is based 50% on achieving certain levels of earnings per share targets, and 50% based on achieving certain performance targets compared to the performance of the Nasdaq Health Care Index. The Company estimates the likelihood of achievement of performance conditions at the end of each period. During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.08</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted during the years ended December&#160;31, 2021, June&#160;30, 2020, and June 30, 2019. During the transition period ended December&#160;31, 2020, 0.7&#160;million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $13.38.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding at December&#160;31, 2021 (number of shares in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number outstanding at December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.38</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$23.98</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$27.07 - 36.55</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of restricted stock units granted during the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June&#160;30, 2020, and June&#160;30, 2019 was $29.83, $13.69, $27.96 and $46.62, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock units that vested during the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June&#160;30, 2020, and June&#160;30, 2019 was $22.6 million, $29.1 million, $32.4 million and $27.6 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $61.7 million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of 2.3 years. We expect all unvested awards to vest, and we recognize forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options fully vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#8220;2012 Purchase Plan&#8221;), under which 2.0 million shares of common stock have been authorized. On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At December&#160;31, 2021, a total of approximately 2.0 million shares of common stock had been purchased under the 2012 Purchase Plan. Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black&#8209;Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438471752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at the statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6,422.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11,880.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13,486.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock option and employee stock purchase plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9,954.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2,568.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(642.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4,174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1,926.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, Dispositions, and Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2,568.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method changes or tax elections</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2,890.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">963.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-14,107.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities were comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act in 2020 made various tax law changes, including among other things (i) increased the limitation under IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest, (ii) enacted technical corrections so that qualified improvement property can be immediately expensed under IRC Section 168(k) and net operating losses arising in fiscal tax years beginning before January 1, 2018 and ending after December 31, 2017 can be carried back two years and carried forward twenty years without a taxable income limitation as opposed to carried forward indefinitely, and (iii) made modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years. As a result of the provision provided under the CARES Act, the Company was able to carry-back federal net operating losses to previous periods, resulting in a $20.7&#160;million tax benefit in the year ended December 31, 2020 and $2.7 million tax expense in the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized the sale of Myriad RBM, Inc., Myriad myPath, LLC, and select assets of Crescendo Biosciences, LLC (formerly known as Crescendo Biosciences, Inc. ("CBI") in the year ended December 31, 2021, which resulted in differences between book and tax treatments. This resulted in the recognition of a $187.0 million capital loss for the tax basis in the stock of Crescendo, which the Company utilized in the current year due to the $282.3&#160;million overall capital gain from the three divestitures. Other consequences due to the dispositions were the removal of deferred tax assets and corresponding valuation allowances. The overall net tax benefit of the divestitures during the year ended December 31, 2021 was $23.4&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the economic impact of COVID-19, the Company has incurred a cumulative three-year loss. Pursuant to ASC Topic 740, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by I.R.C. Section 382 and certain jurisdictional limitations. For the year ended December 31, 2021, the Company's valuation allowance decreased by $3.5&#160;million, primarily due to the expiration of Utah research credits upon which a valuation allowance had been established. The Company will continue to evaluate the impact that the COVID-19 pandemic may have on its results of operations and its ability to realize its deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to<br/>sections 382, 383</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expires<br/>beginning in year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal capital loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California net operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other state net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating losses (various jurisdictions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah research credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consistent with the indefinite reversal criteria of ASC 740, the Company intends to continue to invest undistributed earnings of its foreign subsidiaries indefinitely. However, due to the cumulative losses that have been incurred to date in such foreign operations, the changes of the Tax Cuts and Jobs Act and the aforementioned election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company&#8217;s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December&#160;31, 2021, the Company had net unrecognized tax benefits of $32.1 million. The Company&#8217;s gross unrecognized tax benefits as of the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - statute lapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and penalties in year-end balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions are included as a component of income tax expense and all other interest and penalties are included as a component of other income (expense).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017-2018; the State of New Jersey for the years ended June 30, 2013-2017; and Switzerland for the years ended June 30, 2015-2016.&#160;&#160;Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440427896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonable estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, our wholly-owned subsidiary, CBI, received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.&#160;&#160;On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. We have accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend against this case, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah, against the Company, our former President and Chief Executive Officer, Mark C. Capone, and our Chief Financial Officer, R. Bryan Riggsbee (&#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added our former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. We intend to vigorously defend against this action.&#160;Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against our former President and Chief Executive Officer, Mark C. Capone, our Chief Financial Officer, R. Bryan Riggsbee, our former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of our current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding our business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, a third stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock and Marcey stockholder derivative actions. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claimed negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004. The plaintiffs sought damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. As of December 31, 2021, we accrued $14.0&#160;million for a potential settlement of this lawsuit, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet as of December 31, 2021. On January 24, 2022, the Company entered into an agreement with the plaintiffs to settle the lawsuit. Pursuant to the terms of the settlement agreement, the Company agreed to pay $14.0&#160;million to the plaintiffs. The settlement agreement also provides for a full release by the plaintiffs of all claims against the Company and contains no admission of liability, wrongdoing or responsibility on the part of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company&#8217;s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440427896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASESThe Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4MA_466cec83-963f-4b74-b010-f7a16d9ef195">one</span> to fourteen years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options which allows the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These optional periods have not been considered in the determination of the right-of-use-assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the year ended December 31, 2021, the six-month transition period ended December 31, 2020 and the year ended June 30, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. As part of the adoption, the Company elected the package of practical expedients to avoid reassessing prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing right-of-use assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets. We recognize each new lease within right-of-use assets and lease liabilities once the lease commences.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2021, the Company incurred $20.7 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2&#160;million was variable lease expense, which was not included in the measurement of the Company's operating right-of-use assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the transition period ended December 31, 2020, the Company incurred $9.9&#160;million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $1.8 million was variable lease expense and $0.1 million was short-term lease expense, neither of which were included in the measurement of the Company's operating right-of-use assets and lease liabilities.  For the year ended June 30, 2020, the Company incurred $18.4 million in lease costs, of which $2.6&#160;million was variable lease expense and $0.2 million was short-term lease expense. Prior to the adoption of the lease guidance in ASU 2016-02, the Company's total rent expense for the year ended June 30, 2019 was $19.7 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into a non-cancelable operating lease for approximately 63,000 square feet in South San Francisco, California, which will expire in 2033. The lease will commence in April 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: leases not yet commenced</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted average remaining lease term is 8.7 years and the weighted average discount rate used to determine the operating lease liability was 5.10%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company&#8217;s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438456696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Deferred Savings Plan</a></td>
<td class="text">EMPLOYEE DEFERRED SAVINGS PLAN<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a deferred savings plan which qualifies under Section&#160;401(k) of the Internal Revenue Code. Substantially all of the Company&#8217;s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee&#8217;s contribution with the employer&#8217;s contribution not to exceed 4% of the employee&#8217;s compensation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s recorded contributions to the plan are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred savings plan contributions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440429288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Related Information</a></td>
<td class="text">SEGMENT AND RELATED INFORMATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company&#8217;s previously reported other segment. The Company&#8217;s remaining operating segments have been aggregated into a single reporting segment, which primarily provides testing and collaborative development of testing that is designed to assess an individual&#8217;s risk for developing disease later in life, identify a patient&#8217;s likelihood of responding to drug therapy and guide a patient&#8217;s dosing to ensure optimal treatment, or assess a patient&#8217;s risk of disease progression, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles assets by geographical region to total assets:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net equipment, leasehold improvements and property:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable investment <br/>&#160;&#160;&#160;&#160;&#160;securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438476408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text">DIVESTITURES<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5&#160;million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2&#160;million, net of transaction costs of $1.3&#160;million, in Other income (expense) on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $197.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0&#160;million, net of transaction costs of $4.8&#160;million, in Other income (expense) on the Company's Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6&#160;million, net of transaction costs of $4.4&#160;million, in Other income (expense) on the Company's Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $5.2&#160;million and $6.5&#160;million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Company's Consolidated Statements of Operations for the year ended December, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income for the year ended December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Myriad RBM, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of the Myriad myPath, LLC laboratory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Income</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438949064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Acquisitions</a></td>
<td class="text">BUSINESS ACQUISITIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counsyl</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2018, the Company completed the acquisition of Counsyl, Inc. (&#8220;Counsyl&#8221;), a leading provider of genetic testing and DNA analysis services, pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated May 25, 2018 for total consideration of $405.9 million.&#160;&#160;Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a newly created wholly-owned subsidiary of the Company, was merged with and into Counsyl, with Counsyl continuing as the surviving corporation and a wholly-owned subsidiary of Myriad.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complete the purchase transaction, the Company incurred approximately $6.8 million of acquisition costs, which are recorded as selling, general and administrative expenses in the period incurred. For the year ended June 30, 2019, Counsyl contributed revenue of approximately $104.9 million.&#160;For the year ended June 30, 2019, operating expenses related to Counsyl were approximately $67.6 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440423720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">SUBSEQUENT EVENTIn the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately 230,000 square feet in Salt Lake City, Utah, which will commence in 2022, with a lease term of 15 years and total future lease payments of approximately $77.8&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440419544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW INFORMATION<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438447784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transition Period Comparative Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TransitionPeriodComparativeDataTextBlock', window );">Transition Period Comparative Data (Unaudited)</a></td>
<td class="text">TRANSITION PERIOD COMPARATIVE DATA (UNAUDITED)<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month <br/>Period Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statement of Operations Data:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Myriad Genetics Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_TransitionPeriodComparativeDataTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Period Comparative Data</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_TransitionPeriodComparativeDataTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431211688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Financial Statement Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Financial Statement Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and subsidiaries (collectively, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties.&#160;The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.&#160;The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.  </span></div>The accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17%, 16%, 15% and 14% of total revenue for the year ended December 31, 2021, the six-month transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No customer accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2021 or December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Investment Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Investment Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#8217;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#8217;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December&#160;31, 2020 or during the years ended June 30, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#8217;s assessment of current and expected orders from the Company&#8217;s customers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f">five</span> to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b">one</span> to seven years. Repairs and maintenance costs are charged to expense as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company&#8217;s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $6.7 million and $2.3 million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $0.2 million. There was no capitalized software amortization expense for the remaining periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">466.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">789.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">805.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $29.7&#160;million in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of Company&#8217;s performance to date. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of  $6.8 million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(0.05). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Payment Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation &#8211; Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company estimates the likelihood of achievement of the performance conditions at the end of each period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OtherIncomeExpensePolicyPolicyTextBlock', window );">Other Income (Expense)</a></td>
<td class="text">Other Income (Expense)The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December&#160;31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $162.0 million and $1.0&#160;million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $14.6 million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#8217;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute <br/>&#160;&#160;&#160;&#160;basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive <br/>&#160;&#160;&#160;securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately 13.5 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Consolidated Balance Sheets.&#160;Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OtherIncomeExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other income policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OtherIncomeExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435689592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue by Type</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographical Region</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">466.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">789.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">805.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Reconciliation of Deferred Revenue Balances</a></td>
<td class="text">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute <br/>&#160;&#160;&#160;&#160;basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive <br/>&#160;&#160;&#160;securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Common Shares</a></td>
<td class="text">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451443556552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2021 and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432246696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities that are re-measured on a regular basis:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Period Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in the statement of operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments recognized in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451518746584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438675192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Amortizable Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Non-amortizable Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased licenses and technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Recorded Amortization for Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization during the respective periods for these intangible assets as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438643656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438494024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Summary of Other Long-Term Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435928936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Summary of Common Shares Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options and employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending common stock issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock', window );">Schedule of Stock Repurchases</a></td>
<td class="text">The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December&#160;31, 2021, December&#160;31, 2020, June&#160;30, 2020, and June&#160;30, 2019 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased and retired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in-capital reductions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges to retained earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock repurchased table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431138696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.08</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of Stock Options Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding at December&#160;31, 2021 (number of shares in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number outstanding at December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.38</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$23.98</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$27.07 - 36.55</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock', window );">Schedule of Aggregate Intrinsic Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options fully vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Schedule of Intrinsic Value of Options Exercised</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Shares Purchased and Compensation Expenses for ESPP</a></td>
<td class="text">Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for ESPP</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black&#8209;Scholes option-pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431134344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Benefit</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at the statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6,422.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11,880.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13,486.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock option and employee stock purchase plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9,954.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2,568.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(642.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4,174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1,926.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, Dispositions, and Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2,568.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method changes or tax elections</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2,890.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">963.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-14,107.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities were comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to<br/>sections 382, 383</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expires<br/>beginning in year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal capital loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California net operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other state net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating losses (various jurisdictions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah research credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">The Company&#8217;s gross unrecognized tax benefits as of the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows:&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - statute lapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and penalties in year-end balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438955944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: leases not yet commenced</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438435000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Schedule of Contributions to the Plan</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s recorded contributions to the plan are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred savings plan contributions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438491576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Assets by Geographical Region</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles assets by geographical region to total assets:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net equipment, leasehold improvements and property:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable investment <br/>&#160;&#160;&#160;&#160;&#160;securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451443553656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Amounts Recognized in Other Income</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income for the year ended December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Myriad RBM, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of the Myriad myPath, LLC laboratory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Income</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438465160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438646248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transition Period Comparative Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock', window );">Schedule of Transition Period Comparative Data</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month <br/>Period Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statement of Operations Data:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular diagnostic testing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Myriad Genetics Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Transition Period Comparative Data</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432075832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Unamortized software costs</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense for capitalized software</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_CARESActOf2020MedicarePaymentAmount', window );">Advance Medicare payments to provide relief from economic impacts of COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained', window );">Revenue recognized due to expanded local coverage determination for which revenue was previously constrained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued liability for Medicare refund</a></td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">299,800,000<span></span>
</td>
<td class="nump">$ 381,400,000<span></span>
</td>
<td class="nump">690,600,000<span></span>
</td>
<td class="nump">$ 557,100,000<span></span>
</td>
<td class="nump">638,600,000<span></span>
</td>
<td class="nump">851,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized costs incurred to obtain or fulfill contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Net gain on divestiture</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_CARESActOf2020ProviderReliefFundAmount', window );">Provider fund relief under CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Immaterial prior period Medicare claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInEarningsLossPerShare', window );">Change in earnings (loss) per share (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued liability for Medicare refund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember', window );">Performance obligation estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInEarningsLossPerShare', window );">Change in earnings (loss) per share (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember', window );">Government contracts concentration risk | Medicare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_CARESActOf2020MedicarePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act of 2020 medicare payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_CARESActOf2020MedicarePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_CARESActOf2020ProviderReliefFundAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act of 2020 Provider Relief Fund amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_CARESActOf2020ProviderReliefFundAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in earnings (loss) per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mygn_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mygn_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431966744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Revenue by Type (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 381.4<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 557.1<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
<td class="nump">$ 851.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">279.6<span></span>
</td>
<td class="nump">353.1<span></span>
</td>
<td class="nump">666.4<span></span>
</td>
<td class="nump">513.5<span></span>
</td>
<td class="nump">586.9<span></span>
</td>
<td class="nump">789.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">159.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347.4<span></span>
</td>
<td class="nump">479.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
<td class="nump">104.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular diagnostic - Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular diagnostic - Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="nump">$ 43.6<span></span>
</td>
<td class="nump">$ 51.7<span></span>
</td>
<td class="nump">$ 61.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451430597032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 381.4<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 557.1<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
<td class="nump">$ 851.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">279.6<span></span>
</td>
<td class="nump">353.1<span></span>
</td>
<td class="nump">666.4<span></span>
</td>
<td class="nump">513.5<span></span>
</td>
<td class="nump">586.9<span></span>
</td>
<td class="nump">789.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">159.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347.4<span></span>
</td>
<td class="nump">479.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
<td class="nump">104.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular diagnostic - Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular diagnostic - Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">$ 43.6<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">61.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">275.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596.2<span></span>
</td>
<td class="nump">805.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">255.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559.8<span></span>
</td>
<td class="nump">767.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic - Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">140.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.8<span></span>
</td>
<td class="nump">466.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic - Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic - Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.4<span></span>
</td>
<td class="nump">104.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic - Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic - Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Molecular diagnostic - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic - Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic - Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic - Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic - Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic - Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Molecular diagnostic - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="nump">$ 23.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451430547096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Reconciliation of Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - beginning balance</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(40.5)<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityPrepayments', window );">Prepayments</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityDivestitures', window );">Divestitures</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - ending balance</a></td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Divestitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability, prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440311160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic EPS</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive stock options</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive options and RSUs excluded from EPS computation</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451437390632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward', window );"><strong>Cumulative Translation Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Beginning balance</a></td>
<td class="num">$ (3.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease', window );">Period translation adjustments</a></td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Ending balance</a></td>
<td class="num">$ (4.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeTranslationAdjustmentSummaryRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436546312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">$ 258.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">258.4<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCashAbstract', window );"><strong>Total:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Total, Amortized cost</a></td>
<td class="nump">398.9<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax', window );">Total, Gross unrealized holding gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax', window );">Total, Gross unrealized holding gains</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">398.8<span></span>
</td>
<td class="nump">171.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">195.2<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">195.2<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">105.7<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">11.9<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432453784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 258.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Total, Amortized cost</a></td>
<td class="nump">398.9<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">258.4<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">80.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">398.8<span></span>
</td>
<td class="nump">171.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">195.2<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">195.2<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 63.2<span></span>
</td>
<td class="nump">$ 69.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440554648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Narrative (Details) - security<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt securities, available-for-sale, in unrealized loss position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438221464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Measurement input, expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm', window );">Measurement period for earn out liability</a></td>
<td class="text">13 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451437277560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 195.0<span></span>
</td>
<td class="nump">$ 112.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11.9<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">140.4<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11.9<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">$ (8.6)<span></span>
</td>
<td class="num">$ (10.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432148296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of change in fair value of contingent consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment of contingent consideration</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in the statement of operations</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Translation adjustments recognized in other comprehensive income (loss)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435748616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 150.4<span></span>
</td>
<td class="nump">$ 153.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(106.9)<span></span>
</td>
<td class="num">(112.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">38.0<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 112.4<span></span>
</td>
<td class="nump">$ 117.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438525304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember', window );">Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment sold and deconsolidated</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438156808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Depreciation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451442586504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 329.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(88.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustments</a></td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Carrying amount at end of period</a></td>
<td class="nump">$ 239.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431052872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent', window );">Net decrease in intangible assets due to sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent', window );">Accumulated amortization on intangible assets included in sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,600,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember', window );">In-process research and development | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=mygn_MyriadAutoimmuneReportingUnitMember', window );">Myriad Autoimmune reporting unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=mygn_ClinicReportingUnitMember', window );">Clinic reporting unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accumulated amortization of intangible assets attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, net of accumulated amortization, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=mygn_MyriadAutoimmuneReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=mygn_MyriadAutoimmuneReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=mygn_ClinicReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=mygn_ClinicReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432392200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (212.5)<span></span>
</td>
<td class="num">(254.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total, net, amortizable</a></td>
<td class="nump">404.1<span></span>
</td>
<td class="nump">571.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Non-amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount, total</a></td>
<td class="nump">616.6<span></span>
</td>
<td class="nump">830.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net, total</a></td>
<td class="nump">404.1<span></span>
</td>
<td class="nump">576.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="nump">616.6<span></span>
</td>
<td class="nump">818.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(212.5)<span></span>
</td>
<td class="num">(248.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total, net, amortizable</a></td>
<td class="nump">$ 404.1<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total, net, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total, net, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Non-amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451442797240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="nump">$ 50.7<span></span>
</td>
<td class="nump">$ 61.0<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451437402072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total, net, amortizable</a></td>
<td class="nump">$ 404.1<span></span>
</td>
<td class="nump">$ 571.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431018648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 52.8<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal charges pending settlement</a></td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes payable</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_RefundsPayableAndReserveCurrent', window );">Refunds payable and reserves</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short-term contingent consideration</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 156.5<span></span>
</td>
<td class="nump">$ 79.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_RefundsPayableAndReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refunds Payable And Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_RefundsPayableAndReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436685064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Dec. 23, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtCovenantLiquidityCovenantMinimum', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum', window );">Minimum unrestricted cash and cash equivalents threshold per covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtInstrumentLIBORFloorPercentage', window );">LIBOR floor (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantLiquidityCovenantMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Liquidity Covenant Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantLiquidityCovenantMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtInstrumentLIBORFloorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, LIBOR Floor, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtInstrumentLIBORFloorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440491384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435770424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">75,400,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">74,700,000<span></span>
</td>
<td class="nump">73,500,000<span></span>
</td>
<td class="nump">70,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">75,400,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">74,700,000<span></span>
</td>
<td class="nump">73,500,000<span></span>
</td>
<td class="nump">70,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of Company stock</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438239816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common shares issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning common stock issued</a></td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning common stock outstanding</a></td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans', window );">Common stock issued upon exercise of options and employee stock plans</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending common stock issued</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending common stock outstanding</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451437399640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Stock Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares purchased and retired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases', window );">Common stock and additional paid-in-capital reductions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases', window );">Charges to retained earnings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 33.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to retained earnings as a result of stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction in common stock as a result of stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431833432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 05, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember', window );">2012 Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares available for future grant</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per participant per offering period</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember', window );">Options and RSUs | Non-employee director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.69<span></span>
</td>
<td class="nump">$ 29.83<span></span>
</td>
<td class="nump">$ 27.96<span></span>
</td>
<td class="nump">$ 46.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units that vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Certain executive officers and other senior positions | Achievement levels based on EPS targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Certain executive officers and other senior positions | Performance based on Nasdaq Healthcare Provider Index</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mygn_ExecutiveOfficersAndSeniorPositionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mygn_ExecutiveOfficersAndSeniorPositionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431763336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning (shares)</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (shares)</a></td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired (shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending (shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (shares)</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning (dollars per share)</a></td>
<td class="nump">$ 23.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (dollars per share)</a></td>
<td class="nump">24.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired (dollars per share)</a></td>
<td class="nump">25.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending (dollars per share)</a></td>
<td class="nump">20.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (dollars per share)</a></td>
<td class="nump">23.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (dollars per share)</a></td>
<td class="nump">$ 20.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options, Weighted average remaining contractual life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435445064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options Outstanding (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 20.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeOneMember', window );">$ 13.38</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, minimum (in dollars per share)</a></td>
<td class="nump">$ 13.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 13.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeTwoMember', window );">$ 23.98</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, minimum (in dollars per share)</a></td>
<td class="nump">$ 23.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 23.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeThreeMember', window );">$ 27.07 - 36.55</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, minimum (in dollars per share)</a></td>
<td class="nump">27.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, maximum (in dollars per share)</a></td>
<td class="nump">$ 36.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares) | shares</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 27.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mygn_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436483208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - RSUs - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs, Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs unvested and outstanding, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs canceled (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs unvested and outstanding, ending (shares)</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>RSUs, Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs unvested and outstanding, beginning (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (dollars per share)</a></td>
<td class="nump">$ 13.69<span></span>
</td>
<td class="nump">29.83<span></span>
</td>
<td class="nump">$ 27.96<span></span>
</td>
<td class="nump">$ 46.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs canceled (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs unvested and outstanding, ending (dollars per share)</a></td>
<td class="nump">$ 20.56<span></span>
</td>
<td class="nump">$ 24.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436487768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 36.3<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember', window );">Cost of molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember', window );">Cost of pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="nump">$ 27.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435484584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Aggregate Intrinsic Value (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options fully vested</a></td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of RSUs outstanding</a></td>
<td class="nump">$ 86.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438685768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Intrinsic Value of Options Exercised (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436857832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details) - 2012 Purchase Plan - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased under the plans</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Plan compensation expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440237016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions for ESPP (Details) - 2012 Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451437295064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Benefit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (75.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.6<span></span>
</td>
<td class="num">$ (24.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(76.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="num">(24.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51.5)<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="num">$ (41.0)<span></span>
</td>
<td class="num">$ (4.8)<span></span>
</td>
<td class="num">$ (29.9)<span></span>
</td>
<td class="num">$ (59.9)<span></span>
</td>
<td class="num">$ (23.7)<span></span>
</td>
<td class="num">$ (4.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432004440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (101.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (240.9)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax</a></td>
<td class="num">$ (94.1)<span></span>
</td>
<td class="num">$ (33.7)<span></span>
</td>
<td class="num">$ (57.1)<span></span>
</td>
<td class="num">$ (283.6)<span></span>
</td>
<td class="num">$ (223.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431097336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at the statutory rate</a></td>
<td class="num">$ (19.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Incentive stock option and employee stock purchase plan expense</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationCARESAct', window );">CARES Act</a></td>
<td class="num">(20.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Non-deductible meals and entertainment</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation', window );">Non-deductible officer compensation</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationAssetImpairment', window );">Asset impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement', window );">Non-deductible legal settlement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration', window );">Acquisitions, Dispositions, and Contingent Consideration</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod', window );">Method changes or tax elections</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="num">$ (41.0)<span></span>
</td>
<td class="num">$ (4.8)<span></span>
</td>
<td class="num">$ (29.9)<span></span>
</td>
<td class="num">$ (59.9)<span></span>
</td>
<td class="num">$ (23.7)<span></span>
</td>
<td class="num">$ (4.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at the statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">6422.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(11880.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(13486.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Incentive stock option and employee stock purchase plan expense</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(9954.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">2568.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(642.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationCARESAct', window );">CARES Act</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Non-deductible meals and entertainment</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">4174.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation', window );">Non-deductible officer compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">1926.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment', window );">Asset impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements', window );">Non-deductible legal settlement</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6101.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration', window );">Acquisitions, Dispositions, and Contingent Consideration</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">2568.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod', window );">Method changes or tax elections</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2890.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">963.40%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax benefit</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="num">(14107.70%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation asset impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, changes in revenue recognition/method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non deductible legal settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non-deductible officer compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation asset impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation changes in revenue recognition method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation non-deductible legal settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense officers compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451437331224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 67.2<span></span>
</td>
<td class="nump">$ 72.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation expense</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DeferredTaxAssetsLeaseRightOfUseAsset', window );">Lease right-of-use asset</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and liabilities</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">131.3<span></span>
</td>
<td class="nump">145.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(38.5)<span></span>
</td>
<td class="num">(42.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">92.8<span></span>
</td>
<td class="nump">103.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">104.9<span></span>
</td>
<td class="nump">144.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DeferredTaxLeaseLiability', window );">Lease liability</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">128.6<span></span>
</td>
<td class="nump">174.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (35.8)<span></span>
</td>
<td class="num">$ (71.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DeferredTaxAssetsLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DeferredTaxAssetsLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DeferredTaxLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DeferredTaxLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432094072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>divestiture</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct', window );">Tax expense (benefit) related to operating loss carryback, CARES Act</a></td>
<td class="num">$ (2.7)<span></span>
</td>
<td class="num">$ (20.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupCapitalLossOnTaxBasis', window );">Capital loss for the tax basis on stock</a></td>
<td class="nump">187.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupCapitalGainOnDivestiture', window );">Overall capital gain on divestitures</a></td>
<td class="nump">$ 282.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_NumberOfDivestitures', window );">Number of divestitures | divestiture</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture', window );">Overall net tax benefit of divestitures</a></td>
<td class="nump">$ 23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod', window );">Decrease in valuation allowance</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="nump">$ 37.6<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdictions | California | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdictions | California | Latest tax years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdictions | New Jersey | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdictions | New Jersey | Latest tax years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Switzerland | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Switzerland | Latest tax years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupCapitalGainOnDivestiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Capital Gain On Divestiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupCapitalGainOnDivestiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupCapitalLossOnTaxBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Capital Loss On Tax Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupCapitalLossOnTaxBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Net Tax Expense (Benefit) On Divestiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Operating Loss Carryback, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_NumberOfDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Divestitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_NumberOfDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Increase (Decrease) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451432348328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 31.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Capital loss</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 13.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Capital loss | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Capital loss | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Research credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Research credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Research credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Research credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_TaxCreditCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforwards Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_TaxCreditCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=stpr_UT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=stpr_UT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=mygn_OtherStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=mygn_OtherStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435450024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at the beginning of period</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 37.6<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases - current year tax positions</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases - prior year tax positions</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Gross increases - acquisitions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases - prior year tax positions</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Gross decreases - settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Gross decreases - statute lapse</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at end of year</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties in year-end balance</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431148744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal charges pending settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mygn_CrescendoBioscienceIncMember', window );">CBI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal charges pending settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mygn_AbelliAndPricoloMatterMember', window );">Abelli and Pricolo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal charges pending settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mygn_AbelliAndPricoloMatterMember', window );">Abelli and Pricolo | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement agreement</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mygn_CrescendoBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mygn_CrescendoBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mygn_AbelliAndPricoloMatterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mygn_AbelliAndPricoloMatterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431072648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense (prior to adoption of ASU 2016-02)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease weighted average discount rate</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LeaseArrangementAxis=mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LesseeOperatingLeaseAreaOfLeasedSpace', window );">Operating lease area (sq ft) | ft&#178;</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LesseeOperatingLeaseAreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Leased Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LesseeOperatingLeaseAreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LeaseArrangementAxis=mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LeaseArrangementAxis=mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440382696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">88.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">179.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amounts representing interest</a></td>
<td class="num">(27.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced', window );">Present value of future lease payments</a></td>
<td class="nump">151.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced', window );">Less: leases not yet commenced</a></td>
<td class="num">(58.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities of operating lease liabilities</a></td>
<td class="num">(13.0)<span></span>
</td>
<td class="num">$ (13.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">$ 79.3<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Including Leases Not Yet Commenced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Leases Not Yet Commenced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438485816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company matching contribution as percentage of employee contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Company matching contribution, maximum as percentage of employee compensation</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451435380680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan - Contributions to Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Deferred savings plan contributions</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451438537912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451430939720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment and Related Information - Assets by Geographical Region (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net equipment, leasehold improvements and property</a></td>
<td class="nump">$ 43.5<span></span>
</td>
<td class="nump">$ 40.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable investment securities</a></td>
<td class="nump">398.8<span></span>
</td>
<td class="nump">171.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,320.7<span></span>
</td>
<td class="nump">1,418.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable geographical components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net equipment, leasehold improvements and property</a></td>
<td class="nump">43.6<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_AssetsLessCashCashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">921.9<span></span>
</td>
<td class="nump">1,247.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable geographical components | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net equipment, leasehold improvements and property</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_AssetsLessCashCashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">870.8<span></span>
</td>
<td class="nump">1,190.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable geographical components | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net equipment, leasehold improvements and property</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_AssetsLessCashCashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">$ 51.1<span></span>
</td>
<td class="nump">$ 56.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_AssetsLessCashCashEquivalentsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Less Cash, Cash Equivalents, And Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_AssetsLessCashCashEquivalentsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431980456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>May 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Loss on non-cancelable purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Loss on inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Myriad myPath LLC laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees', window );">Net gain on sale of assets adjusted for transaction fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Myriad RBM, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Select operating assets and intellectual property of Myriad Autoimmune business unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of business</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4578-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451431825560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures - Other Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.2)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="nump">$ 139.3<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory', window );">Loss on inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember', window );">Myriad RBM, Inc. | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember', window );">Myriad myPath LLC laboratory | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember', window );">Myriad Autoimmune assets | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationGainLossOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451442599336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions - Narrative (Details) - Counsyl Inc - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition consideration</a></td>
<td class="nump">$ 405.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition costs</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod', window );">Revenue contributed by acquired entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses related to acquired entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue reported by the acquired entity for its previous full fiscal year before the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_CounsylIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_CounsylIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451440266472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - Subsequent event - Salt Lake City<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 24, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LesseeOperatingLeaseAreaOfLeasedSpace', window );">Operating lease area (sq ft) | ft&#178;</a></td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments', window );">Total future lease payments | $</a></td>
<td class="nump">$ 77.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LesseeOperatingLeaseAreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Leased Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LesseeOperatingLeaseAreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Estimated Future Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LeaseArrangementAxis=mygn_SaltLakeCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LeaseArrangementAxis=mygn_SaltLakeCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451430517992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash received for income tax receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Establishment of operating lease right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityEstablished', window );">Operating lease liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(48.1)<span></span>
</td>
<td class="num">(78.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid', window );">Accrued liabilities and other long-term liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Related Expenditures Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LeaseRelatedExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Established</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451436778392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transition Period Comparative Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TransitionPeriodFinancialInformationLineItems', window );"><strong>Transition Period Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 381.4<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 557.1<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
<td class="nump">$ 851.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
<td class="nump">85.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">260.4<span></span>
</td>
<td class="nump">270.4<span></span>
</td>
<td class="nump">537.8<span></span>
</td>
<td class="nump">496.9<span></span>
</td>
<td class="nump">507.3<span></span>
</td>
<td class="nump">556.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">387.6<span></span>
</td>
<td class="nump">411.1<span></span>
</td>
<td class="nump">881.1<span></span>
</td>
<td class="nump">846.8<span></span>
</td>
<td class="nump">870.3<span></span>
</td>
<td class="nump">843.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(87.8)<span></span>
</td>
<td class="num">(29.7)<span></span>
</td>
<td class="num">(190.5)<span></span>
</td>
<td class="num">(289.7)<span></span>
</td>
<td class="num">(231.7)<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">139.3<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">133.4<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax</a></td>
<td class="num">(94.1)<span></span>
</td>
<td class="num">(33.7)<span></span>
</td>
<td class="num">(57.1)<span></span>
</td>
<td class="num">(283.6)<span></span>
</td>
<td class="num">(223.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(29.9)<span></span>
</td>
<td class="num">(59.9)<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(53.1)<span></span>
</td>
<td class="num">(28.9)<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="num">(223.7)<span></span>
</td>
<td class="num">(199.6)<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (28.9)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (223.6)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (2.99)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (2.99)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (weighted average shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (weighted average shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TransitionPeriodFinancialInformationLineItems', window );"><strong>Transition Period Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 279.6<span></span>
</td>
<td class="nump">$ 353.1<span></span>
</td>
<td class="nump">$ 666.4<span></span>
</td>
<td class="nump">$ 513.5<span></span>
</td>
<td class="nump">$ 586.9<span></span>
</td>
<td class="nump">$ 789.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs and expenses</a></td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
<td class="nump">157.9<span></span>
</td>
<td class="nump">157.5<span></span>
</td>
<td class="nump">168.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_TransitionPeriodFinancialInformationLineItems', window );"><strong>Transition Period Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">43.6<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">61.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs and expenses</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="nump">$ 28.6<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_TransitionPeriodFinancialInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Period Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_TransitionPeriodFinancialInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>mygn-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mygn="http://www.myriad.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mygn-20211231.xsd" xlink:type="simple"/>
    <context id="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i011796a61d54499b94960d86773ccedd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id7e46e716764498e9302a87cd85a5607_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="iaceaf21b23b24746aa59d14b069c4f07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb206a81fa074a46aa6939c9e5bcf636_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie3490fe6c43d44fcb68f2c3625bd038a_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ia5ca914745a941f2966e50ba77e955a7_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i16e7b1ebad7642a0add5c645bc552fee_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i18300b74b3df4d46b493a707d825fa4a_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ia567c09cf0824dc693153bb83c1fd300_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4b54a1e9583a4c6e990c5bbb9c0a73f8_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia1599623c9f04291a999dead8f1a5395_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i59def4575be14308a65eb8292ac6d700_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8d812645f92f414592b573945dc3f6b1_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i186bb32cbaf64bd6b7957d74964ad3b8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i00f04a427cbe430a863042cf46917020_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia83e7c3186b049569961b26ad3e07b35_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i04d0772a72c84c40ad62e094c4956f82_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i88c1ff8d939f49a5bc5fda3040bcf994_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i727bfef5fdaf4a68b74905d96ed0bd75_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if0952f21f7474270a815f3514f44ab52_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1c18b43bb290475583b6c04c962cc4f5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i67c1f04497634a03acfacae132470000_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3255cc95fb79446f82e34f0ba20d9dcb_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c16edcf998c4da5b8b0515c6fd6a34e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d9a7dea4d3a492eab5b13130045cf86_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49f010022d8844beba34499bcd02fcfa_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f56df5636b24717996902df4b351edb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b042f9bbfff4fd7b823711711b5022a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8e819d3e2be4e7589e9091e181dd161_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04ecb918ca8845c18dd2d6175330f6df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81acdb427fb040d1b79807f720522dcf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i406964000440469a8b2a3301d473abfa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4402fe2fdb042e993c87738c61d4381_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide1a7957d8ba47e8b3c57b590a8f1c6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5861584aeaf34ebd8b71efbbb80709c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5633da0a55ce4fbfbc6f2f94c0888afd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d7070eac7a949dcbb79b9e02a3aacf2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e0e54e9b3ce4a3a9110635bf28d65bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad15d513ac03478199e9e31a63c2e46d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i701057b14190407c804d2064afc26532_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1aa5bdf689894b6ab2ba9eb4389ee963_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i55202b0f51cd439d9b1c5849f46eaeca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic25baf947458498cbc5ec1d41a505594_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63f8cb8dfa0542e0b8ad06c716ac9a06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f0b6b5784d44e638df0d82d2332ca5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i804cc2b055a3466fbb3e15bd020c759d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58fd5561929d497eaf7992c43061cee2_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i484dc209f37b4adf909bfa0878315aac_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idfd1e4144cb64cc2be192b5f21702ee2_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i23674b92559340f5b730b6afcc5f3e1f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44258853a0d44e2b9701f666527520b1_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic14004bb5c3043ef94f2f37784092276_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i868860485c4b4abeb0e46251d83d47df_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia0c94826adb64c97800cb3e9f2f19447_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib56d8f8d202742b8adbccfc987f7d6aa_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if15aec7363f947d18a16d8514fa80f9a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ab9b81676e64707a024e71a8dadfab0_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i31f918798d8d4876955bdfe1781192bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0720541a493427c9ac9e47764246d06_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf2d8ee96d1842a89bf2eb52509f39c8_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i090f85aa323b4d5aa89a4ef95bbff252_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i83f3a2eee80d4e39b6b467a461ee1164_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79122a39eed648d294ae1358b2622bf2_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8608277b4c9f4d1d8452c383fd7509c3_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i150c0623a2d04f00b701fe362396760e_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i288dd68612f8451489b037c3444d9bf4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2397e1764fa64b159eaa4444a72537d4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9dddabbe8f644f90b6c63a2383f8793c_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i129a1c23ee0f4732a50e53e3e8927e0f_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0298c605b2cc48e9a78c5e3cd557802a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cca08c16e854e23a8787d0bc760adbc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3970c7875cbc464db2a7a85cb7ba05be_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b9608c73ed34af285fe6c4c9fb6f968_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4ef79d3516c4f77b9ffd69e6257d787_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7c78ab7c6f04b4cb49ccbc3b2572957_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ac2a8aac44f4c039ce9c9739247a018_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib74f7d15a9df4096b33799ed18b6d983_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic04f84748937427db317a660c8aa5694_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee8de44f5f1c410599b481b8c80dbffb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i445a32ad37ae4a4cbcbea691e2e68241_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52d75f83f7f84447a1524a301b921946_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibdaec0b909474eda8eee58534fbd0e9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04da1cbfee0c46dcbaec497c3feb4cb6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf55993a60224a2990dd01e9cff341d4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i706f35d8790f490f917a84f064c29039_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c6b105e8804486dad3802a06c5f3c30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e31518757a047b4b8acd5c9c6584b2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96a6d32ed385415289c8a82922c2e387_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1202a0ed3b3942fc98fdc69ccb249509_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5801c36efd234e02b91dbea98f7d3e00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95ef34040e2948f2abbaab8f194748d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73d2040b564247bfb340b997780ebec6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60635ff66fa64b69966774de4439af5e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33fb7f026e344cc98c08acf5ec62babe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05a23258ea8e458393c125d83313b4a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e1fa64c828d4462a20186e9d1460d97_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ba16b7c64ec499aa4e9285f47ed97e8_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55f89783405a449ba8e650af0370be7b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i903acccd51c14e7db28f40da3937c802_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d6524bb7e0441428b64b01d2565544d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d422ad60e04435ba4213ff4258db4ea_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf717ff001aa48f3898b6bad81b7074e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b308819639648ebb0241dce3fee0e0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f4ddb7736b546099130bd23f3e3bf81_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd6371c107dc4037900af9562f284dd2_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a25d7789ed04de38b87467b38c075c0_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0371d7615c143a1a2f93c9c51117fd2_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc48edd4cd4e4d54b269125a5eddbe4d_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3b993db4c69b427d8483546c0c8b8414_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0d121e6f796d42b5862758d3e57021f4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67b0e5857240418899f53180ceb70c6d_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iba2729ff5f4d4076a392c72d3aff48fc_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie40ae86ad5c541fcaf7e88efb9f20b4e_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i702d3c75cf5c4f2fb78e549b2d2e07b0_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i91e9d08b5b5b4218a39576afaba6ff6d_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie936759bad6c4f768bfdcaad6c185260_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia86ab20ba60c457c91783c694e76c402_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iab7934e0625841d3a44b1f9aecb81682_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0036422f15ae438fb80d6285f3b97550_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c2b20aa35ae4a3ea1712a93847ca7b2_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifb8491e37cb24bc3b4dc9fb8f3c5e60f_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2d596e3878504d22b86d326e8ca08613_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97117ebb3cae4051af1ac90be6bb19c0_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i102893003cb44b69875935664fcd4cfe_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8c4ca98d253f439984d89ffe162f4048_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib644def5081d44de96b13a4ec090e55d_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idaa7d7f8f59743e19ec25ad143e2a6f4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5819703f324d41349027f3813ef7b49b_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3bc1fef06d7444e6bd2ce7b0f247ad53_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i204cd1955cec41cf9852a26d4402e885_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i43e5e361d21d4734af2a1a30525f5d04_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib58b31ce77e7445aae0d209f9e0fbc19_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4e64446e4bae4f2ebd45cae070670f11_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6faa7a7476b140628d02a78558ca348b_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78b4f16f2653401187ed5044b51e074f_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i90c85822b51b4d35985a06435eee8bfa_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0903d5f700b14c0f82cced2c6973459a_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic3faafc5dbad46dba5234c91f2b7c8d2_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6ea93dfc8c9b4d418d726e1503143b00_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i433ffee4dc83441d8a68d42763e78e7d_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia021741aa8d343d79f2d259b408c46a0_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ief14d1a627f44e8aa55a13b03bf21cfd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2684048ee70b4d07beca518b514fbc45_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e458e0265a748528393f9775e33c560_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i75ba6d883e7547e7af3798c78f6badf4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15cb1bb25065402192f586c58c6ea68d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1095829af9974d7ab288fb2d7ac09c8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a3b6101149c43809996e3a4fa47cce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1643807ee3c4be2affc28b493b9971d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40284936a2134287b22a5d55f29d89c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb01a0871980449b8e481ac37f3f1f9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3445c0b98e214b96840337b96fa87ab1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74dc0fe0c62e4eea8fd54a19e76b42e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if50744aeaad04d8e898fb75a7a4cd403_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i377b3cbb17e643b7a874393768f6b99a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i247f388a3aa24cea9da562bc5232fa78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53c7a2cd0dae41d7a18fabc16b2d6351_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifacab91f64734e07850b1d1ccdcef519_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7d33dac4dba4cc4a2b1b2e4b46390a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieea675210e024b6c916b2862b628898c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32ea39f951fe43d7bd7edbf117b03d28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i649ff7da9f344b3594372e0db1334cf1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9950e80ecb934b8aad3038826649ece1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6caf215e4694c5297b327ebab5489f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4d609efbd994ab6a4717ae77454f9c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1ea51262455422b9b58287df633fdba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfc35c6df6dd437cba1f343922b27753_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b1173e0a575429c87230088f831bd1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d46cebc1ad34bfd93e108133ea4a5a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c2ac1ffa79241d7ae0a435a564bec54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6aef68764004a7ab2c3d1cafa4e6070_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22dbec5ca02d419cb74d488ed87eaf6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05ca8c5b9c4f42a7b049cd5568304428_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48a6e30e15d44c27a12c044d297fe0ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a1bafe663bf4dd2af911643d8115191_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i330057192ddd491eb64b21392abce0f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i155d082ec2ff4209a45f170e667ea25c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21a3f606f6ce45719deb8e96cd7ddf12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id34fd0ce23d9465eafda8ac8e370a4d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f303592870940ab8b8f59b374e18736_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7d9ee368f974e858e239cc4f7cc09d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1e01d25b7bf4a20a4ae7b3bc411229b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i068bcc7826fd40a29f15703667578d91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i295380b6567e4eb1b4eeb49fa5fe93d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie43572fc1976464398da328af82d7f20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e5a59ec1d4d4de1ba8ba076c80e3226_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c3c7d94999a4ee5a93ec6842932756b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95aadf27c0ee42a2b79894a26f7a6303_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b4a40cfd6c04ce599bbc8e4a83deadc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida4f8a6107a54f86952fd151b5a13c08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id43790812a0c4238a84dddd512d335ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f3fc1feaa3146ef881ca19357b23ae2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6b9a6da1e624a6299e316b70d8feaac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79d3ae940d944d56b1fa894aaf7ce150_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4b8c164b3e1486ebec72f7e98f21e80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71e83b77ce534f3b9bd0073625848436_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8f0556ba0524239b520e549288db90f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30c0e0850ab04139a8cc19022cb08ee3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ae2473b59214583a165b28061b320ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30c0dba4e084466d8bddadc615f6025a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b398db0d1554733a657d72060893c6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3d6ed83b23f459e9db3a9380f2701a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6c5626096e543389cd9c3f775245cfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i803545905c564efc93735544226e6480_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57ab8cfb4e2c4f0d807f2b535c421e2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12da925d57d847f29779b2a54f0c1d8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76caa3c0609e438280d6a0504611599f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6ec5554c31b4ce8828d34f1b36e247a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:MyriadAutoimmuneReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08c34d03cc5d4ce3adff6edc114a7d3d_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:ClinicReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2300757198c24415b7c3c129a5f3fabf_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="iba866a3cd6cf4800bbcea6f210f6455a_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="i3f3b8d69d56b45199b92513424091532_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="i275498a5a52849dea83b241134bb7e51_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="ida1425b0bad34a70afc41eb45c93a582_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="ic75f471c9cdf49ab96d540192ad0b502_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b9f2d157d1e4cadaae10cf7ad53658e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2d57af1e55643e69c2cef6564b8c029_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72c3ca18e45c49898939a280f53e8a87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib683c703779c41d19954bb1ac378479f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92a4983803bd4497b2c5b4c486bbbbe6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefacdace64394337b4ef1aba897012f9_D20180731-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ica35c1f0cab448d081723c1fef35a424_I20161223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-23</instant>
        </period>
    </context>
    <context id="i168fbf7f34f14b48b159064776b4fdfc_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i54fc9148f3ce4861a7ad8db525b9a0a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id223da0fe55a40c58f22c4b23b424f4d_I20210221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="i961cf7e1f4884ffdace1af14ca9070a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i82d39802808f4ef89f2381762fc4eb35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a989512a05b4160b8ec803a03de9836_D20200401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i333e25208a214f52b7d6bdff1719f67a_D20200401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0c5178ceac7d4f5fbc4391a28c678d89_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i3265f06cbffc47d085ee813629587542_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i9f99bcdbffc6436f919414c49880ae46_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="idc6b324d8d7d49119edb7e86615e72bb_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i915c2ce66e394e6ebfd548241511f5c7_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="id54bd12e649d48069a7463458d653da6_I20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="i5017805749294720bfc1102605257804_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3842c62c98f4eff8442478a102c1f76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id019278a4e69463fa389582d302cd096_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib67b2cb2c62d457c8bfa89045a0ac26f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0941bbd4ec3549fe8c0210b756b9c68d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:ExecutiveOfficersAndSeniorPositionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0493562cfc8d469d90ebecc52d7cf045_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:ExecutiveOfficersAndSeniorPositionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0aea44508ff4dfbb5ee1282d27b02b2_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee48b219c6314207b2b8c51e655bad7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic585d4b282fa403da809d437637d7786_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4aaf305cdc4c4b3783ad7772ad83b376_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b47a20179364be1a601e6386dcdc7c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9edc8741087a458da983569f09876507_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i561d9e41bc564e37b2cdadb9540775cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mygn:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab3c3decbc9b4749a615c444461f2714_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib14d08a6c91d4a4d9a5f3397abc5c101_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17009626ef9e40fea086f24d4e4d938e_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i55c1d65d2fea4fb897497c39c3c543bb_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if55a0576781b4fe09cd0002c1cf57591_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id40d4e8c980d4d749c48652760c59dcb_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f3271f5fd8d4f9cae87d273d0119cf6_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2d82b14159db4173bec06da40fa3fba0_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia3e5585fea71439f950bf077fd864a6b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9a7c61994bb46c687fdf99107cfd671_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35c6f499764943a9b6668276c03a7dca_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0dd00bad76d24a0ba7fbe37165e9ea1e_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i932fedfaff694d47a9c810a8ed5c652a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36668e3bf1614b139d53bd0dd4a1737f_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i220876603bc44dc4b5d5cba857b18a98_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3a0fbec0d2524cbfb381bcf39f515a31_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i14606df79fcb41208a7deba7ab883c8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id273969844de4a42b563bdd13fe471ee_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5b5430845bd4bf0bdf1c90acbf50400_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3df27cee9a9e44d4b90685ca4d691bfe_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8feb4bec474149ac84ceec0cbaaa45af_I20121205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-05</instant>
        </period>
    </context>
    <context id="i57656916c4ad4a29bc0dda34d93091b5_D20210923-20210923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-23</startDate>
            <endDate>2021-09-23</endDate>
        </period>
    </context>
    <context id="i6f2deacdf28047ffa7f76605879c01a3_D20211205-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83383bd4b0654a95842e069decbe0d94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d865748020e4effaae21a66a663077b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8dfa542a04ef4e41ac83b425d14fdea0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08ceba9140e2414aa168f8323513eb92_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cb7a3dbd0394b3a98b2fa3967024ce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9589f80194a941a98f9394776dc93210_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16e65e9f289e470e8192dacb960d4a43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea5670d0442144a9827fb94b02527d5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief421c0a8d774da3a0d3e029188f8bb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia343da359530413f9f43cba7387074bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3acf17d910cc465bb94c96ceb1075337_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i78965414e66747c19486ba7a6e74f9c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfce3d729fbe4d2982bbceb25a61b887_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i203e33449c4d47478858a4e96feba476_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b129110cdcf40da82c792a626cb5140_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6fc7f4bae0a24544870e68c5081d1eae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice0285b61cc74e72912725920fceec85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7de9b7a4b6ea43ce99df84afe005c51f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1dd974f0a354b7e918ff359564e3487_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60e9618d910a43b3b0cf3e5ca1018738_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9ff73e805544f00a995a79e7beabfd7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39aada1c97204d7ba76be4c96523dd65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f9d97eb20794fe5ad342b5b3244164a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a2fec96267b42df8bdcd32ac76c5bfc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13f5587e0ffc403b998eeeaf70866baa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e7bfc4c89d34726b342ff9738bb6c21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e54383ae03647b4bdc0042c788b7d92_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2d1f694a2b246dd97539cfbc90fdaa5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4c32f4affc04ac8ad57b0fb12effb75_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92e766bbdac2412db386420a0fd67410_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37ac628246aa47a9856eff8943bb53da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i75ab306877b54340b9ceca58fc63cf74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40459a0ffb804202863c2399057f5faa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ed6f2b7a99e46259c13006a1c7fb525_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3720a9cb33664b36ac16fd27520f3445_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia65ea439046741879c10f71b82d8c8af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cb51262d87a469e9b16924d435ec74e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26a7872b3c3e43d1a1a6e18f0a9a61eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:CrescendoBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b60c3a470b443f8bbf026504b9c59d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:AbelliAndPricoloMatterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i971ef08a521a4060839a354e9f1482db_D20220124-20220124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:AbelliAndPricoloMatterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-24</startDate>
            <endDate>2022-01-24</endDate>
        </period>
    </context>
    <context id="i60c092841990477a992d7f353b1ed612_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i403644c63d2f42ce9be417d4645c4d3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb1bf33b7a68483c99cef4bfc39ec4d0_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:OperatingLeaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50f6939f15de4b44bc5d205c498f9bb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i730cf00f21e24233aa2438bc079c00fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1693400cad7b453cbf24b4b49eaaf843_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i035d000528f94d29bec8473ab8e23f80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77ae176a47c5401292f15f20d1f2b493_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4a3f1dfa4a24709971fbcfbce8f1bdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-13</startDate>
            <endDate>2021-09-13</endDate>
        </period>
    </context>
    <context id="i860c89a3309f4862aa45108d2d164008_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4881a7b97e68483588b542d1107dfc7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie93081e2cf534cd9ae7518a1f0407820_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd8184e7f9d64fdfa830a7580e392ea8_D20180731-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:CounsylIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i6757f736730d439fb934901528230b15_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:CounsylIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="iff236b6484f74a869a405f4676bd6810_D20180701-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:CounsylIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia83408ec29ac462bb67762046411429e_D20220101-20220224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:SaltLakeCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-24</endDate>
        </period>
    </context>
    <context id="i27de6b0d5d5e480a85e618df1ee1b0e1_I20220224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:SaltLakeCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="iaaeba814f5004cb58a2f97d102345f21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9293cf2bcc0f4d2a920e6ccd2d4f11d1_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e5947d8d1f246f8b9440687d0122811_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i123f7f47f2d641448a50320ff8fc12b3_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>mygn:security</measure>
    </unit>
    <unit id="divestiture">
        <measure>mygn:divestiture</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="segment">
        <measure>mygn:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF80LTEtMS0xLTM2MzU5_6008d18f-b9e7-4886-8cb5-3cdf28497d70">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF81LTEtMS0xLTM2MzU5_95168b37-3031-45fa-a20c-d7367fda0c78">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF82LTEtMS0xLTM2MzU5_05c72a36-c4c1-42ce-8ced-eea36558439e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN180L2ZyYWc6YWFjY2QxYmQ2OWFkNGJmN2EwMWExNjllOWRiYjJkNTkvdGFibGU6MGIyYzQ3NzUwYmY1NDc0MGI3MmM1NDE5OTY1ZDBjMDQvdGFibGVyYW5nZTowYjJjNDc3NTBiZjU0NzQwYjcyYzU0MTk5NjVkMGMwNF83LTEtMS0xLTM2MzU5_38310361-d0d6-4b9d-a165-3e1c2a79b19b">0000899923</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i55202b0f51cd439d9b1c5849f46eaeca_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i63f8cb8dfa0542e0b8ad06c716ac9a06_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i60c092841990477a992d7f353b1ed612_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4MA_466cec83-963f-4b74-b010-f7a16d9ef195">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:NumberOfReportableSegments
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTcwL2ZyYWc6N2YwM2EzMDVhMWNlNGQ2YThlNDI0ZGQ4MTY0YmRlNzMvdGV4dHJlZ2lvbjo3ZjAzYTMwNWExY2U0ZDZhOGU0MjRkZDgxNjRiZGU3M18xNjQ5MjY3NDQxNjcwNg_1fce3220-dff5-4c7f-b770-945e4708f9df"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ5_5b9db3f8-284e-481c-8bdd-213d43cf7c12">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6NTNlNDI5NGRhMTM5NDAzNDg3M2QyOTkyYTcwNzE1ZDgvdGFibGVyYW5nZTo1M2U0Mjk0ZGExMzk0MDM0ODczZDI5OTJhNzA3MTVkOF8wLTAtMS0xLTM2MzU5_2e7ef74c-c0b8-4d08-befd-e016cfb001a0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18xNjQ5MjY3NDQ1NjAw_04ec8150-f409-4c73-a5a0-ae7019a0b7d7">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18xNjQ5MjY3NDQ1NjAw_75899769-2424-4e1d-b26e-519059d77f05">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6NTk5ODdkZWRkNDUwNGE4NTljNDQ1MDliYmI0NzA1ZTEvdGFibGVyYW5nZTo1OTk4N2RlZGQ0NTA0YTg1OWM0NDUwOWJiYjQ3MDVlMV8wLTAtMS0xLTM2MzU5_07b75915-9f4d-4bc8-9e7b-a96cc36818f1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODUx_741fc5f4-f7ed-4855-bf4c-ab18102415df">0-26642</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODMx_453bb259-2012-4d5a-9526-a5983b3f2cc3">MYRIAD GENETICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ2_f6d75739-53e4-4168-8a8a-a7c230396c89">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQz_0047b0fb-d522-46e7-9427-66cc956d106c">320 Wakara Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODM3_5ac20428-7e11-456b-bdd3-1a41f1592a63">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODMy_839e0f8b-c79b-490c-bf64-7ad2bcecc886">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODMz_09e992ce-5275-448c-ac75-021b7078e174">87-0494517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODYw_f4704bfb-9b05-4434-b7c2-28ec6372c3dd">84108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODU0_dcaf83d3-b58b-4b92-81ca-ec3fbbee3bd5">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODM0_ea5db6aa-0dc6-4d20-98ad-496f26af696b">584-3600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZDJlY2Q5NzIxMjA1NDIxOTlkNzkxNjgxMWFhNjJmYmIvdGFibGVyYW5nZTpkMmVjZDk3MjEyMDU0MjE5OWQ3OTE2ODExYWE2MmZiYl8xLTAtMS0xLTM2MzU5_96878073-8645-41a6-8d5c-b72b1c37f257">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZDJlY2Q5NzIxMjA1NDIxOTlkNzkxNjgxMWFhNjJmYmIvdGFibGVyYW5nZTpkMmVjZDk3MjEyMDU0MjE5OWQ3OTE2ODExYWE2MmZiYl8xLTItMS0xLTM2MzU5_099b39db-0f44-4496-b97e-5625c61081a4">MYGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZDJlY2Q5NzIxMjA1NDIxOTlkNzkxNjgxMWFhNjJmYmIvdGFibGVyYW5nZTpkMmVjZDk3MjEyMDU0MjE5OWQ3OTE2ODExYWE2MmZiYl8xLTQtMS0xLTM2MzU5_f7830835-c9ab-4655-844a-da6d053d6607">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODYx_e3e2e5c2-f25f-4832-90f4-46a77cb7d34c">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODYy_9ef408de-90aa-4695-b0aa-43827c5d936c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ0_166c9694-8655-4479-971c-1222fb174569">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODU2_8e5433bb-ecc6-4eab-aefb-15bf03551591">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZWFlYzljNWNjZjdhNDZhMTg0NTRkMzNkYjZmNjI5NDQvdGFibGVyYW5nZTplYWVjOWM1Y2NmN2E0NmExODQ1NGQzM2RiNmY2Mjk0NF8wLTAtMS0xLTM2MzU5_1999bb30-58ea-4980-a930-42d05f1f251a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZWFlYzljNWNjZjdhNDZhMTg0NTRkMzNkYjZmNjI5NDQvdGFibGVyYW5nZTplYWVjOWM1Y2NmN2E0NmExODQ1NGQzM2RiNmY2Mjk0NF8xLTQtMS0xLTM2MzU5_afde5b04-1153-4532-ba7a-d338d67375a7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGFibGU6ZWFlYzljNWNjZjdhNDZhMTg0NTRkMzNkYjZmNjI5NDQvdGFibGVyYW5nZTplYWVjOWM1Y2NmN2E0NmExODQ1NGQzM2RiNmY2Mjk0NF8yLTEtMS0xLTM2MzU5_fcff0440-cecc-40b8-ab17-d13a4ebf9f25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQw_bae9d7c8-bfb7-4496-9f42-48c63ae3280c">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODQ1_a274be14-3788-49e2-8c2c-4dbf05e075af">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i011796a61d54499b94960d86773ccedd_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM180OTQ3ODAyMzI5MTkw_a6429c6e-a0bf-4136-83d9-dd0f01d7a1ef"
      unitRef="usd">2376886737</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id7e46e716764498e9302a87cd85a5607_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zMzg2_90b317bb-c150-4f62-914c-f4d9a506ee53"
      unitRef="shares">80022885</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xL2ZyYWc6YjRkZmY1YWJlNDcxNDEyNzgwZWUyZjViNDVjZWY3MjMvdGV4dHJlZ2lvbjpiNGRmZjVhYmU0NzE0MTI3ODBlZTJmNWI0NWNlZjcyM18zODU3_6ed0da46-a9d2-4332-9418-0c39df84fd83">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:&#160;&#160;Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December&#160;31, 2021, for the Annual Meeting of Stockholders to be held on June 2, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN182Ny9mcmFnOjlkMTk5ZDI3NzAxMjRlZDg5M2RiNGJiYTViMGJhNjBlL3RhYmxlOjg0NDc0MDZjODY5YjQzNWM4MDE0Y2EwY2FlZWUwMjI5L3RhYmxlcmFuZ2U6ODQ0NzQwNmM4NjliNDM1YzgwMTRjYTBjYWVlZTAyMjlfMi0wLTEtMS02NDQyNC90ZXh0cmVnaW9uOmZlMjk5MzFkM2NhMDQyMjdiMTM5YWMyMTlhM2MzZmZkXzMyOTg1MzQ4ODM0MTY_0c522558-bfce-4031-84a5-3600e2fe5f60">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183MC9mcmFnOmRkMTJiMWM3YzdiZTQ5NDJhMjgwMzIwMTk1NDBkZjNkL3RleHRyZWdpb246ZGQxMmIxYzdjN2JlNDk0MmEyODAzMjAxOTU0MGRmM2RfMzI5ODUzNDg4Njk1MA_510381d2-ae61-43be-bc5a-ab7decca2b15">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183MC9mcmFnOmRkMTJiMWM3YzdiZTQ5NDJhMjgwMzIwMTk1NDBkZjNkL3RleHRyZWdpb246ZGQxMmIxYzdjN2JlNDk0MmEyODAzMjAxOTU0MGRmM2RfMzI5ODUzNDg4Njk1Mg_9829e32b-c947-46a8-966d-14ea0519fd09">Salt Lake City, UT</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNC0xLTEtMS0zNzM4OQ_d353ab4d-fc30-4659-ba30-6e53065a7f85"
      unitRef="usd">258400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNC0xLTEtMS0zNjM1OQ_6db8b4a1-6371-4e89-8f94-67c7d1107c92"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNS0xLTEtMS0zNzM4OQ_6097f452-335e-43be-942d-0f7d7049094d"
      unitRef="usd">81400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNS0xLTEtMS0zNjM1OQ_bc27b936-94fb-4c0e-a6ba-20990232bb33"
      unitRef="usd">33700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNi0xLTEtMS0zOTA1Ng_a8e4162a-6255-4cfe-a9a9-15a29f24a6d4"
      unitRef="usd">91300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNi0zLTEtMS0zOTA1Ng_0e55208c-6339-4a8d-8f1e-625d00e3e07e"
      unitRef="usd">89500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNy0xLTEtMS0zNzM4OQ_7a534a8d-1389-4ce6-8f64-dd4102b70b6f"
      unitRef="usd">15300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNy0xLTEtMS0zNjM1OQ_ba2eb238-d71c-409d-9980-ee895064b103"
      unitRef="usd">27100000</us-gaap:InventoryNet>
    <us-gaap:PrepaidTaxes
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfOS0xLTEtMS0zNzM4OQ_f166590e-1f3c-4413-8c8a-90e49a07cd82"
      unitRef="usd">18400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfOS0xLTEtMS0zNjM1OQ_c7843afa-3cab-4fd1-aef7-f6967857991a"
      unitRef="usd">108400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTAtMS0xLTEtMzczODk_46b919b3-8f02-456c-b8ec-90c8b74c3663"
      unitRef="usd">20000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTAtMS0xLTEtMzYzNTk_1421b5f4-6713-4119-8db3-f728f3000214"
      unitRef="usd">13700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTEtMS0xLTEtMzczODk_9cfb09f1-c354-4a15-9e2e-0ab0f63aa08a"
      unitRef="usd">484800000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTEtMS0xLTEtMzYzNTk_8338031b-1f91-4f18-b610-d981e32c84ca"
      unitRef="usd">389400000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMS0xLTEtMzczODk_a1f47c52-8d4d-48d4-b6a5-63e3ca7926ac"
      unitRef="usd">81800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMS0xLTEtMzYzNTk_ef23de6b-479e-49e4-b6a3-f875424aa9b8"
      unitRef="usd">59700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMS0xLTEtMzkwNzg_b14964bf-ef4c-45ae-9931-37dea8134a7c"
      unitRef="usd">59000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTItMy0xLTEtMzkwNzg_d280357a-ea08-40d1-a8a2-724fb41413da"
      unitRef="usd">21000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTQtMS0xLTEtMzczODk_80c7ad52-bacb-4ff0-8601-83638be3a77c"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTQtMS0xLTEtMzYzNTk_a20f919b-df4d-41ef-b387-f0a6a668c1d9"
      unitRef="usd">40700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTUtMS0xLTEtMzczODk_17e94b39-41c9-48ca-a68f-54ac494689de"
      unitRef="usd">404100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTUtMS0xLTEtMzYzNTk_44c73a4e-a94b-486f-a085-8de8b09aebbc"
      unitRef="usd">576500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTYtMS0xLTEtMzczODk_5fac40ba-5dbf-4a82-83fc-a96adacc5a41"
      unitRef="usd">239200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTYtMS0xLTEtMzYzNTk_69599445-e01a-4ac3-8186-a9b4ca458234"
      unitRef="usd">329200000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTctMS0xLTEtMzczODk_05aa2732-8b58-4994-a1d0-d7409e0ce472"
      unitRef="usd">8300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTctMS0xLTEtMzYzNTk_501cc74d-70a8-4da1-a809-93a194fedb4b"
      unitRef="usd">2300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTgtMS0xLTEtMzczODk_d6e9a9bb-7967-40a9-8074-23200707fcd0"
      unitRef="usd">1320700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMTgtMS0xLTEtMzYzNTk_69fc245c-76d9-4e07-b22e-bb84e9023105"
      unitRef="usd">1418800000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjEtMS0xLTEtMzczOTU_e6418bad-2222-4ba7-b4f6-223673b21795"
      unitRef="usd">29600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjEtMS0xLTEtMzYzNTk_383f16fe-f2b2-400b-b7bb-a6e26e829501"
      unitRef="usd">20500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjItMS0xLTEtMzczOTU_8a63cab3-a62b-49a8-acf2-d8191596538d"
      unitRef="usd">156500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjItMS0xLTEtMzYzNTk_bb62e48e-d75c-49d2-bbf6-f5fc35c34248"
      unitRef="usd">79100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjMtMS0xLTEtMzczOTU_aa5f9b1b-df5a-41da-8396-5978ac590b8d"
      unitRef="usd">13000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjMtMS0xLTEtMzYzNTk_5e9609ce-e4aa-4989-a9b8-c329932a0e59"
      unitRef="usd">13600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjQtMS0xLTEtMzczOTU_658bf126-ba87-4bf2-b788-cdc3b8f53701"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjQtMS0xLTEtMzYzNTk_9cc23f7f-7a4c-4131-b41b-352105fcd793"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjUtMS0xLTEtMzczOTU_a45e821f-1281-432e-8404-71f44fcbe2f8"
      unitRef="usd">204300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjUtMS0xLTEtMzYzNTk_582adb75-8a8a-482d-9004-44a6a91437d5"
      unitRef="usd">145900000</us-gaap:LiabilitiesCurrent>
    <mygn:UnrecognizedTaxBenefitsNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjYtMS0xLTEtMzczOTU_e710d7e3-bcf8-49c6-9668-b6558aec9a2b"
      unitRef="usd">27900000</mygn:UnrecognizedTaxBenefitsNet>
    <mygn:UnrecognizedTaxBenefitsNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjYtMS0xLTEtMzYzNTk_d4b61978-22db-423c-b41d-b1ecad8049de"
      unitRef="usd">30500000</mygn:UnrecognizedTaxBenefitsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjctMS0xLTEtMzczOTU_8b5403b7-72b1-401b-a88c-184fe39c078a"
      unitRef="usd">35800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjctMS0xLTEtMzYzNTk_d868bb4c-f12f-40de-84be-9c8d38f3b209"
      unitRef="usd">71300000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjgtMS0xLTEtMzczOTU_128eb676-c2fa-4f96-aa61-bbbfcea286a0"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjgtMS0xLTEtMzYzNTk_f653adcb-7949-42f6-9de5-a75f83ea85ec"
      unitRef="usd">224800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjktMS0xLTEtMzczOTU_62e675c5-1550-480d-823e-41ccaed4fac4"
      unitRef="usd">79300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMjktMS0xLTEtMzYzNTk_0974a583-e433-4142-a4a7-362872f1c4b1"
      unitRef="usd">50600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzAtMS0xLTEtMzczOTU_4da3bb9e-fde8-44bf-8114-67fca6822259"
      unitRef="usd">5600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzAtMS0xLTEtMzYzNTk_a98023ed-ceb8-42f6-86ea-cc8bd6190693"
      unitRef="usd">14700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzEtMS0xLTEtMzczOTU_377919b7-7d2c-448b-a9a5-45f1a9a04023"
      unitRef="usd">352900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzEtMS0xLTEtMzYzNTk_52a31a00-5734-4546-9c33-dd842b5c8e9b"
      unitRef="usd">537800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzItMS0xLTEtMzczOTU_6fc19e49-85d0-4afa-a9ac-532e2f17419f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzItMS0xLTEtMzYzNTk_fe1532c1-9bfe-4270-a93b-ecc70c21e93b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN18xNjQ5MjY3NDQxNjg0Nw_b221cda9-b1d8-4b33-84e1-b0c9f5cc1143"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN18xNjQ5MjY3NDQxNjg0Nw_d4ad09d5-7454-4d39-b7e1-01a4aa291e96"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN180OTQ3ODAyMzI1MTMy_477167f9-8080-47e1-9941-b74bd5c410b4"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpiYmE2ZGQwMGRjZDY0YWRhYWMwMzE2MTUzZGEyOGRhN18xOA_1a35b63c-9b25-4751-a5a6-d2fcf122cd0f"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMS0xLTEtMzc0MTM_46d0a840-29d7-4c58-9826-ba61065bfb33"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzQtMS0xLTEtMzYzNTk_9ac2da0c-9ca7-419d-b54b-857d5ec2aa91"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzUtMS0xLTEtMzc0MTM_a8b0f5e5-834f-46cd-a631-65b22e75fff6"
      unitRef="usd">1226300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzUtMS0xLTEtMzYzNTk_59444c3b-0e21-4b5b-95a4-2ec34501d10f"
      unitRef="usd">1109500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzYtMS0xLTEtMzc0MTM_65513996-177b-42e2-b08a-c740d4254fad"
      unitRef="usd">-5100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzYtMS0xLTEtMzYzNTk_475adef8-d869-442d-ad2d-fd8ba7c8169a"
      unitRef="usd">-2300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzctMS0xLTEtMzc0MTM_4b8c0349-f86d-4da9-a8ab-e3b87346b35f"
      unitRef="usd">-254200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzctMS0xLTEtMzYzNTk_bab9ea63-29ee-435e-8ecd-ef15983c204a"
      unitRef="usd">-227000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzgtMS0xLTEtMzc0MTM_c3944181-79a4-4ed8-b647-5cb4987cd0c3"
      unitRef="usd">967800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzgtMS0xLTEtMzYzNTk_805bd443-b88c-4894-9f05-55b00fd7c65e"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzktMS0xLTEtMzc0MTM_f5636b38-d855-4edc-b590-77c0f410cf11"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfMzktMS0xLTEtMzYzNTk_e246d4c8-2139-455e-87d5-46ff66d9368c"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDAtMS0xLTEtMzc0MTM_900298ba-9982-4bef-bad2-83d7d83e5867"
      unitRef="usd">967800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDAtMS0xLTEtMzYzNTk_e343b38a-b992-4ed0-985e-c80e0d9c88cd"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDAtMS0xLTEtNDM0OTA_4683d066-222d-4861-b9db-5da9807e07f9"
      unitRef="usd">1320700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183My9mcmFnOjcxZTA5NDM1ZDQ0YjRjNTc5NjEyZjc1NWY0NDExNDBmL3RhYmxlOjI3MTUwMTNmMTY2NDQ5YWRhNjcwZjFiZDIyMzlmNmIxL3RhYmxlcmFuZ2U6MjcxNTAxM2YxNjY0NDlhZGE2NzBmMWJkMjIzOWY2YjFfNDEtMS0xLTEtMzYzNTk_555e1c3a-ee85-4459-a304-9d5e56e2b01c"
      unitRef="usd">1418800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi0xLTEtMS0zNzUxNg_55694e24-04d0-4572-a79d-999dced95188"
      unitRef="usd">666400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi0xLTEtMS0zNjM1OQ_38cfb534-f50d-42f3-aa1b-27d7d58ff19b"
      unitRef="usd">279600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi0zLTEtMS0zNjM1OQ_08d88c61-b58c-46ba-8b3d-69894eb7c5cf"
      unitRef="usd">586900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMi01LTEtMS0zNjM1OQ_6315a314-69cb-4dcd-9be9-d596c0c75727"
      unitRef="usd">789400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy0xLTEtMS0zNzUxNg_e249b058-5ad0-4f92-96cb-b40752eb4422"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy0xLTEtMS0zNjM1OQ_a5d7eb97-8741-4636-ae21-f25e07ed7beb"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy0zLTEtMS0zNjM1OQ_bba63231-a553-4b14-907e-82a540d58681"
      unitRef="usd">51700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMy01LTEtMS0zNjM1OQ_2c44318c-dc25-4066-b10f-44a08fcc0f49"
      unitRef="usd">61700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC0xLTEtMS0zNzUxNg_19bde853-a3c2-4705-9272-7ef58f3588ae"
      unitRef="usd">690600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC0xLTEtMS0zNjM1OQ_63658f0a-e792-4a58-84d5-5da21948e925"
      unitRef="usd">299800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC0zLTEtMS0zNjM1OQ_8c562015-1e8b-4682-b613-8f949e04e75d"
      unitRef="usd">638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNC01LTEtMS0zNjM1OQ_f5591803-5bcc-4cfc-9620-8192910cf5b9"
      unitRef="usd">851100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi0xLTEtMS0zNzUxNg_453f62ed-51b0-4979-8d62-6287a5d3f5bb"
      unitRef="usd">185700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi0xLTEtMS0zNjM1OQ_e723d402-5a3e-47e0-be0d-fa2bd4b5f47d"
      unitRef="usd">82600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi0zLTEtMS0zNjM1OQ_76fa23c5-5863-43ea-996d-99f6abe6344f"
      unitRef="usd">157500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNi01LTEtMS0zNjM1OQ_77237df2-091f-4fb8-a503-01899ae07776"
      unitRef="usd">168200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy0xLTEtMS0zNzUxNg_ada9bf8b-da09-49d9-9beb-3b21cbf5b3a0"
      unitRef="usd">11900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy0xLTEtMS0zNjM1OQ_45595ef0-5e5d-4c20-b7fa-502d2d96328f"
      unitRef="usd">8800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy0zLTEtMS0zNjM1OQ_2c0f5bf2-f27d-4ea1-94eb-dd7be54824e3"
      unitRef="usd">28600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfNy01LTEtMS0zNjM1OQ_dc646224-f4ee-473e-bc44-6a6d3edb1b31"
      unitRef="usd">32800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC0xLTEtMS0zNzUxNg_853c1e8a-de04-4f7c-a15a-a4597fa4364f"
      unitRef="usd">81900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC0xLTEtMS0zNjM1OQ_41d0d173-4d0f-458f-870a-945319f9067a"
      unitRef="usd">35800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC0zLTEtMS0zNjM1OQ_73f29c43-72a8-432c-94b2-b84bdd905aaa"
      unitRef="usd">77200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOC01LTEtMS0zNjM1OQ_49cd036d-37f8-4bc5-b730-34fc233e0997"
      unitRef="usd">85900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS0xLTEtMS0zOTE4OA_2669481c-0359-4383-a9b2-74a2aacc582e"
      unitRef="usd">537800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS0zLTEtMS0zOTE4OA_88d5b5f4-2545-4a98-8648-5c128d38124a"
      unitRef="usd">260400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS01LTEtMS0zOTE4OA_0a4bacde-4c6c-4f5a-971e-ae813c79a7bb"
      unitRef="usd">507300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfOS03LTEtMS0zOTE4OA_6a0b79f7-b9da-41b3-95da-e8181b46b5b6"
      unitRef="usd">556600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtMS0xLTEtNDk5MTg_1d114045-575c-402c-9ebc-be30821c4679"
      unitRef="usd">62000000.0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtMy0xLTEtNDk5Mjg_8b6da10c-1a29-4e7e-bd07-0cb740bda697"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtNS0xLTEtNDk5Mjg_13bcc9c9-28ec-420b-bc15-d2683fa40c24"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTAtNy0xLTEtNDk5Mjg_8cbc587c-bbe3-4392-8aeb-cb39bdfd85c4"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtMS0xLTEtMzc1MTY_d526b778-238f-4e1a-a019-d3e9b2db8a21"
      unitRef="usd">1800000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtMS0xLTEtMzYzNTk_859ba6a7-6b22-4e12-adeb-953c4888821e"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtMy0xLTEtMzYzNTk_28a17364-3806-45bd-bcbb-9fc25375869b"
      unitRef="usd">99700000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTEtNS0xLTEtMzYzNTk_9e45c501-b487-4ed6-aa8f-32d0660c4a98"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:CostsAndExpenses
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItMS0xLTEtMzc1MTY_3cfb9b68-3e86-4311-96f4-7d21e2acc0c1"
      unitRef="usd">881100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItMS0xLTEtMzYzNTk_815c953a-3f68-4f08-a1ec-cb6829d09f6b"
      unitRef="usd">387600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItMy0xLTEtMzYzNTk_bb200a81-5694-46fe-a1ce-28ee1d5234f7"
      unitRef="usd">870300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTItNS0xLTEtMzYzNTk_f1a66ed6-74f3-4f4d-bed0-9bf1a00b766d"
      unitRef="usd">843500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtMS0xLTEtMzc1MTY_77dc282c-e475-43c0-b491-8990fc7cd5a1"
      unitRef="usd">-190500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtMS0xLTEtMzYzNTk_af4faaec-fa42-4b0f-a7ff-467ec11e91b2"
      unitRef="usd">-87800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtMy0xLTEtMzYzNTk_7ddf282b-5a7a-4faf-9b60-18f0d8c30ede"
      unitRef="usd">-231700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTMtNS0xLTEtMzYzNTk_86525e84-ec3a-4e0f-8b7d-f277f5efac8a"
      unitRef="usd">7600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtMS0xLTEtMzc1MTY_e84433d2-972e-4a88-8317-2771c0394fff"
      unitRef="usd">700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtMS0xLTEtMzYzNTk_ed345dc6-5577-4bf0-a560-aafefa1cbeb7"
      unitRef="usd">700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtMy0xLTEtMzYzNTk_ca0f15c4-8624-4d11-9846-460f0c47e3e9"
      unitRef="usd">3000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTUtNS0xLTEtMzYzNTk_a5316298-c60d-42cf-938b-342ad929f57f"
      unitRef="usd">3200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtMS0xLTEtMzc1MTY_c04ac715-07f8-4b58-b27d-65725c9aeb45"
      unitRef="usd">6600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtMS0xLTEtMzYzNTk_50df3339-4daa-438e-afdd-2d581204382f"
      unitRef="usd">5800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtMy0xLTEtMzYzNTk_3f640d66-4f0e-44b7-b87c-ccdb4922f86f"
      unitRef="usd">10800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTYtNS0xLTEtMzYzNTk_f5b27b55-ff55-4ef5-9e5d-8bf84e42e5c6"
      unitRef="usd">12000000.0</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctMS0xLTEtMzc1MTY_3206da36-5aa7-4e7c-8c70-e4fcf9f0e508"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctMS0xLTEtMzYzNTk_f2047320-fdba-41f0-aea0-323f26146a76"
      unitRef="usd">-1200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctMy0xLTEtMzYzNTk_ce3a8cf5-4420-4029-88ce-d12e1447e83e"
      unitRef="usd">16200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTctNS0xLTEtMzYzNTk_e8b03820-e756-4a32-985a-8ddad844c31f"
      unitRef="usd">1200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtMS0xLTEtMzc1MTY_c1652076-dd51-470f-b3fb-8c8089c20b1f"
      unitRef="usd">133400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtMS0xLTEtMzYzNTk_a784ff6f-9009-4015-a966-afa24e651825"
      unitRef="usd">-6300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtMy0xLTEtMzYzNTk_1c6d23cc-4d83-46df-b1c7-bed0856b2bdd"
      unitRef="usd">8400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTgtNS0xLTEtMzYzNTk_fbdb403d-6988-4366-91f7-68363cc3a829"
      unitRef="usd">-7600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktMS0xLTEtMzc1MTY_ccfac10d-c0bc-40bf-8833-bfea5ea54f0f"
      unitRef="usd">-57100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktMS0xLTEtMzYzNTk_c664550c-a590-49ae-97c0-51856ce79f89"
      unitRef="usd">-94100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktMy0xLTEtMzYzNTk_af615a0b-f7e1-49f4-bab7-a5462c79ebcd"
      unitRef="usd">-223300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMTktNS0xLTEtMzYzNTk_3a1a4440-2362-4cf1-8d52-ca849c6bb5b8"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtMS0xLTEtMzc1MTY_2a66141a-7fdf-4067-a171-a98d70b7443d"
      unitRef="usd">-29900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtMS0xLTEtMzYzNTk_72ee5bf7-5bd4-4374-babd-2769878ac9c1"
      unitRef="usd">-41000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtMy0xLTEtMzYzNTk_edab9c4c-25e8-4c21-93ed-1e1258f790f1"
      unitRef="usd">-23700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjAtNS0xLTEtMzYzNTk_04714302-ff25-495e-a95e-d488cb4c1c8f"
      unitRef="usd">-4400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtMS0xLTEtMzc1MTY_102d21cf-3a75-46b2-ab95-48e94e9f3543"
      unitRef="usd">-27200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtMS0xLTEtMzYzNTk_0f780454-3a03-4a1f-8a83-01d790a0276d"
      unitRef="usd">-53100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtMy0xLTEtMzYzNTk_e248eb77-0258-48e0-a6cc-dc081d6a505e"
      unitRef="usd">-199600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjEtNS0xLTEtMzYzNTk_a9d29cb0-a12a-47cb-bde5-ec4f3fe538b5"
      unitRef="usd">4400000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItMS0xLTEtMzc1MTY_a3d98b01-04ef-4de7-94a4-19f478e659ad"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItMS0xLTEtMzYzNTk_8830558a-8818-48dd-8d9b-02ac8f893b2d"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItMy0xLTEtMzYzNTk_d33d6230-7d9b-43b3-8f4a-420b176b7ec4"
      unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjItNS0xLTEtMzYzNTk_88ba0960-8758-4c28-be6c-5d42b4bfa568"
      unitRef="usd">-200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtMS0xLTEtMzc1MTY_4cb0230c-1e2c-4f1e-ba3b-3f51818118c9"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtMS0xLTEtMzYzNTk_255b4388-8fd0-4dc3-a901-3df315257f67"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtMy0xLTEtMzYzNTk_d5970281-4b8a-4863-96d9-874c0a248d24"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjMtNS0xLTEtMzYzNTk_01dd1d9f-931b-4db5-8198-bdb278c2ae1c"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtMS0xLTEtMzc1MjM_99f0e88f-742c-4a4e-bf51-13afd906b362"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtMS0xLTEtMzYzNTk_55103031-f704-4a26-8788-a8ef5a6bcec9"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtMy0xLTEtMzYzNTk_cee6a0ad-c706-4029-aa80-1b864674fd31"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjUtNS0xLTEtMzYzNTk_73cc575d-14ef-4b18-be8c-925c1c654c3b"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtMS0xLTEtMzc1MjM_4ef3cd65-9572-4d2d-80bf-3b60664a53ac"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtMS0xLTEtMzYzNTk_10b5809c-f581-41c9-bee8-e85a6d50a8a3"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtMy0xLTEtMzYzNTk_249e1ede-66ee-4c1b-9034-f1995ef66b82"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjYtNS0xLTEtMzYzNTk_5c11732d-ad67-40a9-80a1-7e8db35fa57d"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtMS0xLTEtMzc1MjM_2ba862d5-d9d5-4d85-b3fc-6fdf6cea2c63"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtMS0xLTEtMzYzNTk_a6e16e56-5e36-4277-80ae-273229ab7960"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtMy0xLTEtMzYzNTk_e3104486-3fc7-45a8-ad9d-7820ebd169f5"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjgtNS0xLTEtMzYzNTk_6c5e6ea8-4ed7-4a82-9b10-b39626ba0be3"
      unitRef="shares">73500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktMS0xLTEtMzc1MjM_bbeb6472-3483-43ba-81ae-a7fc08b42210"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktMS0xLTEtMzYzNTk_8dbb0b0c-8c42-4edd-990d-4b947499ae3e"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktMy0xLTEtMzYzNTk_462797e8-b180-446a-bf3c-a5e178bea6be"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183Ni9mcmFnOjIwZmUwNjk3MDk1ZDQ3Y2NiZTgzMjg4MzFiNzdkNmNhL3RhYmxlOjliZDkwYWY3ZWZiZTRmNTc5OTgyNGRlYWQxYzIwYzVhL3RhYmxlcmFuZ2U6OWJkOTBhZjdlZmJlNGY1Nzk5ODI0ZGVhZDFjMjBjNWFfMjktNS0xLTEtMzYzNTk_455381f3-4b3f-493a-9a89-3563793b6f99"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi0xLTEtMS0zNzU5OQ_23a11766-3487-4ea9-aaa0-0723513adb62"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi0xLTEtMS0zNjM1OQ_f660310a-4479-4489-b128-36f9e36f3b7a"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi0zLTEtMS0zNjM1OQ_52757f64-f7d9-4203-9e7c-b612d85824c0"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMi01LTEtMS0zNjM1OQ_78bb2bd4-eb52-4cd7-abb3-ce0eb1e0834f"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy0xLTEtMS0zNzU5OQ_bc9daa81-12fa-436d-bd2e-87c83804ea7c"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy0xLTEtMS0zNjM1OQ_78f72bb8-ce72-4e05-966a-4573533231fc"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy0zLTEtMS0zNjM1OQ_e60e007b-9d03-47d6-ab8a-9eb3a6ebea35"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfMy01LTEtMS0zNjM1OQ_94214cf5-83ce-4028-a541-a98cdcf67f2b"
      unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC0xLTEtMS0zNzU5OQ_5e7687ea-e1e4-4b56-94f2-d2ab3de5ce59"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC0xLTEtMS0zNjM1OQ_cce4d034-d8a6-48c3-8f83-f19a8e30dff7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC0zLTEtMS0zNjM1OQ_1f7afdbf-dd80-4c08-bf97-8015e89a8d3c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNC01LTEtMS0zNjM1OQ_206ed6e2-4d12-4b82-ba41-a966aad0fba9"
      unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS0xLTEtMS0zNzU5OQ_11a6ee21-45be-456b-83a3-87609ff673c5"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS0xLTEtMS0zNjM1OQ_7f203565-ffa4-4761-a1af-030246222ff2"
      unitRef="usd">3400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS0zLTEtMS0zNjM1OQ_1905a6fe-9fa4-431b-a060-cbca0faa4caa"
      unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNS01LTEtMS0zNjM1OQ_183dcf99-b2a9-4545-9de2-b0e0d42c05ea"
      unitRef="usd">-3100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi0xLTEtMS0zNzU5OQ_e54476b2-9c1a-4b2a-9304-7549d5706073"
      unitRef="usd">-30000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi0xLTEtMS0zNjM1OQ_d6f45803-6ec5-4f7e-a7f1-bdd632c8aff4"
      unitRef="usd">-50200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi0zLTEtMS0zNjM1OQ_0d57f8e8-a957-40b2-a54f-9426d9dbbfe4"
      unitRef="usd">-199400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN183OS9mcmFnOjQ3MjA1ZTM5Y2NkNDRiOTA5Mzg1NGJjYWQ4MDZlM2QxL3RhYmxlOmY3NTRlNzQ3ZWU1NjRkMzc5YWVkODdhZjUxYTYxYmVhL3RhYmxlcmFuZ2U6Zjc1NGU3NDdlZTU2NGQzNzlhZWQ4N2FmNTFhNjFiZWFfNi01LTEtMS0zNjM1OQ_a6f28374-34f4-4aec-af2a-5b26fe8b2b52"
      unitRef="usd">3300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3490fe6c43d44fcb68f2c3625bd038a_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi0xLTEtMS0zNjM1OQ_881c8aae-2f2d-4519-ab21-1dc55ae42019"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5ca914745a941f2966e50ba77e955a7_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi0zLTEtMS0zNjM1OQ_978e1b70-56a2-4e6b-9526-ef436bb4d964"
      unitRef="usd">915400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16e7b1ebad7642a0add5c645bc552fee_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi01LTEtMS0zNjM1OQ_e731cad9-f366-4e22-a437-6dbcddd85ab7"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18300b74b3df4d46b493a707d825fa4a_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi03LTEtMS0zNjM1OQ_fc9b70f5-1e0b-4925-aa52-6530d6990d62"
      unitRef="usd">54100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNi05LTEtMS0zNjM1OQ_15d2ce8d-c670-4256-b423-78ea760313c4"
      unitRef="usd">966100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNy0zLTEtMS0zNjM1OQ_079d375a-a9b0-4517-8316-38a5453bf0a5"
      unitRef="usd">136000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfNy05LTEtMS0zNjM1OQ_917d77f2-978c-47eb-b584-88476d7857fb"
      unitRef="usd">136000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOC0zLTEtMS0zNjM1OQ_f0556e06-129d-46cc-858e-dca8f1abf97d"
      unitRef="usd">33500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOC05LTEtMS0zNjM1OQ_cc2da388-ebf2-4292-b292-b2b2961da871"
      unitRef="usd">33500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i9e2460d246fe48c392e68b1f707ac13c_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOS0zLTEtMS0zNjM1OQ_9805612c-bc7a-4f60-af46-8c67f5fd6e63"
      unitRef="usd">16900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i4b54a1e9583a4c6e990c5bbb9c0a73f8_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOS03LTEtMS0zNjM1OQ_c4250a01-6c73-456d-b0af-7472c6240032"
      unitRef="usd">33100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfOS05LTEtMS0zNjM1OQ_f615f87f-a600-4b2f-8af3-0d9fedbd6c20"
      unitRef="usd">50000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4b54a1e9583a4c6e990c5bbb9c0a73f8_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTAtNy0xLTEtMzYzNTk_5aede6c6-97d2-4278-96d1-df3a690c9cba"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTAtOS0xLTEtMzYzNTk_556c578e-055c-459c-8138-cb7da83004b9"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia1599623c9f04291a999dead8f1a5395_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTEtNS0xLTEtMzYzNTk_a81f5cdb-b120-4bd0-ad2a-2d279db65765"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTEtOS0xLTEtMzYzNTk_a1086e70-4c64-4455-897e-77c01e1bbf48"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59def4575be14308a65eb8292ac6d700_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItMS0xLTEtMzYzNTk_8cf1346d-3aac-4866-8ece-b8259a8dc854"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d812645f92f414592b573945dc3f6b1_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItMy0xLTEtMzYzNTk_f228cf73-1459-4005-913e-05b081b700c5"
      unitRef="usd">1068000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i186bb32cbaf64bd6b7957d74964ad3b8_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItNS0xLTEtMzYzNTk_2ad3b8b6-fd69-479f-80e1-7a44e8e2a3fb"
      unitRef="usd">-5400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00f04a427cbe430a863042cf46917020_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItNy0xLTEtMzYzNTk_faef8a04-316f-4e66-b586-c2e94549f8fb"
      unitRef="usd">25600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTItOS0xLTEtMzYzNTk_44081fa9-41dc-4559-8acb-b8e42ce7cb6a"
      unitRef="usd">1088900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia83e7c3186b049569961b26ad3e07b35_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTMtMy0xLTEtMzYzNTk_246b6416-b529-4cbc-bf65-23ed9aa38706"
      unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTMtOS0xLTEtMzYzNTk_15797ea2-f638-4292-847b-07491cdfb3c4"
      unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia83e7c3186b049569961b26ad3e07b35_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTQtMy0xLTEtMzYzNTk_3613068e-a54b-47dd-9e5e-f8f3758fe5c7"
      unitRef="usd">25200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTQtOS0xLTEtMzYzNTk_051679ca-4b44-4e3f-bf8f-16c096a50ca9"
      unitRef="usd">25200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i04d0772a72c84c40ad62e094c4956f82_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTUtNy0xLTEtMzYzNTk_65eb85ff-9ddb-4950-9dd7-05765f5185cf"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTUtOS0xLTEtMzYzNTk_55b7109d-274b-47b1-938e-255214431206"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary
      contextRef="i88c1ff8d939f49a5bc5fda3040bcf994_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTYtNS0xLTEtMzYzNTk_4be5513a-9e64-434a-80be-c11412a862dc"
      unitRef="usd">100000</mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary>
    <mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTYtOS0xLTEtMzYzNTk_7d30dedb-c3ff-4247-b57b-4351fddcc303"
      unitRef="usd">100000</mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i88c1ff8d939f49a5bc5fda3040bcf994_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTctNS0xLTEtMzYzNTk_1a0302c9-5f1f-45ef-9704-b613ea2e50d7"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTctOS0xLTEtMzYzNTk_5f412f6f-15f4-4fcf-86cf-aec50b6b6838"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i727bfef5fdaf4a68b74905d96ed0bd75_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtMS0xLTEtMzYzNTk_a549a134-1c73-42a0-a681-67af2aee9cf2"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0952f21f7474270a815f3514f44ab52_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtMy0xLTEtMzYzNTk_d1ce2a7e-2b3e-409b-9eef-4fa32d096564"
      unitRef="usd">1096600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c18b43bb290475583b6c04c962cc4f5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtNS0xLTEtMzYzNTk_ff5dbd2a-8286-4993-b381-423d93c847bd"
      unitRef="usd">-5200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67c1f04497634a03acfacae132470000_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtNy0xLTEtMzYzNTk_627509f6-decc-4b3a-adcb-194b3d07e558"
      unitRef="usd">-173900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTgtOS0xLTEtMzYzNTk_95f05caa-bb0a-4527-9983-58cc3e70686f"
      unitRef="usd">918200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3255cc95fb79446f82e34f0ba20d9dcb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktMS0xLTEtMzYzNTk_1fcae54c-a60e-4492-ac5b-0173d6a744a5"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6c16edcf998c4da5b8b0515c6fd6a34e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktMy0xLTEtMzYzNTk_666387e3-64b3-47a0-a93c-591975d660e4"
      unitRef="usd">-2000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktOS0xLTEtMzYzNTk_b93ec8d3-bc55-4403-8a67-cb8211792434"
      unitRef="usd">-1900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6c16edcf998c4da5b8b0515c6fd6a34e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtMy0xLTEtMzYzNTk_aa5dbdad-272a-4a9b-b7ac-d2efcd97bf35"
      unitRef="usd">14900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtOS0xLTEtMzYzNTk_ae8d4ea6-ea72-4154-90c3-321b28d8f2d1"
      unitRef="usd">14900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7d9a7dea4d3a492eab5b13130045cf86_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtNy0xLTEtMzYzNTk_14de7b31-f8ce-4381-8605-ce086c6b74c0"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtOS0xLTEtMzYzNTk_63038e6b-5208-4eec-8c01-9e7f45e686b6"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i49f010022d8844beba34499bcd02fcfa_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItNS0xLTEtMzYzNTk_9eefe851-b939-4a6c-87e1-a022362e27e5"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItOS0xLTEtMzYzNTk_56c62480-f03d-43d7-a2b2-fc3ffc1c7461"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f56df5636b24717996902df4b351edb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMS0xLTEtMzYzNTk_c7f5cb7f-7499-4032-a0f9-6247f1d7848a"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b042f9bbfff4fd7b823711711b5022a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMy0xLTEtMzYzNTk_3b281c90-1a7d-46e1-9af9-bc29f4b9d982"
      unitRef="usd">1109500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8e819d3e2be4e7589e9091e181dd161_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNS0xLTEtMzYzNTk_6bfdb436-5e5a-48f0-b477-a2b7653b099a"
      unitRef="usd">-2300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04ecb918ca8845c18dd2d6175330f6df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNy0xLTEtMzYzNTk_1ab767d0-2373-4e18-bf32-eb4cee613b7f"
      unitRef="usd">-227000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtOS0xLTEtMzYzNTk_ef25b678-35b2-49ad-9b6d-21cbde646882"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i81acdb427fb040d1b79807f720522dcf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktMy0xLTEtMzc4ODc_9f52e90d-f55a-4ab2-aeca-893b30eb3f3f"
      unitRef="usd">80300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMTktOS0xLTEtMzc4OTM_88fc66de-bd0d-4a95-82e1-c3874c8d4305"
      unitRef="usd">80300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81acdb427fb040d1b79807f720522dcf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtMy0xLTEtMzc4ODc_3aff33f2-881a-40d7-958c-4294aa82af51"
      unitRef="usd">36500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjAtOS0xLTEtMzc4OTM_8b206af5-8d2d-438f-b246-263646dd1f0f"
      unitRef="usd">36500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i406964000440469a8b2a3301d473abfa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtNy0xLTEtMzc4OTM_96db4e17-e382-446f-83f2-8ac8ca95dd5d"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjEtOS0xLTEtMzc4OTM_3eaf5538-92f4-45c4-a6d6-1d1172bcc662"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if4402fe2fdb042e993c87738c61d4381_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItNS0xLTEtMzc4OTM_44fe69b6-eb5f-42fc-b9c7-07368ac218da"
      unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjItOS0xLTEtMzc4OTM_4c8b5f54-2e78-4521-a520-7f7690b60056"
      unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide1a7957d8ba47e8b3c57b590a8f1c6e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMS0xLTEtMzc4ODc_c6bd90af-b9d6-4bfe-a788-f53c41b2d4f7"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5861584aeaf34ebd8b71efbbb80709c9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtMy0xLTEtMzc4ODc_f7ee726a-b8de-4c5a-8515-ed3e667ae074"
      unitRef="usd">1226300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5633da0a55ce4fbfbc6f2f94c0888afd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNS0xLTEtMzc4OTM_7ae31273-3c5d-4cc3-9d68-2fb9399b32b5"
      unitRef="usd">-5100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d7070eac7a949dcbb79b9e02a3aacf2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtNy0xLTEtMzc4OTM_cfda61eb-b258-4029-89b8-8ba28a2c37cb"
      unitRef="usd">-254200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184Mi9mcmFnOmFlOWQ5ZDJiZTM5MzQ0YTM4MWNhMDI3YmMwZjYzNjA3L3RhYmxlOmIwYTVlYmYxYWFiMDRlZGU5ZWY2ZDQ0YTgzZTM4MmE4L3RhYmxlcmFuZ2U6YjBhNWViZjFhYWIwNGVkZTllZjZkNDRhODNlMzgyYThfMjMtOS0xLTEtMzc4OTM_bae6a0a2-6b79-47f4-abce-7f95f2a5608a"
      unitRef="usd">967800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy0xLTEtMS0zNzY5Ng_223cf017-9cb6-449a-b380-1831d13ce9ac"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy0xLTEtMS0zNjM1OQ_2c0aeb99-5f54-4b7f-8696-8defa7f761bf"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy0zLTEtMS0zNjM1OQ_3d8e67db-e57a-4e03-96c8-f82d166a250f"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMy01LTEtMS0zNjM1OQ_49ed4d63-c3a8-4af8-9df9-aac89c6d34d2"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS0xLTEtMS0zNzY5Ng_33bd5291-3e50-4c5c-8e0c-7eb4dbe3ee07"
      unitRef="usd">62800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS0xLTEtMS0zNjM1OQ_168db79b-7430-483a-8f5a-5f4756dfb123"
      unitRef="usd">35800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS0zLTEtMS0zNjM1OQ_a869adee-3e4f-4ffb-ab50-bc19e654619b"
      unitRef="usd">72000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNS01LTEtMS0zNjM1OQ_c9b27252-4196-46d2-8b09-7eb55e9dd178"
      unitRef="usd">73000000.0</us-gaap:DepreciationAndAmortization>
    <mygn:NonCashInterestExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi0xLTEtMS0zNzY5Ng_6c188d29-abdc-4739-87d1-0b43ae1b66f4"
      unitRef="usd">1500000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi0xLTEtMS0zNjM1OQ_340fd115-6322-449d-8801-f9b14e75dc9f"
      unitRef="usd">400000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi0zLTEtMS0zNjM1OQ_75969505-b23a-44bf-878a-2012a12d76b6"
      unitRef="usd">500000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNi01LTEtMS0zNjM1OQ_793a0b0f-6481-463e-8a1e-a27356df8489"
      unitRef="usd">400000</mygn:NonCashInterestExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy0xLTEtMS0zNzY5Ng_f367dd71-2a76-424c-9b70-cbb566f0d38b"
      unitRef="usd">12800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy0xLTEtMS0zNjM1OQ_12ca7baa-b9ba-4be9-8761-e8d2370c7e44"
      unitRef="usd">6400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy0zLTEtMS0zNjM1OQ_7d75babe-08b4-4a8d-a364-cae3be2e093a"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNy01LTEtMS0zNjM1OQ_64bbdbf3-a382-4b4a-97ae-00b486ed0113"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC0xLTEtMS0zOTIxMw_054d7ebd-53ea-4b64-993b-5db7041aaf72"
      unitRef="usd">36300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC0zLTEtMS0zOTIxMw_26aa22f2-1fc2-4d78-870d-6655597fed2a"
      unitRef="usd">14900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC01LTEtMS0zOTIxMw_73687c95-9f9a-462d-b394-416f5d47f855"
      unitRef="usd">25200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfOC03LTEtMS0zOTIxMw_a1074479-21c0-4dbe-929c-a9f2bc46c554"
      unitRef="usd">33500000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItMS0xLTEtMzc2OTY_1709a580-df66-428d-be5f-16a84555365c"
      unitRef="usd">32100000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItMS0xLTEtMzYzNTk_5194c7ee-38fd-4c23-94d2-eff52734e318"
      unitRef="usd">-44200000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItMy0xLTEtMzYzNTk_2431e41a-3031-4eac-8ed6-ae54aa1e0f5b"
      unitRef="usd">55800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTItNS0xLTEtMzYzNTk_e967bf79-3186-43e8-b1fb-794e62283ca6"
      unitRef="usd">-18600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMS0xLTEtMzc2OTY_473c7772-f7c6-442c-acb5-0f7b962ea34c"
      unitRef="usd">2600000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMS0xLTEtMzYzNTk_82034a27-80dd-4538-86b5-3f3cd7c81a5f"
      unitRef="usd">-7100000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMy0xLTEtMzYzNTk_1cc20358-2e3a-41cc-bf7e-1c7683689cd7"
      unitRef="usd">-1700000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtNS0xLTEtMzYzNTk_5da6b4db-745b-494d-b015-ae9eecdfc9dd"
      unitRef="usd">5500000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMS0xLTEtMzkyNzc_af63ad37-9897-4044-9f2a-e3405d756ca3"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMy0xLTEtMzkyNzc_3de724ac-0133-4c03-8807-335be88724a1"
      unitRef="usd">1000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtNS0xLTEtMzkyNzc_b4ac5708-b14d-4f31-8cd8-d6eac835d1b5"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtNy0xLTEtMzkyNzc_ec97ae7e-d855-49ad-aecd-dc43671a8e35"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InventoryWriteDown
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMS0xLTEtNDM2MjA_2b003d96-3abc-48a2-a8c0-9908f8478d52"
      unitRef="usd">6500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtMy0xLTEtNDM2Mjc_c2b81f73-212f-4a65-b971-e1789f3003fc"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtNS0xLTEtNDM2MzQ_55e37ae4-602f-41e6-ad72-c4d9acbe6e01"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTMtNy0xLTEtNDM2MzQ_4e04c381-872e-42a2-b7e9-b88cdf4fe081"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtMS0xLTEtMzc2OTY_44157838-e1dd-4036-80db-268bab651974"
      unitRef="usd">1800000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtMS0xLTEtMzYzNTk_beb2c444-6719-41a2-99ce-e7794622dc4f"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtMy0xLTEtMzYzNTk_f763b495-fa1b-4d23-bbbb-75b35c8f15a9"
      unitRef="usd">99700000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTQtNS0xLTEtMzYzNTk_8cf4239c-3d09-45b0-9625-b85831c3b9d0"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMS0xLTEtMzc2OTY_dcc2d345-2eaa-46ef-9879-f77da16434ec"
      unitRef="usd">162000000.0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMS0xLTEtMzYzNTk_9f553bde-1562-4475-9387-3da9488b6508"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtMy0xLTEtMzYzNTk_b862252b-af92-4e00-ae3d-e49c943159df"
      unitRef="usd">1000000.0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTUtNS0xLTEtMzYzNTk_61e3c13e-50a1-4437-9d44-cbc4ecd21885"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtMS0xLTEtMzc2OTY_34220428-62a2-421c-8bd5-89d81671b35c"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtMS0xLTEtMzYzNTk_ecaccc7d-477e-43bb-8211-6f9103076dcf"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtMy0xLTEtMzYzNTk_3224c62f-6ba6-4cfc-abaf-85a7ab6aac06"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTYtNS0xLTEtMzYzNTk_e5e536de-63d4-4c7c-914c-a09326fce782"
      unitRef="usd">1500000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtMS0xLTEtMzc3MDI_af615186-7ba7-4493-bd56-f63dce7d406e"
      unitRef="usd">6600000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtMS0xLTEtMzYzNTk_7bd2efa0-bfbe-46e0-9594-2204e7a06af6"
      unitRef="usd">-3100000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtMy0xLTEtMzYzNTk_de7bb576-9ac6-4131-8be3-2221db7068f1"
      unitRef="usd">-2800000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTgtNS0xLTEtMzYzNTk_51576ca6-fa48-48a9-8868-a93ae5122363"
      unitRef="usd">3900000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktMS0xLTEtMzc3MDI_b4ee6948-230a-4e1d-98bc-416fe62b6ef8"
      unitRef="usd">8800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktMS0xLTEtMzYzNTk_54b9361c-c31f-4919-8a80-6112e0761e51"
      unitRef="usd">21400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktMy0xLTEtMzYzNTk_c84e0aa1-6d13-4dfe-80b6-de8f25abc532"
      unitRef="usd">-64000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMTktNS0xLTEtMzYzNTk_2ec185fa-3d69-4c8f-a3a7-2b47a63a40b1"
      unitRef="usd">18200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtMS0xLTEtMzc3MDI_79ec963a-2f0c-4b2c-9bdd-e25836764f8f"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtMS0xLTEtMzYzNTk_db0a674b-ca4c-4528-bd2c-ff0036e63b16"
      unitRef="usd">-2200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtMy0xLTEtMzYzNTk_4535ff4f-6332-4f69-9802-1c006fec770a"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjEtNS0xLTEtMzYzNTk_d2733898-3c4f-4838-8b73-cb74fb27b85a"
      unitRef="usd">-8000000.0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItMS0xLTEtMzc3MDI_c346fc0b-4431-4098-81bf-9689d1f90956"
      unitRef="usd">-89900000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItMS0xLTEtMzYzNTk_186a6754-95f5-4a57-84f4-d3c937204d42"
      unitRef="usd">108400000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItMy0xLTEtMzYzNTk_10fbf562-1923-4819-ab71-ebc530d97b45"
      unitRef="usd">-25100000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjItNS0xLTEtMzYzNTk_5181f88d-9441-47f4-b87f-ecc24226684d"
      unitRef="usd">25100000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtMS0xLTEtMzc3MDI_807b925c-30b8-42de-8f9a-e8a1352627a6"
      unitRef="usd">4000000.0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtMS0xLTEtMzYzNTk_b57bad1b-e4bd-4ee6-bdd8-edfe93548ec0"
      unitRef="usd">2300000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtMy0xLTEtMzYzNTk_1e44fc99-2381-4dea-aa53-0773661f9e25"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjMtNS0xLTEtMzYzNTk_3808bce9-a1af-4f0a-8048-6f8ef401a95e"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtMS0xLTEtMzc3MDI_b93f655b-e905-4f2a-9fd6-4ecd1c16e9f6"
      unitRef="usd">9200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtMS0xLTEtMzYzNTk_1947057b-8a09-40ee-aad5-be80e4ee3029"
      unitRef="usd">-1200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtMy0xLTEtMzYzNTk_d26b895d-a759-41e1-afcd-6df53d3a0389"
      unitRef="usd">-10700000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjQtNS0xLTEtMzYzNTk_01d442d1-5fbe-446a-891c-9c768ef763f8"
      unitRef="usd">1100000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtMS0xLTEtMzc3MDI_88e8c9d6-d180-4565-8198-99de5b0f83b7"
      unitRef="usd">65700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtMS0xLTEtMzYzNTk_c0aabe08-80c1-4907-832e-dc2ac98244a6"
      unitRef="usd">-200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtMy0xLTEtMzYzNTk_ba7b2604-f59d-4497-937e-4bb7ff4cbfd7"
      unitRef="usd">4400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjUtNS0xLTEtMzYzNTk_6ca658ac-945e-479b-8887-0fee5f05ed27"
      unitRef="usd">-800000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtMS0xLTEtMzc3MDI_d3eabea3-bbf9-423d-94d5-8561115653a2"
      unitRef="usd">-26600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtMS0xLTEtMzYzNTk_903db587-321b-4713-ab40-16b2eac643c4"
      unitRef="usd">-200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtMy0xLTEtMzYzNTk_3c9ec302-d858-4387-a162-90a78b4554d8"
      unitRef="usd">30700000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjYtNS0xLTEtMzYzNTk_bdd10d84-a1a7-4048-89e5-78f3efed2bb7"
      unitRef="usd">-500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctMS0xLTEtMzc3MDI_185792e8-127b-4d0e-a7eb-501d67e49c39"
      unitRef="usd">18200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctMS0xLTEtMzYzNTk_5b7fd162-d38c-49c5-aeff-1f6cf4eda5c6"
      unitRef="usd">-73700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctMy0xLTEtMzYzNTk_1fd38e92-8523-4014-9379-4ab90aee59eb"
      unitRef="usd">60700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjctNS0xLTEtMzYzNTk_88a038e8-e7d7-419f-a5bf-0c055f9d60e4"
      unitRef="usd">83700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktMS0xLTEtMzc3MDg_aa35696a-b69d-4e1e-a94d-ee8fcf505687"
      unitRef="usd">18000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktMS0xLTEtMzYzNTk_5ad96947-6006-4d4c-af74-2970c29f84ee"
      unitRef="usd">7900000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktMy0xLTEtMzYzNTk_f29357e4-adfb-4e07-8f31-c5afd6c5bd86"
      unitRef="usd">10200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMjktNS0xLTEtMzYzNTk_555af17b-6c69-4086-bad0-133325b4fac0"
      unitRef="usd">8600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtMS0xLTEtMzc3MDg_78ec30e2-cee1-4792-a2f8-2db01ebb6d55"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtMS0xLTEtMzYzNTk_ad6cd2ec-1fc8-42fc-a9e6-a46d85439f1a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtMy0xLTEtMzYzNTk_8174625c-a61a-4a9f-aeff-40a96adcfe5b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzAtNS0xLTEtMzYzNTk_f88c96be-5673-4a38-80d1-db69fe86b20c"
      unitRef="usd">278500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtMS0xLTEtMzc3MDg_ee5ee437-1e04-470a-9927-f9062b1fc016"
      unitRef="usd">379100000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtMS0xLTEtMzYzNTk_f12e6691-a61c-4a66-9bc4-9f048d7569b4"
      unitRef="usd">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtMy0xLTEtMzYzNTk_c99f7e64-4a5b-45e6-8661-6e41ff02d3b6"
      unitRef="usd">21300000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzEtNS0xLTEtMzYzNTk_a7ed0dab-382a-49d8-b897-0900bbcf85ce"
      unitRef="usd">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItMS0xLTEtMzc3MDg_c0074a61-946a-4e3f-8405-02b8b78128be"
      unitRef="usd">147800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItMS0xLTEtMzYzNTk_773d9af7-ed66-4342-b4e5-3d3759021a64"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItMy0xLTEtMzYzNTk_473e2119-1865-4807-a048-7d799c881d87"
      unitRef="usd">60800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzItNS0xLTEtMzYzNTk_92e86e81-9298-45b3-9dde-e18fdc0b6ace"
      unitRef="usd">78500000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtMS0xLTEtMzc3MDg_8913cc47-4c6e-49d9-ae50-55fd98c1770e"
      unitRef="usd">61100000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtMS0xLTEtMzYzNTk_aef23412-1874-48e8-9614-80459f461e93"
      unitRef="usd">35900000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtMy0xLTEtMzYzNTk_b5a069f4-94f0-495f-bcb7-704b43cd8d21"
      unitRef="usd">69000000.0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzMtNS0xLTEtMzYzNTk_63640ff9-3eb6-4401-bba7-2ae90c4be66b"
      unitRef="usd">79200000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtMS0xLTEtMzc3MDg_62aa5c51-2a60-494f-a756-057e8ac0e2bd"
      unitRef="usd">274400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtMS0xLTEtMzYzNTk_f5229314-ec18-43dc-aad5-90b2904b193f"
      unitRef="usd">28000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtMy0xLTEtMzYzNTk_b1175724-1847-4d6a-9549-23635de84645"
      unitRef="usd">19300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzQtNS0xLTEtMzYzNTk_79aef71c-818c-45ed-ad88-97a0c24d5e21"
      unitRef="usd">-286400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtMS0xLTEtMzc3MTQ_5bfc3200-0bf3-49e7-896f-d437a809d4b4"
      unitRef="usd">91800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtMS0xLTEtMzYzNTk_1c65e264-5464-449a-a27a-ad762a087839"
      unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtMy0xLTEtMzYzNTk_26caa3c7-cacb-4ce0-968e-afe62611a487"
      unitRef="usd">13300000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzYtNS0xLTEtMzYzNTk_37b411b5-5338-4f0d-b6cb-1a4070a83440"
      unitRef="usd">23200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctMS0xLTEtMzc3MTQ_dbeba20c-b2f7-49ca-bada-de175d4855ad"
      unitRef="usd">11500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctMS0xLTEtMzYzNTk_f0fad2d6-831a-4f62-8451-7f119b089781"
      unitRef="usd">3800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctMy0xLTEtMzYzNTk_def818e9-dfa2-4c16-8bae-19ad4e306eed"
      unitRef="usd">9800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzctNS0xLTEtMzYzNTk_cb591a00-ff68-4444-a910-d7f6034b0630"
      unitRef="usd">14500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMS0xLTEtMzk0MTA_084afbc7-76c0-4560-a5e0-e9442b03245e"
      unitRef="usd">3300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMy0xLTEtMzk0MTA_cce87246-93b1-44ba-9fef-95ee00a48932"
      unitRef="usd">100000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtNS0xLTEtMzk0MTA_21c47071-e280-43e0-9e08-a7de7d700b1e"
      unitRef="usd">3900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtNy0xLTEtMzk0MTA_4c464892-5f85-47c9-872e-93d2371416ac"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMS0xLTEtMzc3MTQ_7c0f819d-4ce0-49a1-a1c3-ee8c268a694b"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMS0xLTEtMzYzNTk_848e35f9-70b9-4037-a81d-b73dde5ad629"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtMy0xLTEtMzYzNTk_3849328b-01a6-4a61-9141-a13d9d3fd2b4"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzgtNS0xLTEtMzYzNTk_e1b7db23-4d28-4b57-a5ad-fbe6188b078f"
      unitRef="usd">340000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktMS0xLTEtMzc3MTQ_a1ec80d8-338c-4c3c-9a92-8e128a7214ff"
      unitRef="usd">1200000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktMS0xLTEtMzYzNTk_ea23c613-2fcc-4b60-ba50-4200b0c383c2"
      unitRef="usd">0</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktMy0xLTEtMzYzNTk_7b02e7d5-05a9-4a76-80fb-f56069d5e663"
      unitRef="usd">1000000.0</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfMzktNS0xLTEtMzYzNTk_b7f07c43-0c67-4ff2-8931-302b48fa59e5"
      unitRef="usd">1400000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtMS0xLTEtMzc3MTQ_9d45ea0d-55d9-42ba-9060-25767cb03dff"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtMS0xLTEtMzYzNTk_278305c1-5ce4-4048-aa26-be668b438853"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtMy0xLTEtMzYzNTk_ac471b81-a5cd-4a3f-aed3-ff12cf046606"
      unitRef="usd">8600000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDAtNS0xLTEtMzYzNTk_8ba2a51b-ceaa-40f7-a4c2-2cb3207f4805"
      unitRef="usd">115000000.0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItMS0xLTEtMzc3MTQ_7d905a04-5e3d-4da7-9a9f-457dba8e2979"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItMS0xLTEtMzYzNTk_08641a12-8807-42d1-a37c-b182f8a1144a"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItMy0xLTEtMzYzNTk_420dac49-eab2-41e7-87b9-3d97438cb090"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDItNS0xLTEtMzYzNTk_6a4c2ed6-0e41-48e1-bd32-095c18dc1b65"
      unitRef="usd">50000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtMS0xLTEtMzc3MTQ_de520992-7141-4eaa-bbc1-38ef0fe373ed"
      unitRef="usd">-150600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtMS0xLTEtMzYzNTk_446c45e8-2c15-4e76-9be3-cd954d7e36a9"
      unitRef="usd">-2100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtMy0xLTEtMzYzNTk_faabaa3d-0edd-4f64-9b97-ea1d222e7c7e"
      unitRef="usd">-10000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDQtNS0xLTEtMzYzNTk_8fb08a20-3dca-455c-9527-43af1b4a4c3a"
      unitRef="usd">182300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtMS0xLTEtMzc3MTQ_9816f1e4-e3db-4178-a250-12837c67ee12"
      unitRef="usd">-600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtMS0xLTEtMzYzNTk_a5ec92b7-5250-4d30-9c86-f54bb4a18e4f"
      unitRef="usd">1100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtMy0xLTEtMzYzNTk_a0df22b4-fa32-4f1f-8265-376bd2df760b"
      unitRef="usd">500000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDUtNS0xLTEtMzYzNTk_94904673-e35e-4c44-be2f-90af6854b0fc"
      unitRef="usd">2700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtMS0xLTEtMzc3MTQ_ad95947d-f2fe-45be-8c73-83b74b66c6d5"
      unitRef="usd">141400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtMS0xLTEtMzYzNTk_fa50e68f-a23c-4e32-a575-c43f97fec550"
      unitRef="usd">-46700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtMy0xLTEtMzYzNTk_c3a8e6e5-c5bc-4b7e-9afd-f16b46c006f2"
      unitRef="usd">70500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDYtNS0xLTEtMzYzNTk_4875e6e4-782e-4521-9c97-5ddeb9d25582"
      unitRef="usd">-17700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctMS0xLTEtMzc3MTQ_c915b898-6d00-45b1-b55f-7820446d6560"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctMS0xLTEtMzYzNTk_9bfd1774-da1d-4f94-b8df-1785f6a3e6cb"
      unitRef="usd">163700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctMy0xLTEtMzYzNTk_b7f62452-5ffb-4769-a84e-fd68fab98273"
      unitRef="usd">93200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDctNS0xLTEtMzYzNTk_20484388-580f-4d0d-bd46-46d092d9e3ed"
      unitRef="usd">110900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtMS0xLTEtMzc3MTQ_05afba1f-758c-41a9-9d85-0fd7e15799ed"
      unitRef="usd">258400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtMS0xLTEtMzYzNTk_db84693c-1c06-4ae1-9414-91f34c537800"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtMy0xLTEtMzYzNTk_af1d52b9-d0c4-4412-934c-4bbfeec501c3"
      unitRef="usd">163700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184OC9mcmFnOmM5ZTZjODk5N2I5MTRkNTU4MDg4ODhlNTgwNTExMDBjL3RhYmxlOmEwNDhlZmM4OGY5MDQ5MjA4MzgyOTA5MGM5YmE5YzhmL3RhYmxlcmFuZ2U6YTA0OGVmYzg4ZjkwNDkyMDgzODI5MDkwYzliYTljOGZfNDgtNS0xLTEtMzYzNTk_df8317db-7226-4eb4-be97-ff0851523b4b"
      unitRef="usd">93200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODI_2c03e61c-db3f-4dbe-b69d-0766aa76db50">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Financial Statement Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad Genetics, Inc. and subsidiaries (collectively, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties.&#160;The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.&#160;The Company&#x2019;s corporate headquarters are located in Salt Lake City, Utah.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full impact of the COVID-19 outbreak continues to evolve and its future impacts remain uncertain and unpredictable. The Omicron variant, which has become the most common form of the virus circulating throughout the world and appears to be more transmissible than other variants to date, is causing significant uncertainty. The impact of the Omicron variant and other variants that may emerge cannot be predicted at this time and could depend on numerous factors, including, but not limited to, vaccination rates among the population, the effectiveness of COVID-19 vaccinations against emerging variants, and any new measures that may be introduced by governments or other parties in response to an increase in COVID-19 cases. Management is actively monitoring the impact of the global situation on the Company&#x2019;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17%, 16%, 15% and 14% of total revenue for the year ended December 31, 2021, the six-month transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#x2019;s customers as well as their dispersion across many geographic regions. No customer accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders&#x2019; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#x2019;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#x2019;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December&#160;31, 2020 or during the years ended June 30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#x2019;s assessment of current and expected orders from the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f"&gt;five&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b"&gt;one&lt;/span&gt; to seven years. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company&#x2019;s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $6.7 million and $2.3 million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $0.2 million. There was no capitalized software amortization expense for the remaining periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp;amp; Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and clinical service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;466.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;767.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;789.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;805.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 606, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ely $29.7&#160;million in a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#x2019;s right to payment is in an amount that directly corresponds with the value of Company&#x2019;s performance to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of  $6.8 million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(0.05). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Payment Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, Compensation &#x2013; Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#x2019;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#x2019;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company estimates the likelihood of achievement of the performance conditions at the end of each period. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December&#160;31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $162.0 million and $1.0&#160;million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $14.6 million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#x2019;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute &lt;br/&gt;&#160;&#160;&#160;&#160;basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive &lt;br/&gt;&#160;&#160;&#160;securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Period translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjM_8c257998-ad37-4be0-bf19-065020cd8d7f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Financial Statement Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad Genetics, Inc. and subsidiaries (collectively, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties.&#160;The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.&#160;The Company&#x2019;s corporate headquarters are located in Salt Lake City, Utah.  &lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Njg_d4714a50-320d-4049-9861-c4310fbcfa57">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODE_051e07d2-b17e-430e-b13e-faf66e2d7d26">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODA_a29de0e1-10b6-45fb-afe6-9ccd079ae14f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17%, 16%, 15% and 14% of total revenue for the year ended December 31, 2021, the six-month transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#x2019;s customers as well as their dispersion across many geographic regions. No customer accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8e0e54e9b3ce4a3a9110635bf28d65bf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM3NA_d9bdadbd-6c9d-4dd4-8478-2bc921fc6f10"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iad15d513ac03478199e9e31a63c2e46d_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM2Mg_2a760be2-8fe8-4b2c-a40f-6917d8c6f5bc"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i701057b14190407c804d2064afc26532_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM1OA_46426637-610b-42e9-9e1b-cc9f7e134e62"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1aa5bdf689894b6ab2ba9eb4389ee963_D20180701-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM1MjM1NA_49b05797-ac72-48e2-8270-a43736e2941c"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMzI5ODUzNDk0NDY2Mw_ec6bcf03-4bed-4bd1-afaf-99da33266731">Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Njk_820d9db9-64fd-4323-8045-6bb96759f09b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders&#x2019; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#x2019;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#x2019;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December&#160;31, 2020 or during the years ended June 30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_27c8b3d7-b619-4006-bee7-d2cd97cb0a32"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_5e361c5b-7edd-4692-b25c-6ab87f42bf1e"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_a1399c5b-9d1c-40a5-b1fb-b25ff2fcdedd"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNjc0Nw_c31b76ab-80e9-4230-b3da-5c9c4f831fda"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODM_321bcf38-9c32-4ec8-8bb5-a95cc954ec77">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#x2019;s assessment of current and expected orders from the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Njc_ebf6c44f-e551-4948-a9ee-7cbbbaeab093">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjI_1218d81a-b099-4511-86e5-fed17f21cce8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODM5Ng_6cc17539-7120-4c29-90e4-e71d7c3a5e7f"&gt;five&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0MA_86111bf7-63df-4207-a402-fdeccecbbb5b"&gt;one&lt;/span&gt; to seven years. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic25baf947458498cbc5ec1d41a505594_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODQwMg_fd24e593-ee6f-48d6-9e16-a2bbc09999e4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0f0b6b5784d44e638df0d82d2332ca5d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfODU0Ng_75518da4-2d6f-4d87-82f0-8a98be9b051f">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Nzg_56505bb8-472a-4c4a-b48b-e729e0fdebf6">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company&#x2019;s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $6.7 million and $2.3 million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $0.2 million. There was no capitalized software amortization expense for the remaining periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM4NDU0Mg_297b8e78-1eb2-4239-8101-602ff29d9827"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY4ODIxMQ_e829ac67-7050-4bda-bb84-805abc71a291"
      unitRef="usd">2300000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfNDk0NzgwMjM4NDU5Mw_2ad21699-5747-46fa-9140-638798267b43"
      unitRef="usd">200000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODQ_378d248b-d7cb-4a6d-8410-b28789cdd3dd"
      unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODQ_7a11d979-6684-4f71-9741-d33829b92f31"
      unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5ODQ_a994876f-b2dc-41f6-996d-c97270ac0f89"
      unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzE_9c8d5fb5-1510-478d-951d-7a7436d0a0a3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzY_a02df348-17be-4f2b-8b9b-6130bc632e73">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp;amp; Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and clinical service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;466.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;767.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;789.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;805.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 606, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ely $29.7&#160;million in a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#x2019;s right to payment is in an amount that directly corresponds with the value of Company&#x2019;s performance to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of  $6.8 million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(0.05). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Nzk_17cbcd72-54cd-4303-b5ca-ff3bafb5359b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s revenue by type for the year ended December 31, 2021, the transition period ended December&#160;31, 2020, and the years ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and clinical service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i804cc2b055a3466fbb3e15bd020c759d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy0xLTEtMS0zNjM1OQ_5535ddb0-4a0f-4676-b0d2-9262d0ea0134"
      unitRef="usd">316300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58fd5561929d497eaf7992c43061cee2_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy0zLTEtMS0zNjM1OQ_c1ca3f13-27b3-4eaf-ad63-de061514bc83"
      unitRef="usd">159300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i484dc209f37b4adf909bfa0878315aac_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy01LTEtMS0zNjM1OQ_2566b0d8-031a-4634-8bd0-2bed26b0d80c"
      unitRef="usd">347400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfd1e4144cb64cc2be192b5f21702ee2_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMy03LTEtMS0zNjM1OQ_d879c5f3-08f7-497d-ad1c-b0abe2afa345"
      unitRef="usd">479700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23674b92559340f5b730b6afcc5f3e1f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC0xLTEtMS0zNjM1OQ_f449f439-4019-466a-8dfe-e0c2914b0171"
      unitRef="usd">120900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44258853a0d44e2b9701f666527520b1_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC0zLTEtMS0zNjM1OQ_a5782b6b-6325-440c-9c2b-4666478108b9"
      unitRef="usd">33900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic14004bb5c3043ef94f2f37784092276_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC01LTEtMS0zNjM1OQ_24ae0379-fdbe-4355-a440-7ba335ba8e41"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868860485c4b4abeb0e46251d83d47df_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNC03LTEtMS0zNjM1OQ_88abe1f9-e83d-441f-8b19-53f53aaf59d7"
      unitRef="usd">43000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0c94826adb64c97800cb3e9f2f19447_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS0xLTEtMS0zNjM1OQ_858361a3-240f-41ff-8c87-131c7f17ea4a"
      unitRef="usd">106800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib56d8f8d202742b8adbccfc987f7d6aa_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS0zLTEtMS0zNjM1OQ_2ae14b1d-c274-4d3a-836b-38e3f17a636b"
      unitRef="usd">37600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if15aec7363f947d18a16d8514fa80f9a_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS01LTEtMS0zNjM1OQ_69119936-00b6-4fde-8ffd-ba733cbc860b"
      unitRef="usd">76700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ab9b81676e64707a024e71a8dadfab0_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfNS03LTEtMS0zNjM1OQ_6e5b3619-4b01-464e-a4ed-834b03b9b4b8"
      unitRef="usd">104900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31f918798d8d4876955bdfe1781192bb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC0xLTEtMS0zNjM1OQ_2e37adf1-a03a-4bf5-b06e-15f797a6d417"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0720541a493427c9ac9e47764246d06_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC0zLTEtMS0zNjM1OQ_4d4885e7-7eb4-48f0-a9e3-faf09a6ca37a"
      unitRef="usd">29800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf2d8ee96d1842a89bf2eb52509f39c8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC01LTEtMS0zNjM1OQ_1c969869-271a-4b14-b1d2-cde5744fec26"
      unitRef="usd">74100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i090f85aa323b4d5aa89a4ef95bbff252_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOC03LTEtMS0zNjM1OQ_19e3245a-99fb-49b3-9ac5-f678d8bbcea3"
      unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83f3a2eee80d4e39b6b467a461ee1164_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS0xLTEtMS0zNjM1OQ_a9a80ef1-bb27-4bb3-8dfe-10232a01210b"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79122a39eed648d294ae1358b2622bf2_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS0zLTEtMS0zNjM1OQ_1d82ff88-c1ec-48ea-9381-36289c5c5ded"
      unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8608277b4c9f4d1d8452c383fd7509c3_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS01LTEtMS0zNjM1OQ_7de928fa-22ac-47b5-8fbe-2d8c37098282"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i150c0623a2d04f00b701fe362396760e_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfOS03LTEtMS0zNjM1OQ_8a9e962a-2cff-450d-a00e-f09a2ed2d7c5"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i288dd68612f8451489b037c3444d9bf4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtMS0xLTEtMzYzNTk_ce157f6b-003f-42c8-8b44-043a418583cf"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2397e1764fa64b159eaa4444a72537d4_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtMy0xLTEtMzYzNTk_be7b3d60-9f7b-469d-8b2c-ee551f3a4092"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dddabbe8f644f90b6c63a2383f8793c_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtNS0xLTEtMzYzNTk_42fec872-7e6a-4067-b211-9daca0a43627"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i129a1c23ee0f4732a50e53e3e8927e0f_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTAtNy0xLTEtMzYzNTk_776238a6-440b-4c36-8db2-097dae35fe28"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtMS0xLTEtMzYzNTk_fd105afe-9164-428f-9fa8-b729a49de6f8"
      unitRef="usd">666400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtMy0xLTEtMzYzNTk_c2610da8-b05b-4b4b-98d2-4cdb1db44f35"
      unitRef="usd">279600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtNS0xLTEtMzYzNTk_7baba135-f64e-43a9-a888-0b6603b77867"
      unitRef="usd">586900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTEtNy0xLTEtMzYzNTk_bf6027e3-672b-403a-8d56-b6f27834f6c9"
      unitRef="usd">789400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItMS0xLTEtMzYzNTk_fd06370f-f0a2-48ff-a0cc-14fcc2604bff"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItMy0xLTEtMzYzNTk_6b7f9a4b-6718-4bc2-8642-8db0413138d1"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItNS0xLTEtMzYzNTk_92ff9d6c-024a-4268-b081-73dc4d127219"
      unitRef="usd">51700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTItNy0xLTEtMzYzNTk_49dcc769-36c6-47ac-96e7-ef774abbb4ed"
      unitRef="usd">61700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtMS0xLTEtMzYzNTk_46f4d4d3-6b3b-4222-95c0-f8b244996498"
      unitRef="usd">690600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtMy0xLTEtMzYzNTk_0ac3a682-7410-4b35-a474-c4c5544c3411"
      unitRef="usd">299800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtNS0xLTEtMzYzNTk_c98eb615-623e-43db-9018-8b6ad1a83c3a"
      unitRef="usd">638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmU4NDBiOTgxZDYwNjQwNTRhZjZiZTdjNDBmYzRjYTQ5L3RhYmxlcmFuZ2U6ZTg0MGI5ODFkNjA2NDA1NGFmNmJlN2M0MGZjNGNhNDlfMTMtNy0xLTEtMzYzNTk_7c5c3515-9bbb-4cad-9816-53f428b9743d"
      unitRef="usd">851100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTU5NDI5MTg2NjUyMzk_4bf099ee-34c9-4f9d-b2bd-e681c1ce5e50">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;466.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;767.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;789.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;805.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0298c605b2cc48e9a78c5e3cd557802a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0xLTEtMS02MjYzNw_8343a211-9035-475c-8ee7-e13092ecb817"
      unitRef="usd">271000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cca08c16e854e23a8787d0bc760adbc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0zLTEtMS02MjYzNw_c2d55748-8003-4eff-84dd-142ac67e76f9"
      unitRef="usd">45300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i804cc2b055a3466fbb3e15bd020c759d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC01LTEtMS02MjYzNw_4dcabe2d-82a9-46d1-8c0d-d3f3f17b4afe"
      unitRef="usd">316300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3970c7875cbc464db2a7a85cb7ba05be_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC04LTEtMS02MjYzNw_54871fef-104f-4e46-92a5-7401cbcd382a"
      unitRef="usd">140900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b9608c73ed34af285fe6c4c9fb6f968_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0xMC0xLTEtNjI2Mzc_08f6fb35-7399-49ed-9121-537f09ac495b"
      unitRef="usd">18400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58fd5561929d497eaf7992c43061cee2_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNC0xMi0xLTEtNjI2Mzc_83d9c3ef-4046-4821-9ce1-5039a9d7b890"
      unitRef="usd">159300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4ef79d3516c4f77b9ffd69e6257d787_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0xLTEtMS02MjYzNw_cac9b447-dbbe-4ab1-949e-d6590ea7e1a3"
      unitRef="usd">80400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7c78ab7c6f04b4cb49ccbc3b2572957_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0zLTEtMS02MjYzNw_9d8de5d0-7e6f-4686-bb38-8f1dace1124d"
      unitRef="usd">40500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23674b92559340f5b730b6afcc5f3e1f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS01LTEtMS02MjYzNw_256952e4-c466-471f-93ae-638666776c4b"
      unitRef="usd">120900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac2a8aac44f4c039ce9c9739247a018_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS04LTEtMS02MjYzNw_07c460ea-10bd-43cb-9167-5dd5dcbee6d8"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib74f7d15a9df4096b33799ed18b6d983_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0xMC0xLTEtNjI2Mzc_363f4f2f-ec0d-41df-ba90-50d0857cb5e1"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44258853a0d44e2b9701f666527520b1_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNS0xMi0xLTEtNjI2Mzc_4f693552-56dc-4715-aafa-2b7208d097ea"
      unitRef="usd">33900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic04f84748937427db317a660c8aa5694_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0xLTEtMS02MjYzNw_b3ff95ee-2fe5-4852-9340-ef1fe579fc3a"
      unitRef="usd">106200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee8de44f5f1c410599b481b8c80dbffb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0zLTEtMS02MjYzNw_59c0fc92-2342-4f5f-92a6-82ff2cb53c3c"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0c94826adb64c97800cb3e9f2f19447_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi01LTEtMS02MjYzNw_ef0459e3-e761-40c0-9e7a-032c0d6f6d32"
      unitRef="usd">106800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i445a32ad37ae4a4cbcbea691e2e68241_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi04LTEtMS02MjYzNw_f440cc90-f7a7-4bd5-ae4a-26131e9b3d1f"
      unitRef="usd">37400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52d75f83f7f84447a1524a301b921946_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0xMC0xLTEtNjI2Mzc_58e1be6c-a32e-4237-9f9f-34b88ac551e9"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib56d8f8d202742b8adbccfc987f7d6aa_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNi0xMi0xLTEtNjI2Mzc_a844139a-e4ee-4fee-94e6-bf69ee83c19b"
      unitRef="usd">37600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdaec0b909474eda8eee58534fbd0e9b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0xLTEtMS02MjYzNw_f4ec0327-d3ad-466b-9f3c-4401b8211bc6"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04da1cbfee0c46dcbaec497c3feb4cb6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0zLTEtMS02MjYzNw_ba0d2083-539e-45aa-8b4d-5ca5e4e3eabf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31f918798d8d4876955bdfe1781192bb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy01LTEtMS02MjYzNw_0de0a11c-3c16-488b-9d97-280e60726988"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf55993a60224a2990dd01e9cff341d4_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy04LTEtMS02MjYzNw_e243ef18-6c04-4613-837b-c96815b68ac1"
      unitRef="usd">29800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i706f35d8790f490f917a84f064c29039_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0xMC0xLTEtNjI2Mzc_9f80ff97-da7d-4121-8745-36684c31e98c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0720541a493427c9ac9e47764246d06_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfNy0xMi0xLTEtNjI2Mzc_72f3d645-6fcd-47f3-b4f4-54227eb7da8d"
      unitRef="usd">29800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6b105e8804486dad3802a06c5f3c30_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0xLTEtMS02MjYzNw_cd6e82e4-5bc0-4d79-9771-17be2280d5dc"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e31518757a047b4b8acd5c9c6584b2e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0zLTEtMS02MjYzNw_7ed7e58f-606c-4fba-9991-7cd5f4569d80"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83f3a2eee80d4e39b6b467a461ee1164_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC01LTEtMS02MjYzNw_f76537c1-d194-443d-97d5-ea75e90009e9"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96a6d32ed385415289c8a82922c2e387_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC04LTEtMS02MjYzNw_a5badb56-a2ea-49a7-8582-d73df0ef1ae5"
      unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1202a0ed3b3942fc98fdc69ccb249509_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0xMC0xLTEtNjI2Mzc_92bb0bd4-142b-4ffa-814b-e67fd53ce8d3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79122a39eed648d294ae1358b2622bf2_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOC0xMi0xLTEtNjI2Mzc_050278f0-1f34-4636-a95d-e4979bc4af39"
      unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5801c36efd234e02b91dbea98f7d3e00_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0xLTEtMS02MjYzNw_72efec53-ea92-4fb9-ac4f-e5b9759d8c9c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95ef34040e2948f2abbaab8f194748d9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0zLTEtMS02MjYzNw_2d3a5241-1eb0-4ec0-827b-1d60a1b48591"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i288dd68612f8451489b037c3444d9bf4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS01LTEtMS02MjYzNw_4e7f8da8-1c03-43dd-b294-8cdc0ba37d9f"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73d2040b564247bfb340b997780ebec6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS04LTEtMS02MjYzNw_b974a7a0-4fe1-4bc4-ac5a-28dbd0058dc3"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60635ff66fa64b69966774de4439af5e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0xMC0xLTEtNjI2Mzc_cff4142a-4047-4eb0-95e2-68a4b4ae0834"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2397e1764fa64b159eaa4444a72537d4_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfOS0xMi0xLTEtNjI2Mzc_947e8d8e-18bb-429c-8122-e55cb4009e51"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33fb7f026e344cc98c08acf5ec62babe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMS0xLTEtNjI2Mzc_f9e558de-0bad-489a-a055-11651100198f"
      unitRef="usd">579500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05a23258ea8e458393c125d83313b4a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMy0xLTEtNjI2Mzc_8643843f-1a64-4a82-9530-962b62a9d419"
      unitRef="usd">86900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af543975d3c4f0d87f66c4bcf7d02f9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtNS0xLTEtNjI2Mzc_e21ba23b-a1e2-4bf1-9344-c36a3dd5819c"
      unitRef="usd">666400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e1fa64c828d4462a20186e9d1460d97_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtOC0xLTEtNjI2Mzc_7bc9a8f0-d796-4efd-850e-09492dd24199"
      unitRef="usd">255300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ba16b7c64ec499aa4e9285f47ed97e8_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMTAtMS0xLTYyNjM3_bf8dde31-548a-4c64-bbe7-2f9de79cb334"
      unitRef="usd">24300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i986716e4da1a4b04af5c42601dd98df6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTAtMTItMS0xLTYyNjM3_c690c319-a312-4195-aa64-20eea21aec33"
      unitRef="usd">279600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55f89783405a449ba8e650af0370be7b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMS0xLTEtNjI2Mzc_34296b9d-a5f3-4ec9-ae76-0cb55be72f7f"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i903acccd51c14e7db28f40da3937c802_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMy0xLTEtNjI2Mzc_f4c20c24-b671-4181-9ed2-eee6afd3ad68"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i752b862f3eed44d2932dc858a1145fdc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtNS0xLTEtNjI2Mzc_047a9511-7e25-41e6-927e-afa6c3c1fd0c"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d6524bb7e0441428b64b01d2565544d_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtOC0xLTEtNjI2Mzc_983e3d47-78c7-476e-96ca-7686f3c6fc16"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d422ad60e04435ba4213ff4258db4ea_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMTAtMS0xLTYyNjM3_db105192-6c69-487a-ac6d-068e64035163"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8a5f16596a0436fbd42b910adae7e8a_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTEtMTItMS0xLTYyNjM3_5231d768-6cb4-4840-82e5-99853095de33"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf717ff001aa48f3898b6bad81b7074e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMS0xLTEtNjI2Mzc_bac8969f-1c16-4d4c-ac43-4655f2726a9a"
      unitRef="usd">603700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b308819639648ebb0241dce3fee0e0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMy0xLTEtNjI2Mzc_b1ce0ce4-4579-41ec-ae46-91f23dfb34ae"
      unitRef="usd">86900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItNS0xLTEtNjI2Mzc_d3d5952e-7e44-4a4c-8d9c-b6506f6bfbf5"
      unitRef="usd">690600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f4ddb7736b546099130bd23f3e3bf81_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItOC0xLTEtNjI2Mzc_2a462c8b-b366-4efc-a0e1-3c1ab700a6ed"
      unitRef="usd">275400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd6371c107dc4037900af9562f284dd2_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMTAtMS0xLTYyNjM3_c980e5ef-c616-476a-bd94-d7a43bbc400f"
      unitRef="usd">24400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjFhNmIxZWUwNzg5ZDRlMTBhOTViNzMyODQxYTQ2NmU0L3RhYmxlcmFuZ2U6MWE2YjFlZTA3ODlkNGUxMGE5NWI3MzI4NDFhNDY2ZTRfMTItMTItMS0xLTYyNjM3_ffb61337-7711-426a-87f4-b93b695bd180"
      unitRef="usd">299800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a25d7789ed04de38b87467b38c075c0_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMS0xLTEtNjI2NDU_99212a8c-89d6-4058-9cf2-434d36c823f1"
      unitRef="usd">329800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0371d7615c143a1a2f93c9c51117fd2_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMy0xLTEtNjI2NDU_a55a9c6c-8122-44d9-9624-c33d81bb50c5"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i484dc209f37b4adf909bfa0878315aac_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtNS0xLTEtNjI2NDU_4b87b9d2-9b07-4e3f-93e3-16fd5a45053c"
      unitRef="usd">347400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc48edd4cd4e4d54b269125a5eddbe4d_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtOC0xLTEtNjI2NDU_6ad6576a-621a-48c7-a23e-4e557a7e858d"
      unitRef="usd">466700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b993db4c69b427d8483546c0c8b8414_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMTAtMS0xLTYyNjQ1_676ed0e7-44b9-41f2-933d-a7f60ce91f26"
      unitRef="usd">13000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfd1e4144cb64cc2be192b5f21702ee2_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTgtMTItMS0xLTYyNjQ1_e28ea755-2178-499a-b4cb-12505f4a8355"
      unitRef="usd">479700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d121e6f796d42b5862758d3e57021f4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMS0xLTEtNjI2NDU_5fd9a1e1-3cc6-42fc-80b5-ff3adcb55cbe"
      unitRef="usd">39200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67b0e5857240418899f53180ceb70c6d_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMy0xLTEtNjI2NDU_663d200e-9203-4e41-975b-f5103d5e6a88"
      unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic14004bb5c3043ef94f2f37784092276_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktNS0xLTEtNjI2NDU_7080056c-3126-4746-90e5-b7bf1f25adb6"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba2729ff5f4d4076a392c72d3aff48fc_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktOC0xLTEtNjI2NDU_0821be39-4ecc-43de-b09b-6fcc29f77936"
      unitRef="usd">34600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie40ae86ad5c541fcaf7e88efb9f20b4e_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMTAtMS0xLTYyNjQ1_9a151b31-f584-46f7-aee7-8b57f2f7ff6a"
      unitRef="usd">8400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868860485c4b4abeb0e46251d83d47df_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMTktMTItMS0xLTYyNjQ1_fead91e8-35c1-48c9-83a3-8738023bdfd3"
      unitRef="usd">43000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i702d3c75cf5c4f2fb78e549b2d2e07b0_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMS0xLTEtNjI2NDU_d5e9164a-46e3-4c86-a879-8a09f73462a5"
      unitRef="usd">76400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91e9d08b5b5b4218a39576afaba6ff6d_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMy0xLTEtNjI2NDU_9b42f550-8f31-4def-96c5-9694ba7cca2d"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if15aec7363f947d18a16d8514fa80f9a_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtNS0xLTEtNjI2NDU_3975b0af-aa35-4e20-9803-d25c1dbef8c7"
      unitRef="usd">76700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie936759bad6c4f768bfdcaad6c185260_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtOC0xLTEtNjI2NDU_25c33adb-0fa3-4e75-9bd5-37bd9f79bf46"
      unitRef="usd">104900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia86ab20ba60c457c91783c694e76c402_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMTAtMS0xLTYyNjQ1_e5d6dd86-c546-4e7b-9fa0-13dd42e3f3d3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ab9b81676e64707a024e71a8dadfab0_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjAtMTItMS0xLTYyNjQ1_7eaec78a-af58-4923-bb79-7d5cd4d0e633"
      unitRef="usd">104900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab7934e0625841d3a44b1f9aecb81682_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMS0xLTEtNjI2NDU_52339543-4292-4d58-bb1a-3d97cc5239ec"
      unitRef="usd">74100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0036422f15ae438fb80d6285f3b97550_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMy0xLTEtNjI2NDU_827ea960-3d68-46d3-a93e-c0426acffb9d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf2d8ee96d1842a89bf2eb52509f39c8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtNS0xLTEtNjI2NDU_f81dfd8b-592f-4da7-88ec-67f4df47bcd2"
      unitRef="usd">74100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c2b20aa35ae4a3ea1712a93847ca7b2_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtOC0xLTEtNjI2NDU_0c85b02b-082d-4003-8a82-6ebf59e13257"
      unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb8491e37cb24bc3b4dc9fb8f3c5e60f_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMTAtMS0xLTYyNjQ1_6929083c-9c31-4f0c-9374-b93cb10e6a61"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i090f85aa323b4d5aa89a4ef95bbff252_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjEtMTItMS0xLTYyNjQ1_9d4e9301-88eb-4cb3-a459-96afd9519600"
      unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d596e3878504d22b86d326e8ca08613_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMS0xLTEtNjI2NDU_250d6732-0293-4136-8d94-e13da48ee336"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97117ebb3cae4051af1ac90be6bb19c0_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMy0xLTEtNjI2NDU_1d0c6132-8baa-4a5e-b2e9-71721b0ed25b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8608277b4c9f4d1d8452c383fd7509c3_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItNS0xLTEtNjI2NDU_f0de1eca-37f9-4d26-9af6-3a233633409b"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i102893003cb44b69875935664fcd4cfe_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItOC0xLTEtNjI2NDU_846cdfa3-cd5e-433e-8a25-50b3adf0344f"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c4ca98d253f439984d89ffe162f4048_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMTAtMS0xLTYyNjQ1_5069dd74-981d-457a-aae1-fbb42aa5460d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i150c0623a2d04f00b701fe362396760e_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjItMTItMS0xLTYyNjQ1_462e0a00-04d0-4a4a-8560-5b9b79b74618"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib644def5081d44de96b13a4ec090e55d_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMS0xLTEtNjI2NDU_57a43d71-1003-4803-af84-71a96a6a4e27"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaa7d7f8f59743e19ec25ad143e2a6f4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMy0xLTEtNjI2NDU_d871245e-4083-4791-9c95-7944ca6bd645"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dddabbe8f644f90b6c63a2383f8793c_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtNS0xLTEtNjI2NDU_8d1e1d85-c825-45f7-a760-8c7bea484ab1"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5819703f324d41349027f3813ef7b49b_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtOC0xLTEtNjI2NDU_d60bf789-6fee-48bd-80ce-ade18710ebd7"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bc1fef06d7444e6bd2ce7b0f247ad53_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMTAtMS0xLTYyNjQ1_b93427b1-0e35-4fd6-a472-69999aee9330"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i129a1c23ee0f4732a50e53e3e8927e0f_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjMtMTItMS0xLTYyNjQ1_08527678-617f-483a-8297-da062dff9e6d"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i204cd1955cec41cf9852a26d4402e885_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMS0xLTEtNjI2NDU_9ff3b8e5-9450-41b4-82c9-1e2f960b44fc"
      unitRef="usd">559800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43e5e361d21d4734af2a1a30525f5d04_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMy0xLTEtNjI2NDU_4345a52c-fc1f-427b-9267-5ca46071e280"
      unitRef="usd">27100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia41a7f80cc2c4503bc4eb92daa0eb3d4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtNS0xLTEtNjI2NDU_28b51b37-0789-4ceb-9ddf-7abc518a9c14"
      unitRef="usd">586900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib58b31ce77e7445aae0d209f9e0fbc19_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtOC0xLTEtNjI2NDU_0bc0dd23-3473-4086-89f0-4711c74a3466"
      unitRef="usd">767600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e64446e4bae4f2ebd45cae070670f11_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMTAtMS0xLTYyNjQ1_4e30df2b-37a6-4ee0-865a-3d5fb32fefc8"
      unitRef="usd">21800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b2264dd9c05486da1b3cece4daf0464_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjQtMTItMS0xLTYyNjQ1_cc5b0e7e-f94a-409e-aace-1cd872aeaaaa"
      unitRef="usd">789400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6faa7a7476b140628d02a78558ca348b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMS0xLTEtNjI2NDU_10957e8b-02a1-4b6e-b83f-8507e7f3d5e6"
      unitRef="usd">36400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b4f16f2653401187ed5044b51e074f_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMy0xLTEtNjI2NDU_70a1f1b4-c84c-4e62-8ae7-9ac521f4289a"
      unitRef="usd">15300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ff027bbe234c9297a75f8a5f857956_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtNS0xLTEtNjI2NDU_4bfc6a55-8743-4766-9596-005c339b3edf"
      unitRef="usd">51700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90c85822b51b4d35985a06435eee8bfa_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtOC0xLTEtNjI2NDU_a7747f02-398e-4d9a-a8a5-633c46ef3f2b"
      unitRef="usd">37800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0903d5f700b14c0f82cced2c6973459a_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMTAtMS0xLTYyNjQ1_69bb8ca9-259f-4cdd-9b9c-809f9e8c5209"
      unitRef="usd">23900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib111827dd4204cbcb47e31e0713f096d_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjUtMTItMS0xLTYyNjQ1_f444d526-671c-430e-a4f6-e988fc0ad757"
      unitRef="usd">61700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3faafc5dbad46dba5234c91f2b7c8d2_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMS0xLTEtNjI2NDU_586c8529-6c2b-4ea4-8a49-7fd65d523c94"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ea93dfc8c9b4d418d726e1503143b00_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMy0xLTEtNjI2NDU_f5d24ae7-65a0-4624-b9ed-381f8884250f"
      unitRef="usd">42400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtNS0xLTEtNjI2NDU_2069efbc-8472-4131-ada3-99c2f2d478af"
      unitRef="usd">638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i433ffee4dc83441d8a68d42763e78e7d_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtOC0xLTEtNjI2NDU_3d45fae4-d6e4-4390-a7cb-4209e91a0974"
      unitRef="usd">805400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia021741aa8d343d79f2d259b408c46a0_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMTAtMS0xLTYyNjQ1_9899b8b4-44de-4e2f-87c2-22061e705c93"
      unitRef="usd">45700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmUwMzcyNjMzYmJkYjQ5Y2U5NDg2NzNjOTk5ZWExNWM3L3RhYmxlcmFuZ2U6ZTAzNzI2MzNiYmRiNDljZTk0ODY3M2M5OTllYTE1YzdfMjYtMTItMS0xLTYyNjQ1_d1e14354-fa98-4f56-95ae-f4af0a03f135"
      unitRef="usd">851100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mygn:CARESActOf2020MedicarePaymentAmount
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTY0OTI2NzQ0Nzc5OTQ_964ff676-069b-4c22-b2d1-61627d4b74f5"
      unitRef="usd">29700000</mygn:CARESActOf2020MedicarePaymentAmount>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2Nzc_3880ccea-773d-47b9-aaf3-d0ec48116f04">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi0xLTEtMS0zODk2Ng_58ac01c4-3862-4688-bd98-12c39dcd66c4"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi0xLTEtMS0zNjM1OQ_db090f4b-9a37-47a5-ad54-fb40baf4ac47"
      unitRef="usd">32800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi0zLTEtMS0zNjM1OQ_e3d573a7-1e58-4138-a163-3decd24f7c11"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMi01LTEtMS0zNjM1OQ_205ba9da-efa4-4fe0-bd5e-d8a829d65754"
      unitRef="usd">2600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy0xLTEtMS0zODk2Ng_e04bc85d-00e7-4fde-8f5b-85a3c6bac2dd"
      unitRef="usd">40500000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy0xLTEtMS0zNjM1OQ_991eb38a-387e-41c2-b24d-44f6b4404437"
      unitRef="usd">6100000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy0zLTEtMS0zNjM1OQ_7e2f82af-77cf-4e32-880c-40c51413e8e0"
      unitRef="usd">7200000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfMy01LTEtMS0zNjM1OQ_8733be10-a63a-451a-bb4d-0c94bf5e33b0"
      unitRef="usd">7900000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC0xLTEtMS0zODk2Ng_e4bedf0b-c428-452a-8069-9ed7e9ae16b2"
      unitRef="usd">14000000.0</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC0xLTEtMS0zNjM1OQ_66216030-f5af-4b76-b369-cccbb1fdd44e"
      unitRef="usd">6000000.0</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC0zLTEtMS0zNjM1OQ_d79e6ad7-c3b2-48e5-b3c8-7260d42dca22"
      unitRef="usd">37800000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNC01LTEtMS0zNjM1OQ_ae953cca-6e8c-4d31-90de-3a65dafdb778"
      unitRef="usd">7500000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0xLTEtMS00ODgwMQ_a7999a2a-1f37-42cf-b117-1a24ed920115"
      unitRef="usd">1000000.0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0zLTEtMS00ODgwOA_2319711e-49bf-45f9-94b7-c06c397a0e1b"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS01LTEtMS00ODgwOA_1e2dae99-ab5e-4017-9ef1-3d8e4ad150a1"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS03LTEtMS00ODgwOA_0752c0fe-8f7e-4b8a-97d3-926987e6dd6f"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0xLTEtMS0zODk2Ng_fb0da598-f7ca-4181-8d3e-a536290ce71c"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0xLTEtMS0zNjM1OQ_58ac01c4-3862-4688-bd98-12c39dcd66c4"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS0zLTEtMS0zNjM1OQ_9667d6e5-f9ac-4a75-9ee8-994126a7ca43"
      unitRef="usd">32800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjY3ZjdmZWQzZmU2MTQ4YzQ4OGY5Zjc0Mjk2Y2VlZGMzL3RhYmxlcmFuZ2U6NjdmN2ZlZDNmZTYxNDhjNDg4ZjlmNzQyOTZjZWVkYzNfNS01LTEtMS0zNjM1OQ_c042a4ab-2953-4bde-a293-918ae8c6de83"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2NTA5Nw_e37e9309-0bdc-4931-af1a-2eeab4b0c425"
      unitRef="usd">15900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="ief14d1a627f44e8aa55a13b03bf21cfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2NTA4NQ_150bea30-e5be-4bcc-b649-cef0babfc404"
      unitRef="usdPerShare">0.15</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2NTExNw_f803f198-77a2-47ad-bcb4-06264dbb2798"
      unitRef="usd">6800000</mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTc1NjQ_b0218e6e-b907-4353-b2b3-448b8fb88f80"
      unitRef="usd">9900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i2684048ee70b4d07beca518b514fbc45_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTc2MDg_e74ed496-3950-4a85-ac46-ee7030925fb8"
      unitRef="usdPerShare">-0.10</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2e458e0265a748528393f9775e33c560_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTgyMjg_66bd743f-13e9-4c4e-94f4-07be1a6b6e1b"
      unitRef="usd">4700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75ba6d883e7547e7af3798c78f6badf4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTgyMjg_938d94e9-505f-44cc-9b4f-652df34d4b9f"
      unitRef="usd">-4700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i75ba6d883e7547e7af3798c78f6badf4_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTg1NDk_c87e2319-2480-463a-baf4-a83d85579cb7"
      unitRef="usdPerShare">-0.05</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <us-gaap:CapitalizedContractCostGross
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTkwNzA_7fc16a79-6d2c-433c-b854-8f25819e9359"
      unitRef="usd">0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjQ_8f848df7-d68d-4c4e-8399-90ba5664f1bf">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Payment Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, Compensation &#x2013; Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#x2019;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#x2019;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company estimates the likelihood of achievement of the performance conditions at the end of each period. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <mygn:OtherIncomeExpensePolicyPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjU_8aca6eb2-c365-4de2-8838-dc385c0f41ef">Other Income (Expense)The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December&#160;31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $162.0 million and $1.0&#160;million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $14.6 million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.</mygn:OtherIncomeExpensePolicyPolicyTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2OTIyNw_dcc2d345-2eaa-46ef-9879-f77da16434ec"
      unitRef="usd">162000000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMTA5OTUxMTY2OTIzNA_b862252b-af92-4e00-ae3d-e49c943159df"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets>
    <mygn:CARESActOf2020ProviderReliefFundAmount
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjA5NzI_e1b3b560-10ac-4e9b-aaa1-a0e9ebd4e3cc"
      unitRef="usd">14600000</mygn:CARESActOf2020ProviderReliefFundAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzM_2922d111-ede2-4c01-8e24-90742f99abcf">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#x2019;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzI_79d34be2-8b2f-4910-bae7-94d629b75f6b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute &lt;br/&gt;&#160;&#160;&#160;&#160;basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive &lt;br/&gt;&#160;&#160;&#160;securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODE_490c6457-ed0d-481d-a6ac-180f221b1439">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute &lt;br/&gt;&#160;&#160;&#160;&#160;basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive &lt;br/&gt;&#160;&#160;&#160;securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy0xLTEtMS0zNjM1OQ_9db7b96d-beff-4c97-96c4-81fde0e6b16d"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy0zLTEtMS0zNjM1OQ_9f992bf5-a0c8-4db0-9c75-1a7bedb9f977"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy01LTEtMS0zNjM1OQ_ba63ee6d-cf4c-42f2-8a2a-ae9fe3ddd190"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfMy03LTEtMS0zNjM1OQ_fad35eef-f75a-4051-81c3-0a7c68d9c07b"
      unitRef="shares">73500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC0xLTEtMS0zNjM1OQ_1136492d-714d-453a-b372-dae1a65868f9"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC0zLTEtMS0zNjM1OQ_ac6c588e-976a-4ec0-afd6-746048eeecd0"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC01LTEtMS0zNjM1OQ_ea37f558-ab3e-45b7-a23b-0f369ae91c65"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNC03LTEtMS0zNjM1OQ_7cf81ba3-ac4d-481f-bd96-53c55327e153"
      unitRef="shares">2500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS0xLTEtMS0zNjM1OQ_af6b191a-2ca9-4a27-ae96-6198837814c9"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS0zLTEtMS0zNjM1OQ_fa12b354-bdb6-4fd4-9122-dc294390e200"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS01LTEtMS0zNjM1OQ_dd400ff7-0df0-43d3-a177-3aede806471a"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOjAwNTM3NjFmNGUzMzQ3ZTU4ZTQxNmU5NWJmY2UwNzc3L3RhYmxlcmFuZ2U6MDA1Mzc2MWY0ZTMzNDdlNThlNDE2ZTk1YmZjZTA3NzdfNS03LTEtMS0zNjM1OQ_5032a190-b942-4d8e-9550-46d63344d739"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NjE_e719f458-fbee-4c59-bdf0-8b7d3eedf5ff">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi0xLTEtMS0zNjM1OQ_ea8d2a9d-7a5a-415f-99ba-79cfe887373d"
      unitRef="shares">4500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi0zLTEtMS0zNjM1OQ_770b10ab-b1c7-4847-8cc5-5dd144bd4196"
      unitRef="shares">6600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi01LTEtMS0zNjM1OQ_6e2b9b78-43c9-452b-926f-19f04155f6fe"
      unitRef="shares">5500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmEyZDRjMmEzZDFkMzQ5NTg5Y2E0ZjFjYzgzZmFjNmQ1L3RhYmxlcmFuZ2U6YTJkNGMyYTNkMWQzNDk1ODljYTRmMWNjODNmYWM2ZDVfMi03LTEtMS0zNjM1OQ_3d5f20a0-09b0-4d22-a7df-477d3c4fdbae"
      unitRef="shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzQ_742a1281-1395-4613-93ac-7b3717367aad">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Period translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2NzU_b96bcaf1-5952-46e5-9613-1e6980231fe2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Period translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmIwMWJhZWZjMTk3ZDQ2NGFiNDlkNjQ0NWRhZjc4Njg0L3RhYmxlcmFuZ2U6YjAxYmFlZmMxOTdkNDY0YWI0OWQ2NDQ1ZGFmNzg2ODRfMC0xLTEtMS0zNjM1OQ_e62cf793-bb94-4083-b047-d46df46a4c11"
      unitRef="usd">-3100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmIwMWJhZWZjMTk3ZDQ2NGFiNDlkNjQ0NWRhZjc4Njg0L3RhYmxlcmFuZ2U6YjAxYmFlZmMxOTdkNDY0YWI0OWQ2NDQ1ZGFmNzg2ODRfMS0xLTEtMS0zNjM1OQ_c4858c6c-9542-44ee-b9f7-abc7cd4243c7"
      unitRef="usd">-1800000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RhYmxlOmIwMWJhZWZjMTk3ZDQ2NGFiNDlkNjQ0NWRhZjc4Njg0L3RhYmxlcmFuZ2U6YjAxYmFlZmMxOTdkNDY0YWI0OWQ2NDQ1ZGFmNzg2ODRfMy0xLTEtMS0zNjM1OQ_cff68f1e-ab06-4069-a54e-75ce23277493"
      unitRef="usd">-4900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN184NS9mcmFnOmI5NTBlZDBiMDU4NzRiM2E5Y2U5YTE0MmZjN2E3NWZhL3RleHRyZWdpb246Yjk1MGVkMGIwNTg3NGIzYTljZTlhMTQyZmM3YTc1ZmFfMjY2ODQ_95f689c0-8202-432b-ad36-8fc87c234428">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNjQz_82b2aa36-2067-4d4f-9a8c-5b36254a7f1e">MARKETABLE INVESTMENT SECURITIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2021 and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no debt securities classified as available-for-sale in a gross unrealized loss position as of December&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;Additional information relating to fair value of marketable investment securities can be found in Note 3.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNjQ0_2318471b-8694-4a41-9198-800e0146a061">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2021 and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMy0xLTEtMS0zOTIyMw_c2ddc3b0-9749-43b0-9aa8-2057258eb856"
      unitRef="usd">195200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMy03LTEtMS0zOTIyMw_95c55b73-e7af-4706-9171-bc348f444054"
      unitRef="usd">195200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNC0xLTEtMS0zOTIyMw_bfc93922-a185-4af8-acfb-20c0982250ea"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNC03LTEtMS0zOTIyMw_cfae94a9-813b-471c-9335-ed1521aa4197"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNS0xLTEtMS0zOTIyMw_2ef99093-7c18-421d-a92f-683a3b39356d"
      unitRef="usd">258400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNS03LTEtMS0zOTIyMw_c3b628ed-5405-4146-bf5a-885999a895cb"
      unitRef="usd">258400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy0xLTEtMS0zOTIyMw_0e95ae5c-a432-4698-b465-3291d93a3223"
      unitRef="usd">105700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy0zLTEtMS0zOTIyMw_6a900c76-e486-4f13-a30e-5a6fcd0b4196"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy01LTEtMS0zOTIyMw_9fe8c7fc-f0fb-444b-b46d-d2cedb1278ad"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfNy03LTEtMS0zOTIyMw_d771cd58-7d85-45b4-bf8f-a2fc1c6feb21"
      unitRef="usd">105600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC0xLTEtMS0zOTIyMw_aebcf62c-8047-4396-a8fa-83c02b0b8c40"
      unitRef="usd">16100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC0zLTEtMS0zOTIyMw_5ee8b0a6-2065-4343-8779-1011154e2125"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC01LTEtMS0zOTIyMw_2e6e6ca4-d4df-44dd-89c9-05815c43acf4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOC03LTEtMS0zOTIyMw_eef71f7d-fa4e-4714-bca1-41e841d61ae7"
      unitRef="usd">16100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS0xLTEtMS0zOTIyMw_006cbc3e-36b4-4332-985e-b738e850c77c"
      unitRef="usd">6800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS0zLTEtMS0zOTIyMw_c0d9c22d-86eb-4b9b-bebb-a24fd476768a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS01LTEtMS0zOTIyMw_fbe1205a-b11d-4a17-a40c-39390855933d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfOS03LTEtMS0zOTIyMw_34e888c4-ff14-4cab-93ed-8dc5ddc55579"
      unitRef="usd">6800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtMS0xLTEtMzkyMjM_ad21e3e8-2936-4da7-8041-fe4f858af09d"
      unitRef="usd">11900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtMy0xLTEtMzkyMjM_d639bd92-d5ae-4922-9e7e-2172aa222c1c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtNS0xLTEtMzkyMjM_104249b2-ca0b-4fcb-a70f-305493d6cf4c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTAtNy0xLTEtMzkyMjM_fce9f09c-4105-4f46-88b7-176960462102"
      unitRef="usd">11900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtMS0xLTEtMzkyMjM_d941b4a4-1f3b-427a-870a-049b9af64e62"
      unitRef="usd">398900000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtMy0xLTEtMzkyMjM_7adad2fa-ac9e-4971-9a94-bb18949f5043"
      unitRef="usd">100000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtNS0xLTEtMzkyMjM_2b587158-b7fb-4d31-9243-faefc69e07b9"
      unitRef="usd">200000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjRlNjQ4NjZhY2UxYTRhMzhhYTY4MTJjYjllNzI5NTk1L3RhYmxlcmFuZ2U6NGU2NDg2NmFjZTFhNGEzOGFhNjgxMmNiOWU3Mjk1OTVfMTEtNy0xLTEtMzkyMjM_4432ff66-09fd-484d-907a-a3d3868a6838"
      unitRef="usd">398800000</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3445c0b98e214b96840337b96fa87ab1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMy0xLTEtMS0zNjM1OQ_8570acc6-11dd-481c-a9f8-2081b363f2e0"
      unitRef="usd">47900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3445c0b98e214b96840337b96fa87ab1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMy03LTEtMS0zNjM1OQ_a56b0d2c-2369-401a-9831-ea338c6d666f"
      unitRef="usd">47900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74dc0fe0c62e4eea8fd54a19e76b42e0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNC0xLTEtMS0zNjM1OQ_781f66cd-1c70-4ab0-8231-8f1358d1e23e"
      unitRef="usd">69100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74dc0fe0c62e4eea8fd54a19e76b42e0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNC03LTEtMS0zNjM1OQ_ea3792aa-627c-43b7-9600-e9ccbbd60be6"
      unitRef="usd">69100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNS0xLTEtMS0zNjM1OQ_5d9eeed1-90bd-476f-8f20-671bbdf10f2a"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNS03LTEtMS0zNjM1OQ_6e5ed7fc-1a65-4b82-8421-88f727ac919e"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy0xLTEtMS0zNjM1OQ_f2091cc9-1b41-496a-a882-84c24f8e3a6c"
      unitRef="usd">28800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy0zLTEtMS0zNjM1OQ_d3ad5e6a-458c-4f00-9c9a-5340137d4c93"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy01LTEtMS0zNjM1OQ_41823157-20d4-4a7b-9549-b975719b20cc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfNy03LTEtMS0zNjM1OQ_0a427c36-ef70-4243-9de9-8e48111de983"
      unitRef="usd">29300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC0xLTEtMS0zNjM1OQ_d9beda37-8f50-4c84-a859-f739b6de2779"
      unitRef="usd">9400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC0zLTEtMS0zNjM1OQ_b2aad8ad-ce7d-417f-b3bf-e24144b9c8d7"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC01LTEtMS0zNjM1OQ_bffd5391-cd70-4129-bb43-e7a836a068f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOC03LTEtMS0zNjM1OQ_4424da4e-3278-4951-8aef-2dd2d0fc79d5"
      unitRef="usd">9600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS0xLTEtMS0zNjM1OQ_e66b5fc8-928a-4c4a-a01f-81baed9c70f6"
      unitRef="usd">4000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS0zLTEtMS0zNjM1OQ_7f189e7f-3c3b-4ee5-9c57-9ca91deee284"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS01LTEtMS0zNjM1OQ_c4ad60c6-866b-47f2-9337-0e0d80f2051a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfOS03LTEtMS0zNjM1OQ_97f9e953-904f-4049-bb03-b4f842055fd0"
      unitRef="usd">4000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtMS0xLTEtMzYzNTk_821690f5-3775-41a9-b387-f69ac60028c2"
      unitRef="usd">11700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtMy0xLTEtMzYzNTk_2ff8666c-acb2-4f54-8855-08b46443db22"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtNS0xLTEtMzYzNTk_a03cd394-c6c6-4ced-815a-5f4fb8ec131e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTAtNy0xLTEtMzYzNTk_a308551f-e5ae-40e8-b0bb-8ae2d690e3bf"
      unitRef="usd">11800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtMS0xLTEtMzYzNTk_44f3f30b-280d-4739-a022-532efdf15d6c"
      unitRef="usd">170900000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtMy0xLTEtMzYzNTk_013a8847-7f43-456f-b9fc-e363298f0d13"
      unitRef="usd">800000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtNS0xLTEtMzYzNTk_77812a4e-a183-4479-9e5d-466a2de764e1"
      unitRef="usd">0</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOmUwYjNhMjdjMDE3ZDRkY2JhN2E0ZTZhMDZlMWVkOTg3L3RhYmxlcmFuZ2U6ZTBiM2EyN2MwMTdkNGRjYmE3YTRlNmEwNmUxZWQ5ODdfMTEtNy0xLTEtMzYzNTk_4bc9e36a-f932-48c3-b911-f54533793caf"
      unitRef="usd">171700000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNjQ1_b16aa26b-40d5-450e-8927-94aede7154f2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMS0xLTEtMS0zNjM1OQ_d88b2929-523d-4d25-bef7-ca6b1cc331c4"
      unitRef="usd">195200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i15cb1bb25065402192f586c58c6ea68d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMS0zLTEtMS0zNjM1OQ_35a08792-c7b2-44a2-8b59-2846fd2ee8a3"
      unitRef="usd">195200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMi0xLTEtMS0zNjM1OQ_e748b0fc-0de3-42dc-ab5c-b78e4fd14b87"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1095829af9974d7ab288fb2d7ac09c8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfMi0zLTEtMS0zNjM1OQ_b9739a87-96a6-4bfe-9bd7-95a12973abda"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNC0xLTEtMS0zNjM1OQ_189e5706-5490-47fd-a955-24f2a63430b7"
      unitRef="usd">80300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNC0zLTEtMS0zNjM1OQ_3736189c-d0d8-4d53-9fc4-7afca9680b7e"
      unitRef="usd">80400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNS0xLTEtMS0zNjM1OQ_b0f72d22-bbe6-475b-8493-362ce5f2f1c0"
      unitRef="usd">60200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNS0zLTEtMS0zNjM1OQ_6442df21-90b8-4156-a8a5-e81fcfbb528b"
      unitRef="usd">60000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNi0xLTEtMS0zNjM1OQ_04c131e5-ccc4-4658-86bd-1c20e5fe47fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNi0zLTEtMS0zNjM1OQ_6d7dac70-64fa-43be-a3df-387b5a590000"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNy0xLTEtMS0zNjM1OQ_51d896e7-ac47-4607-af4e-2496523a6bf1"
      unitRef="usd">398900000</mygn:InvestmentsAndCashAmortizedCost>
    <us-gaap:InvestmentsAndCash
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RhYmxlOjgxYjIyMWVhMjJjZDQ2N2FhZTNhOTFiNDRhYzBlYzgzL3RhYmxlcmFuZ2U6ODFiMjIxZWEyMmNkNDY3YWFlM2E5MWI0NGFjMGVjODNfNy0zLTEtMS0zNjM1OQ_1e8e4182-aae3-420e-b7b7-86e9af94b041"
      unitRef="usd">398800000</us-gaap:InvestmentsAndCash>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNDIy_a0c7956a-a18e-4d86-8c8e-004b8cdc8f06"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185NC9mcmFnOjRiMGQ4Njg5ZTAxNjRiMjc5OGQwNTBlZjM0ZDY1NmViL3RleHRyZWdpb246NGIwZDg2ODllMDE2NGIyNzk4ZDA1MGVmMzRkNjU2ZWJfNDIy_ad85775c-4864-4b38-9228-02850ce9fc83"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMzUyMg_065d4a77-65d6-4cd6-a8b7-bed8cb89059e">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014; observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#x2019;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately 13.5 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company&#x2019;s Consolidated Balance Sheets.&#160;Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities that are re-measured on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transition Period Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMTY0OTI2NzQ0MjE2MDU_5ecd2169-c5a4-4b21-bd71-bc9e8c6bba7a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014; observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#x2019;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately 13.5 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company&#x2019;s Consolidated Balance Sheets.&#160;Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm
      contextRef="i247f388a3aa24cea9da562bc5232fa78_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMTg2Mg_4dc343a1-657c-4074-b8e9-418dca9a9d64">P13Y6M</mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMzUyMA_5492546d-816e-4af7-9a1f-ed069405acfa">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities that are re-measured on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i53c7a2cd0dae41d7a18fabc16b2d6351_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi0xLTEtMS00MTIyNQ_87a94792-4c66-498f-8305-a628ffb5be96"
      unitRef="usd">63200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifacab91f64734e07850b1d1ccdcef519_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi0zLTEtMS00MTIyNQ_5be79192-3815-4282-921a-96f1cd3595a1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7d33dac4dba4cc4a2b1b2e4b46390a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi01LTEtMS00MTIyNQ_7c4b2e21-d3c7-44b7-a507-165eb8a9f00e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieea675210e024b6c916b2862b628898c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMi03LTEtMS00MTIyNQ_4692083a-cbda-4d94-954c-addb646be1a1"
      unitRef="usd">63200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i32ea39f951fe43d7bd7edbf117b03d28_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy0xLTEtMS00MTIyNQ_e72f364a-f27a-4c47-9a55-e961d0bb02a4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i649ff7da9f344b3594372e0db1334cf1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy0zLTEtMS00MTIyNQ_76cb693f-3d98-4e74-9da1-10cb7e44abc6"
      unitRef="usd">105600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9950e80ecb934b8aad3038826649ece1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy01LTEtMS00MTIyNQ_3c72ec71-dc94-4895-a95b-8bd1bc3177b6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a3b6101149c43809996e3a4fa47cce3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfMy03LTEtMS00MTIyNQ_094221fc-f83a-4837-adc6-02589bcc637c"
      unitRef="usd">105600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic6caf215e4694c5297b327ebab5489f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC0xLTEtMS00MTIyNQ_c8ee4cf4-0b05-450f-9c82-948f10fe5f57"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if4d609efbd994ab6a4717ae77454f9c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC0zLTEtMS00MTIyNQ_cd51b0c2-b9de-41e4-857a-46e66e706995"
      unitRef="usd">16100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id1ea51262455422b9b58287df633fdba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC01LTEtMS00MTIyNQ_741388db-3532-43d9-b631-031ee953249a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1643807ee3c4be2affc28b493b9971d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNC03LTEtMS00MTIyNQ_583b902f-7af7-42e4-a16a-0a485c936a30"
      unitRef="usd">16100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idfc35c6df6dd437cba1f343922b27753_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS0xLTEtMS00MTIyNQ_773848d9-b977-49b3-8477-c4bec3d67afa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5b1173e0a575429c87230088f831bd1c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS0zLTEtMS00MTIyNQ_66cb852c-f0ce-4b10-9419-34575fc4df3d"
      unitRef="usd">6800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d46cebc1ad34bfd93e108133ea4a5a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS01LTEtMS00MTIyNQ_7534da30-149b-4b97-9d4e-a7374756a313"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i40284936a2134287b22a5d55f29d89c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNS03LTEtMS00MTIyNQ_d71204c6-1389-4143-a4f0-e6e02776b5e0"
      unitRef="usd">6800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c2ac1ffa79241d7ae0a435a564bec54_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi0xLTEtMS00MTIyNQ_479910f2-b55e-48ac-85c7-602310901ef1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib6aef68764004a7ab2c3d1cafa4e6070_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi0zLTEtMS00MTIyNQ_4827f211-f71a-4e18-aae1-93cc0bf48b9d"
      unitRef="usd">11900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i22dbec5ca02d419cb74d488ed87eaf6a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi01LTEtMS00MTIyNQ_85b2c6db-f2af-42f1-9076-f6de6b6fae28"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifb01a0871980449b8e481ac37f3f1f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNi03LTEtMS00MTIyNQ_e7175de2-e77a-47ba-9db3-8b7684c54317"
      unitRef="usd">11900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i05ca8c5b9c4f42a7b049cd5568304428_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy0xLTEtMS00MTIyNQ_448205d0-e2ea-4f9e-aded-dd3e42b7ee76"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i48a6e30e15d44c27a12c044d297fe0ee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy0zLTEtMS00MTIyNQ_882d65ad-6245-4de1-9910-39c138e2d48b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7a1bafe663bf4dd2af911643d8115191_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy01LTEtMS00MTIyNQ_4607f6c0-f770-4b52-8a76-d35de941833d"
      unitRef="usd">8600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i330057192ddd491eb64b21392abce0f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfNy03LTEtMS00MTIyNQ_ff36fb11-0cbc-4012-8292-8b4083827e55"
      unitRef="usd">8600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i155d082ec2ff4209a45f170e667ea25c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC0xLTEtMS00MTIyNQ_355e83a4-d8ce-42bd-8d19-8dd6fa3f0c53"
      unitRef="usd">63200000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i21a3f606f6ce45719deb8e96cd7ddf12_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC0zLTEtMS00MTIyNQ_513bc976-87d7-450e-8c2a-df4f573295a5"
      unitRef="usd">140400000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="id34fd0ce23d9465eafda8ac8e370a4d3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC01LTEtMS00MTIyNQ_ca58db33-de44-45f7-b174-d977d2f0a48e"
      unitRef="usd">-8600000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjU3MjFiODJiOGQwZDQyNTM5ZWE5MTBkNmMyYWIwZDIyL3RhYmxlcmFuZ2U6NTcyMWI4MmI4ZDBkNDI1MzllYTkxMGQ2YzJhYjBkMjJfOC03LTEtMS00MTIyNQ_2b3e0738-cc65-4ab8-9e2b-82f52ab8f141"
      unitRef="usd">195000000.0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f303592870940ab8b8f59b374e18736_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi0xLTEtMS0zNjM1OQ_fb9e581c-9249-439e-a07f-6e5d1c9f1a18"
      unitRef="usd">69100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7d9ee368f974e858e239cc4f7cc09d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi0zLTEtMS0zNjM1OQ_1c679173-643b-4723-a2cd-6dab9e9e454e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1e01d25b7bf4a20a4ae7b3bc411229b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi01LTEtMS0zNjM1OQ_65800329-8c17-494f-a4a8-f6a9e64705b1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i068bcc7826fd40a29f15703667578d91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMi03LTEtMS0zNjM1OQ_af9a647b-66c1-4c62-8dd5-a1e68ba8a320"
      unitRef="usd">69100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i295380b6567e4eb1b4eeb49fa5fe93d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy0xLTEtMS0zNjM1OQ_c5f39e79-96e0-4dd0-8658-71021fff49d2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie43572fc1976464398da328af82d7f20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy0zLTEtMS0zNjM1OQ_c4481dff-bc73-47d5-93ab-d1f269790819"
      unitRef="usd">29300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e5a59ec1d4d4de1ba8ba076c80e3226_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy01LTEtMS0zNjM1OQ_b90c4ca4-7549-4a96-836d-71fe67831fa9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if50744aeaad04d8e898fb75a7a4cd403_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfMy03LTEtMS0zNjM1OQ_965f8ee7-ec2c-4774-8c87-1f99968a4e7e"
      unitRef="usd">29300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c3c7d94999a4ee5a93ec6842932756b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC0xLTEtMS0zNjM1OQ_68be33ed-ca1f-4ceb-92c7-811d7f2c1945"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i95aadf27c0ee42a2b79894a26f7a6303_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC0zLTEtMS0zNjM1OQ_21700935-0983-4675-992e-79054d54aed9"
      unitRef="usd">9600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7b4a40cfd6c04ce599bbc8e4a83deadc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC01LTEtMS0zNjM1OQ_1d6b73c8-1d3d-4853-8504-94c7780abf51"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i377b3cbb17e643b7a874393768f6b99a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNC03LTEtMS0zNjM1OQ_39a87287-5607-43ef-a80f-ce8b26701de7"
      unitRef="usd">9600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ida4f8a6107a54f86952fd151b5a13c08_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS0xLTEtMS0zNjM1OQ_ac7376dd-3cba-468f-b151-47d0c28bc17e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id43790812a0c4238a84dddd512d335ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS0zLTEtMS0zNjM1OQ_91f498ec-d8e2-40c3-aae8-bbef5fa186f0"
      unitRef="usd">4000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f3fc1feaa3146ef881ca19357b23ae2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS01LTEtMS0zNjM1OQ_b89c6f72-b65f-47a2-9013-1eb6a95b801f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i28d42fa8dd704029a1fa28dcaa0717e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNS03LTEtMS0zNjM1OQ_36ce5b88-a1e4-4f31-a144-4e1181049b8c"
      unitRef="usd">4000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6b9a6da1e624a6299e316b70d8feaac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi0xLTEtMS0zNjM1OQ_776a5960-4325-4fcf-a04a-3534bc6eac7c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79d3ae940d944d56b1fa894aaf7ce150_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi0zLTEtMS0zNjM1OQ_ec65b450-6e31-4785-8fdd-6bbb27ccac66"
      unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie4b8c164b3e1486ebec72f7e98f21e80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi01LTEtMS0zNjM1OQ_30626fbd-a156-4a23-b719-ce612badca6b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i99ef8a0c519143ebad880a3d69b3bc6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNi03LTEtMS0zNjM1OQ_ec820600-7bf0-4c70-a556-0d5f64f18fbe"
      unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i71e83b77ce534f3b9bd0073625848436_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy0xLTEtMS0zNjM1OQ_2e635960-d46c-48a5-a53b-1969ea351d4c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id8f0556ba0524239b520e549288db90f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy0zLTEtMS0zNjM1OQ_f92ae21e-39c0-4626-bb12-b49d39886e3b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i30c0e0850ab04139a8cc19022cb08ee3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy01LTEtMS0zNjM1OQ_d26c7f4c-7dac-4a7d-88d9-d41a93ce3393"
      unitRef="usd">10900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5ae2473b59214583a165b28061b320ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfNy03LTEtMS0zNjM1OQ_14c97e31-c443-464d-beee-c9440631c835"
      unitRef="usd">10900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i30c0dba4e084466d8bddadc615f6025a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC0xLTEtMS0zNjM1OQ_3a5d2712-9f55-476d-85d6-0610dcffe116"
      unitRef="usd">69100000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i1b398db0d1554733a657d72060893c6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC0zLTEtMS0zNjM1OQ_9e6ff7d6-b367-43b1-8c51-067222db04a9"
      unitRef="usd">54700000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ic3d6ed83b23f459e9db3a9380f2701a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC01LTEtMS0zNjM1OQ_2601a6bb-ba15-457e-a0a1-d07a77919b38"
      unitRef="usd">-10900000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOjgyNjcxNDBjMzhmODRjM2E4YWUxZmM1MjI3YWYzZGQ5L3RhYmxlcmFuZ2U6ODI2NzE0MGMzOGY4NGMzYThhZTFmYzUyMjdhZjNkZDlfOC03LTEtMS0zNjM1OQ_54227045-8f48-48aa-94c4-9b38922c80f1"
      unitRef="usd">112900000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RleHRyZWdpb246NGIxOTZhYWRmMmI0NDVlMmEyZGM5NWY0ZGVjM2NmNzBfMzUyMQ_17ddf6a1-99fa-426e-ba85-22adcf2968ca">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transition Period Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS0xLTEtMS0zOTQwOA_831a9181-7d09-446d-bf36-b6a70b37e669"
      unitRef="usd">10900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS0xLTEtMS0zNjM1OQ_3bd40705-4ea6-4601-ae01-1addb9ff26ea"
      unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS0zLTEtMS0zNjM1OQ_29c83951-6f4e-4103-bf08-eaf4dfe018ce"
      unitRef="usd">13800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMS01LTEtMS0zNjM1OQ_0a90b656-8a9f-44cf-94af-6906340055c8"
      unitRef="usd">14500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi0xLTEtMS00MTI0Nw_affd5def-dc63-414c-a516-26dd94e1a23e"
      unitRef="usd">3300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi0xLTEtMS0zNjM1OQ_fb6c0794-483c-490c-a2c2-edfc181fb998"
      unitRef="usd">100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi0zLTEtMS0zNjM1OQ_b99fea40-1d71-4ad5-84a9-546e2b522c75"
      unitRef="usd">3900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMi01LTEtMS0zNjM1OQ_f709a116-923e-48a8-91ac-d4395a2bf58c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy0xLTEtMS00MTI0Nw_b85733d4-c438-4f03-a78f-c91bccb68826"
      unitRef="usd">-1800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy0xLTEtMS0zNjM1OQ_652a7784-e06e-49fe-ab6b-984e680c1c07"
      unitRef="usd">-3500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy0zLTEtMS0zNjM1OQ_283427f8-c8f5-4975-8a9a-aa9beab1c82e"
      unitRef="usd">2800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfMy01LTEtMS0zNjM1OQ_11c6da8a-3135-4fe7-9d54-c5ab4bb95181"
      unitRef="usd">1100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC0xLTEtMS00MTI0Nw_7307d869-ef8e-4cbe-9cd9-640647bc6d1a"
      unitRef="usd">800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC0xLTEtMS0zNjM1OQ_d1de19e4-0825-4687-bf18-23ffe9bc1756"
      unitRef="usd">-700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC0zLTEtMS0zNjM1OQ_e71111ba-abc6-49e3-8b38-90e32367338e"
      unitRef="usd">300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNC01LTEtMS0zNjM1OQ_c379172f-0ac9-487d-a868-85ecaf38764b"
      unitRef="usd">-400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS0xLTEtMS00MTI0Nw_4ca290f6-fb50-488e-ba12-e6ad93ccddbf"
      unitRef="usd">8600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS0xLTEtMS0zNjM1OQ_08e6365a-ceb8-4af4-bb53-548c480cf200"
      unitRef="usd">10900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS0zLTEtMS0zNjM1OQ_b21d5dc0-0ce3-466e-907f-90bb896c5875"
      unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN185Ny9mcmFnOjRiMTk2YWFkZjJiNDQ1ZTJhMmRjOTVmNGRlYzNjZjcwL3RhYmxlOmNlNzYzODMyYTg4NjQ2YmRiMDlhMDk3MDQzOGZiZGViL3RhYmxlcmFuZ2U6Y2U3NjM4MzJhODg2NDZiZGIwOWEwOTcwNDM4ZmJkZWJfNS01LTEtMS0zNjM1OQ_f2ec8291-52a3-45ec-a723-c890dff1cd55"
      unitRef="usd">13800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90ZXh0cmVnaW9uOjQ4NWE2ZWViMWE1NzRhNzg5YzJjYzhjOGE4MmRjYjNlXzI3OQ_26266fc7-d1d8-4e67-97a3-2b091a973b9e">PROPERTY, PLANT AND EQUIPMENT, NET&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $3.1 million of property, plant and equipment. See Note 16 for additional information regarding these divestitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90ZXh0cmVnaW9uOjQ4NWE2ZWViMWE1NzRhNzg5YzJjYzhjOGE4MmRjYjNlXzI4MA_ac251f90-a1af-4518-a766-e7d084d21b88">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic6c5626096e543389cd9c3f775245cfa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzQtMS0xLTEtMzYzNTk_b9e678ab-308c-46dc-9388-02a4f5cdd5d9"
      unitRef="usd">38000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i803545905c564efc93735544226e6480_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzQtMy0xLTEtMzYzNTk_0798dfca-54c5-4b0e-b68f-61ce36bade05"
      unitRef="usd">35700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i57ab8cfb4e2c4f0d807f2b535c421e2c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzUtMS0xLTEtMzYzNTk_98288574-27ad-45f2-824c-915272084aa5"
      unitRef="usd">112400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i12da925d57d847f29779b2a54f0c1d8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzUtMy0xLTEtMzYzNTk_c1f0907c-90eb-494e-9489-25c93b939254"
      unitRef="usd">117900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzYtMS0xLTEtMzYzNTk_0294ec7d-c5e9-45d1-9a03-6798d21bd4c2"
      unitRef="usd">150400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzYtMy0xLTEtMzYzNTk_96dace15-9c92-45f4-80f0-4690908dbd67"
      unitRef="usd">153600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzctMS0xLTEtMzYzNTk_58287913-35c9-46c8-a13b-3ec7f3aa532d"
      unitRef="usd">106900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzctMy0xLTEtMzYzNTk_59599013-26d9-4cca-9251-7aea5c26ed2f"
      unitRef="usd">112900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzgtMS0xLTEtMzYzNTk_3146e00e-8c82-4e69-9a7f-425c28844558"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo0Yzk3MmIzNzZlNzg0Y2YyYWQ1M2E2N2VmOGI2NGFiNi90YWJsZXJhbmdlOjRjOTcyYjM3NmU3ODRjZjJhZDUzYTY3ZWY4YjY0YWI2XzgtMy0xLTEtMzYzNTk_709d734f-da0a-4a7d-87fb-2e5b362959e1"
      unitRef="usd">40700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i76caa3c0609e438280d6a0504611599f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90ZXh0cmVnaW9uOjQ4NWE2ZWViMWE1NzRhNzg5YzJjYzhjOGE4MmRjYjNlXzEwOTk1MTE2Mjg2NDE_c9c90d1b-4151-4e5b-a29f-c021e47c83ef"
      unitRef="usd">3100000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:Depreciation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItMS0xLTEtMzYzNTk_ab1726f5-553e-4fa3-ba7a-852f117a0a89"
      unitRef="usd">12100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItMy0xLTEtMzYzNTk_0d65ed73-5921-465e-9247-29c1ec0e5711"
      unitRef="usd">5000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItNS0xLTEtMzYzNTk_c4b80f44-8009-4389-9c54-2b1a1a581807"
      unitRef="usd">11000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDAvZnJhZzo0ODVhNmVlYjFhNTc0YTc4OWMyY2M4YzhhODJkY2IzZS90YWJsZTo4NTk5NWM1MWYwNmE0OWFhYWJmMmJhNTNkMmE2ZmFiNi90YWJsZXJhbmdlOjg1OTk1YzUxZjA2YTQ5YWFhYmYyYmE1M2QyYTZmYWI2XzItNy0xLTEtMzYzNTk_9fd94d04-130d-4f77-a91b-40e10e81c747"
      unitRef="usd">13700000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1Njk_9ffc9a44-2b53-467d-9568-0948153a426f">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did not record an impairment of goodwill for the year ended December 31, 2021, the transition period ended December 31, 2020 or for the fiscal year ended June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $80.7&#160;million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;select operating assets and intellectual property, including the Vectra&#xae; test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended June 30, 2020, the Company also recognized a $1.3 million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as a non-amortizable intangible asset of in-process research and development.&#160;Due to the completion of the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, the Company's intangible assets as of December 31, 2021 consist of only purchased licenses and technologies.&#160;In connection with these sales, the Company sold $199.1 million in purchased licenses and technologies, $4.8 million in-process research and development intangible assets, $4.7 million in customer relationships, and $3.0 million in trademarks, resulting in an aggregate decrease of intangible assets of $120.0 million, net of $91.6 million in accumulated amortization. See Note 16 for additional information on these divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s purchased licenses and technologies have estimated remaining useful lives between 1 and 14 years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets.&#160;The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $17.7 million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was no impairment of long-lived assets for the year ended December&#160;31, 2021, the transition period ended December 31, 2020, or for the year ended June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the amounts reported as intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 the weighted average remaining amortization period for purchased licenses and technologies is approximately 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1NzE_87e822a9-255c-4c6a-9cce-50638c2deb08">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzEtMS0xLTEtNDQwMjU_c0a55278-7bc4-489a-b573-0b74d1c5cf3b"
      unitRef="usd">329200000</us-gaap:Goodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzMtMS0xLTEtNDQxNjc_64a3a239-65bb-4706-8815-1e746a88a721"
      unitRef="usd">88500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzUtMS0xLTEtNDQxNzM_f3b65e2e-af34-450e-b11f-1342bab3fe9c"
      unitRef="usd">-1500000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTozN2RjZGE3ZjMxMzg0Mzk4YTA0ZmE1ZmNiODgyYmMwZS90YWJsZXJhbmdlOjM3ZGNkYTdmMzEzODQzOThhMDRmYTVmY2I4ODJiYzBlXzQtMS0xLTEtNTc4NjQ_bbe1cfd6-c42e-4308-949f-f20b983559d4"
      unitRef="usd">239200000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMyOTg1MzQ4OTQ4MjQ_2d0ef281-6850-44ab-abd3-ef9d80c7cf93"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMyOTg1MzQ4OTQ4MjQ_d02bac23-34e5-45e1-936b-e9b453c0de13"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMyOTg1MzQ4OTQ4MjQ_eaaca85c-f7cd-4035-b908-da141f3fd54a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id6ec5554c31b4ce8828d34f1b36e247a_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzkzNQ_575ab57f-cf5f-4b0c-8459-9828d08437de"
      unitRef="usd">80700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i08c34d03cc5d4ce3adff6edc114a7d3d_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzEzMDQ_201a407f-af0c-4932-bd0a-91c0dec5c9cd"
      unitRef="usd">1300000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i2300757198c24415b7c3c129a5f3fabf_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA3NzQ_d3cc9cfd-b428-4a9a-b4a9-fad562b5bf4b"
      unitRef="usd">199100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="iba866a3cd6cf4800bbcea6f210f6455a_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA3OTI_87f26952-1089-440f-9ade-3ed5cc595148"
      unitRef="usd">4800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i3f3b8d69d56b45199b92513424091532_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4MDc_dfe00b35-c7f8-4687-885b-8f56503c5e50"
      unitRef="usd">4700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i275498a5a52849dea83b241134bb7e51_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4MjI_72711e30-e642-4c27-ab01-86fc513cb02f"
      unitRef="usd">3000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent
      contextRef="ida1425b0bad34a70afc41eb45c93a582_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4Mzk_5e801a2d-63d9-4c62-ba12-1cdcbfea3b70"
      unitRef="usd">120000000</mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent>
    <mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent
      contextRef="ida1425b0bad34a70afc41eb45c93a582_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzIxOTkwMjMyNjA4NTU_f71fe604-efb9-4ad4-a06d-7719e588abf9"
      unitRef="usd">91600000</mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic75f471c9cdf49ab96d540192ad0b502_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzE5MjU_c0c56281-e6fc-4726-bf80-5b7760e1fc8f">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6b9f2d157d1e4cadaae10cf7ad53658e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzE5MzI_4ccb6f89-f16d-4241-bc40-a174524423c6">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI2OTM_86d429bd-3546-452b-8f1b-83d8c36d1995"
      unitRef="usd">17700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI5NzE_3aaf7ef5-d761-4633-96a7-0732b01cb75d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI5NzE_b93ad04b-0d93-4799-8bbd-83d8819432fc"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzI5NzE_e922bf41-f8b5-48f2-b051-b072b44bb6e6"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1NzI_04c5af1e-b357-4be0-a06b-7b002c6c242b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the amounts reported as intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1NzI_79599de9-0c2c-4379-ab70-35a52f7a4e51">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the amounts reported as intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id2d57af1e55643e69c2cef6564b8c029_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzEtMS0xLTEtNDAxNTk_561ae847-e61d-43e5-b1e3-beb22c474402"
      unitRef="usd">616600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id2d57af1e55643e69c2cef6564b8c029_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzEtMy0xLTEtNDAxNTk_a22adf02-e098-498e-989e-9600dc34e59f"
      unitRef="usd">212500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id2d57af1e55643e69c2cef6564b8c029_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzEtNS0xLTEtNDAxNTk_bc7d600e-f864-4703-b9e2-90ae5c4a4959"
      unitRef="usd">404100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzctMS0xLTEtNDAxNTk_ff6e07ef-d5e7-414f-bb1e-47572edd26bc"
      unitRef="usd">616600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzctMy0xLTEtNDAxNTk_d001f41c-968e-48f2-8de8-dd174bf330fa"
      unitRef="usd">212500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo2MDNiMWQ4OGJjMDI0ZmZjYWY3MWY1YzI2YWFjNzBjNC90YWJsZXJhbmdlOjYwM2IxZDg4YmMwMjRmZmNhZjcxZjVjMjZhYWM3MGM0XzctNS0xLTEtNDAxNTk_331787f4-1575-4504-8242-4b3740759ddc"
      unitRef="usd">404100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i72c3ca18e45c49898939a280f53e8a87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzEtMS0xLTEtMzYzNTk_682fb30c-16d7-4d90-9803-5fad51f8b30e"
      unitRef="usd">818200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i72c3ca18e45c49898939a280f53e8a87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzEtMy0xLTEtMzYzNTk_69e0ab3c-e6c1-4126-8461-fbccfd002f5e"
      unitRef="usd">248200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i72c3ca18e45c49898939a280f53e8a87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzEtNS0xLTEtMzYzNTk_64986e65-19bb-4dfa-b8d2-cfacfbb2aae3"
      unitRef="usd">570000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzItMS0xLTEtMzYzNTk_6b9acf99-6834-4e34-b6b1-f703987b5042"
      unitRef="usd">4700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzItMy0xLTEtMzYzNTk_13b352d3-8207-4bc1-954f-78cc659e05cc"
      unitRef="usd">4500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i42e78a1eb5ad4165b105a6d0dd3032c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzItNS0xLTEtMzYzNTk_c37de50d-a53e-4bef-a464-86b866aa86e6"
      unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib683c703779c41d19954bb1ac378479f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzMtMS0xLTEtMzYzNTk_da354898-17c4-4b3a-bd12-cd18003a15a3"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib683c703779c41d19954bb1ac378479f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzMtMy0xLTEtMzYzNTk_e4c4f201-3f3a-4667-9168-632b05dbd240"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib683c703779c41d19954bb1ac378479f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzMtNS0xLTEtMzYzNTk_64e2a886-92df-4243-8e82-3f701b9827fb"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzQtMS0xLTEtMzYzNTk_ce43a2f4-65a7-4cd4-b1fd-1e39347677ba"
      unitRef="usd">825900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzQtMy0xLTEtMzYzNTk_7477b9b8-56e9-43ca-9a26-180e51b6c01d"
      unitRef="usd">254200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzQtNS0xLTEtMzYzNTk_3290377e-301b-4ecf-bdde-a9be3c4020fa"
      unitRef="usd">571700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i92a4983803bd4497b2c5b4c486bbbbe6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzUtMS0xLTEtMzYzNTk_1e684c15-6480-4529-afd6-c4ad0c50e3a5"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i92a4983803bd4497b2c5b4c486bbbbe6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzUtNS0xLTEtMzYzNTk_2ea312e9-2b18-45ce-b549-d724238df449"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzYtMS0xLTEtMzYzNTk_c31bfaa6-7e59-41b4-b9a7-58b15ea142f1"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzYtNS0xLTEtMzYzNTk_9835c274-b4f4-4aec-9589-6b19a4f3fbc9"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzctMS0xLTEtMzYzNTk_c9191cc6-4ac1-45de-b4a2-f3d7ac24d4ea"
      unitRef="usd">830700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzctMy0xLTEtMzYzNTk_55e9b0fe-2239-4666-8ca1-bfe3ea34148f"
      unitRef="usd">254200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTo5MjA4MDcxZGVmMGQ0ODA1YWIxZTY2MDU4OTA2ZjJkNS90YWJsZXJhbmdlOjkyMDgwNzFkZWYwZDQ4MDVhYjFlNjYwNTg5MDZmMmQ1XzctNS0xLTEtMzYzNTk_3a87a1a4-746a-4af2-a32b-523be15e514a"
      unitRef="usd">576500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzMzMzk_498bf221-572d-447d-8afd-fd3a30a0e6e6">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1Njc_5a9af84d-5860-4b7c-baad-e15223f7b099">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItMS0xLTEtMzYzNTk_834b72fd-d369-4281-9681-052993d5b5af"
      unitRef="usd">50700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItMy0xLTEtMzYzNTk_fa7b9171-21fc-4faa-8a2e-c2b0a1e03c75"
      unitRef="usd">30800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItNS0xLTEtMzYzNTk_b44b05a7-d399-47bb-9d3a-62fb3167291f"
      unitRef="usd">61000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZTowZTcwYjcyMjE2NmI0ZWZlOGY3NzEzYjVmYWJlMzlhYS90YWJsZXJhbmdlOjBlNzBiNzIyMTY2YjRlZmU4Zjc3MTNiNWZhYmUzOWFhXzItNy0xLTEtMzYzNTk_70c4b110-fd2f-4113-913f-e17f3942c4ba"
      unitRef="usd">59300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90ZXh0cmVnaW9uOjRhMmEyMTFjMWJlMTQwMDQ5N2MyZWFmMjVkNzlhOWMyXzM1Njg_c82ac7d9-6c13-4b9d-9e69-f0abd61464ba">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzEtMS0xLTEtMzYzNTk_d0d547f0-949e-4439-a922-515d5fe7457c"
      unitRef="usd">40800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzItMS0xLTEtMzYzNTk_7e0f38ce-d118-4cff-b580-aae0c84040a3"
      unitRef="usd">40800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzMtMS0xLTEtMzYzNTk_298aba96-9afb-499b-b97d-bb52733fe894"
      unitRef="usd">40800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzQtMS0xLTEtMzYzNTk_7b94e28f-7a99-4c99-9dee-b0d8543d1b2e"
      unitRef="usd">40800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzUtMS0xLTEtMzYzNTk_e0416dcf-2815-4778-9efe-6978e555decb"
      unitRef="usd">40800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzYtMS0xLTEtMzYzNTk_7b45d285-fb50-4101-af83-cd33d4e7b8a2"
      unitRef="usd">200100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDMvZnJhZzo0YTJhMjExYzFiZTE0MDA0OTdjMmVhZjI1ZDc5YTljMi90YWJsZToxN2ZhOTNlY2Q1Mzk0NDMwOTVkZDBjMTkyODc1NTZjZC90YWJsZXJhbmdlOjE3ZmE5M2VjZDUzOTQ0MzA5NWRkMGMxOTI4NzU1NmNkXzctMS0xLTEtMzYzNTk_7d00e07f-a468-464e-ae35-1a7c99326734"
      unitRef="usd">404100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90ZXh0cmVnaW9uOmJiN2RmM2UzMGE4ZDQ3NDhhMTBhOTUyNDkzYmU5MWMxXzI5_275600d9-e39f-41ec-b35b-6d6494764a59">ACCRUED LIABILITIES&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges pending settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90ZXh0cmVnaW9uOmJiN2RmM2UzMGE4ZDQ3NDhhMTBhOTUyNDkzYmU5MWMxXzMw_00d24b49-3ee4-4b2a-b16e-ced06455718c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges pending settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzItMS0xLTEtMzYzNTk_14d3fea8-7fba-4b48-a70f-5ac888026b58"
      unitRef="usd">52800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzItMy0xLTEtMzYzNTk_869c4dd4-7afe-4a0c-aa3d-c6a7d4df716c"
      unitRef="usd">48900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMS0xLTEtNDE0MjQ_e8cd0e65-4c53-42ab-a612-0145c0da3b07"
      unitRef="usd">62000000.0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMy0xLTEtNDE0MzY_f35083c3-186a-43d6-b4a8-a05e82c68d9c"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMS0xLTEtMzYzNTk_78202db6-0ac5-4914-86bb-8eba26b3c41c"
      unitRef="usd">4000000.0</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzMtMy0xLTEtMzYzNTk_16823dd2-3872-4425-b353-33a431b06fd7"
      unitRef="usd">4300000</us-gaap:TaxesPayableCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzUtMS0xLTEtMzYzNTk_afabb3f4-1350-4521-8326-27baac730b35"
      unitRef="usd">9800000</mygn:RefundsPayableAndReserveCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzUtMy0xLTEtMzYzNTk_3c3351a0-a553-4b76-9f92-0b6f6f42f5e6"
      unitRef="usd">9300000</mygn:RefundsPayableAndReserveCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzYtMS0xLTEtMzYzNTk_ee1818f0-2905-4984-9a3f-e7bdc4caec5d"
      unitRef="usd">3200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzYtMy0xLTEtMzYzNTk_12d06a87-9485-446f-8aa6-2b64717979fd"
      unitRef="usd">3400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMS0xLTEtNDE0MjQ_a934180c-554f-4023-a341-be03c6f3f16d"
      unitRef="usd">5400000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMy0xLTEtNDE0MzY_db33a2db-9232-49f5-802b-200926223fa4"
      unitRef="usd">3800000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMS0xLTEtMzYzNTk_cdd74db3-cfd7-48dc-aec2-3af0e2a97ea6"
      unitRef="usd">19300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzctMy0xLTEtMzYzNTk_8fa23660-71a9-4541-86f0-2880888b7b57"
      unitRef="usd">9400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzgtMS0xLTEtMzYzNTk_d1c60009-d6b5-489f-bc41-95b740dbdea1"
      unitRef="usd">156500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDYvZnJhZzpiYjdkZjNlMzBhOGQ0NzQ4YTEwYTk1MjQ5M2JlOTFjMS90YWJsZTphMDRiYzVjYmM3MzY0NjAyYmMzMzMwZDQxMWFhMTRkYy90YWJsZXJhbmdlOmEwNGJjNWNiYzczNjQ2MDJiYzMzMzBkNDExYWExNGRjXzgtMy0xLTEtMzYzNTk_bcee4e0f-0559-43d6-b301-1c855e96a746"
      unitRef="usd">79100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQ2NDA_09ba67c7-041b-4b23-888c-dbc1a27a507c">LONG-TERM DEBT&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#x201c;Facility&#x201d;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#x201c;amend and extend&#x201d; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Amended Facility, which waived the Company&#x2019;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (&#x201c;Modification Period&#x201d;). On February 22, 2021, the Company entered into Amendment No. 3 (the "Amended Facility"), which, among other things, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company's compliance with certain financial covenants through the quarter ended March 31, 2022, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0&#160;million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company&#x2019;s leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#x2019;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#x2019;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0&#160;million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0&#160;million, unless such borrowings are in connection with permitted acquisitions. The Company was in compliance with all applicable financial covenants at December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2021, the Company made principal repayments totaling $226.4 million on the Amended Facility, including a voluntary principal payment on July 30, 2021 of $106.4&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of December 31, 2021. As of December 31, 2020, the Company had a long-term debt balance of $224.8 million.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="iefacdace64394337b4ef1aba897012f9_D20180731-20180731"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQyMw_d2470ce2-329b-4fa7-b21f-0cfab9e38589">2023-07-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ica35c1f0cab448d081723c1fef35a424_I20161223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQ5Mg_e9d21d63-be6a-463d-a15c-02e846b39e9b"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i168fbf7f34f14b48b159064776b4fdfc_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzQ5OA_68ee3e7c-819f-4221-990a-6f51809c3038"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i54fc9148f3ce4861a7ad8db525b9a0a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNjgz_dfbecaaa-6044-41d9-ae3e-975f6bb78129"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNjk5_70575808-f957-4ae5-9fd0-eb323faba70e"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzE1_fe9df11d-cc36-4c20-bbc6-67d8eef5beb2"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i961cf7e1f4884ffdace1af14ca9070a8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzMx_645c41fd-7590-4885-94aa-01e371898ad4"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i82d39802808f4ef89f2381762fc4eb35_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzQ3_635ab3f6-00f6-43ba-a303-5764b311dfba"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4a989512a05b4160b8ec803a03de9836_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIxMzc_f2296d57-e001-4097-89ce-2975238afc21"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i333e25208a214f52b7d6bdff1719f67a_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIyMDg_549a1011-e91d-4133-b966-f43f420762f7"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0c5178ceac7d4f5fbc4391a28c678d89_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzYz_17a2bcd9-2c47-4b1a-bc80-94c484a656b3"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3265f06cbffc47d085ee813629587542_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzcz_83caf0c6-b276-47e4-9f22-22ab51498f60"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i9f99bcdbffc6436f919414c49880ae46_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIzNzM_4fd8b885-b8ca-488e-b8d1-3235df366d83"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="idc6b324d8d7d49119edb7e86615e72bb_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzIzNzk_513e7bc6-b137-4cc6-9d2a-ba971a730c23"
      unitRef="number">0.0045</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <mygn:DebtInstrumentLIBORFloorPercentage
      contextRef="i333e25208a214f52b7d6bdff1719f67a_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzI0NzI_8e8c47db-c23f-46c9-ba05-e6fc428010ed"
      unitRef="number">0.010</mygn:DebtInstrumentLIBORFloorPercentage>
    <mygn:DebtCovenantLiquidityCovenantMinimum
      contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzgz_0c4a9136-dca0-44a8-8cba-078ec5c2da9e"
      unitRef="usd">150000000</mygn:DebtCovenantLiquidityCovenantMinimum>
    <mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum
      contextRef="id223da0fe55a40c58f22c4b23b424f4d_I20210221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwNzk5_6475c9bd-68a9-47dd-9762-56bc89d714b7"
      unitRef="usd">150000000</mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzEwOTk1MTE2MzkzMjU_9d45ea0d-55d9-42ba-9060-25767cb03dff"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i915c2ce66e394e6ebfd548241511f5c7_D20210730-20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwODE1_c915cd57-fb59-40cb-854c-11a504aeb364"
      unitRef="usd">106400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LongTermDebt
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzE2NDkyNjc0NDMwOTY0_36f0b8e0-8572-4636-90d3-bc5f09c76f95"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMDkvZnJhZzo5OGZjOWQxYzA3NzA0MzcxODQ5MzI1M2FmMjRhNjI5Ny90ZXh0cmVnaW9uOjk4ZmM5ZDFjMDc3MDQzNzE4NDkzMjUzYWYyNGE2Mjk3XzEwOTk1MTE2NDEzNTI_0d7154b1-e27a-492f-a9b4-dcce1dc8ab0b"
      unitRef="usd">224800000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90ZXh0cmVnaW9uOmI3MmU3MzAxYzk3NDQxNmRiNDYyMWE2MzVmNjhlMjM4Xzc5NA_e933958f-39a7-414b-89cf-0a5bca4ed7aa">OTHER LONG-TERM LIABILITIES&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The Company&#x2019;s balance of other long-term liabilities as of December&#160;31, 2021 consists primarily of the long-term portion of contingent consideration related to the Sividon acquisition. During the prior periods the Company's portion of social security taxes that had been deferred under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") that do not have to be deposited until December 2022 were also recorded as other long-term liabilities. As of December 31, 2021 that balance has been reclassified to a current liability as it will be deposited within the next year.</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90ZXh0cmVnaW9uOmI3MmU3MzAxYzk3NDQxNmRiNDYyMWE2MzVmNjhlMjM4Xzc5NQ_af70f030-6fc3-4f7c-b35e-62781a66fcb6">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzMtMS0xLTEtMzYzNTk_67a2e222-b43e-42f9-962e-e95bd9d00b1a"
      unitRef="usd">5400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzMtMy0xLTEtMzYzNTk_15151c90-2975-4497-aad4-7dd62e496a54"
      unitRef="usd">7400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzQtMS0xLTEtMzYzNTk_dd98f0ae-8bef-4d15-96d8-496484962dab"
      unitRef="usd">200000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzQtMy0xLTEtMzYzNTk_b2c59ab0-1c0e-4547-89f2-2386d56fc4bc"
      unitRef="usd">7300000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzUtMS0xLTEtMzYzNTk_d427c890-85e6-431e-a5bd-97550cbd7446"
      unitRef="usd">5600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTIvZnJhZzpiNzJlNzMwMWM5NzQ0MTZkYjQ2MjFhNjM1ZjY4ZTIzOC90YWJsZTo3YjdjNjBiMmQ3MWI0ZTgyOWQyODU3ZWIwODAyZWY1Zi90YWJsZXJhbmdlOjdiN2M2MGIyZDcxYjRlODI5ZDI4NTdlYjA4MDJlZjVmXzUtMy0xLTEtMzYzNTk_8dafd43e-7651-4ae7-bd2c-9db964571156"
      unitRef="usd">14700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE2ODc_04442c75-2336-49ca-a052-d8653de3a695">PREFERRED AND COMMON STOCKHOLDERS' EQUITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share.&#160;There were no preferred shares outstanding at December&#160;31, 2021 and December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 80.0&#160;million and 75.4&#160;million shares issued and outstanding at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options and employee stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase and retirement of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#x2019;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company&#x2019;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of December&#160;31, 2021, the Company has $110.7 million remaining on its current share repurchase authorization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the par value method of accounting for its stock repurchases.&#160;&#160;As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to Retained earnings (accumulated deficit).&#160;&#160;During the year ended June 30, 2019, the Company used $50.0 million to repurchase shares of the Company&#x2019;s common stock as part of an accelerated share repurchase. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December&#160;31, 2021, December&#160;31, 2020, June&#160;30, 2020, and June&#160;30, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock and additional paid-in-capital reductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges to retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1Xzky_012d168f-c43a-4b27-b61d-1dec35d65d46"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1Xzky_1404d072-7922-4f07-b825-7ab7df94aac8"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzEzMg_5c40e6de-7106-45f5-ba98-8ea1b7696d3a"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzEzMg_ccaa250b-c391-493d-a20f-fcf401631b1f"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE1Nw_20b07d30-03e2-45e3-8790-b755e46c030f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE1Nw_be152d27-7a0a-4db1-91ef-1a72c1ad8cbc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI1NA_057ed7b4-8b02-47bd-b48b-176d859291b9"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI1NA_6407d80d-9421-4bf7-ab28-6644acaa519a"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI5MQ_42c7b8d0-f23a-45ea-a511-89bc2511b225"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzI5MQ_70e974b7-0cb4-4ff0-8d69-c0d9c22a1b19"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzQ5NDc4MDIzMjY4MDY_6dd28bf6-be70-495c-979c-ea6cfbc01a06"
      unitRef="shares">80000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzQ5NDc4MDIzMjY4MDY_7a386753-57cd-4d8a-8455-1913f6db87be"
      unitRef="shares">80000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzMxNg_4e350455-abe8-47b4-ae7e-6a4a62af8a18"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzMxNg_a52f5142-8353-4e7d-b49e-57e9fecafd08"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE2ODg_e4bd6823-ee12-493c-bda6-6cd73f2d4ae2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options and employee stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase and retirement of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMS0xLTEtMzYzNTk_00205760-598e-4222-bd45-3aae0cfb78bc"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMS0xLTEtMzYzNTk_bf4dfa02-7e7c-4f5d-a4de-fc77b278e349"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMy0xLTEtMzYzNTk_9070855a-5be7-410c-99e5-bf2816a8218c"
      unitRef="shares">74700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItMy0xLTEtMzYzNTk_ddb37f26-8d84-4fb7-913d-1939d929a62f"
      unitRef="shares">74700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNS0xLTEtMzYzNTk_00b05bbb-3c4d-4519-8238-c90022fa91a8"
      unitRef="shares">73500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNS0xLTEtMzYzNTk_64734162-6015-462b-a8ba-51a0be3cc902"
      unitRef="shares">73500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNy0xLTEtMzYzNTk_4edc16f2-fbe8-4ebf-a4ce-f43f00509fb1"
      unitRef="shares">70600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzItNy0xLTEtMzYzNTk_7015892e-eaec-4beb-824e-ad77b47d5001"
      unitRef="shares">70600000</us-gaap:CommonStockSharesOutstanding>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtMS0xLTEtMzYzNTk_42758a94-1229-4a83-8af3-8d67b10d3fa8"
      unitRef="shares">4600000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtMy0xLTEtMzYzNTk_929a24a5-8615-4d73-a85d-931b8b1226db"
      unitRef="shares">700000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtNS0xLTEtMzYzNTk_69e91d52-7c02-4c5a-9b21-e333c4e2f371"
      unitRef="shares">1200000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzMtNy0xLTEtMzYzNTk_b907b343-b619-4aeb-a761-098de334eecf"
      unitRef="shares">4500000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtMS0xLTEtMzYzNTk_64d4e7f7-b716-4406-b289-c6c2eb699f41"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtMy0xLTEtMzYzNTk_87b766f0-8096-456e-8fc4-ddc6c858419b"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtNS0xLTEtMzYzNTk_6824402f-9e14-4692-abf9-24e241f1b94e"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzQtNy0xLTEtMzYzNTk_660f82c2-aee3-451b-8bc1-39bf482dc3d5"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMS0xLTEtMzYzNTk_634dd1ea-6acd-4451-a60a-249795e6a033"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMS0xLTEtMzYzNTk_e94e0af9-956e-4f38-99ab-220dad661b20"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMy0xLTEtMzYzNTk_14e9ca47-54af-48a5-a0e4-0ef29ae0bd6d"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtMy0xLTEtMzYzNTk_d1799438-faed-45d4-80c4-d5a3fa3888d9"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNS0xLTEtMzYzNTk_20133038-304e-42c4-92f8-163a9a6b79c3"
      unitRef="shares">74700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNS0xLTEtMzYzNTk_aa74fa6a-824f-4d29-a20d-3a1568580c55"
      unitRef="shares">74700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNy0xLTEtMzYzNTk_6626cef5-1cab-44a6-a1b2-866b236c4405"
      unitRef="shares">73500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTphNjE3NjJhMGJmMDk0NDU2YTdlOWVjNmFhY2U0MDgwZi90YWJsZXJhbmdlOmE2MTc2MmEwYmYwOTQ0NTZhN2U5ZWM2YWFjZTQwODBmXzUtNy0xLTEtMzYzNTk_c7b182cb-8677-4e8d-8ac3-adaa2bde0423"
      unitRef="shares">73500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="id54bd12e649d48069a7463458d653da6_I20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzU1NA_72f7b794-5c64-4f83-8cc7-fc2ed249fa26"
      unitRef="usd">200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzQ5NDc4MDIzMjY4MjU_3a05fd23-3cfa-4cc9-bc19-99596d6894df"
      unitRef="usd">110700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzEzNzI_1a4a37fc-526f-4a9e-a624-61b35fac0530"
      unitRef="usd">50000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <mygn:ScheduleOfCommonStockRepurchasedTableTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90ZXh0cmVnaW9uOmY0MjBmNzNiYTNiNjRlOWFiMDA3ZDliZWQxZjkwOTM1XzE2ODk_4a735d10-82ff-43d4-8a16-a20369b294c1">The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December&#160;31, 2021, December&#160;31, 2020, June&#160;30, 2020, and June&#160;30, 2019 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock and additional paid-in-capital reductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges to retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mygn:ScheduleOfCommonStockRepurchasedTableTableTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItMS0xLTEtMzYzNTk_edade831-07dd-45b1-859f-2b37fbf0c2eb"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItMy0xLTEtMzYzNTk_e5761b73-8704-4461-afa6-3898c2c26821"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItNS0xLTEtMzYzNTk_7c1626f7-aeb7-4911-8daf-480f53bab75b"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzItNy0xLTEtMzYzNTk_58784409-914d-45c0-8ffc-dad7e2cfd5f1"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtMS0xLTEtMzYzNTk_b4e0f401-430e-44ae-9ea8-4586d5159bf9"
      unitRef="usd">0</mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases>
    <mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtMy0xLTEtMzYzNTk_ef8350f8-93ab-42b2-bcdd-28ec21090152"
      unitRef="usd">0</mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases>
    <mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtNS0xLTEtMzYzNTk_8a518299-cc9a-4b42-8bbf-8f8d11faa3ea"
      unitRef="usd">0</mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases>
    <mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzMtNy0xLTEtMzYzNTk_28e3082f-f885-44e0-bc81-5baf7445ff58"
      unitRef="usd">16900000</mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases>
    <mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtMS0xLTEtMzYzNTk_206b971a-a4c6-45a4-bdce-af407952bd47"
      unitRef="usd">0</mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases>
    <mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtMy0xLTEtMzYzNTk_f431ca5e-bb10-499f-a821-cf41756c985a"
      unitRef="usd">0</mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases>
    <mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtNS0xLTEtMzYzNTk_dd47ede0-6875-4bb0-8795-29290fa26835"
      unitRef="usd">0</mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases>
    <mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTUvZnJhZzpmNDIwZjczYmEzYjY0ZTlhYjAwN2Q5YmVkMWY5MDkzNS90YWJsZTo4ZTliNDY2ODRkMmM0NGZmYjA5ZmZiOGJhYTFkYjAyMy90YWJsZXJhbmdlOjhlOWI0NjY4NGQyYzQ0ZmZiMDlmZmI4YmFhMWRiMDIzXzQtNy0xLTEtMzYzNTk_6b1c4982-003b-42f8-bd65-aa3194bcd1a4"
      unitRef="usd">33100000</mygn:AmountChargedToRetainedEarningsAsResultOfStockRepurchases>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzU_7725a885-4cc0-444d-8edf-ddfc054ded73">STOCK-BASED COMPENSATIONOn November 30, 2017, the Company&#x2019;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#x201c;2017 Plan&#x201d;).&#160;&#160;The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors.&#160;Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant under the 2017 Plan. The 2017 Plan allows for issuance of up to 4.6 million shares of common stock, with 3.6 million shares available for grant as of December 31, 2021.&#160;&#160;If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they will also be available for issuance pursuant to the 2017 Plan. &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares, terms, and vesting periods are determined by the Company&#x2019;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which the anniversary occurs. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to our non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options generally vest ratably over service periods of four years. Options granted generally expire ten years from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of RSUs awarded to certain executive officers and other senior positions that ultimately vest may be increased or reduced based on certain additional performance and market conditions. The performance and market conditions associated with awards granted during the year ended December 31, 2021 include vesting that is based 50% on achieving certain levels of earnings per share targets, and 50% based on achieving certain performance targets compared to the performance of the Nasdaq Health Care Index. The Company estimates the likelihood of achievement of performance conditions at the end of each period. During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no options granted during the years ended December&#160;31, 2021, June&#160;30, 2020, and June 30, 2019. During the transition period ended December&#160;31, 2020, 0.7&#160;million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $13.38.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options outstanding at December&#160;31, 2021 (number of shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of&lt;br/&gt;exercise&lt;br/&gt;prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number outstanding at December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$13.38&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$23.98&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$27.07 - 36.55&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of restricted stock units granted during the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June&#160;30, 2020, and June&#160;30, 2019 was $29.83, $13.69, $27.96 and $46.62, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock units that vested during the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020, and the years ended June&#160;30, 2020, and June&#160;30, 2019 was $22.6 million, $29.1 million, $32.4 million and $27.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $61.7 million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of 2.3 years. We expect all unvested awards to vest, and we recognize forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#x201c;2012 Purchase Plan&#x201d;), under which 2.0 million shares of common stock have been authorized. On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At December&#160;31, 2021, a total of approximately 2.0 million shares of common stock had been purchased under the 2012 Purchase Plan. Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black&#x2011;Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5017805749294720bfc1102605257804_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ0MA_ff35123b-256c-4b6f-af72-bda8e8753272"
      unitRef="shares">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5017805749294720bfc1102605257804_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEwOTk1MTE2NDUyMjI_d86cace2-e58f-4115-acf5-ff4c770d436d"
      unitRef="shares">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEyMzI_e03b94e9-9520-4945-8347-ff8a0a63832b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic3842c62c98f4eff8442478a102c1f76_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEzOTI_1b64c615-5248-409f-b055-023397813fd9">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id019278a4e69463fa389582d302cd096_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE1MTM_6ce7e560-f794-4edd-b56e-544d109c1af9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id019278a4e69463fa389582d302cd096_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE2NDY_70f41984-8945-4f18-a4b1-11b131c203f1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib67b2cb2c62d457c8bfa89045a0ac26f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzMyOTg1MzQ5MDMxMjA_9321b8e1-99db-4e7a-8401-a3dcf16875af">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i0941bbd4ec3549fe8c0210b756b9c68d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzIwODA_920fd529-df31-460e-851b-14bcc37254f1"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i0493562cfc8d469d90ebecc52d7cf045_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzIxNDY_c7681784-8b2a-4e17-adb8-95893b071c5e"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzE_7d1f849f-e5ac-4985-8201-ff2e063a2e8d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzEtMS0xLTEtMzYzNTk_cf94fc36-cab3-4733-9546-d6b28564848c"
      unitRef="shares">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzEtMy0xLTEtMzYzNTk_f7e20a48-506d-4f43-84a5-744ffce825a6"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzItMS0xLTEtMzYzNTk_7fd15bac-c5ef-43e7-b41c-1f8dba0ff364"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzItMy0xLTEtMzYzNTk_c5ef63a0-28d9-455a-a6cc-63626b3789b9"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzQtMS0xLTEtMzYzNTk_38028f0d-540c-45c5-82c7-8542fee6293b"
      unitRef="shares">3700000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzQtMy0xLTEtMzYzNTk_a416a074-af58-4b82-a953-c2417720dc43"
      unitRef="usdPerShare">24.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzUtMS0xLTEtMzYzNTk_909bca5c-cbfc-4728-bc00-f18e4baeff7d"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzUtMy0xLTEtMzYzNTk_506840bd-59fc-4434-b528-aa81b871cce1"
      unitRef="usdPerShare">25.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzYtMS0xLTEtMzYzNTk_4dcf34dc-2631-4e60-a8da-03e13dc04a7c"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzYtMy0xLTEtMzYzNTk_e3333b5d-8a29-46cf-b7d6-8626f455d647"
      unitRef="usdPerShare">20.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzYtNS0xLTEtNTg1NTA_19f682f4-f13e-4ec6-8d75-a0a483a488dc">P3Y29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzctMS0xLTEtMzYzNTk_a020958e-04bc-409c-be4f-a0f575ecc7ad"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzctMy0xLTEtMzYzNTk_bc747f4b-db6e-45bd-ad3e-10171900faba"
      unitRef="usdPerShare">23.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzctNS0xLTEtNTg1NjI_cc24e5ce-9d70-43f4-b70e-4de210f1cd68">P2Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzgtMS0xLTEtMzYzNTk_3b3ae549-0689-4685-b3dd-6ef27dfa91c2"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzgtMy0xLTEtMzYzNTk_03015eab-371f-4fc3-8952-2e0832734a48"
      unitRef="usdPerShare">20.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo1MWM0YTJlOGYyYTU0MjIzODJiNjU1YmY4MTY1ZTkyOS90YWJsZXJhbmdlOjUxYzRhMmU4ZjJhNTQyMjM4MmI2NTViZjgxNjVlOTI5XzgtNS0xLTEtNTg1NjI_ffeefd01-41ab-4cfd-a420-53c07dbac428">P3Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzM4OTE_188e8124-d830-49a4-a70f-4a88b535a1a8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzM4OTE_a262ef6f-f01f-4579-97b7-2d6b5b51a9d0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzM4OTE_f2503f47-d82d-46ea-9707-91c7acd6d16d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id0aea44508ff4dfbb5ee1282d27b02b2_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzMyOTg1MzQ5MDMxMjY_1bf71ccd-d49c-4255-9562-0c5e2c871807"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id0aea44508ff4dfbb5ee1282d27b02b2_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzMyOTg1MzQ5MDMxMzk_842c521e-0a74-4cd1-9805-043532d90fc0"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2Njk_f84de097-2475-46e6-aca5-eb71b5e00628">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options outstanding at December&#160;31, 2021 (number of shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of&lt;br/&gt;exercise&lt;br/&gt;prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number outstanding at December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$13.38&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$23.98&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$27.07 - 36.55&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iee48b219c6314207b2b8c51e655bad7c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjpjYWYwMjIxMGZjNDg0ODk2YmYzNGQwMGJiYWIzYTZhYl80_3433f998-4e26-437e-8025-33fc6597a478"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic585d4b282fa403da809d437637d7786_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItMi0xLTEtMzYzNTk_95f933b6-fec4-454d-9860-5ccb0960523e"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iee48b219c6314207b2b8c51e655bad7c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItNC0xLTEtMzYzNTk_757e3576-6795-495a-a438-17f7d47e49be">P5Y7M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic585d4b282fa403da809d437637d7786_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzItNi0xLTEtMzYzNTk_6afdf2f6-5d6f-4dd5-a1ff-51a7e537913a"
      unitRef="usdPerShare">13.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i4aaf305cdc4c4b3783ad7772ad83b376_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjo5ODRiOGNhYTkwMTc0Y2FhYTc3OGE5OTYzYWJmMGFhOV80_0d3bf01e-62e7-49e1-9e76-cc704fc15268"
      unitRef="usdPerShare">23.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i4b47a20179364be1a601e6386dcdc7c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtMi0xLTEtMzYzNTk_77a86727-270e-4fd4-a0db-bddbc89623de"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i4aaf305cdc4c4b3783ad7772ad83b376_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtNC0xLTEtMzYzNTk_e8a82550-cc51-4a6e-8b21-3432052f32d3">P0Y2M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i4b47a20179364be1a601e6386dcdc7c0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzMtNi0xLTEtMzYzNTk_44994fca-1367-4b51-8159-3b47dc9c598a"
      unitRef="usdPerShare">23.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i9edc8741087a458da983569f09876507_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjo4YzFiNTJkMGFhZGM0OGMwOTBiYjJhYzkxNTdkMGM1NV80_dca26e40-9ef5-467f-8f74-8139128a4754"
      unitRef="usdPerShare">27.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i9edc8741087a458da983569f09876507_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtMC0xLTEtMzYzNTkvdGV4dHJlZ2lvbjo4YzFiNTJkMGFhZGM0OGMwOTBiYjJhYzkxNTdkMGM1NV8xMDk5NTExNjI3ODE0_3c512125-9482-4487-95ea-e947da24e28b"
      unitRef="usdPerShare">36.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i561d9e41bc564e37b2cdadb9540775cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtMi0xLTEtMzYzNTk_c66bba8b-bd46-46fb-aaa8-f99128806dbb"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9edc8741087a458da983569f09876507_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtNC0xLTEtMzYzNTk_5191dd53-bbc5-4135-b117-65ac825d6956">P0Y8M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i561d9e41bc564e37b2cdadb9540775cb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzUtNi0xLTEtMzYzNTk_6a9841dc-25b8-4a66-8753-5ba5e172c1e6"
      unitRef="usdPerShare">27.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzYtMi0xLTEtMzYzNTk_0630b24d-ca21-4494-92e5-02d1935cb5f2"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzYtNC0xLTEtMzYzNTk_19f682f4-f13e-4ec6-8d75-a0a483a488dc">P3Y29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTpkNWM1YzkyYmE3NTk0OGQzOWMzNzZiNzM4NjQ4Y2IzYS90YWJsZXJhbmdlOmQ1YzVjOTJiYTc1OTQ4ZDM5YzM3NmI3Mzg2NDhjYjNhXzYtNi0xLTEtMzYzNTk_96c44423-5279-46e1-8902-fdb81fac0afd"
      unitRef="usdPerShare">20.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzM_b4869643-63fd-4ffc-80e5-40726ce36e21">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzItMS0xLTEtMzYzNTk_f82323bf-8968-4ee0-a0cb-5aac0557b260"
      unitRef="shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzItMy0xLTEtMzYzNTk_d60ba26c-9fbe-44a9-8cfa-050c07346f1c"
      unitRef="usdPerShare">20.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzMtMS0xLTEtMzYzNTk_e536bd1d-bffe-4c8b-bef2-9da52a4a8b92"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzMtMy0xLTEtMzYzNTk_c9c82f65-7906-49f4-97a4-30d9f6251159"
      unitRef="usdPerShare">29.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzUtMS0xLTEtMzYzNTk_855dadf6-1166-4b09-8384-f88c504a8c61"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzUtMy0xLTEtMzYzNTk_ff22c6a3-8bf4-4b06-860d-bee98ee34bfd"
      unitRef="usdPerShare">21.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzYtMS0xLTEtMzYzNTk_acfd772c-d73b-411c-8beb-1297316a6791"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzYtMy0xLTEtMzYzNTk_959f3fbd-906e-4f3d-b8cf-6027254b833c"
      unitRef="usdPerShare">24.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iab3c3decbc9b4749a615c444461f2714_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzctMS0xLTEtMzYzNTk_5e7c8645-ffe3-4359-b786-ac2df8fd202a"
      unitRef="shares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iab3c3decbc9b4749a615c444461f2714_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTphZTljZTc4MmY1MmM0ODFkOWI2OGYxMmYxYTJjMDZiZS90YWJsZXJhbmdlOmFlOWNlNzgyZjUyYzQ4MWQ5YjY4ZjEyZjFhMmMwNmJlXzctMy0xLTEtMzYzNTk_4c3efb9a-1246-4bed-94f8-8b6cdad2945e"
      unitRef="usdPerShare">24.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ2NDQ_c9c82f65-7906-49f4-97a4-30d9f6251159"
      unitRef="usdPerShare">29.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib14d08a6c91d4a4d9a5f3397abc5c101_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ1MjQ_5070c903-6715-48da-bb1e-0e669fc1af97"
      unitRef="usdPerShare">13.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i17009626ef9e40fea086f24d4e4d938e_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ1MjA_d7b0de3b-b3e7-4d5a-aa92-14dab6fbc9a1"
      unitRef="usdPerShare">27.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i55c1d65d2fea4fb897497c39c3c543bb_D20180701-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ1MTY_8594f43e-7c9c-4ec4-a969-2015c743f04d"
      unitRef="usdPerShare">46.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MTQ_e9f6d1f1-38fb-4187-8ab8-9f714246cb73"
      unitRef="usd">22600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib14d08a6c91d4a4d9a5f3397abc5c101_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MTA_8ad088eb-e873-4691-b881-0bc714a5dba7"
      unitRef="usd">29100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i17009626ef9e40fea086f24d4e4d938e_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MDY_7b614235-7322-4129-90a1-7f080b4d7850"
      unitRef="usd">32400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i55c1d65d2fea4fb897497c39c3c543bb_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzQ5NDc4MDIzMzQ4MDI_ee04cd8e-ebed-4a47-a05a-4174d5a54d7d"
      unitRef="usd">27600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2Nzc_17684985-3072-4a81-8793-83a3cf08e7bc">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="if55a0576781b4fe09cd0002c1cf57591_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItMS0xLTEtMzYzNTk_66fa4308-7c90-43e5-86c9-263993c9fd3a"
      unitRef="usd">1500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id40d4e8c980d4d749c48652760c59dcb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItMy0xLTEtMzYzNTk_02159be4-9911-4dd7-8583-723d0f89c598"
      unitRef="usd">600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3f3271f5fd8d4f9cae87d273d0119cf6_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItNS0xLTEtMzYzNTk_50eadc18-0016-49e8-ac5e-6e8bd54d2267"
      unitRef="usd">1200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2d82b14159db4173bec06da40fa3fba0_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzItNy0xLTEtMzYzNTk_d516adcb-7b68-4078-b920-6e778ad2a9d3"
      unitRef="usd">800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia3e5585fea71439f950bf077fd864a6b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtMS0xLTEtMzYzNTk_785e77b6-1d62-4245-b6c9-45fe53258024"
      unitRef="usd">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id9a7c61994bb46c687fdf99107cfd671_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtMy0xLTEtMzYzNTk_a6f2f046-4f32-48bd-9da2-5e2ae90a3a90"
      unitRef="usd">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i35c6f499764943a9b6668276c03a7dca_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtNS0xLTEtMzYzNTk_39832450-3d29-4271-a64b-286f9e43c4be"
      unitRef="usd">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0dd00bad76d24a0ba7fbe37165e9ea1e_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzMtNy0xLTEtMzYzNTk_49547f10-4124-4557-9821-be31233effe2"
      unitRef="usd">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i932fedfaff694d47a9c810a8ed5c652a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtMS0xLTEtMzYzNTk_0f80a3a3-40f0-4e08-97a3-9f86036b7510"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i36668e3bf1614b139d53bd0dd4a1737f_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtMy0xLTEtMzYzNTk_fb6a2fef-ef9e-481a-a0fa-00bc24624d0d"
      unitRef="usd">2400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i220876603bc44dc4b5d5cba857b18a98_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtNS0xLTEtMzYzNTk_c1cb76b3-1b08-4dfd-bd60-2fd9b74be910"
      unitRef="usd">5000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3a0fbec0d2524cbfb381bcf39f515a31_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzQtNy0xLTEtMzYzNTk_41578170-bb70-4892-b5f9-17064809e322"
      unitRef="usd">5400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i14606df79fcb41208a7deba7ab883c8b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtMS0xLTEtMzYzNTk_abeebf95-9a97-4d7d-92a4-b2bc2ea23ab1"
      unitRef="usd">30500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id273969844de4a42b563bdd13fe471ee_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtMy0xLTEtMzYzNTk_846be8fe-9798-418c-b456-134c74edd583"
      unitRef="usd">11800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if5b5430845bd4bf0bdf1c90acbf50400_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtNS0xLTEtMzYzNTk_b27bc0ff-161c-415c-9a3b-6a9078a0dc04"
      unitRef="usd">18700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3df27cee9a9e44d4b90685ca4d691bfe_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzUtNy0xLTEtMzYzNTk_4a341455-9960-4c24-83c3-3985d1cb3d31"
      unitRef="usd">27100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtMS0xLTEtMzYzNTk_177182f9-7e06-4281-bb57-2fa0e710c886"
      unitRef="usd">36300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtMy0xLTEtMzYzNTk_ae320157-fe5e-45e3-bffc-c1e4a8bc76bd"
      unitRef="usd">14900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtNS0xLTEtMzYzNTk_a9d44ba2-de2a-4475-aece-46bace785e23"
      unitRef="usd">25200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo5YzI5MzRlMzk3N2Q0ZTliYmE4N2JmMjIxMmFhNWFhNC90YWJsZXJhbmdlOjljMjkzNGUzOTc3ZDRlOWJiYTg3YmYyMjEyYWE1YWE0XzYtNy0xLTEtMzYzNTk_deaff940-0fb2-4da1-b529-20825f821064"
      unitRef="usd">33500000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEwOTk1MTE2NDU0ODI_25ef9201-9989-495d-9b8d-9f0b37a565e1"
      unitRef="usd">61700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzEwOTk1MTE2NDU2MTU_d789ca7a-1113-42c6-bb8c-beba24b16b17">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzQ_eb180873-3296-49db-979c-dc325e10e6e3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo4Y2UwNTJiZTM3MTE0NGM4OTU3MWE3NGU1OWQ5MjZmYi90YWJsZXJhbmdlOjhjZTA1MmJlMzcxMTQ0Yzg5NTcxYTc0ZTU5ZDkyNmZiXzItMS0xLTEtMzYzNTk_e8afecb2-898b-4a89-98c6-dd9136f26806"
      unitRef="usd">10200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo4Y2UwNTJiZTM3MTE0NGM4OTU3MWE3NGU1OWQ5MjZmYi90YWJsZXJhbmdlOjhjZTA1MmJlMzcxMTQ0Yzg5NTcxYTc0ZTU5ZDkyNmZiXzMtMS0xLTEtMzYzNTk_4dd26d84-e11a-4ae0-8c47-689205f46fd2"
      unitRef="usd">4600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="iab3c3decbc9b4749a615c444461f2714_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTo4Y2UwNTJiZTM3MTE0NGM4OTU3MWE3NGU1OWQ5MjZmYi90YWJsZXJhbmdlOjhjZTA1MmJlMzcxMTQ0Yzg5NTcxYTc0ZTU5ZDkyNmZiXzQtMS0xLTEtMzYzNTk_31c74716-f65d-4e86-9b69-6c5380210371"
      unitRef="usd">86300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzA_c5034b93-fea5-455e-8732-31d530a401a3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItMS0xLTEtMzYzNTk_2f239921-3306-4fa7-b662-4e9edc6146c4"
      unitRef="usd">29200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItMy0xLTEtMzYzNTk_e1e93ded-80de-4bd1-92f2-42b17afc800e"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItNS0xLTEtMzYzNTk_34a40cb8-20d6-422e-8641-828fbe170c2f"
      unitRef="usd">8800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTplMTQ3YTM2YzU5YmU0YzcxOGQ1MzkxZmMwNTAyMTM5Ni90YWJsZXJhbmdlOmUxNDdhMzZjNTliZTRjNzE4ZDUzOTFmYzA1MDIxMzk2XzItNy0xLTEtMzYzNTk_df48941f-2cc2-48ef-a33f-d45c33fadedb"
      unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8feb4bec474149ac84ceec0cbaaa45af_I20121205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzU4NzY_ae5de167-d4d3-4c11-a839-91b8ff03de39"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i57656916c4ad4a29bc0dda34d93091b5_D20210923-20210923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE2NDkyNjc0NDM2NDU5_e7570879-5b37-46b1-bd80-5dd5fb35329e"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i57656916c4ad4a29bc0dda34d93091b5_D20210923-20210923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzE2NDkyNjc0NDM2NDc0_037932a9-2f8f-43c2-b756-34f8a46c55d2"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i6f2deacdf28047ffa7f76605879c01a3_D20211205-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzYwMzg_171b4169-ea93-47ad-83ec-edd063257fef"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2NzY_facfeb04-1386-4e24-978f-2f6fc9fa5149">Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItMS0xLTEtMzYzNTk_a62fc6ca-6501-4fd1-9dc6-11aa680282f2"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItMy0xLTEtMzYzNTk_f78496fe-dfa7-4199-912c-4122bae62123"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItNS0xLTEtMzYzNTk_828cb3c5-23dd-4b10-afd0-71a2f7fd92a5"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzItNy0xLTEtMzYzNTk_520389ad-4d99-44b9-b27e-e69ce748a377"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtMS0xLTEtMzYzNTk_392d5f3f-9924-4dfe-b7f1-8fcd76e1c61e"
      unitRef="usd">1500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtMy0xLTEtMzYzNTk_bbb6c869-55ac-4972-b117-b48f42ae52eb"
      unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtNS0xLTEtMzYzNTk_1af227bf-31b0-4fe4-9455-a2cddc707860"
      unitRef="usd">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTozNzE3MWRlZWU4ZGM0ZWI4OTViYThiNGY2NmE0NGIyOS90YWJsZXJhbmdlOjM3MTcxZGVlZThkYzRlYjg5NWJhOGI0ZjY2YTQ0YjI5XzMtNy0xLTEtMzYzNTk_73c22221-39a7-4680-8939-d5dd93880b18"
      unitRef="usd">1000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90ZXh0cmVnaW9uOmFlMjA4N2VjODE5ZTQzZWE4NDU1Nzc4ZTJkYjAyZTg1XzY2Nzg_f0af60a9-0662-49cb-b5da-98e7e6f60e00">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black&#x2011;Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItMS0xLTEtMzYzNTk_3787e0f0-62cc-4b0b-9222-9d95ce273731"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItMy0xLTEtMzYzNTk_458c9f20-a95a-4c17-a1bd-a5046a314316"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItNS0xLTEtMzYzNTk_c266bf4f-aa96-45df-9a85-c7c0e0fd0287"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzItNy0xLTEtMzYzNTk_2b3caad7-0c48-4db7-8c01-09a70514f55f"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtMS0xLTEtMzYzNTk_da5f43e2-b253-4156-89c8-493e4e76ccc9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtMy0xLTEtMzYzNTk_407997d3-69ec-42e3-bc12-01a13cb932bb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtNS0xLTEtMzYzNTk_4dbecc38-e701-4540-865a-4b93af6bc7eb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzMtNy0xLTEtMzYzNTk_a2bca6da-f5e3-4b1c-8eb9-df20a9cef06d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtMS0xLTEtMzYzNTk_76b95925-3e1f-4c65-9522-83286c9958d2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtMy0xLTEtMzYzNTk_599bc246-4e6f-4186-983d-cd277fd92f4b">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtNS0xLTEtMzYzNTk_fc6a6380-3d6e-460a-8ce7-aff2de0834dd">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzQtNy0xLTEtMzYzNTk_75607677-5f8a-4073-b603-ed7e7c5226ec">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6bd16aca453a464fb8dc46e086df2884_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtMS0xLTEtMzYzNTk_19e80f66-000a-40d6-a667-a0f484cde106"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtMy0xLTEtMzYzNTk_65b2ea52-cb0a-425c-b9eb-09e9f117bfa0"
      unitRef="number">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5f8b2eec0f774284bee4f15fade2fcba_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtNS0xLTEtMzYzNTk_f082c3ba-9673-4ac6-a4c4-63d02dc1f6a5"
      unitRef="number">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if3919ed6628c46f0a4c2759f123927da_D20180701-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMTgvZnJhZzphZTIwODdlYzgxOWU0M2VhODQ1NTc3OGUyZGIwMmU4NS90YWJsZTowZDViNDlkMjIwY2Q0MjIzODljZjllMGM1MjE2NzMwNC90YWJsZXJhbmdlOjBkNWI0OWQyMjBjZDQyMjM4OWNmOWUwYzUyMTY3MzA0XzUtNy0xLTEtMzYzNTk_1578437c-85ca-4753-8590-3e168fe4f96c"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTU_883e6f99-2ff0-483d-acd8-75bcfe2dc527">INCOME TAXES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at the statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,422.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(11,880.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(13,486.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive stock option and employee stock purchase plan expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(9,954.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,568.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(642.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,926.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions, Dispositions, and Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,568.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Method changes or tax elections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2,890.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;963.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;-14,107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act in 2020 made various tax law changes, including among other things (i) increased the limitation under IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest, (ii) enacted technical corrections so that qualified improvement property can be immediately expensed under IRC Section 168(k) and net operating losses arising in fiscal tax years beginning before January 1, 2018 and ending after December 31, 2017 can be carried back two years and carried forward twenty years without a taxable income limitation as opposed to carried forward indefinitely, and (iii) made modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years. As a result of the provision provided under the CARES Act, the Company was able to carry-back federal net operating losses to previous periods, resulting in a $20.7&#160;million tax benefit in the year ended December 31, 2020 and $2.7 million tax expense in the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognized the sale of Myriad RBM, Inc., Myriad myPath, LLC, and select assets of Crescendo Biosciences, LLC (formerly known as Crescendo Biosciences, Inc. ("CBI") in the year ended December 31, 2021, which resulted in differences between book and tax treatments. This resulted in the recognition of a $187.0 million capital loss for the tax basis in the stock of Crescendo, which the Company utilized in the current year due to the $282.3&#160;million overall capital gain from the three divestitures. Other consequences due to the dispositions were the removal of deferred tax assets and corresponding valuation allowances. The overall net tax benefit of the divestitures during the year ended December 31, 2021 was $23.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the economic impact of COVID-19, the Company has incurred a cumulative three-year loss. Pursuant to ASC Topic 740, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by I.R.C. Section 382 and certain jurisdictional limitations. For the year ended December 31, 2021, the Company's valuation allowance decreased by $3.5&#160;million, primarily due to the expiration of Utah research credits upon which a valuation allowance had been established. The Company will continue to evaluate the impact that the COVID-19 pandemic may have on its results of operations and its ability to realize its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;br/&gt;sections 382, 383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expires&lt;br/&gt;beginning in year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other state net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating losses (various jurisdictions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Consistent with the indefinite reversal criteria of ASC 740, the Company intends to continue to invest undistributed earnings of its foreign subsidiaries indefinitely. However, due to the cumulative losses that have been incurred to date in such foreign operations, the changes of the Tax Cuts and Jobs Act and the aforementioned election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company&#x2019;s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December&#160;31, 2021, the Company had net unrecognized tax benefits of $32.1 million. The Company&#x2019;s gross unrecognized tax benefits as of the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - statute lapse&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and penalties in year-end balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to uncertain tax positions are included as a component of income tax expense and all other interest and penalties are included as a component of other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017-2018; the State of New Jersey for the years ended June 30, 2013-2017; and Switzerland for the years ended June 30, 2015-2016.&#160;&#160;Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTY_3f72e3ae-871a-47a0-8538-eec0457eebe9">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtMS0xLTEtMzYzNTk_3333e8c8-0028-45a7-8c12-4cf896a6a9f9"
      unitRef="usd">-1900000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtMy0xLTEtMzYzNTk_9c94869b-03d2-4edd-b536-70c70cb7d5a2"
      unitRef="usd">-75800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtNS0xLTEtMzYzNTk_a0fa89fa-426b-46b8-926b-46e0df0128aa"
      unitRef="usd">26600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzMtNy0xLTEtMzYzNTk_c17a58c2-b483-48ac-8526-346d80c9c29e"
      unitRef="usd">-24200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtMS0xLTEtMzYzNTk_1037196f-4715-49af-8773-5a7a41114c15"
      unitRef="usd">3600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtMy0xLTEtMzYzNTk_88c45f87-9f51-4e3e-b1d8-f34c4d203e0d"
      unitRef="usd">-600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtNS0xLTEtMzYzNTk_1d7e3d95-4725-4a31-be2c-11af18aae50c"
      unitRef="usd">4900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzQtNy0xLTEtMzYzNTk_0da831bb-020d-47f3-a030-9c0490037e09"
      unitRef="usd">-100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtMS0xLTEtMzYzNTk_9d6c9280-6a95-4cf4-aba0-907b349471eb"
      unitRef="usd">100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtMy0xLTEtMzYzNTk_c3da13d5-6673-410f-a12a-401c3da2bf38"
      unitRef="usd">200000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtNS0xLTEtMzYzNTk_1993770e-1a29-4ba4-837a-20ca59f8c3f9"
      unitRef="usd">500000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzUtNy0xLTEtMzYzNTk_3dcc66ff-52c5-48ef-b334-739b7a9033f6"
      unitRef="usd">200000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtMS0xLTEtMzYzNTk_217253d2-8567-4da6-a253-ed7f288977d8"
      unitRef="usd">1800000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtMy0xLTEtMzYzNTk_42ec3b57-9562-49d5-b52c-11e5cdf69ae1"
      unitRef="usd">-76200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtNS0xLTEtMzYzNTk_cf231271-3d26-4289-beb8-cd16e9ec0a25"
      unitRef="usd">32000000.0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzYtNy0xLTEtMzYzNTk_3326f94c-9070-40bb-9b6d-aa9a38d586a9"
      unitRef="usd">-24100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtMS0xLTEtMzYzNTk_a64b6cb5-1579-4c7c-a13a-dbe67b2ecbe8"
      unitRef="usd">-33700000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtMy0xLTEtMzYzNTk_303f8cd6-3bd2-4625-9fad-6ab6ae2ccca4"
      unitRef="usd">39100000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtNS0xLTEtMzYzNTk_f8889b9e-de3d-4008-8e53-b1b0ae36870f"
      unitRef="usd">-51500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzgtNy0xLTEtMzYzNTk_62d2df19-0418-4733-a07a-57b23d9e8e8c"
      unitRef="usd">17800000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktMS0xLTEtMzYzNTk_1f4e2b9f-9a1b-493d-b214-39f4677a7185"
      unitRef="usd">5100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktMy0xLTEtMzYzNTk_73aaed5e-ff94-460e-931f-4ecb59081295"
      unitRef="usd">-3400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktNS0xLTEtMzYzNTk_bb435dcf-fdac-45e5-82e5-b97634478303"
      unitRef="usd">-4100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzktNy0xLTEtMzYzNTk_9e96ef00-0a7b-497d-b7ab-e7080260b825"
      unitRef="usd">1700000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTEtMS0xLTM2MzU5_217d6368-aebf-4d2d-a4c0-bd0f804868f0"
      unitRef="usd">100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTMtMS0xLTM2MzU5_4a0169c3-e851-4793-813e-c5ee523e810c"
      unitRef="usd">-500000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTUtMS0xLTM2MzU5_c31da708-2f53-4cf2-bdd0-ed2ee6b79bb0"
      unitRef="usd">-3600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEwLTctMS0xLTM2MzU5_a837bff2-d5f8-4359-83fa-f3afbfb74081"
      unitRef="usd">400000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTEtMS0xLTM2MzU5_e92e48c8-c019-4bfd-93b8-0196a1022ae7"
      unitRef="usd">3200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTMtMS0xLTM2MzU5_c1bbcd98-791a-4298-874c-5ba3193fe051"
      unitRef="usd">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTUtMS0xLTM2MzU5_c5837e3a-d399-4751-8fcd-c8b0fe47c98e"
      unitRef="usd">-3500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzExLTctMS0xLTM2MzU5_126b8903-03d3-40ca-a4b6-b8acabbac1da"
      unitRef="usd">200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTEtMS0xLTM2MzU5_05328ec9-c972-46fc-9278-2d95202fd342"
      unitRef="usd">-31700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTMtMS0xLTM2MzU5_72586618-12af-4512-878e-725127d72b99"
      unitRef="usd">35200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTUtMS0xLTM2MzU5_15ba58d5-43cb-4d51-b499-746da5a66003"
      unitRef="usd">-55700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEyLTctMS0xLTM2MzU5_d0194d1f-7bb0-48d8-aad6-2d7dde4595ab"
      unitRef="usd">19700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTEtMS0xLTM2MzU5_3eda28ab-9ee4-4a6a-ae33-2a15526900c3"
      unitRef="usd">-29900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTMtMS0xLTM2MzU5_fd3ac481-b38f-4e7b-8f47-324e847bd1cf"
      unitRef="usd">-41000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTUtMS0xLTM2MzU5_7d7a0889-11ba-4335-a91d-dc24806fe453"
      unitRef="usd">-23700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTphZGZhZWYzYjE3YzA0ZmZiOGRiMWE0MzBlMjFkYjQ2OC90YWJsZXJhbmdlOmFkZmFlZjNiMTdjMDRmZmI4ZGIxYTQzMGUyMWRiNDY4XzEzLTctMS0xLTM2MzU5_331f71d3-e0fb-4f6a-96a3-b644b0a86160"
      unitRef="usd">-4400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTM_5fa4bd27-0da0-4ee3-a204-58045e1d95f1">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItMS0xLTEtMzYzNTk_bb3c09ab-dc85-4727-a39c-322afe07827f"
      unitRef="usd">-53800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItMy0xLTEtMzYzNTk_4ef5b2f3-dde0-4f14-a01b-b7c28b57c864"
      unitRef="usd">-101800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItNS0xLTEtMzYzNTk_eef77a5c-7ca6-4068-a4ed-69c15b912607"
      unitRef="usd">-240900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzItNy0xLTEtMzYzNTk_96457948-f969-436e-9e70-b9a5dcd5ac9e"
      unitRef="usd">-600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtMS0xLTEtMzYzNTk_f6f260f0-47ac-45e2-81a8-469e0787a937"
      unitRef="usd">-3300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtMy0xLTEtMzYzNTk_029427fd-b46e-4e26-8736-ecb33f21d7a4"
      unitRef="usd">7700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtNS0xLTEtMzYzNTk_ff217a8b-81d9-487d-9290-85ebe8c3da1b"
      unitRef="usd">17600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzMtNy0xLTEtMzYzNTk_eeffa9d7-6227-43e4-b22b-5f9b86f26aa2"
      unitRef="usd">600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtMS0xLTEtMzYzNTk_50125b03-9372-4bcd-9b85-58e6e278e622"
      unitRef="usd">-57100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtMy0xLTEtMzYzNTk_0649e056-4561-48b2-aa01-981114184afc"
      unitRef="usd">-94100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtNS0xLTEtMzYzNTk_afe157a8-1fe9-4d08-9d36-7619bb70c6eb"
      unitRef="usd">-223300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo3YjAyMTk0Y2UwMDI0YjhmYjcyMGVjMDg3MTIyYmIxNi90YWJsZXJhbmdlOjdiMDIxOTRjZTAwMjRiOGZiNzIwZWMwODcxMjJiYjE2XzQtNy0xLTEtMzYzNTk_0f44afd8-6efd-4d67-b592-e958a83ece85"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTc_192ac97e-3250-4867-9eb8-59661eaf8c8c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at the statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,422.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(11,880.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(13,486.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive stock option and employee stock purchase plan expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(9,954.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,568.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(642.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,926.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions, Dispositions, and Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,568.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Method changes or tax elections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2,890.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;963.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;-14,107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMS0xLTEtMzYzNTk_84277d93-60ee-4b0a-9dcd-6e0962d46384"
      unitRef="usd">-12000000.0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMy0xLTEtMzYzNTk_951db345-7466-4f2f-9fec-8eee24579356"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItNS0xLTEtMzYzNTk_3e7c04bf-ff7d-4029-a020-3c688304b2ae"
      unitRef="usd">-19800000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItNy0xLTEtMzYzNTk_b275369a-942b-4eb9-b1f4-f30c1a20924f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItOS0xLTEtMzYzNTk_05530eef-4f8a-4901-b1e5-5c64e205a45a"
      unitRef="usd">-46900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMTEtMS0xLTM2MzU5_4c123504-e508-4a29-a00e-e193e9a5edda"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMTMtMS0xLTM2MzU5_67ca1af7-560d-48bf-961e-8b5734345d96"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzItMTUtMS0xLTM2MzU5_525dbeb2-a124-47a4-a55f-7939c3c2426d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMS0xLTEtMzYzNTk_341df10f-665d-4fec-8f68-0e379e09e710"
      unitRef="usd">-1800000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMy0xLTEtMzYzNTk_da0db6c1-9cfc-44df-9202-e1faaa1d5dc0"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtNS0xLTEtMzYzNTk_2b6751e3-e681-4b1c-b51b-32a57969eafc"
      unitRef="usd">-1200000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtNy0xLTEtMzYzNTk_b0adafc1-2364-4289-a862-8cd4a59d2a8a"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtOS0xLTEtMzYzNTk_015faaa2-584f-496e-9304-a65140debe13"
      unitRef="usd">4000000.0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMTEtMS0xLTM2MzU5_cfc2f8af-eec8-4b7d-8d5e-65bc6012bd33"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMTMtMS0xLTM2MzU5_b0eb6394-b758-4a40-9e61-6706b6b52c87"
      unitRef="usd">2000000.0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzMtMTUtMS0xLTM2MzU5_791e48c9-fdd8-49b3-9883-ec2674f163be"
      unitRef="number">64.221</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMS0xLTEtMzYzNTk_e5929a64-17b1-4883-a0ae-a428b25b4052"
      unitRef="usd">-2500000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMy0xLTEtMzYzNTk_9081c230-2dd0-452d-baf5-79d6d0dc7b1c"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtNS0xLTEtMzYzNTk_a497fb79-b854-4c40-8fbb-bb13cf620c93"
      unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtNy0xLTEtMzYzNTk_13aeceac-6d9f-493a-8cc8-8abaf31093fb"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtOS0xLTEtMzYzNTk_33bc9fc1-73b3-479c-9384-5b9d5bf69020"
      unitRef="usd">2800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMTEtMS0xLTM2MzU5_8f607a0f-c79a-4910-aa98-81ccf8b6673a"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMTMtMS0xLTM2MzU5_634e09dc-3949-441c-a8c5-3c7b5c787cf6"
      unitRef="usd">3700000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzQtMTUtMS0xLTM2MzU5_fa5c1f15-3898-42c9-ad21-a9b759922d54"
      unitRef="number">118.809</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMS0xLTEtMzYzNTk_6573e5eb-d7c0-4374-acd5-58b46965fa7f"
      unitRef="usd">-3000000.0</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMy0xLTEtMzYzNTk_8bcad95d-1e94-48ec-bf1a-f33b698bf836"
      unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtNS0xLTEtMzYzNTk_95704ce9-0178-4b5a-a0e8-ffd6171b7b09"
      unitRef="usd">600000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtNy0xLTEtMzYzNTk_3c72ca19-6853-43f8-bd77-5f54e0b5ed84"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtOS0xLTEtMzYzNTk_75e9bc16-7347-4313-a3ba-881b0561bf6f"
      unitRef="usd">1500000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMTEtMS0xLTM2MzU5_23d467cc-9a0d-4bfa-b83e-04f9f46b7443"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMTMtMS0xLTM2MzU5_816b1a28-4eef-4f57-8ab7-e20d7f76ca18"
      unitRef="usd">-4200000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzUtMTUtMS0xLTM2MzU5_9f51315b-aa89-4b80-9867-1c25981c22ea"
      unitRef="number">-134.864</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMS0xLTEtMzYzNTk_34203280-2df5-4eab-b531-8a0df15100bb"
      unitRef="usd">700000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMy0xLTEtMzYzNTk_79a721e7-eb30-45b6-9e6f-1d20afc306a4"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctNS0xLTEtMzYzNTk_3d60a9a1-6f04-44cc-a130-e8d1009aad0e"
      unitRef="usd">2500000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctNy0xLTEtMzYzNTk_3c3387d7-fc8e-402f-810d-7e34f4b81266"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctOS0xLTEtMzYzNTk_541ccfc4-a9fb-4ff3-a862-7985c3d7f223"
      unitRef="usd">-200000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMTEtMS0xLTM2MzU5_79ef4101-c671-4f62-96b1-63b9ab7eb8d2"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMTMtMS0xLTM2MzU5_9a8e7f5e-b13d-4ffb-9269-3e81b8b1312f"
      unitRef="usd">-3100000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzctMTUtMS0xLTM2MzU5_8203ef21-420a-428c-b7a6-85f029082db9"
      unitRef="number">-99.543</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMS0xLTEtMzYzNTk_123ab2c2-b203-4930-af51-63fdb357667c"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMy0xLTEtMzYzNTk_ceb4110a-7566-4ab3-87f8-f88d6abc8506"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtNS0xLTEtMzYzNTk_ed293181-4010-4483-9f19-978591e81062"
      unitRef="usd">-2100000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtNy0xLTEtMzYzNTk_0283a6de-ddcd-470c-b9dd-0cb6f36fa6ad"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtOS0xLTEtMzYzNTk_b930b4d8-8411-47d3-80bd-d7edfe5a24af"
      unitRef="usd">700000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMTEtMS0xLTM2MzU5_8e4c2ad4-61b0-4f17-beae-6b3a5f317206"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMTMtMS0xLTM2MzU5_574dc084-1fda-4e83-86c9-b1bcb196a0c9"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzgtMTUtMS0xLTM2MzU5_de1766f8-2020-4bec-9236-ea97e18b5edf"
      unitRef="number">25.688</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMS0xLTEtMzYzNTk_e2456a69-a1ac-47e5-88c5-aafa240ed7d5"
      unitRef="usd">-3200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMy0xLTEtMzYzNTk_72854866-8a63-43e0-a3e5-bb7985fde8a8"
      unitRef="number">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktNS0xLTEtMzYzNTk_ca4722f9-05ed-451b-bc8e-519decf61d8f"
      unitRef="usd">-300000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktNy0xLTEtMzYzNTk_95fbf180-3d55-4618-a122-bf9b1e6d6008"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktOS0xLTEtMzYzNTk_da8fffb7-d426-4e1b-a5dc-2fa7efab09c5"
      unitRef="usd">3500000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMTEtMS0xLTM2MzU5_04d08902-c653-4ff2-ad7e-5aad9d0f4609"
      unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMTMtMS0xLTM2MzU5_bb104123-5d90-425c-a4a4-5313f0fbf96a"
      unitRef="usd">-200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzktMTUtMS0xLTM2MzU5_8b9d087b-8fed-4238-baaa-43d126bf1eef"
      unitRef="number">-6.422</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <mygn:IncomeTaxReconciliationCARESAct
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTEtMS0xLTM2MzU5_e6b37320-746a-42f1-9ba5-5bf6dbcd34b8"
      unitRef="usd">2700000</mygn:IncomeTaxReconciliationCARESAct>
    <mygn:EffectiveIncomeTaxRateReconciliationCARESAct
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTMtMS0xLTM2MzU5_ae66e57c-7c07-4c11-8bf5-dfc9450b92cb"
      unitRef="number">-0.047</mygn:EffectiveIncomeTaxRateReconciliationCARESAct>
    <mygn:IncomeTaxReconciliationCARESAct
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTUtMS0xLTQwNjAw_7c141eb1-bda9-4bd0-ae7b-c5cf559ed1f8"
      unitRef="usd">-20700000</mygn:IncomeTaxReconciliationCARESAct>
    <mygn:EffectiveIncomeTaxRateReconciliationCARESAct
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzExLTctMS0xLTQwNjAw_6a25423d-178d-4fdf-b3a3-bdf671a7ce68"
      unitRef="number">0.220</mygn:EffectiveIncomeTaxRateReconciliationCARESAct>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTEtMS0xLTM2MzU5_bd8a8d9f-be36-42b0-bffa-aa0367c1b49b"
      unitRef="usd">100000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTMtMS0xLTM2MzU5_99b2d4dd-30f1-4e74-8dac-6a84f44b96bf"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTUtMS0xLTM2MzU5_dcacaa40-97a2-4525-9032-4067fbf156a6"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTctMS0xLTM2MzU5_354c8757-5cd6-48eb-991a-c4d8873595a5"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTktMS0xLTM2MzU5_18bf5381-acbc-4ea2-9ba4-6ea7ca2a356b"
      unitRef="usd">1800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTExLTEtMS0zNjM1OQ_b92350cc-9082-498b-bf74-0a995934da9f"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTEzLTEtMS0zNjM1OQ_72151ea0-f2fd-45c4-b986-01b84f727aa6"
      unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE0LTE1LTEtMS0zNjM1OQ_05dbe4cf-ce6d-4592-8396-8b44335d5a1f"
      unitRef="number">41.744</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTEtMS0xLTM2MzU5_cf2a9687-c17f-4815-ac38-8fe702246054"
      unitRef="usd">3300000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTMtMS0xLTM2MzU5_9ec0e2ea-daf2-4a2d-9b93-10e381866a0c"
      unitRef="number">-0.058</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTUtMS0xLTM2MzU5_8c4bba06-6f3e-4751-8b6d-248595c0a657"
      unitRef="usd">100000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTctMS0xLTM2MzU5_c02de851-9ea2-4b51-ae67-d160828e03df"
      unitRef="number">-0.001</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTktMS0xLTM2MzU5_d409d4a0-2024-466e-951c-80e68dd1b9f7"
      unitRef="usd">1600000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTExLTEtMS0zNjM1OQ_589d954d-786f-477b-a8a9-5fdd3556d359"
      unitRef="number">-0.007</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTEzLTEtMS0zNjM1OQ_6321d118-a6f5-422f-b067-b3e809df8a62"
      unitRef="usd">600000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE1LTE1LTEtMS0zNjM1OQ_6e6cff7b-b5dc-47d3-8927-e4150ca81205"
      unitRef="number">19.266</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTEtMS0xLTM2MzU5_19b95dee-a274-4268-ae26-f03d4ba3b5d9"
      unitRef="usd">0</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTMtMS0xLTM2MzU5_bb080b99-30e3-43dd-894f-de990233de92"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTUtMS0xLTM2MzU5_9d463cdf-2b1b-4cc2-a0cc-1f8c284fbcfb"
      unitRef="usd">0</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTctMS0xLTM2MzU5_8a901160-68ad-4b2a-b0c5-f4bc8eaedfe9"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTktMS0xLTM2MzU5_276cf83f-1aa8-496a-8f1e-8ddc561ef5f0"
      unitRef="usd">12600000</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTExLTEtMS0zNjM1OQ_e9920c08-b89a-4950-9d54-0efce3b197f6"
      unitRef="number">-0.056</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTEzLTEtMS0zNjM1OQ_aac11af7-2adf-4070-8a86-113cc74301c4"
      unitRef="usd">0</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE2LTE1LTEtMS0zNjM1OQ_2fe21a4b-0177-4bfc-a216-51c4b22d3edc"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTEtMS0xLTM2MzU5_a3c9f4c8-ceea-491d-80c2-fbd0c873050f"
      unitRef="usd">2500000</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTMtMS0xLTM2MzU5_ddec444a-f9c4-41fe-a263-d6d701af5323"
      unitRef="number">-0.045</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTUtMS0xLTM2MzU5_2f0cbd72-f51a-412f-bbfd-c9936c10402c"
      unitRef="usd">0</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTctMS0xLTM2MzU5_6fd78120-40a2-4f58-ac13-08556ed17690"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTktMS0xLTM2MzU5_c3db6bc0-5503-4670-878f-3de9d2026032"
      unitRef="usd">0</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTExLTEtMS0zNjM1OQ_1f0a4fa2-1bc0-4049-a47c-0a41b3fc0c4b"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTEzLTEtMS0zNjM1OQ_ef986049-caab-4163-8da6-03b81371e860"
      unitRef="usd">1900000</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE4LTE1LTEtMS0zNjM1OQ_5cf241ac-b2e3-44eb-a5af-843302899dec"
      unitRef="number">61.01</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTEtMS0xLTYxOTU0_0d61c8bc-bbde-4222-8e87-cc4a6f59cadb"
      unitRef="usd">-23000000.0</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTMtMS0xLTYxOTU0_8c03185e-6759-42de-be8e-0cf31daa1dba"
      unitRef="number">0.403</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTUtMS0xLTYxOTU0_5dd33fe1-33fd-4b04-ba3b-748774a66730"
      unitRef="usd">700000</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTctMS0xLTYxOTU0_1e547786-400b-4a98-83b6-368ecbed88bf"
      unitRef="number">-0.007</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTktMS0xLTYxOTU0_d8fe7cca-9236-4b3e-b44d-59605bc97506"
      unitRef="usd">-300000</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTExLTEtMS02MTk1NA_1aad91ea-0f26-4bf6-b8cc-54e415c6dc3f"
      unitRef="number">0.001</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTEzLTEtMS02MTk1NA_359c635e-600f-42a5-ac73-4f73de5bba22"
      unitRef="usd">800000</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzE5LTE1LTEtMS02MTk1NA_87918719-4a07-4a63-b4a4-9464046f0e6f"
      unitRef="number">25.688</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTEtMS0xLTM2MzU5_37026ce9-65f6-406a-8ce8-7c2f158e2cca"
      unitRef="usd">0</mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod>
    <mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTMtMS0xLTM2MzU5_3489aaee-34e6-496f-901a-40d1393c7a15"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod>
    <mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTUtMS0xLTM2MzU5_43f41b92-0bd0-47d8-860b-c6da36527ae3"
      unitRef="usd">0</mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod>
    <mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTctMS0xLTM2MzU5_a32de2ee-234e-4e46-b311-1a8595f28b51"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod>
    <mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTktMS0xLTM2MzU5_0e12529d-adc0-4f44-ae78-ade4be55ffc7"
      unitRef="usd">0</mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod>
    <mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTExLTEtMS0zNjM1OQ_5978fc79-5f7e-4100-962b-8250d0cd4661"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod>
    <mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTEzLTEtMS0zNjM1OQ_8f1c805c-bb8e-41ba-a15a-460bde26e283"
      unitRef="usd">-900000</mygn:IncomeTaxReconciliationChangesInRevenueRecognitionMethod>
    <mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIwLTE1LTEtMS0zNjM1OQ_fbad42ef-58d3-4230-b850-eee70bf2a3a3"
      unitRef="number">-28.90</mygn:EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTEtMS0xLTM2MzU5_060bea99-ccee-4f65-9a26-e1419aabd2de"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTMtMS0xLTM2MzU5_a341ad52-9df8-480e-9620-d7ea7d97f7bd"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTUtMS0xLTM2MzU5_3bf77561-ee64-46f7-b999-fa2f7aa7d2d9"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTctMS0xLTM2MzU5_ad9d4f02-0d73-426a-8040-0ee38aa2859c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTktMS0xLTM2MzU5_e817e39a-91d4-4833-82d1-7719739ee339"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTExLTEtMS0zNjM1OQ_6c573134-23aa-4bf6-ac44-2c6d71c3b5ce"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTEzLTEtMS0zNjM1OQ_de656076-619a-4a15-8a26-18b228732052"
      unitRef="usd">300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIxLTE1LTEtMS0zNjM1OQ_ff07d859-93ef-464d-851b-6a2c4905a956"
      unitRef="number">9.634</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTEtMS0xLTM2MzU5_59c71334-f21d-4d60-bdea-7b6a90dc7841"
      unitRef="usd">-29900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTMtMS0xLTM2MzU5_be148edd-1849-45e5-a7a7-dbbf0d5817ca"
      unitRef="number">0.523</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTUtMS0xLTM2MzU5_ad76c171-0c94-4d83-8960-3ffaf3687333"
      unitRef="usd">-41000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTctMS0xLTM2MzU5_ec55947b-85ec-412c-ae37-f9238ab27048"
      unitRef="number">0.435</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTktMS0xLTM2MzU5_35a2a127-af57-405e-9f2d-56a5097c9c52"
      unitRef="usd">-23700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTExLTEtMS0zNjM1OQ_8c9f28f8-5e25-4ffc-abc3-c2eaddbb64d0"
      unitRef="number">0.106</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTEzLTEtMS0zNjM1OQ_ed867682-6cd3-4116-b83a-f7b9c3bf42f5"
      unitRef="usd">-4400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZToyOTZmNzU2YjhjZjg0Y2I5YmVkOTJjYjY3NGRkODYyYi90YWJsZXJhbmdlOjI5NmY3NTZiOGNmODRjYjliZWQ5MmNiNjc0ZGQ4NjJiXzIyLTE1LTEtMS0zNjM1OQ_7220402f-bd71-49c1-9ff8-3a1359cbe060"
      unitRef="number">-141.077</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTg_809efcab-5ef7-4d00-99f9-6dd5ee4f78ce">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzMtMS0xLTEtMzYzNTk_dd58608d-b518-4be9-8574-f37b96ad3eb4"
      unitRef="usd">67200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzMtMy0xLTEtMzYzNTk_24129e36-cc7e-4288-a7c5-530f1b7ce413"
      unitRef="usd">72200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzQtMS0xLTEtMzYzNTk_d1c91bfb-11e1-483d-90e6-ad121fc67dea"
      unitRef="usd">1200000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzQtMy0xLTEtMzYzNTk_8ee2897d-3e15-48e3-913a-8a20dfade64e"
      unitRef="usd">7200000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzUtMS0xLTEtMzYzNTk_d4a6891a-64d4-4fc5-9d5e-561cf1383217"
      unitRef="usd">4500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzUtMy0xLTEtMzYzNTk_ca65165d-aa32-409d-a7c0-79d57129ea36"
      unitRef="usd">11500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzgtMS0xLTEtMzYzNTk_15b2eb9b-33bf-43bc-b115-d41db30e992e"
      unitRef="usd">17300000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzgtMy0xLTEtMzYzNTk_e822072f-d963-40aa-a3a1-fa8be710072d"
      unitRef="usd">24900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <mygn:DeferredTaxAssetsLeaseRightOfUseAsset
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzktMS0xLTEtMzYzNTk_683f881d-eef7-463c-8bcb-ba5d8498e42a"
      unitRef="usd">22400000</mygn:DeferredTaxAssetsLeaseRightOfUseAsset>
    <mygn:DeferredTaxAssetsLeaseRightOfUseAsset
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzktMy0xLTEtMzYzNTk_cf7c2674-bfe0-455f-8c0b-cbde6b870330"
      unitRef="usd">15200000</mygn:DeferredTaxAssetsLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTEtMS0xLTYxOTc1_2ce35441-19dd-48ea-aa81-b5b3430a6193"
      unitRef="usd">14200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTMtMS0xLTYxOTc1_6a3e22d7-a3d4-4268-a598-8323f6da96ab"
      unitRef="usd">7600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzExLTEtMS0xLTM2MzU5_a32e4498-d8a7-437c-8e98-71afd522ec78"
      unitRef="usd">4500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzExLTMtMS0xLTM2MzU5_f663f98e-2f92-459b-a327-f1d2593dd85d"
      unitRef="usd">6400000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEyLTEtMS0xLTM2MzU5_d9af5aaf-b649-4e7c-a2ae-37d14603d8d9"
      unitRef="usd">131300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEyLTMtMS0xLTM2MzU5_6373977b-8f32-4d07-a206-0d04c8cfc59f"
      unitRef="usd">145000000.0</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTEtMS0xLTM2MzU5_3b27ae57-d1c5-442f-855c-277649a2cfc4"
      unitRef="usd">38500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzEzLTMtMS0xLTM2MzU5_f978312f-7ead-4634-b584-74f6e7d47780"
      unitRef="usd">42000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE0LTEtMS0xLTM2MzU5_e05f1ef7-9bcd-425c-b05f-fa5f16ddf843"
      unitRef="usd">92800000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE0LTMtMS0xLTM2MzU5_5ba667b3-2e98-4a50-bf78-e8fd6937ec79"
      unitRef="usd">103000000.0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE2LTEtMS0xLTM2MzU5_052796d7-7d87-4dac-8bf2-d44c45685265"
      unitRef="usd">104900000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE2LTMtMS0xLTM2MzU5_4498d0cc-255a-4ea1-9a6c-5165898c0fd3"
      unitRef="usd">144000000.0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <mygn:DeferredTaxLeaseLiability
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE3LTEtMS0xLTM2MzU5_0abf63a7-1876-47ac-956f-f21e2caa32e6"
      unitRef="usd">20200000</mygn:DeferredTaxLeaseLiability>
    <mygn:DeferredTaxLeaseLiability
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE3LTMtMS0xLTM2MzU5_153a9165-5a98-49fa-ab46-d64542420090"
      unitRef="usd">14600000</mygn:DeferredTaxLeaseLiability>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE4LTEtMS0xLTM2MzU5_8fb6ad31-a361-420b-8469-a128735d35dc"
      unitRef="usd">3500000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzE4LTMtMS0xLTM2MzU5_0159db30-431c-4907-a19d-bb50c46ddf26"
      unitRef="usd">15700000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIwLTEtMS0xLTM2MzU5_cb4b830d-04f8-482d-b1fe-7e5d6f19ee64"
      unitRef="usd">128600000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIwLTMtMS0xLTM2MzU5_fa454328-c069-40eb-9bdd-b385ad2e2900"
      unitRef="usd">174300000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIxLTEtMS0xLTM2MzU5_390bb0e5-d658-4d1c-b31c-7cee79fab3d6"
      unitRef="usd">35800000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpmNWY0NTM4MzZhZmU0YjY4YTMyNDUzYWFjMTU2ZDgzNy90YWJsZXJhbmdlOmY1ZjQ1MzgzNmFmZTRiNjhhMzI0NTNhYWMxNTZkODM3XzIxLTMtMS0xLTM2MzU5_2b355db9-5626-440b-b904-f216b849a365"
      unitRef="usd">71300000</us-gaap:DeferredTaxLiabilities>
    <mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA3ODU_b5d9face-ab33-4211-8ec3-81ec2d98712a"
      unitRef="usd">-20700000</mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct>
    <mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzE0OTg_ce271f06-2564-488a-9cae-9bcd71f1a906"
      unitRef="usd">-2700000</mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct>
    <mygn:DisposalGroupCapitalLossOnTaxBasis
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MDA_b4595a69-75ab-4d4e-866d-e0111258eb5c"
      unitRef="usd">187000000</mygn:DisposalGroupCapitalLossOnTaxBasis>
    <mygn:DisposalGroupCapitalGainOnDivestiture
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MjM_0d61b6f3-7578-44c5-afed-dbea79fd24ef"
      unitRef="usd">282300000</mygn:DisposalGroupCapitalGainOnDivestiture>
    <mygn:NumberOfDivestitures
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MzA_0ade7fa8-d4e0-41a2-b076-d7387604e925"
      unitRef="divestiture">3</mygn:NumberOfDivestitures>
    <mygn:DisposalGroupNetTaxExpenseBenefitOnDivestiture
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4MDg_1abd1267-7606-4f26-b463-4391e6f29be7"
      unitRef="usd">-23400000</mygn:DisposalGroupNetTaxExpenseBenefitOnDivestiture>
    <mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzMyOTg1MzQ5MDA4NTA_3a35e242-5121-4566-be1d-38b1ac6804d3"
      unitRef="usd">-3500000</mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTQ_f01091ac-d374-4c45-a22c-ea880067bc11">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;br/&gt;sections 382, 383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expires&lt;br/&gt;beginning in year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other state net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating losses (various jurisdictions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i83383bd4b0654a95842e069decbe0d94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtMi0xLTEtMzYzNTk_9b655c5c-5fd9-423f-9a44-03b687e5d350"
      unitRef="usd">31200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="i9d865748020e4effaae21a66a663077b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtNC0xLTEtMzYzNTk_f17ba4a9-3392-4c98-bdf6-c36f180424f1">Yes</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i8dfa542a04ef4e41ac83b425d14fdea0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtNi0xLTEtMzYzNTk_2b60fcdb-e28b-4d13-9a60-e20ca38f9996">2036</mygn:OperatingLossCarryforwardsExpirationYear>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i08ceba9140e2414aa168f8323513eb92_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzEtOC0xLTEtMzYzNTk_ef4c1512-155c-483b-b47e-45299c3ab3eb">2037</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i3cb7a3dbd0394b3a98b2fa3967024ce9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItMi0xLTEtNjIwOTE_981c3bbb-f7c3-4279-a94f-443f07ae0562"
      unitRef="usd">13500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="i9589f80194a941a98f9394776dc93210_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNC0xLTEtNjM1NzY_9382c0fa-6dff-43a4-9d80-1e4e62be6c26">No</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="i16e65e9f289e470e8192dacb960d4a43_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNi0xLTEtNjM1NzM_fd4b1b2c-7ce5-4b1b-8c84-cc39cd89fa1a">2026</mygn:TaxCreditCarryforwardsExpirationDate>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="iea5670d0442144a9827fb94b02527d5d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItOC0xLTEtNjM1NzM_df69d326-fcd5-49dd-8443-49ae3a45d3ca">2026</mygn:TaxCreditCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ief421c0a8d774da3a0d3e029188f8bb1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItMi0xLTEtMzYzNTk_876f924a-910e-409d-9ac4-c11c16f44a64"
      unitRef="usd">2400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="ia343da359530413f9f43cba7387074bf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNC0xLTEtMzYzNTk_8fa460f3-5229-4afe-9c36-214f7af3081e">No</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i3acf17d910cc465bb94c96ceb1075337_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzItNi0xLTEtMzYzNTk_3fd3fb9e-0b1f-41c2-bb08-e49841ee19aa">2022</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i78965414e66747c19486ba7a6e74f9c2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtMi0xLTEtMzYzNTk_770c181d-f249-4a49-a686-d4b31f1a3005"
      unitRef="usd">3900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="icfce3d729fbe4d2982bbceb25a61b887_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtNC0xLTEtMzYzNTk_46264fc0-a8e5-4049-a3c6-43b3d56c1500">Yes</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i203e33449c4d47478858a4e96feba476_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtNi0xLTEtMzYzNTk_d615e473-7a75-4f73-bed6-31195c765008">2027</mygn:OperatingLossCarryforwardsExpirationYear>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i8b129110cdcf40da82c792a626cb5140_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzMtOC0xLTEtMzYzNTk_ae9a564d-fe58-47d5-b64e-fcd4fb9ca993">2042</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6fc7f4bae0a24544870e68c5081d1eae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtMi0xLTEtMzYzNTk_6d4028f8-d2a1-4d09-9e9f-5e3cc0e24397"
      unitRef="usd">7400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="ice0285b61cc74e72912725920fceec85_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtNC0xLTEtMzYzNTk_ea48966d-ae71-43af-a24d-a17cf20930d7">Yes</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i7de9b7a4b6ea43ce99df84afe005c51f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtNi0xLTEtMzYzNTk_754bc2d3-62c1-42dd-9cfb-bcfe954edd29">2027</mygn:OperatingLossCarryforwardsExpirationYear>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="ie1dd974f0a354b7e918ff359564e3487_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzQtOC0xLTEtMzYzNTk_4f27b10b-4dd5-4aaf-b1c0-41ed4b4eee8f">2041</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i60e9618d910a43b3b0cf3e5ca1018738_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzUtMi0xLTEtMzYzNTk_478c8f43-617b-46ae-a2c1-9a1b484e0e94"
      unitRef="usd">8800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="id9ff73e805544f00a995a79e7beabfd7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzUtNC0xLTEtMzYzNTk_4d6e657a-48af-48fb-b958-5e4f9a0dcce5">No</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i39aada1c97204d7ba76be4c96523dd65_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtMi0xLTEtMzYzNTk_73168e66-b970-461c-81e5-53d825e620b1"
      unitRef="usd">6400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="i3f9d97eb20794fe5ad342b5b3244164a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtNC0xLTEtMzYzNTk_e37621cf-9317-49ea-91e9-206a322e9d26">Yes</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="i6a2fec96267b42df8bdcd32ac76c5bfc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtNi0xLTEtMzYzNTk_455dc317-b7e7-47d9-be6f-0062acc00a47">2027</mygn:TaxCreditCarryforwardsExpirationDate>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="i13f5587e0ffc403b998eeeaf70866baa_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzYtOC0xLTEtMzYzNTk_a1d6defd-e790-4e5f-9f04-7516ae7e8ac7">2042</mygn:TaxCreditCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i6e7bfc4c89d34726b342ff9738bb6c21_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctMi0xLTEtMzYzNTk_e4a8f16c-1391-4092-a68e-ad0292bb686f"
      unitRef="usd">6900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="i2e54383ae03647b4bdc0042c788b7d92_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctNC0xLTEtMzYzNTk_56e4b9a2-ccaa-4d12-871d-c98e64188ca9">No</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="ie2d1f694a2b246dd97539cfbc90fdaa5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctNi0xLTEtMzYzNTk_9c75bb4d-7d10-49aa-9ec0-9d2edfc62c5b">2022</mygn:TaxCreditCarryforwardsExpirationDate>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="ie4c32f4affc04ac8ad57b0fb12effb75_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzctOC0xLTEtMzYzNTk_57f42ac7-4ab0-41f2-9c44-53954d407a77">2036</mygn:TaxCreditCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i92e766bbdac2412db386420a0fd67410_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzgtMi0xLTEtMzYzNTk_b624183e-028a-42c2-bd75-a2539601df3b"
      unitRef="usd">4000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="i37ac628246aa47a9856eff8943bb53da_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTpkMDQ2NzEwMDU4NTI0NDE1OWMxNWRjNDlmZjdhOGQwNi90YWJsZXJhbmdlOmQwNDY3MTAwNTg1MjQ0MTU5YzE1ZGM0OWZmN2E4ZDA2XzgtNC0xLTEtMzYzNTk_d29f148a-5c93-4e0d-bcb1-c033b8524083">No</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzEwOTk1MTE2NDAxMDU_9ef2e6b1-4269-4141-a0df-09a9258ffce8"
      unitRef="usd">32100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzY2MTI_bb95551f-c878-4308-a16e-8f71bd38890b">The Company&#x2019;s gross unrecognized tax benefits as of the year ended December&#160;31, 2021, the transition period ended December&#160;31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - statute lapse&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and penalties in year-end balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItMS0xLTEtMzYzNTk_ef4e17d2-0f3e-4c3e-a240-8232a35cdc9d"
      unitRef="usd">37600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItMy0xLTEtMzYzNTk_12c1fa82-1495-4be6-bec3-328ee72f748e"
      unitRef="usd">23500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItNS0xLTEtMzYzNTk_9065b8af-082a-4807-af88-192300eb918a"
      unitRef="usd">21700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia567c09cf0824dc693153bb83c1fd300_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzItNy0xLTEtMzYzNTk_62bec1f2-30e4-42f7-a028-030cd824fdb6"
      unitRef="usd">24900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtMS0xLTEtMzYzNTk_10d0bb87-553b-4b3e-9a2c-d8bd86a5e897"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtMy0xLTEtMzYzNTk_01709b7a-0b16-4e1b-9340-aa5bcbfb06dd"
      unitRef="usd">13900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtNS0xLTEtMzYzNTk_1af24363-43f0-4a1b-ae2f-e44a4e9e3156"
      unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzMtNy0xLTEtMzYzNTk_3021d4d1-d0a3-4f31-976d-1179c0c832bc"
      unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtMS0xLTEtMzYzNTk_376e9743-d991-438b-9337-4f2c62a24dcd"
      unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtMy0xLTEtMzYzNTk_b8c04d1a-7900-47d3-bf37-2de543590e8b"
      unitRef="usd">1000000.0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtNS0xLTEtMzYzNTk_b6e34c95-c984-4e7a-b165-8a24828078ed"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzQtNy0xLTEtMzYzNTk_57d1e4d8-3ea9-4cc3-b16e-f67a634e96f1"
      unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtMS0xLTEtMzYzNTk_94043870-54b8-4a93-b10f-94fd098f7272"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtMy0xLTEtMzYzNTk_7807c9a3-2325-411e-baa2-4a531f892f96"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtNS0xLTEtMzYzNTk_9763b700-1c16-4fca-aa59-3c343bd48eb6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzUtNy0xLTEtMzYzNTk_9a1e0000-f19b-4641-b464-6974db651511"
      unitRef="usd">2300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtMS0xLTEtMzYzNTk_0cbb39f7-c524-4a40-a4a4-ad991ebd3de9"
      unitRef="usd">2800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtMy0xLTEtMzYzNTk_7cdf5f31-17e0-4a22-8800-fa0082d9f530"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtNS0xLTEtMzYzNTk_3901e2fe-2ac4-444b-a2c6-499f547d29a5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzYtNy0xLTEtMzYzNTk_bea296cf-f672-4c37-8ced-9652d6b447c2"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctMS0xLTEtMzYzNTk_8d021d13-f96f-45b0-b0d7-bd73fbe591ff"
      unitRef="usd">5100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctMy0xLTEtMzYzNTk_53d29f40-ad73-4623-af1a-fefa05897618"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctNS0xLTEtMzYzNTk_7aa6e305-95ec-4977-9265-daccd759b28a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzctNy0xLTEtMzYzNTk_ca58d878-80f9-40e4-b5b8-c35521e9a1a4"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtMS0xLTEtMzYzNTk_fddd48ef-40d9-4980-96a3-3ffcf5e2094d"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtMy0xLTEtMzYzNTk_6863bac0-26d4-4fff-b91a-efef23b65bda"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtNS0xLTEtMzYzNTk_c824d42a-5f8d-4d58-ab60-2b74b0e17542"
      unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzgtNy0xLTEtMzYzNTk_b7b53756-ebe3-4bba-8bb1-9d23a939473c"
      unitRef="usd">5400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktMS0xLTEtMzYzNTk_9ef2e6b1-4269-4141-a0df-09a9258ffce8"
      unitRef="usd">32100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktMy0xLTEtMzYzNTk_5f625328-cc46-4878-b06e-6f4abc37260e"
      unitRef="usd">37600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktNS0xLTEtMzYzNTk_1ab2a1bf-ee8c-44fb-bece-06d8c134634f"
      unitRef="usd">23500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzktNy0xLTEtMzYzNTk_4c7647ba-033c-4d72-860d-c1c341ce206b"
      unitRef="usd">21700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTEtMS0xLTM2MzU5_d9f18391-2047-4934-a626-234843fdcdb1"
      unitRef="usd">3300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTMtMS0xLTM2MzU5_ac820698-3795-435d-b4a6-8968682425d0"
      unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic56cdf0c7bc84b148ed3d7868192c68b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTUtMS0xLTM2MzU5_e740f515-9e18-4931-9ed3-1beaeb50e4fe"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i8e12abae08574b3f8c6fd1ea68373ca7_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90YWJsZTo1ZmViMjIwMjE4YzA0YjQ3YjdiMTc4OTY4NjYzOTIzNC90YWJsZXJhbmdlOjVmZWIyMjAyMThjMDRiNDdiN2IxNzg5Njg2NjM5MjM0XzEwLTctMS0xLTM2MzU5_d6dfd7ab-f363-4f1f-a4a5-2225eff40e42"
      unitRef="usd">800000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i75ab306877b54340b9ceca58fc63cf74_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzE2NDkyNjc0NDI1NjA5_6c4462ba-9ebb-489d-ba5b-1ac442124aa1">2017</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i40459a0ffb804202863c2399057f5faa_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzE2NDkyNjc0NDI1NjE1_60bec8e8-d456-43b3-897f-d8eab5b2316f">2018</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i9ed6f2b7a99e46259c13006a1c7fb525_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYxNzE_2c5c1189-df40-45be-a1f9-83f30da7d676">2013</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i3720a9cb33664b36ac16fd27520f3445_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYxODI_418ae0fe-8937-4a21-8d3d-38af528ca872">2017</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="ia65ea439046741879c10f71b82d8c8af_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYzNTE_1c125c08-2d52-47f8-8c7b-de9fdf1933b4">2015</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i1cb51262d87a469e9b16924d435ec74e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjEvZnJhZzozMDc3ZGFlZWFmZWE0NzAyOGU0NzgwYTU3NDExNjQ1ZS90ZXh0cmVnaW9uOjMwNzdkYWVlYWZlYTQ3MDI4ZTQ3ODBhNTc0MTE2NDVlXzYzNjI_49c2c016-498d-4934-a5b3-68f228863c36">2016</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzY3MA_f8c4d0ac-a123-494e-af69-3c21596f3d87">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonable estimable in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qui Tam Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, our wholly-owned subsidiary, CBI, received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.&#160;&#160;On January 22, 2020, after a multi-year investigation into CBI&#x2019;s and the Company&#x2019;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#x2019;s motion to dismiss. We have accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend against this case, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah, against the Company, our former President and Chief Executive Officer, Mark C. Capone, and our Chief Financial Officer, R. Bryan Riggsbee (&#x201c;Defendants&#x201d;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added our former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;In re Myriad Genetics, Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. We intend to vigorously defend against this action.&#160;Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholder Derivative Actions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against our former President and Chief Executive Officer, Mark C. Capone, our Chief Financial Officer, R. Bryan Riggsbee, our former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of our current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding our business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, a third stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock and Marcey stockholder derivative actions. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claimed negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004. The plaintiffs sought damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. As of December 31, 2021, we accrued $14.0&#160;million for a potential settlement of this lawsuit, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet as of December 31, 2021. On January 24, 2022, the Company entered into an agreement with the plaintiffs to settle the lawsuit. Pursuant to the terms of the settlement agreement, the Company agreed to pay $14.0&#160;million to the plaintiffs. The settlement agreement also provides for a full release by the plaintiffs of all claims against the Company and contains no admission of liability, wrongdoing or responsibility on the part of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company&#x2019;s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i26a7872b3c3e43d1a1a6e18f0a9a61eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzQ5NDc4MDIzMzcyODk_0c1a1c29-3fbc-4dbe-a571-dbf181afd40b"
      unitRef="usd">48000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i4b60c3a470b443f8bbf026504b9c59d3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzE1OTQyOTE4NjIwMjU1_d1adc4ca-1e91-4fe0-b8ea-cef0597eb59f"
      unitRef="usd">14000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i971ef08a521a4060839a354e9f1482db_D20220124-20220124"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjQvZnJhZzozMzFkZjNjNWY2MmM0MDMyYTZmNThlZWEzZDkyNjY0MC90ZXh0cmVnaW9uOjMzMWRmM2M1ZjYyYzQwMzJhNmY1OGVlYTNkOTI2NjQwXzE1OTQyOTE4NjIwMjcw_7e243792-0d11-47b2-9e08-636883e90578"
      unitRef="usd">14000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQxNzM_793474e9-f47c-4c05-9aef-5355dc655bd5">LEASESThe Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4MA_466cec83-963f-4b74-b010-f7a16d9ef195"&gt;one&lt;/span&gt; to fourteen years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options which allows the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These optional periods have not been considered in the determination of the right-of-use-assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the year ended December 31, 2021, the six-month transition period ended December 31, 2020 and the year ended June 30, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. As part of the adoption, the Company elected the package of practical expedients to avoid reassessing prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing right-of-use assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets. We recognize each new lease within right-of-use assets and lease liabilities once the lease commences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2021, the Company incurred $20.7 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2&#160;million was variable lease expense, which was not included in the measurement of the Company's operating right-of-use assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the transition period ended December 31, 2020, the Company incurred $9.9&#160;million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $1.8 million was variable lease expense and $0.1 million was short-term lease expense, neither of which were included in the measurement of the Company's operating right-of-use assets and lease liabilities.  For the year ended June 30, 2020, the Company incurred $18.4 million in lease costs, of which $2.6&#160;million was variable lease expense and $0.2 million was short-term lease expense. Prior to the adoption of the lease guidance in ASU 2016-02, the Company's total rent expense for the year ended June 30, 2019 was $19.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company entered into a non-cancelable operating lease for approximately 63,000 square feet in South San Francisco, California, which will expire in 2033. The lease will commence in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: leases not yet commenced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current maturities of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the weighted average remaining lease term is 8.7 years and the weighted average discount rate used to determine the operating lease liability was 5.10%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company&#x2019;s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i403644c63d2f42ce9be417d4645c4d3c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE4Ng_45e23a59-1382-4799-86b7-3cf935e1f446">P14Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCost
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQ5NDc4MDIzMjk2ODk_09dae238-f17e-49e5-b39a-59220bf7e67e"
      unitRef="usd">20700000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQ5NDc4MDIzMjk2OTM_15572b79-a8c5-4219-a6d8-9546b9c227f1"
      unitRef="usd">3200000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE2NDkyNjc0NDU5NDA_24a248d2-4ea5-4329-a879-6983b7d655a5"
      unitRef="usd">9900000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE2NDkyNjc0NDYxMDQ_12804738-f4cf-44d8-a18a-cbbf91083fe9"
      unitRef="usd">1800000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzE2NDkyNjc0NDYxMzk_c694d6d7-34cf-4426-8f71-a6547cefe247"
      unitRef="usd">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzI5Njg_bd347815-5498-483f-8c1b-99c7d3d9f272"
      unitRef="usd">18400000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzI5OTY_2ffc670f-0374-4838-a8b2-3534b81773f5"
      unitRef="usd">2600000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzMwMzA_3ac97c23-a723-46b3-8d08-e44172c98772"
      unitRef="usd">200000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzMxODg_7c01a0db-b0e3-4452-94ef-892960ca96b8"
      unitRef="usd">19700000</us-gaap:OperatingLeasesRentExpenseNet>
    <mygn:LesseeOperatingLeaseAreaOfLeasedSpace
      contextRef="idb1bf33b7a68483c99cef4bfc39ec4d0_D20211201-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQ5NDc4MDIzMzA4NzE_96722359-87ec-4d9c-ad1c-a4d32b28e3fc"
      unitRef="sqft">63000</mygn:LesseeOperatingLeaseAreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzQxNzQ_7b72c0eb-2ad7-40c7-8ca0-a3d77a405711">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: leases not yet commenced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current maturities of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzEtMS0xLTEtMzYzNTk_5048df95-5ce3-40f2-ac34-0a3969553e44"
      unitRef="usd">17400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzItMS0xLTEtMzYzNTk_55893377-5ed1-43ac-9ffa-6f432951c71b"
      unitRef="usd">19800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzMtMS0xLTEtMzYzNTk_774262bf-35ca-485d-a383-b1d57099683b"
      unitRef="usd">22400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzQtMS0xLTEtMzYzNTk_fafaaecd-1444-4a0e-b3ad-d492c80d3e22"
      unitRef="usd">16600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzUtMS0xLTEtMzYzNTk_22afd8c7-b24b-4d42-95ef-c1f6432d5258"
      unitRef="usd">14700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzYtMS0xLTEtMzYzNTk_d595cd72-e8be-4b52-9140-4cbfd60f27fe"
      unitRef="usd">88100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzctMS0xLTEtMzYzNTk_13c030dc-8928-4721-bfae-47b661df15cf"
      unitRef="usd">179000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzgtMS0xLTEtMzYzNTk_d4b86c12-8307-4a63-86fe-32df4c9d42ad"
      unitRef="usd">27900000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <mygn:OperatingLeaseLiabilityIncludingLeasesNotYetCommenced
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzktMS0xLTEtMzYzNTk_a50489af-c19b-43e3-a553-ef69b9ad1484"
      unitRef="usd">151100000</mygn:OperatingLeaseLiabilityIncludingLeasesNotYetCommenced>
    <mygn:OperatingLeaseLiabilityLeasesNotYetCommenced
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzEwLTEtMS0xLTU0MzA2_65b65649-fc98-4f20-942b-e9cde147dadd"
      unitRef="usd">58800000</mygn:OperatingLeaseLiabilityLeasesNotYetCommenced>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzEwLTEtMS0xLTM2MzU5_b47c292c-1de6-41c6-8f43-53b2e21e8dbd"
      unitRef="usd">13000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90YWJsZTozNGJhYTJlZjllZjM0NDEyYjVjMjJmZDM1NDIwOWNiZi90YWJsZXJhbmdlOjM0YmFhMmVmOWVmMzQ0MTJiNWMyMmZkMzU0MjA5Y2JmXzExLTEtMS0xLTM2MzU5_a035e276-150e-4dae-af62-b42895f8958e"
      unitRef="usd">79300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzMzNzE_c1ab8cf7-5b7e-41c7-8ca9-ac7f69ea40f4">P8Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMjcvZnJhZzozOGNlM2UwZDMzM2I0NDA5ODEyMTVjZmNjYjhhMWQxMS90ZXh0cmVnaW9uOjM4Y2UzZTBkMzMzYjQ0MDk4MTIxNWNmY2NiOGExZDExXzM0NjU_2eb70ee9-1ec7-49cd-9c2f-fea8c51871bf"
      unitRef="number">0.0510</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzQ1MA_34d351a9-e2cf-47b0-ba6d-10e4a4d6c3e9">EMPLOYEE DEFERRED SAVINGS PLAN&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a deferred savings plan which qualifies under Section&#160;401(k) of the Internal Revenue Code. Substantially all of the Company&#x2019;s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee&#x2019;s contribution with the employer&#x2019;s contribution not to exceed 4% of the employee&#x2019;s compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s recorded contributions to the plan are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred savings plan contributions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzI2Ng_fdc03c0c-b931-4c9b-8423-736109426518"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzM0OA_ed1df737-eb53-413a-a25d-aa632348641f"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90ZXh0cmVnaW9uOjQ2ZDg4YmRiMTY1MTRhYzZiZGVkNjU2NWU2YzI0NzlhXzQ1MQ_1c6bff82-b117-4fbc-8c00-d9b3ece6a3d4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s recorded contributions to the plan are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred savings plan contributions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItMS0xLTEtMzYzNTk_d09e557b-25ad-49db-9070-2588ba4c3395"
      unitRef="usd">8400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItMy0xLTEtMzYzNTk_cc351468-a38b-4dad-aa5f-732b156aa321"
      unitRef="usd">4000000.0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItNS0xLTEtMzYzNTk_da38af85-6250-4c51-af3f-6c8fd4fa3017"
      unitRef="usd">7100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzAvZnJhZzo0NmQ4OGJkYjE2NTE0YWM2YmRlZDY1NjVlNmMyNDc5YS90YWJsZTo3MWJhZWIwNDE2MjM0ODVhYTE2ZmYxOTkzOTY3ZmYzOS90YWJsZXJhbmdlOjcxYmFlYjA0MTYyMzQ4NWFhMTZmZjE5OTM5NjdmZjM5XzItNy0xLTEtMzYzNTk_898b6c87-2ef8-46ea-98eb-d99b7deb6a5e"
      unitRef="usd">8300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90ZXh0cmVnaW9uOjI4ZTgzMzZmNmJlNTQzNTlhMDNmYzNhOTRmMTZjMTcwXzE1OTA_a6c0d48f-2c4b-42ac-8447-a32ac10be4a0">SEGMENT AND RELATED INFORMATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company&#x2019;s previously reported other segment. The Company&#x2019;s remaining operating segments have been aggregated into a single reporting segment, which primarily provides testing and collaborative development of testing that is designed to assess an individual&#x2019;s risk for developing disease later in life, identify a patient&#x2019;s likelihood of responding to drug therapy and guide a patient&#x2019;s dosing to ensure optimal treatment, or assess a patient&#x2019;s risk of disease progression, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles assets by geographical region to total assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net equipment, leasehold improvements and property:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Total assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable investment &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90ZXh0cmVnaW9uOjI4ZTgzMzZmNmJlNTQzNTlhMDNmYzNhOTRmMTZjMTcwXzE1ODg_db66c862-75e5-43dd-9cfb-6352911efd84">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles assets by geographical region to total assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net equipment, leasehold improvements and property:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Total assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable investment &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i50f6939f15de4b44bc5d205c498f9bb6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzMtMS0xLTEtMzYzNTk_1854d99e-688e-4840-9184-0fa26126f578"
      unitRef="usd">41700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i730cf00f21e24233aa2438bc079c00fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzMtMy0xLTEtMzYzNTk_8aabf097-d10a-45ad-91d1-b97ecb017f81"
      unitRef="usd">38400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1693400cad7b453cbf24b4b49eaaf843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzQtMS0xLTEtMzYzNTk_4651f039-df43-4721-b598-1776aeb23a79"
      unitRef="usd">1900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i035d000528f94d29bec8473ab8e23f80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzQtMy0xLTEtMzYzNTk_01984b96-3271-4a7e-b4c9-9c119ac69e78"
      unitRef="usd">2300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i77ae176a47c5401292f15f20d1f2b493_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzUtMS0xLTEtMzYzNTk_c7ebd73b-658b-4b15-a1df-cd79599bae3f"
      unitRef="usd">43600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib4a3f1dfa4a24709971fbcfbce8f1bdc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzUtMy0xLTEtMzYzNTk_f0d829c0-d338-4d42-97d7-6db548232d39"
      unitRef="usd">40700000</us-gaap:PropertyPlantAndEquipmentNet>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i50f6939f15de4b44bc5d205c498f9bb6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzctMS0xLTEtMzYzNTk_65cc8b79-bb45-4d49-b069-164233203fca"
      unitRef="usd">870800000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i730cf00f21e24233aa2438bc079c00fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzctMy0xLTEtMzYzNTk_7c0925d5-b58d-4ccd-bb42-b5400bbcf9d1"
      unitRef="usd">1190300000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i1693400cad7b453cbf24b4b49eaaf843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzgtMS0xLTEtMzYzNTk_d9de6d82-2e4a-48ce-9eef-cc4fd5f4da0d"
      unitRef="usd">51100000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i035d000528f94d29bec8473ab8e23f80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzgtMy0xLTEtMzYzNTk_005ccdb3-cba2-48b6-89e1-06ff65d18682"
      unitRef="usd">56800000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i77ae176a47c5401292f15f20d1f2b493_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzktMS0xLTEtMzYzNTk_2cc9bf70-662d-4ed8-b920-ef49f766af4f"
      unitRef="usd">921900000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="ib4a3f1dfa4a24709971fbcfbce8f1bdc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzktMy0xLTEtMzYzNTk_7bd4c9e5-916f-4e67-946a-8644f3952f68"
      unitRef="usd">1247100000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzEwLTEtMS0xLTM2MzU5_fa4af01b-2a5b-4518-b500-70c62c40f184"
      unitRef="usd">398800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzEwLTMtMS0xLTM2MzU5_138dbaaa-421b-4b36-8345-620cdbce651c"
      unitRef="usd">171700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:Assets
      contextRef="iaceaf21b23b24746aa59d14b069c4f07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzExLTEtMS0xLTM2MzU5_7d662979-327f-4b40-b0ba-fbcc668cd7e5"
      unitRef="usd">1320700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="icb206a81fa074a46aa6939c9e5bcf636_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzMvZnJhZzoyOGU4MzM2ZjZiZTU0MzU5YTAzZmMzYTk0ZjE2YzE3MC90YWJsZTplNjlmZjVmNjU4NGM0MDk5ODdkZGY5OWY0YjJhYTg4Ny90YWJsZXJhbmdlOmU2OWZmNWY2NTg0YzQwOTk4N2RkZjk5ZjRiMmFhODg3XzExLTMtMS0xLTM2MzU5_afa0cba1-b921-4c75-956f-be2a099822a3"
      unitRef="usd">1418800000</us-gaap:Assets>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2Xzc1Ng_c859a7ed-d98d-4c75-9854-e38de36d8e4c">DIVESTITURES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5&#160;million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2&#160;million, net of transaction costs of $1.3&#160;million, in Other income (expense) on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $197.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0&#160;million, net of transaction costs of $4.8&#160;million, in Other income (expense) on the Company's Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra&#xae; test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6&#160;million, net of transaction costs of $4.4&#160;million, in Other income (expense) on the Company's Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating results of these businesses do not qualify for reporting as discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the divestiture transactions, the Company recognized losses of $5.2&#160;million and $6.5&#160;million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Company's Consolidated Statements of Operations for the year ended December, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the amounts recognized in Other income for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of Myriad RBM, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of the Myriad myPath, LLC laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on sale of Myriad Autoimmune assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other Income&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTQ1_bc6bc574-6779-48e1-8e33-bd7e92b787fc"
      unitRef="usd">32500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees
      contextRef="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTYw_d0063b0a-5496-4a61-8c22-d2628ff09401"
      unitRef="usd">31200000</mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="iae325325882b46b38169e2d4a88f8b15_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTc1_468cc1fc-ebce-4774-82cc-1877502246de"
      unitRef="usd">1300000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MTg5_f4674677-84ca-4d8f-b227-9eab12887f45"
      unitRef="usd">197000000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjE5_5eeef1ba-3ece-4ca3-a407-f67292e15719"
      unitRef="usd">121000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="ic82adcccbcc84bddbbcea0d8b3a27791_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjA1_cadb5713-7ffe-4778-b8aa-4595921a30ff"
      unitRef="usd">4800000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjQ5_0923ab0a-49be-4a6f-bb83-aeea0c9337e7"
      unitRef="usd">150000000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjY1_359302f7-9a1b-4065-937b-ea2ee77399a2"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="ic3559d4b0606423fa9af7d61d5ff1f33_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4MjM1_9a6f5d6c-0e95-4b54-9650-77bdeaff1bd1"
      unitRef="usd">4400000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4Mjc5_409b323c-97d6-4f2f-91b3-ec44955b29c8"
      unitRef="usd">5200000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4Mjkz_ec8e14b2-146f-43a5-a87d-07820c8fbd4c"
      unitRef="usd">6500000</us-gaap:InventoryWriteDown>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90ZXh0cmVnaW9uOmZjYjI3ZjNmY2U2MTRlZjc4NzJjZGRmYmFkYTU1ZjM2XzE2NDkyNjc0NDI4OTEx_c9a347bf-a85e-46a4-9b05-f6c82df8170a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the amounts recognized in Other income for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of Myriad RBM, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of the Myriad myPath, LLC laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on sale of Myriad Autoimmune assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other Income&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i860c89a3309f4862aa45108d2d164008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzEtMS0xLTEtNDY0Mzc_a1f5a3d4-2d23-4897-b5a6-6552fe7ef336"
      unitRef="usd">121000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i4881a7b97e68483588b542d1107dfc7d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzItMS0xLTEtNDcxNjA_9ec1fc48-d79c-43ac-a463-38a2e391109c"
      unitRef="usd">31200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory
      contextRef="i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzMtMS0xLTEtNDcxNjg_2cccd134-5ff5-4d83-b9a6-a34b7610e7e0"
      unitRef="usd">-11700000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ie93081e2cf534cd9ae7518a1f0407820_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzQtMS0xLTEtNDcxNzY_34953059-4422-4928-a37d-0b03354b705f"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOther
      contextRef="i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzUtMS0xLTEtNDcyMDk_3efae997-0620-4af0-8812-f0eebf05d3d2"
      unitRef="usd">-600000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzYvZnJhZzpmY2IyN2YzZmNlNjE0ZWY3ODcyY2RkZmJhZGE1NWYzNi90YWJsZTo2N2Y4MmEyYzQ2Y2I0YjM4OWE5NjFiYWI5MjVjMjAwMi90YWJsZXJhbmdlOjY3ZjgyYTJjNDZjYjRiMzg5YTk2MWJhYjkyNWMyMDAyXzYtMS0xLTEtNTgyODc_cc723901-f11f-4256-86b9-9f3e9ac0d477"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU2OTU_470fc2b9-bd35-42df-b283-eeab1bc31539">BUSINESS ACQUISITIONS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Counsyl&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2018, the Company completed the acquisition of Counsyl, Inc. (&#x201c;Counsyl&#x201d;), a leading provider of genetic testing and DNA analysis services, pursuant to the Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), dated May 25, 2018 for total consideration of $405.9 million.&#160;&#160;Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a newly created wholly-owned subsidiary of the Company, was merged with and into Counsyl, with Counsyl continuing as the surviving corporation and a wholly-owned subsidiary of Myriad.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To complete the purchase transaction, the Company incurred approximately $6.8 million of acquisition costs, which are recorded as selling, general and administrative expenses in the period incurred. For the year ended June 30, 2019, Counsyl contributed revenue of approximately $104.9 million.&#160;For the year ended June 30, 2019, operating expenses related to Counsyl were approximately $67.6 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icd8184e7f9d64fdfa830a7580e392ea8_D20180731-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzEwOTk1MTE2NDA0NDc_d2b21b89-7cf3-4be2-ace6-a1e4c2a8179b"
      unitRef="usd">405900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i6757f736730d439fb934901528230b15_I20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU0MDQ_64b7de8f-c047-4c54-bb4b-40e6934529b4"
      unitRef="usd">6800000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod
      contextRef="iff236b6484f74a869a405f4676bd6810_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU1OTg_209aedf0-59ee-481c-954c-fa7f5d1c5da7"
      unitRef="usd">104900000</us-gaap:BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod>
    <us-gaap:OperatingExpenses
      contextRef="iff236b6484f74a869a405f4676bd6810_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xMzkvZnJhZzo5YzhiZDZlNzJjZmE0ZjgzYTRiODEzZjc4M2JkMmFmNS90ZXh0cmVnaW9uOjljOGJkNmU3MmNmYTRmODNhNGI4MTNmNzgzYmQyYWY1XzU2OTI_5d315284-371a-4732-be2d-1568e4918068"
      unitRef="usd">67600000</us-gaap:OperatingExpenses>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzEzMzE_92605bfe-a13d-4d4c-b994-490fbb363e77">SUBSEQUENT EVENTIn the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately 230,000 square feet in Salt Lake City, Utah, which will commence in 2022, with a lease term of 15 years and total future lease payments of approximately $77.8&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <mygn:LesseeOperatingLeaseAreaOfLeasedSpace
      contextRef="ia83408ec29ac462bb67762046411429e_D20220101-20220224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzE1OTQyOTE4NjA3MDc0_4bca6936-2152-4822-871e-f9ffd6cc4a33"
      unitRef="sqft">230000</mygn:LesseeOperatingLeaseAreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i27de6b0d5d5e480a85e618df1ee1b0e1_I20220224"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzE1OTQyOTE4NjA3MDkx_a03a725c-2cbb-442f-9646-2f0addc10e41">P15Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <mygn:LesseeOperatingLeaseEstimatedFutureLeasePayments
      contextRef="i27de6b0d5d5e480a85e618df1ee1b0e1_I20220224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDIvZnJhZzoyNWI1MDY0ZjI4MmY0ODgxYWNhODRlOGZmMmVlNDA3Ny90ZXh0cmVnaW9uOjI1YjUwNjRmMjgyZjQ4ODFhY2E4NGU4ZmYyZWU0MDc3XzEwOTk1MTE2MzIwODc_bf4bb85d-7d71-4d6b-8122-9e23918e8b08"
      unitRef="usd">77800000</mygn:LesseeOperatingLeaseEstimatedFutureLeasePayments>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90ZXh0cmVnaW9uOmNhNWZkNTgwNzQ0YTRkNmRhMGE5OThmYjViYjg1ZGEyXzQ0_bdf477fa-e194-4a9f-b432-c6a14d3040f5">SUPPLEMENTAL CASH FLOW INFORMATION&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received for income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities and other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90ZXh0cmVnaW9uOmNhNWZkNTgwNzQ0YTRkNmRhMGE5OThmYjViYjg1ZGEyXzQ1_fc4aa149-9350-4f3e-b914-3a741593e02b">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received for income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities and other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItMS0xLTEtMzYzNTk_053ae036-2623-4f52-9f58-1d2fcd527a81"
      unitRef="usd">4600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItMy0xLTEtMzYzNTk_5201fb41-9e84-4133-91a9-94efef234615"
      unitRef="usd">1800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItNS0xLTEtMzYzNTk_e3cfd51c-3870-4fe8-aee5-c843fb9d6b5d"
      unitRef="usd">1000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzItNy0xLTEtMzYzNTk_1031e268-6a60-4f8c-8f6e-010cffee0bde"
      unitRef="usd">6500000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtMS0xLTEtMzYzNTk_44deedb9-4623-45b5-bdce-ea96b4c35e24"
      unitRef="usd">4400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtMy0xLTEtMzYzNTk_9613e0c7-f95b-4417-8d5e-c1192d74ef75"
      unitRef="usd">5200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtNS0xLTEtMzYzNTk_fa2a5200-a140-4227-9676-325bd9027026"
      unitRef="usd">9500000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzMtNy0xLTEtMzYzNTk_0f1dd983-e1da-466b-aa71-360e680fd5ee"
      unitRef="usd">11600000</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtMS0xLTEtNjIzNDY_6ddcfa1f-ab86-4a34-9db6-090367668c68"
      unitRef="usd">90000000.0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtMy0xLTEtNjIzNTM_069570db-8c85-42af-b018-29a25eb36712"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtNS0xLTEtNjIzNjA_f42267b7-a7d2-43c5-a69e-55fa73813222"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzQtNy0xLTEtNjIzNjA_867b7f3a-fd5a-4cc2-9680-dca23a5e1444"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctMS0xLTEtMzYzNTk_553d0553-2dd5-4778-99b2-ce0aa1fcdaf4"
      unitRef="usd">41800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctMy0xLTEtMzYzNTk_2ffe1802-9b8f-4b93-9649-6458cfe3ccb3"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctNS0xLTEtMzYzNTk_d8dc4b97-7a19-455d-ad61-0b141782801a"
      unitRef="usd">74500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzctNy0xLTEtMzYzNTk_e79e90b2-ed9e-41d6-851f-a74e3e65428f"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtMS0xLTEtMzYzNTk_95c95dd3-c279-4fda-b586-590c3410d912"
      unitRef="usd">48100000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtMy0xLTEtMzYzNTk_82566b1c-5b20-4b44-932a-ec918fe58ef9"
      unitRef="usd">0</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtNS0xLTEtMzYzNTk_5ad6553e-171d-47c4-935f-99175c3da9af"
      unitRef="usd">78800000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzgtNy0xLTEtMzYzNTk_279598de-6704-408c-b661-1714c11ee8c9"
      unitRef="usd">0</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktMS0xLTEtMzYzNTk_fdf8b22f-0e2e-4cf4-bd69-a81e78d36091"
      unitRef="usd">0</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktMy0xLTEtMzYzNTk_c0230717-1705-41fd-b63a-2dc1c4c9bb9a"
      unitRef="usd">0</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="ib3ef67148e22425a8336f1cb2bbadac8_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktNS0xLTEtMzYzNTk_2e74f98a-38b2-438d-8ce1-a6b53e47ba2b"
      unitRef="usd">4300000</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="iab0f1dfc80b74de29840a824030ebfb1_D20180701-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNDUvZnJhZzpjYTVmZDU4MDc0NGE0ZDZkYTBhOTk4ZmI1YmI4NWRhMi90YWJsZTozNTc1ZDczNzBhYTk0N2QwYmI5Mzc2Y2ZjNzFmMGI3ZS90YWJsZXJhbmdlOjM1NzVkNzM3MGFhOTQ3ZDBiYjkzNzZjZmM3MWYwYjdlXzktNy0xLTEtMzYzNTk_471a628d-1989-4df6-8caa-5f98c57c5f5e"
      unitRef="usd">0</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:TransitionPeriodComparativeDataTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90ZXh0cmVnaW9uOmZhYzU3MWNmMTc5ZjQwMTFiZjE1YTQzY2U5MjdiMjhlXzU4_6bb74d23-86bb-4278-9e74-77ccd1df8e4d">TRANSITION PERIOD COMPARATIVE DATA (UNAUDITED)&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month &lt;br/&gt;Period Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statement of Operations Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and long-lived asset impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Myriad Genetics Inc. stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mygn:TransitionPeriodComparativeDataTextBlock>
    <mygn:ScheduleOfTransitionPeriodComparativeDataTableTextBlock
      contextRef="i3f192cf143b34d569db042b3b74c016a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90ZXh0cmVnaW9uOmZhYzU3MWNmMTc5ZjQwMTFiZjE1YTQzY2U5MjdiMjhlXzU5_3e870bd2-0252-46c0-927d-277ae4217862">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month &lt;br/&gt;Period Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statement of Operations Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and long-lived asset impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Myriad Genetics Inc. stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mygn:ScheduleOfTransitionPeriodComparativeDataTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaaeba814f5004cb58a2f97d102345f21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzItMS0xLTEtMzYzNTk_0f23be1f-ff0a-4ee2-a5ff-f69c6f79341a"
      unitRef="usd">513500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9293cf2bcc0f4d2a920e6ccd2d4f11d1_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzItMy0xLTEtNTA5OTc_9681d126-cccb-4a3a-8180-01b776f91700"
      unitRef="usd">353100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e5947d8d1f246f8b9440687d0122811_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzMtMS0xLTEtMzYzNTk_e4902c0b-7b07-40b2-942f-adbb6aa8ec15"
      unitRef="usd">43600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i123f7f47f2d641448a50320ff8fc12b3_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzMtMy0xLTEtNTA5OTc_dc2d2a8b-840b-409d-9bb6-e766d720c76d"
      unitRef="usd">28300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzQtMS0xLTEtMzYzNTk_6b0b11c7-f8c3-4a8d-8b9b-3f79e68a0134"
      unitRef="usd">557100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzQtMy0xLTEtNTA5OTc_34712255-bd7a-4939-9bf9-12753efd9976"
      unitRef="usd">381400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaaeba814f5004cb58a2f97d102345f21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzYtMS0xLTEtMzYzNTk_84bf579f-70f2-4b26-90f5-9cba61400e38"
      unitRef="usd">157900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9293cf2bcc0f4d2a920e6ccd2d4f11d1_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzYtMy0xLTEtNTEwNDk_2e35418a-2ed8-43ce-8b25-218abca5578c"
      unitRef="usd">82200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3e5947d8d1f246f8b9440687d0122811_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzctMS0xLTEtMzYzNTk_efc1d7c1-c0af-4e01-bc78-5d398d2d3475"
      unitRef="usd">20300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i123f7f47f2d641448a50320ff8fc12b3_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzctMy0xLTEtNTEwNDk_004eb122-d285-4708-abce-1d82f92bb259"
      unitRef="usd">17100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzgtMS0xLTEtMzYzNTk_0633e80e-241d-4326-8309-e1bf5e6f0284"
      unitRef="usd">73300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzgtMy0xLTEtNTEwNDk_d4b91036-9c82-4ea7-aef2-81d7af233be1"
      unitRef="usd">40100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEwLTEtMS0xLTM2MzU5_3e08d7a0-fe75-434b-88f4-03beb38c5f6b"
      unitRef="usd">496900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEwLTMtMS0xLTUxMDQ5_fdc4f91c-d951-4401-b7df-99c1898885b6"
      unitRef="usd">270400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzExLTEtMS0xLTM2MzU5_f0415e93-9e1d-4708-9e23-550e7e0dca35"
      unitRef="usd">98400000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzExLTMtMS0xLTUxMDQ5_9e5fc80c-c573-408b-9fbc-5307e8353b3c"
      unitRef="usd">1300000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:CostsAndExpenses
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEyLTEtMS0xLTM2MzU5_3d9a16c7-bd46-4039-b89a-0c525d4795a3"
      unitRef="usd">846800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEyLTMtMS0xLTUxMDQ5_83b513f8-cb7e-4525-9160-1b5b8166db2b"
      unitRef="usd">411100000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEzLTEtMS0xLTM2MzU5_b4ac5c35-94ac-469b-acd6-d30b6e9cbfd2"
      unitRef="usd">-289700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzEzLTMtMS0xLTUxMDY2_0422a404-276f-4949-8503-bb22a215d85f"
      unitRef="usd">-29700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE1LTEtMS0xLTM2MzU5_7ef59473-0c9c-4053-b623-ada5e1d42ba6"
      unitRef="usd">2000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE1LTMtMS0xLTUxMDU1_8a30e213-c21d-4b1d-aa6a-bc73c90e120d"
      unitRef="usd">1700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE2LTEtMS0xLTM2MzU5_b87f9e73-f4aa-4e6d-8e16-79fd5c543525"
      unitRef="usd">11200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE2LTMtMS0xLTUxMDY2_cc98d626-7ad9-4055-9a2e-f15ea2db922f"
      unitRef="usd">5400000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE3LTEtMS0xLTM2MzU5_61476f12-801c-4f9f-87a0-2ec2b1a4d7ce"
      unitRef="usd">15300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE3LTMtMS0xLTUxMDU1_debbd126-ecab-4341-9717-6f19187a02b8"
      unitRef="usd">-300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE4LTEtMS0xLTM2MzU5_761666ec-6ab2-4ee1-806c-93c78077a138"
      unitRef="usd">6100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE4LTMtMS0xLTUxMDU1_ba93d5e4-dfa0-4738-8992-58eedcbc1ef8"
      unitRef="usd">-4000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE5LTEtMS0xLTM2MzU5_d494ad72-fcf2-4662-99bb-2e3aea70be3e"
      unitRef="usd">-283600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzE5LTMtMS0xLTUxMDU1_38bcc6a8-6381-44e8-983e-ac513f7006a1"
      unitRef="usd">-33700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIwLTEtMS0xLTM2MzU5_6e2dd308-e37a-4634-980e-e244b4bb298b"
      unitRef="usd">-59900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIwLTMtMS0xLTUxMDU1_85fc47b9-4332-49e5-94a5-af6c42bd8b57"
      unitRef="usd">-4800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIxLTEtMS0xLTM2MzU5_3b687dea-ea92-4a2c-9241-f4b3fa9ca6f2"
      unitRef="usd">-223700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIxLTMtMS0xLTUxMDU1_85563737-1cb3-4e45-b1a1-65c6fe9f5858"
      unitRef="usd">-28900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIyLTEtMS0xLTM2MzU5_0dcf3dc1-c2c5-4ebe-8e63-16e357f1185a"
      unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIyLTMtMS0xLTUxMDU1_48a27ebc-6a48-40ca-a3e3-70d5898bd009"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIzLTEtMS0xLTM2MzU5_cb909125-6b1c-48f6-a6c7-6280c1e5af7e"
      unitRef="usd">-223600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzIzLTMtMS0xLTUxMDU1_b0fb9642-8d80-43f1-b2c5-61eb9e396d93"
      unitRef="usd">-28900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI1LTEtMS0xLTM2MzU5_edbedfec-ee54-42ec-9504-d0cd1f19ba3b"
      unitRef="usdPerShare">-2.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI1LTMtMS0xLTUxMDU1_6066e2be-ac24-49ba-99df-690a8de79ebd"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI2LTEtMS0xLTM2MzU5_e893e66c-0632-48a7-bb06-bd9ae0d5885f"
      unitRef="usdPerShare">-2.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI2LTMtMS0xLTUxMDgz_49e6d00b-9a96-470c-a5eb-2eacd2408722"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI4LTEtMS0xLTM2MzU5_1cd3709a-f660-4df9-9639-31bbdb2dea29"
      unitRef="shares">74800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI4LTMtMS0xLTUxMDgz_28680fad-acc9-4e4b-9ab0-14e1b67ca740"
      unitRef="shares">74100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i25062a71db664ae69e26d988eac2f7b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI5LTEtMS0xLTM2MzU5_f6976e21-d2fc-4cdd-921b-2cd9c032e616"
      unitRef="shares">74800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZlYWQ5ZDI4Y2RhNTQ5YzFhZjc2OWQxZDUwZDk1ODA3L3NlYzpmZWFkOWQyOGNkYTU0OWMxYWY3NjlkMWQ1MGQ5NTgwN18xNTEvZnJhZzpmYWM1NzFjZjE3OWY0MDExYmYxNWE0M2NlOTI3YjI4ZS90YWJsZTo5ZWVmZDYyODRjY2Q0ZDIzYTAxMzNhYjVjOWVkMjZjMS90YWJsZXJhbmdlOjllZWZkNjI4NGNjZDRkMjNhMDEzM2FiNWM5ZWQyNmMxXzI5LTMtMS0xLTUxMDgz_62e13b07-afb1-439a-8dc5-36606c66f131"
      unitRef="shares">74100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=,G7^82\??/NK*<!U+SJ>07 AQR '@"P*;D1B0X4N4Q\[K\$Z &;DA+=4?I
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MK46<70:< 6O3 -XOA="[&]-!^9GHXE]02P,$%     @ +8=95&DVHY@@ @
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M>='VPLA5_<AE+HV19?UVR1F(MP;P_4)*L[NP3W'V3^VN_@-02P,$%     @
M+8=95-SO.?21 @  (0<  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6R5
ME=]OFS 0Q_\5"^VAE3H@0'ZT2B*U2:-M4J6HT;:':0\.7()58S/;2=K_?F=#
M(E*1CO$ MKG/]\Z^XQ@?I'K1.8 AKP47>N+EQI1W0:#3' JJ?5F"P#<;J0IJ
M<*JV@2X5T,Q!!0^B,!P$!67"FX[=VE)-QW)G.!.P5$3OBH*JMP?@\C#Q>MYQ
MX9EM<V,7@NFXI%M8@?E>+A7.@I-*Q@H0FDE!%&PFWGWO;I%8>V?P@\%!-\;$
M[F0MY8N=?,TF7F@# @ZIL0H4'WN8 >=6",/X4VMZ)Y<6;(Z/Z@NW=]S+FFJ8
M2?Z392:?>"./9+"A.VZ>Y>$+U/OI6[U4<NWNY%#9#@<>27?:R**&,8*"B>I)
M7^MS: "]Y (0U4#4%8AK(.X*)#60= 7Z-=#O"@QJ8.#.OCHL=])S:NATK.2!
M*&N-:G;@TN5H/& F;&&MC,*W##DSG4FA)6<9-9"1!\JI2(&LK)PF5TNJ0)@<
M#$LIOR:?R2<2$)WCJCX^F"!/C',L$CT.# 9D98.T=OY0.8\N.)]#ZI.X=T.B
M,.JUX+/N>-B"SS_&O^T$XN%%_+$SWKMMP1?=\=$Y'F .3XF,3HF,G%Y\06]E
M,(7XQ1LB-V3!!":244Z64C/W"?^Z7VNC\$/^_8&S^.0L=LZ2BU53%*B)U9F^
MW)"2*K*G? ?D*I.<4Z5)":JJD.NVJJC$;YVX[7S[:>B'6 #[9N[_8706=W**
M._F/N.L2QG:K#149$]NV8"O%02..4?@NU,IDU# 9]OTD;%SO-C=O(1)_>&[T
MV&(4^_USHT6+4>CW;YO7NS,+&MW"_CR>J-HRH0F'#6J$_A!;DJH:<C4QLG0-
M9"T-MB,WS/$?!LH:X/N-E.8XL3WI]%><_@502P,$%     @ +8=95$S;W0C]
M!@  DA\  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM6=MNVS@0_17"
MV(<62&21N@=)@-;V=K/8;(-FNWUF),86*HM>D8[3OU_J8DDF1XP+M ^-99\9
M\0R',X?D]8%7W\6&,8E>MT4I;F8;*7=7\[E(-VQ+A<-WK%2_//-J2Z5ZK-9S
ML:L8S1JC;3$GKAO.MS0O9[?7S7</U>TUW\LB+]E#A<1^NZ75CX^LX(>;&9X=
MO_B2KS>R_F)^>[VC:_;(Y-?=0Z6>YKV7+-^R4N2\1!5[OIE]P%<KSZ\-&L2_
M.3N(T6=44WGB_'O]<)?=S-QZ1*Q@J:Q=4/7GA2U84=2>U#C^ZYS.^G?6AN//
M1^^_-^05F2<JV((7W_),;FYF\0QE[)GN"_F%'_Y@':&@]I?R0C3_HT.'=6<H
MW0O)MYVQ&L$V+]N_]+4+Q,A ^8$-2&= =(-PPL#K##S=P)\P\#L#_UR#H#-H
MJ,];[DW@EE32V^N*'U!5HY6W^D,3_<9:Q2LOZT1YE)7Z-5=V\G;!2\&+/*.2
M9>A1JC\J"Z1 _!E]WK&*UK,IT"7Z^KA$[WY[C\2&5DR@O$3W>5'4/UZ@W\:/
MUW.IAE4[GZ?=$#ZV0R 30PC1/2_E1J!5F;$,L%_8[3&Q.)BK>/1!(<>@?"16
MCTN6.LC#%XBXQ(4&=+XY!LR7=O,_]Z4R=R??OCK;'">68'A]AGB-/W_"WS]<
MTD+5A!=6[ADTNZUYU)C7=>GEEB2)$U_/7\8A,U%AXCKA*6H)H+Q81ZU,5!Q@
M!_>H$YY^S]-OS+S)E2!4WM,R0^Q5E6'!Q)4E>D'O-;!&[PL3C%;IIG&<J2 6
M?%>OL.-+H("V'N,1/2\PXFF"8NPD[N@?UF)K6D210[30 FZ#*;<G 0G[@(36
M@#RJGI"7ZPNT9J6J+\5%$QF:J=J6"UD7G!=F"TYH#)"$KN-KT3%1@1?I,5P"
M*#=R/"TD "H(1SEY$H:H#T-D#<-?;*U65:JJZ5J54\4V4T%!@DE9-!48HMYZ
M#$<#<37:)B+4)GCYII.5#7'"->ZYQE:NGSC/#JH]-#-=\')]6:A)5I,N%%^4
M;W<TKYHUT84#XAZ_R3TVI@D;$VYB5*6*-/ZV5YWP3WK^R1D5-#7J"\0S,==^
M'.D%<&&BXGA< %NV "IRC?0&4+[G!#!E[ ZZPK62[M2#2NJ\3/F6H7<%%^(]
M* ]<8PB7L;%:%Q ,JQX2:+0A'/&P,<\ +II:UGBDI["UC7R6&U;UG+NI?F]K
M)9@,OHDUIG>E9$I]R<X]&$MBD')UYHMS0,L.-%X'>NH ?KQ11SEE.>@-;!<<
M/4M+%^A<G,RQV2,A5&AH#@B%7=W9JH.%)[ ILH/HP+Y]F=3I C+T@5'I[7H!
MH+"7Z&M\"<%"H_=#J,GI' 00MBN@MOIQ<%F Q$T)HB;-TXF;*.QYN@Y8 K!8
M!ZV@-TY7@D'H8+O2N1O7/?3$U*Z>'2,@Z2O(W=0:EXGON,GXGQX)P":(C&8
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MR;?-QPVC2DS7 /7[,^?R^%"_H+^&O_T?4$L#!!0    ( "V'650WJ=Z^B ,
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MAQ*"DV4#50ZTV-L.82,T]!OV,X>>DT@#@/];(?1Y8!S47>SR)U!+ P04
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MCMYAVK5G28A& JT=A(J/IUV;B:HFO?TL&IO%B5/6=@>3OX%2V'S![B(%-(8
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M%_%'C90(U'?%JJ+K@B]/HC-KD8^ZM_6F?ZZU'8ZDD">%"B1BA$U+?87IX#8
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MEYCO5'C1\>8)B/T,/''B6763-2^.Z,L3YA!F4N:B4Z(4<VN'1\<&M/+<>F)
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M<LDO\;-CML(#]/VL) NI;[" _X'1'_X74$L#!!0    ( "V'652Q/J(#+00
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M0^N7.V:T[Z*R!(1/);77YF(5U!OTZ#M02P,$%     @ +8=95![_?!<I"
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M2[/8;TOZ_% [ ;K?*JI'QS@#Q^]T_"]02P,$%     @ +8=95)O /V7>"
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M+7AG)]-_?A/3ZV%E.<@85=4&9,';&UN'+H[WH70RTH R<GS;_^ H1+>.5!A
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;,57;6_;-A#^*P<OV%K
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MPQ9H?U?R'U;E[GYRIRS==MSKDJZ7J'D#_3]7RE8?K&!S81W] U!+ P04
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M[(X"FL'%PQ%A<2Y3'BJXO/UU+@N_W&_+JHFM3H]@V6 HU+D)_S0@IC)V2M>
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M:I_3;W(7+GYR5=ZFV#?8_'JPV3AM_+CQFDP[W'])-?[_CXKTO:T8\+M)\=M
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M O/Q,P+3*##UN(,AC_('[OC=C=%K9F@UM-$/[ZJ7!CBI:%,>G,%7"3EW]T'
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M1TS0 GS/M7;M QGH;L[O?@=02P,$%     @ +8=95*"LG#,[ P   0<  !D
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M9"=90GGK@ZVWRO"@5J9[B\_;..PIS,;?4<BV"EGTNS,4O;P209R=.+LFQ])
MXX](-6K#.64X*8_!85=!+YP]RA(A#B1,00]2BR +NC%=LA&UDU& $18=Y5O
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M%PNU,Z#SI5)V*S@'W1LX_@%02P,$%     @ +8=95 \ Z+Y:!   ,0D  !D
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M-EX!^VNM7;/P#DY_29-_ %!+ P04    "  MAUE4%Z#+]A0G  "$@0  &0
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MH]DNR,M]9D;GU_SW].QR>$9_SRZOR1W>U(NC\<GPVIR>TC]G5W3_V>GP)&C
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M"S'>W/_,5XY'XX'I>*"'DO*\/#LADMRC#U8V6SL!B:"!<=Q]\" :].!HR-D
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M'/BXNJ.)N?I!- AP#:+)(&)/58X9G95RF6:4%-=S!A/F^_@)QN@?^ ,'S:*
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MPV?G'%@;SGU:KAJ2' *$96G<_Y(UEZQA$]G?E]-AY_0O%^7*G'$J9LZOZH-
M^]8>HT[KT\/7[O49[$^\Q#JM6":6&.H,(GSGEO6Y9OV@Y<:<)2ZDUC(WMVO!
M$U%2![0O)=3:/) #>[A\\S=02P,$%     @ +8=95/G6-S=5!   ^@L  !D
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M.H#[2XUU<B^0@>8OP.P+4$L#!!0    ( "V'651M[KOWP@(  #(&   9
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M%I@PC!O<FF%QFQ$[1KTY"F.]F1/V&TE>[9"\@)60DK 7/.,R!G;$>N%Y)\3
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M>MY^Y!H;7L,R6*(HIA#V@KIZ,E83JPKW3%LHBR>G&Z;XR@9-&_#[4BF[F1!
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MN+_?H7_QL5,L!3-XH\0O7MEZ%/0#J'#.5L(^JO57W,;3<WBE$L9_8=W:9ED
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M%PM=<.#[M;6T5T*"X0V<_P502P,$%     @ +8=95,*SV!^@ P  6@D  !D
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M9!FP>V71H:_E^P"9-L*- JH1W*Z#B"+0V +QN(9XO#?$1[.9%C. !'M? .]
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M9:W*:3@7'&"&"^#Y5"F[FJ"!^I/RU;]02P,$%     @ +8=95$P,.B[F"0
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M_4XKA4+#+Q:I*OZC547KM5"<*RVR"@P29(R7O^2Y,L0: /C8 7X%\+<!G3V
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MH*9&(_O*FC6E&@TOQW^NF=/53)7,Z839[*PZ-2#8Z7A:2SUU$S4] @WWB*I
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MV<OWLNT0J_-MLJ1H?CLO+=9=.)MC46:'-K@Z@T.<GOY&?[4#T0FH\L !N W
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MZX;Z"(FLJ\D&BN_LM;WB2C<!]G&K&T$0!J#7UYRKT\!L4+26T[]02P,$%
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M^M<CRI&P7"B^M1/),U=ZOK&O&SU%@S  _3WC7.T7QD$]EX__!U!+ P04
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M7W'UTIF?I%]:BB]KD_\!4$L#!!0    ( "V'653;-OT9OP,  &8/   9
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MOK8?41[JR@O%C\6Y:,>5/F45PT0?A(DP ?IYS+EZOC!'K?IHO?H74$L#!!0
M   ( "V'6529$RB\( (  *H$   9    >&PO=V]R:W-H965T<R]S:&5E=#4T
M+GAM;(U476^;,!3]*U<\;5(2$FBSJ2)(;;)I?=@4-=KV,.W!P$VP8FQJF]#N
MU^_:$,:DINH+^..><WV.[W72*GTT):*%ITI(LPI*:^N;,#1YB14S,U6CI)V]
MTA6S--6'T-0:6>%!E0BC^7P95HS+($W\VE:GB6JLX!*W&DQ354P_WZ%0[2I8
M!.>%!WXHK5L(TZ1F!]RA_5YO-<W"@:7@%4K#E02-^U5PN[A9QR[>!_S@V)K1
M&)R23*FCF]P7JV#N#H0"<^L8&/U.N$8A'!$=X['G#(:4#C@>G]D_>^VD)6,&
MUTK\Y(4M5\''  K<LT;8!]5^P5[/M>/+E3#^"VT7NUP&D#?&JJH'TPDJ+KL_
M>^I]& $65Q< 40^(W@J(>X!W+NQ.YF5MF&5IHE4+VD43FQMX;SR:U'#I;G%G
M->URPMGT*]-'M"P3"/?RA,;2#5G88=YH;CD:F,(WIC5S9L.[#85R8=[3JNE"
MGI/0TC$<69CW*>^ZE-&%E!O,9Q O)A#-H\4+\/7;X?/_X2&)'QR(!@<BSQ=?
MX/LGVTQ@@YD%)@OX]-B0N+$1OVXS8S65W>]7DL9#TM@GO;HH@O*8@7P"[$3&
MNFN84F=.#1,X 2ZAD=2:@O_! H0R!FIEN"O_EUSO,BY]1M>\IY3L.8V-?2VB
MDQ&.*LEU,97'@4L# O>$F<\^7 >@N\[H)E;5OK@R9:E4_;"DQP2U"Z#]O5+V
M/''U.CQ/Z5]02P,$%     @ +8=95/W#QX0] @  !04  !D   !X;"]W;W)K
M<VAE971S+W-H965T-34N>&ULA51-;]LP#/TKA$\;D-6QDW1#D01HVG4KT Q%
MBW6'80?%9F*A^O DNDF _OA1<N)E0)-=;%'B>WRD2(W7UCW["I%@HY7QDZ0B
MJB_2U!<5:N'/;(V&3Y;6:4%LNE7J:X>BC""MTKS?/T^UD":9CN/>O9N.;4-*
M&KQWX!NMA=O.4-GU),F2_<:#7%44-M+IN!8K?$3Z7M\[MM*.I90:C9?6@,/E
M)+G,+F:CX!\=GB2N_<$:0B8+:Y^#<5M.DGX0A H+"@R"?R]XA4H%(I;Q>\>9
M="$#\'"]9[^)N7,N"^'QRJH?LJ1JDGQ*H,2E:!0]V/57W.43!196^?B%=>L[
M9.>B\63U#LP*M#3M7VQV=3@ 9,< ^0Z01]UMH*CR6I"8CIU=@PO>S!86,=6(
M9G'2A$MY),>GDG$TO1'2P9-0#<(<A6\<<L7)PP?X)IP3H63P[AI)2.7?CU/B
MD &8%COZ64N?'Z'/<IA;0Y6'SZ;$\E^"E+5V@O.]X%E^DO$:BS,89#W(^WEV
M@F_0%6 0^89'^.[P!14,X/4P?Y"F;J@'N*FY>[ $0J=/!!MVP88QV."_U>[!
M3"AA"H3'.'M?G&UJ:5;P\XXQ<$NH_:\3$4==Q-')] Z3JM%)6P)/,J!P!GA&
M04FQD$K2]JV[/4V=#6#+/![.0<<[?DMN>M":&MTJ#J"'PC:&VB[M=KL9OVQ;
M^Z][^T#,A5M)XT'ADJ']LX\LS[5#UQIDZ]CH"TL\-G%9\3N%+CCP^=):VALA
M0/?R3?\ 4$L#!!0    ( "V'652L[;"[5P8  (DP   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4V+GAM;,V;46_;-A2%_PIA]*$%6ELD14HN' -M@F #FJ%H
MUNYAV(-BTPY16?1$.6F!_?A1LJHK11(M6R_L0V/9E_0E3_3Y])A=/*OTNWX4
M(D,_=G&BKR:/6;9_/YOIU:/817JJ]B(QKVQ4NHLR<YEN9WJ?BFA=#-K%,^)Y
M?+:+9#)9+HKG/J?+A3IDL4S$YQ3IPVX7I3\_BE@]7TWPY-<37^3V,<N?F"T7
M^V@K[D7V=?\Y-5>S:I:UW(E$2Y6@5&RN)A_P^^O0SP<4%=^D>-:UQRA?RH-2
MW_.+W]=7$R_O2,1BE>531.;'D[@6<9S/9/KXMYQT4KUG/K#^^-?LM\7BS6(>
M(BVN5?R77&>/5Y-P@M9B$QWB[(MZ_DV4"V+Y?"L5Z^)O]%S6>A.T.NA,[<K!
MIH.=3(X_HQ_E1M0&8+]G "D'D*$#:#F %@L]=E8LZR;*HN4B5<\HS:O-;/F#
M8F^*T68U,LEEO,]2\ZHTX[+E;213]"V*#P+=B4@?4F$TRC1ZAVJOJ VZE4F4
MK&04HP]:"U,0)6OT248/,I:9%!J]OA%9)&/]Q@S]>G^#7K]Z@UXAF: [&<=&
M,+V89:;?_%UGJ[*WC\?>2$]O-V(U112_1<0CN&/X]?#A7G/XS.Q2M56DVBI2
MS$=/;M7;ODTHMW"-S"_H%[$ZI*E,MD75'RI)JR<^1EIJ]/<G\P;H]TSL]#^6
M]FC5'BW:\WO:^U-E4=RUR<=AK!B6W]5/2SQGB]E3?2>/-4&]!I/IO*IJ=.17
M'?G6CNY4(GZ:7];TN\'1YI"LM669K)J4N:@"K]KCUC7#?1(5S74)<IPAK&TV
MIU/R0I&.HOG4F]?_=*L35)T&UDZO5;I7:90)]*",-,7^)"H3-I'":N[019'F
M57OST2+-6_N//3;E+U1J5Y'YE'8+@SU@LF>_<0Z)7,F]Z:^0QK)B7.,\=E$2
M#'3%9+0HY10-5?@4OQ"EHVI>4Z[9'^ 5V_EZ*]8BS;O;BF3U$TFM#]9[!0,F
ML>^D-(!<S,9+P]K FH8OE3D6\5J1WZ,+ !?;B?OU'FW5DTB3W+@@G>]%L6>V
ME0,C<>"D- !:'(Z7)FS?-;CVX5YJTUD5]L@#J,5VUEZK)#/KS[59&1<H\YLH
M-_ V0P:@))Z+\A"@+L$#Y8FAIRZ-RGGJN_\N;'W<=%5AK\^GD9JSM;/WDW@2
M,<*V)0,G"752$\ ML=O27J-<CCMAS+JJACDS L E=N"6>J#_T%D>F@ T"7=2
M)  OL;O3(5PKISBE5T?50+V PL1.8=#K$E=- *9D[J)L%(!,[<YUB&SE%'43
MX+W\YZBMI-D:H)C:45R[IP;;:PH$I6Z& [5TX(1]':(,/:V,K:39&@"9VH$,
MRISKL2D0E3H9&U @,AT?')136/6QE31; Q93.XM!GPN\-@6(4B=# PKTI>-C
M@W(*JT2VDF;0!MSU[=RM?P"=[;=]8*CO9(C@ X;]H2'"";]=SF/3R5K2[ \H
M[-LI?-2)V-9:2U>=C U\8*YO=[&]1MMO9P78]Z;^2P':9<R?!CT: &E].VE+
M#<XUUS[PTG<R-/"!M/[XT*"<PGJ#V$J:K0%C?3MC09Q+G#0#8#(GDP,&J&5#
MDX-^C5@[#N@*J3O*^E-J!JQE0T(#<I:A9D!*YF2,P "_S.Y:!PG4S@HZ\NJ.
MJMZ\FM6^)QN2(9 +7#4#E#(G8P0&*&;C8P36$1"TDNNR:$!RS0##;$AJ0"[S
MU0R0RIP,#3BPF(\/#<HI3F38W54]&38'%O,AT0&YS%US "IW,D/@P&0^-$,X
MX:[YZ2#!6M+L#Y#,AP0)U+96P"=W,C#@M8,&=AO;ZZYY^^A QU<)757]7R5P
M("X?$A;0<]TU!VIR)V,"#KSEXV,"?CHFL)8T3WP :8,A,0&]T%T' ,S R9P@
M -0&XP\;!*<C FM)LS6 ;# D(J!GV>H $!DX&1H$P-U@_%F#H'V,H*6,K:39
M&A W&!(<T L<=5 [E.5D=A  ?H/QV4%P.CNPEC1; _ &0[(#>IF?#@&BH9/1
M00CT#<='!^44-HFL)<W6@+OAD,R 7N:D0V!HZ&1X$ *&PZ'AP0DG7<X3V,U<
M5U6'F9O5SHGGA_3OHG0K$XUBL3'CO&D.S?1X[OUXD:E]<73\0669VA4/'T5D
MI,H+S.L;92Q#>9&?1J_^]\'R?U!+ P04    "  MAUE4);0%#F4#  #3"@
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M )>;J1=ZVX-[MBZ-/?#3I*9K> #S6"\4[OQ>I6 5",VD( I64^\ZO)K'%N\
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M_%."NE;)+!A*4%)+3<831,:$)4^:N:Y5-(];97@D[+P6=CXJ[&8GLZW9$'+
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M-T:NG2<LI$&'<<L*OS*@+ #O+Z4TVXT-T'^WLK]02P,$%     @ +8=95)&
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M,!#'_Q4KVD,KK?E)(*D J85-F]1JJ*S;P[0'DQS$JA,SVT#Y[V<[(0TD(/(
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M/EXD6[YGC*2(BU_ XGN)Y2?X%?P).8>Z<L#7.9(0$W&E9E]?YN#KEROP!;A
M9) C 3 %KQ1+<:TFU?@1$Z+*3HQ=J13K==UEK>Z^4A><4!>#1T9E)L""IBBU
MX&?=>#_H('"558U?P=:O^Z"3<8Z6-R#TKT'@!9Y-4'^X;X'/N^%_E%3!O9.K
M+WK#_9$%_M ?/K3 O_6'QQVI")O2#0U?>(*OKLM_[MZ$Y.J5]F\'YZ#A'!C.
MP=G'0>AGX'I;T;"4&>/X/VL1WE><L>'4[_Z/:>29O['[T:Z-\W%[HJ-&='29
MZ )R\ %)J1[4E!$"N0 %XM5>KFP;J/A'+6'>C><?J#\3M"<];J3'/^6W^F@*
MJ=Y(F*YM>N,C(P^M[HK84YHT2I-.I?6K\9*R2(XT^'6^#]7VB=Q3/6Q4#R]0
M?7%=#/O4Q9F@/=VC1O?H<K>Q$*7=Z=&1?TDTL!E]'#BT9F1N81PDEL"%)3",
M+($/ED O[DBQ[^T^X=[E9IUY@FK*'I99(D]X9N.TFV:+M+MFB^RVK=7Y^)VV
MF2Y'M=-%R9>9ZF9!P=F:P_RZ]5@#F+.22MO'KF:/6LJ"DZ*"G:C@)T5QI$\6
M*IWMNUNE4/?UUOZH6BYIOUI\[R8YH7/W[?7#3IW/.PULI?O& M+/J@2MY18>
MF7549V=#YN=#%I:0Z# I;JM=SA%?FY.0 $N=Z:H3;&:;T]:=.6,<S,_\VT5U
M9MK15$>X1\C7F I T$I1*K^5(%Z=BJH+R0K3E+\QJ5I\,\S421)Q':#NKQB3
MVPN]0',VG?X/4$L#!!0    ( "V'653T83B[6P,  /P+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<P+GAM;)U6VV[;.!#]%4(OW06VUL62+X5MH+&]: L$
M#1+L[C,CC2TB%*F25)S\?4E*5A2+EIWU@T52<\[,'([(61RX>)(Y@$(O!65R
MZ>5*E5]\7Z8Y%%B.> E,O]EQ46"EIV+ORU( SBRHH'X4!!._P(1YJX5=NQ.K
M!:\4)0SN!))546#Q>@.4'Y9>Z!T7[LD^5V;!7RU*O(<'4/^4=T+/_)8E(P4P
M23A# G9+[VOX93LW]M;@7P('V1DCD\DCYT]F\CU;>H$)""BDRC!@_7B&-5!J
MB'08OQI.KW5I@-WQD?UOF[O.Y1%+6'/Z'\E4OO1F'LI@ARNJ[OGA&S3Y)(8O
MY53:?W1H; ,/I954O&C .H*"L/J)7QH=.@#-XP9$#2 Z!4S. ,8-8'P*B,\
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MW9K98:[;<Q#&0+_?<:Z.$^.@;?A7OP%02P,$%     @ +8=95+9LN&TO P
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M:\>08U%?3^J&XJ4Y3I^Y@L/9O&9PHR-" V!\Q;G:-O0$[1UQ^@]02P,$%
M  @ +8=95 [)\N4$!@  A!L  !D   !X;"]W;W)K<VAE971S+W-H965T-S(N
M>&ULM5G;;MLX$/T5PN@"*=#8$B7+=I$8R*U-%]O4J)'V8;$/C$3;1"71)2D[
M6>S'[Y"2)=F6*7>SSD.L"V=X.'/F#"5=K+GX(1>4*O2<Q*F\["R46K[O]62X
MH F17;ZD*=R9<9$0!:=BWI-+04EDC)*XAQTGZ"6$I9WQA;DV$>,+GJF8I70B
MD,R2A(B7:QKS]67'[6PN?&7SA=(7>N.+)9G3*56/RXF LU[I)6()327C*1)T
M=MFY<M_?^XXV,".^,;J6M6.DE_+$^0]]\BFZ[#@:$8UIJ+0+ C\K>D/C6'L"
M'#\+IYUR3FU8/]YX_V 6#XMY(I+>\/@[B]3BLC/LH(C.2!:KKWQ]3XL%];6_
MD,?2_$?K8JS306$F%4\*8T"0L#3_)<]%(&H&KG_  !<&^%@#KS#PCC7P"P-_
MQP#W#QCT"X/^L3,$A4%PK,&@,!@<:S L#(8FNWDZ3"YOB2+C"\'72.C1X$T?
M&$(8:T@A2S5WITK 709V:CQ5//QQ?@W9C] -3Z D)#&D.D</1 BBF87.;JDB
M+)9OX>KC]!:=O7F+WJ >D@LBJ$0L18\I4_(=7(3CSRR.P8.\Z"D J*?IA068
MZQP,/@2&+KL(>^\0=K#;8'YC-[^E81=Y[D'SV^/-G0;SN]?-_L%N_GN6@KES
M</:/1YN[HP;S^R/ .WUCCK?->\"HDE:XI!4V_KQ#F=3,.'_:I]6??\!(]$G1
M1/YEF<<KY_',//Z!>;XLM5>)YH*D"N8ZRRGYMBE]N:? >-*2OAI#G%?U#+6.
M^&@;L;4 OUR ;UW 8RIHR.<I^QO02U.,>=3">M3HLSZF3261NQ_4$ 5N=[ -
M^ZYET!;R?HF\;T7^W;0%&IV3%170YM"2"L8C!/T4%6LRV,]>*!'-&;%/@)&Q
M1!Y*>*H6$KE#%)$7::%-4&(/[*X==X F,4DMO@:EK\%)J3XLYQE:,3]DR1,5
MB,\VLDLRM>!"$Z>)%\,]IOJ!H_]VJ-$^;@OMJ$0[LJ*=%AA7T#?(4TP-+4R5
M-H$=[8'P&L&VC]L"ZSI5%W3:"('1)!/A O+8Q@RWUES=DW+#K?36Q?\C.^X+
M;_5(8L<6R4J07;LB7T61J7L2ETBV.##+5";H02I<N_L2:T=6*:UKE]K/Y)DE
M68+2W5"!<*$E$8J%; FHS#F?S4#.TGFA:HU(_3VD_<,P*UEU[;)75 Z3,@/6
M9&D$:-2BB93%GJC_BP&K1-*UJ^0$<+"(0D1("OQ=,#I#=\\TS,RF\,MLQD(J
M;.RM)-0]K8:ZE8BZ=A7]A0W#K;NOC0-;8"MM=.WBN&F=:-,Z#1IH;@IJA#"!
M5B3.J&8HWX4;\3C635%SU$!O1I[//ZHA=[VN-VP&CBN9Q':9W$1/\^'K]%&B
M?] #3\]ILHSY"Z4H8M#Y%;>1 E?BB4\KGKBV6;6+YY2*%7"YOH,A:R(BM*)2
M:1$X@\>:P]N8%N^N,;4!K<05V\75/*UM2&'S6(DB]D\;Y$K7<(NNO3+(=N]^
M;FI#6ND>MNO>E8$%>VXF\E@4D%L VIVZ3CO"2B_QX'@>0!&^5JEQI9]X>%J^
M5"*)[2+Y'[-@=SIH38)7B:%G%T,M@#9'E=!YIQ4ZKQ(Z[Z1"U^*]O0:]VG.]
M7>F.;)%']L-BLIU^&(QV'B\:AN%1=^CMOB9H&#;HCH+==P7[P_R@&^#F)NQ5
MDNW9][$?MG8(4/E*L%!M7A_ CI$I"3M&HDQ6&_?_M][^&P%8J;L;CX91N!OL
MAF-_E(>[_FXT&GP-:KZV@U%U%<^N^\4NY(8*19A^4;(1/9Z+7KY7X;"!!G[0
ME 'CEURRC7!>A:"5*YIHZ8SA()8HKT.HOKO)%"DBYE19*5VU%2\X;9E7[<&S
MMX=O136O31&A,RB.$%;87--V5WVGZSB_V5!5K<.S;[U?F:H)%>9330KZ5>;H
M@<B(_$3WE,1J$4)\H17R%=//3)_@R>G9!KSJ1-[HI(GSJY;BVUO*KR2NQ=7A
MQ/5J7POT]ZG/P'$&(8[I##PYW0%4G,@_^>0GBB_-!X0GKA1/S.&"$HBQ'@#W
M9YRKS8G^)E%^>!O_"U!+ P04    "  MAUE4;NG?9_$#  ">$   &0   'AL
M+W=O<FMS:&5E=',O<VAE970W,RYX;6RM6&UOVS80_BN$T \-D%@BY=?"-A#'
M&]8"W8(&6S_3$FT3D42-I.WDW_=(*9)=RPR]-1\BDN(]]]P=\U"7Z4'(9[5E
M3*.7/"O4+-AJ77X*0Y5L64Y53Y2L@#=K(7.J82HWH2HEHZDURK.01-$PS"DO
M@OG4KCW*^53L=,8+]BB1VN4YE:\+EHG#+,#!V\(WOMEJLQ#.IR7=L">F_RX?
M)<S"!B7E.2L4%P62;#T+[O&G)2'&P.[XA[.#.AHC$\I*B&<S^9S.@L@P8AE+
MM(&@\-BS!Y9E!@EX_%N#!HU/8W@\?D/_W08/P:RH8@\B^\Y3O9T%XP"E;$UW
MF?XF#G^P.J"!P4M$INQO=*CW1@%*=DJ+O#8&!CDOJB=]J1-Q9$#B"P:D-B _
M&>#^!8.X-HA]#?JU0=]FI@K%YF%)-9U/I3@@:78#FAG89%IK")\7INY/6L);
M#G9Z_J1%\GRW@,REZ$'D<)P4M06Y0_85^JLT4X7N38&X?D4?ETQ3GJD;V/(!
MA4AMJ61J&FI@8S##I/:\J#R3"YXQ05]%H;<*_5:D+#T%""&,)A;R%LN".!&7
M+.FA&-\B$A'<0>C!;?YE5X!Y9,VC#O.EMSF>.**)F\K$%B^^@%<G_A;]N<M7
M3"*Q[DSU"7:_P>Y;[+X;&X$0*$V+E!>;6[1B&UX4,$0?*T<W746M@(<6V(C*
M?CX C8&?:;CO8#1H& V\&&TD+32<11>%P1F%UGE5Z'=W+%T[3@(8-@$,O0)@
M+TPF7+T3PO#,_5T\<J1QU+ 8>;%(:)& MJ9(2&!4<OD.G]$Y'^R@,V[HC*\_
M9\P^G73&9W1PWT%GTM"97%,CNLJ8D\;DG$;DH(&C5G0C+R)[ILQAA\R8*L%5
M"!,M[+*36 WOG2!\=!U@/]7Y;F],0V[/)'P!- <;E9(GS"%"F+3.R/^2H51D
M&94*E2!_-AO=R:B<3(Z20>(>Z5](1:N_.+Y.DCSIQ+[2@ENYQGYZ?20NGF0J
M7'->VN3T>V1X@5$KU]A/KSN%QI/;H(/;H(?'%[BU2HS]I+A3=3RY#3NX1;WX
M4MY:?<9^ GTB09Z<1AV<XEXTNL"I%6GLI]).-?+D.#[_6W2DK15N//F/LB29
MZ6Y,:1/XFI301^QHAC*^AKSR KTR('WC^KAL19OXB?;)L;J*3Q>9^L/6[3JN
MXD!D@E+ZZOH")*W2$WSM2?QUX;A=DSH<C'+3 2#R;E3ME4+\KA3'6?YU4;JI
M>!0M/&K<<B8WM@$&416[0E=]3[/:--GWMK7\:7T!S7?5*K<P5>?^E4JX3Q7*
MV!H@H]X(5%=6S7 UT:*T[>%*:&@V[7#+:,JDV0#OUT+HMXEQT/Q+8OX#4$L#
M!!0    ( "V'652 *MBNXP,  !$1   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<T+GAM;,5876_;-A3]*Q="'QH@D43*GX5M($XZK,"R&@G:/@Q[H"7:)B*)
M&DG%"; ?/Y*2):>5Z7G-DA=;E,A[SSW7YU#T9,O%O=Q0JN Q2W,Y]39*%1^"
M0,8;FA'I\X+F^LF*BXPH/13K0!:"DL0NRM( A^$@R C+O=G$WEN(V827*F4Y
M70B09981\32G*=]./>3M;MRR]4:9&\%L4I UO:/J2[$0>A0T41*6T5PRGH.@
MJZEWB3[,<=\LL#.^,KJ5>]=@2EER?F\&GY*I%QI$-*6Q,B&(_GJ@5S1-322-
MXZ\ZJ-?D- OWKW?1?['%ZV*61-(KGGYCB=I,O9$'"5V1,E6W?/LKK0NR &.>
M2OL)VWINZ$%<2L6S>K%&D+&\^B:/-1%["Z)#"W"] %O<52*+\IHH,IL(O@5A
M9NMHYL*6:E=K<"PW7;E30C]E>IV:W2D>WU_,=5T)7/%,-UL22]<%V$?PN3!#
M"9]+)17)$Y:OX?TU582E\@SDA@@J@>5PP]+43)P$2L,RP8.XAC"O(. #$!"&
M&YZKC82/>4*3YP$"74]3%-X5-<?.B-<T]B%"YX!#C-Y!4,.L/AWQHX:TR,:/
M#I%F ETL+6D+\J1_I HNA2#YFIKK\YJT<_CX2$7,)(6%8#&%6S,#_OA-AX-/
MBF;R3P>87@.F9\'T#H#YO<R65 #?[X_N1U7L&?P-7657+%:!1S:PD>_##/F]
M2?#0@:;?H.D[T7RS,M"\D <JM*RU<HTW&%2Q;K+0*BQ)"BE;47C_1(F09UW(
MW$DBL"L!CR$A3ZZ.#AK8@]-@TUWG"MLYPVC"T]1D+33;EM-.Y%6>\1ZG./2C
M43>KPP;>T GO':#(!CE8Z*B)-'K[G^ZX 3-VEE4%Y:OOV);GQNE85F8G\#[^
M@?>:LB[>4=C:8_A_J:N.O"^OT!\> +3GU^@U!'8D2[]6V!"RRII1=$QJ"+<E
MX%<26YWHWW:]]7<4'=$;CORQ2V^HM6?4>WO%H=:?D=L[7U)S=:IG9E?QUDE_
M:\;([<8_([I!A^C0 4"M_2*W_[Z4Z-Q9\$YLO:-::^T>C5Y+:Z.3FMWN <B]
M"6BM#?UPJ%\XHX'?[[M>_UK7QN';:PZWGHW=;OJ2FJM3F<VE[8,AL+L/N'5E
M['9E!TCR>"K('WVY;FXGQM:7L=N7?\(8ZLC/C6%P %!K[MC]\OU"QG DRVAG
M#'APS!EPNQ'@$]_4_[,SX(YM8.CC[[L=[)U2,RK6]BPN-4]EKJH#:W.W.>]?
M5J?<=GKU9\$-$6NF#Z4I7>FE^JU*(Q#5^;L:*%[8,^^2*WV"MI<;2A(JS 3]
M?,6YV@U,@N9?D-D_4$L#!!0    ( "V'651P'(-W@0,  'T,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<U+GAM;*U77V^C.!#_*A:ZAUVI!0R$)*LD4I/T
M='=23U6KWCX[X"16C9VS3;+[[6]L",FV0%GMO00#\_OC\=A,9B>I7O6>4H.^
M%5SHN;<WYO E"'2VIP71OCQ0 6^V4A7$P*W:!?J@*,D=J.!!%(9I4! FO,7,
M/7M4BYDL#6>"/BJDRZ(@ZON2<GF:>]@[/WABN[VQ#X+%[$!V])F:E\.C@KN@
M8<E9085F4B!%MW/O#G^YQXD%N(A_&#WIJS&R4]E(^6IO_LSG7F@=44XS8RD(
M7(YT13FW3.#CWYK4:S0M\'I\9O_=31XFLR&:KB3_RG*SGWL3#^5T2TINGN3I
M#UI/:&3Y,LFU^T6G.C;T4%9J(XL:# X*)JHK^58GX@H /.V J 9$;P%I!R"N
M ?%;0-(!2&I ,A0PJ@%NZD$U=Y>X-3%D,5/RA)2-!C8[<-EW:,@7$[90GHV"
MMPQP9O%L9/9ZNX14YV@E"Z@_3=P*WJ(GJHUBF8$W+@J]"&8TNK-+R\QW]&E-
M#6%<?[:QSR\:+K^A .D]452?+TR@!\8Y,.I98,"PE0VRVMRR,A=UF$O1@Q1F
MK]&]R&G>@E_UXW'40Q! IIIT1>=T+:->QC7-?!3C&Q2%4=AF:#@<M\#7_?"_
M2@'PL%/]?C <3WN2$3>U$SN^N(//+OH-^KLL-E0AN:V7O(<X:8@31YST$*-2
M'*$ H?B(R!$<<=K @(G=#=K0'1,"ANA3)?FY;24JB8F3L,?E<1'[T2PXMO@:
M-;Y&'_O:*2*LK3[MT3MM[$_:M=-&._U8N\Y(GW3Z3OH6^[A=>]QHCS_6SHC(
MX'SO5Q^_5P^[9CYIU">_4@W47?M<+2>]I5 Y;XOI2-NT,3X=L#^^NF^5=7ZD
M"KZ]50&AG!B*MH0I="2\I#V[!H>7LSS\G_9-+CDG2J,#[%R7N-;5K.6F5TF)
M0G^4MJ<%7WUS\$_LHT%>EC7EM1<<^^GTS3+68=;YQ?/4G\0_QJU;Z**Q/TU_
M#+MO"4M2/^TX1W!TR4 T?#</7(RH96;8C[N\7$YQ'/_,[A[H)FYQD_A)QU['
MEZ,?_]+9?][M XLF^:" Z\FTA"77Q5#-);AJLPJJ=JZ_A=3)4IBJA6B>-CWT
MG>L<WSQ?V=[:M6\7FJHQ?R *]JA&G&Z!,O3'\"515:];W1AY<,W<1AIH#=UP
M#_\/J+(!\'XKI3G?6('F'\?B/U!+ P04    "  MAUE4NYR$WIX#   E#@
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M0$[ 8UX4(INJA</%0&HY)VV#KIN@WDC0"#Q2PH\5>" 9S@S\9)H/O0D!1\Q
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M:MF@HV#<F_2!/^A>/\#NQS9QRQN.W0X4@P94J.6Z22I043L#"O:F:NBO5V#
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MQ-)O?"]ZB4T&F:U0HP%%06/D'QEY@]15"X:G[A]2]XVI/_"21T6\K;O@FK_
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M9Y&MJ]/<:R_SZACW<?B5-'N#X+%:*75"K8K4JQEUBAEUO#,:T26W5.1P83E
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M"B,EW1(_%\*I&<[$$D(^67'[DVGA,K1?7Y"2,$G[D!DH:9'XM\$?D@&_"\A
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MAH=8MI0VK$F''V3>>:UP_N[FG;_ZIX7Q8?/"X/G2"O[3/O*'++9+#0];3(/
M[E4R+Y4:UV/X09Z&SW=(&+56LZC](S17<,S)2473:J7?: 6V<=_@5C&A"8<5
M@H+. -&J[(7EQ,B-ZPY+:;#7N.$:OQ] V0!\OY+2/$ULPZF_2)*_4$L#!!0
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MA()"D]$=2;)-4S<&FBHTTL$@M658EC0'P7H'.B^,P8OA";K)NOP-4$L#!!0
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M5N9[ M("S'DIA-YOK(/A"Y7^!5!+ P04    "  MAUE49T@#Y!,"  !G!
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M_;*U+P%H%V#W:Z7P9+@$T]N2OP)02P,$%     @ +8=95(X]VRU^ P  R P
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ME\[,03'LR8&I#3_]#E5 $[->Q)FT5W2JL)Z#HH-4/*N,-8.,YN6=?*L2T3#
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M.!SA;E+8.S=W[P=U@OY%=SDU77^K=/,?T@UN?%/PKU<./C=H[+^ =BHG%[K
MK?W<@0IFHW%/H<YM'P_W_5[]5'9-?[/0:[7 #AC&<V\4]! [-W0\W-&?I:"-
M[N:([\V)C<5#)3TW7SQY 06=VRD>[J<_24'3=A%:6[T#Y/>6Z=RJ<?@_]1.V
M/O,3W&@L%:D.U+3UD7(;QTQSQO]$1$)SJ=.UUV:ZA^J:BO+87 X4+^S)<\>5
M/L?:QU3_:H P /U^S[EZ')C#;/WSLOH/4$L#!!0    ( "V'651>(@/((00
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M,.*C\'A/U![=W2T0=(&#1YP,OT8Z*$@';ZBD8<$R[!S:O> >I;Y$6\'#;&3
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M=X#VYUKC<^!F0_M7D/X%4$L#!!0    ( "V'65280UIH?P(  ,(%   9
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M'/(D]))-O%.IDN\HB5#Y7D;NU(F&'Y-2Q$;3!28^! 9740L,QD)N#O@EBF-
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MN6V_;D2BE\D-0/_^+*5ZOV@:.+PD>/M_4$L#!!0    ( "V'652)15$7&P,
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( "V'652+2_C\U08  --!   /
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MH'H'@-Y!]0X O8/J'0!Z!]4[ /0.LY>5 +V#ZAT >@?5.P#T#JIW .@=5.\
MT#NJWA&@=U2](T#OJ'I'@-Y1]8X O:/J'0%Z1]4[ O2.L\TF +VCZAT!>D?5
M.P+TCJIW!.B=5.\$T#NIW@F@=U*]$T#OI'HG@-Y)]4X O9/JG0!Z)]4[ ?1.
ML\V" +V3ZIT >B?5.P'TSJIW!NB=5>\,T#NKWAF@=U:],T#OK'IG@-Y9]<X
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M4$L! A0#%     @ +8=95 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  MAUE4#CV$<>X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  MAUE4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( "V'650/ICVZF 8  #(:   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  MAUE4:3:CF" "  !M!0  &               @(';#@  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ +8=95&% DB^D!@  P1L  !@
M             ("!,1$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( "V'653<[SGTD0(  "$'   8              " @0L8  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  MAUE43-O="/T&  "2
M'P  &               @('2&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ +8=95#>IWKZ( P  T0H  !@              ("!!2(
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "V'652G' #L
M7@4  *48   8              " @<,E  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    "  MAUE4];M"]BH*  "B,   &
M@(%7*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ +8=9
M5$=>IDQF)0  ;'0  !@              ("!MS4  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( "V'652Q/J(#+00  $T+   9
M      " @5-;  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ +8=95![_?!<I"   [14  !D              ("!MU\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  MAUE4<.$4&5T#  !:!P
M&0              @($7:   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( "V'652;P#]EW@@  *D9   9              " @:MK  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ +8=95!-H#[G'
M @  R@4  !D              ("!P'0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    "  MAUE4UI9B#'$'  "C%   &0
M@(&^=P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "V'
M651ZU%8,7P(  !<%   9              " @69_  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ +8=95)5)A=]Y!0  O X  !D
M         ("!_($  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    "  MAUE4UH@7RXX,  "^)@  &0              @(&LAP  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "V'6524K#XRC0\  %4J
M   9              " @7&4  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ +8=95 ('9#&R#0  ,RP  !D              ("!-:0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  MAUE4%IJI
M"Y<(  !%%P  &0              @($>L@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( "V'652@K)PS.P,   $'   9
M  " @>RZ  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M+8=95,$*8RX7!0  \PH  !D              ("!7KX  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    "  MAUE4H4P%)]D$   *#0  &0
M            @(&LPP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( "V'653&S66.O@,  $((   9              " @;S(  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ +8=95)L).-21 @
M9 4  !D              ("!L<P  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    "  MAUE4 @&&GR0#   /!P  &0              @(%Y
MSP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "V'650/
M .B^6@0  #$)   9              " @=32  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ +8=95!>@R_84)P  A($  !D
M     ("!9=<  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "V'653(U@2EKP0  ,,/   9              "
M@9T2 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ +8=9
M5 V*Z'B^ @  R@4  !D              ("!@Q<! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    "  MAUE4\+'+7%,"   /!0  &0
M        @(%X&@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( "V'653"L]@?H ,  %H)   9              " @0(= 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ +8=95*J(Y'4+!P  7A8
M !D              ("!V2 ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    "  MAUE43 PZ+N8)  #8&P  &0              @($;* $
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "V'651.I:^W
MY0(  $,&   9              " @3@R 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ +8=95+];!CZ8 @  @@4  !D
M ("!5#4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  M
MAUE4BF%IM/,"   G!@  &0              @($C. $ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "V'652L$B;<T0(  /$%   9
M          " @4T[ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#
M%     @ +8=95'1]>\42 P   0<  !D              ("!53X! 'AL+W=O
M<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  MAUE4^,L^<S\$   +
M"0  &0              @(&>00$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM
M;%!+ 0(4 Q0    ( "V'650$?8^AN 8  .\=   9              " @11&
M 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ +8=95$I
MK]?K!   <A8  !D              ("! TT! 'AL+W=O<FMS:&5E=',O<VAE
M970T-RYX;6Q02P$"% ,4    "  MAUE40CJ+/V$(  "J-@  &0
M    @($E4@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M "V'6524V/6E+0,  &8*   9              " @;U: 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ +8=95%H.?S1Y P  HPL  !D
M             ("!(5X! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    "  MAUE4.[9%(VL"  "T!0  &0              @('180$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "V'653A,L'V)P4
M &4;   9              " @7-D 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ +8=95-LV_1F_ P  9@\  !D              ("!
MT6D! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  MAUE4
MF1,HO" "  "J!   &0              @('';0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( "V'653]P\>$/0(   4%   9
M      " @1YP 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ +8=95*SML+M7!@  B3   !D              ("!DG(! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  MAUE4);0%#F4#  #3"@
M&0              @($@>0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( "V'652--\T"N (  .$(   9              " @;Q\ 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ +8=95/'8 U]-
M @  $@4  !D              ("!JW\! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    "  MAUE4XO0$;W@"  ">!@  &0
M@($O@@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "V'
M653GJJP<?0(  /8%   9              " @=Z$ 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ +8=95*,;?4?2!   ^!8  !D
M         ("!DH<! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M    "  MAUE4:YNH4-(#   <$   &0              @(&;C $ >&PO=V]R
M:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( "V'6503"HI'@ (  ,,&
M   9              " @:20 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL
M4$L! A0#%     @ +8=95)& 02MM @  '@<  !D              ("!6Y,!
M 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  MAUE4BRHV
M,Q0#   E"0  &0              @('_E0$ >&PO=V]R:W-H965T<R]S:&5E
M=#8V+GAM;%!+ 0(4 Q0    ( "V'652HI\(PKP0  $ 7   9
M  " @4J9 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
M+8=95.15V(U, @  M 4  !D              ("!,)X! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    "  MAUE4LKW(G<0#  "G#@  &0
M            @(&SH $ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( "V'653T83B[6P,  /P+   9              " @:ZD 0!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ +8=95+9LN&TO P
M+PH  !D              ("!0*@! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    "  MAUE4#LGRY00&  "$&P  &0              @(&F
MJP$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( "V'651N
MZ=]G\0,  )X0   9              " @>&Q 0!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ +8=95( JV*[C P  $1$  !D
M     ("!";8! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "V'653)196#NP(  - '   9              "
M@07' 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ +8=9
M5 #901;D @  APH  !D              ("!]\D! 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    "  MAUE4T4XO=?0#   $$   &0
M        @($2S0$ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( "V'6535%IJE]@(  +<)   9              " @3W1 0!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ +8=95#@Z,-O$!P  ]RH
M !D              ("!:M0! 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    "  MAUE4_$2J#?P#   5#@  &0              @(%EW $
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( "V'650^X[GV
MI@0  .L3   9              " @9C@ 0!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ +8=95+V"R:::!0  EB<  !D
M ("!=>4! 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    "  M
MAUE4G_R$5L\#  !Z#@  &0              @(%&ZP$ >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( "V'653MW_2FH0(  )T(   9
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M970Y,BYX;6Q02P$"% ,4    "  MAUE49T@#Y!,"  !G!   &0
M    @('E_@$ >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M "V'652./=LM?@,  ,@,   9              " @2\! @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ +8=95%XB \@A!   P0\  !D
M             ("!Y 0" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    "  MAUE4 U:[;GP#  "^#0  &0              @($\"0( >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( "V'651)1LO8;@(
M !8&   9              " @>\, @!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ +8=95)A#6FA_ @  P@4  !D              ("!
ME \" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    "  MAUE4
MS!FR%'P#  #B"P  &0              @(%*$@( >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;%!+ 0(4 Q0    ( "V'653X$?#W+ @  # H   :
M      " @?T5 @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0
M   ( "V'652)15$7&P,   H2   -              "  6$> @!X;"]S='EL
M97,N>&UL4$L! A0#%     @ +8=95)>*NQS     $P(   L
M ( !IR$" %]R96QS+RYR96QS4$L! A0#%     @ +8=95(M+^/S5!@  TT$
M  \              ( !D"(" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M "V'653#*Q\]U@(  ,<Z   :              "  9(I @!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "V'652%GR=*6 (  ,,X   3
M              "  : L @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !L
- &P K!T  "DO @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>362</ContextCount>
  <ElementCount>570</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110102 - Disclosure - Marketable Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecurities</Role>
      <ShortName>Marketable Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120104 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125105 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132106 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135107 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Other Long-Term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilities</Role>
      <ShortName>Other Long-Term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Preferred and Common Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</Role>
      <ShortName>Preferred and Common Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2156111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2165112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2167113 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2171114 - Disclosure - Employee Deferred Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlan</Role>
      <ShortName>Employee Deferred Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2175115 - Disclosure - Segment and Related Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformation</Role>
      <ShortName>Segment and Related Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2179116 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2183117 - Disclosure - Business Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisitions</Role>
      <ShortName>Business Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2185118 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2187119 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2190120 - Disclosure - Transition Period Comparative Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited</Role>
      <ShortName>Transition Period Comparative Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Marketable Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesTables</Role>
      <ShortName>Marketable Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/MarketableInvestmentSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Other Long-Term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</Role>
      <ShortName>Other Long-Term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables</Role>
      <ShortName>Preferred and Common Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2346309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/StockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2368311 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2372312 - Disclosure - Employee Deferred Savings Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables</Role>
      <ShortName>Employee Deferred Savings Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/EmployeeDeferredSavingsPlan</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2376313 - Disclosure - Segment and Related Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationTables</Role>
      <ShortName>Segment and Related Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SegmentandRelatedInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2380314 - Disclosure - Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresTables</Role>
      <ShortName>Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Divestitures</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2388315 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2391316 - Disclosure - Transition Period Comparative Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables</Role>
      <ShortName>Transition Period Comparative Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails</Role>
      <ShortName>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2414409 - Disclosure - Marketable Investment Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Investment Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2430419 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2431420 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebtDetails</Role>
      <ShortName>Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesDetails</Role>
      <ShortName>Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Preferred and Common Stockholders' Equity - Stock Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Stock Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Stock-Based Compensation - Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2452432 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails</Role>
      <ShortName>Stock-Based Compensation - Aggregate Intrinsic Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2453433 - Disclosure - Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails</Role>
      <ShortName>Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2454434 - Disclosure - Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails</Role>
      <ShortName>Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2455435 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Income Taxes - Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2459437 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2460438 - Disclosure - Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails</Role>
      <ShortName>Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2462440 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2463441 - Disclosure - Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2464442 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2466443 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/CommitmentsandContingencies</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2469444 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2470445 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2473446 - Disclosure - Employee Deferred Savings Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails</Role>
      <ShortName>Employee Deferred Savings Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2474447 - Disclosure - Employee Deferred Savings Plan - Contributions to Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails</Role>
      <ShortName>Employee Deferred Savings Plan - Contributions to Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2477448 - Disclosure - Segment and Related Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails</Role>
      <ShortName>Segment and Related Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2478449 - Disclosure - Segment and Related Information - Assets by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails</Role>
      <ShortName>Segment and Related Information - Assets by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2481450 - Disclosure - Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresNarrativeDetails</Role>
      <ShortName>Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2482451 - Disclosure - Divestitures - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresOtherIncomeDetails</Role>
      <ShortName>Divestitures - Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2484452 - Disclosure - Business Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails</Role>
      <ShortName>Business Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2486453 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SubsequentEvent</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2489454 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="mygn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2492455 - Disclosure - Transition Period Comparative Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails</Role>
      <ShortName>Transition Period Comparative Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mygn-20211231.htm">mygn-20211231.htm</File>
    <File>mygn-20211231.xsd</File>
    <File>mygn-20211231_cal.xml</File>
    <File>mygn-20211231_def.xml</File>
    <File>mygn-20211231_lab.xml</File>
    <File>mygn-20211231_pre.xml</File>
    <File>mygn-20211231ex211.htm</File>
    <File>mygn-20211231xexx231.htm</File>
    <File>mygn-20211231xexx311.htm</File>
    <File>mygn-20211231xexx312.htm</File>
    <File>mygn-20211231xexx32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mygn-20211231_g1.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1412">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mygn-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 38,
   "contextCount": 362,
   "dts": {
    "calculationLink": {
     "local": [
      "mygn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mygn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mygn-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mygn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mygn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mygn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 763,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 8
   },
   "keyCustom": 62,
   "keyStandard": 508,
   "memberCustom": 36,
   "memberStandard": 51,
   "nsprefix": "mygn",
   "nsuri": "http://www.myriad.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.myriad.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110102 - Disclosure - Marketable Investment Securities",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecurities",
     "shortName": "Marketable Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2492455 - Disclosure - Transition Period Comparative Data (Unaudited) (Details)",
     "role": "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails",
     "shortName": "Transition Period Comparative Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mygn:ScheduleOfTransitionPeriodComparativeDataTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i56578ab4d8254f1ca6a5448f808f1cb4_D20190701-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115103 - Disclosure - Fair Value Measurements",
     "role": "http://www.myriad.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120104 - Disclosure - Property, Plant and Equipment, Net",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125105 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132106 - Disclosure - Accrued Liabilities",
     "role": "http://www.myriad.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135107 - Disclosure - Long-Term Debt",
     "role": "http://www.myriad.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Other Long-Term Liabilities",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilities",
     "shortName": "Other Long-Term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Preferred and Common Stockholders' Equity",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquity",
     "shortName": "Preferred and Common Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Stock-Based Compensation",
     "role": "http://www.myriad.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156111 - Disclosure - Income Taxes",
     "role": "http://www.myriad.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.myriad.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.myriad.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167113 - Disclosure - Leases",
     "role": "http://www.myriad.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171114 - Disclosure - Employee Deferred Savings Plan",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlan",
     "shortName": "Employee Deferred Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175115 - Disclosure - Segment and Related Information",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformation",
     "shortName": "Segment and Related Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179116 - Disclosure - Divestitures",
     "role": "http://www.myriad.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2183117 - Disclosure - Business Acquisitions",
     "role": "http://www.myriad.com/role/BusinessAcquisitions",
     "shortName": "Business Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2185118 - Disclosure - Subsequent Event",
     "role": "http://www.myriad.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2187119 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:TransitionPeriodComparativeDataTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2190120 - Disclosure - Transition Period Comparative Data (Unaudited)",
     "role": "http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited",
     "shortName": "Transition Period Comparative Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:TransitionPeriodComparativeDataTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.myriad.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Marketable Investment Securities (Tables)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables",
     "shortName": "Marketable Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Other Long-Term Liabilities (Tables)",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesTables",
     "shortName": "Other Long-Term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables",
     "shortName": "Preferred and Common Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346309 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.myriad.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.myriad.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2368311 - Disclosure - Leases (Tables)",
     "role": "http://www.myriad.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372312 - Disclosure - Employee Deferred Savings Plan (Tables)",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables",
     "shortName": "Employee Deferred Savings Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2376313 - Disclosure - Segment and Related Information (Tables)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationTables",
     "shortName": "Segment and Related Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2380314 - Disclosure - Divestitures (Tables)",
     "role": "http://www.myriad.com/role/DivestituresTables",
     "shortName": "Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2388315 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:ScheduleOfTransitionPeriodComparativeDataTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2391316 - Disclosure - Transition Period Comparative Data (Unaudited) (Tables)",
     "role": "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables",
     "shortName": "Transition Period Comparative Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:ScheduleOfTransitionPeriodComparativeDataTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i6f4ddb7736b546099130bd23f3e3bf81_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ic56cdf0c7bc84b148ed3d7868192c68b_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ia567c09cf0824dc693153bb83c1fd300_I20180630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails",
     "shortName": "Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414409 - Disclosure - Marketable Investment Securities - Narrative (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails",
     "shortName": "Marketable Investment Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i247f388a3aa24cea9da562bc5232fa78_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i247f388a3aa24cea9da562bc5232fa78_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ic56cdf0c7bc84b148ed3d7868192c68b_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ia567c09cf0824dc693153bb83c1fd300_I20180630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
     "shortName": "Property, Plant and Equipment, Net - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i76caa3c0609e438280d6a0504611599f_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails",
     "shortName": "Property, Plant and Equipment, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i76caa3c0609e438280d6a0504611599f_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails",
     "shortName": "Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430419 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431420 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Long Term Debt (Details)",
     "role": "http://www.myriad.com/role/LongTermDebtDetails",
     "shortName": "Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Other Long-Term Liabilities (Details)",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails",
     "shortName": "Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ia567c09cf0824dc693153bb83c1fd300_I20180630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ia567c09cf0824dc693153bb83c1fd300_I20180630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ic56cdf0c7bc84b148ed3d7868192c68b_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Preferred and Common Stockholders' Equity - Stock Repurchases (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Stock Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:AmountOfReductionInCommonStockAsResultOfStockRepurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icb206a81fa074a46aa6939c9e5bcf636_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Stock-Based Compensation - Stock Options Outstanding (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails",
     "shortName": "Stock-Based Compensation - Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i5d1a0cda0cb44520b0d8ce2dce6d2a87_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ibfe871ca297a43cf85bd10871a289a70_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "id40d4e8c980d4d749c48652760c59dcb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452432 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
     "shortName": "Stock-Based Compensation - Aggregate Intrinsic Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453433 - Disclosure - Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails",
     "shortName": "Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454434 - Disclosure - Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
     "shortName": "Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455435 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i71048f68c5b9410c9e6834cf6b57e822_D20200701-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Income Taxes - Income Tax Benefit (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459437 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Income (Loss) Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460438 - Disclosure - Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails",
     "shortName": "Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462440 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i83383bd4b0654a95842e069decbe0d94_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463441 - Disclosure - Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
     "shortName": "Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i83383bd4b0654a95842e069decbe0d94_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ic56cdf0c7bc84b148ed3d7868192c68b_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464442 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466443 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i26a7872b3c3e43d1a1a6e18f0a9a61eb_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469444 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.myriad.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470445 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473446 - Disclosure - Employee Deferred Savings Plan - Narrative (Details)",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails",
     "shortName": "Employee Deferred Savings Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474447 - Disclosure - Employee Deferred Savings Plan - Contributions to Plan (Details)",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails",
     "shortName": "Employee Deferred Savings Plan - Contributions to Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477448 - Disclosure - Segment and Related Information - Narrative (Details)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails",
     "shortName": "Segment and Related Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478449 - Disclosure - Segment and Related Information - Assets by Geographical Region (Details)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails",
     "shortName": "Segment and Related Information - Assets by Geographical Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "iaceaf21b23b24746aa59d14b069c4f07_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481450 - Disclosure - Divestitures - Narrative (Details)",
     "role": "http://www.myriad.com/role/DivestituresNarrativeDetails",
     "shortName": "Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i3f192cf143b34d569db042b3b74c016a_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482451 - Disclosure - Divestitures - Other Income (Details)",
     "role": "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
     "shortName": "Divestitures - Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i66593c8b720745e19a266ce09a6e2f64_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icd8184e7f9d64fdfa830a7580e392ea8_D20180731-20180731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484452 - Disclosure - Business Acquisitions - Narrative (Details)",
     "role": "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails",
     "shortName": "Business Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "icd8184e7f9d64fdfa830a7580e392ea8_D20180731-20180731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ia83408ec29ac462bb67762046411429e_D20220101-20220224",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mygn:LesseeOperatingLeaseAreaOfLeasedSpace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486453 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.myriad.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "ia83408ec29ac462bb67762046411429e_D20220101-20220224",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mygn:LesseeOperatingLeaseAreaOfLeasedSpace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2489454 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20211231.htm",
      "contextRef": "i1f8cdefcef8e4cc68a637494d53f59cb_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "verboseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mygn_AbelliAndPricoloMatterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abelli And Pricolo Matter",
        "label": "Abelli And Pricolo Matter [Member]",
        "terseLabel": "Abelli and Pricolo"
       }
      }
     },
     "localname": "AbelliAndPricoloMatterMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_AmendmentToCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to Credit Agreement [Member].",
        "label": "Amendment To Credit Agreement [Member]",
        "terseLabel": "Amended facility"
       }
      }
     },
     "localname": "AmendmentToCreditAgreementMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_AmountChargedToRetainedEarningsAsResultOfStockRepurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to retained earnings as a result of stock repurchases.",
        "label": "Amount Charged To Retained Earnings As Result Of Stock Repurchases",
        "terseLabel": "Charges to retained earnings"
       }
      }
     },
     "localname": "AmountChargedToRetainedEarningsAsResultOfStockRepurchases",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_AmountOfReductionInCommonStockAsResultOfStockRepurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction in common stock as a result of stock repurchases.",
        "label": "Amount Of Reduction In Common Stock As Result Of Stock Repurchases",
        "terseLabel": "Common stock and additional paid-in-capital reductions"
       }
      }
     },
     "localname": "AmountOfReductionInCommonStockAsResultOfStockRepurchases",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_AssetsLessCashCashEquivalentsAndInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Less Cash, Cash Equivalents, And Investments",
        "label": "Assets, Less Cash, Cash Equivalents, And Investments",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsLessCashCashEquivalentsAndInvestments",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.myriad.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "terseLabel": "Measurement period for earn out liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mygn_CARESActOf2020MedicarePaymentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act of 2020 medicare payment amount.",
        "label": "CARES Act Of 2020 Medicare Payment Amount",
        "terseLabel": "Advance Medicare payments to provide relief from economic impacts of COVID-19"
       }
      }
     },
     "localname": "CARESActOf2020MedicarePaymentAmount",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CARESActOf2020ProviderReliefFundAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act of 2020 Provider Relief Fund amount.",
        "label": "C A R E S Act Of2020 Provider Relief Fund Amount",
        "terseLabel": "Provider fund relief under CARES Act"
       }
      }
     },
     "localname": "CARESActOf2020ProviderReliefFundAmount",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ClinicReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinic Reporting Unit",
        "label": "Clinic Reporting Unit [Member]",
        "terseLabel": "Clinic reporting unit"
       }
      }
     },
     "localname": "ClinicReportingUnitMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained",
        "label": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained",
        "terseLabel": "Revenue recognized due to expanded local coverage determination for which revenue was previously constrained"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityDivestitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Divestitures",
        "label": "Contract With Customer, Liability, Divestitures",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDivestitures",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "label": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityPrepayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability, prepayments.",
        "label": "Contract With Customer Liability Prepayments",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPrepayments",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CostOfMolecularDiagnosticTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.",
        "label": "Cost Of Molecular Diagnostic Testing [Member]",
        "terseLabel": "Cost of molecular diagnostic testing"
       }
      }
     },
     "localname": "CostOfMolecularDiagnosticTestingMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_CostOfPharmaceuticalAndClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.",
        "label": "Cost Of Pharmaceutical And Clinical Services [Member]",
        "terseLabel": "Cost of pharmaceutical and clinical services"
       }
      }
     },
     "localname": "CostOfPharmaceuticalAndClinicalServicesMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_CounsylIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Counsyl Inc.",
        "label": "Counsyl Inc [Member]",
        "terseLabel": "Counsyl Inc"
       }
      }
     },
     "localname": "CounsylIncMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_CrescendoBioscienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crescendo Bioscience, Inc",
        "label": "Crescendo Bioscience, Inc [Member]",
        "terseLabel": "CBI"
       }
      }
     },
     "localname": "CrescendoBioscienceIncMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_DebtCovenantLiquidityCovenantMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Liquidity Covenant Minimum",
        "label": "Debt Covenant, Liquidity Covenant Minimum",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtCovenantLiquidityCovenantMinimum",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "label": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "terseLabel": "Minimum unrestricted cash and cash equivalents threshold per covenant"
       }
      }
     },
     "localname": "DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtInstrumentLIBORFloorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, LIBOR Floor, Percentage",
        "label": "Debt Instrument, LIBOR Floor, Percentage",
        "terseLabel": "LIBOR floor (percent)"
       }
      }
     },
     "localname": "DebtInstrumentLIBORFloorPercentage",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_DeferredTaxAssetsLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease right-of-use asset.",
        "label": "Deferred Tax Assets Lease Right Of Use Asset",
        "terseLabel": "Lease right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseRightOfUseAsset",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DeferredTaxLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax lease liability.",
        "label": "Deferred Tax Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxLeaseLiability",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupCapitalGainOnDivestiture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Capital Gain On Divestiture",
        "label": "Disposal Group, Capital Gain On Divestiture",
        "terseLabel": "Overall capital gain on divestitures"
       }
      }
     },
     "localname": "DisposalGroupCapitalGainOnDivestiture",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupCapitalLossOnTaxBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Capital Loss On Tax Basis",
        "label": "Disposal Group, Capital Loss On Tax Basis",
        "terseLabel": "Capital loss for the tax basis on stock"
       }
      }
     },
     "localname": "DisposalGroupCapitalLossOnTaxBasis",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accumulated amortization of intangible assets attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Noncurrent",
        "negatedTerseLabel": "Accumulated amortization on intangible assets included in sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, net of accumulated amortization, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Net, Noncurrent",
        "terseLabel": "Net decrease in intangible assets due to sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNetTaxExpenseBenefitOnDivestiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Net Tax Expense (Benefit) On Divestiture",
        "label": "Disposal Group, Net Tax Expense (Benefit) On Divestiture",
        "negatedTerseLabel": "Overall net tax benefit of divestitures"
       }
      }
     },
     "localname": "DisposalGroupNetTaxExpenseBenefitOnDivestiture",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory",
        "terseLabel": "Loss on inventory"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnInventory",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationGainLossOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) Other",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOther",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Transaction Costs",
        "label": "Disposal Group, Not Discontinued Operation, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationTransactionCosts",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "label": "Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "terseLabel": "Acquisitions, Dispositions, and Contingent Consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation asset impairment.",
        "label": "Effective Income Tax Rate Reconciliation Asset Impairment",
        "terseLabel": "Asset impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAssetImpairment",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationCARESAct": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation CARES Act",
        "label": "Effective Income Tax Rate Reconciliation CARES Act",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCARESAct",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, changes in revenue recognition/method.",
        "label": "Effective Income Tax Rate Reconciliation Changes In Revenue Recognition Method",
        "terseLabel": "Method changes or tax elections"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangesInRevenueRecognitionMethod",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation non deductible legal settlements.",
        "label": "Effective Income Tax Rate Reconciliation Non Deductible Legal Settlements",
        "terseLabel": "Non-deductible legal settlement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation non-deductible officer compensation.",
        "label": "Effective Income Tax Rate Reconciliation Non Deductible Officer Compensation",
        "terseLabel": "Non-deductible officer compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EmployeeStockPurchasePlanTwentyTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "label": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "terseLabel": "2012 Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanTwentyTwelveMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ExecutiveOfficersAndSeniorPositionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officers And Senior Positions",
        "label": "Executive Officers And Senior Positions [Member]",
        "terseLabel": "Certain executive officers and other senior positions"
       }
      }
     },
     "localname": "ExecutiveOfficersAndSeniorPositionsMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees",
        "label": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees",
        "terseLabel": "Net gain on sale of assets adjusted for transaction fees"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsNetOfTransactionFees",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_GoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Line Items]",
        "terseLabel": "Goodwill And Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_GoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Table]",
        "terseLabel": "Goodwill And Intangible Assets [Table]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsTable",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process research and development with indefinite lives.",
        "label": "In Process Research And Development With Indefinite Lives [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentWithIndefiniteLivesMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), Operating Loss Carryback, CARES Act",
        "label": "Income Tax Expense (Benefit), Operating Loss Carryback, CARES Act",
        "terseLabel": "Tax expense (benefit) related to operating loss carryback, CARES Act"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitOperatingLossCarrybackCARESAct",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "label": "Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "terseLabel": "Acquisitions, Dispositions, and Contingent Consideration"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation asset impairment.",
        "label": "Income Tax Reconciliation Asset Impairment",
        "terseLabel": "Asset impairment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAssetImpairment",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationCARESAct": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation CARES Act",
        "label": "Income Tax Reconciliation CARES Act",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "IncomeTaxReconciliationCARESAct",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationChangesInRevenueRecognitionMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation changes in revenue recognition method.",
        "label": "Income Tax Reconciliation Changes In Revenue Recognition Method",
        "terseLabel": "Method changes or tax elections"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangesInRevenueRecognitionMethod",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation non-deductible legal settlement.",
        "label": "Income Tax Reconciliation Non Deductible Legal Settlement",
        "terseLabel": "Non-deductible legal settlement"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNonDeductibleLegalSettlement",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense officers compensation.",
        "label": "Income Tax Reconciliation Nondeductible Expense Officers Compensation",
        "terseLabel": "Non-deductible officer compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncreaseDecreaseInEarningsLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in earnings (loss) per share.",
        "label": "Increase Decrease In Earnings Loss Per Share",
        "terseLabel": "Change in earnings (loss) per share (dollars per share)"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsLossPerShare",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mygn_IncreaseDecreaseInUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in unrecognized tax benefits.",
        "label": "Increase Decrease In Unrecognized Tax Benefits",
        "negatedLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInUnrecognizedTaxBenefits",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets.",
        "label": "Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsLineItems",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Total, Gross unrealized holding gains"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Total, Gross unrealized holding gains"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Total, Amortized cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement",
        "label": "Lease Arrangement [Axis]",
        "terseLabel": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement [Domain]",
        "label": "Lease Arrangement [Domain]",
        "terseLabel": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_LeaseRelatedExpendituresIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Related Expenditures Incurred But Not Yet Paid",
        "label": "Lease Related Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Accrued liabilities and other long-term liabilities"
       }
      }
     },
     "localname": "LeaseRelatedExpendituresIncurredButNotYetPaid",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_LesseeOperatingLeaseAreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Leased Space",
        "label": "Lessee, Operating Lease, Area Of Leased Space",
        "terseLabel": "Operating lease area (sq ft)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfLeasedSpace",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "mygn_LesseeOperatingLeaseEstimatedFutureLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Estimated Future Lease Payments",
        "label": "Lessee, Operating Lease, Estimated Future Lease Payments",
        "terseLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEstimatedFutureLeasePayments",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticAutoimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Autoimmune",
        "label": "Molecular Diagnostic Autoimmune [Member]",
        "terseLabel": "Molecular diagnostic - Autoimmune"
       }
      }
     },
     "localname": "MolecularDiagnosticAutoimmuneMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticHereditaryCancerTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic hereditary cancer testing.",
        "label": "Molecular Diagnostic Hereditary Cancer Testing [Member]",
        "terseLabel": "Molecular diagnostic - Hereditary Cancer"
       }
      }
     },
     "localname": "MolecularDiagnosticHereditaryCancerTestingMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticOtherTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic other testing.",
        "label": "Molecular Diagnostic Other Testing [Member]",
        "terseLabel": "Molecular diagnostic - Other"
       }
      }
     },
     "localname": "MolecularDiagnosticOtherTestingMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticPharmacogenomicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Pharmacogenomics",
        "label": "Molecular Diagnostic Pharmacogenomics [Member]",
        "terseLabel": "Molecular diagnostic - Pharmacogenomics"
       }
      }
     },
     "localname": "MolecularDiagnosticPharmacogenomicsMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticPrenatalTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic Prenatal testing.",
        "label": "Molecular Diagnostic Prenatal Testing [Member]",
        "terseLabel": "Molecular diagnostic - Prenatal"
       }
      }
     },
     "localname": "MolecularDiagnosticPrenatalTestingMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic testing.",
        "label": "Molecular Diagnostic Testing [Member]",
        "terseLabel": "Molecular diagnostic revenues"
       }
      }
     },
     "localname": "MolecularDiagnosticTestingMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticTumorProfilingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Tumor Profiling",
        "label": "Molecular Diagnostic Tumor Profiling [Member]",
        "terseLabel": "Molecular diagnostic - Tumor Profiling"
       }
      }
     },
     "localname": "MolecularDiagnosticTumorProfilingMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadAutoimmuneAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad Autoimmune Assets",
        "label": "Myriad Autoimmune Assets [Member]",
        "terseLabel": "Select operating assets and intellectual property of Myriad Autoimmune business unit",
        "verboseLabel": "Myriad Autoimmune assets"
       }
      }
     },
     "localname": "MyriadAutoimmuneAssetsMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadAutoimmuneReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad Autoimmune Reporting Unit",
        "label": "Myriad Autoimmune Reporting Unit [Member]",
        "terseLabel": "Myriad Autoimmune reporting unit"
       }
      }
     },
     "localname": "MyriadAutoimmuneReportingUnitMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadMyPathLLCLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad My Path LLC Laboratory",
        "label": "Myriad My Path LLC Laboratory [Member]",
        "terseLabel": "Myriad myPath LLC laboratory"
       }
      }
     },
     "localname": "MyriadMyPathLLCLaboratoryMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad RBM, Inc. And Myriad Autoimmune Business",
        "label": "Myriad RBM, Inc. And Myriad Autoimmune Business [Member]",
        "terseLabel": "Myriad RBM, Inc. and Myriad Autoimmune business"
       }
      }
     },
     "localname": "MyriadRBMIncAndMyriadAutoimmuneBusinessMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadRBMIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad RBM, Inc",
        "label": "Myriad RBM, Inc [Member]",
        "terseLabel": "Myriad RBM, Inc."
       }
      }
     },
     "localname": "MyriadRBMIncMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee director.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non-employee director"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_NumberOfDivestitures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Divestitures",
        "label": "Number Of Divestitures",
        "terseLabel": "Number of divestitures"
       }
      }
     },
     "localname": "NumberOfDivestitures",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mygn_OperatingLeaseLiabilityEstablished": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Established",
        "label": "Operating Lease Liability Established",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityEstablished",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Including Leases Not Yet Commenced",
        "label": "Operating Lease, Liability, Including Leases Not Yet Commenced",
        "terseLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityIncludingLeasesNotYetCommenced",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OperatingLeaseLiabilityLeasesNotYetCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Leases Not Yet Commenced",
        "label": "Operating Lease, Liability, Leases Not Yet Commenced",
        "negatedTerseLabel": "Less: leases not yet commenced"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityLeasesNotYetCommenced",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OperatingLeaseSouthSanFranciscoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, South San Francisco California",
        "label": "Operating Lease, South San Francisco California [Member]",
        "terseLabel": "South San Francisco, California"
       }
      }
     },
     "localname": "OperatingLeaseSouthSanFranciscoCaliforniaMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration Year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss, expiration in year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mygn_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and Restricted Stock Units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_OtherIncomeExpensePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income policy text block.",
        "label": "Other Income (Expense) Policy [Policy Text Block]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "OtherIncomeExpensePolicyPolicyTextBlock",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_OtherStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other State.",
        "label": "Other State [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherStateMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PerformanceObligationEstimatedTransactionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Obligation Estimated Transaction Price",
        "label": "Performance Obligation Estimated Transaction Price [Member]",
        "terseLabel": "Performance obligation estimate"
       }
      }
     },
     "localname": "PerformanceObligationEstimatedTransactionPriceMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PharmaceuticalAndClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical and clinical services.",
        "label": "Pharmaceutical And Clinical Services [Member]",
        "terseLabel": "Pharmaceutical and clinical services"
       }
      }
     },
     "localname": "PharmaceuticalAndClinicalServicesMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PurchasedLicensesAndTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased licenses and technologies.",
        "label": "Purchased Licenses And Technologies [Member]",
        "terseLabel": "Purchased licenses and technologies"
       }
      }
     },
     "localname": "PurchasedLicensesAndTechnologiesMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range One [Member]",
        "label": "Range One [Member]",
        "terseLabel": "$ 13.38"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Three",
        "label": "Range Three [Member]",
        "terseLabel": "$ 27.07 - 36.55"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Two [Member]",
        "label": "Range Two [Member]",
        "terseLabel": "$ 23.98"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary",
        "label": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary",
        "terseLabel": "Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_RefundsPayableAndReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refunds Payable And Reserve, Current",
        "label": "Refunds Payable And Reserve, Current",
        "terseLabel": "Refunds payable and reserves"
       }
      }
     },
     "localname": "RefundsPayableAndReserveCurrent",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_SaltLakeCityLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salt Lake City Lease",
        "label": "Salt Lake City Lease [Member]",
        "terseLabel": "Salt Lake City"
       }
      }
     },
     "localname": "SaltLakeCityLeaseMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ScheduleOfCommonStockRepurchasedTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock repurchased table.",
        "label": "Schedule Of Common Stock Repurchased Table [Table Text Block]",
        "terseLabel": "Schedule of Stock Repurchases"
       }
      }
     },
     "localname": "ScheduleOfCommonStockRepurchasedTableTableTextBlock",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_ScheduleOfIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Assets [Table]",
        "label": "Schedule Of Intangible Assets [Table]",
        "terseLabel": "Schedule Of Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTable",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value",
        "label": "Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_ScheduleOfTransitionPeriodComparativeDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Transition Period Comparative Data",
        "label": "Schedule Of Transition Period Comparative Data [Table Text Block]",
        "terseLabel": "Schedule of Transition Period Comparative Data"
       }
      }
     },
     "localname": "ScheduleOfTransitionPeriodComparativeDataTableTextBlock",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued upon exercise of options and employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mygn_TaxCreditCarryforwardsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforwards Expiration Date",
        "label": "Tax Credit Carryforwards Expiration Date",
        "terseLabel": "Tax credit, expiration in year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationDate",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mygn_TransitionPeriodComparativeDataTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Period Comparative Data",
        "label": "Transition Period Comparative Data [Text Block]",
        "terseLabel": "Transition Period Comparative Data (Unaudited)"
       }
      }
     },
     "localname": "TransitionPeriodComparativeDataTextBlock",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_TransitionPeriodFinancialInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Period Financial Information",
        "label": "Transition Period Financial Information [Line Items]",
        "terseLabel": "Transition Period Financial Information [Line Items]"
       }
      }
     },
     "localname": "TransitionPeriodFinancialInformationLineItems",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_TransitionPeriodFinancialInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Period Financial Information",
        "label": "Transition Period Financial Information [Table]",
        "terseLabel": "Transition Period Financial Information [Table]"
       }
      }
     },
     "localname": "TransitionPeriodFinancialInformationTable",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen employee director and consultant equity incentive plan.",
        "label": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_UnrecognizedTaxBenefitsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net",
        "label": "Unrecognized Tax Benefits, Net",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNet",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Increase (Decrease) During Period",
        "label": "Valuation Allowance, Increase (Decrease) During Period",
        "negatedTerseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceIncreaseDecreaseDuringPeriod",
     "nsuri": "http://www.myriad.com/20211231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "President and Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r141",
      "r192",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r210",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r141",
      "r192",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r210",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r218",
      "r399",
      "r403",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r334",
      "r367",
      "r422",
      "r425",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r681",
      "r685",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/LongTermDebtDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r334",
      "r367",
      "r422",
      "r425",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r681",
      "r685",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/LongTermDebtDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r218",
      "r399",
      "r403",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r212",
      "r399",
      "r401",
      "r631",
      "r680",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r212",
      "r399",
      "r401",
      "r631",
      "r680",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r334",
      "r367",
      "r411",
      "r422",
      "r425",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r681",
      "r685",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/LongTermDebtDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r334",
      "r367",
      "r411",
      "r422",
      "r425",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r681",
      "r685",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/LongTermDebtDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableGeographicalComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]",
        "terseLabel": "Reportable geographical components"
       }
      }
     },
     "localname": "ReportableGeographicalComponentsMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r170",
      "r251",
      "r252",
      "r468",
      "r510",
      "r553",
      "r554",
      "r555",
      "r556",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r170",
      "r251",
      "r252",
      "r468",
      "r510",
      "r553",
      "r554",
      "r555",
      "r556",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "Immaterial prior period Medicare claims"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r152",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r152",
      "r158",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r399",
      "r402",
      "r683",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r399",
      "r402",
      "r683",
      "r714",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r152",
      "r158",
      "r306",
      "r423",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r220",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_UT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH",
        "terseLabel": "Utah"
       }
      }
     },
     "localname": "UT",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r56",
      "r613"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r20",
      "r41",
      "r221",
      "r222"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r26",
      "r27",
      "r62"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54",
      "r293"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r74",
      "r78",
      "r79",
      "r80",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r78",
      "r79",
      "r80",
      "r668",
      "r691",
      "r695"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r77",
      "r80",
      "r88",
      "r89",
      "r90",
      "r143",
      "r144",
      "r145",
      "r546",
      "r686",
      "r687",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r465",
      "r466",
      "r467",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r427",
      "r429",
      "r471",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r123",
      "r274",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive options and RSUs excluded from EPS computation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r135",
      "r196",
      "r201",
      "r208",
      "r249",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r540",
      "r547",
      "r574",
      "r611",
      "r613",
      "r637",
      "r665"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r23",
      "r25",
      "r73",
      "r135",
      "r249",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r540",
      "r547",
      "r574",
      "r611",
      "r613"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale, Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale, Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r233",
      "r253"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r237",
      "r241",
      "r657"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r237",
      "r240",
      "r656"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r237",
      "r239",
      "r655"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r230",
      "r234",
      "r253",
      "r644"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale, Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r431",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Financial Statement Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r421",
      "r424",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total revenue reported by the acquired entity for its previous full fiscal year before the business acquisition.",
        "label": "Business Acquisition, Revenue Reported by Acquired Entity for Last Annual Period",
        "terseLabel": "Revenue contributed by acquired entity"
       }
      }
     },
     "localname": "BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r528",
      "r529",
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business acquisition consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r527",
      "r530"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Short-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r527",
      "r530"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital loss"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r732",
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Amortization expense for capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r731"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Unamortized software costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Capitalized costs incurred to obtain or fulfill contract"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r18",
      "r50",
      "r125"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Estimated fair value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable investment securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r118",
      "r125",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r118",
      "r579"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Establishment of operating lease right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r152",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r152",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Reconciliation of Deferred Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r68",
      "r305",
      "r645",
      "r673"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r313",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending common stock issued",
        "periodStartLabel": "Beginning common stock issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending common stock outstanding",
        "periodStartLabel": "Beginning common stock outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r613"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 80.0 and 75.4 shares outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r409",
      "r410",
      "r426",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Deferred Savings Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r83",
      "r85",
      "r86",
      "r94",
      "r648",
      "r676"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r218",
      "r572",
      "r573",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r218",
      "r572",
      "r573",
      "r697",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r218",
      "r572",
      "r573",
      "r697",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r177",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r181",
      "r182",
      "r218",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r218",
      "r572",
      "r573",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Reconciliation of Deferred Revenue Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r386",
      "r387",
      "r400"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Deferred revenue - ending balance",
        "periodStartLabel": "Deferred revenue - beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r412",
      "r419",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds and notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r97",
      "r631"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs and expenses"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeTranslationAdjustmentSummaryRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Cumulative Translation Adjustment Summary [Roll Forward]",
        "terseLabel": "Cumulative Translation Adjustments"
       }
      }
     },
     "localname": "CumulativeTranslationAdjustmentSummaryRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r505",
      "r513"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r505"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r505",
      "r513",
      "r515"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r505",
      "r513"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r348",
      "r355",
      "r356",
      "r358",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r134",
      "r141",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r593",
      "r638",
      "r641",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r65",
      "r334",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r66",
      "r134",
      "r141",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r66",
      "r134",
      "r141",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r360",
      "r361",
      "r362",
      "r363",
      "r380",
      "r381",
      "r382",
      "r383",
      "r590",
      "r591",
      "r593",
      "r594",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r243",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Debt securities, available-for-sale, in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r506",
      "r513"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r506",
      "r513"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r136",
      "r506",
      "r513",
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r37",
      "r38",
      "r495",
      "r639",
      "r663"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Long-term deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r506",
      "r513"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r480",
      "r498"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Contributions to the Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Deferred savings plan contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company matching contribution as percentage of employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Company matching contribution, maximum as percentage of employee compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r123",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r123",
      "r291"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r290",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r289",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets included in sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r123",
      "r290",
      "r295"
     ],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Gain (loss) on sale of subsidiary"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r17",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest tax year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r95",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r160",
      "r162",
      "r164",
      "r165",
      "r166",
      "r170",
      "r171",
      "r555",
      "r556",
      "r649",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r95",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r162",
      "r164",
      "r165",
      "r166",
      "r170",
      "r171",
      "r555",
      "r556",
      "r649",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r138",
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax expense at the statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent",
        "terseLabel": "Non-deductible meals and entertainment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r473",
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Incentive stock option and employee stock purchase plan expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r473",
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Incentive stock option and employee stock purchase plan expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r482",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Compensation Expense [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period for recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r157",
      "r174",
      "r250",
      "r379",
      "r384",
      "r465",
      "r466",
      "r467",
      "r509",
      "r510",
      "r554",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r686",
      "r687",
      "r688",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r557",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r346",
      "r360",
      "r361",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r558",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r346",
      "r412",
      "r413",
      "r418",
      "r419",
      "r558",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r346",
      "r360",
      "r361",
      "r412",
      "r413",
      "r418",
      "r419",
      "r558",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r346",
      "r360",
      "r361",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r558",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Reconciliation of change in fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r562",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value recognized in the statement of operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Translation adjustments recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r346",
      "r360",
      "r361",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated remaining useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Recorded Amortization for Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r275",
      "r277",
      "r281",
      "r285",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r281",
      "r633"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r281",
      "r632"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total, net, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted average remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Non-cash impact of foreign currency transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r123",
      "r290",
      "r295"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Gain on sale of businesses and assets",
        "terseLabel": "Net gain on divestiture"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r263",
      "r265",
      "r613",
      "r636"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Carrying amount at end of period",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and long-lived asset impairment charges",
        "verboseLabel": "Impairment of goodwill and long-lived assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r123",
      "r264",
      "r267",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "verboseLabel": "Goodwill impairment charge"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedLabel": "Divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.",
        "label": "Government Contracts Concentration Risk [Member]",
        "terseLabel": "Government contracts concentration risk"
       }
      }
     },
     "localname": "GovernmentContractsConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r123",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r137",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r196",
      "r200",
      "r204",
      "r207",
      "r210",
      "r634",
      "r646",
      "r651",
      "r678"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r137",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (loss) before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Disposal of Subsidiary [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r14",
      "r15",
      "r16",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r296",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r486",
      "r492",
      "r494",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r483",
      "r493",
      "r500",
      "r511",
      "r518",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in YYYY format.",
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Tax year being audited in income tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r139",
      "r156",
      "r157",
      "r195",
      "r481",
      "r512",
      "r519",
      "r679"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Total income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails",
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r477",
      "r478",
      "r493",
      "r494",
      "r499",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income tax expense at the statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "terseLabel": "Non-deductible meals and entertainment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r120",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r122",
      "r628"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "negatedLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Common shares issued and outstanding"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r276",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Non-amortizable"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r276",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount, total"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r273",
      "r279"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Net, total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r91",
      "r194",
      "r589",
      "r592",
      "r650"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r115",
      "r119",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory.",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "terseLabel": "Loss on non-cancelable purchase commitment"
       }
      }
     },
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r19",
      "r71",
      "r613"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r72",
      "r130",
      "r173",
      "r255",
      "r257",
      "r259",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Loss on inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r99",
      "r193"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Total, Estimated fair value",
        "totalLabel": "Total, Estimated fair value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash [Abstract]",
        "terseLabel": "Total:"
       }
      }
     },
     "localname": "InvestmentsAndCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r248",
      "r635",
      "r659",
      "r713",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Investment Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest tax years"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r606",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r60",
      "r135",
      "r202",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r541",
      "r547",
      "r548",
      "r574",
      "r611",
      "r612"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r135",
      "r249",
      "r574",
      "r613",
      "r643",
      "r671"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r64",
      "r135",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r541",
      "r547",
      "r548",
      "r574",
      "r611",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "negatedTerseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum aggregate principal commitment"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Undrawn fee (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r68",
      "r305",
      "r312"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Legal charges pending settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement agreement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Legal charges pending settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Assets by Geographical Region"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r35",
      "r345",
      "r359",
      "r360",
      "r361",
      "r641",
      "r667"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r21",
      "r61"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Investment Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement input, expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r70",
      "r135",
      "r249",
      "r316",
      "r321",
      "r322",
      "r323",
      "r329",
      "r330",
      "r574",
      "r642",
      "r670"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r121",
      "r124"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r16",
      "r81",
      "r84",
      "r90",
      "r93",
      "r124",
      "r135",
      "r146",
      "r148",
      "r149",
      "r151",
      "r152",
      "r156",
      "r157",
      "r163",
      "r196",
      "r200",
      "r204",
      "r207",
      "r210",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r556",
      "r574",
      "r647",
      "r675"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to Myriad Genetics, Inc. stockholders",
        "totalLabel": "Net income (loss) attributable to Myriad Genetics, Inc. stockholders",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r84",
      "r90",
      "r156",
      "r157",
      "r543",
      "r550"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses related to acquired entity"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r196",
      "r200",
      "r204",
      "r207",
      "r210"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current maturities of operating lease liabilities",
        "terseLabel": "Current maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r605",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r604",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense (prior to adoption of ASU 2016-02)"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Net operating loss subject to sections 382,383"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r142",
      "r159",
      "r186",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r62"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "verboseLabel": "Accrued liability for Medicare refund"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustment, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r82",
      "r85",
      "r538",
      "r539",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r76",
      "r78"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Change in pension liability"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other",
        "totalLabel": "Total Other Income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36",
      "r640",
      "r666"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of contingent consideration recognized at acquisition"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase and retirement of common stock",
        "terseLabel": "Repurchase of Company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtRestructuringCosts": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.",
        "label": "Payments of Debt Restructuring Costs",
        "negatedLabel": "Fees associated with refinancing of revolving credit facility"
       }
      }
     },
     "localname": "PaymentsOfDebtRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payment of tax withheld for common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r102",
      "r106",
      "r231"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r108",
      "r532",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r431",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r23",
      "r48",
      "r49"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r22",
      "r24",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).",
        "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries",
        "verboseLabel": "Proceeds from sale of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r121",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash received for income tax receivables"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r109",
      "r464"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r110",
      "r134"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from sale of business and assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r16",
      "r81",
      "r84",
      "r90",
      "r117",
      "r135",
      "r146",
      "r156",
      "r157",
      "r196",
      "r200",
      "r204",
      "r207",
      "r210",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r538",
      "r542",
      "r544",
      "r550",
      "r551",
      "r556",
      "r574",
      "r651"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r54",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r300",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Property, plant and equipment sold and deconsolidated"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r53",
      "r292"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r31",
      "r32",
      "r294",
      "r613",
      "r660",
      "r672"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Net equipment, leasehold improvements and property"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r294",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r31",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r31",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r112",
      "r134"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of revolving credit facility",
        "terseLabel": "Principal repayment"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r475",
      "r630",
      "r733"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research credit"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r384",
      "r468",
      "r613",
      "r669",
      "r690",
      "r695"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r157",
      "r250",
      "r465",
      "r466",
      "r467",
      "r509",
      "r510",
      "r554",
      "r686",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r199",
      "r205",
      "r206",
      "r212",
      "r213",
      "r218",
      "r398",
      "r399",
      "r631"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographical Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r603",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r181",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r80",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Common Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r238",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Common Shares Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r14",
      "r15",
      "r16",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Income"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r429",
      "r461",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r429",
      "r461",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r269",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Non-amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r54",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r203",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.",
        "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]",
        "terseLabel": "Schedule of Intrinsic Value of Options Exercised"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r431",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Shares Purchased and Compensation Expenses for ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r437",
      "r448",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions for ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r492",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r196",
      "r198",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Related Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Service period for award vesting (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs canceled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "RSUs canceled (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "RSUs granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted (dollars per share)",
        "verboseLabel": "Weighted average grant date fair value (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs unvested and outstanding, ending (shares)",
        "periodStartLabel": "RSUs unvested and outstanding, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSUs, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs unvested and outstanding, ending (dollars per share)",
        "periodStartLabel": "RSUs unvested and outstanding, beginning (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "RSUs, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock units that vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "RSUs vested (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation Assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per participant per offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Options, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled or expired (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r439",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending (shares)",
        "periodStartLabel": "Options outstanding, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending (dollars per share)",
        "periodStartLabel": "Options outstanding, beginning (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Options, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Summary of Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r428",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award",
        "terseLabel": "Shares purchased under the plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r428",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Achievement levels based on EPS targets"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Performance based on Nasdaq Healthcare Provider Index"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r431",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Payment Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of exercise prices, minimum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of exercise prices, maximum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting weight (percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount",
        "terseLabel": "Plan compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value of RSUs outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r456",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options fully vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest, Weighted average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (years)",
        "verboseLabel": "Options outstanding, Weighted average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails",
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r601",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "verboseLabel": "State and local jurisdictions"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r69",
      "r88",
      "r89",
      "r90",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r157",
      "r174",
      "r250",
      "r379",
      "r384",
      "r465",
      "r466",
      "r467",
      "r509",
      "r510",
      "r554",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r686",
      "r687",
      "r688",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r174",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r379",
      "r384",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r384",
      "r430",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining repurchase authorization"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r379",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Repurchase and retirement of common stock",
        "terseLabel": "Shares purchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityStockRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r39",
      "r40",
      "r379",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchase and retirement of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r135",
      "r228",
      "r249",
      "r574",
      "r613"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Myriad Genetics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r89",
      "r135",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r249",
      "r250",
      "r384",
      "r465",
      "r466",
      "r467",
      "r509",
      "r510",
      "r536",
      "r537",
      "r549",
      "r554",
      "r574",
      "r580",
      "r581",
      "r586",
      "r687",
      "r688",
      "r747"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Preferred and Common Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r587",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r587",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r587",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r587",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r614",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SwissFederalTaxAdministrationFTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Switzerland.",
        "label": "Swiss Federal Tax Administration (FTA) [Member]",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "SwissFederalTaxAdministrationFTAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credit subject to sections 382,383"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r78",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency.",
        "label": "Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)",
        "verboseLabel": "Period translation adjustments"
       }
      }
     },
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r140",
      "r412",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r412",
      "r652",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Federal agency issues"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r476",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits at end of year",
        "periodStartLabel": "Unrecognized tax benefits at the beginning of period",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Gross decreases - prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Gross decreases - settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties in year-end balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Gross increases - acquisitions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases - current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases - prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Gross decreases - statute lapse"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r179",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r602",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive stock options"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r161",
      "r166"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (weighted average shares)",
        "totalLabel": "Weighted-average shares outstanding and dilutive securities used to compute diluted EPS"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r160",
      "r166"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (weighted average shares)",
        "verboseLabel": "Weighted-average shares outstanding used to compute basic EPS"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails",
      "http://www.myriad.com/role/TransitionPeriodComparativeDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r735": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r736": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r737": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r738": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r739": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r740": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r741": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r742": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r743": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r744": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r745": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0000899923-22-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000899923-22-000033-xbrl.zip
M4$L#!!0    ( "V'653+0W$],68$ %U#+@ 1    ;7EG;BTR,#(Q,3(S,2YH
M=&WL?6U7&\>R[O?S*[@^Z]YS[EI;<;]4OWEG^RX,V)L< S;@>,.7K.KN:A 6
M$EL2&/SK;[4$MK&=!,? :(2<Q)$TH]%,/T]5/=4OU3__O_/CWM(9#4?=0?\?
MC^1/XM'2_WOZ\__J=/[U;/OETNH@G1Y3?[RT,B0<4UYZWQT?+KW--'JW5(:#
MXZ6W@^&[[AEV.I/OK Q.+H;=@\/QDA)*?7%P^ 1"$*B-[R2IJ ,^A$Y0&3IH
MDU4V&BM)_>W@":#E-UYU,)O0 4?808^J8X+P!E.R0:>_Y2>%,(>L?,IH("2)
MQ=F0938B!^.%JS][..:GXR?LCYYDZO[CT>%X?/+D\>/S..S]-*+TT\'@[#$?
M>,RW*_\-CRY/[77[[SZ>^_[]^Y\FYP^&!WR>T(_KX8@CNCK]=#S\W;/#8SYZ
M=6(]T/V#"W?[HS'VT\<+'U\<]*^=?LRMB_FG-#B>W+%46EZ=FP:G_?'PXMN/
M>'EP\J6K+W1' U#2_='M3,^X^L)H./YX<L%1G)S('TZNVA&R\^EF1N.3X;?O
MI!ZY=AOGH^LM\EY?W8!\_*^-ESOID(ZQ\V7+G'\%T>7W9 CA\>3HQ^<\'W?X
MUZ^=?'4WW3Z?297IC\=#[(_*8'B,8[8$_GUI.L)_]DRGH\X!XLG737!YX.MF
M^/W[J[3\G!3Y"VI>MH!]/#WXV:-\&ZX_>@XE.D)UI/ITD=^#7.K/+C0Y_4D/
M^P?_>$3]SIN=1VQ-;'%/?SZF,2[5*W3HWZ?=LW\\6AGTQ^PC.KL7)PQ0FK[[
MQZ,QG8\?3Y[T\=/_^(__^'G<'??H:>5TYXJ\/S^>?OCSX^FEXR!?//TY=\^6
M1N.+'OWC4>Z.3GIX\:0_Z!/?0/?\23V1AM.7W9RI/WG)QS?940V[:?K[Y^-M
M*O]XU-5%!I6*!!TU9,/^(0I044<'24B+OZW66Q'\3^>30?7QN/XT=9\LL^_+
MU?\][^'!HZ5NYDMF_>M%7!V<O53;9WMZXS0?K9WMOPA'6\?[O;VWK\W^ZCKL
MJ>W#S=W79N_#\\/]HZ2VWKX^WU]]\WY_]9W<6EW6+_5F;^_#R?'^V^?O^-C%
MUHO-=WN[;\36VXWSO;=[>O.H]V[C[6NY\>*UV=P]>+\IO7BI]B_VWB:[]_;Y
MT9YZ?;YW_)JO^_S=YHM?CC?5VON-MVOG_+W>UMOM[M[1+^\V=]^=Y1?/N_'%
M&[OQ8OUB[\-KO?GAS?N]XSVYN9H$?Z8WCC?X]9K9VMV3^ZO/CC967U]^YU?^
M+=/?WQV\YVL=\?EZ<_=9=__HC=C\\)H_2WR]-V)C]YW9//KUW<:+C?>;S_D>
M=]?&&SOB_.7NAMKX\,;\9H7P6?K2B8$<>WQO.SY%T]$I%^4AN.S$HZ<%>R/Z
M^?$U'.\2UJNH]KP[2MC;(QP^YT]&"X#_#&#Y%<#!2.NC=ATMM.R *1RKE4B=
M[+1U):-(SC]Z6D%H#-]7?/U!7B!\(X355P@+DYQ";3L)$B.L$K$)4^X0\8?&
M>-"!7?/SO7O$=ZW/8>-BA1$>8F^]G^G\?^AB@>V?8:N_PE9[+86VLI-%MAV(
M(7=06G;/))-"%Z(,\=%3P7]8JP>EOP=C8QBZ*(J1*3-',E\L,5M" 4M(Z8\P
MOE143UX-!R<T'%^\8ADR7N[G-=8;)]6PWXRHG/9>=@LUBSIL[H3C=/R\OW6\
MSI\]ZS%*W8W5-[#Y8;N[H=;,GGIC]G;7Q,;Q_A&S0&^^W3]\J;=[],_MB_VW
M^20JL'M'[_B:%:7U]WQ=O?EB_</>;N]H?[=WN+'[^F+_>$/O[2:Y?_R\;*UN
MF,V#WVQ*TAD=.DZRO(.D.)$2!!UR,KNDT9 KCYZ^,M]EE%87CLT^%Q0&%(GH
M,0N;'-MC"BCL K"_!!B;X?)OWDHI8W$=JW-A)\K9*0++\I(I)4HQ1L.&]DI^
M'V BB< JBG,* <XA6VAV11L=)64KU6_KOX?32QJ-B+88*\X2^@<OB;/9;<ZS
MNOVK=[LT/&X6JO.-HW2VW__E</_#X .?W]M0]7H;'S;4NMA<739;JVL7&[N_
M'NT?;Q[M'1T>\O?/-W:"V/_7H4C'O_;Q;3C=.MK@>WOS87_WV3O^YH>]H]=B
M8_4=;.RNGV^^W3S>4YO=K1=K?*]KY__ZL 8,%5C+B'C="6P0[!,=="*3OE,<
MN\8<B$.7^2.HG@\QU=1KZ;3?G0(UHH-J X]N(08R7;K'K);_\6A]\_F7J/*-
M1!INE6TZ&0S'&'NT,_UEUCU5"/&IHF%,-W?3^ZM(N:GVWK/)?=A8_96QV^QM
MOGBM]G8/>YNKZV+_Q6O&:$_L'6_W-C]L<-3[%?(_?^GMJ]Y9/!KH_:-E-CF.
M:AQ5&5^QO[I_N/6"3>UH^]W^Z@%'VNWN_HLW>J/^YM%KLW'$][/ZFE^G]^P_
M94FD%;O.7(IA_^DX07%.= (8 B=\"9G]YT?)>@7IT\D'GZ6=0RHTI'ZBT3>R
MY=H)\60TZ;]@Q)<FG1)/QIPC,R.ZQR>]VIDQ^>QP6 EQ+3'^Z7R4^1*/KU]C
M^ON??O3R'D:#T^'DW:1_Z<DERZ9 _Q6675V()C+KZETWU_>E2\.ER0W1-WM4
M5M;_Y[I@^/++3Z\^NG[UDXE(OWHW&N-PO(IC>GK5J2+DU?<^'?MXF_G3J5)U
MM/ST$],C5^^O?N3QM8;Z9KL)*5VP:&4V "'$ ,&*[*USFAUVSE/?*JP6,]!<
MT]ZQ\65C6<[%/E[H\LC-6J!ZK,GCGT[8-_WPF,/!Z9">7O8&/GFSLWKU]:M#
M5^_K][_9FMD1JSY6$LYR:WH*6BCT+F5OT%CA)JU9[][/5FNJ2=>9_\'6'!TB
M&^E7#7I)Y\G![VY13(1%R:@T*Q('%M&$+"$*&Q*4RQ:=%7.^QL]K%OI]+7JM
M!5)4PJ*7+%<=8&T!&W1(@4Q,Q6H[:0$Q>RT@?J0%/K?05S3<J>3Y^'BY>\:W
M]?FI$VF"X\'P+QKS5]^O'ZY2?W#<[7_KLC>E]+5+/+Y^]W_&?(_%<#[I3-:5
MZ=F[PHH-&'27A2JA@8AV^=A3L35]F_G'SD]ZW=0=;U"594NYRT>GHVRCX;BF
M2ODTC;>&.S0\ZR9:/N^RBZ@BX,G&H$?IM(?#U2X>] >C<3?MTJ@*]>FE?G[\
MS5_XV'0?;Z05D39P4)66(*-$]E_ \"905LB< R>CT[13"#?%\UX,>E[P%!W.
M,V^&I[@U/!$DNN)%2BJ!$3HFH,B9*:*@J#-4/&7XB.=]2*@YP5.&[\'SF@[\
M 3QM5,H"&V,2!KQE,XV:$^1JL$6 G>+I+_%D8!=XWAA/?V,\*_2WA*<S*GJK
MBB;* %D%K7+RQJ.48$I.[8^?KUA_'+- /F4@L;?<SRN<1M>7EZ>.YC&,%H^F
M2&LX:16@;8F9T_P@!68D1Q[;'T:;AK61:&J@%*%<C*0TI*""0V<F6'OC@K'M
MCZ8-P]I,4(U22J]<9B,5D&**X$A+$D[J(H+-[0^J3</:2&R5Q:=,)5'Q!"E9
MCU8[")"-+B:DV( 3;H67BYH*9X'@22E0!KWF""935#%R_$J^ 2_7"C>"4129
M2_(B.LBD@@>!7H'0G&N5*!MP(ZVP4](01"&;@!-2*"E:7U325IF8A6:QM#YI
MMQGTNE=C?3MC?O3ZG3K$/KY8&1R?#/IUJ&_J@J].X\^/!_V=\2"]NWU_^ZE3
MLZ+XUX<=KE/:) P2'!@,((L*UI(1$9VC8 RZN8%F.>=N'53$WBOLYO7^"IYT
MQ]AK"4S2DHN2V#T["PHYS<@F63 Q&:,*T?S E-+I\6FO+G[8&A_2L)XWI,-Z
MM3-:[Z?!,;4%,J]%C1-1YP(9;(2@T0F7O3(%87Z<WC:-L=NGO(;#.I_E#I3F
M'7D^ZY((J0B.X+FN<I%&Q^AUDB4S=/>'3U,M$$B!%9G_*@0^Z:#(^B@+DQ23
MU*D%6=&L!H'F-1=$ R@YB'N-D"R%()*),88DT.GBYP_<N_=#S:.*TH1@E4ZA
M"%!!(C=V)LR^2#0ZF/E#M1%!T#S0AF$M8)R))$$+C]90]"HH3#:[R^@T#_C>
M5\H4;BUL^NRE8NU=@BH@P005C=,!3$ZZV"CG!IHF4J;;@TEZ&Z-6*6*Q$+.-
M+AB7'00+F'7T\P-3PRG3[4$F!$<U!.52)'9ZZ!D<4*F #=()-3].[UY3IEOT
M?"051B3A3<UKBT^V9$EHO78Z7786S4JWYYVT 'I-+NGJ6P0$8UF,R:@L.Q02
M+FK3@O'!60T"S7?O"\C".85.)0\)!&:K2 1^R4@7K^8/W'M.F1I!U?LD2_$Y
MZ% @8.TR+1DYL(B82@AMF"#7!D'0/-!.N5BH5'0+<$R*K/6$R<%2%C$[,YVA
M/@?XWE/*]"4T/Q VBPA&%26+ \?RCI6=-$4;"04 HU%S TT#*=,MPB23]!%T
MC*JN<#7&ZVB3@!2L2@G*_%A0PRG3+4)F'4<W 1"<U8!"8RJ8D*16X&H3SPUD
M]YDRW2(^R=B4BT@NLJ:,=<I-UMEYZ^LZ48Y1]X=/4RV@E3$I!5.B"P!51Y.&
M(B(JD4-N9))6F^-S\[/';)(LJ:IV]@DR"VH?A9&F]@58U$#S!V@C.7 SX+H<
MT&5"R!HA*&)U%J666@@PJ?@V+ ^;N<#2/*H0BI!"*)6]!X@4V4[K,OM4EW"R
M8I@_5!O/@1L"NAB;^3]MZSIUZ4*P0:A<('*V13G>WRKM-L?8VUH^?CVYJI5
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MSC<DR"! N.0%9"4L8$G*&MV&*;<+-L\@FYN9@2H13<S%^N #1(M110P40?M
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M';C93;X>P@J>7 SK9HU6* Y>*@21LY 44BD:Y)S.BIH_!]10"7);M,G>!5&
M_PN<N7LHPD)20>C0$NXL'%"3)!+)1L[=R7L!X&WF5*Q.!Q*VUC5*6K0DBMW1
M].D6N)YFM ]I::1WQJ$ %R%Z3-FDD*SQ$!6UA#6SZWKF>V55L&BS5L2^Q@"G
M[3XDCUX%I9(B?3G</ON1Z^$ZG49"E50U,#%IH@Z@:AV9DI.MP^T*@A$+O=,:
MI]-,?Z$7,FE+)2L-)%0,,D="9I'+FL1\*IWOF-;> K?33+ RQ+FX $$J@"\*
M8T2,OI8F<^!S: EO9M?MS/O*-Z>S8OI$4\NRN%@BLRF&X)P7%"G-YT#%?#F>
M1@*6K5N'EF+M9,6D#<%:YZ .N>N Q;1ECOS"\31%(*U+=$4H2QH@L5Y.@O-T
M9DZR*F)L2Y;^G5.VYL7G--.Q8U!I93RA)S!>!YVD,MEK+74$] O*M&(PO9DM
M3$C62)6\\AG *JQK72V%+,&*'.:S5V=NW$TS]0,B2EL73T =.P^(0*$NY )'
M3!B:TZGO<^=NFNG/,<4'YSF9,@C 3/)DC< BM!.1W!S,W;D<?Z33\036?E[I
M=?OUY>6I<S!PWDR/CM"84LI&)@GD<E2^@,C(:J=NY*U:PIP92:Q^E*6MI)#)
MUBB(T9$ D*!\Y!1=R*R,-08@MS]P/0#GTTQ2GD$IS%94YF@3$934I=1]B'($
M:LNF" OGTV1U:"==*4)(%LR^:!_8_43,7D8G'+2E7^<!*@\9M?!>!JN#!4\Q
M"@4R)])U%O%E::UV(S?WO1RV0,[1.6VC 2M"D%K$K'31I&/Q;5FQ]  C;\E6
M.Y;\PN4$G"4&P=EB,%85Y1G3MM1SGA'C:P1"A<IDYWR@+""3]M$[L"YJGX0S
M2<QEO<EY+1O53'5+9,N7V5EI./G7*%&5H%-(1DH655,OL*!0V[H@F^'2I)1F
MSI R$&0#4=D@E4'#'T::]@+,7:74N75'S>S-%4/0G/@G&V*MO^'!:]:5222.
M;2!A0:%6NJ-F:OQFJ239XH+-H*+Q5CGCLR;C. .:ULV?N] V9X6DF@ED+*%%
M7?CN% B0GO$L1K/;212=2#:WA#DSTBG9]";.C5 HHG(JE&(*9!#.H@XJ.94U
ME@*^I+D,9//F?!H)6P0"R5O,)AF0)6%QY#V5&(H2$=JR@\_"^31'(=8W62=G
M4C$)BBK1>3(0HLJ*A(OSV2\T;V6D&MKT6E+(PD?#_X"2GN.6X>A5,*(MI372
M9Y:I,_?]0!2T=29$S)/RX=;'DA/6=](;91<;I[?"_302N9"%3V29@U8D,"X%
MZ;Q.-@ YYI*8TPV!Y];]-,.AZ$)=TFR5\2 YXP*(L@2D%+VT?CZ'-.:NB%1#
M&Y(+;4&I(@T2:%^B%]G6*?@Z!F=,6Y3S["9?#V%7>TB*8QBBKB1"32B=5!BT
M!Y?0Q3D-8G/G@!H)7NQQ@',P[6H9E[IQ"N2ZA9,O.AFRK=EM<N& FB21RB;8
M6CG*&P%9J>AK?2E+ONY8:.4#W]>]!:ZGF:X?)Z6C&'7BL"6,Q"(Q!1')QBA#
M:V:3S:[KN;=MZIO9)UDH'S0+Z!2AUN?PS@1MK(62,J32EG&+A^MT&@E5/D'"
MX+,RNH .P4/VH1225A40X%O"FH73:88^T0)D*D9XF>NK8*/4")1$$&3,? Y7
MS%4QJ6:"549TV15?3'"@209*RF"6_%JA;<W<L-EU._=73*H9 ADO@Q.Z: 49
MI(8@E"O:2TW%19ANE=*"N/60'4]#$YR3+%2$S0X .+7**I&+HM3=3;/1+>'-
MPO$TUK<C(&49C$F40*82O%&H+*L?H<A[TY+(-8LU@N95[+"H,:2MS(I%LM.
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M0170*XQ6#K%_0.O]Y32QMV[_8&TT[AYSPSR[V+TXN29R:%@&+'/ZB;9BKWN
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M;50ZRU;SER#;'6*F8QR^6P28F3?>63&5C!*4B2+66O7H!)8$DCC6I*#1^$6
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M""H:R]$X2UT(G*0V[!W70J@;B<O%1 -:># Q0RPBYB)3$,@>W @08M[B\DQ
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M_.!DBBTC^<#RQRD;6025$CCGC=$FM9AX.4,*:[X&0A09T%XC"6V!Q0L+%R%
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MYYA_\[!^K9/QHE/OK4/]5OJ!ORRBSC>/7IN-([Z7U==R\VCY_6\"*'EI1*>
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M>7"2E%&:EW71:H7;<N=V^U],&+O-C7CJW(CACLF-:),C6@7@@;2S+PK ;JL
M;(\" (?&/<PH!=ME>B/4:G__91E(.\S3W^NDFH?P1$K)X5Y:=O :<0R*DB -
MN#-3\*XNHHDJN=:$?^LU4FAUB^VXSKN#UM+:O)/9Z0FCW7L$1OL4!_+_OM?P
MRRL=_W^?'H.T90^?C@AWARU[V,"3&0I[V&_UL*W1P_#07EOH)ZM\H3^F+LM$
M\**.,I7.RX3+O"V\TW&>Q8P0AL\ [ZQ3KAM\.],\I5;AVI)[N[O3<M3-.YF]
M'<-1V\37IY[+PT[MWPAMF%14/$K<$3Y(S=^>LSLX&B%JCUC"F"[;<LSMN)=[
MK0ZZB2=C?($'+</<'H8)A^:T2HOPP'Z]\WHV2^EO5<RIJU_+(;?C'N[MMAQR
M\TZFOVN4RL.616X-BZ13.R8 6 3+(<X(:J2Z*+3P2L+C/F(H9(4?@%E^Y)"1
M\0>.QSH-M&6F6W)E^[T[\BU:=OHT9V,TSL/61G_JN3SPV(YS0JUG/9/R<>,V
M 6V+KEW+$C?S;/9,G/BPK55]ZKD\\-C>4KN",P?JV#+#+;EP_=YCAG">XEB8
MI1QW/V-N1LM(/HENM7OX[#MG8F)RGRKP/!#S%5Z& *I%4L9)Q#W?J5/!NT)?
M8;^ALZR<<9N@5A';!MY#AWTG\]FBM.VV&."IBP'Z>Q8IL2T':,V/!U./!4OL
MM>;']F@->&PG2:$)+"P,3F]T5%.ZQ-OQ.(E,FO^Q@8D/?L!F@^C0;GW8VW(K
M^[TV)+B19V,!%EM\V:>>RP./S;%);(BHL[+UVFS3K6LYXF:>S;Z%6VSAQ9YZ
M+@\\-JGVG =OKS/0&B?)#$L23+^B[W6F09W$) C^GK1*5P$AI0QK:TU;SKHE
MM[?EK!MZ-@:WL=_BECWU7!YX;(:'$GM$!SWPUK+!,#\4,$WN^0@F/">IL44?
MG,%;03^-=6NP;\]%;9GHAIZ-P7[LMZ!G3SV7!Q[;NR+)HF0&^J=+U@U>:2W5
M#KJX2J(V!VUK;N&=''*+(E1MY//)(Y\'?1/Y_/F+(:M6*W@D?G1@*GOZ+1+:
M4\_E@<=V>C-)1HGT!-G:5: *L^4K6%&'&IQ'$QW7::N5;0T7[/?:)E8;>3:F
M6*K_&!!RK83Z5)P1"_3S C.J.O\*SNOI5!7SEAENR87K]^[HW[+5ML0#AF^9
MQU,PC\/>L^_.85]5U197;@G7P"/K]V_M=O)-I4:I-I_;R_+=_XZ*;Q9^Y!V(
M3')GT-W?A87,\I+P [\M**)TI5]>)W$U,=OF_7"45U4^_;;G?J)&99[6U?J?
M/+X/:NDL!CBGP<(6>O^-LTWB_WMVCR/I/3,_FA3N>ESHSJC0ZK*CQK# ;U5Z
MK>;ELV\:^S!-LL["OB]NV:,SNL$&,;K;YW+_6P.2]@/>B4<W@#_A C!39IOG
MCQ7]:UJK+K(B4&$OX&: S( 9S#Z_:%AR%Q-S.%8UKA>AK9R_H5$O=PW_[/R8
MYY?XM\/&6LMB%];ER\S?ZK)*QO,GXH,?)MI#XJ=HU^E-1) VA/6?,-RLSJ*\
M+A3BW$3Y%.:)#U=Y$',]H<9V ;0GJ>Q)XHJ5@S+G8L(DN](EUA$$$2QTI#%U
M*R":*BM\L9*QYQ;P=ERC>A+,BIS*#WE^4W6I97P=RZ!T0D"I"<ZV[ 8?)DD9
M'&59K5(XN%E>5(B\(]82#M\[?/DO>%V&J1-E4-;1),"/![C7S964]G3I@?Y+
M O5),EB3#J8:M@(>@AN*?[XKDBNL@O!V]$?XGPO>A_<:YQP<114^WS\\W.VN
M)9BU!'*'+-\8POHE+V+96%6:O9VJ>6AV43Y"1$Z,O%9Z\1LXUF2ZZO,;HH7%
MCX%(?EOU>8+,)UY^/(7%+7XXTFFB@9X6/R^UOES\#"Y$&B]_B,!.]=*<T^12
MITMKOT[2=.E5%=;17,S-QTCQ\M5%KE+_XVO:8OP77*0I83R7"1RE EVD'N&=
MBG10EW1)D-8SKN!E4"JX9G1[!4\:?BN7+6>8:"3J(AA;QRM\2C<:QTQBN Y
M6DNWWMV5;G"4IK=\'RAXU709XGH&U@C>93YD3FCR)D?5R+QF' "6B6>.G$@%
M63T= 4.!AXNDO.2':I@NI4?1720N1.<&' @V)E!1A1RB$)!L8FCC,0R"=%?
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M+'>2D/A%$CK]O<;*(^:5\%OB%C_2<*'\^K58[?;G^#!_]:.^:'SA0JLX9YP
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M,A@DS!.I_ZN.5S1.>LH][ 8+IVJ+Z<\-@HHA\09TF !_2:"%H=M_KU6!O2B
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M^/NRA'!-DE$IG**NR4U$L6@T]I"K;8#.6,EDZZ.E+W**$^5"SJZ0%LXP.O<
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MM(JY$;$>CPEQ*&L@V6RA-#/]!0ML)E_/<N3;?"*:MMW"-/A=W]DU2/0WK@F
M#G?9E-(3"5,=?,3M$$R?@Y6J,F(0>,JR(0-4KD1\-(Y%$;P/$%ZIHT*+9BLB
M"_DIH9,E@CAJR^8#D,&H!,%4G [GN):M[^9R;6VK^''6(LI#GAK_\_V;(P\0
M(0RF=660=E4Z)T2"(A_EJ E0D\XD]SRIC?4X)0!V@WRKL.+%]A311"'L&WQ
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M,# $IT7.#-C+CH6C(LQ6<3I1;DR<$$8LHVH9UU-^;7<P2M'X&9,BP'(+>$P
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M05U$UH&+,M-[=7)L'>OV /U;9G:%TGUA+1)X1WLMQY-?.7$5YS/8 V,D@9Q
M.Z5TL\?7AD%=@;;X!TNWE1>-N!LBSB\XQE%U8XZ@8YZ5 >CQP)5 T-2% 8ZG
MPR/G$^44<0J#.3'"$ (6L'CR?%2,78VB4\MA<:\<VJ[5)(RC3_)RALJ:H%.B
M?U'8Q@*E4"_/(L^,=S.WC(@<9N1$4"G.#7T__&KT,8!HB@/J9@77T3 4SN4@
M&03?\V[ABX&=N9@/.U'([\,N"K:>!892KKNE4!+5N&SC]^4L)7*8+*.NCM<(
M*?2@&,A7=C@1<U"HI!3XRQIL$S"<M<CL&?!5YN)GV/0 @:Q(%%U/M$#;+I_4
M2)-OE?T*/O]!WZEY#[$JM&A(7C(:*FC\1LU[A^T?XT9.59LF\NR[_EZ;)K(9
M<VG31+9I_E]BF@C9W#^3TG-B>?T60F-^X"X%-M.!Y!0E<["^"!+;TQ=1(/O&
MM3A%22JQEN&$M0?9S*(3]534AF#R*TUC8[66SD"./<=#UY87&[<#VGS>HR3%
M) 19 7W*EXP^B8. 9L7N!C:"Q6Z/,7W8?Y'D!+A&/>0*$95J[G0P0C]78RT9
M#HR""**/TU2.\=W!66.RGE]!+#T[#=_- 6J43LF-3CIOC"VH<'/=(5@_@$FQ
M$)6H$<9TMC//H6-=#1?H_'(V L>SL3D$I2'(S-=.W5FB8*!ZX;K%)7&7]ASU
M;218>GMCQ2;.ZO<W0LSQ6!5QN>1HH8A;DJ;XF)ODVEE.\[(R9^TE]3)6.]%+
M(_W$<[8VENA4SR/X=M6A@LT_G8E1LFBDASR-I1TU>/6[_=[SRQ?N_H36*;N\
M/KJ4UJ&\-$$@64R@9L>;*)HE!G5694AQ[Q1_7U"UM#<);^N";17GFAT21''C
MN=6C90F@JDZN":J48XP9;6+,OG,9P_;[2BH)X:Y&F)?9NZ,*%_B#JD&%5)48
M"XLLP&Z=Y_PPP3'K&[/*,O8&@#>AHR@%1D0QHYA":F2.A2;_P,\2,FL_T<&;
M_"JW,Y#0A6W'\N'.9_"L\VO/9V=\8P5SG=]K])D8CRKL*GR[>#34?<;;!->*
M05F"Q?!)DPC#1G\,Z6V65%Z6/KD2,36H@QNQ1)&+F6TK2++IB2*3V<NX#\8:
M_;$NO!VC*"2'75;C)V%#[& ;XEK @Z5=S?6$_%-"@DUNM&(Z7HLZ<@"O.1JS
MZTRB+ "W+?3Q[#O9E'=V&][D?C8<1CYD^<>-Y6^?"G.TB@!<5)?\7+.<P*&I
MI=(4_ET5MK85)HR:R6T,R4OEL1X7<XLP'H$T&X@S:9'KA>)9$C=$R1VWTKD;
M:6UK2Y<UINX@9^O*>O?:>;*NQ87L<@"./!YZZV*7>3<P4& .$\F*(K^A#2_4
MTF#3(7XC=W(-;$@U=@E5,O)+ZGV^=D#,(.! 2K/IR(JA0^G262WHLBO55RO(
M"I6@G (:I.O._=/&:S4Z^L0CGM)Q94\P57"\6,0&R\*!FL.8+5BB !Z@ZY*#
M*XS:2EY.2BH$.Q$:;<;*>C;+"]2NX=0;U$!*1*$]Y<O^CMQI=W$^>L8(]I7:
MWG9F/U@:,%VKO$.4_<LJJUO?[ZX0T3FE<O'B/"]?A+Z_D0*$W*14+:E_0!G4
M&HOY$E>^_<$YV0*=WVR,YQ$?H<A[.2]6UT^RV+9EE3A@-WC/!\V?>'EOV/')
MMT1<FTOZ@B<OH2,N 44'ZX*E1'YSUE8J(FMOYR51P=MWX;UX(Q_&DD@S:VRG
M\$ 0=,%Y8ZA3.Y1AQKS17)O ;F.C8<'<;1#%=CMH]"Z(,5$@ ?XDL44..YIQ
M[(F0^K2H-!FKC.;MNE:)J4V=Q230(4R>%"6\WTZ]7YPCM>5C3H)6"JPK(Q=L
M*N$\2]F+#97$(7\G.X!'.6BXI!VN5R\I;O<VJO(1T#-&O4)/DZ->QXH2=F 7
M:IX-\6W2Y_,8#8R&>68K-5!MCNO"-/8J$LIP86\YIS$X%;KD85'#9E61@]T<
M:[E]S2_M1I_D_)P?9$<C9ZH]Q@X__">8TW@%AB$N=P G,<7N5[GHV/!2;G)!
M<2LO/$?M,4M/@Y>)-$P9WKPUQT.&H<FM D.B4.-*8E.PO=1\;<'T=B'SQM4U
M_<C61Y!85*\1D V&U-W"YJV8E8R%(O8&&?Y^NPT7+I]IY()FV.V:=G3QQ]CE
MC+04UQX5]!KL"$R7UIBX#18BC(93,Y28@^0D4:9NR' &#H&>2S;T;G_X?/SB
M^?"%.24,/K))1ADIRA3(@!)*&:A+\^56*OHFX31W8]+/9T3]&%S"1 _Y/>R=
M&WS5?0>=]P1(;\K<H7] J^>T %Z^EY!UI:VU;+H^VOQ7(U8] QCY4M-"WDI:
MQ-"1.$X7['WQ 97+ZH,76C[B_O)3Y*7F"#D&2:3IU8RCY<T-7/ 0Y79C<8=_
MN;G&C3*<Z/?H-2%L,6X(\QM&@9EX)=+HZ_*A,\9X04L3S\V562,2C13T*#;G
MOD-2R2^5*'J52\HERBQLI,NTQ%"U37BYEG@Q7#>0+R,M255KLF!,DD:2P6UD
M:O72 68YB%[#7*G&4+%^)KH*+D-/08U7G(2$NLE"CDV0)F!(1/,(^^WZF0B+
M67@F(X,:[\#)2A?@F+I-TYJXY9&G[_&9E:R.Y)A10T89.^1%617BH,(I"1]C
M5BWW@+7-YS?RACW09>)\)4>B?FWDJNZ,YZ"Z:#@FJ-9$;Y+CA0TV2[KR4B[)
MO5&GH@-GC?MCW)A'IC_I'4I3N,(4=:$D,E8YT$(S B-,):GHT#B]0D^XN7Q0
M8DT5&9N!1HV$/.-KK9(EI\ZBC@+/1J9-.-D;J!,UF)04 %M3Q9E^UE2,)2Y0
M4L6LN;\^]@:YBYVWQWF=G"%Q0>F'4</,%PRUI+(%>"JC%K(EI:R*8<83XEB#
M[_ Y.SFU#A_/RT$\CX)S92,@QU,@RPW??8MD_"H3//;;!(_-F$N;X+%-\]^2
M!(][*-R5B$\_]M-,BM[9!;$S+SF[X1+U.<PU**E^KEF=8'U*=L Q5PM3"T>2
MQPQ P$5VF)=NO%97)O_42B09P_S,S8ET-#(RY3'?\&J4MS;B[!<YQ>?85X=Z
M #N&\34F4-$_Z/%2K5D12YT%O([3$])J0O98DMD$@H"P0OV1,>:1@YKY_[/W
MKLV-',>VZ%]!^.YSCQ0!TC-Z6;+NW1'4:&2/;5GC&>DJXGQK @VR/4 W=C](
MP;_^UEJ96975:( <63,B97RQ-2#0CZJLJGRL7*L]G_TC9MKS4*4]DH_T_1_.
M<_4^@#8J26NV-)HO;ZH.#C@R=YA%;4%;AM-KES))71?KO\!VR-#U32_4C_P[
M?H6X(,3I-X0WH)FXLZYYZ;*LF]G5@% FW">?=N%*#3]DWDU[8<]GSV_0V+Z*
MGZ3I9*M[I3C9O>1MBGL/Y?^P&D8^&+O@\!E\L+63)F7AV-4%?+ 8FWK&,!%-
M>22,BE6#->%LZ!/K/>/=)7,A89QE#M3*8H.PQ?9][L$^OLIK(OJ1%H)->"K\
M(^'$T*" D.WQA1>$C9A?JSG9_;Q^,<8_8Z(A@,R$?$SF3E3(!F'A 3E "#5Q
MHZ6FU=MB6PZXGH:<\\S%5N=^XGNR!!/*@-A\#6<H_JJ0=1_+:TEX$:?.O8ZE
ME YDMZZ&:LD-=MDL!N;C*O2O//U$E&X1[ZCG;I/_,(S6T(SO^*F./L/1M3(N
MHWN^( 2C76_S17PA)U*I6+0WY?!L=C$&W?OYA$7%[IRM4]Z.ANL*;\=N?/<:
MT$,*=V0Q!?\VZTKGA?4'WFVR66N@,&1)OK_;!X#^\LLU+1CFF4,XS"V_X/I
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MEY>UB&3C(W@L\XN_?_WAJ'? :4()9GMWYPRD4S)S^GF[Z&=RFJ0%/R90,^"
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MD#""@C"[-=)$W36QBRKJ<%L:R!!&!1G 3:5\!4CD>]*":N78@W>P@. >-+>
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M!</R7>8C?5F,X*BKF6W++5.,2%[O1*V^&;89'YJC/)-S35J*02'1NER0_)!
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M9SF!.1[3\[\'2IN//GZZ^N@]\4CSC/PNQ.Z"*'WZN?@SS]?*+!QV5-NMB72
MUW9C*G+2=?)Y3$ \_^LKWW52)(&*4:GPM8#LPTGX0U>>?1T.(6I8OV2A-<DF
MO R'3X-CY;MMU53+=',<"]]'O1<<FB^-[IC:%@V=HCY"5%V.^?4/+U]^]^K[
M'*J*!V<@3K;>,X$_4QGOC1U5*.*ILM\;D-V@B!2/5\1?=5=J_SH/)A]G39W\
MY.F3Z,5'6O-$W)PZ!.()2.>KM5&X#@<F,_)Q-)&:2:*+:8"T-,8;IIK:^>QB
MK2B5JI?$AU&_<$ P@=YO%7$#2^Z&:.F-U!^%,%B.^<QS3J\=?@1$[A4]H_QY
M6S^I\9FU=!"N-2A@W.;(HC15?3DWD/,\,02N9F:)+ , \;Y5=0!Z[NQXZ7JF
MJ*UP-.UGN9)M<"H3_@<Q,A]HB\I)+\[WA :'YOPX$JA-9#7@11@P+7<<>EZ8
M(;O^/'HX_5T$-AA'^ O3"X.WO2M5<X0W7[JQZDF'6<$I%W=ZEU1&,!'!7/HU
M 3\MP1.+<JD^/F)\<@(!2J&)O5MZZ#]Q1,5T%(UKF2V?77V8L>HOEJ!*C+FO
MR_7J[)5E2+XJ'B,U\/=.8^"RH#)J*AMU>,&XH\T)PV,HE%$(A[74,E,W]^FM
MB48Q;]?I)FG'#.O)=8+I+BF53*E]:N6*S*:FK*5RT$F<)V52<L+@B;[&N;71
MN$J9] A-D^5&CLWX]6OVI>\<,Y#$%$U-IMZX^UCMUKA@XYB--R^ 66X*68G9
M7IN*)I,*"SY$,A1$*@;_<?;!TP\1XK=*AZK83+#HA(--#K%$]&N- $C0,$Q+
M^;KNR]D''WV8\OHYW; FN.- W]58&B[V\8>S8/<F"&7Y+B _^W&BAB>7J=5'
M_3:7/2$=R>R#3SY,%.NN>NOS,"^/1.1I;LQT)!/:#RV'9!4V@]C\)* YI'$2
M+F/FELP*>90[%(!^7E@^(1;B5N)F'+1+31G+-EO56/1QJ2#QP5U>2A7K]=X.
M(*3V:T4!2T8J^%*_\2W_=2P+6CWWI4ZV'.( D:Z#J_.,Q9P'.1;W/@3\F]"Y
M-G&#=:2K8X?E3M<8T]2R.V-]WE77V HC@*3!B5WJM"M9_U*"AA&]I)T04*!8
M.*S)(HYG\NQ#8XV<1,UMFG#LD1N]$"ZOCPZ:*?=L%=1ON-=1L*&S[DI\8UTN
MKR(V(I,2;^4RTAP&!6X6_:[J1D /$@*$W>(-5\VRZF0-1:+T=D JO.4K.UA'
M3B%N4!6ZZWSQ92EUU$KRKDD1'9,9_GO6%YL)>NB]Z2T@T\;V+VN=CQA#S(L&
M *9!ACIG>5VL5W:]_;$WGQ'@)-%'";9BT#CITQ503W@#L,*G>737("-B7:L,
M1SQ&Y2G.9V[_CGH :A,0J=G*%='5VW.=N%99$3CI@G_2:5%8'R?=/7@G:_#<
MY_E47/FR[&_A;O_7I_-/GSSAF_[7TZ?SL#I3,[^8+HTU(_C\>;N\UZO)GBB-
M*<OZ2^P@=,1K$:-=T?!6:[4@P#;'+X1V0G842EM^:CW\V$#TM\2Z.[*#F$'O
M)$/>QE__/0R?X(?9M?KIX2>>M4))$0<SC.#G3SZ6T?SHX_EG3_[ %@,.X7F.
M9<@0#R,N?0M1A14>P+;X<).6+QCW>^2CV=>:"#"JI2.2%^C%-&HEJA-F @!S
M1X<?[ZY@BN T;Q#U*H!/,]L/E!C@%SM>G]%(OC7G**WMX,D\R#>_]V%Z[,VR
MK-6S;U_BLY1<NP,H '<>/X\8\2;)J0C[6YZ=*E)DU1PQVE0C;7<Q-I*S$H>@
M! +7;!+"OY%6(NCT3:F+*&PX TMQK$ZFBR58,.6Y31_82:=%O.0\DVR9"V<'
MTPRM+Y3O58O\"Q:'7W$>P4(N(#5 JP0WHM6BHVK@)_Q32K8>!C'R?E+\A.UB
M>L@Z.0"0<Y-*+8>@VLI<L;)ZE'4+$9.GZG8#XD&:!$6%SVML7^/X-CZ!/6N*
MG/RE58<$F+ ZJ47;#>^N;:I5QS,ZGGSSC*-(8R2%A]YQBFL;'%'&\WVUU[KH
MHW9?:7G;4V4PJPQ^<JH,/HQG.54&']/S_Z>)78AB (L>JGZ'U-TKEV][5,X9
MVV!5;]HEI]>F\.<++-S^$^O3-BE"ZL%2UC=5V]2IDG6=T-L '4D<GT3?#+MF
M,I!S\=;0?YLT=M'STW0"MC0)L-BEA4B"G8@(?]@W6/RK:)?XUVW1:7JJ+995
MHXK8IM@Y[CZ/E:SO0@"W-=W/U_+01)_+JUPX+2SH7W[W^L\7'S(MXBE8F"X$
MD'XL?JEN@#792"M/@PZW-]LU\KTZ3/ :'.Q.AXR(.GG4FBE5IN Z;>B/K7_9
M/9D4(4.5B"C$+L_-$!R48$^+4CK7%/3ND'IXJM@#7OZT%0%@Y#_63;,\NVS:
MFB6)Z^:JS"5KMUK2%F<1([81R".BMW0E[8FORW()6%IP^-Z$BT UUHCK%%DF
MB9K,-N:"G+JLP%I HXA3*Z4\EU<W["C9N" >+YU<1>?,)?_U'L585#R]%,@;
M7JM)+M6J0<*(;Z@HO3\>*HY^/WJ-^+67HB2GAJ9]#O/]Z9Z];#I4 ;)OI,Z*
M,&QA;=>SBZXKP_QC?VZ;=>H;?B%R*FKA%U6;G@B_84Z#R9''MX]]-[0Y%>9H
M&C6"F+N.EG6S8'EJM,MIKY;?G/8V(_V1\LCA,MQRYM/[S7QR:PKF._K8+Z/%
M=;GAA?6K9NFP,05]H%;5H/0REU4I7X6%AEEJ0V35<8/S J/7[*/I61P/6\=N
M*_L0>0, 36B&'IQJL[""EQ0E4.E.B_DDD]8$8[VRX\!K]>6<X_NG"#8DCJ*B
M(A;7\N*&Y[3;"DF&AFH SO>F#"@-D]HZPNDIW>2,+_N0S?@/TVUD4=_S14IW
M/^37F(ZHU*LHPOX7#$$L*.SF>G+25D SL6V#P8= 'P@/(IEO2NO,Y.K4!NF/
M/WHR^[%X4[1%^+]@K*_#+AG"Z#<AGB;&YX>^N)Y]_LG3)Y^',WP ^\NZW%YC
M(=0#,[#AA/S@\R=//YQ]^ODG9Q]_IHEJ/$%L*5TNR2@7OOF.":_?RAO]W7_?
MWMZ>;]@C>QY6VJ]'QOV[_SZ?_5B* &H2H5TA%X&F+6ENME-=SAH(\H;%ZPP9
M$NWF-/K1QW\_ XMP^#P<6J#0F?/#"TJ'L<Y(/$%)I!L2PJ7;U1;Q,SQ';RP-
MU ;7+XCQ64TCTQ';$QV[8,5 (7=AP"I5/A=96-0VP_O,GCXY^^M\]@_A+5SO
MIO[^CWFDT6U'?_W\[*_B;."VZ >*'IM1)<GW04W2-+5HIQ:HX%^R9DC=5TZ!
MY/.YZ45)>J34D%4,#KDZFI"X569F5-8B"['5R848TNKOSPV?Q]'N.OH$W]_K
M>^$A*@JF=Y(7A,-1@J(S#/X'#VMI7??]]H^__SU66+#+\V :O^;R^G"F$G0Z
M>FH!3'S_M-M30:,;HVU6:27D.FFHJI)I2/E3A,828L<CZXCEQ/O8P8]E3%].
M[J"(4H(!ZBJ299&M&FD>*=1 U%G"T370':.ZH,)?E*I#,)E(KDME7,NO-_ 2
MZC?4#DY/<LIM9KG-3P_G-O&XU?+__=W=R9ZG7_SNE!!]\/FX4T+T<29$/Q\+
MPGSZR3T$8?"E7RE*>8&6Y:<7Y__W__7TLR=?[O_OJQ>O_SK[YN+9]]^]>OV0
M@Y?IMWM5=6]FWRB]P^MA$QYT]Y#?XDC5/::FT.H1G$2^2P0JQNBK#6\<)7!1
MF"V6P4WN4,,NE% RG*_6 QM<\ZU6TM7Y\&!?<#5T?WS0&:3#T]Z!-]TR&P@E
MOXI]O^$U\<%KI'_+J\,&<?!]_OO_N6Q__]\'?_>N%:%^4>-Z:-I0GYQ_BK'
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MP]R*' UAESCOUL+5*?R;2R X%VVIE$1Q=2/'%<*O,N,A\E_PNBVGF7WG*];
MC;[/B65R(6UD?D?$.Y1AD4H)"4M97+6ETX&?6-RR>:^1I;9+M'@TQ=(1 6\0
MW1&L]V0 [V=I>ZU!$5+AU-QRLMD3%8F81=$!>1SVV[$'[K9MZBM)R0Q*P:G[
M04G*NA*YRFQ/^"WXH']*:DNO8C+TY'\^0$,_O--18@G_+G\:4?[.E>]7(8.L
MO4V3U&8J2'E30MS]T),.VD7 ,$B/VT%KI%[D366&<U,HV_W@2X?0Y*>]\QV;
MU$AQ34BSP^%WAL-/E:>Z:'4J%,-6Y1:*S3+#XDA%V18#I\8>5$ZNU&@-K0&
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MG:'SE*-F%*)PWT<EB&@1:MSA9RK("U&6!.1WNIM=$B1*;Z5*LE%&="'6K^-
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M3H I_>!EVKRK:=$&IX&#[YSVZ,[E/J?S2*?\0IN63!M\LEQ^>S@@.DYH+ +
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MY)C9TYB[9.F,J2.63LR\>2KV<HYF6QE;#; D9=#G:8_L[CIE:7:L7$B.XY:
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M*$#9B%=X*U;[K*')J +T7 @V'4[?0GPR-JZS;M%L(K&!J>YM(4@A'O"7266
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MUC&XZ%*3G=V,5UTVL[Q0+(PSJ HMB<4V,7@)L#921)VX%V>;!4%-R#B(?FJ
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M"Y  1;1!@(U%*LZO?V?-/ F"$N6R+-+F1$R7)9% +B=/GO7[W%<H DS^K_V
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MG)#N!4S7,M_1PJ;Y.4O#5DC [L7(?&07^9Q.R/^EY:5,1$:R*#O/+Z,+4I(
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M)U12HKD_\R*F[[JAHM"Q>_$U2H6R&%7K;=)6BKI5*E2J2:63I,;Z(6'L!M^
MD),8],)&]GJ)T) R.4<B->XXM@>[YWW94K_W%NK<C].TJQ?J3@>\X=[T4<)
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M[Y8R844P:F&?R.I/#I139L*%3+F# ?FLWA:'M#!*"?>9"JYX@)3"TA4@&28
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M?7"&C>$,)FF"Z <#YL\<$*RN1-\%U:*7$XX="P(T73*NW5D0FT?87% I,$.
MYHSY4YHNDB!9;^2IG];-YP<0[N^&<-0&2.3J,@3?#"Z'VFE;RMP3/=SG[=2
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MFZJ<:],70EF0.>=R\[^UL/(8R$2OCOP,M0$YKH#'/!Z7 JQ?1Z]/3AWC+Q>
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M=7Q9.]> \](K92&20<AR1/UE3@N8YK*>H[_NPM#YCPMW.H2@T&%%+O=,+O5
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MJBZ;%0??/&%A__55&I!*H3IP+%DY.,2LEI%35+ZBMV7_(3B;#+A*6$!_Y,3
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MA^O)H)9KGT[E'"BLBZ1BP/1$M#['=V*!,@>^=H2$%PX_#,F$#8*8C&R1AZW
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M37&R_?>G)7^8@H%)>55<P+QPR=V<_$F@>_F+G 76="SV_4,T&P-&(^'VA+O
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M+\>OH_<?WIV\?'EZ]O:7M6,U&Y,X_#]M%GV,9YA=P #W.N/O[PRX/Y?AM[9
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MOZB5DE2?NL5,=3D2P"4'37?RX?Q]])&J(3YP-03=: 1G@G!2U=C!0R12&(N
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MKP:87//$/?E+)^YK'ZIWX,)>9NG5]GDG?W +?7DI&(S4!E#AOL)#R,, UYP
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M&C8591?$N*U3917&PO87T8/#APQF#$^OL7!^[F&<469<:[&%WJCAX=1#+ W
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M04E!U9W-<XK4^6=I3P3(;Y.1"TX+.FGS"8ZX-#J-9(F&G9=@6Z-JMR(*8YZ
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MYF&^_=M"O-<7T46<,2,K2GY:J\"C)J7&/1;0TNI\;I)$JB 0-+%*Q@MY$A_
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MJK_X3J7CNPKI$:SK=Q;'V]_5%6WZ%AW<.K.^VZ*O;=L=#(_6M^UVV_.5MX?
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M#D5K7])O<@X-)(\W 9) .E_R2TZI5#("VV(DF^VO_]Y;55J\@0T&9*,W<]*
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M6]8"X;R7H-TEQ=WFQ3^OM_<E^!GOPO*(<,%:,=BT]369AQ8*B3\IUO,($?]
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MOF"BRU($6*@&2Q=^MGP@!JOLON++]!*&ODEZ\"L&#;;L?VQI.ZH>30Y[D<1
M,1B R+1A?Y@/X8U@6_=RC69<R_DES>23M9!--,R*Z)0,?&!LHNQS<JNEC,$*
M<7XP,AB@,,T\'69,S.>*9@D-RY &#L(GA+:*N*C1L5.*#+ T,M1Q[UE/6N+S
MA3DQ>O6;--X*3]FFV%+8R"D;)KZ/.N$?,D#&A(]Q]@;/-PD8\YZJ4D"Y4X-:
M];4BU621#//=7SRJC*QMB@&* -I\ XS7T,HW[YU%O2;4^#RB!#8KPR9%.3P_
MN.9</A.FZ86,"N/ -$]$V%25A)+12AYMPD\Y[7;3:QB0WW V%+N.FPBKD?6@
MB@CEIHH RJ)0@N^O:'<HOR3&H*)3$KXS'Z3L8NHPLUGB3;;8\V>WV,/I)M'_
M;#S<<\PQ-SZT??E>82YM7[Y5FO\C^_+YKZ.>)Z(*0F!\3OYOF$2(15#,[M!+
M#&%IW[C$*Y-MQYJ,-XQ 84NID6\5Z!)ZJENM$V =8@A&\[--\:_&X3-0/:(B
M(6X#/'S!95(%9O#D,J$G!VV6@3Y S54,H,6@IA182P&C"7J:\;D<"H$CIO)<
MJ9'@?9LB!TA!4I9D;-@#-"L4,$75FK-ACADT(8?!X(E>.A0SO:*)3#]"+!.F
M699>RX*30,UB!N,I-%O:D9B7/.2(7W93F7R3#Q 3=6YA)'@7[EA?&TJEG!6D
M4&"'"R[VD.;JTZGU*$&W<W;6AS/O2,JB#/98:M-\2_O!<3$)1T!V1@>UK4FS
M#NVC"8=PZBQ+AYVSV44O,16K&!?SJA#"Y,-+K+Q9Y7J5:P,SX"J)N#0W0DQ2
MROA@F/4UD?$D\8O:G(+LYR3@;4#TW1ED&\Q%M=TM;<%W+I5I=BN#YCX\+.FZ
M8J4J<S&\U7ZSO&#+*!LYEAEC96JBJ&'*Z\ED,[,/-Q](X-N<+SU1F0+(AQU
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M4I^6]#^1A20SX!A%U!JFZ47UU=$#$^X;?L-$B![..JLQ5MXRRY/RLJ6@&A-
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M.$!R9N+=-$R' ^Q&(QKJS.CL+#DESJ1L+>$*GE+QE<URC&@HF\ED62J:.(%
M'4:2;\K5JWYX:KJJM1WCT3"3GEELMIE+;"8;D,UZ;;%1TSM1WCNES?J.C4\!
M-U9R>219(\W+)F;'0P PM2^7RY%MAD4'7Z1=;<"+ACF;&A>M@1A7U>V+CJNR
M-99D@"C)65?TQ2KAT+1EC6RE0 ?5!%0WTV+P:2A(&^:JN'V]P6S5RKB';69
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MQ,:4&NK3D' K]#W+=D/+ 4,'D,24IF?S2Z#69=%@METZAFC9]AG95O59IV'
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MR?[.\::V?[@S6Z(V9=;;A[O:\?>_CO=W][>_[>\=-VC"T\7R3EV+'9>Z"QE
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MR@+O;DS@Z7[D^PQ3&!TL"."&E/AP=L0-?$!^H<<<%F]\<'QW*V@%7BOPWK;
M<T/3=&V <TQW;-\%H!=:C#.$?+%NNU+@^4K@@>1K!=[K"SQC3."YEN%0R[!!
MPK&0V!$#:S;D 8F<P&4Z\\#&]38^>'ZP.B;M2W<F?@TN_7)&LQYE?"AF)"[Q
M,/B6^ 6&O$H8?VMEXA<07)YCAKX+U@SGD6U'9F"9$?,=GQJ&[<01:WUQ31-<
MMQ.^.&[:0:@[/G$H^N+BP"0@L4(2VCH<+P]MVS3!-)U6Y;5M;[<VG!S[U(D-
M%Y05U6W+C</(-L/ T&E$N<=]VCJ9FLS)$H)0)_+ 4/:([]D&V%R62RCVJ(E-
MA^L>C[R0HY-);SEYG3G9L>-8-[TPY*9EL\ ,/.HY@KU]QPL<M_6>-(^3Q[TG
M84A="T0LH8YC$3L$LP).C!/?I(ZM1X[O^L;&!\=X^CW0EI.;R\FA81B^Z46@
MBG6;A2RT/6X9(,H-*]8#-VK= LWCY'&W@,ELVS)\1B*&[=;Q>G=HZ#&Q;:K[
M,</"@\'&![=9G+P>A3SF9$A9R2.3K/&4:J=ON#:1%1N!R6(#2]K8D>,&4:B#
M_6"%GLUTPZ6M'Z!ADNIP9\(/8 1AQ'V &]1B)K$]W2&!Z9G$X['CQY;C^Y2#
MI KT-Q>B;H7 7$+ B'T6\9CQV.<V8ZX/&-:S Y '5NP$+&Q="$T6 D44PP5F
MURGA'E8EHXY/?#A K$%C&H'M\\!T-CZ80;#LD@FM$%@/(1!:/'8] RC%-&W3
MH;YEN;'!0A-,VH@RO_4^-$\(C'L??.:X<$H.,;@?$MOU31*ZAD7\.+ #KMO<
M<R)  I;?(H''K&G-)0 -]=B(8N;K@/XC;@:^K5/?M'5+YV$<&JW7HGD28-QK
M$3M. &=D$2=DC-@L9B0 D4!\,/,";)3@A,'&!]\QIK2/7K($:#,9YF31G30?
MR"JD_.:2]X$7WL]S)^_1[MEVC.:,L3:]BA:@=:R?TEO@*N$BNGN]-?32;]#A
M<1S%G](T$H4.5=K4<=J-6D6\B"*>O"AG.U;LFCPBCA'JQ Z\@/B1:Q+7]#T*
MYP>*.-SX8/C.TBK"KBC:7F^.7?H5L)9CE\^Q$CISS[0B6S>)0RU.;(_K).1Z
M!"1DAI$=.K'M85U_<VFV<\NP#638I5]A:AEV60P[[NWR7&!-BSG$\5V+V!;'
M%CTNWD6/71IRU[+M&%2LXVTY+<>N+\<N_0Y.R['+XMAQ[Y0'*M:+8I/H@1$3
M.PY]0D'&$CB?(*!<]SRL86RX_M,371O:"W"5;/3+]H9-DV[8M&)I.6)I\B(-
MC6@0QGY((JH'8*M' =X #(D5F@8+P5*WJ YBR7CZC><V:;>Y#+OTBS0MPRZ?
M826.L!TG<'BL$X<[$;&9"::Z%U/BZ&9D1H%KF3X@_R5T!VGYM;G\NO3K,BV_
M+HM?QRUUD^F@10'WQZ8'_,JI0;"6"(GP9AL8;:;-K8T/YA+24EJ&;2[#+OU6
M3,NPRV+8<4,]8J[MFJ9-8INC+]SB)&2V35SJ1A:/0B,$\//!,ANE8=]:+/T;
MSSG-V)FPS"-^Q;OI)38H*=)(VCCZ"]YZD4<!8FBW.H@]>0ZM,%I &!U-WF_Q
M'8L98("1B.LVL6./$6HXE%#;"0#U@ZV&?GY_">9YZ^9O+L\^PR65EF>?@6>5
MA6Y$>F1X%K$CO#/K^#'Q/9T"['<L(X@!W'D4 (2SM-LH+<\VD&>?X4Y)R[-+
MX]F)>+H5FP&S+>*9U">V93)@U] DH6^'413H#J7 LY[7J.!<R[/-OP72\NS2
M>';<4+<#%NF6&Q'+BX%G0^:0T+-T8MDQ,RV+ZT'@X7V/1F'CMQ90/^9=^&-G
M4^OP/L]H=U-8[#3J)?TD'V2BK?63C/8WX3Y<NM&NCN63/!003]LC)])*J$=(
MJ./*$C@ZV;./MG^9KAO8OL&(;CD!H K?(C0 5.'9U*24,<<W^<8'Q_(:Y4ML
MG?]--]];[GT.[KT;XU[?CQQ,?2>F8SO$IH%/?-?VB<,,TX\LWS!ML E,5W]Z
M<>R6>YO+O4LWY%ON?0[N-<:X5Z<V$&S$B<U<1NS8H23P#$XH]PV+>0'U\!*:
MHWM;5LN]Z\N]2S?I6^Y]#NZUQKC7I7!>0>R1,(@HL8W0(H$#/P'S^D9HNZ$3
MNL"]CMNHM)FW%H7_S#NTJ[$SFG5@4"!\7(66\\&@R]'1U4;A7\R@_YP,D@[%
MUQZ7V]_*HD=4PSW91CDD+/G#W0OGX*3SRX@,P];!!G \!Z"$CL$!'C(2<DOW
M38/9KH?E<,TMO4&.QC8XT'0K_EZ6C=.L1P?PVIO!^SBYX1&YXUG:LO*BK'Q;
M8^7SSB\_Q$N2.B,&-0-B<X^3,-(]HC.0O'H841=C!O_]7\#6YI\M-Z\O-R_=
MJF^Y^?FY^?!XE)L-*V0L8 $Q?0Z*V=1#$C+#(9'I^E9,;9V9=LO-;X";EV[E
MM]S\ MP\KIM9R!S? UP-P)K85F 2G_*0L- *PBB.?(<UDIO?6D@?+YU<)UUY
M*[Z;]CNDFUSQ2*,Y6/Y:TKND229R\95CH WKOY@7H#B:[7ZTWQ_0?B<)NQQ+
MS [VRV-IY=1"<FJO= <<W#'CX.3T5^28;NAY/C$M/P8;PJ"$@E(AD<6#T(Q"
MGYK&Q@>CC>FO,^LNW1LP'^NVT&/)+'UZ=WAR\<MW@I"ZU"-84 E9VB0T N@1
M.!:S??B?:?"E08^6K9O+UDMW"[0:^3G8]W:4?4V?&I[EVL3R=9?83AB1D(7
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MCG+E\%9CHL9$>QO>:DQT1R::"7 )Y3//*8,Q.8.*/(!G4@'9MEZ3+$UP8N4
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M"$@"@TQ9QZS] 3&9$US\:TUAR@ZE5!I3;&QL3V.*?6&*B1T48U:IKNI)]&B
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MT$T_/PA\K[UNO^'['O ]H[9SK(WV-D-R6H/RF !S3)"BDD3FZ++L)+X?6&%
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M3"U;4H)'<"%I<#XY3J9ES41T,5K9TA#=CP\TQ'<+\=-)Q!%CC#:!LC8#T7L
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MBGZ.YWSW*)4ID84Z3H>#8D1$CH<"WCB?>/',:S+^G5]0\-,"_ETW'SJ6<6_
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M63",&5!)1<!B%0AO612^.)7)++4+%MXTU.X):M<>;FNH73MJ9Z)L17BI;5:
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MSEWL%CCZ'?L7533?70XKISW_))4G.8P:12U%4<=SD81(SB%Y%1Q\W5&DLBQ
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MK#$9X1N:'P2:-]K7T-"\V:#?M&C9*2^%"\ X&IAL4R-_@12T3#[)DD3;T?Q
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M8CS!<W(G@]/1SV]L[22H?Y[A]9@>%W6K7L#XOPLWG=>;@]<0F5.E"]R %WA
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MG,Q,2:L<!:&RC\"]9=1%EW0R?1W!3L+ AHBCO,[6@4<1AQD"/G!B%/#BK*'
M!!,FLM*)O(>!'@8N:3,*.:.4['WB H+E5CLM*S88J:WLR_UW$08V[1V6YVRC
M"H1R< 2X*O9/PX@6,4!D7'.&FHYD-U;9J(>!.P8#GC%FN(XH!% (/GA Q9DE
MJIG(U*K8&SRZ" ,;T@#8&()6E@@5% 'M K$J:9*RUN"\]U"R)=5M@H%[$M1Q
MB4GCBO:F9LLN.H(O,^'>FJZLWV*#[@S4B\PL#YF!\ *B5+;H"MP+KR%0IEQO
M_^D<U.^>L_^ RA A"J+PX%#BXYQ8&2C)QG, :Q78$NUBZ4W[N6^ E+ZS"ZP'
MU1Y4;S[J.9L04PXIFP0A*..4T& 17T66-OC>FM9%4-V0GZD+PBG#B09&"7A1
MVN9I( &"E !! "O6-'L#=45[4.U!M0?53QDE1,I*,S")<^#2&2%49L%S[UUT
M?8'73H+JIFTR6).\8I(H+DHL5O3$4E:RM96+#,\4,1<E56%Z2;4'U1Y4OWZ
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M+RDK?[MJ1%X7DR(D1*$H)$,9*6OM;<Y1V:2XU!'UN]Y*U35,>G'.L1=<L!Y
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M*V>0M8FA@*/GFA"9,-^8K';8RDCEC0W&PNI$"2:/(48K(F,PA*=(;+0;C0C
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M7?"(&T; ^"<6T1BMXPY[3O,I,K$@K]2X!.44!%>87?)'66K=_IS._HG]C\>
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M@]:@5@.NHP;,!U3B:(2-PB/+62Y9831R7 K$J"'!@/E.*=MX1;#85&NTN_\
MNGW-OBM@WXMTH\5QP$^3DX!O;:O[5\SE=]8HA>ACX>GS&9Z6UF#LE421:XEX
M(@Q9AB,25B8?L"MKS^(%F>YKCEYOCKY.LN"'9NF<.+AFZ1NR-)D-PDM1>Y4\
M2C@YQ#EW64P'%*B/P1&JM V9I><W 1^D>$7-S8]$/E\P\F6VKOGU>OPZZUT+
M2A$?A$8JY- UX3AR22=D:?+$RQ0=):5:??L"\'70[(VX;Q?8S;=.;;LT\NN8
MV678$XG,D*-B9)Z[2&U*GFK'#7/&*'+EB/W:M+]##-J;#Y^U,1<OHQ[I7.:*
M,R.1U<DBS3RF#COM.08,DK>W ^J OV?/O5>U[.%#Q^8TG#^&+U/K1PSH//9[
M-:M?C]5G+7X1HW;8%JE;0=U@G"&ME$%98R2"1TJHF.S7U]Q><_L]&?TUMZ^"
MVV>= 33**+WE*/"0$.<A(&V\05AH(L \M#[QFMMK;K\QM]=>@=4P[JQ7  QU
M19(*0#@\YEA^CIRW!'$2-2=!$AO5VFGDSVKG_TT,L6_;#7N4"]V5=8/J7?^E
M ,0QU8 VTE+".-7*46I%$")1$T D73GJKW8-W"40S0?L8RR]\RPB)AT'>X%1
M9+2(R"FFHQ;8*^4W7LD%567K'<*:>6O/P/IR^JQGP.-@/*5@(<CH$'?&(1>=
M0Y;R%+B22FJ[,ENAYO::VVO/P#UR^ZQG(+E(*!86.4("XI8H9#GVB!EFL!;"
M,!9J;J^Y_<;<7GL&5L.XLYX!QJ/6VG.4$@&%W%N'# -0U,&+ /\70IEU4\B?
M5;3 IX^-HQYTJ)MK#4X5R*K#!I9!4'*86*P5,1IS;IR.7!/KF4HLD61L[1M8
M RC:W=_*,%3Z!\Z_GNV>['ZQ@9+(HD84! CBP:H<04!0BCQIH6W"!I0(0C;-
M&GDIZ[V%Q\F^M7?@?GG][#*O!\F,"X:B(&Q$/"?;,U%%1(FBUE)*/?'U5F+-
M[G?.[K5[X"[8O3DCV@GF%!:7(F^Q0SQYAZS""3$LP%H,TB=>LWO-[C=G]]H_
ML"K.G1'4R4<#BK='G.1T'8E+I+53B"AI).:2$DS73BE_5J$#11[ &^9$J8I.
M,QAKZ(UR">O<WUOF$UJ[&;IV!815S<Z3@>W;9EGJG,%@WW6_Q<&P4^1!+#,M
M77*BU%!]+:C>F?.?!,.)XY8CDG+&5JHLT@I;A$'.&ILDCQ*@FAE]>ZQ>+9^L
M><F7&BMKK%P#K*QS6-P-BLXHO,H&&VBRR'J3/5.*(&,-1\X1;;A) G.VRB06
M-8;6&/H\,/0Z243N'43KK"&W =%9?Q]U0BLB-'(JIPT)#$"4<@9T%9.7)F+E
MS(K2AM3X6>/G\\#/!\B*/(^@-31>%QIG]$O.&4U)2H1-"HAK'I#!8*I;%IB6
MVDK-=&FEKRKFZH$1LG#&_C',SGKX-[2^O?H/_!GWNF/[1ZUN\7IY&99.1H-A
M*YU!,\6SDV&6_84AMNWI(+X<?_@SM :G;7OVLM4M6*=XZ,^J^6KLXG2NK\4+
MR\M_?F^%X7%FMDU<,ESE0J[>7%W>+"[-3'YY3>!-)LG2RV T++WVLV8)WA1&
MW*C9GU]CFM>=?4R=E9A>J=E?;(#,L/7#* -Z+/2*!E^VAO R?Q4SHM5MP'O:
M (B#.6WQ%O&@T[/@0>+%_CW/0S5JM3CO^MA5_A_7_^.5[PV&JQCZ*O*!/XKI
M*ZR]8NI&$Y.O^'K<:^=1%)^/;*N[/+"VGM8;3FL;[OE)P'(]K_/SN@.J3R=[
M*8H)3+;5;WS+94@N3>**=KG7VA3<CCYV7.PW&'G1 )L%WZS:Q'4J@=R(R*YZ
M0*CNY%IW\CE5<GF]K'+DK0JZK$NED;J-*[3QK.*D,KW?YKC:$_6=/DT'*.-<
M>.R,CI1P9Z3FF#$%'Y+5RCI2.$!Q7<9URB?:^?3]X*1YO'L23G:W=]CA]H>O
M!_3OXR;=P8?[A\>[VX?MW<__?MW;/V*S/M'#_;]:NW3GK$EWO^_NAZ_-MQ].
M#CH[[&#_0[O9V?G>['SZ<0CCWML.:7>J%DSS9)?LO?^BA<+6>XD("=DE2CRR
M)FE$L2:.299HQ!NON%I9W-(CVOBI$6B=QG:KRJ,UU=545U-=376/A.K61MMZ
MLD5X[T_C8C,:EQ72X4 ]HDP:Q#&QR&A&4+2,:2^#E#*MG<;UK/)^O)YQRM3Y
M/I:!C^+!XQ2QES3R&*U.07!+3%32<; <:E/OH8"G^7K.U%.:)"E]0,0KC+AU
M&&E8&:0384('$BF+&Z^D6:M,Q/4IX+O34NMEJI>I7J8U%H"U]GUK(3BK?8.6
MK0RU%DFJ/.+,*60DQB@:[YT+$KLHUTX(KG*O:-VW1HLC]>6^Z*(-TMODY;]=
MJ/ZCQBGO*)86%$"+%;<Y*%T:9KR)(M>+8[)6U!\,HS[.*>HBF!AC(,A@%Q!7
M,H&.3C&2B@!$)8(3M3GOA]K$JPU37_NC.L^9VV_EB:X7N%[@>H%K>5W;%2N2
MV;-VA8PB!I4\(C97XW2:(LTI05HG197U!FS"1R:SGU- YB2G'4J]/AH )]PJ
M$O/N0G17&)98=_+A.OF\HC][_=->WPYCP_6Z85#8]=W>L"ZR]Y-<G0+D/K?1
MVH!YT%$;G9P25EGN \?LJO+_>2;2OR\U8#Z<$LQT0[PWB#A.$#?2(JL+7<!3
MGG1D5OJ-5W1U!\P?J6I?<^\*N/<Y926[/Y8^GV'IP&P0$1B9"^T13Q@C,,0L
M$HQCPE3@WA1)R43-T35'UZGR'Q&GDQE.YR3'PPB%* X<<:L<,H(;Y(P2BAA'
ML5]=IOR:VY\?MS_M3/GWQ[BSSC=L.56>2113CFS+V>Y,B 85%0X(@8\:1#0U
MFVR-N/99A=3N K?YUJEMERZ .J)V:3B_4HYYYXB*,D>G6*TX,TQ)G:0S59&.
MVO!_6 C:FP^N#<;%8)E"&H0'XEYS,/R%04DQXV2(5.5BGF:3KU%841T-^#B9
MM[;[[X*C9^U^1T']TQ8H.*J .%$).>82BI03SIWQ.JC%>71KCJXYNK;[UY?3
M9^U^EU(0S!#D0S8?" 63WX$-$6&YF;08%IO7%?)J;K\QM]=V_VH8=];NYV#J
M!\LC8E1IQ(T@2-N8$ V!!IR\,D%DI5NN$=,^JYW_-S'$/AC]]BAV_5FC-1B,
MZEW_Y?A#=> T61U #G%,C27)PF_>6JP DW1M_*\##LT'[$<IG4A>(T.U!>.?
M6V0Q24@39V,P7N$D-U[QE87^U9L&SY=YKVK\UZ;"*CA]UBF@$M$FJH28SW4>
M8Q3(>*'@CS4DQ!BI7IVI4'-[S>VU8^ >N7W6,0""/$CL)=(@X!%7B2+#F$(X
MXJ!QHE@06W-[S>TWYO;:,; :QIUU#!B53#2"(8-Y0ASG(!Z'&7(\:0YL*U+
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M849B-/ ;-[86LT^?@2.1V?Q6,3+/7:0V)4^UXX8Y8Q0)M9B]9T:=M<.%AI7
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M2? (C?7&XJM0L81=XE>Q;,(,-.Q9-[X>__)'J'?/&O;\=;U5C&-QTQ^CYX]
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M9WT&I\XC=W?4.36W<_O1=BK;K<PSMJ*/31<[%49>5?*:OT!?KXU\6=-AV>O
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MFQY\_[M>_;Y-:@-HY^ (VOGI!.X[V?VXS3-J[)_4&O\9[+"B8"B5,GF%0.#
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MJ%X0A?U<G>1D^Q<\OWZPMXV!1.#=O7!2;?X-[]LA!UM>[.\U3JKUZ0# +\=
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MMX3=M:.JM=@KB>I]<7;:%\$845HECHA0.3T_YDC3G#C%,<6Q@ID+?DF^B-4
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M5(N5A<-7"YHR2=K[V2X1:2%$FMT75Q$GIGU$@>2,CSXEY(3&R-J(O>:8XUR
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M].4'#,_<C&.-@&0N%)I&8&WV4<K(#(\RNA0$UY0304@27HTD2S&,QK^4DO6
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M-.B/ER1+<Z'.)_U^+@"8V3_&NXO--UA?O2UU$L9.LG(7:GW1S;4;87C%A@I
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M1OSRDW\X D')JG,"4MR-<3C9CV@<*;N\[> $E*VXUZ5X_P[XQP\VWJIND-6
MB:$@FSQ*PV71Z!KV>AH8R&K II+5YY154F_6]Z2/*@J)4<J]P'@,8"((&9'@
M8*'APOHSO]L+)L1F!(:7XC/R@9]"0-S- N*F!60K/U[QYE(\*NF8E [:V&SM
M*9PX,9HCG8T$GHA&ECN""'&$$4\QRV0LX E<8RB4+=PF$&H::BXWT*L1E;_
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M_J@W8S/?_,*(5?W:5CR#W]*?OZE].CF*H]?PN#-$#HWEUVOE2\3<J<7$E4^
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M=IJM<_CL;OWCAX.=OS7>PX&YA$E$DD8%QDTDR$2P=;Q7F"=/!"U*4MFZ66A
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M4X)@L<#:83&E2+.RKC97^(JEYGR)@VC[_J#PO4/\&3N]XUS0,"Z'>&5\X7>
M'<-HBB'9E*3A@2MKO";8ZAC >!!T?M%2!3N/##N?9[QOG'2VVAGB. 'V1*PS
M_Q%#)FF)F71*$##H^<(Z,B_1F4:EK!<&?3;@(W.)2,(=828(Y@)8#MP2Q52J
MO.]G4M;ICB).6H#5A')M.WC?Q"*+<_]?[#SEDG)8L[6->87.KT199\V+EZ>L
ME&*M)("S\YP'\.$$;*G.:J$<T=;HROM^'F6=]KX]\4Y)QQ!QL*GRD )R06)$
M4S!.@>MM\LXJUO&"SMTJ95U"966 S_E@/%!!N7?),4V<3\PD081EI/*^GTE9
MI[UO(I0F"B/GX O7AB(GDD'PDN0:F\@HS<KZ\)UU<<KZXL_!O\8.O+C_IK8?
MCV+?=DJ:,QNZ[:/V8)C)!'[&!WGBKR( 2+C$,B1EDG><@/%@58C.*NNT9EY7
MY^#/ D&S#46MB]$E(Y"Q)C-[JH ,M1PY"L9]M)191]8V&'YX>4@5KE]>;<U)
MP48:#:9]Y)93)R2XXH&P%+DB,5:N^#-IZY3!H+ET4:>(C#(Z$R=ZY+B0B##N
M%8\A",W6-@AY>%I=I:W+JZU).)$K^KAP@;N$74C$&VS!TA<8[E[YXL^CK=.^
MN*/*>9P2(I)XT%;A89=E#DD+BZ,M#AYST%:]KBIM?;G:RD*BRL<(!E:$_94[
M\+>U\)8':8A+U5'X<VGKM#-N&2=<@"5L)#CCGG($G@I#S&@1B'<LL)+C?IFR
MS!9T%GZ7OMG/YYD7+**UP0UD@?>L[QRQ\$V5K%>,%@^<F9<#X_?A0ZU@_)%A
M?+9C.%&*:)H,4C&W5J*:(.>$0C19'!7!7FNYML'DP_,/%Z<E2UMF>?,(?SO(
M"B?O.#\O!BU)TC[$Y&/2D7LOM95,<0/ R9(P%9G&LZ'E=&5%9+G1CD(IBHBX
MB RYE#SR)'*KG5?2!7!1^?ILO[#%H^6==&5I,?-*/6J%F8\^/R\&,QV+22K"
M=:244V$U8S*!XTF=L\'Z*L7FF3!S.JQG3>#<68I"I!9QK@2RT0-Z2I#VF M+
M:>Y>)!9-UU%A9H69%69.=W3'B83D-08_'/31:(ZMIAPS'%UR5:;3<V'F-!U(
MM"D9CA%.CB(>+'CE@N8NCYJ*I"G!DH-7SA; 0KDDF/E".K6_*[JH_*:Y9#_>
MN=\C[)(V4>(H<Y0K+JT5)A#NL#2>)ZSVMF\70;M55Z%&[ZCLFUGTK1H4,>3)
MOV?:DT9OV(K#RYY#58.J^6V(MDYWFC](O;E%X>]X9W-[CXJ8#" K,D8;Q(T(
MR#@-7Q)V3%DA121K&Y+,.>*\Z((&\C4L(OLG1Q-]?FX*\Y<M44_A'C5WI4%0
M#]2R9FNGHRZ\R)9M>,>=3^'3'KGMU:.)9=D:XT.O/WHIOX]<D570<O\VG/1S
MX];7+9VTWORV%Y0VWBJ+""$,<>HE<B[GS$0PW[DCTI'<!?(R%#R&YK+S[7KM
M>YGIZ8>Y<13(YZ@#KRW6#*2V:,E;)HB>3@AA7I(4V\.3/@"QS=U[XUFMY_U)
M_TGZKW7/8-NX;+YV[R9_[_;W^W'?#N/VT;#?/AJT?=&^KYGWM-?=B^WS7G1@
M5N;>HHR:3-D87,[)\BAX!IA(<)21K60OMMR2VHX7OM8>K_QEA^I>V>"QUCL9
M#H8@^46N]*VN*! ;!*V63CJ=LW$[ZR*[^G>7?_GZ;3#YYE(CX9>1_M7:@]?7
MS4W3=:GNUP#LMVV\Q#JAMVL25_4<6M&V6X5)_R_7_V-CLKU6;:;AT-US2^;6
M;RYO/LF[.\+<XY'HO[1XU:MM(K HU_;>-MNH_?+.I=1>-=Y6WGL=1;+@F;Z=
M-IJ?VKO-.@.;'S<^UOE.\QNK?]]BC8_?"#R'J!_N=EOMZ4C6P>%N\QVI=S]U
MZN<>GN,SAL^%Y_*_6DV/=YO?8,P_SAK=W?:\=BI1VQ2]HT@;[7(37H.,!L<B
M!$.83%1J+-<VR (H<YZJ_\"+K^B[%<Y/VJ156=^3X)N[&=_<-?BV]2OV?7N0
M#>^K^$8J@+L3P,TRX_(0J R:HTB(!8"+&&G/%9+:4"P2ERG0S,WSX/XJSYH&
M_9),U<)!_HV=6E$.71X7,L\ EYPW#N#+6$F$Y_!/DD05X8\.7UO_/FD/S[:/
M!L/^2=&C?B<?H30/[-$(V*Z)N4W8<Q7 W0G@9LG'&/&**R)1DB(@'K5$QDF#
MI!=,YY@J4V1M0R\N0_B)CA/S[UG:VT<GA3A>"7Z--(;3=95#4\>]LMWVVW[L
M%(P&EQ&I_[P:J!S%L_#E)=:!#7HRO/Z2F>C',X4RM;D:"YS\>M"_C-WL1^3Z
MT?Y -L'#OK6=4WLV6/OC:O"P?82FYG!Z^-<.,J5'&V0I10!5O7ZQYF]!^F(_
MOPN>R2[-L]0.^AE__Z.=H@TF4.V#%=QX8I.28$ &@8,1&NQ'M;91G"_\ZP^[
ML@,HSAA7^/G?YRT3]J9B#',T: IGREV(@U>L!>QXQ#(NO-<2*_BN.!8!ME>]
M]EBG71=[\L,/O$9[\$=XXW"P?52>MQ:_;5:G8+.G8._VO,",.\,0B)7(],$1
M:<4H8B!0#%N.01A6]A2L3$KX3<@@EDYH#$4&S*L[@A)PI;S=6=&=CJ#PNC#B
M7K?]_=^8YJOSL* ^K_YA)::+/(F\EJ)@1<_Q6M'V:UNPQ8?:Y$'>'8XK7]J,
M?&W_0EUXUT&M"9MVZ:[4REW\D2;*K.9$9=$9C*;DT\E1K#'\YBYGOZ_J</_6
M-;S+O>8SY_L/QH:7,S'XB2;FI<[-K0;\RB:.F->53=.\M;M4Y=%4>33+P;9R
M^YC0Z, Y7H2%"G%_D;DUQYUZ\S-K->NT=?Y-M+K?<.O<_]KY")]Q_N/7;K=^
MVFB^.ZLWZZ(Q?3+3_?:KL1D.ZN>[AXUFI[W;_'+8.-_B,)[SG>:';NO\':EO
M;O^"^]!YN34T468,)8BQS-V2K$).YO:LT<3@)>'2<X!6LSJY-?<$^WLRM%0(
M^7H0\HD85BJ$?%Z$G*JCC20:!EX[TCA$Q%T@R !J(M@;B;*Y#AH7S34?7D9;
M 60%D"L-D$]$IU(!Y+,"Y$SW86XY]D[#FH9,_T<CTI(3I*E.+A*%/4UK&_KA
M!.D50%8 N=H ^43<*15 /B] 3C.Q)*X-)PE1[\%NU#$ARUA"@0L/WRT8ERY;
MD(OJYE@1K>"[GU,5.2AC'HG:UTR%4?OKI.\/0'-J?W7LT6TR3)8OHR;#@CTZ
MJP%^]&H'.6?FJ/:[48XX/O(;CX_[O9\QU-Q9R0QRT.N 6 UJ[:-:=FYK_QC"
M_?^__]"4XG\6+URY4?$'\L__>E,K4N)JIP=M?U"[%BL'&:4&4W"I4W3<1<\5
M)]R  <E!P#W8&M9:+FS*N>.$PF#%)$IN-SXL#"9!GEWLC_+;!N].A@>]?D57
M<WV.&EQ_WMJS481(I *$"PQQ3P@"7\ @0YQ."8,WS4PF 9GMB'G!4%/*0S[+
M\+UN-[]0R.J!_1EK+L:CFKU8B_7:SE'M:SP>EFD&E$U0)=7^[,$J%GQ*[7[T
MPUZ_N.=P4C/&<@["#T)3'-!GS@/X^*'-G >%;/].9]Z,A/OBD0HMRSB;QV0[
M=Y1ZH:20ADC/;>"6&N=Q");Q8!B&&12C0+RA#(U_>"0C82S][RZ&4NG!+8EQ
M:".70QQZW-BL9W(<L1>54%@K@X1C*C-7$N2"QDB$())C@E$3YRM%:07<H!DE
M3<<0Y+<@OZD-8[\[%O59=,Y$'@V0^C(Q!V>-8?1-;7#B#C/U#D!\M"#1/K\?
MWMIS0]L^ K-A<B<8:8[MK-<*!I-[Z4ZY,8VO]6!UP ?5\GW;@Y(,X-HA@*D#
MSYI;0YX<PS2,GR;O5_,U_PV,RW=.LOF3&4W*VI[BO2&F=DGNE"]8Z\&=^_EO
M)8'56IZ"XI'"B /K&F3IVC.X59YYV(N+-XT8L&!(UGLPR^R1C[73]O#@8HTN
M1GA<($F>/0]#&3_94:&"^3VC=2\^/W^0@TM&\U'LT1G+CFVVVMHPM&$MG!1#
ML'E(5X93@QL\*2(M<D.NVU_M[DGWZKX,KLM8QFX'2/C5 Y+'>Y@IPZ@UB":=
M$&?@FS@E)&(\:<NE%R)7G8HW8*3.[M.EG*S7R@4H*(;:@\$)B&)I[ET'.Z=M
M4(!,]=4YJXT4"50_RW<!.%.BNEY[-[R6"=&.TL7AVD+W03  <^"^=Q-NF6B
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M#!D'#81,$@S#']YJQ44IETEX26AQG^WQBN/N2NJEF? 5O<M ;SL-=[(J94*
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M8!RJ!DZ)Y=D7D,_+A0<Q"#H!F:H9.I_PI6J&U=!).Y:#<Q]LB0_3:$:"T#:
MY4: ]#9*GY7%\2K^A05DYZN:84TTPX-&<53-L  70SM^PV1%M",9@K8E4Q,E
MX)Q%T4!#R,8KI?EBHD"K:-A,XEF":%A5%$<5#0O@DW8Z$"X2L3$ M\*"$#2
M,T$"#]K+H(T.6953:;JJA@Z =T4;$@\1NW$=N&O4QD*AWXK:R$X&FBEBW:"
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M_V(8U3^,KWF02X\_2J&4B(O;O7\.1_CUX3A]^<+%/<L+O;.#/G8*3KXOSW"
M36RN<>QBT]\^31\*F])J?;G F^U?MTN#>R>GHQ.\S:P[W<G):'B"LP:[OOG(
MY4-&5YX4+SI.LXX^ZCO?/YJV[IJ':<G@!GD=1QJ;5BO_"A;LEC_Z<=;[IX.
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M<][]G1'\"6;HM\'X)XXC[G9TMVW]X=6AK&]US% )MK3N#:RI[,!"=F#G(MB
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MG'NRJ2F<;6-UMQ<DY5UP+_VG8$QR9<92:_8\"O^ON]<H ;?=AWS^YU_RU3Z
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M.I/J!,&Z*<0,(TAPZY#&+@:WRW#"B\JMUS?[WQ3O>;F]B -?HC,4XZBHSZK
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M/ K<?CA\F$58@MR+>I#"H4#X!-G>>3><J07M_9EI>"D<PO1YB5G'J\MZK3D
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M'O_PGRB'4KXT^OQX3$6R8JC&QXOG+O*O EE]W%%'D^*4V<0)$S-GG$QI)!-
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MO00,PCQ.+1,P];Z?:)S,";"/!.H^I:ON&59AY)6'5=*-V@O%57RI%/O? <S
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M691:3834+"9*Q4D2DXC%# /4"!O4B@S5RO^/35D7.K7]Z]M?6SLR,)_\ +?
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MZ^&G7A)M=[E46A,CNJ#5RK68(S#^";:C@Z7*N9+#S[USF 4& NTY #H5KH(
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MY^FVVM]&LSD;^'VL%/!,X+>U=N!7W8.^ZX!Q 08>,0BV3S1#@>"A@Z JAZ]
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M1[,ML,ZV1/1"9=75-]?,@MV15:+39NDQ\V_?=Z;PGV$T'GW\_U!+ P04
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MP68>FT( X 4#6R:7F#<;@>9LF-/IH5>/M0+1GMDUS6B"Q7S;Y7XH*'Q)RS%
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M;:COXPD8_/_J>\B>B(L[%:1?PLT=<M]"<7^NPJ.AZ9O'9_XXYR'>!?Z (41
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MK';Y0^/I;+Z:@(M!10TQ:I-8(4^":="D5XP2+!FDGY4UEHL^&4.WD S)JQL
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MXET;=A@4:.@/70"]4!07]\I'HFB?@M=,HB#G+.7 /-C$$J)Q3FKO3)];F0\
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M![+OH8_.>1361@PZ=LY,<PHU$]01KH+<.QF$--<32)2@:^$@2TR/D5D I6Q
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M4B[-R/($@2TY-M*&4#-^H1;U0>9+)-L!LK,YI:!\'TMO&[6R\Z@OW+N[PT;
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MZW%B/D_SM].+U(\77T:S(^UM<-+7)=!BS1>S#(SB#++0H%" 3YTNIND%U]A
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M 430PG'PNLW5U.&%[NVB_^V%VF,,_\()IJ7J!&:S41DM*\O6#(47*9V?GI_
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M2)Z?1Y/SV<G7*FEZ4CVB/XK2<I>A1@G(1 .B+]Z8P(RS05J4Q=SN0K1N>VZ
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MD&;S<XL!.;.)+AIPI6;DS2[B,_[ ^:JV0Y1<EP(,2ZT.&DQB'L"P1!MLYL4
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MT9<&6OC*%VF%5W6I5@F&UU9&)P2&Y 0S)M+8N486!8^T4-I4BB!K'QL%%75
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M=S(D.RI^<X3#QC/MJ-#)@-KHVQ:HAM%B,AB0WD:OF:AWX#H;3_:Q2_7*4IK
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MJ?&(73(T,S:1^P",^.7+&=9+AWHTM3KZ!YV"4(D)5?M]@'4L*DUVF+>UJZ]
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MG$:]'M-^C1_F,%\\]\W%.!?^0= %2DZ>(2@RG6PD"5N-++N<+$01DFVSP#X
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M'G"6,'_"Q?F[\HH\H06DE9CH4B>.8&;T]2'Y[B@8A*B8$Z'X[(LPN4V1RIZ
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MBJ;.,<0Q ^>ZU>1NY\+U\&S(=4W7Q!BT8$N-I+H-><&H:^P4L'HWLMLW41:
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MI^1Q!9M2Y5W1)B7SBP(9P6&'."$Q2HD1Y6_78 E_&?S%HDAK;&8]'A#7:=9
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MY!1<4ZG/6*1=6VH.PA '&#&Y_.K5?=3^AA''ZC4:%5(K:M@=%:7!QLTI[<J
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M6P.WPC'*-<8JNG5E54U)$Q*L<%T?=\6.VWCU]Z;JHR<QWF*H;42-JNO)TB%
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MJG\ 41OF;%G ?9K.A@%QZ(/+-G#R@,B4T"H^OQ$;:+F= VH1=N\<V)'"[=T
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M@FU/@^#4-7MAJ%']J]/J[CM)9Z[NQPHJ%W43TJ_:W,\Y]D.!4P0#&C*((I3
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M1C"COR&@'9CS&B@W,H\6KVN+E?L>BR:#C]]IT0*2H_T6;;[?LQU9U\#F7?&
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MQO7G3BE[X)6=O+C'?GN71W6]W.JV=2V:\F!?>'TM=-XKUAO]'SBOYC3"A*
MP4RWO_1\#$GDJV2G-, ^]4@6&Q4_[#?\U#A#R@CN5(ZFZG"%FPA%W-;8T\<B
M<@&F:IK6&S6 X*;14#U-9+#?/2CP S/0=D[L]7*[W>"F0\\,*,M<"["E!O@P
M-/ 6>]*#&F"D3>=A#&&WJ]P;QY/;QO9W'6]?N+?&.QN__>_2MQ</XR)?YC77
M[7\^RH=S>9>315/TM_J,_[LHWRXD=7Z1#UP;?T5HQ%&",\A0))?N/L<PPTD*
M$\[D))/(:2>RBE_K(</4YIN-"FVSK(T2ZQ=.ZP&T(D!ITC,:KH_%S%S<@>TP
M\/0SC EZM/[I#:+C3D#V<HS<&*@W4(=]@OK?JA]M_G)S6^J""<]72_9S\<3+
MY5:8&0UPD*(X@$*H;"V144@"C\!44F,6)&&<!59[FR='FQH5?N!J2V0!L,J#
M?@:YJ@9HF65P&ETS,G.&V<"T]<L-Z 351T(;41U&Y5F!XI2&3H\X*N$8*;]/
M+69?ZMG]E4MZXB_T4&@/#ZMW*_Y?')>WTBI\+IVK(/0B 8,PD$O[2(00TSB%
MGJ>ZCU%"0[L6,M823(ULY%.'+-N[6H-NQC>#0CDP!S6RS_8[O.R<<=0%(!Q\
MQ3F; :4#T$HX;//:%S^WG5ZMI1BWV6M?D [ZO?:^4>^V Y1S5GV0*MW@!:^N
M17>T<B6$+BK%=6A3P59R:?O4>FYSE!%"HI1#3K@Z)8X3F'F"P"!B@M&84)99
MM73I*<?4:*]3 ZA'9+W!2;H33.5'].F:U==*9@PY O8#\^0N[%H'A7NGQ0RL
M]6B#.SM-V@6HT_X&EV#INNE!+UG&[H1P"6!'VB-<=+N>#J.\:U7?XN^*EKM$
MLT!XQ.,^#%*6010C!#&+*:3<XRP-,..)5;;[D3&FQGZ-B*#&W\&S%-*2Y(Z!
M:.CB70;-T$Y<@XI*+M7^F?O5XPG]W3IA1\89U\UZ6=$#1^K$I3TK5K^\D77U
MH$IL-%'A;1SIE9!OG!K[@_S"/&8AS0@B,!62$1!E#)(LBF&:XLR7M) *W[,A
M@PMDF1IIW-YSN9!7$EJ6>K[ '&:T,A+( ]-/HP7\='3KO0E[INK4?5NE&= &
M:?A*Z>.P.O+EH+JM;WR!/.-6*+X<N(,:PPYN>4$7F</PZ(..!&_V.Q*H=E?U
M\\=E59?ZQ+[2I4)N[_'R^E'=HOI2+)^X"B/YLM(>! Y3C^ (01:'(41,")C%
M)(5I&%&/)X*$T@UK<MYO:ES69OP[FOPV1+*OQ7"<\NWFEPJL6D'UDJI8U95\
M@EB^O)L!PN_RI8J[ C_H:$#;*O[C/1V)EZ#8SQ@,,AI A-2!4!0RZ,D_X"CS
M.*99^W2\7[(__;/1Z?!J3P;7_YW\8V'F'TS2T -[$PXZ&C7:@RWUVS)HM00
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MYJ--]XM3&)XF7Z?(#$R@:S'!1LZ9:H=W_FS*$C.;/B&.L!NK.\A+&+IJ!&(
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M39]E<_)U#^U(-/RUS!]4#2>Q3F^LNN*B@.*FO5^^!'_<Y_0>U/<<E+K2&&=
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MI^'J(QITYFE>2S*W)_Z[=40[<9!&VU-?KW_1G%Z8>*19*'G LS" (HH(1&E
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M#"6AP))"684_!"B%!$41E '/9((#1(25'-3Y9J8VZ-2&-K%29FJX7M@*/%W
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M,;6:\?.NL>YQ?J<0MN,?3[@-O:FX!]D'*\AZQ?]= ,-[*."I]D:/"KS@^+$
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M>(Z"/=ODR!&Q-NX?1L=:W=5S'967S\N2SG\MENOG#W-:EKG*>;TS_U=>SM)
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MN6XV;9?K5:F[T.RP.&>B.G6('3D."// M-A:#MZUMO]BB@IWS?]?H*T 85P
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M:2*$B5!WJZ!@T^C45@*US69UW3D<:LV^N:;NDU47V+&W;V 'IF,OF+I+JSN
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M_(F^,7T'X K8SFE;.:BF3E_P?!_[NQDQ=AQ +XB.! ;T>XZGT",]V]GL1:A
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MEZ33[-VAU[2="-:NW]TPUM((.QP-=37>WX#&_QM0(V#J\K6"-2T*H($!M#B
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M\5NYVCQ]6:WU;;Y:3WNCV/2I5=+^C11+3:%?E]WC<RHR''!*(<<!A8A%")*
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M9@C2.)&:V"*(PRB"(F%9PI)49-Q*R;J_NJG1V!_+EL14EZM:,P%;5;97RZZ
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M6C@OC1:$.%#4'D**LA B%(<0QP)#0A.<9 RC."+S)L7[CS4IUU-MNF,3AVO
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M5,>VT0#B4(8\C>,,2V2N%'VQ'ILO>1RYZ,Y4T-@*&F-!;:WYXN$RL-<7#E[
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MG#P -C -=18"96)#/#/06NF/;:[ X)57+M4U*H-<<?B8*ZX][GC>IA?E.@Q
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MC9!Y1A@' Z;&E?O70V[),^+2%OT,.0;"0^\^=>!^E8?I7?8\ +7U[?T;H+T
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MIL-N20(Q#2+(91ICFK*(<W,!:*,JIT;*W6XQ:^P%#[4BQM++5O%%V&UWB'V
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M#1P9*XBS7/^$DU3A+%&:%5W8;T#9QT:>G1;&%ET?%[R WXW H);8,=)JR/?
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MGKMJ@I*<Y;B@VOY-,$0QE1"+F,.<\CB/.58,.W8?]"&6%1,-VJ2PZ38L.B4
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MRFVZ,-[8=BHG,GIO@!&YY]'5)<CM^-$CD($9\$H,G0G.$AFO%'9IS$%)RA*
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ML33'0Y^UF2KV^TK]NC#IS$BO%6DB$8RSE)K )@DI+P2D&.>(%CG)F9/S_M*
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MZ,)X8Z/ MF62JR__/*:V+GUO2 7W[#>2@E94T,H*WFAI0[CC+*'Q[.$_/^;
MCGXK  []_7:W]:.2]V7U/*_H]-?%?/7\;DJKJE0EKXVYMIQ.D0J42:9@HG ,
M$3;=-O(<0\9C+I*")CR5+F1R<<2QT4DG,*@E!KLB]ZQA=!EV.[[Q"F9@QKD2
M1V?"L<;&*^5<'G50TK$&89]V[&_L7XO49!_N5F-;]UO5P_/IO%J9DBPX107B
M&)+41",H5$"2"VW<Q"G#>5:PI!!NCBK+D<=&1"=+4MZ #]6R?*H+BO1M5FX_
M'RAG:<:)7@%8HJU+7##(4*8@S3B+DRS*9:0F/^6"S5]U1K8E>(4Y"86^K:LP
M *+!?84ME(?%/K<:G6]$]UO2TPDM[^4[[48?O%2G$RC'RG*Z/<!M)1&RG'R8
M+<OERZT0^D74>^MJ2:?_7_G\;B[D1.2((VJ"V$P%'41-Y4VBEXTD56F".2I4
M8>49/#_,V-:(1E+0BFJ<3498H*4%1EP[5KJ ['D*\H=78+[I"Y4UO=@A<:9"
MGWY 32/_1.9'V/Q8<\>%1P]"%';J=:Q@>77?\CIS_L>GJEI)\7ZU*&>/S5EJ
M7:&KJO]X]URWF_WPEUSPLI)B8NIJ*4P45"JB$!4IU_9EHME";W>%2''.B9S,
MY*,QJNRL&'<AK#X&TGP,VZ*$^R9:"8'L1 1OZDI_KCUF>TR(G6$3".2!XOR-
ME)#1JCT-E;.JV?S>+A;ZNJ;N#GL!V]?=TY?ZU[=-S=]6.VWQM_I5H/0?.M(?
M9<\E>9S%&+@J3U^8#@OS]'Y2/\9LO8FFFYQIRVU2K_Y1+G^\6U7+^9-<[ >T
M(QS3/&$IS+,TA8A(O1LG*-7_EW 4<2IRYE23T&WXL1E9G<O<9+X_SLJST0L^
MT+>CQG"8!J;%#LZZDV4G.OA3RPXZX<.>EO9#SBO5.8HP*,WU@V>?XGH^I4<1
MHN^S1?-A_DN*;_2OMW(F5;FLOLCEA.$XPR05D/-(\UB2:*N/$PY-S=4H2QFE
MJ94O\<(X8R.L;4GK@BNLE=6AILT95,_SDT>L A/1#DRF0% GY@W0@OK!RJ',
MCQ_,!JKFTQ,[MXH]EQ$Y6YCGS.W#U=^YK,-.F1V+R_M9@%V&P&V3(/!E94Z3
M[]3[<KK2OVTLS[O54F_29T(;I).<%*0HE(!(L-SXTQ D"!,8Y5P)2B*49TXE
M,!S''QNEMG*"-W_N9UKTVC"[SD:B,J0H19#B0IA21QDDF$60Q]HX+P31+W\^
M6<Z7=/KZL[&6(MQL=.+#W4D \XW(]=&",/J88K:;5O1@9;;9RSG@36!K<XW^
MU8?[TQTYO,RAG5D?<&8"+Z?K'*16=-#(;JH<-&*#+;EO0*N1/[.^)W)>[7I7
M&08U['L"M&_9]WW,-?4+3+OC;BM1SE;ZL7?/>O3:1[+75%5675O5B2@(R2E+
M8(Z5-+6'"T@D95 B28E*:81SIU""*V09VWK6H_62CQFQX\"!< [,A[NMNM?>
MCD85L-'EL(.TK#8]I'T76[@*U0#U&/K)\PHE&ZX"[GA5A^L>V?/LS/#S6W/6
ML'TDT;#V[6KY8[XP6X_O,_W$+4?TO7ZSU\[H^T7)Y5=S@M$&+RHLB(@UL28)
M3B B<0Z93#"D1:QD2BF.*'<JJ>5?QK'Q;R<GJ 4%M:0]@TM#S*CEZ=SKSE/H
M@(%>4^1^^!8.1+^G<P'D'/;X+AS0!^=[ 8?R$/BO5Y7IRMCF)BBK67ND6"\]
M^SE,7S2\;8>MA!(184DA2I.H2;\DF6;[1*4H2V5<<)KU3@[H*]78J'TK![#I
M_P'*6C-M;I<SH+5U#-7U,W5VC#[XA 3F\-TD!).?V:H$MG7:&.-',S@WF@7*
M5K@6Z' 9#;TE>[VLAVO!/)L9<?7#^['W![J8EMKZUQN!_Y)TT>8H*I1'J118
MTR\GFHU19)+A,<1Y5/"$TIQSJTXJ9T<9&[MV0M;GFB]:3#<R/8ZD'3E>C4]H
M@[6#QIS'&0D#I'6>Q< K#QT?:5!>.:OL/D^<O_C*XJV;Z/E-F%"*BPB)7, T
MC4R1^@A#0E,$)1(1504CG#@5LCXWV-A8P$,1UV.0NK@GKP=J&/^C(8.-H.#W
ML(5<ST 2IICKL0%?IZ#K&=5/%G4]=T__1,N]')S;F7C06\[E-[EX^C3[J3G*
M!(A4DPS%1)FPSH@S!A'",<2%WM?%!14<HRQ.4>J::6DW]-CHQ$A]<R3/TIPA
M/]'%'W)9EV$OUQIL'2B[9_Y93H\=&84!/3 U-7@?)OX9O&O1H9[U)[ EO-_L
M/S? O*?_60X_>/Z?&RS'$@ =GW!MUX\3?K:M /I;OBQ_ELN7O3833-)4\2B!
ML:!ZZQ0G N)8ZIT4BJ.H8%&>NU'?]2*-C1*WFU34TK>Y** 3OV\OD-YS9GDF
M,>A,!.;)HYE!F^2A+C_H9CTI S4,N1;:0/U#>HOU2NU$KH7Q='>1JY_<>[^Z
M,/V=WLOFOY]F]POY3$OQH2FT6M6%"2<\UEM7'A=01B; -$,$4JHX1&F<IH*R
MB&6\2\;\YK2!M1C=ZO/>S<+\-@#?MJ)V)6F;.H[SNHXCW^DF[KS=M9D1ZXVO
M+X 'VP+7@H(WG<B_U/F3+=:=V#=-P4ROVV$'H'QOC&V&'GJ+[ #'D<VRR]T]
M,HCJ8]9O?\Y;;W"$25$4(H)"I#E$/$LA$WD$94YC3%"NF%WWQR//'IN5]S]!
MDOZ-8(=<ESVLSA/'E0@$9H<FHD-+=ME/?A$'ASR?_G@,E-OC@(M;/L]QS<_F
M\.S=,ES>SG%9=W)U3ES2,T!#LN6G6;5<U#.L3;>R>GC6?"?N9G^GB])8::8#
M2SRA!:>"%QE$E*80B4A!%NMU($-)A),D9CDNG&(P+ <>&W75DH*J%A7H?>FB
M;B_T+/7C9TO'=!QK\.WLI!"0!N9"(S+8R'P#&G@?UO!V@M=MG#S&03A"Y3?4
MP7;P8:,9'"$Y"%APO?^*(CP_YE-]1V5<?LN7+_.E/':J%A&B-&$A6$240I23
M%!+&<QA%N4P2CG&FG%()K4<>&V5INU7)A>F%5M>]FS\]Z0]K6YO_!1I]>E3?
ML9H)2Q=:"'Q#>\J.H B,V.'//IWA\E\TQVKTX6OEN(!RM$2.TP.N/4S8"?2J
MSD=Z5<T);IT^U;"L?ANY?/@AY?)V)FZ%J,O$T.E&X&KK]"%A4N8%@@G5K(AB
M22#-< &+0LE"9I%@RJG&]BOH,#9JW6MAOIHMJZY>S[^:P-NF)TJC<]^SB^%>
M$=?#CE%.?&B;=2>XM[H<W3M4/_7!)R/0><IP>KS2 <S@$W7ZQ&9X4?JMER<*
ME'S5:O!:MJ^R6DVUP(\FL_$S?:ZT<K?/S].2FT_/R+Q:ZE]]+I_*QI%535BF
M1$)1# LL"$19GD"2%QC&"B7F)<TS&;D5YPP@98]SH\!KGGY5J@J(UBU> 0BJ
M1FXP-0JY+7(AYM5N$7NMN7KU(E-K#<%:PR9-O-:QMF366H)63?/;+47]K5X!
M9\'KZA1"SD%7GX! [Z\N(8?RWO9[N[%D>[)GXN@_ZFLG61+%.,%";Y-8#!%+
M$<2XB&"N8E&GNF0">^KZ?4:,L>UY3-$G;ZV\S\%OQ^/A00U,U6<;>=_4T0*\
MKF^TI<U-DVAC-!FDE;<%DD-U\CXGRE@:>5O Y=#'V^9IUWJA;K6QWY4M>U@'
MF7_XJ\D@;JJ%F,)EM1!WZ@-=F,;BU;U<U#%?&P\"26*>\YS .%*FD9M2$--8
MPCQ.",TDHJ+H&>+J2\2Q\>FV#^E^OM0;JY).FSIEIH9<YZ^OL_C[>I"\3:^K
M@^@U)BVTSW_;Y[>E'MCH!SH%N_I+:Q7-39V2IJ!^,Z\#.8A\3T8@_X\W,5_)
MO>,;YM/>&^\C]3V3;3U"=\ID8GR<SO^L;EE55]^>Q$5*,18IU)8S-EX6#JG*
M4IBG41&G,F(B=NJ=?FZPT5%[)ZOY[.N\HUI<\'LGL&O-I7- VYZR^H$O^,%J
M;^1ZG*1>AL3SX>F9 0<^+[VL^N$1J<4]_8CDRWPV;[S-L\?&V=S:N^N77.6R
M2 I,($&$042PA$RE*2RX)#)%DJ9N+4(NCC@V2FG.$\NVR&,;MO_+?[KQR&6<
M[<C$*WJ!&65;UJ[HY9M6W%^"\(HU.E[)Y?*H@S*,-0C[-&-_HWM#Q]N5*/7<
M?2P73Y_$A).\2#$MH. H@0@1!6F2)C")HR*-<!:)V*J.Y,&3Q\8=K7# 2 <^
MO;=OT[B+UWENN J%P!Q@"X!3\\6CRO;NM[C[M,%:+!Y58KNKXO$+>F2]?%!*
MFB3 39%9$Q9J@F9FO)R6]5:E]GM]>GJF>C1318XAE6."(I@D2.\A*$D@%ICI
M+Y1&!/$\*S"R3HWI(<#H/F0C'BC7\CDDD/2!__P'/P2H@7EA+?U6->PZXASL
M:M#XY,&GH8!W2.\)/ $#Y0!M)J*U<$VYM3K%8K$[$73O"_B;IURA*V \FU#4
MY[G#91U=H?5.:M(USPE3E&.K;,';E\TE;56#NMUIFYG^J[YP67V:-3TQZW^]
MU\)_FBT7Y:PJ>=U.?*\VA!!"IEE&8%X("A&3"F*9FA./B*<"1TPE/2-J7T&;
ML2URVW[VM=R@%MS\JFLBO.Y5ZK<R2-@7Q_489>2OPX G+CZ[&S>H;%H;M[\!
M!IJ#5^XU2YP,,M&#5D<)J]&H"JL,,GFN-5F&$:IW403]+LHNQ3TOXHC%*<QD
MDD+$J2F+@')8)"+."IFRA+J61=@\?6QKWO\$2?&WJ  0I/G?LLRY,, 6;A:;
MMFO0"$SY;3$ (UO_,@G;;Y%KH81^J Q;*L'(Z+5&PJ'2%E42MFX:ND["H;Q'
M*B4<N:AGC=.%%.7R(S5;F>7+[5]E-1$JCPK%*4RI$!#A5$(2(P85CE/"1$ZP
M="J&?#C$V!BJD1!T(H+?C9".Q]A'@+0SB*^#)S!E.2+C7D'TI/)^*X4>#C-L
M1="3:AY4_CQ]I?<P\=_H?\\7[Z:TJK[H5Z!M5X4)1RE3,<Q9H2!"3$#,"8%I
MQA.2I'E*8Z<* X[CCXT:S@8RZ^U6K0.HE0!&BYZ-QUQGR8Y: F(?F'?\P^XS
M<OP<>$.%C!^582RQXN< <@@2/_L8]Q/R#[.EX50A])M:M?_Y7,YD/$F8P'E,
M8X@CI$T>%.60I;&"1 F4I7IK1C*K9EQG1QD;M36"@E;$F^X'8(0%=S/+I,?S
MP%X^5O<"5^BCM+Y(.9VY7T2B]_G[Z2</=A9_4;GM<_G+%_<,Q9-+$]UWOYC_
M+(44;U^^5X9TFG+JY>RQ+>1;RFJ""R:((IH16!1!E"+3AQ7'4*DL0A3'*$%J
MLIPOZ=3.#+(?VHDFU@($C#&3RZ:=PW,KN_%$OUE5=2F07]I&#B;^C*Y5< S<
MLY\5.[,G#-:!.<; 7,<$WV_#_+V#>2T\N+T,LWM4GS-B?L/[[(<?-L[/&9:#
M@#_W)_@J%W[7!1J^H\^EIHEU&"P1FKLD3F"JE-3&3LXA,R7EXDQ%"J$D(\)I
MAV<_]-@LH'<_C#.M/BQKVXN:8G+3DC*S^]:3XAB"[# )=DP6!MK 3':B4OA:
M<M"*'B0^V1VQP"7#3P[_RF7#+\%RN73XQ2?T8[);SE=/JZDI^O)>/B\D;T)L
M],]369_RS<1V\K"F5BW'\L5T?#85>TR!N^<ZT(PF><8*RB%)!(>(2P09RSA,
M]&8.BP*)5&]0G$KA^!+-ZF,=M/[-9[.=H1OU@-C2SXT$O<V?'44..B<#171O
MS<.V3C=@K56]4.T63^@TTS\9W9H.8&OU_#&L;\"]\J\WX09E9]^0[G.W]^=[
MW7ZOUY&-,;PVDSB*\Y@K!"5F.40TU=OP7%&84\D4SM(DD[E3:IRS"*.S66\?
M_@_X^/GN'P_@X]>[W\#=_8>OM]\^??D5W+[[]NGOG[Y]^O#@FCGG/B]7;<0]
MH?VZ&_*-.;O1(DS&76\0A]BCGQ-C#'MU"Y@L]^PV3^K;KZ(I9?Z-_M6<>YBV
M/'.N3;*OLI+Z<3\T";^7/^5TWEA&D6E+KVD1XD0E$*D(09PF N8,*\R3' OL
M5,/+58"Q<6(G96WRB(V<@->GZ8[^2.?IL"/#D" 'IL).]#J%J#N"K9M_U?*#
M'?RW5/#9VZ(?>)Y[7#@*,7"OBWX0'?:\Z/F<GLDN?4-YFTKVF^X<3>^R;S_H
MK WR_;NLEH:XFR#??\CR\8?^]^U/3>./<AWS^Y&6BSK<=R*)4%E&A,EY01!Q
MI%E51!F,65;$^L/($2$3?3>;6Z>^C$4W%R[9UC @93]\K\#/6@OP1LRG4[JH
M@%YA064 <>PY-!J<;7-@QB+OB-88#SDP;:N2+7C:3@5+#= F0Z;!:#M#IL,)
MM$!MI\P8K)IL&8^I,6.;?[]I,J/1;MB4F=&H?6)A'Y^ ?4.X'G[(Z=0H06<O
MD[1@:2'U[B?BF3#5DW)(69%"E.(BX11E19:XQ6YM/WYL6YTV%*D6$;0RN@9J
M[<!G&Z'5%Y1A0K/L\.@1CG5,[2OCL'8>.7  UC%U#B.OCE[5IRS*7Y+7=1SO
ME"JY_CKTSN%!SLKYXGY>U7TUJC:5B6)"$8I34XN<0R1P EE,$OT3)[&B!*G4
M*@#3;=BQ?=SOY&))M5TB.P7 O-5@JX5Y56L"GCM57,IU6,_'>58(AW)HME@#
MVPD-M-2@$1NLY>Z3G6>/K4L!E! 8#U7VQ YK7S5.7)$Z7]G$^FD#UC-QU7"W
MBHGSW5>X<]AE(Y/M&YEKZ_"VJE9/C5W9M0GX)A=/\22G&,6QS&&&<V4Z5Q00
MYX6 )"M$DDDNL\PI+S&<J&-;5];M%J:EDN"-7F%>)%U4?;PL8:;6P6WRZA,V
M?C_(QF4!MA3>ZKIA=/;LS0@Z+?[=$V'$'=[?$!3VHPZ$L"/V6W0^;R)VWZT6
MB_J(5/$\CV4$BSR/(%(B@X1P!DF41CC*XAPQZ9*_<3B$$\D/D*?QS8P!>"/<
M=A"S&\L?P=*.G:]#*#"K;@EW UKQ_#'@:=6],M>1809EG--J[C/%F2O[?>$M
MFU1?91W%]FW^C?[UCW+YPW2U-CW7YHOCWLV)T*9A$M5)[#C11F,F(68YA9P+
M)O(<Y3PMNB#@;_:V8U]Y>D3^?AO 0.P,B+FJBU/^:3214P&4WJGQIE=/99J(
M@U(3N#8@5C-A/!'F5ZT)PK=-E6?]<$?:Z3W!=N04=+Z&H;!6A9LZ"&-+]IOC
MIN!F5?;'<]>BZ)4->PLS*&=>"]D^LU[]O!YNW+I,]J>9)H.GQN*SBP(]>^^(
M/JQ:1+ EHW,KF_,H.?C[?* UD'OO #5/CKQ+$)SUVYV\>3@WW27Y=[QR%R_N
M6=2K;6%S)&35)/K(34N4M& RYBR%#/,4(BD8Q$3E=4O8#$M*"2V<:GW9CCPZ
M%UFUI&Q:5C\Z.VC35V5:)S,NS*$VG"NXTO_8SA:M_]I[NV4_57:&3I )"$S
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M<4LZ[1P5)C?D<]^LD "3;4>KKSN%@>EW:\9:5>K0T!NP5J>>M6V%6G\3,.J
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MKJ(L*W+$M:W(<HBPQ!!G&8<1)K0H"BE53EW8PJMT8V.95EA0UD+6;<_;4P9
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M7PG*A4P"E9DDRWA$NTFXG ^&R,//WPXA#4<Y!Q)M$YO(YZ_HAE_ 6T>?/5!
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M^LU/N\+:)#,P*MA0)J>AQ6J5(I8S1IP0-GG)/+HL5?"U#77C)IW7!=K@VFD
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MZ!4\,7A&9&<=T5D+(HU'CIWGQ&4;(A69\501NCO1VLB^.2!,ZZFJ@;WU6F;
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M'8@<]\JZ&=C65F\[R69EI/(<WW+^MVZZ@M>+/^83Q:64W$F"9$LB-<7C@--
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MW8F?;\:9^'GZ?'9ZZKOS1?X\/9GW8\7GJTUY>3_,=C:-Q9N[P=9V$USW>]
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M+NX6,?35=Z<^+DY@OCB=QN5E36XH$U^!>$[1_0RJA.%X(,J6*%H(.MT.4^P
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M\/NQIP1EU8%?PFM8_SOA@<8HG2.<&49D4D!\\8R]5,(X:[/S=;).AN9DY*2
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M)0&\QR.+9Q)\R=\S*BC/(AY?E8:)'U:_TD"[@YU L'W]RBX::0!;!^4JIVB
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M= "L:]9<M57(J(JT''+RACP+IR"4X@!=T3$&3"ZT<=+N+63<6I;6 #J$ZQV
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M$2$-<8]SE\>WC?>.<HMSQZ2&,2AK4V2F<B($"06NSG26FAFT@84@VY1N'R7
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MGSFDUF9R.!F>7'OO!YVGFO1UV_26MNW=MJ)ME"YO+*0LI$R 7E.D$QP'GU@
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M'7,V+FD<+#82_;R%'#H U&/\^?CISTMB?,Z2=H<ZJYF1$U,X[0Y"*JCSP+E
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M$[#OY%^3U:583@I,G3*@)&W_*.KD 26S*!%YT;PW)?T<-0/GTY^%]NY5HN<
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MJ4L%2K 16>!USE3MUZBD E^O3+F/V@43R?H\T0WS@?5&S1+<3P>N(\4RBI8
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MI8>,>1N^XEIGHR37+WH-6>DZRCP3_IU$2)9GQJ)T'$]E&UW1-!(0-;:/#I+
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MWB^X_?_E@ABZ<6$G)L9D3.U-Z;@'96*HE9L:?/&QA,C1AM0)7/N]=]@&38W
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M5B7=+;1QP7-B0H;@:[5-=AJB=@BBA&*\S"HW2E5ZE)RQ@><02=_O-7$TVT>
MG><J_>B=B0EBBT2#]>Z7@2\E ,M.J10Y+ZY-7F0?19>G+Y<[!D]]BF($R'JT
M^H_(+TH'8@TR!LK7+B^:U^:/M%T$&9=1M$G@/KCD\H3IVCU@Z&BFCP X3Y1]
MF6RBL.1XF"))N>K@(8BD:3-8;V(2HKAR(IMH'"67I[6O#Y+#:!&UW6XY>B4"
MG=4YNU3S1S,XE1C(&#P9EZ)D?JH&%6=0>+F7Y/<IO-Q'#*. %#UK%BZV8]T_
MXN+[-.'O'SYN=6[$G+2UI&1C"&0&*EJ.D(6^15<4]_2YC=WT#&%C!-8A"'@
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M%TY?:UK0Q/C$1&V8E8*(H 3M/:<+0C$L9ZN,]K;-E-@GB!IK%DT_N.I+&B,
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MJ;+:!Q7WE55/ C@_Q;11SO&6<@X7'_ S_::1IGK^A8U5UYXK;JW+BI!":U>
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MK/$1R-O742?OC=--@/[O:HH161AC1=P(-N.AF6V%&Z=J(W-;!XPHSW5MX:H
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M)-F^5]7V%_5+#$O\O__G_P-02P,$%     @ +8=95$B,GO3R!   +$,  !8
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M*"_5( )A."<^45J@@^PPC(Q3(@["N#XU]UN0=*@7CUX@JAJP>"15X<15*?5
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MMT?VN0_<%>,&/$0PY#)20*%D@+B,E+0I]2"Q#/F1.)+NA;2QTK;$?L2<1JN
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M9VXM,C R,3$R,S$N:'1M4$L! A0#%     @ +8=95$HTI>$4&@  H"\! !$
M             ( !8&8$ &UY9VXM,C R,3$R,S$N>'-D4$L! A0#%     @
M+8=95 82D'&9,@  1!," !4              ( !HX $ &UY9VXM,C R,3$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( "V'65352;:+"WL  .]^!0 5
M      "  6^S! !M>6=N+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  M
MAUE46;PR7B]   !!0   %               @ &M+@4 ;7EG;BTR,#(Q,3(S
M,5]G,2YG:6902P$"% ,4    "  MAUE4FOXKH6AS 0 M70\ %0
M    @ $.;P4 ;7EG;BTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ +8=9
M5&TTRV/WV@  _4P* !4              ( !J>(& &UY9VXM,C R,3$R,S%?
M<')E+GAM;%!+ 0(4 Q0    ( "V'651(C)[T\@0  "Q#   6
M  "  =.]!P!M>6=N+3(P,C$Q,C,Q97@R,3$N:'1M4$L! A0#%     @ +8=9
M5'-+5CZ=!   ;Q4  !@              ( !^<(' &UY9VXM,C R,3$R,S%X
M97AX,C,Q+FAT;5!+ 0(4 Q0    ( "V'652/(&PPYP<  +0E   8
M      "  <S'!P!M>6=N+3(P,C$Q,C,Q>&5X>#,Q,2YH=&U02P$"% ,4
M"  MAUE4EN_Z;.$'  "U)0  &               @ 'ISP< ;7EG;BTR,#(Q
M,3(S,7AE>'@S,3(N:'1M4$L! A0#%     @ +8=95&M1R6>G!   =Q0  !<
M             ( ! -@' &UY9VXM,C R,3$R,S%X97AX,S(N:'1M4$L%!@
0   ,  P )P,  -S<!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
